<SEC-DOCUMENT>0001737287-19-000020.txt : 20191105
<SEC-HEADER>0001737287-19-000020.hdr.sgml : 20191105
<ACCEPTANCE-DATETIME>20191105160247
ACCESSION NUMBER:		0001737287-19-000020
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191105
DATE AS OF CHANGE:		20191105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		191193224

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>allo-20190930x10qq319.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1C784897DB8C5CEF8BDE8BE2203F4A83"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WASHINGTON, DC 20549</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">________________________________________________________</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">10-Q</font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">________________________________________________________</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#9746;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#9744;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;to&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-38693</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">________________________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">Allogene Therapeutics, Inc.</font><font style="font-family:inherit;font-size:24pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">________________________________________________________</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:33%;"></td><td style="width:35%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">82-3562771</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">210 East Grand Avenue</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">South San Francisco, California</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">94080</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (650) 457-2700</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:31%;"></td><td style="width:38%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">N/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(Former name, former address and former fiscal year, if changed since last report)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:32%;"></td><td style="width:31%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Title of each class</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Trading Symbol(s)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Common Stock, $0.001 par value per share</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">ALLO</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">The Nasdaq Stock Market LLC</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:37px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Arial Unicode MS;font-size:8pt;">&#160;&#9746;</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</font></div><div style="line-height:120%;padding-top:6px;text-indent:37px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</font></div><div style="line-height:120%;padding-top:6px;text-indent:37px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:22%;"></td><td style="width:3%;"></td><td style="width:49%;"></td><td style="width:22%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-accelerated filer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Emerging growth company</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</font><font style="font-family:Arial Unicode MS;font-size:8pt;">&#160;&#9744;</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</font></div><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-indent:37px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">As of </font><font style="font-family:inherit;font-size:8pt;">November&#160;1, 2019</font><font style="font-family:inherit;font-size:8pt;">, the registrant had 121,902,101 shares of common stock, $0.001 par value per share, outstanding.</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s1A1D948A8A70516C829A32EB05B78FA9"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:12%;"></td><td style="width:81%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Page no.</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;" href="#s66F1FB35577B51B9B80D65DCC90639C8"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">PART I:</font></a><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><a style="font-family:inherit;font-size:10pt;" href="#s66F1FB35577B51B9B80D65DCC90639C8"><font style="font-family:inherit;font-size:10pt;">FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sEDBD62AECB0654E493D69A4271A9454D"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 1.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEDBD62AECB0654E493D69A4271A9454D"><font style="font-family:inherit;font-size:10pt;">Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sEDBD62AECB0654E493D69A4271A9454D">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s37C00CD020AD59A782097BA8A51BFC49"><font style="font-family:inherit;font-size:10pt;">Condensed Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s37C00CD020AD59A782097BA8A51BFC49">1</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9334E54A13EB55E49FF68AB3F77924E2"><font style="font-family:inherit;font-size:10pt;">Condensed Statements of Operations and Comprehensive Loss</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s9334E54A13EB55E49FF68AB3F77924E2">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s153EE7F3CB025E379A8D3558C0B8CD32"><font style="font-family:inherit;font-size:10pt;">Condensed Statements of Stockholders&#8217; Equity (Deficit)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s153EE7F3CB025E379A8D3558C0B8CD32">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFCF4DDE252645B5897800E867C7E9046"><font style="font-family:inherit;font-size:10pt;">Condensed Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sFCF4DDE252645B5897800E867C7E9046">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFFFABFADBF1D56B9823056678A9B8F0B"><font style="font-family:inherit;font-size:10pt;">Notes to Condensed Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sFFFABFADBF1D56B9823056678A9B8F0B">6</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s7BBA2A3B9C1E5D028AE1D9E4BB988FDA"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 2.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7BBA2A3B9C1E5D028AE1D9E4BB988FDA"><font style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s7BBA2A3B9C1E5D028AE1D9E4BB988FDA">18</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3BAA8A611E9056EF96EB6052F4D2CA3C"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 3.</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3BAA8A611E9056EF96EB6052F4D2CA3C"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3BAA8A611E9056EF96EB6052F4D2CA3C">27</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s705FCBB809EA58CDA2797C728A930A1F"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s705FCBB809EA58CDA2797C728A930A1F"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s705FCBB809EA58CDA2797C728A930A1F">27</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;" href="#sEEF1D3C55E915344BC23F2A6AACF1C43"><font style="font-family:inherit;font-size:10pt;color:#000000;font-weight:bold;text-decoration:none;">PART II:</font></a><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><a style="font-family:inherit;font-size:10pt;" href="#sEEF1D3C55E915344BC23F2A6AACF1C43"><font style="font-family:inherit;font-size:10pt;">OTHER INFORMATION</font></a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD4E8965FBF215874B4EDA03CE17E5795"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD4E8965FBF215874B4EDA03CE17E5795"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD4E8965FBF215874B4EDA03CE17E5795">29</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s4F573D370CCC56C49E63CC47F95A6E96"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 1A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4F573D370CCC56C49E63CC47F95A6E96"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s4F573D370CCC56C49E63CC47F95A6E96">29</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sBA1EE90C86555D2193950C4E882AEC8B"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBA1EE90C86555D2193950C4E882AEC8B"><font style="font-family:inherit;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sBA1EE90C86555D2193950C4E882AEC8B">67</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sE9B6781B10975DB799A8011280EEB56F"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE9B6781B10975DB799A8011280EEB56F"><font style="font-family:inherit;font-size:10pt;">Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sE9B6781B10975DB799A8011280EEB56F">67</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s90CC6E244E535E679C8231293E5D9EB1"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s90CC6E244E535E679C8231293E5D9EB1"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s90CC6E244E535E679C8231293E5D9EB1">67</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sB1EB81D4F8ED57FB8DA4A520ED48A25B"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 5.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB1EB81D4F8ED57FB8DA4A520ED48A25B"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sB1EB81D4F8ED57FB8DA4A520ED48A25B">67</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sF1E908B93EBA5BF796F185A3B66E75BC"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF1E908B93EBA5BF796F185A3B66E75BC"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sF1E908B93EBA5BF796F185A3B66E75BC">68</a></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD9E77836075855ACBC23BC06A88B8671"><font style="font-family:inherit;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD9E77836075855ACBC23BC06A88B8671">69</a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">i</font></div></div><hr style="page-break-after:always"><div><a name="s66F1FB35577B51B9B80D65DCC90639C8"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I: FINANCIAL INFORMATION</font></div><div><a name="sEDBD62AECB0654E493D69A4271A9454D"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Financial Statements</font></div><div><a name="s37C00CD020AD59A782097BA8A51BFC49"></a></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALLOGENE THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Balance Sheets</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands, except share and per share amounts)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,432</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,254</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,952</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,513</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,598</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">509,757</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">467,982</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease right-of-use asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,015</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">301</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">754</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,105</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">695,544</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">773,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,047</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,338</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,307</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,121</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,354</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,459</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liability, noncurrent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,689</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,828</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and Contingencies (Notes 6 and 7)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock, $0.001 par value: 10,000,000 shares authorized as of September 30, 2019 and December 31, 2018; no shares were issued and outstanding as of September 30, 2019 and December 31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Common stock, $0.001 par value: 200,000,000 shares authorized as of<br>   September 30, 2019 and December 31, 2018; 121,895,479 and <br>   121,482,671 shares issued and outstanding as of September 30, 2019 <br>   and December 31, 2018, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">952,820</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">914,265</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(335,092</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(211,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,866</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">619,716</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">703,164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">695,544</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">773,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed financial statements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:90px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s9334E54A13EB55E49FF68AB3F77924E2"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALLOGENE THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Statements of Operations and Comprehensive Loss</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands, except share and per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,870</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,356</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,317</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,261</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,440</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,011</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,187</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,433</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,796</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Change in fair value of convertible note payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Interest and other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,702</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,497</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(123,740</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180,996</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Benefit (expense) from income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,735</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,497</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(123,564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180,996</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net unrealized gain (loss) on available-for-sale investments, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,560</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51,030</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,645</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(122,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(181,144</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10.71</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average number of shares used in computing net loss per share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,186,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,060,419</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,801,001</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,048,451</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><a name="s153EE7F3CB025E379A8D3558C0B8CD32"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALLOGENE THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Statements of Stockholders&#8217; Equity (Deficit)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands, except share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90817263544535%;border-collapse:collapse;text-align:left;"><tr><td colspan="39"></td></tr><tr><td style="width:14%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Convertible Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Subscription Receivable from Preferred Stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common Stock</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Notes</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Receivable</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">from&#160;</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Stockholders</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Paid-in</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Capital</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Deficit</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Comprehensive</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Income</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Stockholders&#8217;</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Balance - June 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">121,631,278</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">937,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(284,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">2,161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">655,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of common stock upon exercise of stock options</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">200,868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">467</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">467</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Vesting of early exercised common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">710</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Stock-based compensation</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">12,835</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">12,835</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Employee stock purchase plan</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">63,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,099</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net loss</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(50,735</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(50,735</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net unrealized (loss) on available-for-sale investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(295</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Balance - September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">121,895,479</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">122</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">952,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(335,092</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">619,716</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90817263544535%;border-collapse:collapse;text-align:left;"><tr><td colspan="39"></td></tr><tr><td style="width:14%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Convertible Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Subscription Receivable from Preferred Stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common Stock</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Notes</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Receivable</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">from&#160;</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Stockholders</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Paid-in</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Capital</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Deficit</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Comprehensive</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Income</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Stockholders&#8217;</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Balance - December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">121,482,671</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">121</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">914,265</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(211,528</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">306</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">703,164</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of common stock upon exercise of stock options</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">304,826</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">704</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Vesting of early exercised common stock</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">3,880</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">3,880</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Stock-based compensation</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">32,189</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">32,189</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Employee stock purchase plan</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">107,982</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,783</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,783</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net loss</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(123,564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(123,564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net unrealized gain on available-for-sale investments</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,560</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,560</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Balance - September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">121,895,479</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">122</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">952,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(335,092</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1,866</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">619,716</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALLOGENE THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Statements of Stockholders&#8217; Equity (Deficit) - (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands, except share amounts)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90817263544535%;border-collapse:collapse;text-align:left;"><tr><td colspan="39"></td></tr><tr><td style="width:14%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Convertible Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Subscription Receivable from Preferred Stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Notes</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Receivable</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">from&#160;</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Paid-in</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Comprehensive</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Stockholders&#8217;</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Deficit</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Balance - June 30, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">11,743,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">411,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(150,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">27,714,743</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">8,054</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(137,522</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(129,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Subscriptions receivable from preferred stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">150,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of common stock for early exercise of stock option</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">3,555,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">4,639</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">4,639</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net and comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(43,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(43,497</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net unrealized gain (loss) on available-for-sale investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Balance - September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">11,743,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">411,052</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">31,270,573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">31</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">12,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(181,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(168,443</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90817263544535%;border-collapse:collapse;text-align:left;"><tr><td colspan="39"></td></tr><tr><td style="width:14%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Convertible Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Subscription Receivable from Preferred Stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Notes</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Receivable</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">from&#160;</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Common</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Paid-in</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Comprehensive</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Stockholders&#8217;</font></div><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Deficit</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Balance - December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">26,249,993</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of Series A convertible preferred shares at $35.06 per share, net of issuance costs of $635</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">7,557,990</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">264,365</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of Series A-1 convertible preferred shares at $35.06 per share in connection with asset acquisition</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">3,187,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">111,770</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of Series A-1 convertible preferred shares at $35.06 per share, net of issuance costs of $84</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">998,225</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">34,917</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Proceeds received from common stockholders for issuance of founders' stock at inception</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Issuance of common stock for early exercise of stock option</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">5,020,580</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">12,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">12,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(180,996</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(180,996</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Net unrealized gain (loss) on available-for-sale investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">Adjustment for fractional shares from forward stock split</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">Balance - September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">11,743,987</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">411,052</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">31,270,573</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">31</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">12,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(181,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(148</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">(168,443</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sFCF4DDE252645B5897800E867C7E9046"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALLOGENE THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(123,564</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(180,996</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Acquired in process-research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">109,436</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">32,189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amortization of other intangible assets acquired</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">452</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">302</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net amortization/accretion on investment securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,136</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash rent expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,827</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Change in fair value of convertible notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19,415</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Debt issuance costs on convertible notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,358</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(176</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">86</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,132</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other long-term assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,137</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,083</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accrued and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,510</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,991</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net cash (used in) operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(87,083</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,172</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(36,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash paid for acquisition of assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,098</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from maturities of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">355,765</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Purchase of investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(162,931</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(315,399</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">156,155</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(319,410</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from issuance of convertible preferred stock, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">299,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from issuance of convertible notes, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">116,842</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from early exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,375</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Payments of deferred offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(839</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from issuance of common stock and upon exercise of stock options</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">703</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,783</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,486</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">426,660</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net increase in cash, cash equivalents and restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">71,558</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">84,078</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash, cash equivalents and restricted cash &#8212; beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">93,731</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash, cash equivalents and restricted cash &#8212; end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">165,289</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">84,078</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-cash investing and financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Property and equipment purchase in accounts payable and accrued liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,571</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">204</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Right-of-use asset obtained in exchange for lease liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Series A-1 convertible preferred stock issued in asset acquisition</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">111,770</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred offering costs included in accounts payable and accrued and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,388</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Supplemental disclosure:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash paid for amounts included in the measurement of lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash received for amounts related to tenant improvement allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,934</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The accompanying notes are an integral part of these unaudited condensed financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="sFFFABFADBF1D56B9823056678A9B8F0B"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ALLOGENE THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div><a name="s72F4A869D058549FBEF94E2036DFBFBD"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on</font><font style="font-family:inherit;font-size:10pt;">&#32;November&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company completed an initial public offering (IPO) of its common stock. In connection with its IPO, the Company issued and sold </font><font style="font-family:inherit;font-size:10pt;">20,700,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock, which included </font><font style="font-family:inherit;font-size:10pt;">2,700,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock issued pursuant to the over-allotment option granted to the underwriters, at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$18.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. As a result of the IPO, the Company received approximately </font><font style="font-family:inherit;font-size:10pt;">$343.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds, after deducting underwriting discounts and commissions of </font><font style="font-family:inherit;font-size:10pt;">$26.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and offering expenses of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payable by the Company. At the closing of the IPO, all </font><font style="font-family:inherit;font-size:10pt;">11,743,987</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of outstanding convertible preferred stock were automatically converted into </font><font style="font-family:inherit;font-size:10pt;">61,655,922</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and our outstanding convertible promissory notes in </font><font style="font-family:inherit;font-size:10pt;">$120.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;principal amount were automatically converted into </font><font style="font-family:inherit;font-size:10pt;">7,856,176</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. Following the IPO, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of convertible preferred stock or preferred stock outstanding.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Need for Additional Capital</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of </font><font style="font-family:inherit;font-size:10pt;">$601.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. Since inception through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company has incurred cumulative net losses of </font><font style="font-family:inherit;font-size:10pt;">$335.1 million</font><font style="font-family:inherit;font-size:10pt;">. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed financial statements are filed with the Securities and Exchange Commission (SEC).</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Forward Stock Split</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2018, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward split of shares of the Company&#8217;s common stock on a </font><font style="font-family:inherit;font-size:10pt;">1-for-5.25</font><font style="font-family:inherit;font-size:10pt;">&#32;basis (the Forward Stock Split). In connection with the Forward Stock Split, the conversion ratio for the Company&#8217;s then-outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split. The par value of the common stock was not adjusted as a result of the Forward Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these condensed financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.</font></div><div><a name="s68CC77B91A9353F69179E11BA51787D6"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the condensed statements of operations and comprehensive loss for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the condensed statements of stockholders&#8217; equity (deficit) as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the condensed statements of cash flows for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;are not necessarily indicative of the results to be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 8, 2019.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no significant changes to the accounting policies during the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued&#160;Accounting Standards Update No.&#160;2018-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement &#8211; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</font><font style="font-family:inherit;font-size:10pt;">, which provided amended guidance to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Additionally, under the new guidance, an entity will be required to provide certain disclosures regarding stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company adopted this guidance on January 1, 2019. Adoption of the new guidance had no significant impact on the Company&#8217;s condensed financial statements.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles &#8211; Goodwill and other &#8211; Internal-Use Software (Subtopic 350-40)</font><font style="font-family:inherit;font-size:10pt;">, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is evaluating the impact of adopting this amendment to its financial statements.</font></div><div><a name="sDB6E6C5D0ED25BAB8EE9C8540F6E04BA"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;Level 3 assets or liabilities as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and as of December 31, 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and as of December 31, 2018 are presented in the following tables:&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,657</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,657</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">316,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included within cash and cash equivalents on the Company&#8217;s balance sheets</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;transfers between Levels 1, 2 or 3 for the period presented.</font></div><div><a name="sB2404000184258C4BA165E693FB24731"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Instruments</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and as of December 31, 2018 are presented in the following tables:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">September&#160;30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Gains</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Losses</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,893</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">744</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,633</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,433</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551,187</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,174</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Classified as:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,254</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,702</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Gains</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Losses</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341,696</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,001</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">713,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Classified as:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,952</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">,&#160;the remaining contractual maturities of available-for-sale securities were less than </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;">. There have been no significant realized losses on available-for-sale securities for the period presented. Based on the Company&#8217;s review of its available-for-sale securities, the Company believes it had&#160;no&#160;other-than-temporary impairments on these securities as of&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, because the Company does not intend to sell these securities&#160;nor does the Company believe that it will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were immaterial for the three and nine months ended&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="sF0C76884CAE45C82A0A48C9A9C10F2B0"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheets Components</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Prepaid expenses and Other Current Assets</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and Other Current Assets consist of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest on investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,337</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,108</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other prepaid and current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,376</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,513</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,598</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and Equipment consist of the following:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,233</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,566</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,534</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers equipment and purchased software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,496</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,327</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,638</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,703</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,711</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,643</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,768</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,048</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,943</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,672</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,111</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested shares liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,842</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,590</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,969</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,307</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sBF434354A9CD5435BB258E073EDAB353"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License Agreements</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Asset Contribution Agreement with Pfizer</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;">, depending on the target, with aggregate potential regulatory and development milestones of up to </font><font style="font-family:inherit;font-size:10pt;">$840.0 million</font><font style="font-family:inherit;font-size:10pt;">, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are </font><font style="font-family:inherit;font-size:10pt;">$325.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2018 respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) </font><font style="font-family:inherit;font-size:10pt;">12 years</font><font style="font-family:inherit;font-size:10pt;">&#32;from the first sale of such product in such country.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Collaboration and License Agreement with Cellectis</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of our intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Cellectis Agreement provides for development and sales milestone payments by the Company of up to </font><font style="font-family:inherit;font-size:10pt;">$185.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to </font><font style="font-family:inherit;font-size:10pt;">$2.8 billion</font><font style="font-family:inherit;font-size:10pt;">. The Company is obligated to pay Cellectis </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the dosing of the first patient in its Phase </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">&#32;clinical trial of ALLO-715. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#8217; prior written notice in the event of the other party&#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.</font></div><div style="line-height:120%;padding-top:16px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">All costs the Company incurred in connection with this agreement were recognized as research and development expenses. </font><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">For the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, $</font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">.0 million of costs were incurred related to the achievement of a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical development milestone under this agreement. For the three and nine months ended September 30, 2018, </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of costs were incurred associated with research services performed by Cellectis under this agreement. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million related to a clinical development milestone payable was recorded in the accrued and other current liabilities in the accompanying condensed balance sheet.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License and Collaboration Agreement with Servier</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19 in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For product candidates that the Company is co-developing with Servier, including UCART19 and ALLO-501, the Company is responsible for </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the specified development costs and Servier is responsible for the remaining </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#8217;s sole expense.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to </font><font style="font-family:inherit;font-size:10pt;">$137.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to </font><font style="font-family:inherit;font-size:10pt;">$78.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are </font><font style="font-family:inherit;font-size:10pt;">$42 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">&#8364;70.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">$77.1 million</font><font style="font-family:inherit;font-size:10pt;">), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#8217;s election not to pursue such rights.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of costs incurred under the cost-sharing terms of the Servier Agreement as research and development expenses. For the three and nine months ended September 30, 2018, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of costs as research and development expenses. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, amounts due to Servier of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;were recorded in accrued and other current liabilities in the accompanying condensed balance sheet.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sACAB785D4D775991837AB76609A21693"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately </font><font style="font-family:inherit;font-size:10pt;">68,000</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet located in South San Francisco, California. The lease term is </font><font style="font-family:inherit;font-size:10pt;">127 months</font><font style="font-family:inherit;font-size:10pt;">&#32;beginning August 2018 through February 2029 with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of </font><font style="font-family:inherit;font-size:10pt;">$5.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million. The rent payments began on March 1, 2019 after an abatement period. In connection with the&#160;lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million. In connection with this lease, the Company recognized an operating lease right-of-use asset of </font><font style="font-family:inherit;font-size:10pt;">$23.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and an aggregate lease liability of </font><font style="font-family:inherit;font-size:10pt;">$29.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the accompanying condensed balance sheet. The remaining lease term is 9 years and 5 months, and the estimated incremental borrowing rate is </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of </font><font style="font-family:inherit;font-size:10pt;">14,943</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet located in South San Francisco, California. The lease term is </font><font style="font-family:inherit;font-size:10pt;">124 months</font><font style="font-family:inherit;font-size:10pt;">&#32;beginning November 2018 through February 2029, with an option to extend the term for another </font><font style="font-family:inherit;font-size:10pt;">seven years</font><font style="font-family:inherit;font-size:10pt;">&#32;which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million. Rent payments began in November 2018. In connection with the lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of </font><font style="font-family:inherit;font-size:10pt;">$0.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million. In connection with this lease, the Company recognized an operating lease right-of-use asset of </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and an aggregate lease liability of </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the accompanying balance sheet. The remaining lease term is 9 years and 5 months, and the estimated incremental borrowing rate is </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">December 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into two operating leases for office space in New York and Los Angeles for </font><font style="font-family:inherit;font-size:10pt;">4,358</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">1,293</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet respectively. The Company recognized operating lease right-of-use assets of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and aggregate lease liabilities of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;respectively for these leases. The lease term for the New York operating lease is 6 years and 7 months, with no option for renewal. The lease term for the Los Angeles operating lease is </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;">&#32;with an option to extend the lease term for another </font><font style="font-family:inherit;font-size:10pt;">two years</font><font style="font-family:inherit;font-size:10pt;">&#32;which is not reasonably certain of exercise. There were no lease incentive allowances for either location. In connection with the New York lease, the Company maintains a letter of credit for the benefit of the landlord in the amount of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">. The remaining lease terms were </font><font style="font-family:inherit;font-size:10pt;">5 years and 9 months</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2 years and 2 months</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and the estimated incremental borrowing rates applied were </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2019, the Company entered into a lease agreement for approximately </font><font style="font-family:inherit;font-size:10pt;">118,000</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease has a term of </font><font style="font-family:inherit;font-size:10pt;">188 months</font><font style="font-family:inherit;font-size:10pt;">&#32;and is expected to commence in April 2020. Upon certain conditions, the Company has two ten-year options to extend the lease. Subject to rent abatement for the second through nine months of the lease, the Company will be required to pay </font><font style="font-family:inherit;font-size:10pt;">$159,150</font><font style="font-family:inherit;font-size:10pt;">&#32;per month for rent for the first twelve months of the lease term which will increase at a rate of </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;per year. The Company will be entitled to a tenant improvement allowance of&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million for costs related to the design and construction of certain Company improvements. In connection with the lease, the Company maintains a letter of credit for the benefit of the landlord in the amount of </font><font style="font-family:inherit;font-size:10pt;">$3.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million. The total commitment of undiscounted lease payments for this lease was </font><font style="font-family:inherit;font-size:10pt;">$36.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. The Company had not recognized a right-of-use asset or aggregate lease liability as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as the underlying asset was unavailable for use by the Company at any time in the period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The undiscounted future lease payments under the lease agreements as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were as follows:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ending December&#160;31:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 (remaining 3 months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,981</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,961</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024 and thereafter </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,516</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total undiscounted lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Undiscounted lease payments related to Newark lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,231</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Present value adjustment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Tenant improvement allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for all operating leases was </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. Short-term lease expense was </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. Variable lease payments for operating expenses was </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div><a name="sB8E2B1DF1B095E76AC4A5C83432080A8"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the Company adopted the 2018 Equity Incentive Plan (2018 Plan). The 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#8217;s board of directors and consultants of the Company under terms and provisions established by the Company&#8217;s board of directors. In October 2018, the Board of Directors approved an amendment and restatement of the 2018 Plan, increasing the shares of common stock issuable under the 2018 Plan as well as allowing for an automatic annual increase to the shares issuance under the 2018 Plan to the amount equal to </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;">. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the fair market value of the Company&#8217;s common stock on the grant date. Options granted typically vest over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a four-year period but may be granted with different vesting terms.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">9,915,688</font><font style="font-family:inherit;font-size:10pt;">&#32;shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Activity</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes option activity under the 2018 Plan:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,235,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.62</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,781,316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.55</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(304,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.72</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(220,151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.91</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,492,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,553,432</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.03</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.00</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,492,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Activity</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes restricted stock unit activity under the 2018 Plan:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value at Date</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of Grant per</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,795,905</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.46</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27.55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended September 30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,301</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,212</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,177</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,253</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,639</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,695</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Early Exercised Options</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company allows certain of its employees and its directors to exercise options granted under the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Company&#8217;s board of directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the noncurrent portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;recorded in accrued and other liabilities and </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed financial statements since the exercise date.</font></div><div><a name="s9a792de0a02b491da3c2f82d8c3a61ac"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Notes Payable (2018 Notes)</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, the Company entered into a note purchase agreement pursuant to which it sold and issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$120.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in convertible promissory notes (convertible notes payable or 2018 Notes) and received net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$116.8 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2018 Notes did not accrue interest. The 2018 Notes were settled in </font><font style="font-family:inherit;font-size:10pt;">7,856,176</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock in connection with the closing of the Company&#8217;s IPO (see Note 1) at a settlement price equal to </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the IPO price per share. &#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On issuance, the Company elected to account for the 2018 Notes at fair value with any changes in fair value being recognized through the statements of operations until the 2018 Notes settled. The fair value of the 2018 Notes was determined to be </font><font style="font-family:inherit;font-size:10pt;">$120.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;on issuance and </font><font style="font-family:inherit;font-size:10pt;">$139.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of September 30, 2018. For the three-months and nine-months ended September 30, 2018, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the accompanying condensed statements of operations as the change in fair value of the 2018 Notes. On issuance, total debt issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;were expensed and recognized as interest expense in the accompanying condensed statements of operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><a name="sFA1DB287B1BF5328A432753A42D6756B"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, Pfizer held </font><font style="font-family:inherit;font-size:10pt;">22,032,040</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Common Stock and had appointed one member to the Company&#8217;s board of directors.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, the Company and Pfizer entered into a transition services agreement (the Pfizer TSA) for Pfizer to provide professional services to the Company related to research and development, project management, and other administrative functions. For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the costs incurred under the Pfizer TSA were&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and $</font><font style="font-family:inherit;font-size:10pt;">4.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million, respectively. For the three and nine months ended September 30, 2018, the costs incurred under the Pfizer TSA were $</font><font style="font-family:inherit;font-size:10pt;">3.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million and $</font><font style="font-family:inherit;font-size:10pt;">7.4</font><font style="font-family:inherit;font-size:10pt;">&#32;million, respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also purchased certain lab supplies from Pfizer in connection with its research and development activities. For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the total lab supplies and services purchased from Pfizer were </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">&#32;and $</font><font style="font-family:inherit;font-size:10pt;">1.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million, respectively. For the three and nine months ended September 30, 2018, the total lab supplies and services purchased from Pfizer were $</font><font style="font-family:inherit;font-size:10pt;">2.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million and $</font><font style="font-family:inherit;font-size:10pt;">6.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million, respectively. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and December 31, 2018, the Company had an amount payable to Pfizer of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and $</font><font style="font-family:inherit;font-size:10pt;">5.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million, respectively, which was recorded in the accrued and other current liabilities on the accompanying condensed balance sheets.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2019, the Company and Pfizer terminated the Pfizer TSA.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sublease Agreement</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2019, the Company subleased </font><font style="font-family:inherit;font-size:10pt;">2,180</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet of its office space in New York, New York, to ByHeart, Inc., formerly known as Second Science, Inc. (ByHeart).&#160;ByHeart is a development-stage infant formula company.&#160;Two of the Company&#8217;s board members have beneficial ownership in ByHeart and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;serves on the board of directors of ByHeart. In September 2019, the Company entered into an amendment to the sublease agreement and increased the subleased space to </font><font style="font-family:inherit;font-size:10pt;">2,907</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet. Sublease income for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and $</font><font style="font-family:inherit;font-size:10pt;">0.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million, respectively, and was recognized as other income. Sublease income for the three and nine months ended September 30, 2018 was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consulting Agreements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and $</font><font style="font-family:inherit;font-size:10pt;">0.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$0.3</font><font style="font-family:inherit;font-size:10pt;">&#32;million and $</font><font style="font-family:inherit;font-size:10pt;">0.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the three and nine months ended September 30, 2018.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the Company entered into a consulting agreement with Bellco Capital LLC (Bellco). The Company&#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is the Chairman and an owner of Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company pays Bellco </font><font style="font-family:inherit;font-size:10pt;">$33,333.33</font><font style="font-family:inherit;font-size:10pt;">&#32;per month in arrears commencing January 2019 and, in the Company&#8217;s discretion, may pay Bellco an annual performance award in an amount up to </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The cost incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and $</font><font style="font-family:inherit;font-size:10pt;">0.4</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million and </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the three and nine months ended September 30, 2018.</font></div><div><a name="s0E91205385745CA9966601A8563C1BD9"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a history of losses, and expects to record a loss in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</font></div><div><a name="sF2A134EFCE5554EE9CAA0EC152E29A99"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:75%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,492,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,075,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,655,922</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,856,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units subject to vesting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,155</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected shares purchased under Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Founder shares of common stock subject to future vesting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,144,224</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,201,908</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Early exercised stock options subject to future vesting</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,306,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,020,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,878,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,810,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s6e05a2209971414c8413f6356bf5976c"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Collaboration Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch has granted to Allogene an exclusive, worldwide, royalty-bearing, sublicenseable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Collaboration Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee.  Allogene will reimburse Notch&#8217;s costs incurred in accordance with such plan and budget.  The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Collaboration Agreement, (ii) at Allogene&#8217;s election, following the joint development committee&#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the execution of the Collaboration Agreement, Allogene made an upfront payment to Notch of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">. In addition, Allogene made a </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;investment in Notch&#8217;s series seed convertible preferred stock, resulting in Allogene having a </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment.  In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#8217;s board of directors.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Collaboration Agreement, Notch will be eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$7.25 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon achieving certain agreed research milestones, up to </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per exclusive target upon achieving certain pre-clinical development milestones, and up to </font><font style="font-family:inherit;font-size:10pt;">$283.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term of the Collaboration Agreement will continue on a product-by-product and country-by-country basis until Allogene&#8217;s payment obligations with respect to such product in such country have expired.  Following such expiration, Allogene&#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free.  Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#8217; prior written notice to Notch.  Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#8217;s insolvency. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><a name="s7BBA2A3B9C1E5D028AE1D9E4BB988FDA"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December&#160;31, 2018 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2018 (Annual Report), which was filed with the Securities and Exchange Commission (SEC) on March 8, 2019. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company&#8221;, &#8220;Allogene,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Allogene Therapeutics, Inc., and references to &#8220;Servier&#8221; collectively refer to Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; under Part II, Item 1A below. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; or the negative of these terms or other similar expressions.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements</font><font style="font-family:inherit;font-size:10pt;color:#32406b;font-style:italic;">.</font></div><div><a name="sB5E890B9A43E536088AF2E2DDB4FA054"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient&#8217;s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a deep pipeline of allogeneic chimeric antigen receptor (CAR) T cell product candidates targeting multiple promising antigens in a host of hematological malignancies and solid tumors. In collaboration with Servier, we are developing UCART19 and ALLO-501, CAR T cell product candidates targeting CD19.&#160;Servier is sponsoring two Phase 1 clinical trials of UCART19 in patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL), one for adult patients (the CALM trial) and one for pediatric patients (the PALL trial). Servier expects UCART19 to be advanced to potential registrational trials in 2020.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are sponsoring a Phase 1/2 clinical trial (the ALPHA trial) of ALLO-501 in patients with R/R non-Hodgkin lymphoma (NHL). In January 2019, the&#160;U.S. Food and Drug Administration (FDA) cleared&#160;our investigational new drug application (IND) and the ALPHA trial is ongoing at multiple clinical trial sites. We expect to report top-line data from the Phase 1 portion of the trial in the first half of 2020. We plan to file a protocol amendment that would permit us to further explore the optimal dose and schedule of ALLO-647, allow re-dosing of certain patients, and expand the enrollment criteria. We also plan to develop a second-generation version of ALLO-501, known as ALLO-501A. We have removed rituximab recognition domains in ALLO-501A, which we believe will potentially facilitate treatment of patients who were recently treated with rituximab. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2019, the FDA cleared our IND to initiate a Phase 1 clinical trial (the UNIVERSAL trial) of ALLO-715, an allogeneic CAR T cell product candidate targeting B-cell maturation antigen (BCMA), in adult patients with R/R multiple myeloma.  The UNIVERSAL trial was initiated in the third quarter of 2019.&#160; </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since inception, we have had significant operating losses. Our net losses were </font><font style="font-family:inherit;font-size:10pt;">$50.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million and </font><font style="font-family:inherit;font-size:10pt;">$123.6</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the three and nine months ended September 30, 2019, respectively. As of September 30, 2019, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$335.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million.&#160;As of September 30, 2019, we had </font><font style="font-family:inherit;font-size:10pt;">$601.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million in cash and cash equivalents and investments.&#160;We expect to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Developments</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 1, 2019, we entered into a Collaboration and License Agreement (the Collaboration Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch has granted to us an exclusive, worldwide, royalty-bearing, sublicenseable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted us an option to add certain specified targets to our exclusive license in exchange for an agreed per-target option fee.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Collaboration Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to our exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. In connection with the execution of the Collaboration Agreement, we made an upfront payment to Notch of $10.0 million. In addition, we made a $5.0 million investment in Notch&#8217;s series seed convertible preferred stock, resulting in us having a 25% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. See Note 13 to our condensed financial statements included elsewhere in this report for further description of the Collaboration Agreement.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="s11E94030C49B5A9094A55BFB79944988"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Research and Development and License Agreements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Collaboration and License Agreement with Cellectis</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, Pfizer entered into a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). In April 2018, Pfizer assigned the agreement to us pursuant to the Pfizer Agreement.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 8, 2019,&#160;the Company&#160;entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement, pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement. The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The material rights and obligations of the parties under the Cellectis Agreement are otherwise consistent with the material rights and obligations of the parties under the Original Cellectis Agreement. See Note 6 to our condensed financial statements included elsewhere in this report for further description of the Cellectis Agreement.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exclusive License and Collaboration Agreement with Servier</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2015, Pfizer entered into an Exclusive License and Collaboration Agreement (Servier Agreement) with Servier to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR products, including UCART19, in the United States with the option to obtain the rights over additional allogeneic anti-CD19 CAR product candidates and for allogeneic CAR T cell product candidates directed against one additional target. In April 2018, Pfizer assigned the agreement to us pursuant to the Pfizer Agreement. In October 2019, we agreed to waive our rights to the one additional target. See Note 6 to our condensed financial statements included elsewhere in this report for further description of the Servier Agreement.</font></div><div><a name="s4497DFE432CD58E18251A6D0573636CA"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transition Services Agreement</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the closing of the Pfizer Agreement, we entered into a Transition Services Agreement (TSA) with Pfizer in April 2018, pursuant to which we obtained from Pfizer certain (i)&#160;research and development services, including services relating to testing, studies, and clinical trials, project management services, laboratory equipment and operations services, animal care services, data storage services and regulatory strategy services, and (ii)&#160;general and administrative services, including business technology services, compliance services, finance/accounting services, and procurement, manufacturing and supply chain services, with respect to the assets that we purchased from Pfizer. Under the TSA, Pfizer also provided us with certain facilities and facility management services. The services were provided by certain employees of Pfizer as independent contractors of Allogene. We believe that it was helpful for Pfizer to provide such services to us under the TSA to help facilitate the efficient operation of our business after the asset purchase. Pfizer began providing the services in May 2018 and the TSA was terminated in September 2019. </font></div><div><a name="s1926BA91EB675573A5E9D6CFAEEA856F"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Components of Results of Operations</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, our research and development expenses have related primarily to discovery efforts and preclinical and clinical development of our product candidates. Research and development expenses that were incurred for the three and nine months ended September 30, 2019 related mostly to the development of pipeline product candidates UCART19, ALLO-501 and ALLO-715. The most significant research and development expenses relates to the following costs incurred for the development of our product candidates, which include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expenses incurred under agreements with our collaboration partner and third-party contract organizations, investigative clinical trial sites that conduct research and development activities on our behalf, and consultants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs related to production of clinical materials, including fees paid to contract manufacturers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">laboratory and vendor expenses related to the execution of preclinical and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">employee-related expenses, which include salaries, benefits and stock-based compensation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">facilities and other expenses, which include expenses for rent and maintenance of facilities, depreciation and amortization expense and supplies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other significant research and development costs include costs relating to overhead costs. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expense all research and development costs in the periods in which they are incurred. We accrue for costs incurred as the services are being provided by monitoring the status of&#160;the project and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to reimburse Servier for 60% of the costs associated with the development of UCART19, including for the CALM and PALL clinical trials. We accrue for costs incurred by monitoring the status of the CALM and PALL clinical trials and the invoices received from Servier. We adjust our accrual as actual costs become known. Servier is required to reimburse us for 40% of the costs associated with the development of ALLO-501, including for the ALPHA clinical trial.&#160;Collaboration expenses and cost reimbursement is recorded on a net basis as a research and development expense in our condensed statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase over the next several years as&#160;the UCART19, ALLO-501 and ALLO-715 clinical programs progress and as we seek to initiate clinical trials of additional product candidates. The cost of advancing our manufacturing process as well as the cost of manufacturing product candidates for clinical trials are included in our research and development expense. We also expect to incur increased research and development expenses as we selectively identify and develop additional product candidates. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">per patient trial costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">biomarker analysis costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost and timing of manufacturing for the trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number of patients that participate in the trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number of sites included in the trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the countries in which the trials are conducted;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the length of time required to enroll eligible patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the total number of cells that patients receive;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the drop-out or discontinuation rates of patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential additional safety monitoring or other studies requested by regulatory agencies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the duration of patient follow-up; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the efficacy and safety profile of the product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the case of UCART19, we are also dependent on Servier&#8217;s ability to manage the CALM and PALL clinical trials. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#8217;s commercial potential.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because our product candidates are still in clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability.</font></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses consist primarily of salaries and other staff-related costs, including stock-based compensation for options and restricted stock units granted and modification of shares of common stock issued to our founders to include vesting conditions, for personnel in executive, finance, accounting, legal, investor relations, facilities, business development, information technology and human resources functions. Other significant costs include costs relating to facilities and overhead costs, legal fees relating to corporate and patent matters, insurance, investor relations costs, fees for accounting and consulting services, information technology, and other general and administrative costs. General and administrative costs are expensed as incurred, and we accrue for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from our service providers, and adjusting our accruals as actual costs become known.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, potential commercialization of our product candidates and the increased costs of operating as a public company. These increases are anticipated to include increased costs related to the hiring of additional personnel, developing commercial infrastructure, fees to outside consultants, lawyers and accountants, and increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change in Fair Value of 2018 Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We elected on issuance to account for our convertible promissory notes (2018 Notes) at fair value until their settlement. In this reporting period, the change in fair value of the 2018 Notes was recognized through the statement of operations. The 2018 Notes settled on the closing of our IPO in October 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense consists of debt issuance costs we incurred to issue the 2018 Notes. The debt issuance costs were expensed on issuance because we elected to record the 2018 Notes at fair value.</font></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest and Other Income, Net</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net consists of interest earned on our cash equivalents and investment gains and losses recognized during the period.</font></div><div><a name="s1F635ABA326755889FC1B5D2DC39071C"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the Three Months Ended September 30, 2019 and 2018</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following sets forth our results of operations for the three months ended September 30, 2019 and 2018 (dollars in thousands):</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,995</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,870</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,016</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,317</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,699</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,011</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,187</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,824</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(55,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,187</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Change in fair value of convertible note payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,358</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Interest and other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,463</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,702</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,497</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,205</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,735</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,497</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,238</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$40.0</font><font style="font-family:inherit;font-size:10pt;">&#160;million and </font><font style="font-family:inherit;font-size:10pt;">$10.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the three months ended September 30, 2019 and 2018, respectively. The increase of </font><font style="font-family:inherit;font-size:10pt;">$29.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million was driven primarily by increased external costs relating to the advancement of our pipeline candidates of $14.1 million, increased personnel related costs of $11.3 million, of which $5.2 million is increased stock-based compensation expense, and increased allocated building rent and facilities costs of $5.1 million, offset by a decrease in TSA costs of $1.8 million.</font></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses were $</font><font style="font-family:inherit;font-size:10pt;">15.0</font><font style="font-family:inherit;font-size:10pt;">&#160;million and $</font><font style="font-family:inherit;font-size:10pt;">11.3</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the three months ended September 30, 2019 and 2018, respectively. The net increase of $</font><font style="font-family:inherit;font-size:10pt;">3.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million was primarily due to an increase in personnel related costs of $4.6 million, of which $3.0 million is increased stock-based compensation expense, a $0.6 million increase in advisory costs including legal fees and professional consulting fees, offset by a decrease of $1.4 million in expenses incurred under the TSA.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change in Fair Value of 2018 Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in fair value of convertible notes was zero and $19.4 million for the three months ended September 30, 2019 and 2018, respectively. The decrease was directly attributable to the Company&#8217;s progress towards completing an IPO from the issuance date of the 2018 Notes through September 30, 2018. There was no comparative transaction in the three months ended September 30, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense was zero and $3.4&#160;million for the three months ended September&#160;30, 2019 and 2018, respectively. The decrease was due to the debt issuance costs that were expensed during the three months ended September 30, 2018 upon issuance of the 2018 Notes. There was no comparative transaction in the three months ended September 30, 2019.</font></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest and Other Income, Net</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net was $</font><font style="font-family:inherit;font-size:10pt;">4.3</font><font style="font-family:inherit;font-size:10pt;">&#160;million and $</font><font style="font-family:inherit;font-size:10pt;">1.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the three months ended September 30, 2019 and 2018, respectively. The increase of $</font><font style="font-family:inherit;font-size:10pt;">2.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million was due to interest earned on our cash, cash equivalents and investments as our combined cash, cash equivalents and investments balance was $</font><font style="font-family:inherit;font-size:10pt;">601.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million as of September 30, 2019 compared to $398.3 million in cash, cash equivalents and investments as of September 30, 2018.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of the Nine Months Ended September 30, 2019 and 2018</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following sets forth our results of operations for the nine months ended September 30, 2019 and 2018 (dollars in thousands):</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133,356</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,184</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,440</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,821</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137,433</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159,796</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,363</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(159,796</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of convertible note payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,415</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,358</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,120</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(123,740</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180,996</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,256</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Benefit (expense) from income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net Loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(123,564</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180,996</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,432</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$95.2</font><font style="font-family:inherit;font-size:10pt;">&#160;million and </font><font style="font-family:inherit;font-size:10pt;">$133.4</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the nine months ended September 30, 2019 and 2018, respectively. The decrease of $38.2 million was primarily due to a $109.4 million decrease in expense related to the in-process research and development assets with no alternative future use, which was acquired from Pfizer in April 2018. This was offset by an increase of $71.2 million in other research and development expenses, driven primarily by increased personnel related costs of $32.6 million, of which $12.6 million is increased stock-based compensation expense, increased external costs relating to the advancement of our pipeline candidates of $26.1 million, and increased allocated building rent and facilities costs of $13.7 million. These increases were offset by a decrease of $2.5 million in expenses incurred under the TSA.</font></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses were $</font><font style="font-family:inherit;font-size:10pt;">42.3</font><font style="font-family:inherit;font-size:10pt;">&#160;million and $</font><font style="font-family:inherit;font-size:10pt;">26.4</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the nine months ended September 30, 2019 and 2018, respectively. The increase of $15.8 million was primarily due to increased personnel costs of $15.7 million, of which $6.9 million is related to increased stock-based compensation expense, and $1.6 million of increased advisory costs which include legal fees and professional service fees. These increases were offset by a decrease of $2.1 million in transaction costs related to the Pfizer acquisition.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Change in Fair Value of 2018 Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in fair value of convertible notes was zero and $19.4 million for the nine months ended September 30, 2019 and 2018, respectively. The decrease was directly attributable to the Company&#8217;s progress towards completing an IPO from the issuance date of the 2018 Notes through September 30, 2018. There was no comparative transaction in the nine months ended September 30, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense was zero and $3.4&#160;million for the nine months ended September&#160;30, 2019 and 2018, respectively. The decrease was due to the debt issuance costs that were expensed during the nine months ended September 30, 2018 upon issuance of the 2018 Notes. There was no comparative transaction in the nine months ended September 30, 2019.</font></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest and Other Income, Net</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net was $</font><font style="font-family:inherit;font-size:10pt;">13.7</font><font style="font-family:inherit;font-size:10pt;">&#160;million and $</font><font style="font-family:inherit;font-size:10pt;">1.6</font><font style="font-family:inherit;font-size:10pt;">&#32;million for the nine months ended September 30, 2019 and 2018, respectively. The increase of $12.1 million was due to interest earned on our cash equivalents and investments as our combined cash, cash equivalents and investments balance was $</font><font style="font-family:inherit;font-size:10pt;">601.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million as of September 30, 2019 compared to $398.3 million in cash, cash equivalents and investments as of September 30, 2018. Our cash equivalents and investments were also zero for the three months ended March 31, 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><a name="s5B439F35306C522B9827FB6C7ED55F39"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity, Capital Resources and Plan of Operations</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have incurred significant net losses and negative cash flows from operations. As of September 30, 2019, we had $</font><font style="font-family:inherit;font-size:10pt;">601.9</font><font style="font-family:inherit;font-size:10pt;">&#160;million in cash and cash equivalents and investments. We anticipate that the aggregate of our current cash and cash equivalents and investments available for operations will enable us to maintain our operations for a period of at least one year from the date this Quarterly Report on Form 10-Q is filed with the SEC.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with our IPO, we sold an aggregate of 20,700,000 shares of our common stock (inclusive of 2,700,000 shares of common stock pursuant to the over-allotment option granted to the underwriters) at a price of $18.00 per share and received approximately $343.3 million in net proceeds. At the closing of the IPO, our outstanding convertible promissory notes&#160;of $120.2 million in principal amount were automatically converted into 7,856,176 shares of common stock.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Capital Resources</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures related to UCART19, ALLO-501 and ALLO-715, and other research efforts, fund construction projects and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product candidates are still in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain.&#160;&#160;Accordingly, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise capital when needed, we will need to delay, reduce or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans.</font></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes our cash flows for the periods indicated:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(87,083</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,172</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,155</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(319,410</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,486</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">426,660</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase in cash, cash equivalents and restricted cash</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,558</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,078</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cff0fc;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Activities</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine months ended September 30, 2019, cash used in operating activities of $</font><font style="font-family:inherit;font-size:10pt;">87.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million was attributable to a net loss of $123.6 million, partially offset by non-cash charges of $</font><font style="font-family:inherit;font-size:10pt;">36.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million and a net change of $</font><font style="font-family:inherit;font-size:10pt;">0.4</font><font style="font-family:inherit;font-size:10pt;">&#32;million in our net operating assets and liabilities. The non-cash charges consisted primarily of stock compensation expense of $</font><font style="font-family:inherit;font-size:10pt;">32.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million, depreciation of $</font><font style="font-family:inherit;font-size:10pt;">2.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million and non-cash rent expense of $</font><font style="font-family:inherit;font-size:10pt;">4.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million, offset by net accretion on investment securities of $</font><font style="font-family:inherit;font-size:10pt;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million. The change in operating assets and liabilities was primarily due to a $</font><font style="font-family:inherit;font-size:10pt;">7.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million increase in accrued and other current liabilities. This was offset by $</font><font style="font-family:inherit;font-size:10pt;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million decrease in accounts payable, a $</font><font style="font-family:inherit;font-size:10pt;">2.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million decrease in other long-term liabilities, a $</font><font style="font-family:inherit;font-size:10pt;">0.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million decrease in prepaid expenses and other current assets and a $</font><font style="font-family:inherit;font-size:10pt;">2.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million increase in other long-term assets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine months ended September&#160;30, 2018, cash used in operating activities of $23.2&#160;million was attributable to a net loss of $181.0&#160;million, partially offset by non-cash charges of $146.6&#160;million and a net change of $11.2&#160;million in our net operating assets and liabilities. The non-cash charges consisted primarily of acquired in-process research and development expense resulting from the asset acquisition from Pfizer of $109.4&#160;million, change in fair value of convertible notes payable of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$19.4 million&#160;and $12.7&#160;million of stock-based compensation. The&#160;net&#160;change&#160;in operating assets and liabilities was primarily due to a $12.7&#160;million increase in accrued and other liabilities resulting from the timing of payments made to our&#160;collaboration partners and Pfizer and accrued professional and consulting services, a $3.1&#160;million increase in accounts payable driven by increased professional fees and&#160;partially offset by&#160;a $3.1&#160;million increase in prepaid expenses and other current&#160;assets&#160;and a $1.5&#160;million increase in other long-term assets.</font></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investing Activities</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine months ended September 30, 2019, cash provided by investing activities of $</font><font style="font-family:inherit;font-size:10pt;">156.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million was related to investment maturities of $</font><font style="font-family:inherit;font-size:10pt;">355.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million, offset by purchases of investments of $</font><font style="font-family:inherit;font-size:10pt;">162.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million and purchases of property and equipment of $</font><font style="font-family:inherit;font-size:10pt;">36.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine months ended September&#160;30, 2018, cash used in investing activities of $319.4&#160;million was related to the purchase of investments of $315.4 million, cash transaction costs of $2.1 million incurred in the asset acquisition from Pfizer and the purchase of property and equipment of $1.9&#160;million.</font></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financing Activities</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine months ended September 30, 2019, cash provided by financing activities of $</font><font style="font-family:inherit;font-size:10pt;">2.5</font><font style="font-family:inherit;font-size:10pt;">&#160;million was related to net proceeds from the purchase of common stock through the employee stock purchase program of $</font><font style="font-family:inherit;font-size:10pt;">1.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million and net proceeds from the issuance of common stock upon exercise of stock options of $</font><font style="font-family:inherit;font-size:10pt;">0.7</font><font style="font-family:inherit;font-size:10pt;">&#32;million.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the nine months ended September&#160;30, 2018, cash provided by financing activities of $426.7&#160;million was related to net proceeds of $299.3&#160;million from the issuance of our Series A and A-1 convertible preferred stock, $116.8 million in net proceeds from the issuance of the 2018 Notes and $11.4&#160;million from the issuance of common stock in connection with stock option exercises, partially offset by $0.8 million cash payment of deferred offering costs incurred in connection with our IPO.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s51D9D9E0DA79503DBEE400D60C6F90ED"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For our contractual obligations and commitments as of December 31, 2018, please see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Contractual Obligations&#8221; in our Annual Report.&#160;&#160;In the nine months ended September 30, 2019, we entered into a lease agreement for approximately 118,000 square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease has a term of 15 years and 8 months and is expected to commence in May 2020. Upon certain conditions, we have two ten-year options to extend the lease. Subject to rent abatement for the second through nine months of the lease, we will be required to pay $159,150 per month for rent for the first twelve months of the lease term which will increase at a rate of 3% per year.</font></div><div style="line-height:120%;padding-top:24px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commitments</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commitments primarily consist of obligations under our agreements with Pfizer, Cellectis and Servier. Under these agreements we are required to make milestone payments upon successful completion of certain regulatory and sales milestones on a target-by-target and country-by-country basis. The payment obligations under the license agreements are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under these agreements. As of September 30, 2019, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. For additional information regarding our agreements, see &#8220;&#8212;Our Research and Development and License Agreements&#8221; above.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, we have entered into agreements with third-party contract manufacturers for the manufacture and processing of certain of our product candidates for clinical testing purposes, and we have entered and will enter into other contracts in the normal course of business with contract research organizations for clinical trials and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have a Change in Control and Severance Plan that require the funding of specific payments, if certain events occur, such as a change of control and the termination of employment without cause.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><a name="s113E4CEB771A5676A73B9DB4598B2A2E"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</font></div><div><a name="s2AE160D2FE2C5CD4923E08AD081775CE"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that the assumptions and estimates associated with accrued research and development expenditures and stock-based compensation have the most significant impact on our condensed financial statements. Therefore, we consider these to be our critical accounting policies and estimates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Operations&#8221; included in our Annual Report.</font></div><div><a name="s9316D364018A50B6BAA0C21FD97ECD37"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Please refer to Note 2 to our unaudited condensed financial statements appearing under Part 1, Item 1 of this report for a discussion of new accounting standards updates that may impact us.</font></div><div><a name="s3BAA8A611E9056EF96EB6052F4D2CA3C"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate fluctuations.</font></div><div style="line-height:120%;padding-top:24px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our cash, cash equivalents and investments of $</font><font style="font-family:inherit;font-size:10pt;">601.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million as of September 30, 2019 consist of bank deposits, money market funds and available-for-sale securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. A 10% change in the interest rates in effect on September 30, 2019 would not have had a material effect on the fair market value of our cash equivalents and available-for-sale securities.</font></div><div style="line-height:120%;padding-top:24px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Exchange Rate Risk</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our collaboration agreement with Servier requires collaboration payments for shared clinical development costs to be paid in Euros, and thus we face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. An adverse movement in foreign exchange rates could have an effect on payments due and made to our collaboration partner as well as other foreign suppliers and for license agreements. A 10% change in the applicable foreign exchange rates during the periods presented would not have had a material effect on our condensed financial statements. As of September 30, 2019, we had $</font><font style="font-family:inherit;font-size:10pt;">1.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million of liabilities denominated in Euros.</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s705FCBB809EA58CDA2797C728A930A1F"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Controls and Procedures.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An evaluation was also performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial and accounting officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any changes in our internal control over financial reporting during the quarter ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="sEEF1D3C55E915344BC23F2A6AACF1C43"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II-OTHER INFORMATION</font></div><div><a name="sD4E8965FBF215874B4EDA03CE17E5795"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. Legal Proceedings</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.</font></div><div><a name="s4F573D370CCC56C49E63CC47F95A6E96"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A. Risk Factors</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 (Annual Report), which was filed with the Securities and Exchange Commission (SEC) on March 8, 2019.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business and Industry</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have a limited operating history and face significant challenges and expense as we build our capabilities.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We were incorporated in 2017 and acquired certain rights to UCART19, ALLO-501 and ALLO-715 and other allogeneic CAR T cell therapy assets from Pfizer in April 2018. We have a limited operating history and are subject to the risks inherent in any newly-formed organization, including, among other things, risks that we may not be able to hire sufficient qualified personnel and establish operating controls and procedures. Several support services were provided by Pfizer through a Transition Services Agreement (TSA), including certain research and development and general and administrative services, which terminated in September 2019. As we build our own capabilities, we expect to encounter risks and uncertainties frequently experienced by growing companies in new and rapidly evolving fields, including the risks and uncertainties described herein. If we are unable to build and manage our support services in a timely manner, our operating and financial results could differ materially from our expectations, and our business could suffer.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a company, we have not progressed any product candidates through clinical development to commercialization. Our collaboration partner, Servier, conducts the CALM and PALL clinical trials of UCART19, and we cannot be certain that our planned clinical trials of our other product candidates will begin or be completed on time, if at all.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical-stage biopharmaceutical company and investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We have only recently acquired rights to an allogeneic CAR T platform of primarily early-stage product candidates and have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses in each period since our inception. For the year ended December 31, 2018, we reported a net loss of $211.5 million. For the nine months ended September 30, 2019, we reported a net loss of $</font><font style="font-family:inherit;font-size:10pt;">123.6</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;million. As of September 30, 2019, we had an accumulated deficit of $</font><font style="font-family:inherit;font-size:10pt;">335.1</font><font style="font-family:inherit;font-size:10pt;">&#32;million.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase as we continue our research and development of, and seek regulatory approvals for, product candidates based on our engineered allogeneic T cell platform, including UCART19,&#160;ALLO-501 and ALLO-715. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing a pipeline of allogeneic T cell product candidates that are engineered from healthy donor T cells to express CARs and are intended for use in any patient with certain cancers. Advancing these novel product candidates creates significant challenges for us, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing our product candidates to our or regulatory specifications and in a timely manner to support our clinical trials, and, if approved, commercialization;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sourcing clinical and, if approved, commercial supplies for the raw materials used to manufacture our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">understanding and addressing variability in the quality of a donor&#8217;s T cells, which could ultimately affect our ability to produce product in a reliable and consistent manner;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">educating medical personnel regarding the potential side effect profile of our product candidates, if approved, such as the potential adverse side effects related to cytokine release syndrome (CRS), neurotoxicity, graft-versus-host disease (GvHD), prolonged cytopenia and neutropenic sepsis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">using medicines to manage adverse side effects of our product candidates which may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conditioning patients with chemotherapy and&#160;ALLO-647&#160;or other lymphodepletion agents in advance of administering our product candidates, which may increase the risk of adverse side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining regulatory approval, as the U.S. Food and Drug Administration (FDA) and other regulatory authorities have limited experience with development of allogeneic T cell therapies for cancer; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The gene-editing technology we use is relatively new, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cellectis&#8217;s TALEN technology involves a relatively new approach to gene editing, using&#160;sequence-specific&#160;DNA-cutting&#160;enzymes,&#160;or nucleases, to perform precise and stable modifications in the DNA of living-cells and organisms. Although Cellectis has generated nucleases for many specific gene sequences, it has not created nucleases for all gene sequences that we may seek to target, and we may not be able do so, which could limit the usefulness of this technology. This technology may also not be shown to be effective in clinical studies that Cellectis, we or other licensees of Cellectis technology may conduct, or may be associated with safety issues that may negatively affect our development programs.&#160;&#160;For instance, gene-editing may create unintended changes to the DNA such as a non-target site gene-editing, a large deletion, or a DNA translocation, any of which could lead to oncogenesis. The gene-editing of our product candidates may also not be successful in limiting the risk of GvHD or rejection by the patient.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the gene-editing industry is rapidly developing, and our competitors may introduce new technologies that render our technology obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates. As competitors use or develop new technologies, any failures of such technology could adversely impact our program. We also may be placed at a competitive disadvantage, and competitive pressures may force us to implement new technologies at a substantial cost. In addition, our competitors may have greater financial, technical and personnel resources that allow them to enjoy technological advantages and may in the future allow them to implement new technologies before we can. We cannot be certain that we will be able to implement technologies on a timely basis or at a cost that is acceptable to us. If we are unable to maintain technological advancements consistent with industry standards, our operations and financial condition may be adversely affected.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are heavily reliant on our partners for access to key gene editing technology for manufacturing our product candidates and for the development of UCART19,&#160;ALLO-501 and ALLO-501A.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A critical aspect to manufacturing allogeneic T cell product candidates involves gene editing the healthy donor T cells in an effort to avoid GvHD and to limit the patient&#8217;s immune system from attacking the allogeneic T cells. GvHD results when allogeneic T cells start recognizing the patient&#8217;s normal tissue as foreign. We use Cellectis&#8217;s TALEN gene-editing technology to inactivate a gene coding for TCR&#945;, a key component of the natural antigen receptor of T cells, to cause the engineered T cells to be incapable of recognizing foreign antigens. Accordingly, when injected into a patient, the intent is for the engineered T cell </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">not to recognize the tissue of the patient as foreign and thus avoid attacking the patient&#8217;s tissue. In addition, we use TALEN gene editing to inactivate the CD52 gene in donor T cells, which codes for the target of an anti-CD52 monoclonal antibody. Anti-CD52 monoclonal antibodies deplete CD52 expressing T cells in patients while sparing therapeutic allogeneic T cells lacking CD52. By administering an anti-CD52 antibody prior to infusing our product candidates, we believe we have the potential to reduce the likelihood of a patient&#8217;s immune system from rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which the engineered allogeneic T cells can actively target and destroy the cancer cells.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on an agreement with Cellectis for rights to use TALEN and electroporation technology for 15 select cancer targets, including BCMA, FLT3, CD70, DLL3 and other targets included in our pipeline. We also rely on Cellectis, through our agreement with Servier, for rights to UCART19 and ALLO-501. Pursuant to our agreement with Servier, we are also dependent on Servier for us to obtain rights to ALLO-501A from Cellectis. We would need an additional license from Cellectis or access to other gene-editing technology to research and develop product candidates directed at targets not covered by our existing agreements with Cellectis and Servier. In addition, the Cellectis gene-editing technology may fail to produce viable product candidates. Moreover, both Servier and Cellectis may terminate our respective agreements in the event of a material breach of the agreements, or upon certain insolvency events. If our agreements were terminated or we required other gene editing technology, such a license or technology may not be available to us on reasonable terms, or at all, particularly given the limited number of alternative gene-editing technologies in the market.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, under the Servier Agreement, Servier is responsible for conducting the two clinical trials of UCART19, CALM and PALL. We plan to support Servier in advancing the CALM and PALL trials, and we expect Servier to support our clinical trials of&#160;ALLO-501 and ALLO-501A&#160;for the treatment of patients with R/R NHL. Other than the agreed-upon global research and development plan for UCART19, we have limited control over the nature or timing of Servier&#8217;s clinical trials and limited visibility into their&#160;day-to-day&#160;activities. In addition, we rely on Servier for access to data from the UCART19 trials, and as a result at any given time we may not be aware of one or more significant trial developments. If UCART19 encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed. Additionally, other clinical trials being conducted by Servier may at times receive higher priority than research on our programs. Moreover, if Servier does not provide its share of support for the UCART19, ALLO-501&#160;and ALLO-501A clinical trials,&#160;our expenses may be greater than we currently expect and we may have difficulty progressing&#160;our ongoing and planned clinical trials&#160;in a timely manner.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have concentrated our research and development efforts on our engineered allogeneic T cell therapy and our future success depends on the successful development of this therapeutic approach. We are in the early stages of developing our platform and there can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be overcome. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, since we are in the early stages of clinical development, we do not know the doses to be evaluated in pivotal trials or, if approved, commercially. Finding a suitable dose may delay our anticipated clinical development timelines. In addition, our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The clinical study requirements of the FDA, European Medicines Agency (EMA) and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the EMA and FDA for existing autologous CAR T therapies, such as Kymriah and Yescarta, may not be indicative of what these regulators may require for approval of our therapies. Also, while we expect reduced variability in our products candidates compared to autologous products, we do not have significant clinical data supporting any benefit of lower variability.&#160;&#160;More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates. Moreover, our product candidates may not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the autologous CAR T therapies that have previously been approved. For instance, allogeneic product candidates may result in GvHD not experienced with autologous products. Even if we collect promising initial clinical data of our product candidates, longer-term </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">data may reveal new adverse events or responses that are not durable. Unexpected clinical outcomes would significantly impact our business.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business is highly dependent on the success of UCART19, ALLO-501 and ALLO-501A. If we or Servier are unable to obtain approval for UCART19 and ALLO-501A and effectively commercialize UCART19 and ALLO-501A for the treatment of patients in approved indications, our business would be significantly harmed.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business and future success depends on our ability to obtain regulatory approval of, and then successfully commercialize, our most advanced product candidates, UCART19 and ALLO-501A. UCART19 is in the early stages of development and has only been administered in a limited number of patients in Phase 1 clinical trials. The results to date may not predict results for our planned trial or any future studies of UCART19 or any other allogeneic CAR T product candidate. Because UCART19 and ALLO-501 are among the first allogeneic products to be evaluated in the clinic, the failure of either product candidate, or the failure of other allogeneic T cell therapies, may impede our ability to develop ALLO-501A, and significantly influence physicians&#8217; and regulators&#8217; opinions in regards to the viability of our entire pipeline of allogeneic T cell therapies, particularly if high or uncontrolled rates of GvHD are observed. If significant GvHD events are observed with the administration of UCART19, ALLO-501 or ALLO-501A, or if any of the product candidates is viewed as less safe or effective than autologous therapies, our ability to develop other allogeneic therapies may be significantly harmed.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also dependent on Servier to oversee the manufacturing of UCART19 and conduct the UCART19 trials in a timely and appropriate manner. Servier has experienced UCART19 supply issues that limited its ability to recruit new patients. Significant delays in enrollment, due to supply issues or results from the CALM and PALL studies or other reasons, could affect the progress and success of the CALM and PALL clinical trials, our leadership position in the allogeneic CAR T industry and the ability to progress additional product candidates.&#160;&#160;In addition, we expect Servier to submit a revised pediatric investigation plan for UCART19 to the EMA in the first half of 2020. The EMA could reject the revised pediatric investigation plan, which would affect Servier&#8217;s ability to progress the PALL2 clinical trial on the timeframe currently anticipated or at all.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our product candidates, including UCART19 and ALLO-501A, will require additional clinical and&#160;non-clinical&#160;development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. In addition, because UCART19 and ALLO-501 are our most advanced product candidates, and because our other product candidates are based on similar technology, if any of the product candidates encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Undesirable or unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Approved autologous CAR T therapies and those under development have shown frequent rates of CRS and neurotoxicity, and adverse events have resulted in the death of patients. We expect similar adverse events for allogeneic CAR T product candidates. Our allogeneic CAR T cell product candidates undergo gene engineering by using lentivirus and TALEN nucleases that can cause insertion, deletion, or chromosomal translocation.&#160;These changes can cause allogeneic CAR T cells to proliferate uncontrollably and may cause adverse events. In addition, our allogeneic CAR T cell product candidates may cause unique adverse events related to the differences between the donor and patients, such as GvHD or infusion reaction.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the PALL and CALM clinical trials, the most common severe or life threatening adverse events resulted from CRS, prolonged cytopenia and neutropenic sepsis. Multiple patients have died in these trials, including deaths that were attributed to UCART19.  In the future, patients may experience additional adverse events related to the lymphodepletion regimen as well as UCART19, some of which may result in death. As we treat more patients with UCART19 in our clinical trials, new less common side effects may also emerge.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As an anti-CD19 CAR&#160;T cell therapy, we expect&#160;ALLO-501&#160;and ALLO-501A to cause similar toxicities as UCART19. Other of our allogeneic CAR T product candidates may also cause similar or worse toxicities. For instance, because ALLO-715 may require a higher dose than UCART19 and could be used in a more elderly patient population, it is possible that the risk of GvHD or other adverse events for ALLO-715 could be greater than UCART19.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If unacceptable toxicities arise in the development of our product candidates, we or Servier could suspend or terminate our trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. The data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T&#160;cell therapy are not normally encountered in the general patient population and by medical personnel. We have trained and expect to have to train medical personnel using CAR T&#160;cell product candidates to understand the side effect profile of our product candidates for both our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before obtaining regulatory approvals for the commercial sale of our product candidates, including UCART19, ALLO-501A and ALLO-715, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, including in any post-approval studies.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, for ongoing and any future trials that may be completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interim &#8220;top line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we may publish interim &#8220;top line&#8221; or preliminary data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For instance, we and Servier have published preliminary data from the CALM and PALL clinical trials, however such results are preliminary in nature, do not bear statistical significance and should not be viewed as predictive of ultimate success. It is possible that such results will not continue or may not be repeated in ongoing or future clinical trials of UCART19 or our other product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preliminary or &#8220;top line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to submit INDs for additional product candidates in the future. We cannot be sure that submission of an IND or IND amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials.  The manufacturing of allogeneic CAR T cell therapy remains an emerging and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">evolving field. Accordingly, we expect chemistry, manufacturing and control related topics, including product specification, will be a focus of IND reviews, which may delay the clearance of INDs. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if our trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical study can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical studies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulty sourcing healthy donor material of sufficient quality and in sufficient quantity to meet our development needs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in reaching a consensus with regulatory agencies on study design;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in obtaining required institutional review board (IRB) approval at each clinical study site;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology broadly; or if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in recruiting suitable patients to participate in our clinical studies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulty collaborating with patient groups and investigators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure by our CROs, other third parties or us to adhere to clinical study requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to perform in accordance with the FDA&#8217;s good clinical practice (GCP) requirements or applicable regulatory guidelines in other countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">transfer of manufacturing processes to any new contract manufacturing organization (CMO) or our own manufacturing facilities or any other development or commercialization partner for the manufacture of product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in having patients complete participation in a study or return for post-treatment&#160;follow-up;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patients dropping out of a study;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of clinical studies of our product candidates being greater than we anticipate;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical studies of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Monitoring and managing toxicities in patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For our clinical trials of UCART19, ALLO-501 and ALLO-715 and in our planned clinical trials of other product candidates, we and Servier contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using our product candidates, if approved, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of our product candidates may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment. Use of these medicines may increase with new physicians and centers administering our product candidates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the patient eligibility criteria defined in the protocol;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the proximity of patients to study sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the design of the trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain and maintain patient consents; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, prior treatment with rituximab may interfere with ALLO-501 as ALLO-501 contains rituximab recognition domains.&#160;&#160;Since rituximab is a typical part of a treatment regimen for a patient with NHL, patient eligibility for the ALLO-501 trial may be limited. Patients may also undergo plasmapheresis to remove rituximab prior to infusion of ALLO-501, which may cause separate adverse effects. We have removed the rituximab recognition domains in the second generation of ALLO-501, known as ALLO-501A, which we believe will potentially facilitate treatment of patients who were recently treated with rituximab. However, we may have difficultly manufacturing or otherwise advancing ALLO-501A.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trials will also compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites are also being used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic cell transplantation or autologous CAR T&#160;cell therapies, rather than enroll patients in our clinical trial. Patients eligible for allogeneic CAR T&#160;cell therapies but ineligible for autologous CAR T&#160;cell therapies due to aggressive cancer and inability to wait for autologous CAR T&#160;cell therapies may be at greater risk for complications and death from therapy.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical trials are expensive, time-consuming and difficult to design and implement.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our allogeneic T cell product candidates are based on new technologies and will require the creation of inventory of mass-produced,&#160;off-the-shelf&#160;product, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. In addition, costs to treat patients with R/R cancer and to treat potential side effects that may result from our product candidates can be significant. We also have less control of costs incurred by our development partner, Servier, for the clinical trials of UCART19. Accordingly, our clinical trial costs are likely to be significantly higher than for more conventional therapeutic technologies or drug products.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA often approves new therapies initially only for use in patients with R/R metastatic disease. We expect to initially seek approval of our product candidates in this setting. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment. There is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials, including potentially comparative trials against approved therapies. We are also targeting a similar patient population as autologous CAR T product candidates, including approved autologous CAR T products. Our therapies may not be as safe and effective as autologous CAR T therapies and may only be approved for patients who are ineligible for autologous CAR T therapy.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our projections of both the number of patients who have the cancers we are targeting, as well as the subset of patients with these cancers in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we expect our most advanced product candidate, UCART19, to initially target a small patient population that suffers from R/R ALL. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to develop additional product candidates, our commercial opportunity will be limited.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">One of our core strategies is to pursue clinical development of additional product candidates beyond UCART19, including&#160;ALLO-501&#160;and&#160;ALLO-715.&#160;Developing, obtaining regulatory approval and commercializing additional CAR T&#160;cell product candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that we will be able to successfully advance any of these additional product candidates through the development process.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if we receive FDA approval to market additional product candidates for the treatment of cancer, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity will be limited. Moreover, a failure in obtaining regulatory approval of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional product candidates may have a negative effect on the approval process of any other, or result in losing approval of any approved, product candidate.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our development strategy relies on incorporating an anti-CD52 monoclonal antibody as part of the lymphodepletion preconditioning regimen prior to infusing allogeneic CAR T cell product candidates.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We utilize an anti-CD52 monoclonal antibody as part of a lymphodepletion regimen to be infused prior to infusing our product candidates, such as UCART19,&#160;ALLO-501 and&#160;ALLO-715.&#160;While we believe an anti-CD52 antibody may be able to reduce the likelihood of a patient&#8217;s immune system rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which such engineered allogeneic T cells can actively target and destroy cancer cells, the antibody may not have the benefits that we anticipate and could have adverse effects. For instance, our lymphodepletion regimen, including using an anti-CD52 antibody, will cause a transient and sometimes prolonged immune suppression.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ongoing CALM and PALL trials, we use a commercially available monoclonal antibody, alemtuzumab, that binds CD52. Alemtuzumab is known to have risk of causing certain adverse events.&#160;&#160;The EMA is currently reviewing alemtuzamab in the context of the treatment of multiple sclerosis following reports of immune-mediated conditions and problems affecting the heart and blood vessels, including fatal cases. If the EMA limits the use of alemtuzumab or anti-CD52 antibodies, our clinical program would be adversely affected.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To secure our own readily available source of anti-CD52 antibody, we are developing our own monoclonal anti-CD52 antibody,&#160;ALLO-647.&#160; We are using ALLO-647 in our clinical trial of ALLO-501 and ALLO-715. Subject to regulatory acceptance, Servier may also use ALLO-647 in the Servier sponsored clinical trials of UCART19. However, we may be unable to agree with Servier an appropriate arrangement for the use of&#160;ALLO-647. ALLO-647 may also cause adverse events, such as those events that alemtuzumab may cause. In addition, we may explore a higher dose of ALLO-647 in our clinical trial of ALLO-501, which may increase the risk of adverse events.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to successfully develop and manufacture&#160;ALLO-647&#160;in the timeframe we anticipate, or at all, or if the FDA does not approve the use of&#160;ALLO-647 in combination with our allogeneic T cell product candidates, we may be unable to source alemtuzumab and our engineered allogeneic T cell product candidates may be less effective, which could result in delays in our product development efforts and/or the commercial potential of our product candidates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We intend to operate our own manufacturing facility, which will require significant resources and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not be able to achieve clinical or commercial manufacturing and cell processing on our own or at our CMO, including mass-producing&#160;off-the-shelf&#160;product to satisfy demands for any of our product candidates. While we believe the manufacturing and processing approaches are appropriate to support our clinical product development, we have limited experience in managing the allogeneic T cell engineering process, and our allogeneic processes may be more difficult or more expensive than the approaches taken by our competitors. We cannot be sure that the manufacturing processes employed by us or the technologies that we incorporate for manufacturing will result in T cells that will be safe and effective.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2019, we entered into a lease for approximately 118,000 square feet to develop a state-of-the-art cell therapy manufacturing facility in Newark, California. The facility requires substantial improvements and there can be no assurance that we will complete the build-out of our manufacturing facility in a timely manner or at all.&#160;&#160;We also do not yet have sufficient information to reliably estimate the cost of the clinical and commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. In addition, the ultimate clinical and any commercial dose will affect our ability to scale and our costs per dose. For instance, because ALLO-715 may require a higher dose than ALLO-501, it is possible that it may be more difficult to scale ALLO-715 production.&#160;&#160;As a result, we may never be able to develop a commercially viable product.&#160;The commercial manufacturing facility we build will also require FDA approval, which we may never obtain. Even if approved, we would be subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with current good manufacturing practices (cGMPs), and other government regulations.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. The application of new regulatory guidelines or parameters, such as those related to release testing, may also adversely affect our ability to manufacture our product candidates. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We or our CMO may fail to manage the logistics of storing and shipping our raw materials and product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in the inability to manufacture product, the loss of usable product or prevent or delay the delivery of product candidates to patients.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also experience manufacturing difficulties due to resource constraints or as a result of labor disputes. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently have no marketing and sales organization and as a company have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. We intend to develop an&#160;in-house&#160;marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There can be no assurance that we will be able to develop&#160;in-house&#160;sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product that receives regulatory approval in the United States or in other markets.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The CALM&#160;&#160;and PALL clinical trials are currently being conducted in the United States and multiple countries in Europe, and we plan to globally develop our future product candidates. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">differing regulatory requirements in foreign countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">differing standards for the conduct of clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States and shipping the product candidate to the patient abroad;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">import and export requirements and restrictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">foreign taxes, including withholding of payroll taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulties staffing and managing foreign operations;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">workforce uncertainty in countries where labor unrest is more common than in the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">differing payor reimbursement regimes, governmental payors or patient&#160;self-pay&#160;systems, and price controls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">business interruptions resulting from&#160;geo-political&#160;actions, including war and terrorism.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These and other risks associated with our international operations and our collaborations with Servier and Cellectis, each based in France, and with Notch Therapeutics Inc. (Notch), based in Canada, may materially adversely affect our ability to attain or maintain profitable operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The biopharmaceutical industry, and the immuno-oncology industry specifically, is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specifically, engineered T cells face significant competition from multiple companies. Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For additional information regarding our competition, see &#8220;Item 1. Business&#8212;Competition&#8221; in our Annual Report.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Executive Chairman, our President and Chief Executive Officer, our Chief Financial Officer, our Executive Vice President of Research &amp; Development and Chief Medical Officer, and our Chief Technical Officer. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conduct substantially all of our operations at our facilities in South San Francisco. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock unit (RSU) awards that vest over time. The value to employees of stock options and RSU awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for&#160;at-will&#160;employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior,&#160;mid-level&#160;and senior managers as well as junior,&#160;mid-level&#160;and senior scientific and medical personnel.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of November 4, 2019, we had 190 full-time employees. As our development and commercialization plans and strategies develop, and as we continue to transition into operating as a public company, we have rapidly expanded our employee base and expect to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">identifying, recruiting, integrating, maintaining and motivating additional employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">improving our operational, financial and management controls, reporting systems and procedures.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of its attention away from&#160;day-to-day&#160;activities in order to devote a substantial amount of time to managing these growth activities.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants.&#160;&#160;In September 2019, we terminated support services previously provided by Pfizer, and our internal build-out of such services may disrupt our operations and be more expensive than we expect. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. We may also be subject to penalties or other liabilities if we mis-classify employees as consultants. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur&#160;non-recurring&#160;and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. For instance, our agreements with Servier and Notch require significant research and development commitments that may not result in the development and commercialization of product candidates.&#160;We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not realize the benefits of acquired assets or other strategic transactions.*</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, including our acquisition of CAR T cell assets from Pfizer, licenses with Cellectis, Servier and Notch, and any future strategic transactions depends on the risks and uncertainties involved including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated liabilities related to acquired companies or joint ventures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulties integrating acquired personnel, technologies and operations into our existing business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">retention of key employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increases in our expenses and reductions in our cash available for operations and other uses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disruption in our relationships with collaborators or suppliers as a result of such a transaction; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">possible write-offs or impairment charges relating to acquired businesses or joint ventures.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to spend a substantial amount of capital in the development and manufacture of our product candidates, including UCART19,&#160;ALLO-501&#160;and&#160;ALLO-715.&#160;We will need substantial additional financing to develop our products and implement our operating plans. In particular, we will require substantial additional financing to enable commercial production of our products and initiate and complete registration trials for multiple products. Further, if approved, we will require significant additional amounts in order to launch and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of September 30, 2019, we had $</font><font style="font-family:inherit;font-size:10pt;">601.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million in cash, cash equivalents and investments. Changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may also need to raise additional capital sooner than we currently anticipate if we choose to expand more rapidly than we presently plan. In any event, we will require additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the payment obligations under the agreements. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our internal computer systems, or those used by our CROs, collaborators or other contractors or consultants, may fail or suffer security breaches.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our internal computer systems and those of our CROs, collaborators, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, cybersecurity threats, and telecommunication and electrical failures. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in funding for the&#160;FDA, the SEC&#160;and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the&#160;FDA and the SEC, have had to furlough critical&#160;FDA, SEC and other government&#160;employees and stop critical activities. If a prolonged government shutdown&#160;occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operations, and those of our CMO, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or&#160;man-made&#160;disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to manufacture our product candidates could be disrupted if our operations or those of our suppliers are affected by a&#160;man-made&#160;or natural disaster or other business interruption. Our corporate headquarters and planned manufacturing facility are located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal, state, local and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These laws may impact, among other things, our clinical research program, as well as our proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of identifiable patient information. The U.S. healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully, offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchasing, leasing, ordering or arranging for the purchase, lease, or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that may be alleged to be intended to induce prescribing, purchases or recommendations, include any payments of more than fair market value, and may be subject to scrutiny if they do not qualify for an exception or safe harbor. In addition, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act and the civil monetary penalties statute;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal government programs that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government, including federal healthcare programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services&#8217; (HHS) Centers for Medicare&#160;&amp; Medicaid Services (CMS) information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, we may be subject to state, local and foreign equivalents of each of the healthcare laws described above, among others, some of which may be broader in scope. For example, we may be subject to the following: state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by&#160;non-governmental&#160;third party payors, including private insurers, or that apply regardless of payor; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of information related to drug pricing; state and local laws requiring the registration of pharmaceutical sales and medical representatives; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, or our arrangements with physicians, some of who receive stock options as compensation, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions and/or significant penalties. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of&#160;non-compliance&#160;with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The collection and use of personal data in the European Union (EU) are governed by the General Data Protection Regulation (GDPR). The GDPR imposes stringent requirements for controllers and processors of personal data, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, California recently enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States.&#160;&#160;Known as the California Consumer Privacy Act (CPPA), it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households.&#160;&#160;When it goes into effect on January 1, 2020, the CCPA will require covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. Legislators have stated that amendments will be proposed to the CCPA before it goes into effect, but it remains unclear what, if any, modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact (possibly significantly) our business activities and exemplifies the vulnerability of our business to evolving regulatory environment related to personal data and protected health information.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased demand for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injury to our reputation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">initiation of investigations by regulators;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs to defend the related litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a diversion of management&#8217;s time and our resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial monetary awards to trial participants or patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss of revenue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exhaustion of any available insurance and our capital resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability to commercialize any product candidate; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a decline in our share price.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. While we have obtained clinical trial insurance for our ALPHA trial and UNIVERSAL trial, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The global credit and financial markets have experienced extreme volatility and disruptions in the past, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Our portfolio of corporate and government bonds would also be adversely impacted.&#160;&#160;Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under Sections&#160;382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income and taxes may be limited. As a result of our private placements, IPO and other transactions that have occurred in 2018, we may have experienced, an &#8220;ownership change.&#8221; We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. We anticipate incurring significant additional net losses for the foreseeable future, and our ability to utilize net operating loss carryforwards associated with any such losses to offset future taxable income may be limited to the extent we incur future ownership changes. In addition, at the state level, there may be periods during which the use of net operating loss </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could adversely affect our future cash flows.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Reliance on Third Parties</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely and will continue to rely on third parties, including Servier, to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners to conduct our preclinical and clinical trials under agreements with us. In addition, we depend on our collaborator, Servier, to sponsor and lead the conduct of the CALM and PALL clinical trials.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with good clinical practices (GCPs), which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Servier is responsible for UCART19 manufacturing and is working with a CMO in Europe to provide clinical supply for the CALM and PALL clinical trials. Servier has experienced UCART19 supply issues that limited its ability to recruit new patients. ALLO-501&#160;has the same molecular design as UCART19, but is produced by a different CMO using a different manufacturing process. ALLO-501 and&#160;ALLO-715&#160;will be manufactured in the United States, at least initially, by a CMO, and we will manage other aspects of the supply, including planning, CMO oversight, disposition and distribution logistics. There can be no assurance that we or Servier will not experience additional supply or manufacturing issues in the future.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we have leased space to build a manufacturing facility, we must currently rely on outside vendors to manufacture supplies and process our product candidates. We do not have long-term agreements in place with CMOs for the manufacture of our cell therapies or of ALLO-647.  If we are unable to contract with CMOs on acceptable terms or at all, our clinical development program would be delayed and our business would be significantly harmed. </font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to achieve manufacturing and processing and may be unable to create an inventory of mass-produced,&#160;off-the-shelf&#160;product to satisfy demands for any of our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our third-party manufacturers could breach or terminate their agreement with us.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. For instance, our CMO has certain responsibilities for storage of raw materials, and the damage or loss of such raw materials could materially impact our ability to manufacture and supply our product candidates. Each of these risks could delay our clinical trials, the approval, if any of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product candidates require many specialty raw materials, including viral vectors that deliver the CAR sequence and electroporation technology that we currently obtain through Cellectis, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. We do not have contracts with many of the suppliers, and we may not be able to contract with them on acceptable terms, or at all. Accordingly, we may experience delays in receiving, or fail to secure entirely, key raw materials to support clinical or commercial manufacturing. Certain raw materials also require third-party testing, and some of the testing service companies may not have capacity or be able to conduct the testing that we request.&#160;&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, many of our suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be&#160;ill-equipped&#160;to support our needs, especially in&#160;non-routine&#160;circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also face competition for supplies from other cell therapy companies.&#160;&#160;Such competition may make it difficult for us to secure raw materials or the testing of such materials on commercially reasonable terms or in a timely manner.&#160;&#160;</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unlike autologous CAR T companies, we are also reliant on receiving healthy donor material to manufacture our product candidates. Variation in donor material or delay in receiving donor material that meets our specifications, including specifications required by regulatory authorities, could adversely affect our ability to manufacture sufficient supply of our product candidates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that we and our suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Government Regulation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive approval of a biologics license application (BLA) from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of allogeneic T cell therapies for cancer. We may also request regulatory approval of future&#160;CAR-based&#160;product candidates by target, regardless of cancer type or origin, which the FDA may have difficulty accepting if our clinical trials only involved cancers of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining regulatory authorization to begin a trial, if applicable;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of financial resources to commence and complete the planned trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining approval at each clinical trial site by an independent IRB;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recruiting suitable patients to participate in a trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment&#160;follow-up;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical trial sites deviating from trial protocol or dropping out of a trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">addressing any patient safety concerns that arise during the course of a trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adding new clinical trial sites; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing sufficient quantities of qualified materials under cGMPs and delivering product candidates for use in clinical trials.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. The FDA&#8217;s review of our data of our ongoing clinical trials of UCART19, ALLO-501 and ALLO-715 may, depending on the data, also result in the delay, suspension or termination of one or more clinical trials of UCART19, ALLO-501 and ALLO-715, which would also delay or prevent the initiation of our other planned clinical trials. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for&#160;the&#160;12-year&#160;period&#160;of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">that is similar to traditional generic substitution&#160;for&#160;non-biological&#160;products&#160;is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we are developing novel CAR&#160;T cell&#160;immunotherapy product candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies (OTAT), formerly known as the Office of Cellular, Tissue and Gene Therapies (OCTGT), within its Center for Biologics Evaluation and Research (CBER) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the EU a special committee called the Committee for Advanced Therapies (CAT) was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products (ATMPs) to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. In this regard, on May&#160;28, 2014, the EMA issued a recommendation that UCART19 be considered a gene therapy product under Regulation (EC) No 1394/2007 on ATMPs. We believe this recommendation is likely to be applicable to our UCART19 product candidate; however, this recommendation is not definitive until UCART19 obtains regulatory approval for commercialization.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAR&#160;T cell&#160;immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If and when our ongoing and planned Phase 1 clinical trials for UCART19 and ALLO-715 are completed and, assuming positive data, we expect to advance to potential registrational trials. The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. We expect registrational trials for UCART19 and ALLO-715 to be designed to evaluate the efficacy of the product candidate in an open-label, non-comparative,&#160;two-stage,&#160;pivotal, multicenter,&#160;single-arm&#160;clinical trial in patients who have exhausted available treatment options. If the results are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for the relevant product candidate. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA. For </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">example, the FDA may require that we conduct a comparative trial against an approved therapy including potentially an approved autologous T cell therapy, which would significantly delay our development timelines and require substantially more resources. In addition, the FDA may only allow us to evaluate patients that have failed or who are ineligible for autologous therapy, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our product candidates may fail to improve outcomes for such patients.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Given the molecular similarities between UCART19, ALLO-501 and ALLO-501A, we may have additional difficulties progressing any clinical trial of ALLO-501A, if emerging data from the clinical trials of ALLO-501 or UCART19 have safety or other issues.  In addition, the protocol amendment for ALLO-501 is subject to FDA review, and any adverse review may limit our ability to progress ALLO-501 and ALLO-501A.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. We believe our accelerated approval strategy is warranted given the limited alternatives for patients with R/R cancers, but the FDA may ultimately require a Phase&#160;3 clinical trial prior to approval, particularly since our product candidates represent a novel treatment. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ALLO-647 will also require regulatory review prior to its use in new clinical trials and the FDA may not accept the use of ALLO-647 in our clinical trials in a timely manner or at all. In addition, we cannot be certain we will be able to successfully obtain regulatory approval of ALLO-647 in a timely manner or at all. Any delays to ALLO-647 approval could delay any approval or commercialization of our allogeneic T cell product candidates. Additionally, regulatory authorities may seek to understand the contribution of the lymphodepletion regimen, including the use of an anti-CD52 antibody, to any treatment effect.&#160;&#160;</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility and may not approve our manufacturing process or facility; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</font></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and&#160;user-fee&#160;waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such designations.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regenerative Medicine Advanced Therapy designation, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may seek Regenerative Medicine Advanced Therapy (RMAT) designation for one or more of our product candidates. In 2017, the FDA established the RMAT designation to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. There is no assurance that we will be able to obtain RMAT designation for any of our product candidates. RMAT designation does not change the FDA&#8217;s standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategy, or REMS, in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and cGCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for&#160;direct-to-consumer&#160;advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved uses (known as&#160;&#8220;off-label&#160;use&#8221;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fines, warning letters or holds on clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions or the imposition of civil or criminal penalties.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. President&#8217;s administration may impact our business and industry. Namely, the current U.S. President&#8217;s administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, FDA&#8217;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose restrictions on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The gene-editing technologies that we use are novel. Public perception may be influenced by claims that gene editing is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in our targeted diseases prescribing our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of gene editing may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments or participate in clinical trials for our product candidates. In addition, given the novel nature of gene-editing and cell therapy technologies, governments may place import or export restrictions in order to retain control of the technologies. Increased negative public opinion or more restrictive government regulations either in the United States or internationally, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for such product candidates.&#160;&#160;</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The use of engineered T cells as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. We expect physicians in the large bone marrow transplant centers to be particularly influential and we may not be able to convince them to use our product candidates for many reasons. For example, certain of the product candidates that we will be developing target a cell surface marker that may be present on cancer cells as well as&#160;non-cancerous&#160;cells. It is possible that our product candidates may kill these&#160;non-cancerous&#160;cells, which may result in unacceptable side effects, including death. Additional factors will influence whether our product candidates are accepted in the market, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the clinical indications for which our product candidates are approved;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the potential and perceived advantages of our product candidates over alternative treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the prevalence and severity of any side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product labeling or product insert requirements of the FDA or other regulatory authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations or warnings contained in the labeling approved by the FDA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing of market introduction of our product candidates as well as competitive products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of treatment in relation to alternative treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of coverage and adequate reimbursement by third-party payors and government authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the willingness of patients to pay&#160;out-of-pocket&#160;in the absence of coverage and adequate reimbursement by third-party payors and government authorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effectiveness of our sales and marketing efforts.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a product is:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a covered benefit under its health plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">safe, effective and medically necessary;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">appropriate for the specific patient;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cost-effective; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">neither experimental nor investigational.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require&#160;co-payments&#160;that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers, and reduce the willingness of physicians to use our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from&#160;low-priced&#160;markets exert a commercial pressure on pricing within a country.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably. In particular, in 2010 the Affordable Care Act was enacted. The Affordable Care Act and its implementing regulations, among other things, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs and certain biologics, including our product candidates, under the Medicaid drug rebate program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid drug rebate program, extended the Medicaid drug rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. Additionally, the Affordable Care Act allowed states to implement expanded eligibility criteria for Medicaid programs, imposed a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service pharmaceutical pricing program and implemented a new Patient-Centered Outcomes Research Institute. We are still unsure of the full impact that the Affordable Care Act will have on our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of the provisions of the Affordable Care Act have yet to be implemented, and there have been legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, the U.S. President has signed two Executive Orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. In December 2017, Congress repealed the tax penalty for an individual&#8217;s failure to maintain Affordable Care&#160;Act-mandated&#160;health insurance, commonly known as the &#8220;individual mandate&#8221;, as part of the Tax Cuts and Jobs Act of 2017 (Tax Act). On January&#160;22, 2018, the U.S. President signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care&#160;Act-mandated fees, including the&#160;so-called&#160;&#8220;Cadillac&#8221; tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share,&#160;and the medical device excise tax on&#160;non-exempt&#160;medical devices. The Bipartisan Budget Act of 2018 (BBA), among other things, amended the Affordable Care Act, effective January&#160;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. In July 2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act qualified health plans and health insurance issuers under the Affordable Care Act risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April&#160;1, 2013 and will stay in effect through 2027, unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance programs, and reform government program reimbursement methodologies for drugs. At the federal level, the U.S. President&#8217;s administration&#8217;s budget proposal for fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for&#160;low-income&#160;patients. Further, the current U.S. President&#8217;s administration released a &#8220;Blueprint&#8221;, or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. HHS has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step therapy for Part B drugs beginning January 1, 2019, and in October 2018, CMS proposed a rule that would require direct-to-consumer television advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product. On January 31, 2019, the HHS Office of Inspector General proposed modifications to federal Anti-Kickback Statute safe harbors which, among other things, may affect rebates paid by manufacturers to Medicare Part D plans, the purpose of which is to further reduce the cost of drug products to consumers. While some of these and other proposed measures may require authorization through additional legislation to become effective, Congress and the current U.S. President&#8217;s administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the demand for our product candidates, if we obtain regulatory approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to set a price that we believe is fair for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to generate revenue and achieve or maintain profitability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the level of taxes that we are required to pay; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of capital.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are dependent on patents,&#160;know-how&#160;and proprietary technology, both our own and licensed from others.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We depend substantially on our license agreements with Pfizer, Servier and Cellectis. These licenses may be terminated upon certain conditions. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates. For example, we are dependent on our license with Cellectis for gene-editing technology that is necessary to produce our engineered T cells. In addition, we are reliant on Servier&#160;in-licensing from Cellectis&#160;some of the intellectual property rights they are licensing to us, including certain intellectual property rights relating to ALLO-501. To the extent these licensors fail to meet their obligations under their license agreements, which we are not in control of, we may lose the benefits of our license agreements with these licensors. In the future, we may also enter into additional license agreements that are material to the development of our product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those related to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the ownership of inventions and&#160;know-how&#160;resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely upon a combination of patents, trade secret protection and license agreements to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have an exclusive collaboration with Servier to develop and commercialize UCART19 and ALLO-501, and we hold the commercial rights to these product candidates in the United States. We also have an exclusive worldwide license from Cellectis to its TALEN gene-editing technology for the development of allogeneic T cell product candidates directed against 15 different cancer antigens. Our collaboration with Servier gives us access to TALEN gene-editing technology for all product candidates under the Servier Agreement. Certain intellectual property which is covered by these agreements may have been developed with funding from the U.S. government. If so, our rights in this intellectual property may be subject to certain research and other rights of the government.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional patent applications have been filed, and we anticipate additional patent applications will be filed, both in the United States and in other countries, as appropriate. However, we cannot predict:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if and when patents will issue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Composition of matter patents for biological and pharmaceutical products such as&#160;CAR-based&#160;product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products&#160;&#8220;off-label.&#8221;&#160;Although&#160;off-label&#160;prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or&#160;in-license&#160;may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the patentability, validity, enforceability or scope thereof, for example through inter partes review (IPR) post-grant review or ex parte reexamination before the USPTO or oppositions and other comparable </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">proceedings in foreign jurisdictions, which may result in such patents being cancelled, narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. United States patent applications containing or that at any time contained a claim not entitled to a priority date before March&#160;16, 2013 are subject to the &#8220;first to file&#8221; system implemented by the America Invents Act (2011).</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This first to file system will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for United States applications in which all claims are entitled to a priority date before March&#160;16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For United States applications containing a claim not entitled to priority before March&#160;16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the United States patent laws, including new procedures for challenging patent applications and issued patents.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary&#160;know-how&#160;that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary&#160;know-how,&#160;information or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. Although we require all of our employees to assign their inventions to us, and require all of our employees and key consultants who have access to our proprietary&#160;know-how,&#160;information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize our product candidates.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third parties may assert that we infringe their patents or are otherwise employing their proprietary technology without authorization and may sue us. We are aware of several U.S. patents held by third parties relating to certain CAR compositions of matter and their methods of use. Generally, conducting clinical trials and other development activities in the United States is not considered an act of infringement. If and when UCART19, ALLO-501A, ALLO-715 or another&#160;CAR-based&#160;product candidate is approved by the FDA, third parties may then seek to enforce their patents by filing a patent infringement lawsuit against us. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. We may not be able to prove in litigation that any patent enforced against us is invalid.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, there may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">result in issued patents that our product candidates may be alleged to infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held not infringed, unpatentable, invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held not infringed, unpatentable, invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and&#160;in-licenses.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Presently we have rights to the intellectual property, through licenses from third parties and under patent applications that we own or will own, that we believe will facilitate the development of UCART19 and our other product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire,&#160;in-license&#160;or use these proprietary rights.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to acquire or&#160;in-license&#160;any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be&#160;non-exclusive,&#160;thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put one or more of our pending patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits,&#160;non-payment&#160;of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The lives of our patents may not be sufficient to effectively protect our products and business.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We or our licensors may in the future be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or&#160;co-inventor.&#160;For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we or our licensors are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include IPR, ex parte&#160;re-examination&#160;and post grant review in the United States, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of unpatentability, invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</font><font style="font-family:inherit;font-size:10pt;">, the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not be able to protect our intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Ownership of Our Common Stock</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to our IPO in October 2018, there was no public market for our common stock. We cannot assure you that an active, liquid trading market for our shares will develop or persist. You may not be able to sell your shares quickly or at a recently reported market price if trading in our common stock is not active. The trading price of our common stock following our IPO has been and is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, these factors include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the commencement, enrollment or results of our ongoing and planned clinical trials of our product candidates or any future clinical trials we or Servier may conduct, or changes in the development status of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our or Servier&#8217;s decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse results or delays in clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our failure to commercialize our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse developments concerning the manufacture or supply of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our inability to establish collaborations if needed;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additions or departures of key scientific or management personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unanticipated serious safety concerns related to immuno-oncology or related to the use of our product candidates or pre-conditioning regimen;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">introduction of new products or services offered by us or our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to effectively manage our growth;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the size and growth of our initial cancer target markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to successfully treat additional types of cancers or at different stages;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">actual or anticipated variations in quarterly operating results;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our cash position;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the market valuations of similar companies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">overall performance of the equity markets;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of our common stock by us or our stockholders in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">trading volume of our common stock;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in accounting practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ineffectiveness of our disclosure controls or internal controls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disagreements with our auditor or termination of an auditor engagement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the structure of healthcare payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant lawsuits, including patent or stockholder litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general political and economic conditions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other events or factors, many of which are beyond our control.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the stock market in general, and the Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are an emerging growth company, as defined in the JOBS Act enacted in April 2012. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the completion of our IPO, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by&#160;non-affiliates&#160;to exceed $700&#160;million as of the prior June&#160;30th, and (2)&#160;the date on which we have issued more than $1&#160;billion in&#160;non-convertible&#160;debt during the prior three-year period.  We expect that we will no longer be an emerging growth company on December 31, 2019.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to various compliance initiatives.*</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), which requires, among other things, that we file with the Securities and Exchange Commission (SEC) annual, quarterly and current reports with respect to our business and financial condition.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;">In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and the Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) was enacted, pursuant to which the SEC adopted rules and regulations related to corporate governance and executive compensation, such as &#8220;say on pay&#8221; and proxy access. Emerging growth companies are permitted to implement many of these requirements over time, however we expect that we will no longer be an emerging growth company on December 31, 2019 and expect to incur additional compliance-related expenses as a result. </font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect the rules and regulations applicable to public companies to continue to increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations make it difficult and expensive for us to maintain director and officer liability insurance. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate, and make it more difficult for you to sell shares of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain holders of our securities are entitled to rights with respect to the registration of their shares under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</font></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have registered on Form S-8 all shares of common stock that are issuable under our 2018 Plan. As a consequence, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to the 2018 Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. We may also sell our common stock as part of entering into strategic alliances, creating joint ventures or collaborations or entering into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the 2018 Plan, our management is authorized to grant stock options and RSU awards to our employees, directors and consultants. We have registered on Form S-8 all shares of common stock that are issuable under our 2018 Plan. Additionally, the number of shares of our common stock reserved for issuance under the 2018 Plan will automatically increase on January&#160;1 of each year and continuing through and including January&#160;1, 2028, by&#160;5% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have broad discretion in the use of the net proceeds from our IPO and our prior financings and may not use them effectively.*</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management has broad discretion in the application of the net proceeds from our IPO, including for any of the purposes described in the section of our final prospectus, filed with the SEC on October 11, 2018, titled &#8220;Use of Proceeds&#8221;. Because of the number and variability of factors that will determine our use of the net proceeds from our IPO, their ultimate use may vary substantially from the use described in the final prospectus. Our management might not apply our net proceeds or our net proceeds from prior financings in ways that ultimately increase the value of your investment. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest the net proceeds from our IPO and prior financings in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from our IPO and prior financings in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than&#160;two-thirds&#160;of all outstanding shares of our voting stock then entitled to vote in the election of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a requirement of approval of not less than&#160;two-thirds&#160;of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-top:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if the clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more analysts do not initiate coverage of us, cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</font></div><div><a name="sBA1EE90C86555D2193950C4E882AEC8B"></a></div><div style="line-height:120%;padding-top:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Proceeds from our Initial Public Offering of Common Stock</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We commenced our IPO pursuant to registration statements on Form S-1 (File Nos.&#160;333-227333 and 333-227774) that were declared or became effective on October 10, 2018 and registered an aggregate of 20,700,000 shares of our common stock for sale at a public offering price of $18.00 per share and an aggregate gross offering price of $372.6 million. On October 10, 2018, we sold 18,000,000 shares of our common stock at a public offering price of $18.00 per share for an aggregate gross offering price of $324.0 million. An additional 2,700,000 shares were sold pursuant to the underwriters&#8217; option to purchase additional shares with a public offering price of $18.00 per share for additional gross proceeds of $48.6 million. On October 15, 2018, we completed our IPO. Goldman Sachs&#160;&amp; Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies LLC acted as joint book-running managers for our IPO.</font></div><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The underwriting discounts and commissions for the offering totaled approximately $26.1 million. We incurred additional costs of approximately $3.2 million in offering expenses, which when added to the underwriting discounts and commissions paid by us, amounts to total fees and costs of approximately $29.3 million. Thus, net offering proceeds to us, after deducting underwriting discounts and commissions and offering costs, were approximately $343.3 million. No offering costs were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</font></div><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon receipt, the net proceeds from our IPO were held in cash and cash equivalents, primarily bank money market accounts. Through September 30, 2019, we have not used any of the net proceeds from our IPO. We are investing these funds in some combination of short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. We expect to use the net proceeds from our IPO as described under &#8220;Use of Proceeds&#8221; in the Prospectus. We cannot predict with certainty all of the particular uses for the net proceeds from our IPO, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including our ability to access additional financing, the relative success and cost of our research, preclinical and clinical development programs and whether we are able to enter into future licensing arrangements. As a result, our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from our IPO.</font></div><div><a name="sE9B6781B10975DB799A8011280EEB56F"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. Defaults Upon Senior Securities.</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s90CC6E244E535E679C8231293E5D9EB1"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. Mine Safety Disclosures.</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><a name="sB1EB81D4F8ED57FB8DA4A520ED48A25B"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5. Other Information.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 1, 2019, we entered into a Collaboration and License Agreement (the Collaboration Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch has granted to us an exclusive, worldwide, royalty-bearing, sublicenseable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, we made a $5.0 million investment in Notch&#8217;s series seed convertible preferred stock, resulting in us having a 25% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">investment. See Note 13 to our condensed financial statements included elsewhere in this report for further description of the Collaboration Agreement.</font></div><div style="line-height:120%;padding-top:8px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sF1E908B93EBA5BF796F185A3B66E75BC"></a></div><div style="line-height:120%;text-align:justify;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6.&#160;&#160;&#160;&#160;Exhibits.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Description of document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex31.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on October 15, 2018).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex32.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on October 15, 2018).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reference is made to Exhibits </font><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex31.htm"><font style="font-family:inherit;font-size:10pt;">3.1</font></a><font style="font-family:inherit;font-size:10pt;">&#160;and </font><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex32.htm"><font style="font-family:inherit;font-size:10pt;">3.2</font></a><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518290441/d548088dex41.htm"><font style="font-family:inherit;font-size:10pt;">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on October 2, 2018).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex42.htm"><font style="font-family:inherit;font-size:10pt;">Investors Rights Agreement, dated April 6, 2018, as amended September 5, 2018, by and among the Registrant and certain of its stockholders (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 14, 2018).</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="allo-20190930xex101.htm"><font style="font-family:inherit;font-size:10pt;">First Amendment, dated September 4, 2019, to the Lease Agreement, dated February 19, 2019, by and between the Registrant and Silicon Valley Gateway Technology Center, LLC.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="allo-20190930xex311.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="allo-20190930xex312.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="allo-20190930xex321.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><a name="sD9E77836075855ACBC23BC06A88B8671"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1A1D948A8A70516C829A32EB05B78FA9"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:16px;text-indent:37px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:4%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;5, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ David Chang</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Chang, M.D., Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;5, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">/s/ Eric Schmidt</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Eric Schmidt, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>allo-20190930xex101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF9D91461399BB4E2C175FE73F7F0B92C"></a></div><div><div style="line-height:120%;text-align:right;padding-left:1px;text-indent:-2px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">FIRST AMENDMENT TO LEASE AGREEMENT</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:126%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This FIRST AMENDMENT TO LEASE AGREEMENT (this "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Amendment</font><font style="font-family:inherit;font-size:11pt;">") is entered into as of September 4, 2019, by and between SILICON VALLEY GATEWAY TECHNOLOGY CENTER, LLC, a Delaware limited liability company ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Landlord</font><font style="font-family:inherit;font-size:11pt;">"), and ALLOGENE THERAPEUTICS, INC., a Delaware corporation ("</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Tenant</font><font style="font-family:inherit;font-size:11pt;">"). </font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RECITALS</font><font style="font-family:inherit;font-size:11pt;">&#32;</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">A.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Landlord and Tenant are parties to that certain Lease Agreement dated as of February 19, 2019 (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Original Lease</font><font style="font-family:inherit;font-size:11pt;">").   </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">B.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Pursuant to the Original Lease, Landlord leases to Tenant, and Tenant leases from Landlord, certain space (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Premises</font><font style="font-family:inherit;font-size:11pt;">") consisting of approximately 117,889 rentable square feet of space (inclusive of approximately 4,325 rentable square feet of mezzanine area) comprising the entire interior of that certain building to be constructed and located at 7400 Gateway Boulevard, Newark, California (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Building</font><font style="font-family:inherit;font-size:11pt;">"), as more particularly described in the Original Lease. </font></div><div style="line-height:130%;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">C.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Pursuant to Paragraph 1(c) of the Original Lease, Tenant was granted a right of early access to the Premises, subject to the terms and conditions contained in such Paragraph 1(c).   </font></div><div style="line-height:130%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:130%;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">D.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Tenant has requested that Landlord grant Tenant even earlier access to a certain portion of the Premises than the access rights provided by Paragraph 1(c) of the Original Lease.</font></div><div style="line-height:130%;text-align:left;padding-left:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:130%;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">E.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">As a result of such request, Landlord and Tenant desire to amend the Original Lease to, among other things, (i) grant Tenant a right of earlier access to a certain portion of the Premises, and (ii) modify the scope of the Landlord Work and the Tenant Improvements, all in accordance with the terms and conditions set forth below.   </font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#32;&#160;&#160;&#160;&#160; </font></div><div style="line-height:130%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">AGREEMENT </font></div><div style="line-height:130%;text-align:center;padding-left:4px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:126%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOW, THEREFORE,</font><font style="font-family:inherit;font-size:11pt;">&#32;for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows: </font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:130%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Defined Terms</font><font style="font-family:inherit;font-size:11pt;">. Unless otherwise defined herein, all capitalized terms used herein shall have the meanings ascribed to them in the Original Lease.  The Original Lease, as amended hereby, shall herein and hereafter be referred to as the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Lease</font><font style="font-family:inherit;font-size:11pt;">."  All references in the Lease to the "Lease" shall herein and hereafter refer to the Original Lease, as amended hereby. </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Earlier Access</font><font style="font-family:inherit;font-size:11pt;">.  Subject to all Legal Requirements and Private Restrictions, Tenant may enter that certain portion of the Premises depicted on </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:11pt;">&#32;attached hereto (the "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">First Amendment Early Access Portion</font><font style="font-family:inherit;font-size:11pt;">"), [i] approximately five (5) business days following the date Landlord completes installation of all of the fire sprinklers within the Building (but excluding the installation of the fire sprinklers under the mezzanine within the Building) (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Sprinkler Work</font><font style="font-family:inherit;font-size:11pt;">&#8221;) for the sole purposes of taking certain preparatory and mobilization measures in connection with performing the Tenant Improvements (including taking measurements and delivering toilets/wash stations, but in no event commencing construction or </font></div><div><br></div><div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:7pt;">1201967v5</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">1</font></div></td></tr></table></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;padding-left:1px;text-indent:-2px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">delivering construction materials), and (II) approximately ten (10) business days following the date Landlord completes the Sprinkler Work, for the sole purposes of constructing the Tenant Improvements only (and not for the purpose of installing Tenant's furniture, fixtures and equipment), all in accordance with the terms and conditions contained in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:11pt;">&#32;attached to the Original Lease, and taking other preparatory measures; provided, however, that Tenant shall not unreasonably interfere with the completion of any of the Landlord Work and/or any Punchlist Items.  Landlord and Tenant shall reasonably cooperate (and shall cause their respective contractors, subcontractors and agents to cooperate) with each other in good faith to reasonably accommodate the construction scheduling of each party and in order that the work being performed by each party may be completed without material interference with the completion of the work being completed by the other party and without increase in cost to the other party; provided, however, notwithstanding the foregoing or anything herein to the contrary, Tenant acknowledges and agrees that in the event there is any conflict between the construction scheduling or activities for completion of Tenant's work and the Landlord Work, the completion of the Landlord Work shall take priority over the completion any Tenant's work and Tenant shall not interfere with (and Tenant shall cause its contractors, subcontractor and agents to not interfere with) the completion of the Landlord Work.  Without limiting the other terms and conditions contained herein and/or in Paragraph 1(c) of the Original Lease, as a condition to Tenant's right to such early entry into the First Amendment Early Access Portion, Tenant shall be required to comply with all of the provisions of the Original Lease including, without limitation, the insurance and indemnity provisions contained in the Original Lease and with the provisions of the Original Lease governing the Tenant Improvements, but excluding only the obligation to pay Base Rent and Operating Expenses.  Notwithstanding the foregoing or anything to the contrary contained in the Original Lease, in no event shall Tenant be permitted to stage and/or store any improvements, furniture, fixtures and/or equipment outside of the Building during any such early access period granted pursuant to this Section, and in no event shall Tenant access or enter into any portion the Premises until such time as Tenant has delivered to Landlord written evidence that Tenant has fulfilled its obligation to provide insurance pursuant to the provisions of the Lease.  This Section does not grant rights for Tenant and/or any Tenant Party to enter into any other portion of the Premises other than the First Amendment Early Access Portion (nor shall Tenant and/or any Tenant Party be permitted to enter into any such other portions of the Premises except as expressly permitted by Paragraph 1(c) of the Original Lease).  Such early entry to the First Amendment Early Access Portion in and of itself will not advance the Commencement Date.  Tenant shall have no obligation to pay any Base Rent, utilities, or Operating Expenses until the Commencement Date has occurred, whereupon, subject to the Base Rent Credit, Base Rent, utilities, and Operating Expenses shall immediately commence.  During any such early entry, Landlord shall not be responsible for any loss, including theft, damage or destruction to any work or material installed or stored by Tenant at the Premises or for any injury to Tenant or any Tenant Party. Landlord shall continue to have the right to post appropriate notices of non-responsibility in connection with any early entry by Tenant.  Landlord anticipates completing the Sprinkler Work on or about September 23, 2019 (subject to extension for Force Majeure and/or Tenant Delays). Landlord shall notify Tenant approximately one (1) week prior to the scheduled completion of the Sprinkler Work to confirm that the completion of the Sprinkler Work is on schedule, and, if not on schedule, the anticipated completion date.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:11pt;">&#32;&#32;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Landlord Work</font><font style="font-family:inherit;font-size:11pt;">.  Tenant acknowledges and agrees that as inducement for Landlord allowing Tenant to access and begin work in the First Amendment Early Access Portion of the Premises prior to the date that Landlord would otherwise be obligated pursuant to Paragraph 1(c) of the Original Lease, the Landlord Work shall exclude and Landlord shall no longer be under any obligation to complete any of the following work (which work was previously included as part of the Landlord Work and Base Building </font></div><div><br></div><div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:7pt;">1201967v5</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">2</font></div></td></tr></table></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;padding-left:1px;text-indent:-2px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Specifications) and in no event shall Tenant be compensated (nor shall the Tenant Improvement Allowance be increased except as set forth in Section 5 of this Amendment below) for such reduction in the scope of the Landlord Work and/or modification to the Base Building Specifications:</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Painting of the interior of the tilt-wall panels within the Building;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Painting of any interior columns and beams within the Building; and</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Scrubbing and/or sealing the Building slab.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Tenant Improvements</font><font style="font-family:inherit;font-size:11pt;">.  Tenant acknowledges and agrees that as an inducement for Landlord allowing Tenant to access and begin work in the First Amendment Early Access Portion of the Premises prior to the date that Landlord would otherwise be obligated pursuant to Paragraph 1(c) of the Original Lease, the following work shall now be included within the scope of the Tenant Improvements (such additional work shall hereinafter be referred to collectively as, "</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Additional Tenant Improvements</font><font style="font-family:inherit;font-size:11pt;">") and Tenant shall be obligated to complete the same (in accordance with the terms and conditions contained in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:11pt;">&#32;attached to the Original Lease) at Tenant's sole cost and expense (subject to use of funds from the Tenant Improvement Allowance, as applicable):  </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Paint the interior of all concrete walls and all gypsum board walls with two (2) coats of white latex paint.&#160; Such work shall include painting the full panel area up to the roof of the Building but may exclude portions of the concrete walls which will be covered by Tenant Improvements; </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Paint interior and exterior of the electrical room of the Premises with two (2) coats of white latex paint; </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Paint the interior side of all hollow metal man doors and frames with two (2) coats of white latex paint;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Paint all interior steel columns (including brace frame) (i) up to ten (10) feet above finished floor level utilizing OSHA yellow and (ii) ten (10) feet above finished floor level to bottom of truss utilizing white paint (in each case no less than one coat primer and two coats finish);</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Seal all areas of the Building slab that will not be receiving alternate floor finishes in conjunction with the Tenant Improvements.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Scrub Building slab and seal with two (2) coats Shur-Seal (or equivalent as may be approved by Landlord) per product recommendations; </font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Tenant shall ensure that the floor slab surface is mechanically and chemically scrubbed to remove all traces of the chemical bond breaker and curing compound and the floor is tested in accordance with applicable ASTM Standard prior to any floor finish installation (in connection with related floor finish to be installed with the Tenant Improvements). ASTM Standards F710, F1869 and F2170 require the Building to be at occupied temperature and humidity when the floor is tested for relative humidity or moisture vapor emission rates.  Tenant and Tenant&#8217;s contractors must coordinate with Landlord the installation of floor finishes following the commissioning of the RTU&#8217;s and Building acclimation.</font></div><div><br></div><div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:7pt;">1201967v5</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">3</font></div></td></tr></table></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;padding-left:1px;text-indent:-2px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Additional Tenant Improvement Allowance</font><font style="font-family:inherit;font-size:11pt;">.  In consideration of Landlord being relieved of the work described in Section 3 above, subject to and in accordance with the terms and conditions contained in </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:11pt;">&#32;attached to the Original Lease, Landlord and Tenant hereby agree that Tenant shall be entitled to an increase to the Tenant Improvement Allowance in the amount of Twenty-Six Thousand Dollars ($26,000.00); provided, however, that such additional Tenant Improvement Allowance shall be disbursed by Landlord solely for the cost incurred relating to the Additional Tenant Improvements set forth herein.</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:11pt;">.    Any provision of this Amendment which shall prove to be invalid, void, or illegal shall in no way affect, impair or invalidate any other provision hereof and such other provisions shall remain in full force and effect.  </font><font style="font-family:inherit;font-size:11pt;color:#0000ff;">&#32;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Estoppel</font><font style="font-family:inherit;font-size:11pt;">.  Tenant warrants, represents and certifies to Landlord that to the best of Tenant&#8217;s knowledge, as of the date of this Amendment: (a) Landlord is not in default under the Lease; and (b) Tenant does not have any defenses or offsets to payment of rent and performance of its obligations under the Lease as and when same becomes due.</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;">&#32;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Authority</font><font style="font-family:inherit;font-size:11pt;">.  Tenant has full power and authority to enter into this Amendment and the person signing on behalf of Tenant has been fully authorized to do so by all necessary corporate or partnership action on the part of Tenant.</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;">&#32;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:11pt;">.  Each of the parties hereto agrees to execute and deliver all such further documents and to take all such further actions as may be reasonably requested by the other party hereto to effectuate fully the terms and provisions of this Amendment, provided such documents or actions do not limit, reduce or impair the rights of the party upon whom such request is made.</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;">&#32;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Binding Effect</font><font style="font-family:inherit;font-size:11pt;">.  This Amendment shall be binding upon and inure to the benefit of Landlord, its successors and assigns and Tenant and its permitted successors and assigns.</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;">&#32;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Original Lease in Full Force</font><font style="font-family:inherit;font-size:11pt;">.  Except for those provisions which are inconsistent with this Amendment and those terms, covenants and conditions for which performance has heretofore been completed, all other terms, covenants and conditions of the Original Lease shall remain unmodified and in full force and effect.  Landlord and Tenant ratify the Original Lease, as amended hereby.</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;">&#32;</font></div><div style="line-height:130%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">12.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Electronic Signatures; Counterparts</font><font style="font-family:inherit;font-size:11pt;">.  Each party hereto, and their respective successors and assigns shall be authorized to rely upon the signatures of all of the parties hereto on this Amendment which are delivered by PDF or other electronic means as constituting a duly authorized, irrevocable, actual, current delivery of this Amendment with original ink signatures of each person and entity.  This Amendment may be executed in counterparts, each of which shall be deemed an original part and all of which together shall constitute a single agreement.</font><font style="font-family:inherit;font-size:11pt;color:#0000ff;">&#32;</font></div><div style="line-height:126%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[SIGNATURE PAGE FOLLOWS]</font></div><div style="line-height:126%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:126%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div><br></div><div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:7pt;">1201967v5</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">4</font></div></td></tr></table></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;padding-left:1px;text-indent:-2px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:126%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, this Amendment is executed as of the day and year first set forth above.</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:130%;text-align:left;padding-left:1px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">LANDLORD</font><font style="font-family:inherit;font-size:11pt;">: </font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:126%;text-align:justify;padding-left:1px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">SILICON VALLEY GATEWAY TECHNOLOGY CENTER, LLC, </font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a Delaware limited liability company </font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:126%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ Timothy Schaedler&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; </font></div><div style="line-height:130%;padding-bottom:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;Timothy Schaedler&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;Local Partner&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;</font></div><div style="line-height:130%;text-align:left;padding-left:1px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">TENANT</font><font style="font-family:inherit;font-size:11pt;">: </font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ALLOGENE THERAPEUTICS, INC., </font></div><div style="line-height:126%;text-align:justify;padding-left:1px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">a Delaware corporation </font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ Alison Moore&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; </font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;Alison Moore&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;Chief Technical Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div><br></div><div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:11.5pt;padding-left:0px;"><font style="font-family:inherit;font-size:7pt;">1201967v5</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;">5</font></div></td></tr></table></div><hr style="page-break-after:always"><div><a name="s453F36B65748B2F98A75FE73F8217245"></a></div><div><div style="line-height:120%;text-align:right;padding-left:1px;text-indent:-2px;font-size:11.5pt;"><font style="font-family:inherit;font-size:11.5pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:130%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXHIBIT A</font></div><div style="line-height:130%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">DEPICTION OF FIRST AMENDMENT EARLY ACCESS PORTION</font></div><div style="line-height:130%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:130%;text-align:center;"><img src="exhibit101image1.jpg" alt="exhibit101image1.jpg" style="height:774px;width:577px;"></div><div><br></div><div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:1px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:126%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:7pt;">1201967v5</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div></td><td style="vertical-align:top;"><div style="line-height:126%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit A&#8212;Page </font><font style="font-family:inherit;font-size:11.5pt;">1</font></div></td></tr></table></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>allo-20190930xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4E889D32EAF85554A91457CDF8CEFE09"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, David Chang, M.D., Ph.D., certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Form 10-Q of Allogene Therapeutics, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:108px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:108px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:108px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:108px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:108px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:60%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: November&#160;5, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ David Chang</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">David Chang, M.D., Ph.D.</font></div><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">President and Chief Executive Officer</font></div><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>allo-20190930xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCB96E29E392C593BB91625668C8E5E95"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Eric Schmidt, Ph.D., certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Form 10-Q of Allogene Therapeutics, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:108px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:108px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:108px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:108px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:108px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:216px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:108px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:60%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: November&#160;5, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ Eric Schmidt</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Eric Schmidt, Ph.D.</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Financial Officer</font></div><div style="font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>allo-20190930xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9160BB45CA195C569ED2B540809832D4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002&#160;</font></div><div style="line-height:120%;padding-top:16px;text-indent:62px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the quarterly report of Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David Chang, M.D., Ph.D., President and Chief Executive Officer of the Company, and I, Eric Schmidt, Ph.D., Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;); and&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.&#160;</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:57%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: November&#160;5, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ David Chang</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">David Chang, M.D., Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: November&#160;5, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">/s/ Eric Schmidt</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Eric Schmidt, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:62px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act or otherwise subject to the liability of Section&#160;18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>allo-20190930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:33c5306a35284ffea19efd91254ea6b5,x:f3317a9a5eba4a35a26414a181c5e316-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:allo="http://allogene.com/20190930" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="allo-20190930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2019Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Nov1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-11-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionReceivableFromPreferredStockholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionReceivableFromPreferredStockholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionReceivableFromPreferredStockholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionReceivableFromPreferredStockholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionReceivableFromPreferredStockholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionReceivableFromPreferredStockholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">allo:SubscriptionReceivableFromPreferredStockholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">allo:SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4oct31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4oct31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4oct31_us-gaap_DebtInstrumentAxis_allo_ConvertiblePromissoryNotesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">allo:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q4Oct01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_allo_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_allo_ComputerEquipmentAndPurchasedSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_allo_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_allo_ComputerEquipmentAndPurchasedSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_RelatedPartyTransactionAxis_allo_RegulatoryMilestoneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_allo_AssetContributionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionAxis_allo_AssetContributionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_RelatedPartyTransactionAxis_allo_SalesMilestoneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_allo_RegulatoryMilestoneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_allo_SalesMilestoneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_allo_MilestoneTypeAxis_allo_Phase1ClinicalTrialFirstPatientDoseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:Phase1ClinicalTrialFirstPatientDoseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_AssetContributionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_allo_MilestoneTypeAxis_allo_DevelopmentAndSalesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:DevelopmentAndSalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Feb_srt_StatementGeographicalAxis_allo_NewarkMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-01</xbrli:startDate>
			<xbrli:endDate>2019-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4oct31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Aug31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_srt_StatementGeographicalAxis_stpr_NY">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_srt_StatementGeographicalAxis_allo_NewarkMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Feb28_srt_StatementGeographicalAxis_allo_NewarkMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_srt_StatementGeographicalAxis_allo_LosAngelesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:LosAngelesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_allo_LosAngelesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:LosAngelesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_stpr_NY">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">allo:LeaseTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_srt_StatementGeographicalAxis_allo_LosAngelesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:LosAngelesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Sep">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_TwoRiverConsultingLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_TwoRiverConsultingLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_allo_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">allo:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Feb_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-01</xbrli:startDate>
			<xbrli:endDate>2019-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_allo_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">allo:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Sep_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-09-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_TwoRiverConsultingLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_TwoRiverConsultingLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Aug_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-08-01</xbrli:startDate>
			<xbrli:endDate>2018-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:TransitionServicesAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Aug_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-08-01</xbrli:startDate>
			<xbrli:endDate>2018-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ByHeartIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_allo_EarlyExerciseOfStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_allo_FounderSharesOfCommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_allo_FounderSharesOfCommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_allo_EarlyExerciseOfStockOptionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleNotesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Nov1_allo_MilestoneTypeAxis_allo_ResearchMilestoneMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:ResearchMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-11-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q4Nov1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-11-01</xbrli:startDate>
			<xbrli:endDate>2019-11-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Nov1_allo_MilestoneTypeAxis_allo_ClinicalRegulatoryandCommercialMilestoneMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:ClinicalRegulatoryandCommercialMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-11-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Nov1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-11-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Nov1_allo_MilestoneTypeAxis_allo_PreClinicalDevelopmentMilestoneMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-11-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="U_alloRenewal">
		<xbrli:measure>allo:Renewal</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="U_alloDirector">
		<xbrli:measure>allo:Director</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="eur">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<allo:AccruedAndOtherLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-64A3A494917156068F4F2E0C21D002CB" unitRef="usd">17121000</allo:AccruedAndOtherLiabilitiesCurrent>
	<allo:AccruedAndOtherLiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-1FC8CF442EE353F383EC6FD89B089A76" unitRef="usd">25307000</allo:AccruedAndOtherLiabilitiesCurrent>
	<allo:AccruedAndOtherLiabilitiesCurrent contextRef="FI2019Q3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember" decimals="-5" id="Fact-4F0D0E46EE948A48305015073794C6AE" unitRef="usd">5000000</allo:AccruedAndOtherLiabilitiesCurrent>
	<allo:AccruedAndOtherLiabilitiesCurrent contextRef="FI2019Q3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="-5" id="Fact-277BE8DFAFF65D72A69AD8F355C1A751" unitRef="usd">1200000</allo:AccruedAndOtherLiabilitiesCurrent>
	<allo:AccruedCompensationAndRelatedBenefitsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-84C0A820C2625427AD5FC2CBE72DC072" unitRef="usd">4111000</allo:AccruedCompensationAndRelatedBenefitsCurrent>
	<allo:AccruedCompensationAndRelatedBenefitsCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-4C7EAAA324485655836BB0AC16E56913" unitRef="usd">6672000</allo:AccruedCompensationAndRelatedBenefitsCurrent>
	<allo:AccruedPropertyAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-7560B286CF1B5EA194FDDEA906E294DC" unitRef="usd">0</allo:AccruedPropertyAndEquipment>
	<allo:AccruedPropertyAndEquipment contextRef="FI2019Q3" decimals="-3" id="Fact-C93D284D6CAA563586D959AB1206B232" unitRef="usd">4444000</allo:AccruedPropertyAndEquipment>
	<allo:AccruedResearchAndDevelopmentExpenseCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-7325F734AA3DD997A70814FF6D1F38CE" unitRef="usd">7808000</allo:AccruedResearchAndDevelopmentExpenseCurrent>
	<allo:AccruedResearchAndDevelopmentExpenseCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-765C63C22D98BAF0BDAD14FF6D0B47AC" unitRef="usd">9380000</allo:AccruedResearchAndDevelopmentExpenseCurrent>
	<allo:AggregatePotentialMilestonePayments contextRef="FD2019Q3QTD_allo_MilestoneTypeAxis_allo_DevelopmentAndSalesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember" decimals="INF" id="Fact-7CB1FD7024AF57F88282D31207CED3A8" unitRef="usd">2800000000</allo:AggregatePotentialMilestonePayments>
	<allo:AggregatePotentialMilestonePayments contextRef="FD2019Q3QTD_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_allo_RegulatoryMilestoneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="INF" id="Fact-3F805D04B1EE51BEAE9B3564F019CDA5" unitRef="usd">137500000</allo:AggregatePotentialMilestonePayments>
	<allo:AggregatePotentialMilestonePayments contextRef="FD2019Q3QTD_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_allo_SalesMilestoneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="INF" id="Fact-659711CE56175525BDA251F18E688757" unitRef="usd">78000000</allo:AggregatePotentialMilestonePayments>
	<allo:AggregatePotentialMilestonePayments contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_AssetContributionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="INF" id="Fact-C11444965D5356D2957488872E2281A3" unitRef="usd">325000000</allo:AggregatePotentialMilestonePayments>
	<allo:AggregatePotentialMilestoneReceivable contextRef="FI2019Q3_us-gaap_RelatedPartyTransactionAxis_allo_RegulatoryMilestoneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="-6" id="Fact-1A09E505261E5E4FA52FE9C051344255" unitRef="usd">42000000</allo:AggregatePotentialMilestoneReceivable>
	<allo:AggregatePotentialMilestoneReceivable contextRef="FI2019Q3_us-gaap_RelatedPartyTransactionAxis_allo_SalesMilestoneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="-5" id="Fact-472A13F5F2325C0D890DC21FB5CDF669" unitRef="usd">77100000</allo:AggregatePotentialMilestoneReceivable>
	<allo:AggregatePotentialMilestoneReceivable contextRef="FI2019Q3_us-gaap_RelatedPartyTransactionAxis_allo_SalesMilestoneMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="-5" id="Fact-9BC1F14805F054EA9EDDF1390B0BA53A" unitRef="eur">70500000</allo:AggregatePotentialMilestoneReceivable>
	<allo:AggregatePotentialRegulatoryAndDevelopmentMilestones contextRef="FD2019Q3QTD_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_allo_AssetContributionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="INF" id="Fact-E24524B57CA6515B86091E6054B36F97" unitRef="usd">840000000</allo:AggregatePotentialRegulatoryAndDevelopmentMilestones>
	<allo:AllowanceForTenantImprovements contextRef="FI2019Q3" decimals="-3" id="Fact-D0D3FE357FF75311A82A4AE980969939" unitRef="usd">2849000</allo:AllowanceForTenantImprovements>
	<allo:AllowanceForTenantImprovements contextRef="I2018Q3Aug31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember" decimals="-5" id="Fact-BBD10821676452EA888303C8B8876A34" unitRef="usd">5000000</allo:AllowanceForTenantImprovements>
	<allo:AllowanceForTenantImprovements contextRef="I2018Q4oct31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember" decimals="-5" id="Fact-150EF65C6FC0592292D54457120EC13F" unitRef="usd">800000</allo:AllowanceForTenantImprovements>
	<allo:AllowanceForTenantImprovements contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_allo_NewarkMember" decimals="-5" id="Fact-14B1E6E540985810B69B04AC05774B72" unitRef="usd">2900000</allo:AllowanceForTenantImprovements>
	<allo:AreaOfNewOfficeBuilding contextRef="FI2018Q4_srt_StatementGeographicalAxis_allo_LosAngelesMember" decimals="0" id="Fact-4C68B6307AA25AD08C88847B49FC3CA0" unitRef="sqft">1293</allo:AreaOfNewOfficeBuilding>
	<allo:AreaOfNewOfficeBuilding contextRef="FI2018Q4_srt_StatementGeographicalAxis_stpr_NY" decimals="0" id="Fact-6C0F13D6FEB2541CB4DD394C23136977" unitRef="sqft">4358</allo:AreaOfNewOfficeBuilding>
	<allo:AreaOfNewOfficeBuilding contextRef="I2018Q3Aug31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember" decimals="0" id="Fact-8615D037911B54F2BB37B722FA812F92" unitRef="sqft">68000</allo:AreaOfNewOfficeBuilding>
	<allo:AreaOfNewOfficeBuilding contextRef="I2018Q4oct31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember" decimals="0" id="Fact-C07B28260ED0508F96147924B96AB62A" unitRef="sqft">14943</allo:AreaOfNewOfficeBuilding>
	<allo:AreaOfOffice contextRef="D2019Q1Feb_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember" decimals="0" id="Fact-E680F27D721B51C2AEE8E2F265E872A6" unitRef="sqft">2180</allo:AreaOfOffice>
	<allo:AreaOfOffice contextRef="D2019Q3Sep_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember" decimals="0" id="Fact-E1838633EF4D9961D78F188C1344E3E9" unitRef="sqft">2907</allo:AreaOfOffice>
	<allo:AreaOfOperatingLease contextRef="D2019Q1Feb_srt_StatementGeographicalAxis_allo_NewarkMember" decimals="-3" id="Fact-87A74D32000B5AF4A3105F7E40149EF1" unitRef="sqft">118000</allo:AreaOfOperatingLease>
	<allo:CashEquivalentsAndShortTermInvestments contextRef="FI2018Q4" decimals="-3" id="Fact-24299184ADF050C0936C0CF7D672DE83" unitRef="usd">714132000</allo:CashEquivalentsAndShortTermInvestments>
	<allo:CashEquivalentsAndShortTermInvestments contextRef="FI2019Q3" decimals="-3" id="Fact-4B3E45389A4952538FF95E488533CC93" unitRef="usd">553350000</allo:CashEquivalentsAndShortTermInvestments>
	<allo:CashReceivedForAmountsRelatedToTenantImprovementAllowances contextRef="FD2018Q3YTD" decimals="-3" id="Fact-A05A561E5C9084E65C1614F5AB9ECEC9" unitRef="usd">0</allo:CashReceivedForAmountsRelatedToTenantImprovementAllowances>
	<allo:CashReceivedForAmountsRelatedToTenantImprovementAllowances contextRef="FD2019Q3YTD" decimals="-3" id="Fact-7829DE687ECDB47ED7A014F5ABA3B03B" unitRef="usd">2934000</allo:CashReceivedForAmountsRelatedToTenantImprovementAllowances>
	<allo:ChangeInFairValueOfConvertibleNotePayable contextRef="FD2018Q3QTD" decimals="-3" id="Fact-B4FDBCC866DA2C6293A1F46B65CE333B" unitRef="usd">19415000</allo:ChangeInFairValueOfConvertibleNotePayable>
	<allo:ChangeInFairValueOfConvertibleNotePayable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-CF1494EE4A8E0C4E3A35F46B65AC4ED4" unitRef="usd">19415000</allo:ChangeInFairValueOfConvertibleNotePayable>
	<allo:ChangeInFairValueOfConvertibleNotePayable contextRef="FD2019Q3QTD" decimals="-3" id="Fact-67918C9B19825AE11D3CF46B66430851" unitRef="usd">0</allo:ChangeInFairValueOfConvertibleNotePayable>
	<allo:ChangeInFairValueOfConvertibleNotePayable contextRef="FD2019Q3YTD" decimals="-3" id="Fact-C85867393AA21E398B3CF46B65B6C6DD" unitRef="usd">0</allo:ChangeInFairValueOfConvertibleNotePayable>
	<allo:CollaborativeArrangementContingentConsiderationLiability contextRef="I2019Q4Nov1_allo_MilestoneTypeAxis_allo_ClinicalRegulatoryandCommercialMilestoneMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-60EFDED1395C4D2AB15918AABAA59BD7" unitRef="usd">283000000.0</allo:CollaborativeArrangementContingentConsiderationLiability>
	<allo:CollaborativeArrangementContingentConsiderationLiability contextRef="I2019Q4Nov1_allo_MilestoneTypeAxis_allo_PreClinicalDevelopmentMilestoneMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-DE02127B76A13802A24918AA25C9ECEA" unitRef="usd">4000000.0</allo:CollaborativeArrangementContingentConsiderationLiability>
	<allo:CollaborativeArrangementContingentConsiderationLiability contextRef="I2019Q4Nov1_allo_MilestoneTypeAxis_allo_ResearchMilestoneMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-3C4F34ED1A39DF4A902E18A9F633A17F" unitRef="usd">7250000.00</allo:CollaborativeArrangementContingentConsiderationLiability>
	<allo:CollaborativeArrangementInitialFee contextRef="D2019Q4Nov1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-0070B1C3F54DD4CD585818A2026498D1" unitRef="usd">10000000.0</allo:CollaborativeArrangementInitialFee>
	<allo:ConvertiblePreferredStockIssuedInAssetAcquisition contextRef="FD2018Q3YTD" decimals="-3" id="Fact-6E8E10D41ECB58EAB03035FD1BE7A522" unitRef="usd">111770000</allo:ConvertiblePreferredStockIssuedInAssetAcquisition>
	<allo:ConvertiblePreferredStockIssuedInAssetAcquisition contextRef="FD2019Q3YTD" decimals="-3" id="Fact-471D9BC2880052FD8ADD56F9A7397F8D" unitRef="usd">0</allo:ConvertiblePreferredStockIssuedInAssetAcquisition>
	<allo:FairValueAssetsTransfersBetweenLevelsAmount contextRef="FD2019Q3YTD" decimals="INF" id="Fact-92DE0202AE0C5932A2287A1FF1DB55D7" unitRef="usd">0</allo:FairValueAssetsTransfersBetweenLevelsAmount>
	<allo:LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_allo_NewarkMember" decimals="3" id="Fact-B1739C91BA8555A59C7F845DFDE3F861" unitRef="number">0.030</allo:LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent>
	<allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember" decimals="INF" id="Fact-70CDFEFD4FC65E6BBE66845F74ABB0FA" unitRef="usd">185000000</allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget>
	<allo:MilestonePayments contextRef="FD2019Q3QTD_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_allo_AssetContributionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="INF" id="Fact-F0FD8E263611505282736EBBBCA33F56" unitRef="usd">60000000</allo:MilestonePayments>
	<allo:MilestonePayments contextRef="FD2019Q3QTD_srt_RangeAxis_srt_MinimumMember_us-gaap_RelatedPartyTransactionAxis_allo_AssetContributionAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="INF" id="Fact-928512B84C66563B89499AE06A352955" unitRef="usd">30000000</allo:MilestonePayments>
	<allo:MilestonePayments contextRef="FD2019Q3YTD_allo_MilestoneTypeAxis_allo_Phase1ClinicalTrialFirstPatientDoseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember" decimals="-5" id="Fact-D7828EFE01345561988FEC105F2BF149" unitRef="usd">5000000</allo:MilestonePayments>
	<allo:NumberOfMembersAppointedToBoardOfDirectors contextRef="FI2019Q3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="INF" id="Fact-F31F495E5CD043F6F633188EBE671DDD" unitRef="U_alloDirector">1</allo:NumberOfMembersAppointedToBoardOfDirectors>
	<allo:NumberOfOptionsToExtendLease contextRef="D2019Q1Feb_srt_StatementGeographicalAxis_allo_NewarkMember" decimals="INF" id="Fact-952855FECFDD11376CCD15444F728123" unitRef="U_alloRenewal">2</allo:NumberOfOptionsToExtendLease>
	<allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding contextRef="FD2019Q3QTD" decimals="INF" id="Fact-42360A945A6556AF8B2AD88BC7F65F0B" unitRef="number">0.05</allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding>
	<allo:OperatingLeaseRemainingTerm contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_allo_LosAngelesMember" id="Fact-09B6DE434D82F112476B154618DDD0ED">P2Y2M</allo:OperatingLeaseRemainingTerm>
	<allo:OperatingLeaseRemainingTerm contextRef="FD2019Q3YTD_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember" id="Fact-1B11C7B95E254ABC78E31534E99F6E65">P9Y5M</allo:OperatingLeaseRemainingTerm>
	<allo:OperatingLeasesUndiscountedLeasePayments contextRef="FI2019Q3" decimals="-3" id="Fact-A3C0A77D97855EBDA9C6390F135C36A7" unitRef="usd">36231000</allo:OperatingLeasesUndiscountedLeasePayments>
	<allo:OperatingLeasesUndiscountedLeasePayments contextRef="FI2019Q3_srt_StatementGeographicalAxis_allo_NewarkMember" decimals="-5" id="Fact-E30EA2D37F6B55028869FADBC333FBCE" unitRef="usd">36200000</allo:OperatingLeasesUndiscountedLeasePayments>
	<allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate contextRef="FD2019Q3QTD_srt_RangeAxis_srt_MaximumMember" decimals="INF" id="Fact-A4752D9AE2F553A8AA3A30A629ABAB91" unitRef="number">1</allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate>
	<allo:PaymentOfLeaseRentalPerMonth contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_allo_NewarkMember" decimals="0" id="Fact-CEE8861F44FC52C7BAE38F45610768EB" unitRef="usd">159150</allo:PaymentOfLeaseRentalPerMonth>
	<allo:PercentageOfDevelopmentCostPayableByCollaborationPartner contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="2" id="Fact-51F3A4C5D4D35BCCAB5927D6D1CCBC7C" unitRef="number">0.40</allo:PercentageOfDevelopmentCostPayableByCollaborationPartner>
	<allo:PercentageOfDevelopmentCostPayableByTheCompany contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="2" id="Fact-2ED81CDDD4865046A5C1FDB4B4DB0724" unitRef="number">0.60</allo:PercentageOfDevelopmentCostPayableByTheCompany>
	<allo:PrepaidResearchAndDevelopmentExpensesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-402BF0E0DC5E5CDCB1DEFD51C933563E" unitRef="usd">2356000</allo:PrepaidResearchAndDevelopmentExpensesCurrent>
	<allo:PrepaidResearchAndDevelopmentExpensesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-181E086C08D45BDD86DE442D8A3221D4" unitRef="usd">4124000</allo:PrepaidResearchAndDevelopmentExpensesCurrent>
	<allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions contextRef="FD2018Q3YTD" decimals="-3" id="Fact-1439A56E57FB586427CD14E64AC02E79" unitRef="usd">11375000</allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions>
	<allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions contextRef="FD2019Q3YTD" decimals="-3" id="Fact-18E40B6C2B6A193983F914E64ABCF044" unitRef="usd">0</allo:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions>
	<allo:RelatedPartyTransactionCompensationPercentage contextRef="D2018Q3Aug_srt_RangeAxis_srt_MaximumMember_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember" decimals="INF" id="Fact-052F4B72EF9B57DCBB8CED1B10DD0B5C" unitRef="number">0.6</allo:RelatedPartyTransactionCompensationPercentage>
	<allo:RelatedPartyTransactionMonthlyPaymentsInArrears contextRef="D2018Q3Aug_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember" decimals="INF" id="Fact-A6BE6C242B955ACA9D465FE438ABDE71" unitRef="usd">33333.33</allo:RelatedPartyTransactionMonthlyPaymentsInArrears>
	<allo:RoyaltyObligationPeriodFromDateOfFirstSale contextRef="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" id="Fact-D1DC05404FB8ACEDF22F15147EA3BD1A">P12Y</allo:RoyaltyObligationPeriodFromDateOfFirstSale>
	<allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-FFAE5EC171F05C6BB7D6410E272DAED2" unitRef="shares">1773155</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
	<allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-EB58370B344A57C29E7D27A5853D018B" unitRef="usdPerShare">27.46</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm contextRef="FD2019Q3YTD" id="Fact-AE8258EA94E05B398F90F9FCDB046CE8">P7Y8M19D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm>
	<allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1 contextRef="FD2019Q3YTD" id="Fact-5BE5C0C5B349557B9C99E38D97A62244">P8Y10M28D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1>
	<allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1 contextRef="FD2019Q3YTD" id="Fact-48FFC43752EC533C8A85CF2DBE5A99FA">P9Y6M18D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1>
	<allo:StockIssuedDuringPeriodValueCommonStockIssues contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F574F6B6D9A30874771B14D7C521ADFB" unitRef="usd">5000</allo:StockIssuedDuringPeriodValueCommonStockIssues>
	<allo:StockIssuedDuringPeriodValueCommonStockIssues contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-939A79A6469D6F4457B414D7C535A55F" unitRef="usd">5000</allo:StockIssuedDuringPeriodValueCommonStockIssues>
	<allo:StockOptionGrantedPeriod contextRef="FD2019Q3QTD_srt_RangeAxis_srt_MaximumMember" id="Fact-CB822CCDFA6B5400ABE34F784E893860">P10Y</allo:StockOptionGrantedPeriod>
	<allo:SubscriptionsReceivableFromPreferredStockholders contextRef="FD2018Q3QTD" decimals="-3" id="Fact-83135EF771665A5492EEB76899D07D61" unitRef="usd">0</allo:SubscriptionsReceivableFromPreferredStockholders>
	<allo:SubscriptionsReceivableFromPreferredStockholders contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember" decimals="-3" id="Fact-FE966283961C57D2BC75AAE3C6FCA1BA" unitRef="usd">150000000</allo:SubscriptionsReceivableFromPreferredStockholders>
	<allo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-CFAFDB1417BD5654BBE8AB57B0856956" unitRef="shares">998225</allo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<allo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-AFF8CBA880D356B8864C4D9CA5008E14" unitRef="shares">7557990</allo:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
	<allo:UnvestedSharesLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-78014C2FEC85589DA94FFD9E2008DACB" unitRef="usd">4590000</allo:UnvestedSharesLiabilitiesCurrent>
	<allo:UnvestedSharesLiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-0550E3A6BE93572F94397270597D694F" unitRef="usd">2842000</allo:UnvestedSharesLiabilitiesCurrent>
	<dei:AmendmentFlag contextRef="FD2019Q3YTD" id="Fact-67B17AD336F35E76863B16287825068A">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2019Q3YTD" id="Fact-61292D8285055B77A2600E2F523A33C2">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2019Q3YTD" id="Fact-7CF680544BA65907A829DDACCEF9C3EF">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2019Q3YTD" id="Fact-F3F02BBBDA355CEEBEA4ED7E72AD33D9">2019</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2019Q3YTD" id="Fact-6D654A566C815F0798167C8272ADA583">2019-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2019Q3YTD" id="Fact-6871767E6772564E801842218AD5CB3A">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2019Q3YTD" id="Fact-D711372CCBD753E9A9CAC7BFC4AF8CDE">0001737287</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q4Nov1" decimals="INF" id="Fact-AE5F33905E165942A658713F9A2B1144" unitRef="shares">121902101</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2019Q3YTD" id="Fact-00FC37BC1DBF5BDDB6AC18A68129F99F">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2019Q3YTD" id="Fact-DE4A5B5251E05A2698788142AC6ABFB6">true</dei:EntityEmergingGrowthCompany>
	<dei:EntityExTransitionPeriod contextRef="FD2019Q3YTD" id="Fact-5AA93D38145353559739E5076AA2413F">false</dei:EntityExTransitionPeriod>
	<dei:EntityFilerCategory contextRef="FD2019Q3YTD" id="Fact-B87ECC10871B5530BCFAFEFFA01DAD52">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityInteractiveDataCurrent contextRef="FD2019Q3YTD" id="Fact-C1BC146D47EC5D7DAC31A3A9FE361F17">Yes</dei:EntityInteractiveDataCurrent>
	<dei:EntityRegistrantName contextRef="FD2019Q3YTD" id="Fact-CEC1F3F06413556592FF1161C0771C1B">Allogene Therapeutics, Inc.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2019Q3YTD" id="Fact-50DBC0A77B28513A95C98B2BC7BF370F">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2019Q3YTD" id="Fact-DD63F88CBAC655EAAD74CFBB93BA673F">false</dei:EntitySmallBusiness>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-8CFAD8185EF65D6CBEBA0F49D337B761" unitRef="usd">12338000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-8F6E81EA09BD58FB9CBDB7ED24AC83D2" unitRef="usd">8047000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_allo_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="-5" id="Fact-18A80874B34A5243B9A5027DFBA5096C" unitRef="usd">5700000</us-gaap:AccountsPayableRelatedPartiesCurrent>
	<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_allo_AccruedAndOtherCurrentLiabilitiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="-5" id="Fact-76EE5A89B8B0504E9C492CE1C0E838D3" unitRef="usd">700000</us-gaap:AccountsPayableRelatedPartiesCurrent>
	<us-gaap:AccruedInvestmentIncomeReceivable contextRef="FI2018Q4" decimals="-3" id="Fact-B71DEF59F9D45C1592E7870E0087E55B" unitRef="usd">3108000</us-gaap:AccruedInvestmentIncomeReceivable>
	<us-gaap:AccruedInvestmentIncomeReceivable contextRef="FI2019Q3" decimals="-3" id="Fact-076FC185660B52B9A7602CAC395BC695" unitRef="usd">2337000</us-gaap:AccruedInvestmentIncomeReceivable>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-EEF0BB4A93945F8CA62FA83D01796F0D" unitRef="usd">1048000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2019Q3" decimals="-3" id="Fact-0721B0C7ACC55435ABC76FAD69E9D42B" unitRef="usd">3768000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="-3" id="Fact-3DD3E484BB625068B2D0F964B3789F75" unitRef="usd">306000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q3" decimals="-3" id="Fact-8ECE89552D3E55C8812000EF6E34487E" unitRef="usd">1866000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2018Q4" decimals="-3" id="Fact-2D8AC2A6F1525F05B54F26AE8DEDC27C" unitRef="usd">914265000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2019Q3" decimals="-3" id="Fact-C2D715F81A2758F4855FF5A4CB90BB21" unitRef="usd">952820000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q3QTD" decimals="-3" id="Fact-04BE87664C615FA2BCA1C558EAE78E23" unitRef="usd">4639000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6C537BEAD68254C493625BA7C1A53CD1" unitRef="usd">4639000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q3YTD" decimals="-3" id="Fact-FEE7C80F1C4E51BE925D14D7C14D0827" unitRef="usd">12695000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-276DB298F035E9B5718114D94D9E408E" unitRef="usd">12695000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q3QTD" decimals="-3" id="Fact-BF98F348EB375F5FA0CDCA2253841427" unitRef="usd">12835000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-92FAD484A0495DCDBFD341D592095DD5" unitRef="usd">12835000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q3YTD" decimals="-3" id="Fact-54412837CC725D14ACC2D0911DA18434" unitRef="usd">32189000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-35AA9F9656265C2EB5352FB6E646085B" unitRef="usd">32189000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-4F3BAFA9C64B37BCCEA314D7C19B7BEC" unitRef="usd">1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E3C0D4D4E78CF8EA64A914D7C17EDC97" unitRef="usd">2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-040B704D329141E5554F14D7C1689B1F" unitRef="usd">-1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-5FD9003E986959908D1A79DBD4EBDDFA" unitRef="usd">4639000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-0D70AAB6171E566BB7D80F8845788537" unitRef="usd">4212000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-CEF2966C16225E4A8D1DF09A7D4B5413" unitRef="usd">427000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3545837FD8CF5A00B9B976CFAA7F5CD0" unitRef="usd">12695000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-518597ABA5EB5300B8333BB3F3FE7297" unitRef="usd">12253000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-B422BB435FCD5A58B986B7866200FF74" unitRef="usd">442000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-6895DA702AFF5F7B8950C583C5FBC999" unitRef="usd">12834000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-6793824295DA5E5B887CB399779BDB28" unitRef="usd">7301000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-2B3A57815D0E53B1AFE7BBCE3E4804E2" unitRef="usd">5533000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-E557521DC01857D8AABC1EEAA4B6B188" unitRef="usd">32189000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-140BB407660659D6B35F710C1DA66AB5" unitRef="usd">19177000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-3FC6AF1C88AA56FEA1B52A69F2D49706" unitRef="usd">13012000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2018Q3YTD" decimals="-3" id="Fact-9C2A66CB35C232A7962314E2924F72E5" unitRef="usd">3358000</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfFinancingCosts contextRef="FD2019Q3YTD" decimals="-3" id="Fact-99E2C8DB3862C6B9696814E292483B9A" unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q3YTD" decimals="-3" id="Fact-71B19927AE0159339CC9C3A582711DAB" unitRef="usd">302000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2019Q3YTD" decimals="-3" id="Fact-390A751E36EC5E8791084037109363BB" unitRef="usd">452000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD" decimals="0" id="Fact-8946B86D1A795AE7A0DA541F9A6E665A" unitRef="shares">101810405</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_allo_EarlyExerciseOfStockOptionsMember" decimals="0" id="Fact-4D68F62282D952E9B663D403FC11E697" unitRef="shares">5020580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_allo_FounderSharesOfCommonStockMember" decimals="0" id="Fact-472A9465627053C7B05B6AD8A7B005D7" unitRef="shares">21201908</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleNotesPayableMember" decimals="0" id="Fact-B9A18EEF83FE7D4B650FF4706738E4A0" unitRef="shares">7856176</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-97D854CC17E7504F9012096125A98291" unitRef="shares">61655922</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember" decimals="0" id="Fact-5A01E6506B4B5653A30EAC867904B624" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-FEBD9F7E4F545F789F9C00F0BAF9171E" unitRef="shares">6075819</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-F35D18080AAA5F0E9021BAC10823BDF0" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD" decimals="0" id="Fact-9F73DDCFD6D05968B121F37F61DA8A61" unitRef="shares">29878302</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_allo_EarlyExerciseOfStockOptionsMember" decimals="0" id="Fact-002AFF5D22975A899BA712142BDE16F4" unitRef="shares">3306080</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_allo_FounderSharesOfCommonStockMember" decimals="0" id="Fact-E3FB20AA1DE858F594BBF7FAA9C0041B" unitRef="shares">15144224</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleNotesPayableMember" decimals="0" id="Fact-E6AAC95A461B4E2BFF00F47065474BCC" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-609FDEA6ED4457AFA38650258FD08723" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember" decimals="0" id="Fact-AA3CA5D7E6045EE58FD6A83576D7030D" unitRef="shares">162709</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-236E52B59D3D5B89818CDFB8B533C2B6" unitRef="shares">9492134</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-66604677E5975ADA930AAE2F8AC42130" unitRef="shares">1773155</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-3" id="Fact-ABE9B9B766865B22B017521E80CF462C" unitRef="usd">773855000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2019Q3" decimals="-3" id="Fact-259926A1992E50F4B443DE121249A867" unitRef="usd">695544000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4B492C86AA1F569C9BFDB13AA8664509" unitRef="usd">467982000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-3330757FE18953219B7FF4605E289E1B" unitRef="usd">509757000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1F56219D111B506994B7C54FD793C208" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BB685173ADEC574996B308746ED181D9" unitRef="usd">4917000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C83537B5881B591582EEAD95566F1C2F" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4314E46D94A955609E2C939A35492B74" unitRef="usd">4917000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-CE0F9A54D52057E296A6B91399FE456C" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-8CBC2450753A514895E50862AE15806B" unitRef="usd">244076000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5F2EB136D0765ABD829ECBB38E3F1028" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E0C4B7C085BC5E52A7F41C0C3C5368AF" unitRef="usd">244076000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D4964B90DC745C0295E4D0B0B147286D" unitRef="usd">61023000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BCB750CC49E654D586FBF8B75E3FE236" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-46182DA2F7C053DABE81AFF1427B7B6F" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-83F6D9EB6C535CA39F45743A96CC3EC7" unitRef="usd">61023000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-0CDF460B65F158F0B833A4F1334D427F" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-258D4C4E6D1053208ACF0F9765D91133" unitRef="usd">62115000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-95AF22CE2EA157EDB98C5D10AEDA14A1" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9A7C4CD035E5542B8590B66FDBB3E52A" unitRef="usd">62115000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-B980BABB9387516A8AC15E3955047CEE" unitRef="usd">342001000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3E323284D39E5D50916F7DE5EBF3D894" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-02577C035AE257E7B410E0A79E0F58C1" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-E92E659E1E4956A3A6D617CC591796A7" unitRef="usd">342001000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3F4BF76CB5AC5F0692A0701ABF71D30B" unitRef="usd">403024000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-454227E03A4052C484A0495E4641236A" unitRef="usd">311108000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9DACAF953F61580D8C2F14DA9C3F0FA1" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-AD7F60A147AB527C85A3E94B5438B9FF" unitRef="usd">714132000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C47BDB570C4C5E49A4AF70A79FD2E676" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-10A478404D1F570CA67E84C2BD2585A4" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-A6F22184317E531F8599BBB7AA632261" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-87D05FB9030E5055AD79F1916D18AFDD" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9C8F4E2C23FF50F2AFFD53279C85E509" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-3D6D425B196852E0BEEDD8F0F2D154BF" unitRef="usd">191657000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-802ACA105A675790823BAF458D303A19" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateBondSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D63E2295B383504883035E373A6817C8" unitRef="usd">191657000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BD9C537B364D59219437251C1A7966BB" unitRef="usd">112394000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DED1A783F9455156A07AB09215611A18" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-4777E3E225AC5AEFBE8A52802630EA30" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-52BBB8ECD64A5F37BCFB3E505D8774A9" unitRef="usd">112394000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-857F6529C4BD5CAF896376D912358D87" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-5AA1C414D6D55BE091AD4F15A60FE22E" unitRef="usd">45666000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-D028B6182FFF5F6EA69E3962D93D3DCB" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-C751B59A342A534A9885C94F3D9AFE83" unitRef="usd">45666000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-6A6D544A16765B41AB94F38ED281E5EF" unitRef="usd">203633000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-1803A1AAABB1567AA0676FCEA10FF5ED" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-437D1F12439850E686ACE300E2342A7A" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-90DE5384DEFF598E8B56D5A76A136B3E" unitRef="usd">203633000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-DEE2F74052C75AA9A726E476921B809E" unitRef="usd">316027000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-9C4C480670F05D5E8007A22AB54EDCB8" unitRef="usd">237323000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="INF" id="Fact-9BF09CD6291E5EC5904F73D80294DD15" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="Fact-BF7F2DE2674A5CE1B7813B28511B740F" unitRef="usd">553350000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4" decimals="-3" id="Fact-7CE0204955FD5BBA90EAFED21C01C494" unitRef="usd">743000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-EEF5A06F01695CEBA5A072278F2C91B5" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-ECFF4F9A4A3055F29404CE81197E585D" unitRef="usd">220000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-20294A08D4C9564396999EACCC6DD92E" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" decimals="-3" id="Fact-F21535401CEB558DBF53E35496BB748E" unitRef="usd">181000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-EA1352D77BD75384B6D5EEF457DC5497" unitRef="usd">342000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q3" decimals="-3" id="Fact-56DD9B31C5A25DA18B63225EB44A6597" unitRef="usd">2174000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-56DDF99A30AB562AA77DAE2B880FA5A1" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-1455781DF40A583C92464DEEE4E387ED" unitRef="usd">1195000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-08C119391D465E0883107F8C382FD59F" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" decimals="-3" id="Fact-4625D9AAA5DD59FFA939F7556D8A09EB" unitRef="usd">235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-43D79869C60F5C5A8098973F79075016" unitRef="usd">744000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4" decimals="-3" id="Fact-A22E17BEBABD5986963FEAE95C78C5CE" unitRef="usd">320000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-2AC95D6766475A818969498844DAEBCC" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-14629A20D31B5549AA520D55A7EEAAEC" unitRef="usd">280000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-164CE60C2EB85D02B90B710049ED51A2" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" decimals="-3" id="Fact-54EB06E154375DAA9F5DFA33BC31C021" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-0DD895070688569C8168827FBB3C0785" unitRef="usd">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q3" decimals="-3" id="Fact-2F719108C543584AA82B3C05C6C1D9A6" unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-F89E3C91124B56979207739A859F3455" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-5182BA54D71E5DB889F6FE991DF1D0E8" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-14A2B8E2CC7D50C6B8FEB7D932FFA3DD" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" decimals="-3" id="Fact-1E9CE6FE2691522CAF315194128EEDBF" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-A823212745695822BBD58F0827C08551" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4" decimals="-3" id="Fact-E244E008DB0F5B999E483A304486F9D8" unitRef="usd">713709000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-89FE36CECCD05AF49BBBF41CB055F265" unitRef="usd">4917000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-006827008A0C5EFB8F0269615A831B71" unitRef="usd">244136000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-8518302CCD2D5A2DAA25B1EE34059214" unitRef="usd">61023000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" decimals="-3" id="Fact-786D5F43075855149F3C2B088BC6970C" unitRef="usd">61937000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-94E60F5A9AE558DA881898FC35EEEE4A" unitRef="usd">341696000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q3" decimals="-3" id="Fact-E221ECD5897B57AE980D8585EF39CF80" unitRef="usd">551187000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-9851BF03464C5234B3869A963A04BD54" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-A52721FBE2225179BEEDF9760E11EAFB" unitRef="usd">190467000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-7804991F88895CBC8D13E39B3873818D" unitRef="usd">112394000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" decimals="-3" id="Fact-A083C5CBF566575588B38BFEEC366ECB" unitRef="usd">45433000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-83571D8CED635814BAB11EF606633927" unitRef="usd">202893000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-0BDA0D0A217654B99E028645EB50DDF2" unitRef="usd">4917000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-727C2591EEFB5A3A8835ABA82E6D7251" unitRef="usd">244076000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-7946C7C81AA15C998ACC4A958C7F1FB9" unitRef="usd">61023000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" decimals="-3" id="Fact-5CFD1D727D835C39B5DD28B691ABF8C8" unitRef="usd">62115000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-4DF8C37DBC5B508DB4C4E6AF0CF7CD01" unitRef="usd">342001000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-3" id="Fact-2EF3BCC316E0550CB06FE0F9FB60BE32" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_CorporateBondSecuritiesMember" decimals="-3" id="Fact-FD1D773A6979571A8C37DB489631D78C" unitRef="usd">191657000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-CFC212A56EF45E50B574BCCD3BFBBF36" unitRef="usd">112394000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" decimals="-3" id="Fact-6F29D12D5057548C9D83AADF72523D3B" unitRef="usd">45666000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q3_us-gaap_InvestmentTypeAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-E27C38C271A35A00B19EA3CD35FDBF2D" unitRef="usd">203633000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-CE2E8C13342850CD8DC011A3ACD46C42" unitRef="usd">366952000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-A935EBA28B96569FAA90010D4AC69BD3" unitRef="usd">340254000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-CB17F3E67F0E5F53B6BCAB7CBCFC28C6" unitRef="usd">261966000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-3DC7E6B24A1756A89484ABDA12F62F04" unitRef="usd">100702000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2018Q3YTD" decimals="-3" id="Fact-FE1F9DF96F155841A3EB36A294383A64" unitRef="usd">204000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2019Q3YTD" decimals="-3" id="Fact-FAA01724D6C856FDBF3C616DF64AFC36" unitRef="usd">6571000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-BCB01CFEB94255F0ACF7D764516D38F0" unitRef="usd">92432000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q3" decimals="-3" id="Fact-92F537FA4B435378AD4764DDC594C5D5" unitRef="usd">160990000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="FI2019Q3" decimals="-5" id="Fact-037EE783C09952C48C3378619643F233" unitRef="usd">601900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="-3" id="Fact-1280CCC15DE359BBBBD95A58EB4ADBA0" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q3" decimals="-3" id="Fact-75A64F4736095D138D2FFECA3366428B" unitRef="usd">84078000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="-3" id="Fact-382998A8130051A8AC05DDBE9751363D" unitRef="usd">93731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2019Q3" decimals="-3" id="Fact-6F3DA09350085C758BEFF8F76196F870" unitRef="usd">165289000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q3YTD" decimals="-3" id="Fact-4F3835E5DE9A53D592020570154D7CC4" unitRef="usd">84078000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2019Q3YTD" decimals="-3" id="Fact-97EE1BE80E3052C7A848E4156BF3A7D0" unitRef="usd">71558000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-72FB6E5418CA57ABA600921FFC3838F9" unitRef="usd">85214000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2019Q3" decimals="-3" id="Fact-DEA82D99F311591EA92C077AC1B60484" unitRef="usd">112394000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-00091596B59A5F90BA3AAC64F1C58991" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2019Q3" id="Fact-EEBE27F0AA675BC4B2C31BAAE399CA04" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2019Q3" decimals="INF" id="Fact-EE4B4DF090CD59D69307D62AB1881886" unitRef="shares">9915688</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-FEA932A136BB57CA90458BA3FF98CA5F" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2019Q3" decimals="INF" id="Fact-B3428E58114558F1B3ED32836E883D5A" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-1724B366064C597690354AD7BDE2A471" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2019Q3" decimals="INF" id="Fact-09750AC8944A5E93BF3541F83E496705" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-393F43A40FED5E25A2BBAE81C7119882" unitRef="shares">121482671</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2019Q3" decimals="INF" id="Fact-6A7E0301C2B55DD5BCF38BC24D7E9808" unitRef="shares">121895479</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D7D7CC84EA615D9198984CB17ECC559E" unitRef="shares">26249993</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-AED96949FF3F5C4797644115079D2408" unitRef="shares">27714743</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D1817B4408FA542A871C02B0153633C3" unitRef="shares">31270573</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-09077C26A0F25C23909310930196C226" unitRef="shares">121482671</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-86A0D7A46B385B5CBBF0AB5750023822" unitRef="shares">121482671</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-713E4EDABCC05725B0AF5B1E04369F07" unitRef="shares">121631278</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q3" decimals="INF" id="Fact-12C974D1A22B58779BD2296EE27DE13B" unitRef="shares">121895479</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q3_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="INF" id="Fact-BCF626609FFB57AF92AF024FDC2CF009" unitRef="shares">22032040</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-60AAC0EAB00551EBAC460FAEEB07DD16" unitRef="shares">121895479</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-02C087840AEC57229C1EE0A739A95F25" unitRef="usd">121000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2019Q3" decimals="-3" id="Fact-9D2FB8F387B75192AA22067C4EBC301E" unitRef="usd">122000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q3QTD" decimals="-3" id="Fact-9BC068AB712B50A18ACD5A4629E02244" unitRef="usd">-43645000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q3YTD" decimals="-3" id="Fact-FF5745F8F22E5D79A710883C54D6C310" unitRef="usd">-181144000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q3QTD" decimals="-3" id="Fact-8647195EA88A50B98340C7765414E259" unitRef="usd">-51030000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q3YTD" decimals="-3" id="Fact-8C3F6583B04A50C2978235252295A0D6" unitRef="usd">-122004000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2018Q4oct31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-A62F76EE0FFC5C969529C053E81DE8FC" unitRef="shares">61655922</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:DebtConversionConvertedInstrumentRate contextRef="D2018Q3Sep" decimals="INF" id="Fact-548A62E8A3A5BBD5D6D1242F4CC101E7" unitRef="number">0.85</us-gaap:DebtConversionConvertedInstrumentRate>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2018Q3" decimals="-5" id="Fact-3979F59EACD1913DAF30241DF7F58A1C" unitRef="usd">120200000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2018Q3YTD" decimals="-3" id="Fact-A412CFF9E45E5E1C8B08CBE1F27462B1" unitRef="usd">1388000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2019Q3YTD" decimals="-3" id="Fact-055841C8C38252A1906FF69DDAEDC16D" unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
	<us-gaap:DebtSecuritiesAvailableForSaleTerm contextRef="FI2019Q3" id="Fact-017FA9164B23531EB2A3BD31E85131A8">P3Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
	<us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent contextRef="FI2019Q3" decimals="-5" id="Fact-7AADE0ACD91B5920BE4897CBB9C0F92C" unitRef="usd">2800000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
	<us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent contextRef="FI2019Q3" decimals="-5" id="Fact-BAD0A846EC8F5B649E9C54D6BC0CCA27" unitRef="usd">4600000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2018Q3" decimals="-5" id="Fact-80429511B84E9E344965243CF91B341D" unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3ED6290055DB5D519065A321F95D2217" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2019Q3YTD" decimals="-3" id="Fact-1E14CBD014D3566785B244FD56A2B383" unitRef="usd">-176000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DepreciationAndAmortization contextRef="FD2018Q3YTD" decimals="-3" id="Fact-7B16006D84E955A78208A78543EABCA7" unitRef="usd">651000</us-gaap:DepreciationAndAmortization>
	<us-gaap:DepreciationAndAmortization contextRef="FD2019Q3YTD" decimals="-3" id="Fact-FA6FE91D688655E19B0A6A902326F91D" unitRef="usd">2720000</us-gaap:DepreciationAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3QTD" decimals="2" id="Fact-AA288C47901A5C42B7018E4E3CFDF738" unitRef="usdPerShare">-10.71</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3YTD" decimals="2" id="Fact-0B36BF7E384B5B6980916B6F1941C63F" unitRef="usdPerShare">-16.38</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q3QTD" decimals="2" id="Fact-146C6688B89F5C36953733160C3010AF" unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q3YTD" decimals="2" id="Fact-BD6DCB29FE8454D2BDF13779F1AE904F" unitRef="usdPerShare">-1.24</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="I2019Q4Nov1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="2" id="Fact-FD0688B4C3A7C109F48418A89623F779" unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-F1B2DADA67DE592995BCAC1732EB5015" unitRef="usd">11317000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-C4C14F670DFF5B88A44F23A5BFD3E3BB" unitRef="usd">26440000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-971B73DDFBFB5015BC1F2859D2A41A29" unitRef="usd">15016000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9F74B99C2F9455A89AD4C35432CF7F50" unitRef="usd">42261000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q3QTD" decimals="-3" id="Fact-DC9FF4C64B4A50BEB10333D40554607D" unitRef="usd">-43497000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q3YTD" decimals="-3" id="Fact-772CB360AEDB5E48A138B6CF6E1BCC24" unitRef="usd">-180996000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q3QTD" decimals="-3" id="Fact-962A7645F86C5347802CDDB01DA6DA54" unitRef="usd">-50702000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9B3D7D95E8B454758AFFCC9BA3D9274A" unitRef="usd">-123740000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3QTD" decimals="-3" id="Fact-87C8973818B25F0786723918D272ACC0" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-72FCC0BC26C25E7C8DCF711528BF1E20" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q3QTD" decimals="-3" id="Fact-CF281A8070C3503C9691104820DA600E" unitRef="usd">33000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9C06D10651CF5E54BAA5157B6E6E5146" unitRef="usd">-176000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-9E5D45D67B285428AA9C3AE106D82C04" unitRef="usd">3083000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2019Q3YTD" decimals="-3" id="Fact-2DE0A1E2108B5993B312FFE4E4F37721" unitRef="usd">-3137000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3B110730EB4952F58F3651B3CE546B3A" unitRef="usd">12695000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-0F7BF9F396DE5C6F8D08F7C979C54CB7" unitRef="usd">7510000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInNotesPayableCurrent contextRef="FD2018Q3QTD" decimals="-5" id="Fact-2852A6252978C17A4A62243C263D0BFE" unitRef="usd">19400000</us-gaap:IncreaseDecreaseInNotesPayableCurrent>
	<us-gaap:IncreaseDecreaseInNotesPayableCurrent contextRef="FD2018Q3YTD" decimals="-5" id="Fact-E94A62680C05A7506D7124415F182FD4" unitRef="usd">19400000</us-gaap:IncreaseDecreaseInNotesPayableCurrent>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="FD2018Q3YTD" decimals="-3" id="Fact-9B12636F84E25D1C86E069269F7C1AB0" unitRef="usd">1468000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="FD2019Q3YTD" decimals="-3" id="Fact-7FAA0AC621595D79A0A5D6C3117E7F39" unitRef="usd">2863000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-B2B1DAB0037059B0882D3CFA6409E826" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-45D06A367DB85A0B920F4A694D4611F1" unitRef="usd">-1991000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3CCA2808EEF95D849629094CF3FABBD8" unitRef="usd">3132000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2019Q3YTD" decimals="-3" id="Fact-05F8D3B89CA9595288C1E349408D052D" unitRef="usd">-86000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2018Q4" decimals="-3" id="Fact-E4EEF4E032ED546CB3AFAE5E276CB3C5" unitRef="usd">754000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2019Q3" decimals="-3" id="Fact-7466C043034F56A7876B15B0B97DD1F7" unitRef="usd">301000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-340C9750E23D717E19D6F46C45DDD944" unitRef="usd">3358000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-380081BB1F1C592BC359F46C45E5381A" unitRef="usd">3358000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-326F36A112C9FA0499F9F46C45E14E1A" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-4B6A10C15450E51E3C97F46C4618F9F2" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="FD2018Q3YTD" decimals="-3" id="Fact-FBE6D223B8105DA78F37138CB894BC56" unitRef="usd">-125000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
	<us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="FD2019Q3YTD" decimals="-3" id="Fact-F4EABA56556A5E1D83EA50F6B95C27DE" unitRef="usd">3136000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-CC1C896E33BD52C1A57C58A6D7C09F96" unitRef="usd">664000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-F1DFDA105125572A94317564C88D1FDE" unitRef="usd">4827000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LesseeOperatingLeaseDiscountRate contextRef="FI2019Q3_srt_StatementGeographicalAxis_allo_LosAngelesMember" decimals="3" id="Fact-C7326893D34254A0B57F66C7B372CFDF" unitRef="number">0.070</us-gaap:LesseeOperatingLeaseDiscountRate>
	<us-gaap:LesseeOperatingLeaseDiscountRate contextRef="FI2019Q3_srt_StatementGeographicalAxis_stpr_NY" decimals="3" id="Fact-F331B88100CA50CCAFB6A38AF5EE179E" unitRef="number">0.080</us-gaap:LesseeOperatingLeaseDiscountRate>
	<us-gaap:LesseeOperatingLeaseDiscountRate contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember" decimals="3" id="Fact-B444951DCAA253559F17A6676C62B982" unitRef="number">0.080</us-gaap:LesseeOperatingLeaseDiscountRate>
	<us-gaap:LesseeOperatingLeaseDiscountRate contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember" decimals="3" id="Fact-2DCF3D9E74B353E7BDE0300CB3DB867B" unitRef="number">0.080</us-gaap:LesseeOperatingLeaseDiscountRate>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="FI2019Q3" decimals="-3" id="Fact-19F6A6FE574D5E1B89ADBF34381A7DD1" unitRef="usd">94853000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-15EC05A5677B51209C4042AA9202F79A" unitRef="usd">63516000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-6E1453A41DB758F0AE1C185AF61A2546" unitRef="usd">8213000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="FI2019Q3" decimals="-3" id="Fact-B39D7AD4B83957B3955DF9E29FCFCE3D" unitRef="usd">7961000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="FI2019Q3" decimals="-3" id="Fact-063D5DECDACB5D38BD27D4CB1F310192" unitRef="usd">7801000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="FI2019Q3" decimals="-3" id="Fact-406F6EAD49445F7798910E08A0E5D61D" unitRef="usd">5981000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="FI2019Q3" decimals="-3" id="Fact-681C2133FA3A596280570EFA172A02D4" unitRef="usd">1381000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
	<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="FI2019Q3" decimals="-3" id="Fact-138353A805125A68BFDF1BDBCFB2ADEC" unitRef="usd">17756000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="FI2018Q4_srt_StatementGeographicalAxis_allo_LosAngelesMember" id="Fact-B762B5E00C7E581A935B791C9D56ACBF">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="I2018Q3Aug31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember" id="Fact-EBD94E8BF7D519359E4B15344529E31D">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="I2018Q4oct31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember" id="Fact-16999A3FFDFA251AE650277FB46AC62B">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_allo_NewarkMember" id="Fact-2EF7B032E2F36BB39D981545513764B7">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="FI2018Q4_srt_StatementGeographicalAxis_allo_LosAngelesMember" id="Fact-EA65C27B7A92CD3BA71A15431E3ABF5A">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="FI2018Q4_srt_StatementGeographicalAxis_stpr_NY" id="Fact-340471172265128E752A154096695C66">P79M</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="I2018Q3Aug31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember" id="Fact-2E65E84B7BB8DA16D74F1534435E1929">P127M</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="I2018Q4oct31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember" id="Fact-1EEB4277B9D655CC930C8A89983A34E9">P124M</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:LesseeOperatingLeaseTermOfContract contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_allo_NewarkMember" id="Fact-5F08256A74E16708C8661545112826BB">P188M</us-gaap:LesseeOperatingLeaseTermOfContract>
	<us-gaap:LettersOfCreditOutstandingAmount contextRef="FI2018Q4_srt_StatementGeographicalAxis_stpr_NY" decimals="-5" id="Fact-ECE8DDBC66AF5B2AAB5B757959EB8FB3" unitRef="usd">100000</us-gaap:LettersOfCreditOutstandingAmount>
	<us-gaap:LettersOfCreditOutstandingAmount contextRef="I2018Q3Aug31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember" decimals="-5" id="Fact-6840B48404825196B405CCAD4A4CBFEB" unitRef="usd">1000000</us-gaap:LettersOfCreditOutstandingAmount>
	<us-gaap:LettersOfCreditOutstandingAmount contextRef="I2018Q4oct31_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember" decimals="-5" id="Fact-A7A878A7519D56AFB08921E97AF53B94" unitRef="usd">200000</us-gaap:LettersOfCreditOutstandingAmount>
	<us-gaap:LettersOfCreditOutstandingAmount contextRef="I2019Q1Feb28_srt_StatementGeographicalAxis_allo_NewarkMember" decimals="-5" id="Fact-7C21757E30E35860AC3C85C12A326498" unitRef="usd">3000000</us-gaap:LettersOfCreditOutstandingAmount>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-3" id="Fact-27271DB6623B578586887FC9245CF967" unitRef="usd">70691000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2019Q3" decimals="-3" id="Fact-F95BCA2CFB4155C3AA49D65016D48191" unitRef="usd">75828000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-4C90EF4BDF6C55D9B73B421D8E4A1C58" unitRef="usd">773855000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2019Q3" decimals="-3" id="Fact-935B69583CC05AA98BEEFA33F99C2A86" unitRef="usd">695544000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-6E59DDF3D7F254CEB385148A10123BF8" unitRef="usd">29459000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-2925F1ACD23751269B988B2FB2C6439A" unitRef="usd">33354000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="INF" id="Fact-CD2CE4003284566A8ED42CEA9324B82F" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LongTermDebtFairValue contextRef="FI2018Q3_srt_RangeAxis_srt_MaximumMember" decimals="-5" id="Fact-BF761140B6420235AD342432ED1169D9" unitRef="usd">139600000</us-gaap:LongTermDebtFairValue>
	<us-gaap:LongTermDebtFairValue contextRef="FI2018Q3_srt_RangeAxis_srt_MinimumMember" decimals="-5" id="Fact-336FA6E3052B8CB84182241D89839EF3" unitRef="usd">120200000</us-gaap:LongTermDebtFairValue>
	<us-gaap:LongTermInvestments contextRef="FI2018Q4" decimals="-3" id="Fact-13D91880F1E054DB9D2F95D5F3DB837F" unitRef="usd">261966000</us-gaap:LongTermInvestments>
	<us-gaap:LongTermInvestments contextRef="FI2019Q3" decimals="-3" id="Fact-3B33E18A7FD950BFA5ECBA88726F2C58" unitRef="usd">100702000</us-gaap:LongTermInvestments>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F15ADB18BDE85D91A1FF9022DB7BEE5B" unitRef="usd">426660000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-D159A70E8A3453249452478E266FBF63" unitRef="usd">2486000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-E3882B42879C5EB588508C7734066E95" unitRef="usd">-319410000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-DEDC7320D3545BC0A35B59F621942745" unitRef="usd">156155000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3E3A529F75F15A14B84AD25EEEF30443" unitRef="usd">-23172000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-F27C5AF2729D564BAE9E7135A18FD8F9" unitRef="usd">-87083000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3QTD" decimals="-3" id="Fact-0BB8756A5B575ACC849EEFC2EF6BA83B" unitRef="usd">-43497000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-EB17EAAD8A6B52698FD262576B00CD7A" unitRef="usd">-43497000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-82B3DAAC22C85146A59FDC74192430FA" unitRef="usd">-180996000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E8FC4E2A02710E817CAE14DA283F1B2A" unitRef="usd">-180996000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3QTD" decimals="-3" id="Fact-4FC3E8D0A7ED566D977E558F80D3E4F6" unitRef="usd">-50735000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-81735D30F37E57B5948F683343FBB85D" unitRef="usd">-50735000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3YTD" decimals="-3" id="Fact-AA1F09B374295012A2E453481EFB4719" unitRef="usd">-123564000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-78B275E0977A586D8BFEFCB9C9AC8F9E" unitRef="usd">-123564000</us-gaap:NetIncomeLoss>
	<us-gaap:OperatingExpenses contextRef="FD2018Q3QTD" decimals="-3" id="Fact-06F78D240F5B5E3D9802478B47190EAF" unitRef="usd">22187000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q3YTD" decimals="-3" id="Fact-50571F1A98B85306A8A919C296F0B5AF" unitRef="usd">159796000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q3QTD" decimals="-3" id="Fact-9687EA05FFA25552B637E64F56724DC0" unitRef="usd">55011000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q3YTD" decimals="-3" id="Fact-A398A1A78E93535C9B3C271CFA443131" unitRef="usd">137433000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q3QTD" decimals="-3" id="Fact-ECD68F0517A45AAE9659CAB15AA8B806" unitRef="usd">-22187000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-92A3501E864052B291876E89880FA2D5" unitRef="usd">-159796000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q3QTD" decimals="-3" id="Fact-A037838F8E09501E83A049276CADDDBD" unitRef="usd">-55011000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q3YTD" decimals="-3" id="Fact-5D25B736F22D5F50B9C8353861A3509E" unitRef="usd">-137433000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeaseExpense contextRef="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="-5" id="Fact-26EBA66962395C14A5DEF175925A62C0" unitRef="usd">2400000</us-gaap:OperatingLeaseExpense>
	<us-gaap:OperatingLeaseLiability contextRef="FI2019Q3" decimals="-3" id="Fact-B2906B1A74EE584C9EF3F04252A882B3" unitRef="usd">38017000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-8D8254A051D853C18BE072593A521810" unitRef="usd">34456000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-F7AF7B8B50E7534992C4025A5D4B586C" unitRef="usd">37689000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q3_srt_StatementGeographicalAxis_allo_LosAngelesMember" decimals="-5" id="Fact-F45855F83037542A862BC8E2BF264F23" unitRef="usd">200000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q3_srt_StatementGeographicalAxis_stpr_NY" decimals="-5" id="Fact-0113A90AB50F5F72B19D620B83AFB29B" unitRef="usd">1800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember" decimals="-5" id="Fact-032A791700235A668FAB79D1B5845688" unitRef="usd">29800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember" decimals="-5" id="Fact-8869B1CFA8BF56BBB10CCCC467C80994" unitRef="usd">6300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2018Q4" decimals="-3" id="Fact-383E1160F3C759CC89E40ECED24C71DC" unitRef="usd">33015000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q3" decimals="-3" id="Fact-8B1E0E292693568EAE52E5B975C9A54F" unitRef="usd">31437000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q3_srt_StatementGeographicalAxis_allo_LosAngelesMember" decimals="-5" id="Fact-0A1DF49475665408822C363EB61133BC" unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q3_srt_StatementGeographicalAxis_stpr_NY" decimals="-5" id="Fact-542AD3EB50665E03A1670CE7C73D941C" unitRef="usd">1800000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember" decimals="-5" id="Fact-16EAF4D46EEA59EB871EF20EF3A2E784" unitRef="usd">23600000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_allo_LeaseTwoMember" decimals="-5" id="Fact-D203304033C1596084243DC5D319211D" unitRef="usd">5900000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2019Q3_srt_StatementGeographicalAxis_stpr_NY" id="Fact-DB34C9C2A9B58BC882721540ACF23208">P5Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
	<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2019Q3_us-gaap_LeaseArrangementTypeAxis_allo_LeaseOneMember" id="Fact-AC85CB2F59EC60C8D6A21534476B21C4">P9Y5M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2019Q3YTD" decimals="-5" id="Fact-E97B7782DCA75648B0E768F84B416015" unitRef="usd">4100000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-7AD058D4ED2551B590BF2F3DC78B39F7" unitRef="usd">244000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-044505AFE9CA5D469239964DA9FA5946" unitRef="usd">3105000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2018Q3QTD" decimals="-3" id="Fact-0D9EE80BC66352858D4C52F6273C8587" unitRef="usd">-148000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-8F6F85A217A50C4B180323EF8435AE9B" unitRef="usd">-148000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2018Q3YTD" decimals="-3" id="Fact-9055F3A3A8325914973EC1A523D21EE3" unitRef="usd">-148000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-0A8337887B570E042BB714DA9078929C" unitRef="usd">-148000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2019Q3QTD" decimals="-3" id="Fact-25B59AFC7A0C5E6B8ED86FF339BBFB10" unitRef="usd">-295000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-1C32AAD0628C57B49B067AE7DA428815" unitRef="usd">-295000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2019Q3YTD" decimals="-3" id="Fact-5D0C6C9ADE485FDD8720CE3FEAD4EBE8" unitRef="usd">1560000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-3787FEDA544A5B8883BA1B414C3F5C8E" unitRef="usd">1560000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-93E13F609BC05215863895AA7010E93E" unitRef="usd">612000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-C4D7B79439F15F85BEC1DB62361A259A" unitRef="usd">1969000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-7E01981BDB935124814DC216F70FEB31" unitRef="usd">6776000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-9B22C22B7B2B5757AB98999F96BD9F0E" unitRef="usd">4785000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-66A389E67F56506A9FFFB81B99A82A44" unitRef="usd">1463000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-4058E302600C52A98A6EB93315B91E13" unitRef="usd">1573000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-A61BA3E276BA5F3997352D982E271696" unitRef="usd">4309000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-69A68C778B275966BDBF09ABB3C9CF6D" unitRef="usd">13693000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherPrepaidExpenseCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4CE49DD643215055AD1702FE75C18EA6" unitRef="usd">758000</us-gaap:OtherPrepaidExpenseCurrent>
	<us-gaap:OtherPrepaidExpenseCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-2218F987AC625678BAC667588E26D706" unitRef="usd">1938000</us-gaap:OtherPrepaidExpenseCurrent>
	<us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements contextRef="FD2018Q3YTD" decimals="-3" id="Fact-494FE87B1EF65C198746610478B2F158" unitRef="usd">0</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
	<us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements contextRef="FD2019Q3YTD" decimals="-3" id="Fact-58C7A6D43AF65FE4A8D918A2BA817559" unitRef="usd">2182000</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
	<us-gaap:PaymentsForUnderwritingExpense contextRef="D2018Q4Oct_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-5" id="Fact-A1176953FE3D5C0A84375916DBB0F80B" unitRef="usd">26100000</us-gaap:PaymentsForUnderwritingExpense>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2018Q3YTD" decimals="-3" id="Fact-194FB6CBD94B666A28A514E8BD76EB4F" unitRef="usd">839000</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2019Q3YTD" decimals="-3" id="Fact-80808BEDC4BB2A7B609914E8BD7E8455" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2018Q4Oct_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-5" id="Fact-9C268E26016E5BF58665CEB071D1D073" unitRef="usd">3200000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-1673DECF96565552BB398B8355E535DF" unitRef="usd">84000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-F6A682509F0A5745B1129F5BBEA44D8E" unitRef="usd">635000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquireAssetsInvestingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F0D4C48B560E57CA994D82CEE993DC64" unitRef="usd">2098000</us-gaap:PaymentsToAcquireAssetsInvestingActivities>
	<us-gaap:PaymentsToAcquireAssetsInvestingActivities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-15A16728E0505F11B1E59D1A285E09C0" unitRef="usd">0</us-gaap:PaymentsToAcquireAssetsInvestingActivities>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="D2019Q4Nov1_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_allo_NotchTherapeuticsInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-35D31FD097D72D2342ED18A6A45C446C" unitRef="usd">5000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3060527DF30857D288F4736B973F60AC" unitRef="usd">315399000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-03494CC2DE79587281DCC687BFC4A382" unitRef="usd">162931000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q3YTD" decimals="-3" id="Fact-70A6EF78042A5657AD7A43A7AB267018" unitRef="usd">1913000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2019Q3YTD" decimals="-3" id="Fact-4451B2328545507EBCF43E7779F7D65F" unitRef="usd">36679000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q3_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-039F9BC647B65C3180DB486E6012FEA3" unitRef="usdPerShare">35.06</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q3_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-63A37741F3B256B9AD5347B978D18D1E" unitRef="usdPerShare">35.06</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-541522C989F356B69912E2F01A53CE56" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2019Q3" decimals="INF" id="Fact-85F5A7B9BA915BDF82DDEB694C929F2C" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-404C3B9690AF546C95D3BD1DF4EE4A9A" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2019Q3" decimals="INF" id="Fact-90CA59455B885CA0B1E499671366633E" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-C7A3469A4A8B5E14BA535A85AA77AD3C" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2019Q3" decimals="INF" id="Fact-B4BD0D9E770456B682DD9FBD600E5C54" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-E11AAF2BC756533F82D16868DDBB737D" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2019Q3" decimals="INF" id="Fact-E5A449C77A655BA68EEDFDB740B607B0" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="I2018Q4oct31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-18A57CDAD97255858021BB6D1BD83824" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-D9C6A31602095913B927FB4A7AB1BF14" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2019Q3" decimals="-3" id="Fact-09B556BDAB34573DB529618D3235346E" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-82C7470D38D85B07B741228DDC552096" unitRef="usd">8598000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-04C7FFB5304C57B6AA0DAAA58C0ED8A4" unitRef="usd">8513000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidInsurance contextRef="FI2018Q4" decimals="-3" id="Fact-12C813F89B515B01A3CDE18781FFDC98" unitRef="usd">2376000</us-gaap:PrepaidInsurance>
	<us-gaap:PrepaidInsurance contextRef="FI2019Q3" decimals="-3" id="Fact-B472973596515A00A0C5F96C2C18848A" unitRef="usd">114000</us-gaap:PrepaidInsurance>
	<us-gaap:ProceedsFromConvertibleDebt contextRef="D2018Q3Sep" decimals="-5" id="Fact-B370AF11F6086D119FB4241FB6F0F983" unitRef="usd">116800000</us-gaap:ProceedsFromConvertibleDebt>
	<us-gaap:ProceedsFromConvertibleDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-40C45C8880047D5B81D314E5A71226D9" unitRef="usd">116842000</us-gaap:ProceedsFromConvertibleDebt>
	<us-gaap:ProceedsFromConvertibleDebt contextRef="FD2019Q3YTD" decimals="-3" id="Fact-00461E9F7E5933546ED214E5A716E9B0" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2018Q4Oct" decimals="-5" id="Fact-722DCCE0A9425CFEADA1C3DBA469174A" unitRef="usd">343300000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2018Q3YTD" decimals="-3" id="Fact-E6D75DD03681517682E513296A40FD93" unitRef="usd">299282000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="FD2019Q3YTD" decimals="-3" id="Fact-E6D3BBE3AE4E58B787843E7318C86E5B" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2018Q3YTD" decimals="-3" id="Fact-C4A02A69A6075EBCBC46FE8E7C9305F1" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="FD2019Q3YTD" decimals="-3" id="Fact-7B2510EEC1E653A88B601859303BC6C3" unitRef="usd">703000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-37A3E949A0B95E4A95400BECD7D5384C" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-DE99C372654759D887F31A1E8F0ED617" unitRef="usd">355765000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
	<us-gaap:ProceedsFromStockPlans contextRef="FD2018Q3YTD" decimals="-3" id="Fact-DEE28F0474605B45BC102CDF324DFB6D" unitRef="usd">0</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProceedsFromStockPlans contextRef="FD2019Q3YTD" decimals="-3" id="Fact-D99B57BA99B95E19AE959053BEE3C8F8" unitRef="usd">1783000</us-gaap:ProceedsFromStockPlans>
	<us-gaap:ProfitLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-2E4D7EBF38475207B2B4C201D375005C" unitRef="usd">-180996000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q3YTD" decimals="-3" id="Fact-29E3E7BE10FE5D738C7F0E836CC19A2E" unitRef="usd">-123564000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4" decimals="-3" id="Fact-21B9ED74EA52565CB0FD053AAE5AE9A2" unitRef="usd">9643000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_allo_ComputerEquipmentAndPurchasedSoftwareMember" decimals="-3" id="Fact-5CDB21AC8DAF5BEC9D4585A74AE46365" unitRef="usd">1327000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_allo_LaboratoryEquipmentMember" decimals="-3" id="Fact-D1811334BD505A8C86E8A87E26EA1D5C" unitRef="usd">5534000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-DC4FAE601D08595EAE2222DC0C5039A9" unitRef="usd">2703000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-0E956BE417155443A4D2B7F62303DD12" unitRef="usd">64000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-510D852E8B5F5A7282FAD584914B8D01" unitRef="usd">15000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q3" decimals="-3" id="Fact-63BE05B7CC51545DAB1E9E9A077F821F" unitRef="usd">49711000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_allo_ComputerEquipmentAndPurchasedSoftwareMember" decimals="-3" id="Fact-A156A0CB433E57AB928E09FB22945D35" unitRef="usd">3496000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_allo_LaboratoryEquipmentMember" decimals="-3" id="Fact-40E7BD3566855349886C5AB16BAA7253" unitRef="usd">11566000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" decimals="-3" id="Fact-91FD009738DA581BB0F3F0E8AEB432D8" unitRef="usd">6778000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-BC39F9592B355D95BB47668D20B16959" unitRef="usd">2638000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-3183A72A26755588A71D1B342820B086" unitRef="usd">25233000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="-3" id="Fact-D429CEAD89165167BCEE5FFD2AFBE48B" unitRef="usd">8595000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q3" decimals="-3" id="Fact-8F2F8998DB8454A2AD06FEFAD8AE7809" unitRef="usd">45943000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:RelatedPartyCosts contextRef="FD2018Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember" decimals="-5" id="Fact-7617A6904560B9089EB11893FE3D6602" unitRef="usd">100000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2018Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_TwoRiverConsultingLLCMember" decimals="-5" id="Fact-2E1D7FEC6507BD3FB93D1891C53C94A2" unitRef="usd">300000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2018Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="-5" id="Fact-7E4F0B181AB2519D84158D6B920AACAF" unitRef="usd">3800000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2018Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember" decimals="-5" id="Fact-C83834439403087F4244189408F639A9" unitRef="usd">100000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2018Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_TwoRiverConsultingLLCMember" decimals="-5" id="Fact-ECA757262FBC5FB79F015A8382D8CD54" unitRef="usd">700000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2018Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="-5" id="Fact-DCA00EDD8C065935AED0DF3F39F25C39" unitRef="usd">7400000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember" decimals="-5" id="Fact-7608F7713C365BFB94E0FAC74D0193EC" unitRef="usd">100000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_TwoRiverConsultingLLCMember" decimals="-5" id="Fact-5C2F3A0DBC9B533E86DC84CE80BD4FAB" unitRef="usd">200000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="-5" id="Fact-6687ABB26DF353CFB7B0A6F5606DA985" unitRef="usd">700000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2019Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_BellcoCapitalLLCMember" decimals="-5" id="Fact-21789A2A45035F499E3FC05C319B6D5B" unitRef="usd">400000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2019Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_ConsultingAgreementsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_TwoRiverConsultingLLCMember" decimals="-5" id="Fact-1B84EFBDBC5A5490B15EBF0641B7E5A5" unitRef="usd">500000</us-gaap:RelatedPartyCosts>
	<us-gaap:RelatedPartyCosts contextRef="FD2019Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="-5" id="Fact-41B6071254F05581878F500194E80320" unitRef="usd">4900000</us-gaap:RelatedPartyCosts>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-9F2FC8EB909E5F0CAB2F15AB3D025C06" unitRef="usd">10870000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember" decimals="-5" id="Fact-A353B5DFD76A59339AA503603F74F7A9" unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="-5" id="Fact-BE3097143628551BA2C8F017B5F0D35B" unitRef="usd">4800000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5632279AFA7B50059C24E88EBF2457E0" unitRef="usd">133356000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember" decimals="-5" id="Fact-B8ADFA3DAFD9532EA58A5D1EA67B1EC6" unitRef="usd">400000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="-5" id="Fact-AF801AFFC92734C16A9A150A3E57C47F" unitRef="usd">7500000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-0D6B0C509D7C5B79A3114F6DD1A6CFA6" unitRef="usd">39995000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember" decimals="-5" id="Fact-2A7BFBEA8B6456DAA96D7FCC8320492E" unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="-5" id="Fact-8E0F5091D9675AC886E7F810E1F66EB7" unitRef="usd">1500000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-5A312A8A689E5D639D25161B60CF3577" unitRef="usd">95172000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_CellectisSAMember_us-gaap_TypeOfArrangementAxis_allo_ResearchCollaborationAndLicenseAgreementMember" decimals="-5" id="Fact-810513EA9214579E9D33A7BAC5DD15B5" unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ServierMember_us-gaap_TypeOfArrangementAxis_allo_LicenseAndCollaborationAgreementMember" decimals="-5" id="Fact-31A0A9514B695D6A838D8003614F3641" unitRef="usd">4500000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2018Q3YTD" decimals="-3" id="Fact-4E2CD08BCB9C5602B60883267C367D46" unitRef="usd">109436000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2019Q3YTD" decimals="-3" id="Fact-EE6063F1CF3454A38029199CAAB7EA4E" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RestrictedCashNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-76C01F48CB6D56CCB4A8D76BF2660CE8" unitRef="usd">1299000</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RestrictedCashNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-321586ED1036508AAF02216EE2F2E5D2" unitRef="usd">4299000</us-gaap:RestrictedCashNoncurrent>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-3" id="Fact-16A30DEEE6B4505BA6B995F2834E4E86" unitRef="usd">-211528000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q3" decimals="-3" id="Fact-25233E101F9E51D38065BEE6D5EC4C5A" unitRef="usd">-335092000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q3" decimals="-5" id="Fact-65532EF26D235FB284E4EED722729237" unitRef="usd">-335100000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2018Q3YTD" decimals="-3" id="Fact-645CF2FC1B87584EB12E3F98088A4174" unitRef="usd">25322000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
	<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2019Q3YTD" decimals="-3" id="Fact-CF35993AE15F5E22A775D3FD8B6381E2" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q4oct31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-5E6FEE574BEC5A84BD5D229DCB778FC2" unitRef="usdPerShare">18.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5DAC7B6106325D1FBB57C3A485B4BE4D" unitRef="usd">12695000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q3YTD" decimals="-3" id="Fact-BC063BD81E1A5822AD2FA272886DEA8F" unitRef="usd">32189000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember" id="Fact-4EAED170B07BCD3FD5B137A35170CDCE">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-93E2D70C2A2D579889A08EEA2459B392" unitRef="shares">22500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-889909A1666554629CA30F77F6EB69F0" unitRef="shares">1795905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-48BC12E70811522AA9B88913DCBA408F" unitRef="usdPerShare">27.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-B577CA41A8685E819FBE36BB90B5557F" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-F5A44B524A7052EFBEC5DF517A7C7E30" unitRef="shares">1773155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-783A1C516A655360BF7A95B651D93969" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-C2335D0E05C45ABD9290CAF3863943CD" unitRef="usdPerShare">27.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-385C5B5C809852EFB27F1686B4D6DC8E" unitRef="shares">250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-8523A509AEF2583D9E92294E08126995" unitRef="usdPerShare">25.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2019Q3" decimals="INF" id="Fact-C7A2FB9C7A705BD480F0D95FB245D1D2" unitRef="shares">4553432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2019Q3" decimals="2" id="Fact-AF28801937F75F7191A4C63FA96E95C2" unitRef="usdPerShare">10.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2019Q3YTD" decimals="INF" id="Fact-91D2A2FAB28E509C8AB20B6ADC144D8F" unitRef="shares">220151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2019Q3YTD" decimals="INF" id="Fact-49DF43280C8E52A890D9C14DA94936F5" unitRef="shares">2781316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4" decimals="INF" id="Fact-4BD07404C0A35F19AA8EED8F7D35F5D9" unitRef="shares">7235545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2019Q3" decimals="INF" id="Fact-92261F7ACC1757AEA25FC398B2AADEF8" unitRef="shares">9492134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-78EEB60F44475590B6E9D33D5B436C00" unitRef="usdPerShare">7.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2019Q3" decimals="2" id="Fact-A54B0EFEFF585C9791C1FA9ABD54363E" unitRef="usdPerShare">13.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2019Q3" decimals="INF" id="Fact-65786EF1D51250E9AB19B625ABB10515" unitRef="shares">9492134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2019Q3" decimals="2" id="Fact-0BD08A94ACFB564DBB00060D2A6AB5DB" unitRef="usdPerShare">13.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2019Q3YTD" decimals="2" id="Fact-FCE1F562214451F98FE11ED0FB461872" unitRef="usdPerShare">2.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2019Q3YTD" decimals="2" id="Fact-CEE5F04804EB570D950F5C9AD02089DB" unitRef="usdPerShare">9.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2019Q3YTD" decimals="2" id="Fact-8F25CD9264495EDBBCAB06D597EABB62" unitRef="usdPerShare">27.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2019Q3YTD" id="Fact-593B8314A82C54B192FCED490AB07151">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-2C1F02B03D665127985E2CAB7E900E24" unitRef="usdPerShare">27.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD" id="Fact-EB59AA55D8DA5DA59C5176B0616EDC44">P9Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2019Q3YTD" id="Fact-5BBC03C08E6957EEB6F7F31B43D2064F">P9Y26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2019Q3YTD" id="Fact-E9BD17D32C9A5D1F94B62F4C3619F067">P9Y26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2019Q3QTD" decimals="-3" id="Fact-BA826D9A9CC5549DAED6C45FA54E65C8" unitRef="usd">710000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E9A62566D4EC55B0A5DF796F29BA94AF" unitRef="usd">710000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2019Q3YTD" decimals="-3" id="Fact-32B2BC4BA33E5E38A1DACDC7A86BDEC9" unitRef="usd">3880000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C4F3709C49355657A5F88522DB2C9215" unitRef="usd">3880000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:ShortTermInvestments contextRef="FI2018Q4" decimals="-3" id="Fact-612C11D9FADB5571A235B70CD0D7ADC4" unitRef="usd">366952000</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="FI2019Q3" decimals="-3" id="Fact-11C5BD65DA845CB48FD64DEDA0F2D5C2" unitRef="usd">340254000</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2018Q4Oct" decimals="INF" id="Fact-07E4EE07269F1D38FFCA2422F377D608" unitRef="shares">7856176</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2018Q4Oct_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-2B3404120F8D5E329F60E9104BA63838" unitRef="shares">7856176</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A22CBA7499376FDF06FB14D463A97A6F" unitRef="shares">63333</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-ECA9E4F18E20586591EF0D9F43E6FF8B" unitRef="shares">107982</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2018Q4Oct_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-971C6C7408EC578C839E13D48D49DAFD" unitRef="shares">20700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2018Q4Oct_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-73A76600A1F45A759086E7852608CCF9" unitRef="shares">2700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-BC8E5823D8B05225BF399718C7A723A0" unitRef="shares">3187772</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E20F2F566F065683B7A2E9D858ED0DF9" unitRef="shares">3555830</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C3060432BB44979DFBA014D80E17FDD4" unitRef="shares">5020580</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-8D42B4DE08C356B3984896352CA22FE5" unitRef="shares">200868</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q3YTD" decimals="INF" id="Fact-56E994A10E8F5F1081A2575D294C5B97" unitRef="shares">304576</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C21DBFD3AD795CD19FC4660A0ACB39C8" unitRef="shares">304826</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2019Q3QTD" decimals="-3" id="Fact-FB3A98B10FA9C32A352314D46A806D74" unitRef="usd">1099000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-16953572FA1DC6941BFB14D466DC6271" unitRef="usd">1099000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2019Q3YTD" decimals="-3" id="Fact-7948B531FF4152F698DDBEE3FCC6CB01" unitRef="usd">1783000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6D40BBA638C0531EB393B5CC22CCA7B8" unitRef="usd">1783000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-B119C7CA9C8851948B3C43C2CFB15F4D" unitRef="usd">111770000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q3QTD" decimals="-3" id="Fact-29B17787FF835587B193C715DD348C04" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-36DAB00B0292535A9D320291CDC52D13" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q3YTD" decimals="-3" id="Fact-9539147D82AFA1CAA67714D7C195D801" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5050802116341267107A14D80FF6864D" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q3QTD" decimals="-3" id="Fact-77FCB1C92A815108900FEE7EE8466AF9" unitRef="usd">467000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-840A28721AFD58EF92419EFA0D6D5A3C" unitRef="usd">467000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-54987382F19D54B497B46AE1E1A29B7B" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q3YTD" decimals="-3" id="Fact-1CE8C97ED7FA57DDA986DB2858D5038D" unitRef="usd">704000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-781D54153E235374A33756D619C005A8" unitRef="usd">703000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-42EB879033F454F0A81EF493E0174E03" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-F446E1CD3C545D5EBCCFE31D11C3F478" unitRef="usd">-2000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember" decimals="-3" id="Fact-9B9EEB531FBC54E9B07B22BCA29F5EA0" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-855B97D714B955A99B2140C891ED61B4" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-45540E8375F1587B8BC5892FF46BE806" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7F6D2CB87E5553659451BF3F3EED07C9" unitRef="usd">26000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-A719E7F3BA0F55799F76315990602E16" unitRef="usd">-5000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-A195C5EECC8958D1A3EE6AAAE2AA8B27" unitRef="usd">-23000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2" decimals="-3" id="Fact-F0BE46CC3435539FA4314FF10251B25F" unitRef="usd">-129440000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember" decimals="-3" id="Fact-6315A31EEA065B01ADDACB21191DCAB1" unitRef="usd">-150000000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-BD35592D804F55BDBD7D324F385D3593" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-789939693A505DC1B2E2A2421684B00D" unitRef="usd">8054000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-AD9247FAEDAB53B9BE2825235EFE357A" unitRef="usd">28000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-4D2189E83CF8567A96BC09452948070D" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-862DDA7729005B15A075D3DDCC31E5BE" unitRef="usd">-137522000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3" decimals="-3" id="Fact-1A25E377FB785C6AA2FF8AE2E937DB2D" unitRef="usd">-168443000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember" decimals="-3" id="Fact-616C195FDC815863BCD987FC7D5066B9" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-924D87073823536DAA10D2733CA8AA31" unitRef="usd">-148000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9DD8F39483AD51AEBE51F5DCAE64561B" unitRef="usd">12693000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-B75B6EA2CA69563B8F5BB054C7621642" unitRef="usd">31000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-76EC9A580FDA5718BED71D62CFFA5A30" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-3CC830B1CDD55841B9D26A0BE1F8571A" unitRef="usd">-181019000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-1791F59D87E4549AA932A140D2DEBFE6" unitRef="usd">703164000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember" decimals="-3" id="Fact-9EEE55784E1D5A9A9D092D0B643AA631" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-43D751BFEF8A5C28A4FFDC835D85041D" unitRef="usd">306000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-24BD8EFC6EEA5670B81C549520C593A3" unitRef="usd">914265000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A468EC8C976F59038C0A8A7E610226C7" unitRef="usd">121000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-AE74B5C4D8D1566596750240ABBF3B2F" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-BCBE968B8F7A5E2684A098D7F8FB217C" unitRef="usd">-211528000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2" decimals="-3" id="Fact-59091A8CC0FD5A20A551F70B564218B4" unitRef="usd">655635000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember" decimals="-3" id="Fact-F5017F2B6D995E4592D567F8CEBBAF63" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-5DA2A6C384E855428853D156E3C8B819" unitRef="usd">2161000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-350CEEE129845D9FBF0F74FB4D4BF85E" unitRef="usd">937709000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-FC353B11EF2D51CFB15DF79476FBA36A" unitRef="usd">122000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-C036F97D08A5550BBDF51BFF203DCC19" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-25888FDAF0765B84BDA3527231D72A15" unitRef="usd">-284357000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3" decimals="-3" id="Fact-441B59D9EB045D37BAA58C762BFE0F03" unitRef="usd">619716000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_allo_SubscriptionReceivableFromPreferredStockholdersMember" decimals="-3" id="Fact-23B11ADD4A605CE4B88B8D6F4E8836FF" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-393A79EDF9A95E33A69402F6898B0D16" unitRef="usd">1866000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C52D6A94B8D95B01A2AC2C9317A43318" unitRef="usd">952820000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-64AD6AF5AA2A5C5DAFA13047D1986935" unitRef="usd">122000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember" decimals="-3" id="Fact-D4B3725ED82953729410F460ED59819B" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E1BF862C6C8F5BA084064942DD86C1C1" unitRef="usd">-335092000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2018Q4Oct01" decimals="4" id="Fact-AF10E1BA5ADB5D46AF35F6DCC284289B" unitRef="number">0.1905</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:SubleaseIncome contextRef="FD2018Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember" decimals="INF" id="Fact-612F2110509427116B15188DFA146C8D" unitRef="usd">0</us-gaap:SubleaseIncome>
	<us-gaap:SubleaseIncome contextRef="FD2018Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember" decimals="-5" id="Fact-53D9EFE6AA5A7FD7E07DFD8D128C1A35" unitRef="usd">0</us-gaap:SubleaseIncome>
	<us-gaap:SubleaseIncome contextRef="FD2019Q3QTD_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember" decimals="-5" id="Fact-AC1C32D5D5B65E9D8F7BD01018CB2E1D" unitRef="usd">100000</us-gaap:SubleaseIncome>
	<us-gaap:SubleaseIncome contextRef="FD2019Q3YTD_us-gaap_RelatedPartyTransactionAxis_allo_SubleaseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_ByHeartIncMember" decimals="-5" id="Fact-430E1DD1F124523892F6709B31B536DE" unitRef="usd">200000</us-gaap:SubleaseIncome>
	<us-gaap:SuppliesExpense contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="-5" id="Fact-968623FEC4515D1A9E3CB5C2B9BED660" unitRef="usd">2800000</us-gaap:SuppliesExpense>
	<us-gaap:SuppliesExpense contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="-5" id="Fact-1AE8FA3A368E55B0A9A9AD89D16EAF5E" unitRef="usd">6100000</us-gaap:SuppliesExpense>
	<us-gaap:SuppliesExpense contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="-5" id="Fact-FE4E7E0B645058A7AA9A1331625F6015" unitRef="usd">0</us-gaap:SuppliesExpense>
	<us-gaap:SuppliesExpense contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionAxis_allo_TransitionServicesAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_allo_PfizerIncMember" decimals="-5" id="Fact-689486C373C656AAA209E8406F8909A5" unitRef="usd">1100000</us-gaap:SuppliesExpense>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-B7893D8064FF53849CEADD7003D02050" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2018Q2_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-96021FDC82D159EEAC735830002D22CC" unitRef="usd">411052000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2018Q3_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-105FA84B10F555C8A3C4A56A1FE989FC" unitRef="usd">411052000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-EDECB3AFDC155515A07C286A7255539A" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2019Q2_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-0C2CBCAEE31251CD9F48C1A7F246A2FB" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2019Q3_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-0DC6F52CF3665E36B2FE3DB81DDC8851" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2018Q4oct31_us-gaap_DebtInstrumentAxis_allo_ConvertiblePromissoryNotesMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-5" id="Fact-9895CC9D8C8B50B0A8B9B3945EA07FC9" unitRef="usd">120200000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-EFE057C78466599DB74ACB70238FD63C" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2018Q2_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-779ADF3DD48754758A6A8696E408457B" unitRef="shares">11743987</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2018Q3_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-80562A4F386658E0BB56735F3C0B064A" unitRef="shares">11743987</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-B10729DCD0265E678F67FC40632146CC" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2019Q2_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-D479F7F2BBC9511280DFC21183DFA870" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2019Q3_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-B152A2AB1DB85AC1B1DC0FD215A540BC" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2018Q4oct31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-688364C4A747518EA2BCC257BDB64826" unitRef="shares">11743987</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-B99278D86B205FE2A65C7DCC2DF1FF56" unitRef="usd">34917000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3YTD_us-gaap_StatementClassOfStockAxis_allo_SeriesAConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-ACA46988F70F5C4EAF139BCED4C2B691" unitRef="usd">264365000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
	<us-gaap:VariableLeasePayment contextRef="FD2019Q3QTD" decimals="-5" id="Fact-43B556B170EC5C0985C88451FEA6DDA6" unitRef="usd">300000</us-gaap:VariableLeasePayment>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3QTD" decimals="0" id="Fact-8FF859B0347A546FA721CB5C4E4440A0" unitRef="shares">4060419</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3YTD" decimals="0" id="Fact-2FAF966C694A57ABA2ABA35510EFBC45" unitRef="shares">11048451</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q3QTD" decimals="0" id="Fact-7E35CE0A01F658CAB2BF74C7D0EC467E" unitRef="shares">102186644</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q3YTD" decimals="0" id="Fact-9BAFE11FBD5C597582E4BAE2D3B36AFA" unitRef="shares">99801001</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<allo:ChangesInSignificantAccountingPoliciesPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-5D925033827651B894FA0DD11F6AC12A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There have been no significant changes to the accounting policies during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as compared to the significant accounting policies described in Note 1 of the &amp;#8220;Notes to Financial Statements&amp;#8221; in the Company&amp;#8217;s audited financial statements included in its Annual Report.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</allo:ChangesInSignificantAccountingPoliciesPolicyTextBlock>
	<allo:LicenseAgreementsTextBlock contextRef="FD2019Q3YTD" id="Fact-312D186CB26458CDBA6E7A74B9816548">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;License Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Asset Contribution Agreement with Pfizer&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&amp;#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, depending on the target, with aggregate potential regulatory and development milestones of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$840.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$325.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the three and nine months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2018 respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&amp;#160;6, 2023. The Company&amp;#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&amp;#160;expiration of the last claim of any applicable patent or (ii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the first sale of such product in such country.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research Collaboration and License Agreement with Cellectis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&amp;#160;&amp;#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&amp;#160;&amp;#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&amp;#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of our intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Cellectis Agreement provides for development and sales milestone payments by the Company of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$185.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per product that is directed&amp;#160;against an&amp;#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.8 billion&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company is obligated to pay Cellectis &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the dosing of the first patient in its Phase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; clinical trial of ALLO-715. Cellectis is&amp;#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&amp;#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&amp;#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&amp;#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i)&amp;#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&amp;#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&amp;#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&amp;#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&amp;#8217; prior written notice in the event of the other party&amp;#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:12pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All costs the Company incurred in connection with this agreement were recognized as research and development expenses. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the three and nine months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.0 million of costs were incurred related to the achievement of a clinical development milestone under this agreement. For the three and nine months ended September 30, 2018, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of costs were incurred associated with research services performed by Cellectis under this agreement. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million related to a clinical development milestone payable was recorded in the accrued and other current liabilities in the accompanying condensed balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;License and Collaboration Agreement with Servier&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19 in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For product candidates that the Company is co-developing with Servier, including UCART19 and ALLO-501, the Company is responsible for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the specified development costs and Servier is responsible for the remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&amp;#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&amp;#8217;s sole expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$137.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$78.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$42 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8364;70.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$77.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&amp;#8217;s election not to pursue such rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&amp;#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&amp;#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of costs incurred under the cost-sharing terms of the Servier Agreement as research and development expenses. For the three and nine months ended September 30, 2018, the Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of costs as research and development expenses. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, amounts due to Servier of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were recorded in accrued and other current liabilities in the accompanying condensed balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</allo:LicenseAgreementsTextBlock>
	<allo:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-8EAC523A7761524A9014DDDEA5952217">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued Accounting Standards Update No. 2018-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles &amp;#8211; Goodwill and other &amp;#8211; Internal-Use Software (Subtopic 350-40)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&amp;#160;hosting arrangement&amp;#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&amp;#160;hosting arrangement&amp;#160;that is a service contract over the term of the&amp;#160;hosting arrangement.&amp;#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is evaluating the impact of adopting this amendment to its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</allo:RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
	<allo:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-776C8AD124325FE1BAEA10A4ED69C5E7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2018, the FASB issued&amp;#160;Accounting Standards Update No.&amp;#160;2018-02,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Statement &amp;#8211; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which provided amended guidance to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Additionally, under the new guidance, an entity will be required to provide certain disclosures regarding stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company adopted this guidance on January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</allo:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
	<allo:ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock contextRef="FD2019Q3YTD" id="Fact-5F48A7FCAB68530FBF10D3BF281621BF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and Other Current Assets consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest on investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other prepaid and current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;758&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid insurance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</allo:ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-B54D61DFB5D6525BBFB68BB4E8C0DBC2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company&amp;#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the condensed statements of operations and comprehensive loss for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the condensed statements of stockholders&amp;#8217; equity (deficit) as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the condensed statements of cash flows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of operations for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results to be expected for the year ending &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company&amp;#8217;s audited financial statements and related notes for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the SEC on March 8, 2019.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-F67E18F86012F383CDF5241BBEB5007A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Convertible Notes Payable (2018 Notes)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2018, the Company entered into a note purchase agreement pursuant to which it sold and issued an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$120.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in convertible promissory notes (convertible notes payable or 2018 Notes) and received net cash proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$116.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2018 Notes did not accrue interest. The 2018 Notes were settled in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,856,176&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock in connection with the closing of the Company&amp;#8217;s IPO (see Note 1) at a settlement price equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the IPO price per share. &amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On issuance, the Company elected to account for the 2018 Notes at fair value with any changes in fair value being recognized through the statements of operations until the 2018 Notes settled. The fair value of the 2018 Notes was determined to be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$120.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on issuance and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$139.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of September 30, 2018. For the three-months and nine-months ended September 30, 2018, the Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$19.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the accompanying condensed statements of operations as the change in fair value of the 2018 Notes. On issuance, total debt issuance costs of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were expensed and recognized as interest expense in the accompanying condensed statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="FD2019Q3YTD" id="Fact-BF2A8A8ADBA3517C8ABA5CC6829807D0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and as of December 31, 2018 are presented in the following tables:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Unrealized&amp;#160;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Unrealized&amp;#160;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;190,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;202,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;203,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. agency securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;235&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;551,187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;553,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Classified as:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;340,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,702&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;553,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Unrealized&amp;#160;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Unrealized&amp;#160;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;341,696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;342,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. agency securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,937&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;181&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;713,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;714,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Classified as:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;366,952&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;261,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;714,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2019Q3YTD" id="Fact-754316D65BA95ED6A64CBE9153F4B3DF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the Company adopted the 2018 Equity Incentive Plan (2018 Plan). The 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&amp;#8217;s board of directors and consultants of the Company under terms and provisions established by the Company&amp;#8217;s board of directors. In October 2018, the Board of Directors approved an amendment and restatement of the 2018 Plan, increasing the shares of common stock issuable under the 2018 Plan as well as allowing for an automatic annual increase to the shares issuance under the 2018 Plan to the amount equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the fair market value of the Company&amp;#8217;s common stock on the grant date. Options granted typically vest over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a four-year period but may be granted with different vesting terms.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,915,688&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Option Activity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following summarizes option activity under the 2018 Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contract&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(In years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,235,545&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,781,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(304,576&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(220,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,492,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,553,432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,492,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Stock Unit Activity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following summarizes restricted stock unit activity under the 2018 Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value at Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;of Grant per&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,795,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(22,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;27.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,773,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,773,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&amp;#8217; common stock was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Three Months Ended September 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nine Months Ended September 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;442&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,177&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,639&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,695&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Early Exercised Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company allows certain of its employees and its directors to exercise options granted under the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&amp;#8217;s lapsing repurchase right upon termination of employment or service on the Company&amp;#8217;s board of directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the noncurrent portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recorded in accrued and other liabilities and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed financial statements since the exercise date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2019Q3YTD" id="Fact-1C4A8236308557D4BBF1A17AC716EEC8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,492,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,075,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,655,922&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible notes payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,856,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units subject to vesting&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,773,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected shares purchased under Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Founder shares of common stock subject to future vesting&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,144,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,201,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Early exercised stock options subject to future vesting&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,306,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,020,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,878,302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101,810,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="FD2019Q3YTD" id="Fact-B4E2E985B69B5187B6774903AE8E72B1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and as of December 31, 2018 are presented in the following tables:&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;203,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;203,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. agency securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;316,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;237,323&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;553,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;342,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;342,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. agency securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;403,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;311,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;714,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Included within cash and cash equivalents on the Company&amp;#8217;s balance sheets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2019Q3YTD" id="Fact-1401AE458BDE5B50B86A7D14A0ECAF0D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:42px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&amp;#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Level 3 assets or liabilities as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and as of December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and as of December 31, 2018 are presented in the following tables:&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;203,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;203,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. agency securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;316,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;237,323&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;553,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;342,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;342,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. agency securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total financial assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;403,024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;311,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;714,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Included within cash and cash equivalents on the Company&amp;#8217;s balance sheets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; transfers between Levels 1, 2 or 3 for the period presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-F364CB8B79605300AC5566BD00ABB9FB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and as of December 31, 2018 are presented in the following tables:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Unrealized&amp;#160;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Unrealized&amp;#160;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;190,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,195&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;202,893&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;203,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. agency securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,433&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;235&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;551,187&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;553,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Classified as:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;112,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;340,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,702&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;553,350&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Unrealized&amp;#160;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Unrealized&amp;#160;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;font style="font-family:inherit;font-size:7pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;220&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;244,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;341,696&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;342,001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. agency securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,937&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;181&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,115&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;713,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(320&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;714,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Classified as:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85,214&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;366,952&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;261,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total cash equivalents and investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;714,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&amp;#160;the remaining contractual maturities of available-for-sale securities were less than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. There have been no significant realized losses on available-for-sale securities for the period presented. Based on the Company&amp;#8217;s review of its available-for-sale securities, the Company believes it had&amp;#160;no&amp;#160;other-than-temporary impairments on these securities as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, because the Company does not intend to sell these securities&amp;#160;nor does the Company believe that it will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were immaterial for the three and nine months ended&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-F583D78EF2975D679A8841A7CB6B3582">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has a history of losses, and expects to record a loss in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company continues to maintain a full valuation allowance against its net deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="FD2019Q3YTD" id="Fact-0FD05B55D92A5A4EB44E550C7F168406">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The undiscounted future lease payments under the lease agreements as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ending December&amp;#160;31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019 (remaining 3 months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,381&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total undiscounted lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Undiscounted lease payments related to Newark lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,231&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Present value adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Tenant improvement allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
	<us-gaap:LesseeOperatingLeasesTextBlock contextRef="FD2019Q3YTD" id="Fact-6F3ABB2A3D19579292D9C5E2847C25C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;68,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet located in South San Francisco, California. The lease term is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; beginning August 2018 through February 2029 with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million. The rent payments began on March 1, 2019 after an abatement period. In connection with the&amp;#160;lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million. In connection with this lease, the Company recognized an operating lease right-of-use asset of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and an aggregate lease liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$29.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the accompanying condensed balance sheet. The remaining lease term is 9 years and 5 months, and the estimated incremental borrowing rate is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,943&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet located in South San Francisco, California. The lease term is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; beginning November 2018 through February 2029, with an option to extend the term for another &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;seven years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million. Rent payments began in November 2018. In connection with the lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million. In connection with this lease, the Company recognized an operating lease right-of-use asset of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and an aggregate lease liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the accompanying balance sheet. The remaining lease term is 9 years and 5 months, and the estimated incremental borrowing rate is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into two operating leases for office space in New York and Los Angeles for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,358&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,293&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet respectively. The Company recognized operating lease right-of-use assets of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and aggregate lease liabilities of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; respectively for these leases. The lease term for the New York operating lease is 6 years and 7 months, with no option for renewal. The lease term for the Los Angeles operating lease is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with an option to extend the lease term for another &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which is not reasonably certain of exercise. There were no lease incentive allowances for either location. In connection with the New York lease, the Company maintains a letter of credit for the benefit of the landlord in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The remaining lease terms were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years and 9 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2 years and 2 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the estimated incremental borrowing rates applied were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2019, the Company entered into a lease agreement for approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;118,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease has a term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;188 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and is expected to commence in April 2020. Upon certain conditions, the Company has two ten-year options to extend the lease. Subject to rent abatement for the second through nine months of the lease, the Company will be required to pay &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$159,150&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per month for rent for the first twelve months of the lease term which will increase at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year. The Company will be entitled to a tenant improvement allowance of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.9&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million for costs related to the design and construction of certain Company improvements. In connection with the lease, the Company maintains a letter of credit for the benefit of the landlord in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million. The total commitment of undiscounted lease payments for this lease was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company had not recognized a right-of-use asset or aggregate lease liability as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as the underlying asset was unavailable for use by the Company at any time in the period ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The undiscounted future lease payments under the lease agreements as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:86%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year ending December&amp;#160;31:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in&amp;#160;thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019 (remaining 3 months)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,381&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,213&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;63,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total undiscounted lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Undiscounted lease payments related to Newark lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(36,231&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Present value adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(17,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: Tenant improvement allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Rent expense for all operating leases was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the nine months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Short-term lease expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the nine months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Variable lease payments for operating expenses was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the three months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
	<us-gaap:NatureOfOperations contextRef="FD2019Q3YTD" id="Fact-0F5C8AA7F5B158769AC119C336C0EB64">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; November&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&amp;#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Initial Public Offering &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2018, the Company completed an initial public offering (IPO) of its common stock. In connection with its IPO, the Company issued and sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,700,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock, which included &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,700,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock issued pursuant to the over-allotment option granted to the underwriters, at a price to the public of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. As a result of the IPO, the Company received approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$343.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in net proceeds, after deducting underwriting discounts and commissions of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$26.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and offering expenses of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payable by the Company. At the closing of the IPO, all &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,743,987&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of outstanding convertible preferred stock were automatically converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,655,922&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and our outstanding convertible promissory notes in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$120.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; principal amount were automatically converted into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,856,176&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. Following the IPO, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of convertible preferred stock or preferred stock outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Need for Additional Capital&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&amp;#8217;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$601.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Since inception through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has incurred cumulative net losses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$335.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed financial statements are filed with the Securities and Exchange Commission (SEC).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Forward Stock Split&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On October 1, 2018, the Company filed an amendment to the Company&amp;#8217;s amended and restated certificate of incorporation to effect a forward split of shares of the Company&amp;#8217;s common stock on a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1-for-5.25&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; basis (the Forward Stock Split). In connection with the Forward Stock Split, the conversion ratio for the Company&amp;#8217;s then-outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split. The par value of the common stock was not adjusted as a result of the Forward Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these condensed financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2019Q3YTD" id="Fact-0D5D1C48722D52908FFE6A07C3AEDA64">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and Equipment consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,566&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computers equipment and purchased software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,496&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,703&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,711&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,048&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,943&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-7325E243C3245CE296466744030BFE94">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, Pfizer held &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,032,040&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Common Stock and had appointed one member to the Company&amp;#8217;s board of directors.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2018, the Company and Pfizer entered into a transition services agreement (the Pfizer TSA) for Pfizer to provide professional services to the Company related to research and development, project management, and other administrative functions. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the costs incurred under the Pfizer TSA were&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.9&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million, respectively. For the three and nine months ended September 30, 2018, the costs incurred under the Pfizer TSA were $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.4&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company also purchased certain lab supplies from Pfizer in connection with its research and development activities. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the total lab supplies and services purchased from Pfizer were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million, respectively. For the three and nine months ended September 30, 2018, the total lab supplies and services purchased from Pfizer were $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and December 31, 2018, the Company had an amount payable to Pfizer of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.7&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million, respectively, which was recorded in the accrued and other current liabilities on the accompanying condensed balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In September 2019, the Company and Pfizer terminated the Pfizer TSA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Sublease Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2019, the Company subleased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,180&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet of its office space in New York, New York, to ByHeart, Inc., formerly known as Second Science, Inc. (ByHeart).&amp;#160;ByHeart is a development-stage infant formula company.&amp;#160;Two of the Company&amp;#8217;s board members have beneficial ownership in ByHeart and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; serves on the board of directors of ByHeart. In September 2019, the Company entered into an amendment to the sublease agreement and increased the subleased space to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,907&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet. Sublease income for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million, respectively, and was recognized as other income. Sublease income for the three and nine months ended September 30, 2018 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;zero&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Consulting Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&amp;#8217;s President and Chief Executive Officer, the Company&amp;#8217;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million for the three and nine months ended September 30, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the Company entered into a consulting agreement with Bellco Capital LLC (Bellco). The Company&amp;#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is the Chairman and an owner of Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&amp;#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company pays Bellco &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$33,333.33&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per month in arrears commencing January 2019 and, in the Company&amp;#8217;s discretion, may pay Bellco an annual performance award in an amount up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The cost incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million for the three and nine months ended September 30, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2019Q3YTD" id="Fact-1BEF99A7FB245A6EBE0445860487A022">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested shares liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total accrued and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2019Q3YTD" id="Fact-1F30EA9DB3BF53E6AFBBF6ACC0A8CB5B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,492,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,075,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,655,922&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible notes payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,856,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units subject to vesting&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,773,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected shares purchased under Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;162,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Founder shares of common stock subject to future vesting&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,144,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,201,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Early exercised stock options subject to future vesting&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,306,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,020,580&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,878,302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101,810,405&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2019Q3YTD" id="Fact-CC4804ED3B955E2EA2B491B044F7845C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&amp;#8217; common stock was as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Three Months Ended September 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Nine Months Ended September 30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,533&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;442&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,177&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,253&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,834&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,639&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,695&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="FD2019Q3YTD" id="Fact-558B6716A148521A9969B59F12883A78">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following summarizes restricted stock unit activity under the 2018 Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value at Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;of Grant per&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,795,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(22,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;27.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,773,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,773,155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2019Q3YTD" id="Fact-F284C8C93DCA5CE498EB78ED73604DA6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following summarizes option activity under the 2018 Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contract&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(In years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,235,545&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,781,316&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;27.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(304,576&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(220,151&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.91&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,492,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,553,432&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,492,134&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2019Q3YTD" id="Fact-E94238E352305856AA127FB939933FFC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company&amp;#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The condensed balance sheet as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the condensed statements of operations and comprehensive loss for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the condensed statements of stockholders&amp;#8217; equity (deficit) as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the condensed statements of cash flows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of operations for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are not necessarily indicative of the results to be expected for the year ending &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company&amp;#8217;s audited financial statements and related notes for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, included in the Company&amp;#8217;s Annual Report on Form 10-K filed with the SEC on March 8, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There have been no significant changes to the accounting policies during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three and nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as compared to the significant accounting policies described in Note 1 of the &amp;#8220;Notes to Financial Statements&amp;#8221; in the Company&amp;#8217;s audited financial statements included in its Annual Report.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2018, the FASB issued&amp;#160;Accounting Standards Update No.&amp;#160;2018-02,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Statement &amp;#8211; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which provided amended guidance to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Additionally, under the new guidance, an entity will be required to provide certain disclosures regarding stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company adopted this guidance on January 1, 2019. Adoption of the new guidance had no significant impact on the Company&amp;#8217;s condensed financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In August 2018, the FASB issued Accounting Standards Update No. 2018-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles &amp;#8211; Goodwill and other &amp;#8211; Internal-Use Software (Subtopic 350-40)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&amp;#160;hosting arrangement&amp;#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&amp;#160;hosting arrangement&amp;#160;that is a service contract over the term of the&amp;#160;hosting arrangement.&amp;#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is evaluating the impact of adopting this amendment to its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2019Q3YTD" id="Fact-93663934A2DFE052BA6D18983C2EE33C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Collaboration Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch has granted to Allogene an exclusive, worldwide, royalty-bearing, sublicenseable license under certain of Notch&amp;#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Collaboration Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&amp;#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee.  Allogene will reimburse Notch&amp;#8217;s costs incurred in accordance with such plan and budget.  The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Collaboration Agreement, (ii) at Allogene&amp;#8217;s election, following the joint development committee&amp;#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&amp;#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the execution of the Collaboration Agreement, Allogene made an upfront payment to Notch of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition, Allogene made a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; investment in Notch&amp;#8217;s series seed convertible preferred stock, resulting in Allogene having a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; ownership interest in Notch&amp;#8217;s outstanding capital stock on a fully diluted basis immediately following the investment.  In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&amp;#8217;s board of directors.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Collaboration Agreement, Notch will be eligible to receive up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.25 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon achieving certain agreed research milestones, up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per exclusive target upon achieving certain pre-clinical development milestones, and up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$283.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&amp;#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The term of the Collaboration Agreement will continue on a product-by-product and country-by-country basis until Allogene&amp;#8217;s payment obligations with respect to such product in such country have expired.  Following such expiration, Allogene&amp;#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free.  Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&amp;#8217; prior written notice to Notch.  Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&amp;#8217;s insolvency.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="FD2019Q3YTD" id="Fact-4EB743370351549899F6F56C178783A4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Balance Sheets Components&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Prepaid expenses and Other Current Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and Other Current Assets consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest on investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,337&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,108&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other prepaid and current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;758&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid insurance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,513&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,598&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and Equipment consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,233&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,566&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computers equipment and purchased software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,496&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,327&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,703&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,711&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,768&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,048&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,943&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accrued Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(In thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued research and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,380&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,808&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued property and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unvested shares liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;612&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total accrued and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,307&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,121&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2019Q3YTD" id="Fact-8DE0A270BCF1535494EDA441D9CBADEB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-00091596B59A5F90BA3AAC64F1C58991" xlink:label="Fact-00091596B59A5F90BA3AAC64F1C58991_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-02C087840AEC57229C1EE0A739A95F25" xlink:label="Fact-02C087840AEC57229C1EE0A739A95F25_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-13D91880F1E054DB9D2F95D5F3DB837F" xlink:label="Fact-13D91880F1E054DB9D2F95D5F3DB837F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-16A30DEEE6B4505BA6B995F2834E4E86" xlink:label="Fact-16A30DEEE6B4505BA6B995F2834E4E86_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-1791F59D87E4549AA932A140D2DEBFE6" xlink:label="Fact-1791F59D87E4549AA932A140D2DEBFE6_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-27271DB6623B578586887FC9245CF967" xlink:label="Fact-27271DB6623B578586887FC9245CF967_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2D8AC2A6F1525F05B54F26AE8DEDC27C" xlink:label="Fact-2D8AC2A6F1525F05B54F26AE8DEDC27C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-383E1160F3C759CC89E40ECED24C71DC" xlink:label="Fact-383E1160F3C759CC89E40ECED24C71DC_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3DD3E484BB625068B2D0F964B3789F75" xlink:label="Fact-3DD3E484BB625068B2D0F964B3789F75_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-4B492C86AA1F569C9BFDB13AA8664509" xlink:label="Fact-4B492C86AA1F569C9BFDB13AA8664509_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-4C90EF4BDF6C55D9B73B421D8E4A1C58" xlink:label="Fact-4C90EF4BDF6C55D9B73B421D8E4A1C58_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-612C11D9FADB5571A235B70CD0D7ADC4" xlink:label="Fact-612C11D9FADB5571A235B70CD0D7ADC4_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-64A3A494917156068F4F2E0C21D002CB" xlink:label="Fact-64A3A494917156068F4F2E0C21D002CB_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6E59DDF3D7F254CEB385148A10123BF8" xlink:label="Fact-6E59DDF3D7F254CEB385148A10123BF8_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-76C01F48CB6D56CCB4A8D76BF2660CE8" xlink:label="Fact-76C01F48CB6D56CCB4A8D76BF2660CE8_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-7AD058D4ED2551B590BF2F3DC78B39F7" xlink:label="Fact-7AD058D4ED2551B590BF2F3DC78B39F7_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-7E01981BDB935124814DC216F70FEB31" xlink:label="Fact-7E01981BDB935124814DC216F70FEB31_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-82C7470D38D85B07B741228DDC552096" xlink:label="Fact-82C7470D38D85B07B741228DDC552096_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8CFAD8185EF65D6CBEBA0F49D337B761" xlink:label="Fact-8CFAD8185EF65D6CBEBA0F49D337B761_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8D8254A051D853C18BE072593A521810" xlink:label="Fact-8D8254A051D853C18BE072593A521810_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-ABE9B9B766865B22B017521E80CF462C" xlink:label="Fact-ABE9B9B766865B22B017521E80CF462C_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-BCB01CFEB94255F0ACF7D764516D38F0" xlink:label="Fact-BCB01CFEB94255F0ACF7D764516D38F0_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-D429CEAD89165167BCEE5FFD2AFBE48B" xlink:label="Fact-D429CEAD89165167BCEE5FFD2AFBE48B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-D9C6A31602095913B927FB4A7AB1BF14" xlink:label="Fact-D9C6A31602095913B927FB4A7AB1BF14_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-E4EEF4E032ED546CB3AFAE5E276CB3C5" xlink:label="Fact-E4EEF4E032ED546CB3AFAE5E276CB3C5_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-00091596B59A5F90BA3AAC64F1C58991_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-02C087840AEC57229C1EE0A739A95F25_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-13D91880F1E054DB9D2F95D5F3DB837F_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-16A30DEEE6B4505BA6B995F2834E4E86_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-1791F59D87E4549AA932A140D2DEBFE6_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-27271DB6623B578586887FC9245CF967_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2D8AC2A6F1525F05B54F26AE8DEDC27C_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-383E1160F3C759CC89E40ECED24C71DC_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3DD3E484BB625068B2D0F964B3789F75_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-4B492C86AA1F569C9BFDB13AA8664509_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-4C90EF4BDF6C55D9B73B421D8E4A1C58_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-612C11D9FADB5571A235B70CD0D7ADC4_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-64A3A494917156068F4F2E0C21D002CB_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6E59DDF3D7F254CEB385148A10123BF8_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-76C01F48CB6D56CCB4A8D76BF2660CE8_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7AD058D4ED2551B590BF2F3DC78B39F7_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-7E01981BDB935124814DC216F70FEB31_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-82C7470D38D85B07B741228DDC552096_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8CFAD8185EF65D6CBEBA0F49D337B761_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8D8254A051D853C18BE072593A521810_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-ABE9B9B766865B22B017521E80CF462C_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-BCB01CFEB94255F0ACF7D764516D38F0_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-D429CEAD89165167BCEE5FFD2AFBE48B_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-D9C6A31602095913B927FB4A7AB1BF14_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-E4EEF4E032ED546CB3AFAE5E276CB3C5_lbl" xlink:to="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-802E44CE9FE458FB8D633A67F2D129DB_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>allo-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20190930" xmlns:allo="http://allogene.com/20190930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="BalanceSheetsComponents" roleURI="http://allogene.com/role/BalanceSheetsComponents">
        <link:definition>2105100 - Disclosure - Balance Sheets Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsComponentsAccruedLiabilitiesDetails" roleURI="http://allogene.com/role/BalanceSheetsComponentsAccruedLiabilitiesDetails">
        <link:definition>2405404 - Disclosure - Balance Sheets Components - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails" roleURI="http://allogene.com/role/BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails">
        <link:definition>2405402 - Disclosure - Balance Sheets Components - Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsComponentsPropertyAndEquipmentDetails" roleURI="http://allogene.com/role/BalanceSheetsComponentsPropertyAndEquipmentDetails">
        <link:definition>2405403 - Disclosure - Balance Sheets Components - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsComponentsTables" roleURI="http://allogene.com/role/BalanceSheetsComponentsTables">
        <link:definition>2305301 - Disclosure - Balance Sheets Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://allogene.com/role/CondensedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://allogene.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementOfCashFlows" roleURI="http://allogene.com/role/CondensedStatementOfCashFlows">
        <link:definition>1004000 - Statement - Condensed Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementOfStockholdersEquityDeficit" roleURI="http://allogene.com/role/CondensedStatementOfStockholdersEquityDeficit">
        <link:definition>1003000 - Statement - Condensed Statement of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://allogene.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsOfStockholdersEquityDeficitParenthetical" roleURI="http://allogene.com/role/CondensedStatementsOfStockholdersEquityDeficitParenthetical">
        <link:definition>1003001 - Statement - Condensed Statements of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayable2018NotesDetails" roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails">
        <link:definition>2409402 - Disclosure - Convertible Notes Payable (2018 Notes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayable2018NotesTables" roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesTables">
        <link:definition>2309301 - Disclosure - Convertible Notes Payable (2018 Notes) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayable2019Notes" roleURI="http://allogene.com/role/ConvertibleNotesPayable2019Notes">
        <link:definition>2109100 - Disclosure - Convertible Notes Payable (2019 Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://allogene.com/role/CoverPage">
        <link:definition>0002000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusiness" roleURI="http://allogene.com/role/DescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessDetails" roleURI="http://allogene.com/role/DescriptionOfBusinessDetails">
        <link:definition>2401401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://allogene.com/role/FairValueMeasurements">
        <link:definition>2103100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>2403402 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail" roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail">
        <link:definition>2403403 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://allogene.com/role/FairValueMeasurementsTables">
        <link:definition>2303301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://allogene.com/role/FinancialInstruments">
        <link:definition>2104100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAdditionalInformationDetails" roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails">
        <link:definition>2404403 - Disclosure - Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails" roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails">
        <link:definition>2404402 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://allogene.com/role/FinancialInstrumentsTables">
        <link:definition>2304301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://allogene.com/role/IncomeTaxes">
        <link:definition>2111100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://allogene.com/role/Leases">
        <link:definition>2107100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://allogene.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2407402 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://allogene.com/role/LeasesTables">
        <link:definition>2307301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedFutureLeasePaymentsDetails" roleURI="http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetails">
        <link:definition>2407403 - Disclosure - Leases - Undiscounted Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedFutureLeasePaymentsDetailsCalc2" roleURI="http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetailsCalc2">
        <link:definition>2407403 - Disclosure - Leases - Undiscounted Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://allogene.com/role/LicenseAgreements">
        <link:definition>2106100 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://allogene.com/role/LicenseAgreementsDetails">
        <link:definition>2406401 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://allogene.com/role/NetLossPerShare">
        <link:definition>2112100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://allogene.com/role/NetLossPerShareDetails">
        <link:definition>2412402 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://allogene.com/role/NetLossPerShareTables">
        <link:definition>2312301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://allogene.com/role/RelatedPartyTransactions">
        <link:definition>2110100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2410401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://allogene.com/role/StockBasedCompensation">
        <link:definition>2108100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2408402 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpenseDetails" roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails">
        <link:definition>2408405 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsActivityDetails" roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails">
        <link:definition>2408404 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2408403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://allogene.com/role/StockBasedCompensationTables">
        <link:definition>2308301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://allogene.com/role/SubsequentEvents">
        <link:definition>2113100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://allogene.com/role/SubsequentEventsDetails">
        <link:definition>2413401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://allogene.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://allogene.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="allo_AccruedAndOtherCurrentLiabilitiesMember" name="AccruedAndOtherCurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_AccruedAndOtherLiabilitiesCurrent" name="AccruedAndOtherLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="allo_AccruedCompensationAndRelatedBenefitsCurrent" name="AccruedCompensationAndRelatedBenefitsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="allo_AccruedPropertyAndEquipment" name="AccruedPropertyAndEquipment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="allo_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="allo_AggregatePotentialMilestonePayments" name="AggregatePotentialMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="allo_AggregatePotentialMilestoneReceivable" name="AggregatePotentialMilestoneReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" name="AggregatePotentialRegulatoryAndDevelopmentMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="allo_AllowanceForTenantImprovements" name="AllowanceForTenantImprovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="allo_AreaOfNewOfficeBuilding" name="AreaOfNewOfficeBuilding" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element id="allo_AreaOfOffice" name="AreaOfOffice" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_AreaOfOperatingLease" name="AreaOfOperatingLease" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_AssetContributionAgreementMember" name="AssetContributionAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_BellcoCapitalLLCMember" name="BellcoCapitalLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_ByHeartIncMember" name="ByHeartIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_CashEquivalentsAndShortTermInvestments" name="CashEquivalentsAndShortTermInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances" name="CashReceivedForAmountsRelatedToTenantImprovementAllowances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_CellectisSAMember" name="CellectisSAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_ChangeInFairValueOfConvertibleNotePayable" name="ChangeInFairValueOfConvertibleNotePayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock" name="ChangesInSignificantAccountingPoliciesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_ClinicalRegulatoryandCommercialMilestoneMember" name="ClinicalRegulatoryandCommercialMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_CollaborativeArrangementContingentConsiderationLiability" name="CollaborativeArrangementContingentConsiderationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="allo_CollaborativeArrangementInitialFee" name="CollaborativeArrangementInitialFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_ComputerEquipmentAndPurchasedSoftwareMember" name="ComputerEquipmentAndPurchasedSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_ConsultingAgreementsMember" name="ConsultingAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_ConvertiblePreferredStockIssuedInAssetAcquisition" name="ConvertiblePreferredStockIssuedInAssetAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_ConvertiblePromissoryNotesMember" name="ConvertiblePromissoryNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_DevelopmentAndSalesMember" name="DevelopmentAndSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_EarlyExerciseOfStockOptionsMember" name="EarlyExerciseOfStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_FairValueAssetsTransfersBetweenLevelsAmount" name="FairValueAssetsTransfersBetweenLevelsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_FounderSharesOfCommonStockMember" name="FounderSharesOfCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_LeaseOneMember" name="LeaseOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_LeaseTwoMember" name="LeaseTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent" name="LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="allo_LicenseAgreementsLineItems" name="LicenseAgreementsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_LicenseAgreementsTable" name="LicenseAgreementsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_LicenseAgreementsTextBlock" name="LicenseAgreementsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_LosAngelesMember" name="LosAngelesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" name="MaximumPaymentsRequiredPerProductAgainstSelectedTarget" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="allo_MilestonePayments" name="MilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_MilestoneTypeAxis" name="MilestoneTypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_MilestoneTypeDomain" name="MilestoneTypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_NewarkMember" name="NewarkMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_NotchTherapeuticsInc.Member" name="NotchTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_NumberOfMembersAppointedToBoardOfDirectors" name="NumberOfMembersAppointedToBoardOfDirectors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="allo_NumberOfOptionsToExtendLease" name="NumberOfOptionsToExtendLease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" name="NumberOfSharesAsPercentageOfCommonSharesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_OperatingLeaseRemainingTerm" name="OperatingLeaseRemainingTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_OperatingLeasesUndiscountedLeasePayments" name="OperatingLeasesUndiscountedLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" name="OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_PaymentOfLeaseRentalPerMonth" name="PaymentOfLeaseRentalPerMonth" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" name="PercentageOfDevelopmentCostPayableByCollaborationPartner" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_PercentageOfDevelopmentCostPayableByTheCompany" name="PercentageOfDevelopmentCostPayableByTheCompany" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_PfizerIncMember" name="PfizerIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_Phase1ClinicalTrialFirstPatientDoseMember" name="Phase1ClinicalTrialFirstPatientDoseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_PreClinicalDevelopmentMilestoneMember" name="PreClinicalDevelopmentMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_PrepaidResearchAndDevelopmentExpensesCurrent" name="PrepaidResearchAndDevelopmentExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions" name="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_RegulatoryMilestoneMember" name="RegulatoryMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_RelatedPartyTransactionCompensationPercentage" name="RelatedPartyTransactionCompensationPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_RelatedPartyTransactionMonthlyPaymentsInArrears" name="RelatedPartyTransactionMonthlyPaymentsInArrears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_ResearchCollaborationAndLicenseAgreementMember" name="ResearchCollaborationAndLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_ResearchMilestoneMember" name="ResearchMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_RoyaltyObligationPeriodFromDateOfFirstSale" name="RoyaltyObligationPeriodFromDateOfFirstSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_SalesMilestoneMember" name="SalesMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember" name="SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_ServierMember" name="ServierMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_StockIssuedDuringPeriodValueCommonStockIssues" name="StockIssuedDuringPeriodValueCommonStockIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="allo_StockOptionGrantedPeriod" name="StockOptionGrantedPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_SubleaseAgreementMember" name="SubleaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_SubscriptionReceivableFromPreferredStockholdersMember" name="SubscriptionReceivableFromPreferredStockholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_SubscriptionsReceivableFromPreferredStockholders" name="SubscriptionsReceivableFromPreferredStockholders" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_TransitionServicesAgreementMember" name="TransitionServicesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="allo_TwoRiverConsultingLLCMember" name="TwoRiverConsultingLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="allo_UnvestedSharesLiabilitiesCurrent" name="UnvestedSharesLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>allo-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponents" xlink:href="allo-20190930.xsd#BalanceSheetsComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsAccruedLiabilitiesDetails" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsPropertyAndEquipmentDetails" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheets" xlink:href="allo-20190930.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:href="allo-20190930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementOfCashFlows" xlink:href="allo-20190930.xsd#CondensedStatementOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementOfStockholdersEquityDeficit" xlink:href="allo-20190930.xsd#CondensedStatementOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:href="allo-20190930.xsd#CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsOfStockholdersEquityDeficitParenthetical" xlink:href="allo-20190930.xsd#CondensedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:href="allo-20190930.xsd#ConvertibleNotesPayable2018NotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesTables" xlink:href="allo-20190930.xsd#ConvertibleNotesPayable2018NotesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2019Notes" xlink:href="allo-20190930.xsd#ConvertibleNotesPayable2019Notes" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:href="allo-20190930.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/DescriptionOfBusiness" xlink:href="allo-20190930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/DescriptionOfBusinessDetails" xlink:href="allo-20190930.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:href="allo-20190930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="allo-20190930.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail" xlink:href="allo-20190930.xsd#FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:href="allo-20190930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstruments" xlink:href="allo-20190930.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:href="allo-20190930.xsd#FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails" xlink:href="allo-20190930.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsTables" xlink:href="allo-20190930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:href="allo-20190930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/Leases" xlink:href="allo-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:href="allo-20190930.xsd#LeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LeasesTables" xlink:href="allo-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetails" xlink:href="allo-20190930.xsd#LeasesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetailsCalc2" xlink:href="allo-20190930.xsd#LeasesUndiscountedFutureLeasePaymentsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreements" xlink:href="allo-20190930.xsd#LicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreementsDetails" xlink:href="allo-20190930.xsd#LicenseAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShare" xlink:href="allo-20190930.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:href="allo-20190930.xsd#NetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareTables" xlink:href="allo-20190930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:href="allo-20190930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:href="allo-20190930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:href="allo-20190930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:href="allo-20190930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:href="allo-20190930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:href="allo-20190930.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="allo-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="allo-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetsComponents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherLiabilitiesCurrent" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_f106f71b-9ada-6c18-2be5-ddd3715b9a7f" xlink:type="locator" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent_38696b14-d581-4e11-4531-ddd37140210e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_f106f71b-9ada-6c18-2be5-ddd3715b9a7f" xlink:to="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent_38696b14-d581-4e11-4531-ddd37140210e" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedCompensationAndRelatedBenefitsCurrent" xlink:label="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent_d01c3a01-f718-6a41-1710-ddd37197104e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_f106f71b-9ada-6c18-2be5-ddd3715b9a7f" xlink:to="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent_d01c3a01-f718-6a41-1710-ddd37197104e" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedPropertyAndEquipment" xlink:label="loc_allo_AccruedPropertyAndEquipment_DB91B6E5D07DFF24E5B71501409F29DA" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_f106f71b-9ada-6c18-2be5-ddd3715b9a7f" xlink:to="loc_allo_AccruedPropertyAndEquipment_DB91B6E5D07DFF24E5B71501409F29DA" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_UnvestedSharesLiabilitiesCurrent" xlink:label="loc_allo_UnvestedSharesLiabilitiesCurrent_7990d9de-6930-4bd3-320f-ddd371830227" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_f106f71b-9ada-6c18-2be5-ddd3715b9a7f" xlink:to="loc_allo_UnvestedSharesLiabilitiesCurrent_7990d9de-6930-4bd3-320f-ddd371830227" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_f106f71b-9ada-6c18-2be5-ddd3715b9a7f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:label="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent_327eabe7-3115-2511-5749-ddd3718040f6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:to="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent_327eabe7-3115-2511-5749-ddd3718040f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_5194a9fc-115c-f59a-adef-21b602d3ebcc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:to="loc_us-gaap_AccruedInvestmentIncomeReceivable_5194a9fc-115c-f59a-adef-21b602d3ebcc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_9288e0b2-8aad-49d6-163c-6e82e46379e3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:to="loc_us-gaap_PrepaidInsurance_9288e0b2-8aad-49d6-163c-6e82e46379e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_f8bba565-b2b1-7745-e5f2-79c3ddd7f45e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_f8bba565-b2b1-7745-e5f2-79c3ddd7f45e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_4f46bf2c-e8aa-a88a-d064-0418c3eb39b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_ShortTermInvestments_4f46bf2c-e8aa-a88a-d064-0418c3eb39b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ce9014ac-0ac4-6ed2-b53f-a0edc046d6b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_82393af8-00cf-c878-caac-887e4fcb1248" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_LongTermInvestments_82393af8-00cf-c878-caac-887e4fcb1248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52f5671e-53e6-6055-795e-6bd414fd86c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0c57e6e5-1856-148a-c665-8f26e53c3400" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0c57e6e5-1856-148a-c665-8f26e53c3400" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherLiabilitiesCurrent" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_f106f71b-9ada-6c18-2be5-ddd3715b9a7f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_f106f71b-9ada-6c18-2be5-ddd3715b9a7f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7e28dff2-da63-21d2-137e-ce9d56cb1b6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f0c68f4f-7ec1-d447-8ba7-0f2766abbe67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df284507-8ac7-eed1-41db-05e81b70be6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedStatementOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_afd0f625-a29a-3806-bad0-ad0ca19e7015" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_97b88949-d4fc-dff4-be7f-d39018557f4e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationAndAmortization_97b88949-d4fc-dff4-be7f-d39018557f4e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2e4e7778-759c-bb90-4954-46dd703615e0" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_2e4e7778-759c-bb90-4954-46dd703615e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_9c76d791-6c0d-f746-41d8-e19c56450041" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_LeaseAndRentalExpense_9c76d791-6c0d-f746-41d8-e19c56450041" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ChangeInFairValueOfConvertibleNotePayable" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable_3E461094BA3A6FBA0F64F46B59937F54" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_allo_ChangeInFairValueOfConvertibleNotePayable_3E461094BA3A6FBA0F64F46B59937F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b412c390-dfec-d4c8-f13e-036e3b49278c" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b412c390-dfec-d4c8-f13e-036e3b49278c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e4168a9-901d-abb5-15c0-3622e9e2c070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_366aa09e-f759-b63b-77e0-83ad3a947a55" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_366aa09e-f759-b63b-77e0-83ad3a947a55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0a39d2ee-656d-ead5-a676-41794b4da8f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_a7e5a9b0-da37-f993-db8e-55e01b78deb4" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_a7e5a9b0-da37-f993-db8e-55e01b78deb4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4e0ea51c-d09a-0164-9f15-a1d8d4927a87" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_4e0ea51c-d09a-0164-9f15-a1d8d4927a87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:label="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities_76a6f30e-1917-aef3-eee4-a32e1b034210" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities_76a6f30e-1917-aef3-eee4-a32e1b034210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_9d96fe52-eed0-e442-4c00-33d2270f0962" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_9d96fe52-eed0-e442-4c00-33d2270f0962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_94ef4f28-36c0-ebcc-c252-3b37968b424e" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_94ef4f28-36c0-ebcc-c252-3b37968b424e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9743d583-dfae-6ae9-f133-a1e331df792c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7c2a31aa-de85-3d78-fe3c-7d70dce934c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_7c2a31aa-de85-3d78-fe3c-7d70dce934c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_212a3895-370b-f5d5-9315-668e76c6ad50" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_212a3895-370b-f5d5-9315-668e76c6ad50" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions" xlink:label="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_510CCE92441B35D0198B14ED56A83AD1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_510CCE92441B35D0198B14ED56A83AD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6accd1a2-f190-7888-29dd-29802af49bdc" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6accd1a2-f190-7888-29dd-29802af49bdc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ee462479-f066-2ef4-feb4-a24474e585e7" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ee462479-f066-2ef4-feb4-a24474e585e7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_89070439-f162-e2de-a2eb-96e6bf6232c9" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromStockPlans_89070439-f162-e2de-a2eb-96e6bf6232c9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedStatementOfStockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ChangeInFairValueOfConvertibleNotePayable" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable_3E461094BA3A6FBA0F64F46B59937F54" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_allo_ChangeInFairValueOfConvertibleNotePayable_3E461094BA3A6FBA0F64F46B59937F54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4d8b6d19-6a54-06aa-2077-c10380bd20d1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7f6d9e2c-c748-5cf7-7279-5c01f0cb27b7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7f6d9e2c-c748-5cf7-7279-5c01f0cb27b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_11c9d7e5-c56e-e78a-ae7b-17989a817204" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a2f4cf19-54a3-c9c5-9b4d-23b76125e270" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a698662c-5d68-9b87-98fe-02485cda58f8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018NotesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2019Notes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionOfBusinessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D92B5D14940A540184570985B8DD474E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11DA18E29A8B538AA50112282BDBC7B6" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D92B5D14940A540184570985B8DD474E" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11DA18E29A8B538AA50112282BDBC7B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2260F1B061DE5CABB95B26C652E1AAFF" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D92B5D14940A540184570985B8DD474E" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2260F1B061DE5CABB95B26C652E1AAFF" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_CashEquivalentsAndShortTermInvestments" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_BE4866AEF83356C787C05BCE78348FD6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D92B5D14940A540184570985B8DD474E" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_BE4866AEF83356C787C05BCE78348FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_FECA740B027C500A85BF2F4DD046F3B1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_BE4866AEF83356C787C05BCE78348FD6" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_FECA740B027C500A85BF2F4DD046F3B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3B8C2D48204553AAB50A121001874EAC" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_BE4866AEF83356C787C05BCE78348FD6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_3B8C2D48204553AAB50A121001874EAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_E902BD29B77A57BDBABD268E0C5DB478" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_BE4866AEF83356C787C05BCE78348FD6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_E902BD29B77A57BDBABD268E0C5DB478" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6910ED564F0659BBAC98F4BEDFCC9ABE" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D92B5D14940A540184570985B8DD474E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6910ED564F0659BBAC98F4BEDFCC9ABE" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_FD75ADBC2395E4C9240715283FD250B2_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FD75ADBC2395E4C9240715283FD250B2_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_FD75ADBC2395E4C9240715283FD250B2_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FD75ADBC2395E4C9240715283FD250B2_d0e3c4ab-df94-52c6-3761-ce2ed0f2f507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_FD75ADBC2395E4C9240715283FD250B2_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_FD75ADBC2395E4C9240715283FD250B2_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_FD75ADBC2395E4C9240715283FD250B2_e0f20176-305e-e29f-ab09-584aea596901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FD75ADBC2395E4C9240715283FD250B2_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_FD75ADBC2395E4C9240715283FD250B2_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_FD75ADBC2395E4C9240715283FD250B2_8e35e675-3955-0e95-1b9c-d08dd410962e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD75ADBC2395E4C9240715283FD250B2_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_FD75ADBC2395E4C9240715283FD250B2_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_FD75ADBC2395E4C9240715283FD250B2_852d78fc-d4b9-e5fb-fd5a-9da7d3d49669" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_FD75ADBC2395E4C9240715283FD250B2_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_FD75ADBC2395E4C9240715283FD250B2_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_FD75ADBC2395E4C9240715283FD250B2_7a6864a2-d55e-24e7-17f1-75d5cad038ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FD75ADBC2395E4C9240715283FD250B2_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_FD75ADBC2395E4C9240715283FD250B2_4d26bd18-43c4-5981-04d4-83d0e9328a1d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FD75ADBC2395E4C9240715283FD250B2_a8c7556a-9f4c-b4fb-2e42-b21cf84287a7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://allogene.com/role/LicenseAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://allogene.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>allo-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponents" xlink:href="allo-20190930.xsd#BalanceSheetsComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsAccruedLiabilitiesDetails" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsPropertyAndEquipmentDetails" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheets" xlink:href="allo-20190930.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:href="allo-20190930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementOfCashFlows" xlink:href="allo-20190930.xsd#CondensedStatementOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementOfStockholdersEquityDeficit" xlink:href="allo-20190930.xsd#CondensedStatementOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:href="allo-20190930.xsd#CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsOfStockholdersEquityDeficitParenthetical" xlink:href="allo-20190930.xsd#CondensedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:href="allo-20190930.xsd#ConvertibleNotesPayable2018NotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesTables" xlink:href="allo-20190930.xsd#ConvertibleNotesPayable2018NotesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2019Notes" xlink:href="allo-20190930.xsd#ConvertibleNotesPayable2019Notes" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:href="allo-20190930.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/DescriptionOfBusiness" xlink:href="allo-20190930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/DescriptionOfBusinessDetails" xlink:href="allo-20190930.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:href="allo-20190930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="allo-20190930.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail" xlink:href="allo-20190930.xsd#FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:href="allo-20190930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstruments" xlink:href="allo-20190930.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:href="allo-20190930.xsd#FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails" xlink:href="allo-20190930.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsTables" xlink:href="allo-20190930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:href="allo-20190930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/Leases" xlink:href="allo-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:href="allo-20190930.xsd#LeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LeasesTables" xlink:href="allo-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetails" xlink:href="allo-20190930.xsd#LeasesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreements" xlink:href="allo-20190930.xsd#LicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreementsDetails" xlink:href="allo-20190930.xsd#LicenseAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShare" xlink:href="allo-20190930.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:href="allo-20190930.xsd#NetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareTables" xlink:href="allo-20190930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:href="allo-20190930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:href="allo-20190930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:href="allo-20190930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:href="allo-20190930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:href="allo-20190930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:href="allo-20190930.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="allo-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="allo-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetsComponents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsAccruedLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LaboratoryEquipmentMember" xlink:label="loc_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="loc_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="loc_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D8E5CC3073415989C81B14D38F083E73" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_D8E5CC3073415989C81B14D38F083E73" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedStatementOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedStatementOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:to="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:to="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:to="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SeriesAConvertiblePreferredStockMember" xlink:label="loc_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:to="loc_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember" xlink:label="loc_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:to="loc_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1179732F428624C0E49227760E1C32D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1179732F428624C0E49227760E1C32D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1179732F428624C0E49227760E1C32D9" xlink:to="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1179732F428624C0E49227760E1C32D9" xlink:to="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SubscriptionReceivableFromPreferredStockholdersMember" xlink:label="loc_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AF27FC392B722B332DC027760E1C273B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_CommonStockMember_AF27FC392B722B332DC027760E1C273B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_EAB772ABD85E205DF70127760E206380" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_EAB772ABD85E205DF70127760E206380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_30774CF4174B21A7C3E827760E2064BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_30774CF4174B21A7C3E827760E2064BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_495A95AC40225B718EDE27760E2038EE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_495A95AC40225B718EDE27760E2038EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SubscriptionsReceivableFromPreferredStockholders" xlink:label="loc_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_StockIssuedDuringPeriodValueCommonStockIssues" xlink:label="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D5B2AD1483DA9CC0E87927760E20ED13" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D5B2AD1483DA9CC0E87927760E20ED13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_A3E0427AB74BA32E61F427760E20E8DB" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_A3E0427AB74BA32E61F427760E20E8DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_65C3363054678EA983A927760E24154A" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_NetIncomeLoss_65C3363054678EA983A927760E24154A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7B9B925D679D5BCDC87123C4C92CFA80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B9D544C9C677630F752423C4C925C117" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7B9B925D679D5BCDC87123C4C92CFA80" xlink:to="loc_us-gaap_StatementTable_B9D544C9C677630F752423C4C925C117" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_D92CF2E49971CBE4A45423C4C925DB7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_B9D544C9C677630F752423C4C925C117" xlink:to="loc_us-gaap_StatementClassOfStockAxis_D92CF2E49971CBE4A45423C4C925DB7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9BE7E07687E7C5AA847023C4C925BF69_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D92CF2E49971CBE4A45423C4C925DB7F" xlink:to="loc_us-gaap_ClassOfStockDomain_9BE7E07687E7C5AA847023C4C925BF69_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9BE7E07687E7C5AA847023C4C925BF69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D92CF2E49971CBE4A45423C4C925DB7F" xlink:to="loc_us-gaap_ClassOfStockDomain_9BE7E07687E7C5AA847023C4C925BF69" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SeriesAConvertiblePreferredStockMember" xlink:label="loc_allo_SeriesAConvertiblePreferredStockMember_C56E7E03BE2E1E69AB9823C4C926D51D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9BE7E07687E7C5AA847023C4C925BF69" xlink:to="loc_allo_SeriesAConvertiblePreferredStockMember_C56E7E03BE2E1E69AB9823C4C926D51D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember" xlink:label="loc_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_D1A3FA3E2FE8CFACA76F23C4C9264E6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9BE7E07687E7C5AA847023C4C925BF69" xlink:to="loc_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_D1A3FA3E2FE8CFACA76F23C4C9264E6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_BCBDDC057144B7868D7C23C4C926BA12" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_B9D544C9C677630F752423C4C925C117" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_BCBDDC057144B7868D7C23C4C926BA12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_166807528C3529B68FF523C4C9265509_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BCBDDC057144B7868D7C23C4C926BA12" xlink:to="loc_us-gaap_EquityComponentDomain_166807528C3529B68FF523C4C9265509_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_166807528C3529B68FF523C4C9265509" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BCBDDC057144B7868D7C23C4C926BA12" xlink:to="loc_us-gaap_EquityComponentDomain_166807528C3529B68FF523C4C9265509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_2A8EE108E6B69936EAFB23C4C92CF700" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_166807528C3529B68FF523C4C9265509" xlink:to="loc_us-gaap_PreferredStockMember_2A8EE108E6B69936EAFB23C4C92CF700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DD542F9F4C7D1B05BE4923C4C92C8A1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7B9B925D679D5BCDC87123C4C92CFA80" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DD542F9F4C7D1B05BE4923C4C92C8A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_367FD26B7E05147D32A223C4C92D742F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7B9B925D679D5BCDC87123C4C92CFA80" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_367FD26B7E05147D32A223C4C92D742F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9F4C044112FF292F732F27760C69FEE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:to="loc_srt_RangeAxis_9F4C044112FF292F732F27760C69FEE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_813DFBEC83F1B569DDE127760C692C2E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9F4C044112FF292F732F27760C69FEE1" xlink:to="loc_srt_RangeMember_813DFBEC83F1B569DDE127760C692C2E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_813DFBEC83F1B569DDE127760C692C2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9F4C044112FF292F732F27760C69FEE1" xlink:to="loc_srt_RangeMember_813DFBEC83F1B569DDE127760C692C2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_DE57033657BD64F66DC027760C699BA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_813DFBEC83F1B569DDE127760C692C2E" xlink:to="loc_srt_MinimumMember_DE57033657BD64F66DC027760C699BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_743139B516E854C6C9E027760C69E665" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_813DFBEC83F1B569DDE127760C692C2E" xlink:to="loc_srt_MaximumMember_743139B516E854C6C9E027760C69E665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_78E3565F0C230BAC2B7427760C695213" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_78E3565F0C230BAC2B7427760C695213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_69CD86E51EC3FB90041F27760C6990CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_69CD86E51EC3FB90041F27760C6990CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018NotesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2019Notes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:to="loc_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:to="loc_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:to="loc_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:to="loc_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:to="loc_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:to="loc_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ConvertiblePromissoryNotesMember" xlink:label="loc_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:to="loc_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41257DF7E2F854438D56167DFCABCA25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11086084D82557759BB9D5CC5DCD2447" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41257DF7E2F854438D56167DFCABCA25" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11086084D82557759BB9D5CC5DCD2447" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_069A1F1F6F9E5F37944B7278A110CA16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11086084D82557759BB9D5CC5DCD2447" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_069A1F1F6F9E5F37944B7278A110CA16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_C17ACCCC4873A8030003E218761865B2_4C057ECD989155919B5B81850E10D3BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_069A1F1F6F9E5F37944B7278A110CA16" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_C17ACCCC4873A8030003E218761865B2_4C057ECD989155919B5B81850E10D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DD69360A33965DCEBE5E78EB45479DF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_069A1F1F6F9E5F37944B7278A110CA16" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_DD69360A33965DCEBE5E78EB45479DF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_770EC3300D9E59F1868E3BD31368407A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_DD69360A33965DCEBE5E78EB45479DF1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_770EC3300D9E59F1868E3BD31368407A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38DD54E7173B5230ADE91CEE978E7285" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11086084D82557759BB9D5CC5DCD2447" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38DD54E7173B5230ADE91CEE978E7285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2107E674BE14E2997C3EE218761985CB_4C057ECD989155919B5B81850E10D3BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38DD54E7173B5230ADE91CEE978E7285" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2107E674BE14E2997C3EE218761985CB_4C057ECD989155919B5B81850E10D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEFA68DA566D5ED783DEABA63802179A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38DD54E7173B5230ADE91CEE978E7285" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEFA68DA566D5ED783DEABA63802179A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3F853B16092D50039271F3AE1F7F70C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEFA68DA566D5ED783DEABA63802179A" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3F853B16092D50039271F3AE1F7F70C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8DC1A8A611835379B382DFD52D0F542A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41257DF7E2F854438D56167DFCABCA25" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8DC1A8A611835379B382DFD52D0F542A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_C1BD29A9263750548B8C492B53D90481" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41257DF7E2F854438D56167DFCABCA25" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_C1BD29A9263750548B8C492B53D90481" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_FairValueAssetsTransfersBetweenLevelsAmount" xlink:label="loc_allo_FairValueAssetsTransfersBetweenLevelsAmount_7283977DC8305DEF8855462743275ACF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41257DF7E2F854438D56167DFCABCA25" xlink:to="loc_allo_FairValueAssetsTransfersBetweenLevelsAmount_7283977DC8305DEF8855462743275ACF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8B6D96FB06745B0F9ACFCC1E3CB61A0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8B6D96FB06745B0F9ACFCC1E3CB61A0C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1A393F72FAA759D98C070A3B17F41507" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1A393F72FAA759D98C070A3B17F41507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2E4E3E2A2B429448960405C2B8B17BE5_4C057ECD989155919B5B81850E10D3BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1A393F72FAA759D98C070A3B17F41507" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2E4E3E2A2B429448960405C2B8B17BE5_4C057ECD989155919B5B81850E10D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9B509AEF3E9E5538A6393F2E827C115E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1A393F72FAA759D98C070A3B17F41507" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9B509AEF3E9E5538A6393F2E827C115E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6E0F9FC35EBE577BBDD3AF4D3959135C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9B509AEF3E9E5538A6393F2E827C115E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6E0F9FC35EBE577BBDD3AF4D3959135C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21080A62C6FB5104A7491B2D3C828665" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21080A62C6FB5104A7491B2D3C828665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D38924B76BE5D4559D505C2B8B24A9F_4C057ECD989155919B5B81850E10D3BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21080A62C6FB5104A7491B2D3C828665" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D38924B76BE5D4559D505C2B8B24A9F_4C057ECD989155919B5B81850E10D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C53DD61C2E025764A455B586E42743EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21080A62C6FB5104A7491B2D3C828665" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C53DD61C2E025764A455B586E42743EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B6C3A3AE57B95AF8A1CF8F136BA9924C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C53DD61C2E025764A455B586E42743EC" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_B6C3A3AE57B95AF8A1CF8F136BA9924C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2A27540DD93157EDAE737B3159527F07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C53DD61C2E025764A455B586E42743EC" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2A27540DD93157EDAE737B3159527F07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_69003A7C97F050ED9D5E758652038591" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C53DD61C2E025764A455B586E42743EC" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_69003A7C97F050ED9D5E758652038591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_BC4BAD64D56ACC705C9605C2B8B3D6D1_4C057ECD989155919B5B81850E10D3BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_BC4BAD64D56ACC705C9605C2B8B3D6D1_4C057ECD989155919B5B81850E10D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8852385AAF3D55499E10ADC8E6FBAAB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8852385AAF3D55499E10ADC8E6FBAAB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_D09DB3B5A50E533CBE77DE63CE9E5432" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="loc_us-gaap_CommercialPaperMember_D09DB3B5A50E533CBE77DE63CE9E5432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_02800BB0E24051A5A291C360FE71147A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_02800BB0E24051A5A291C360FE71147A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_55C93ADFF7C55F76B269A4E94335E44A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_55C93ADFF7C55F76B269A4E94335E44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DABB1D94178E5CD0BD30B43C6D973B8C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DABB1D94178E5CD0BD30B43C6D973B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2AAB4DD959C85A1A96DDEAC5EDFCDF87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8B6D96FB06745B0F9ACFCC1E3CB61A0C" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2AAB4DD959C85A1A96DDEAC5EDFCDF87" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:to="loc_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_CF2ABB12974FD71843D50B822A105806_4C057ECD989155919B5B81850E10D3BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_CF2ABB12974FD71843D50B822A105806_4C057ECD989155919B5B81850E10D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_F9078761C01D56B18B1DC1C115C9EF9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="loc_us-gaap_MoneyMarketFundsMember_F9078761C01D56B18B1DC1C115C9EF9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_3C1348FFC85E5D019C292A63E273D815" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="loc_us-gaap_CommercialPaperMember_3C1348FFC85E5D019C292A63E273D815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_106AB19DAA7655E09AA9652A846C5E5A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_106AB19DAA7655E09AA9652A846C5E5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_43E901317C79523CA8DBC944AB14F96C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_43E901317C79523CA8DBC944AB14F96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2FB8DDC646FD5A4C9627F307D1690F4A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2FB8DDC646FD5A4C9627F307D1690F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6A70154D907652958BC366CB946D2891" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6A70154D907652958BC366CB946D2891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6CCF37333E165EFFB45233741A6C97CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6CCF37333E165EFFB45233741A6C97CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_B677BC1CCF9A5303B2240C43FB9DFECB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_B677BC1CCF9A5303B2240C43FB9DFECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5C1D9264276C54879E74A781F2D61CA9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5C1D9264276C54879E74A781F2D61CA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_A76683BF50855FF58E88D0DC8BDB0A4F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_A76683BF50855FF58E88D0DC8BDB0A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D0981054DA8457FAABDB9676BAB63AAD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D0981054DA8457FAABDB9676BAB63AAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5896A6BE1A7A5395AF456E0CC3980AE5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5896A6BE1A7A5395AF456E0CC3980AE5" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_CashEquivalentsAndShortTermInvestments" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_F8D823F872275E3BB0CD017E83EB5914" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_F8D823F872275E3BB0CD017E83EB5914" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FEB7FC0D8869A0C2B26937858CAE0298_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FEB7FC0D8869A0C2B26937858CAE0298_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FEB7FC0D8869A0C2B26937858CAE0298" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FEB7FC0D8869A0C2B26937858CAE0298" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAndCollaborationAgreementMember" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_0E2D6CFDE75ACF74F9C837858CAFBEC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FEB7FC0D8869A0C2B26937858CAE0298" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_0E2D6CFDE75ACF74F9C837858CAFBEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9FC1EFC9B23AAC9E05A037858CAF342F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:to="loc_us-gaap_RelatedPartyDomain_9FC1EFC9B23AAC9E05A037858CAF342F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9FC1EFC9B23AAC9E05A037858CAF342F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:to="loc_us-gaap_RelatedPartyDomain_9FC1EFC9B23AAC9E05A037858CAF342F" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ServierMember" xlink:label="loc_allo_ServierMember_1296FEA6D562E23DCC0737858CAF4528" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9FC1EFC9B23AAC9E05A037858CAF342F" xlink:to="loc_allo_ServierMember_1296FEA6D562E23DCC0737858CAF4528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_F97E69BE6801A3A3FA9937858CB031BF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_F97E69BE6801A3A3FA9937858CB031BF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_F97E69BE6801A3A3FA9937858CB031BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_F97E69BE6801A3A3FA9937858CB031BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LeaseOneMember" xlink:label="loc_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:to="loc_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LeaseTwoMember" xlink:label="loc_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:to="loc_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:to="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:to="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:label="loc_stpr_NY_F6BFDB6DE897303328B337858CB23A9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:to="loc_stpr_NY_F6BFDB6DE897303328B337858CB23A9B" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LosAngelesMember" xlink:label="loc_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:to="loc_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_NewarkMember" xlink:label="loc_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:to="loc_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AreaOfNewOfficeBuilding" xlink:label="loc_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AllowanceForTenantImprovements" xlink:label="loc_allo_AllowanceForTenantImprovements_CCC662AF95E7D5C18C1537858CB367D3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_AllowanceForTenantImprovements_CCC662AF95E7D5C18C1537858CB367D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_OperatingLeaseRemainingTerm" xlink:label="loc_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AreaOfOperatingLease" xlink:label="loc_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_NumberOfOptionsToExtendLease" xlink:label="loc_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PaymentOfLeaseRentalPerMonth" xlink:label="loc_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent" xlink:label="loc_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_OperatingLeasesUndiscountedLeasePayments" xlink:label="loc_allo_OperatingLeasesUndiscountedLeasePayments_A713865D741195EF095D37858CB5BB70" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_OperatingLeasesUndiscountedLeasePayments_A713865D741195EF095D37858CB5BB70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/LicenseAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAgreementsLineItems" xlink:label="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:type="locator" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAgreementsTable" xlink:label="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeAxis" xlink:label="loc_allo_MilestoneTypeAxis_E27C07E969D736928B5018985B3991B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_allo_MilestoneTypeAxis_E27C07E969D736928B5018985B3991B9" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeDomain" xlink:label="loc_allo_MilestoneTypeDomain_A125B4C548405EB034B718985B39B600_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_MilestoneTypeAxis_E27C07E969D736928B5018985B3991B9" xlink:to="loc_allo_MilestoneTypeDomain_A125B4C548405EB034B718985B39B600_default" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeDomain" xlink:label="loc_allo_MilestoneTypeDomain_A125B4C548405EB034B718985B39B600" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_MilestoneTypeAxis_E27C07E969D736928B5018985B3991B9" xlink:to="loc_allo_MilestoneTypeDomain_A125B4C548405EB034B718985B39B600" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_DevelopmentAndSalesMember" xlink:label="loc_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_MilestoneTypeDomain_A125B4C548405EB034B718985B39B600" xlink:to="loc_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_Phase1ClinicalTrialFirstPatientDoseMember" xlink:label="loc_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_MilestoneTypeDomain_A125B4C548405EB034B718985B39B600" xlink:to="loc_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:to="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:to="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PfizerIncMember" xlink:label="loc_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:to="loc_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_CellectisSAMember" xlink:label="loc_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:to="loc_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ServierMember" xlink:label="loc_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:to="loc_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AssetContributionAgreementMember" xlink:label="loc_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:to="loc_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_RegulatoryMilestoneMember" xlink:label="loc_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:to="loc_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SalesMilestoneMember" xlink:label="loc_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:to="loc_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:to="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:to="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:to="loc_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:to="loc_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ResearchCollaborationAndLicenseAgreementMember" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:to="loc_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAndCollaborationAgreementMember" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestonePayments" xlink:label="loc_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AggregatePotentialMilestonePayments" xlink:label="loc_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherLiabilitiesCurrent" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AggregatePotentialMilestoneReceivable" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_FounderSharesOfCommonStockMember" xlink:label="loc_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_EarlyExerciseOfStockOptionsMember" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C481F29E4053D0E3FDCC37858C4A3BE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C481F29E4053D0E3FDCC37858C4A3BE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C481F29E4053D0E3FDCC37858C4A3BE3" xlink:to="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C481F29E4053D0E3FDCC37858C4A3BE3" xlink:to="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PfizerIncMember" xlink:label="loc_allo_PfizerIncMember_6581E668F3E0C0F8583637858C4BB57D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:to="loc_allo_PfizerIncMember_6581E668F3E0C0F8583637858C4BB57D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ByHeartIncMember" xlink:label="loc_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:to="loc_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_TwoRiverConsultingLLCMember" xlink:label="loc_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:to="loc_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_BellcoCapitalLLCMember" xlink:label="loc_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:to="loc_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_245402D91BF4E6BC7BC237858C4CC06E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_245402D91BF4E6BC7BC237858C4CC06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_245402D91BF4E6BC7BC237858C4CC06E" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_245402D91BF4E6BC7BC237858C4CC06E" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_TransitionServicesAgreementMember" xlink:label="loc_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4" xlink:to="loc_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SubleaseAgreementMember" xlink:label="loc_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4" xlink:to="loc_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ConsultingAgreementsMember" xlink:label="loc_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4" xlink:to="loc_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="loc_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:to="loc_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6F235CCAFA5F5EBB140437858C4F66CC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_srt_RangeAxis_6F235CCAFA5F5EBB140437858C4F66CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CFAB6EB685D7CB06DCBC37858C4FB50B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6F235CCAFA5F5EBB140437858C4F66CC" xlink:to="loc_srt_RangeMember_CFAB6EB685D7CB06DCBC37858C4FB50B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CFAB6EB685D7CB06DCBC37858C4FB50B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6F235CCAFA5F5EBB140437858C4F66CC" xlink:to="loc_srt_RangeMember_CFAB6EB685D7CB06DCBC37858C4FB50B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_93A8388E7F8D064E398F37858C50AF35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_CFAB6EB685D7CB06DCBC37858C4FB50B" xlink:to="loc_srt_MaximumMember_93A8388E7F8D064E398F37858C50AF35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5F8C49F8432EAB995A2637858C50EE87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5F8C49F8432EAB995A2637858C50EE87" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:label="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense" xlink:label="loc_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AreaOfOffice" xlink:label="loc_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_RelatedPartyTransactionCompensationPercentage" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:to="loc_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:to="loc_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D4E9D382A016533A51FB37858C8F2563" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:to="loc_srt_RangeAxis_D4E9D382A016533A51FB37858C8F2563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FE5FE6CD37D077CEC6A537858C8F0BD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_D4E9D382A016533A51FB37858C8F2563" xlink:to="loc_srt_RangeMember_FE5FE6CD37D077CEC6A537858C8F0BD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FE5FE6CD37D077CEC6A537858C8F0BD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_D4E9D382A016533A51FB37858C8F2563" xlink:to="loc_srt_RangeMember_FE5FE6CD37D077CEC6A537858C8F0BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9C802D7F4CBA0261BB1337858C907A6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_FE5FE6CD37D077CEC6A537858C8F0BD0" xlink:to="loc_srt_MaximumMember_9C802D7F4CBA0261BB1337858C907A6E" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_StockOptionGrantedPeriod" xlink:label="loc_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C985C36CFFC3582298D1FD9D5CFCE581" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C985C36CFFC3582298D1FD9D5CFCE581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_08C2D368ADD8713962B653D93D228B85_4C057ECD989155919B5B81850E10D3BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C985C36CFFC3582298D1FD9D5CFCE581" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_08C2D368ADD8713962B653D93D228B85_4C057ECD989155919B5B81850E10D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7C9E9A09DCB959BD9F24ACBA610B5398" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C985C36CFFC3582298D1FD9D5CFCE581" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7C9E9A09DCB959BD9F24ACBA610B5398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F7672936F885969939173B383330937" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7C9E9A09DCB959BD9F24ACBA610B5398" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F7672936F885969939173B383330937" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A2E0368DBBE657689CA98DE1A65E7C30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7C9E9A09DCB959BD9F24ACBA610B5398" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A2E0368DBBE657689CA98DE1A65E7C30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D190269E15D556BDA7C9994844602801" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D190269E15D556BDA7C9994844602801" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ABD6BB424A0457AC8D3B640E6DFEA5AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ABD6BB424A0457AC8D3B640E6DFEA5AA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E45301313D865574BF6B8927228CCB59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ABD6BB424A0457AC8D3B640E6DFEA5AA" xlink:to="loc_us-gaap_AwardTypeAxis_E45301313D865574BF6B8927228CCB59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_942947417451C7A59D0A6310DB82D451_4C057ECD989155919B5B81850E10D3BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E45301313D865574BF6B8927228CCB59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_942947417451C7A59D0A6310DB82D451_4C057ECD989155919B5B81850E10D3BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7E285A01D35C5F769B8626513949E383" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E45301313D865574BF6B8927228CCB59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7E285A01D35C5F769B8626513949E383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_A5183049A10E54AB8D384ED2957D73DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7E285A01D35C5F769B8626513949E383" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_A5183049A10E54AB8D384ED2957D73DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C1E373469AD5E92A4DB471D6C58949B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C1E373469AD5E92A4DB471D6C58949B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99D3CACD435758E0BCDC7EECE0F1D941" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99D3CACD435758E0BCDC7EECE0F1D941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F6C06F3797E150F8A6E5A1375A236002" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F6C06F3797E150F8A6E5A1375A236002" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6A3A93A8D16F5FACBF722D4D9C68746D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6A3A93A8D16F5FACBF722D4D9C68746D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_71B0DC973E8A5A0FAFBF11FEF1D4CE99" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_71B0DC973E8A5A0FAFBF11FEF1D4CE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08E939706FFC559CB3B0C8E5787BB680" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08E939706FFC559CB3B0C8E5787BB680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FE05E67A0C6D5A1E8C3C9492FFC781F7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FE05E67A0C6D5A1E8C3C9492FFC781F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_57424237B3845B3C8A3DE1688F33D228" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_57424237B3845B3C8A3DE1688F33D228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_C6FF5A996BCD514FAEB08565B76C8BC3" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_C6FF5A996BCD514FAEB08565B76C8BC3" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_005B79DBF6DD55AA95A98E58F8AB8729" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_005B79DBF6DD55AA95A98E58F8AB8729" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:to="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_NotchTherapeuticsInc.Member" xlink:label="loc_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:to="loc_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:to="loc_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeAxis" xlink:label="loc_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:to="loc_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeDomain" xlink:label="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:to="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4_default" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeDomain" xlink:label="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:to="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ResearchMilestoneMember" xlink:label="loc_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:to="loc_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PreClinicalDevelopmentMilestoneMember" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:to="loc_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ClinicalRegulatoryandCommercialMilestoneMember" xlink:label="loc_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:to="loc_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_CollaborativeArrangementInitialFee" xlink:label="loc_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:to="loc_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_CollaborativeArrangementContingentConsiderationLiability" xlink:label="loc_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:to="loc_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://allogene.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://allogene.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>allo-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B565B1751537EFB71EFB2774EFB5E22E_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B565B1751537EFB71EFB2774EFB5E22E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B565B1751537EFB71EFB2774EFB5E22E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B565B1751537EFB71EFB2774EFB5E22E" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B565B1751537EFB71EFB2774EFB5E22E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:to="lab_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169" xlink:to="lab_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85_label_en-US" xlink:label="lab_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85" xlink:to="lab_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA" xlink:to="lab_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:to="lab_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:type="arc" />
    <link:label id="lab_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440_terseLabel_en-US" xlink:label="lab_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes</link:label>
    <link:label id="lab_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440_label_en-US" xlink:label="lab_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
    <link:label id="lab_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440_documentation_en-US" xlink:label="lab_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ConvertiblePromissoryNotesMember" xlink:label="loc_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440" xlink:to="lab_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock price per share</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting discounts and commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9_label_en-US" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Underwriting Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9" xlink:to="lab_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares converted from preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number common shares converted from convertible notes payable (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding convertible promissory notes</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_F064C2E02963BB834B642774EFB739B6_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_F064C2E02963BB834B642774EFB739B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_F064C2E02963BB834B642774EFB739B6_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_F064C2E02963BB834B642774EFB739B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_F064C2E02963BB834B642774EFB739B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_F064C2E02963BB834B642774EFB739B6" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_F064C2E02963BB834B642774EFB739B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0FE95379B2CA319E45822774EFBB675E_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0FE95379B2CA319E45822774EFBB675E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0FE95379B2CA319E45822774EFBB675E_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0FE95379B2CA319E45822774EFBB675E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0FE95379B2CA319E45822774EFBB675E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0FE95379B2CA319E45822774EFBB675E" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0FE95379B2CA319E45822774EFBB675E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7933C3A5B76515C446FC2774EFBBEBD7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7933C3A5B76515C446FC2774EFBBEBD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock forward split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7933C3A5B76515C446FC2774EFBBEBD7_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7933C3A5B76515C446FC2774EFBBEBD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7933C3A5B76515C446FC2774EFBBEBD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7933C3A5B76515C446FC2774EFBBEBD7" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7933C3A5B76515C446FC2774EFBBEBD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_74EB8DF75FDE22ADF36C0B822A0F092A_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_709FD58D38AF511ABE5C2479CC36E2C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_709FD58D38AF511ABE5C2479CC36E2C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_709FD58D38AF511ABE5C2479CC36E2C6" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_709FD58D38AF511ABE5C2479CC36E2C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EB67CC11FED1571DD3E80B822A0FCB95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_EB67CC11FED1571DD3E80B822A0FCB95_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_88D1CB1F1548B196098C0B822A0FDFB2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_88D1CB1F1548B196098C0B822A0FDFB2_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:to="lab_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_CF2ABB12974FD71843D50B822A105806_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_CF2ABB12974FD71843D50B822A105806_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7AAB5954BAE924EEDF3E0B822A15AF4D_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_F9078761C01D56B18B1DC1C115C9EF9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7AAB5954BAE924EEDF3E0B822A15AF4D_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_F9078761C01D56B18B1DC1C115C9EF9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_F9078761C01D56B18B1DC1C115C9EF9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_F9078761C01D56B18B1DC1C115C9EF9A" xlink:to="lab_us-gaap_MoneyMarketFundsMember_F9078761C01D56B18B1DC1C115C9EF9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_3FC17A6A0B4A286843810B822A15ADCC_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_3C1348FFC85E5D019C292A63E273D815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_3FC17A6A0B4A286843810B822A15ADCC_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_3C1348FFC85E5D019C292A63E273D815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_3C1348FFC85E5D019C292A63E273D815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_3C1348FFC85E5D019C292A63E273D815" xlink:to="lab_us-gaap_CommercialPaperMember_3C1348FFC85E5D019C292A63E273D815" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_88A4AE709D0292EFA61B0B822A168D58_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_106AB19DAA7655E09AA9652A846C5E5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_88A4AE709D0292EFA61B0B822A168D58_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_106AB19DAA7655E09AA9652A846C5E5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_106AB19DAA7655E09AA9652A846C5E5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_106AB19DAA7655E09AA9652A846C5E5A" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_106AB19DAA7655E09AA9652A846C5E5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_E3C2DF2F57F88F36783F0B822A16CCB7_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_43E901317C79523CA8DBC944AB14F96C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_E3C2DF2F57F88F36783F0B822A16CCB7_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_43E901317C79523CA8DBC944AB14F96C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_43E901317C79523CA8DBC944AB14F96C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_43E901317C79523CA8DBC944AB14F96C" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_43E901317C79523CA8DBC944AB14F96C" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_B68774E1B7815969D2C00B822A166221_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2FB8DDC646FD5A4C9627F307D1690F4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_B68774E1B7815969D2C00B822A166221_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2FB8DDC646FD5A4C9627F307D1690F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2FB8DDC646FD5A4C9627F307D1690F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2FB8DDC646FD5A4C9627F307D1690F4A" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2FB8DDC646FD5A4C9627F307D1690F4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1C6FCB1E0F3BA36CD9600B822A162B50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1C6FCB1E0F3BA36CD9600B822A162B50_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_780A1A262FE63FF77EA30B822A17AD87_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6A70154D907652958BC366CB946D2891" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_780A1A262FE63FF77EA30B822A17AD87_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6A70154D907652958BC366CB946D2891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6A70154D907652958BC366CB946D2891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6A70154D907652958BC366CB946D2891" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6A70154D907652958BC366CB946D2891" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E64520361087FE68D3BD0B822A17F646_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6CCF37333E165EFFB45233741A6C97CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E64520361087FE68D3BD0B822A17F646_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6CCF37333E165EFFB45233741A6C97CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6CCF37333E165EFFB45233741A6C97CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6CCF37333E165EFFB45233741A6C97CB" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6CCF37333E165EFFB45233741A6C97CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6315E9D1DAF3FE55119D0B822A1764ED_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_B677BC1CCF9A5303B2240C43FB9DFECB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6315E9D1DAF3FE55119D0B822A1764ED_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_B677BC1CCF9A5303B2240C43FB9DFECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_B677BC1CCF9A5303B2240C43FB9DFECB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_B677BC1CCF9A5303B2240C43FB9DFECB" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_B677BC1CCF9A5303B2240C43FB9DFECB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_18701A4AD9FD95E16C2E0B822A17D747_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5C1D9264276C54879E74A781F2D61CA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_18701A4AD9FD95E16C2E0B822A17D747_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5C1D9264276C54879E74A781F2D61CA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5C1D9264276C54879E74A781F2D61CA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5C1D9264276C54879E74A781F2D61CA9" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5C1D9264276C54879E74A781F2D61CA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_12088CE300FE8721DE0A0B822A17FBA5_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_A76683BF50855FF58E88D0DC8BDB0A4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_12088CE300FE8721DE0A0B822A17FBA5_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_A76683BF50855FF58E88D0DC8BDB0A4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_A76683BF50855FF58E88D0DC8BDB0A4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_A76683BF50855FF58E88D0DC8BDB0A4F" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_A76683BF50855FF58E88D0DC8BDB0A4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_23991D8E6679DCCCF5900B822A186C1A_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D0981054DA8457FAABDB9676BAB63AAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_23991D8E6679DCCCF5900B822A186C1A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D0981054DA8457FAABDB9676BAB63AAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D0981054DA8457FAABDB9676BAB63AAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D0981054DA8457FAABDB9676BAB63AAD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D0981054DA8457FAABDB9676BAB63AAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_586C93AC691EA3B646B40B822A1851EF_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5896A6BE1A7A5395AF456E0CC3980AE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_586C93AC691EA3B646B40B822A1851EF_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5896A6BE1A7A5395AF456E0CC3980AE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5896A6BE1A7A5395AF456E0CC3980AE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5896A6BE1A7A5395AF456E0CC3980AE5" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5896A6BE1A7A5395AF456E0CC3980AE5" xlink:type="arc" />
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_6691BBDFF22735A3657C0B822A18F177_totalLabel_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments_F8D823F872275E3BB0CD017E83EB5914" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash equivalents and investments</link:label>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_6691BBDFF22735A3657C0B822A18F177_label_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments_F8D823F872275E3BB0CD017E83EB5914" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents And Short Term Investments</link:label>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_6691BBDFF22735A3657C0B822A18F177_documentation_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments_F8D823F872275E3BB0CD017E83EB5914" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_CashEquivalentsAndShortTermInvestments" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_F8D823F872275E3BB0CD017E83EB5914" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_F8D823F872275E3BB0CD017E83EB5914" xlink:to="lab_allo_CashEquivalentsAndShortTermInvestments_F8D823F872275E3BB0CD017E83EB5914" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_320EE4A4195B48F734F8F46CDE9F29A5_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_320EE4A4195B48F734F8F46CDE9F29A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_320EE4A4195B48F734F8F46CDE9F29A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_320EE4A4195B48F734F8F46CDE9F29A5" xlink:to="lab_us-gaap_EarningsPerShareAbstract_320EE4A4195B48F734F8F46CDE9F29A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE" xlink:to="lab_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units subject to vesting</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected shares purchased under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D" xlink:to="lab_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D" xlink:type="arc" />
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829_terseLabel_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Founder shares of common stock subject to future vesting</link:label>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829_label_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Founder Shares Of Common Stock [Member]</link:label>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829_documentation_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Founder shares of common stock.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_FounderSharesOfCommonStockMember" xlink:label="loc_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829" xlink:to="lab_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829" xlink:type="arc" />
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E_terseLabel_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early exercised stock options subject to future vesting</link:label>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E_label_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Early Exercise Of Stock Options [Member]</link:label>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E_documentation_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Early exercise of stock options.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_EarlyExerciseOfStockOptionsMember" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E" xlink:to="lab_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0111FCD56F5A3E7EA0BCDDD39752D536_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFF00D882BB15BA5B56A5709A5A51EDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFF00D882BB15BA5B56A5709A5A51EDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFF00D882BB15BA5B56A5709A5A51EDF" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFF00D882BB15BA5B56A5709A5A51EDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_76ABBA1172C1CD37C211DDD397520985_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5C60553C5D87595DBBECD063F04B889C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_76ABBA1172C1CD37C211DDD397520985_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5C60553C5D87595DBBECD063F04B889C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5C60553C5D87595DBBECD063F04B889C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5C60553C5D87595DBBECD063F04B889C" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5C60553C5D87595DBBECD063F04B889C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_3467E899C911FAED504427760C87BEC8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_3467E899C911FAED504427760C87BEC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3467E899C911FAED504427760C87BEC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3467E899C911FAED504427760C87BEC8" xlink:to="lab_us-gaap_SubsequentEventsAbstract_3467E899C911FAED504427760C87BEC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:to="lab_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:type="arc" />
    <link:label id="lab_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC_terseLabel_en-US" xlink:label="lab_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notch Therapeutics Inc.</link:label>
    <link:label id="lab_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC_label_en-US" xlink:label="lab_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notch Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC_documentation_en-US" xlink:label="lab_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notch Therapeutics Inc. [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_NotchTherapeuticsInc.Member" xlink:label="loc_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC" xlink:to="lab_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71" xlink:to="lab_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71" xlink:type="arc" />
    <link:label id="lab_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE_terseLabel_en-US" xlink:label="lab_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE_label_en-US" xlink:label="lab_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE_documentation_en-US" xlink:label="lab_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeAxis" xlink:label="loc_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:to="lab_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:type="arc" />
    <link:label id="lab_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4_terseLabel_en-US" xlink:label="lab_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4_label_en-US" xlink:label="lab_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4_documentation_en-US" xlink:label="lab_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Milestone Type [Axis]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeDomain" xlink:label="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:to="lab_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:type="arc" />
    <link:label id="lab_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2_terseLabel_en-US" xlink:label="lab_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Milestone</link:label>
    <link:label id="lab_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2_label_en-US" xlink:label="lab_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Milestone [Member]</link:label>
    <link:label id="lab_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2_documentation_en-US" xlink:label="lab_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Milestone [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ResearchMilestoneMember" xlink:label="loc_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2" xlink:to="lab_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2" xlink:type="arc" />
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290_terseLabel_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Clinical Development Milestone</link:label>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290_label_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290_documentation_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Clinical Development Milestone [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_PreClinicalDevelopmentMilestoneMember" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290" xlink:to="lab_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290" xlink:type="arc" />
    <link:label id="lab_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6_terseLabel_en-US" xlink:label="lab_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone</link:label>
    <link:label id="lab_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6_label_en-US" xlink:label="lab_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone [Member]</link:label>
    <link:label id="lab_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6_documentation_en-US" xlink:label="lab_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical, Regulatory, and Commercial [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ClinicalRegulatoryandCommercialMilestoneMember" xlink:label="loc_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6" xlink:to="lab_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:to="lab_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:type="arc" />
    <link:label id="lab_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5_terseLabel_en-US" xlink:label="lab_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, initial fee</link:label>
    <link:label id="lab_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5_label_en-US" xlink:label="lab_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Initial Fee</link:label>
    <link:label id="lab_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5_documentation_en-US" xlink:label="lab_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Initial Fee</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_CollaborativeArrangementInitialFee" xlink:label="loc_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5" xlink:to="lab_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire interest in affiliate</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847" xlink:type="arc" />
    <link:label id="lab_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867_terseLabel_en-US" xlink:label="lab_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, contingent consideration payable</link:label>
    <link:label id="lab_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867_label_en-US" xlink:label="lab_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contingent Consideration, Liability</link:label>
    <link:label id="lab_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867_documentation_en-US" xlink:label="lab_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_CollaborativeArrangementContingentConsiderationLiability" xlink:label="loc_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867" xlink:to="lab_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_C8C265E78D21546642A3DDD396768A96_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_D4820ABC485555B4A08AE47B50ED5353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D4820ABC485555B4A08AE47B50ED5353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D4820ABC485555B4A08AE47B50ED5353" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_D4820ABC485555B4A08AE47B50ED5353" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F6F8B0EAED7CCC9234E3DDD39676105C_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2295527A16A5525986A8C1771596C5A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_F6F8B0EAED7CCC9234E3DDD39676105C_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2295527A16A5525986A8C1771596C5A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2295527A16A5525986A8C1771596C5A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2295527A16A5525986A8C1771596C5A8" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2295527A16A5525986A8C1771596C5A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_3CBCAC8249D99A4CC1CBE32075599AB4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_AD295914FC875DF280EE55F3EB80E8C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum remaining contractual maturities of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_3CBCAC8249D99A4CC1CBE32075599AB4_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_AD295914FC875DF280EE55F3EB80E8C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_AD295914FC875DF280EE55F3EB80E8C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_AD295914FC875DF280EE55F3EB80E8C2" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_AD295914FC875DF280EE55F3EB80E8C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_993EFE78C0BCF17E7B1718985B3812CD_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract_993EFE78C0BCF17E7B1718985B3812CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_993EFE78C0BCF17E7B1718985B3812CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_993EFE78C0BCF17E7B1718985B3812CD" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract_993EFE78C0BCF17E7B1718985B3812CD" xlink:type="arc" />
    <link:label id="lab_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8_terseLabel_en-US" xlink:label="lab_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements [Table]</link:label>
    <link:label id="lab_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8_label_en-US" xlink:label="lab_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements [Table]</link:label>
    <link:label id="lab_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8_documentation_en-US" xlink:label="lab_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information of license agreements.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAgreementsTable" xlink:label="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="lab_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:type="arc" />
    <link:label id="lab_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209_terseLabel_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Sales</link:label>
    <link:label id="lab_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209_label_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Sales [Member]</link:label>
    <link:label id="lab_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209_documentation_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Sales [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_DevelopmentAndSalesMember" xlink:label="loc_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209" xlink:to="lab_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209" xlink:type="arc" />
    <link:label id="lab_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D_terseLabel_en-US" xlink:label="lab_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 1 Clinical Trial First Patient Dose</link:label>
    <link:label id="lab_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D_label_en-US" xlink:label="lab_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 1 Clinical Trial First Patient Dose [Member]</link:label>
    <link:label id="lab_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D_documentation_en-US" xlink:label="lab_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 1 Clinical Trial First Patient Dose [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_Phase1ClinicalTrialFirstPatientDoseMember" xlink:label="loc_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D" xlink:to="lab_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:to="lab_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:type="arc" />
    <link:label id="lab_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E_terseLabel_en-US" xlink:label="lab_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E_label_en-US" xlink:label="lab_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Inc [Member]</link:label>
    <link:label id="lab_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E_documentation_en-US" xlink:label="lab_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_PfizerIncMember" xlink:label="loc_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E" xlink:to="lab_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E" xlink:type="arc" />
    <link:label id="lab_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453_terseLabel_en-US" xlink:label="lab_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cellectis</link:label>
    <link:label id="lab_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453_label_en-US" xlink:label="lab_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cellectis S A [Member]</link:label>
    <link:label id="lab_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453_documentation_en-US" xlink:label="lab_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cellectis S.A..</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_CellectisSAMember" xlink:label="loc_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453" xlink:to="lab_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453" xlink:type="arc" />
    <link:label id="lab_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8_verboseLabel_en-US" xlink:label="lab_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8_label_en-US" xlink:label="lab_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servier [Member]</link:label>
    <link:label id="lab_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8_documentation_en-US" xlink:label="lab_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Servier.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ServierMember" xlink:label="loc_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8" xlink:to="lab_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:type="arc" />
    <link:label id="lab_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027_verboseLabel_en-US" xlink:label="lab_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset Contribution Agreement</link:label>
    <link:label id="lab_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027_label_en-US" xlink:label="lab_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Contribution Agreement [Member]</link:label>
    <link:label id="lab_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027_documentation_en-US" xlink:label="lab_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset contribution agreement.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AssetContributionAgreementMember" xlink:label="loc_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027" xlink:to="lab_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027" xlink:type="arc" />
    <link:label id="lab_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED_terseLabel_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestone</link:label>
    <link:label id="lab_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED_label_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestone [Member]</link:label>
    <link:label id="lab_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED_documentation_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory milestone member.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_RegulatoryMilestoneMember" xlink:label="loc_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED" xlink:to="lab_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED" xlink:type="arc" />
    <link:label id="lab_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5_terseLabel_en-US" xlink:label="lab_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Milestone</link:label>
    <link:label id="lab_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5_label_en-US" xlink:label="lab_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:label id="lab_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5_documentation_en-US" xlink:label="lab_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales milestone member.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_SalesMilestoneMember" xlink:label="loc_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5" xlink:to="lab_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB_label_en-US" xlink:label="lab_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:to="lab_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B_terseLabel_en-US" xlink:label="lab_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B_label_en-US" xlink:label="lab_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:to="lab_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237_label_en-US" xlink:label="lab_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237" xlink:to="lab_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD_label_en-US" xlink:label="lab_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD" xlink:to="lab_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:to="lab_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:type="arc" />
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E_terseLabel_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreement</link:label>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E_label_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E_documentation_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research collaboration and license agreement.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ResearchCollaborationAndLicenseAgreementMember" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E" xlink:to="lab_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E" xlink:type="arc" />
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318_verboseLabel_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318_label_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318_documentation_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and collaboration agreement.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAndCollaborationAgreementMember" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318" xlink:to="lab_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318" xlink:type="arc" />
    <link:label id="lab_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059_terseLabel_en-US" xlink:label="lab_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements [Line Items]</link:label>
    <link:label id="lab_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059_label_en-US" xlink:label="lab_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements [Line Items]</link:label>
    <link:label id="lab_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059_documentation_en-US" xlink:label="lab_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line items represent license agreements.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAgreementsLineItems" xlink:label="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="lab_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:type="arc" />
    <link:label id="lab_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6_terseLabel_en-US" xlink:label="lab_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate potential milestone payments</link:label>
    <link:label id="lab_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6_label_en-US" xlink:label="lab_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6_documentation_en-US" xlink:label="lab_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestonePayments" xlink:label="loc_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6" xlink:to="lab_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6" xlink:type="arc" />
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate potential regulatory and development milestones</link:label>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE_label_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Potential Regulatory And Development Milestones</link:label>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE_documentation_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential regulatory and development milestones.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE" xlink:to="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE" xlink:type="arc" />
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate potential milestone payments</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Potential Milestone Payments</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential milestone payments.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AggregatePotentialMilestonePayments" xlink:label="loc_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39" xlink:to="lab_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39" xlink:type="arc" />
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B_terseLabel_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty obligation period from date of first sale</link:label>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B_label_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Obligation Period From Date Of First Sale</link:label>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B_documentation_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Obligation Period From Date Of First Sale</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B" xlink:to="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B" xlink:type="arc" />
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8_terseLabel_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum payments required per product against selected target</link:label>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8_label_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Payments Required Per Product Against Selected Target</link:label>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8_documentation_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum payments required per product against selected target.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8" xlink:to="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B" xlink:type="arc" />
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB_terseLabel_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB_label_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued And Other Liabilities Current</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB_documentation_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherLiabilitiesCurrent" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB" xlink:to="lab_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB" xlink:type="arc" />
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40_terseLabel_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of development costs payable by the Company</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40_label_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Development Cost Payable By The Company</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40_documentation_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Development Cost Payable By The Company</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40" xlink:to="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40" xlink:type="arc" />
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40_terseLabel_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of development cost payable by collaboration partner</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40_label_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Development Cost Payable By Collaboration Partner</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40_documentation_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Development Cost Payable By Related Party</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40" xlink:to="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40" xlink:type="arc" />
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate potential milestone receivable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Potential Milestone Receivable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential milestone receivable.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AggregatePotentialMilestoneReceivable" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7" xlink:to="lab_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9F2FA288D702B7361D0115283FED9A34_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9F2FA288D702B7361D0115283FED9A34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 (remaining 3 months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9F2FA288D702B7361D0115283FED9A34_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9F2FA288D702B7361D0115283FED9A34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9F2FA288D702B7361D0115283FED9A34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9F2FA288D702B7361D0115283FED9A34" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9F2FA288D702B7361D0115283FED9A34" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E1A74CE083355116CE7E15283FEE236D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E1A74CE083355116CE7E15283FEE236D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E1A74CE083355116CE7E15283FEE236D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E1A74CE083355116CE7E15283FEE236D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E1A74CE083355116CE7E15283FEE236D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E1A74CE083355116CE7E15283FEE236D" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E1A74CE083355116CE7E15283FEE236D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50901D166C478FEB078A15283FEE9EDB_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50901D166C478FEB078A15283FEE9EDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50901D166C478FEB078A15283FEE9EDB_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50901D166C478FEB078A15283FEE9EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50901D166C478FEB078A15283FEE9EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50901D166C478FEB078A15283FEE9EDB" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50901D166C478FEB078A15283FEE9EDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79BAEC4CF60F68629F3915283FEE2700_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79BAEC4CF60F68629F3915283FEE2700" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79BAEC4CF60F68629F3915283FEE2700_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79BAEC4CF60F68629F3915283FEE2700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79BAEC4CF60F68629F3915283FEE2700" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79BAEC4CF60F68629F3915283FEE2700" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79BAEC4CF60F68629F3915283FEE2700" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_330F8578B135EF77C0E815283FEE6DC0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_330F8578B135EF77C0E815283FEE6DC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_330F8578B135EF77C0E815283FEE6DC0_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_330F8578B135EF77C0E815283FEE6DC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_330F8578B135EF77C0E815283FEE6DC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_330F8578B135EF77C0E815283FEE6DC0" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_330F8578B135EF77C0E815283FEE6DC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FBF78B1CD471C338A02115283FEEBB8F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FBF78B1CD471C338A02115283FEEBB8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FBF78B1CD471C338A02115283FEEBB8F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FBF78B1CD471C338A02115283FEEBB8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FBF78B1CD471C338A02115283FEEBB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FBF78B1CD471C338A02115283FEEBB8F" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FBF78B1CD471C338A02115283FEEBB8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37303F4C73A9D1B1F0D915283FEF6871_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37303F4C73A9D1B1F0D915283FEF6871" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37303F4C73A9D1B1F0D915283FEF6871_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37303F4C73A9D1B1F0D915283FEF6871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37303F4C73A9D1B1F0D915283FEF6871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37303F4C73A9D1B1F0D915283FEF6871" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37303F4C73A9D1B1F0D915283FEF6871" xlink:type="arc" />
    <link:label id="lab_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16_negatedLabel_en-US" xlink:label="lab_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Undiscounted lease payments related to Newark lease</link:label>
    <link:label id="lab_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16_label_en-US" xlink:label="lab_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases Undiscounted Lease Payments</link:label>
    <link:label id="lab_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16_documentation_en-US" xlink:label="lab_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating leases undiscounted lease payments.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_OperatingLeasesUndiscountedLeasePayments" xlink:label="loc_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16" xlink:to="lab_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_030133CE6159301FD00E15283FEF45EA_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_030133CE6159301FD00E15283FEF45EA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_030133CE6159301FD00E15283FEF45EA_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_030133CE6159301FD00E15283FEF45EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_030133CE6159301FD00E15283FEF45EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_030133CE6159301FD00E15283FEF45EA" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_030133CE6159301FD00E15283FEF45EA" xlink:type="arc" />
    <link:label id="lab_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8_negatedLabel_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Tenant improvement allowance</link:label>
    <link:label id="lab_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8_label_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Tenant Improvements</link:label>
    <link:label id="lab_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8_documentation_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance for tenant improvements.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AllowanceForTenantImprovements" xlink:label="loc_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8" xlink:to="lab_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4255F7419ECA96CF96CC15283FEFFB0E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_4255F7419ECA96CF96CC15283FEFFB0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4255F7419ECA96CF96CC15283FEFFB0E_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_4255F7419ECA96CF96CC15283FEFFB0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_4255F7419ECA96CF96CC15283FEFFB0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_4255F7419ECA96CF96CC15283FEFFB0E" xlink:to="lab_us-gaap_OperatingLeaseLiability_4255F7419ECA96CF96CC15283FEFFB0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_24A5480E7D98DC6F1848DDD396BB8572_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_19B6BBFC2ECE5782AA374D35D2BD147C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_19B6BBFC2ECE5782AA374D35D2BD147C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_19B6BBFC2ECE5782AA374D35D2BD147C" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_19B6BBFC2ECE5782AA374D35D2BD147C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_C9893DFE1FEC3095BA16DDD396BB68D4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_19BCD15A84675C98896328893C936683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_C9893DFE1FEC3095BA16DDD396BB68D4_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_19BCD15A84675C98896328893C936683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_19BCD15A84675C98896328893C936683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_19BCD15A84675C98896328893C936683" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_19BCD15A84675C98896328893C936683" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_59A2AFD5558125127852DDD3968461B3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B79E6A4F2365923ADD6E6B2B27D4AE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_59A2AFD5558125127852DDD3968461B3_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B79E6A4F2365923ADD6E6B2B27D4AE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B79E6A4F2365923ADD6E6B2B27D4AE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B79E6A4F2365923ADD6E6B2B27D4AE4" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B79E6A4F2365923ADD6E6B2B27D4AE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93785EBDD6AB1073E9D06310DB8DC2CB_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_902ADB3EBDBE587B90D0A8894A26E946" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Number of options, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_93785EBDD6AB1073E9D06310DB8DC2CB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_902ADB3EBDBE587B90D0A8894A26E946" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_902ADB3EBDBE587B90D0A8894A26E946" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_902ADB3EBDBE587B90D0A8894A26E946" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_902ADB3EBDBE587B90D0A8894A26E946" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70A8E78A3F6F3DCE41426310DB8D8BE0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7225417AE86B5D70AC74248CFCB0F717" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options, options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70A8E78A3F6F3DCE41426310DB8D8BE0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7225417AE86B5D70AC74248CFCB0F717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7225417AE86B5D70AC74248CFCB0F717" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7225417AE86B5D70AC74248CFCB0F717" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7225417AE86B5D70AC74248CFCB0F717" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_975220BF4218E8DC64506310DB8DE1E6_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1299D34B27CF5AFA9C66D177BAFDCD7B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of options, options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_975220BF4218E8DC64506310DB8DE1E6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1299D34B27CF5AFA9C66D177BAFDCD7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1299D34B27CF5AFA9C66D177BAFDCD7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1299D34B27CF5AFA9C66D177BAFDCD7B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1299D34B27CF5AFA9C66D177BAFDCD7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF428841690FBF66B54F6310DB8D8FFD_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A76994249C9C542E9EC4D86F84C14F80" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Number of options, options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_EF428841690FBF66B54F6310DB8D8FFD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A76994249C9C542E9EC4D86F84C14F80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A76994249C9C542E9EC4D86F84C14F80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A76994249C9C542E9EC4D86F84C14F80" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A76994249C9C542E9EC4D86F84C14F80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_36FD2F85D52F21341EFE6310DB8D10DB_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0E72BF7EF39857B4AA419023984DC415" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Number of options, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0E72BF7EF39857B4AA419023984DC415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0E72BF7EF39857B4AA419023984DC415" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0E72BF7EF39857B4AA419023984DC415" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E454854BDEBEC44268A56310DB8EA251_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6F69D83E76A555F481D7EB409DA116C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_E454854BDEBEC44268A56310DB8EA251_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6F69D83E76A555F481D7EB409DA116C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6F69D83E76A555F481D7EB409DA116C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6F69D83E76A555F481D7EB409DA116C8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6F69D83E76A555F481D7EB409DA116C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F64DB441774C5FD81B076310DB8E544D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_88DBD0548DF75A9B8E659FA6763F6B1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_F64DB441774C5FD81B076310DB8E544D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_88DBD0548DF75A9B8E659FA6763F6B1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_88DBD0548DF75A9B8E659FA6763F6B1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_88DBD0548DF75A9B8E659FA6763F6B1C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_88DBD0548DF75A9B8E659FA6763F6B1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A31CAC45CF35B16AD6E36310DB8E990D_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31ABFA45D7355F2F91039CDF7C8DB9DE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_A31CAC45CF35B16AD6E36310DB8E990D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31ABFA45D7355F2F91039CDF7C8DB9DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31ABFA45D7355F2F91039CDF7C8DB9DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31ABFA45D7355F2F91039CDF7C8DB9DE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31ABFA45D7355F2F91039CDF7C8DB9DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CCA61A41DE1DE62635626310DB8E7D2E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0A53C5B4E01255AE9E77110A5374B63E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_CCA61A41DE1DE62635626310DB8E7D2E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0A53C5B4E01255AE9E77110A5374B63E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0A53C5B4E01255AE9E77110A5374B63E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0A53C5B4E01255AE9E77110A5374B63E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0A53C5B4E01255AE9E77110A5374B63E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_25ECEF7E66B0FBCCEA316310DB8E2601_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_AB5084C7B3A05BB183726E693B452A5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_25ECEF7E66B0FBCCEA316310DB8E2601_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_AB5084C7B3A05BB183726E693B452A5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_AB5084C7B3A05BB183726E693B452A5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_AB5084C7B3A05BB183726E693B452A5F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_AB5084C7B3A05BB183726E693B452A5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F25C0205AF898C3CC6EA6310DB8ECB9A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_531C6A61A0CF5FFDB9ADB1FE1F916C9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_F25C0205AF898C3CC6EA6310DB8ECB9A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_531C6A61A0CF5FFDB9ADB1FE1F916C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_531C6A61A0CF5FFDB9ADB1FE1F916C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_531C6A61A0CF5FFDB9ADB1FE1F916C9A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_531C6A61A0CF5FFDB9ADB1FE1F916C9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_29F370528080259457E26310DB8F6BA2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FABDD4034C7158E59CA409305A1F4E99" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FABDD4034C7158E59CA409305A1F4E99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FABDD4034C7158E59CA409305A1F4E99" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FABDD4034C7158E59CA409305A1F4E99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2AF636BFF617E917B5B06310DB8F0C30_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C7C4966D0A1850FA858DFCBBCDA67D51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2AF636BFF617E917B5B06310DB8F0C30_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C7C4966D0A1850FA858DFCBBCDA67D51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C7C4966D0A1850FA858DFCBBCDA67D51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C7C4966D0A1850FA858DFCBBCDA67D51" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C7C4966D0A1850FA858DFCBBCDA67D51" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_09974C8684CF5D7ED89A6310DB8FA54E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CC7C79C624935BA983973280D4DD5984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_09974C8684CF5D7ED89A6310DB8FA54E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CC7C79C624935BA983973280D4DD5984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CC7C79C624935BA983973280D4DD5984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CC7C79C624935BA983973280D4DD5984" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CC7C79C624935BA983973280D4DD5984" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_464E23DB3AA09AB35DA96310DB8F4B52_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E6E833F92E3856BBB0498E070380FB9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contract term, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_464E23DB3AA09AB35DA96310DB8F4B52_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E6E833F92E3856BBB0498E070380FB9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E6E833F92E3856BBB0498E070380FB9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E6E833F92E3856BBB0498E070380FB9F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E6E833F92E3856BBB0498E070380FB9F" xlink:type="arc" />
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_E108A6A1C8B49AFE6E2B6310DB8F50D9_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_DF79E50A580D51489E8FA6B352B79105" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contract term, options granted</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_E108A6A1C8B49AFE6E2B6310DB8F50D9_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_DF79E50A580D51489E8FA6B352B79105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term1</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_E108A6A1C8B49AFE6E2B6310DB8F50D9_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_DF79E50A580D51489E8FA6B352B79105" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_DF79E50A580D51489E8FA6B352B79105" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_DF79E50A580D51489E8FA6B352B79105" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_DF79E50A580D51489E8FA6B352B79105" xlink:type="arc" />
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_9310E4235A4B3D3C920C6310DB8FAD94_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_AC3237E5D77D515BAC32D2F7AC9F77A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contract term, options exercised</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_9310E4235A4B3D3C920C6310DB8FAD94_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_AC3237E5D77D515BAC32D2F7AC9F77A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_9310E4235A4B3D3C920C6310DB8FAD94_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_AC3237E5D77D515BAC32D2F7AC9F77A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_AC3237E5D77D515BAC32D2F7AC9F77A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_AC3237E5D77D515BAC32D2F7AC9F77A8" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_AC3237E5D77D515BAC32D2F7AC9F77A8" xlink:type="arc" />
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_BE28ECCCC2A0D925F0BE6310DB8FE6AD_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_2C564F740282586DAF7A26118B97DEA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contract term, options forfeited</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_BE28ECCCC2A0D925F0BE6310DB8FE6AD_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_2C564F740282586DAF7A26118B97DEA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term1</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_BE28ECCCC2A0D925F0BE6310DB8FE6AD_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_2C564F740282586DAF7A26118B97DEA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently forfeited or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_2C564F740282586DAF7A26118B97DEA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_2C564F740282586DAF7A26118B97DEA5" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_2C564F740282586DAF7A26118B97DEA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7FAB924F7301712D25B36310DB90A164_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3779A94E6E905B569E6A61D7581A4937" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contract term, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7FAB924F7301712D25B36310DB90A164_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3779A94E6E905B569E6A61D7581A4937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3779A94E6E905B569E6A61D7581A4937" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3779A94E6E905B569E6A61D7581A4937" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3779A94E6E905B569E6A61D7581A4937" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_AC9599A52D5BAAB9744C6310DB9022CD_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_A537C5111233550BB8841BB99EB36BBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contract term, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_AC9599A52D5BAAB9744C6310DB9022CD_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_A537C5111233550BB8841BB99EB36BBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_A537C5111233550BB8841BB99EB36BBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_A537C5111233550BB8841BB99EB36BBE" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_A537C5111233550BB8841BB99EB36BBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F9851D154059A8ACBE26DDD396EECBA7_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_173B08AD898E5C46BCDC088190ACF274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_F9851D154059A8ACBE26DDD396EECBA7_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_173B08AD898E5C46BCDC088190ACF274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_173B08AD898E5C46BCDC088190ACF274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_173B08AD898E5C46BCDC088190ACF274" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_173B08AD898E5C46BCDC088190ACF274" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_238EEAFD3ECA3E4688E7DDD396EF70DB_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_DAD7760E0FB55DFDAB7AF49092EA7E35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_238EEAFD3ECA3E4688E7DDD396EF70DB_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_DAD7760E0FB55DFDAB7AF49092EA7E35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_DAD7760E0FB55DFDAB7AF49092EA7E35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_DAD7760E0FB55DFDAB7AF49092EA7E35" xlink:to="lab_us-gaap_UseOfEstimates_DAD7760E0FB55DFDAB7AF49092EA7E35" xlink:type="arc" />
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_BCE15EC8A96DDB6AF1BBDDD396EF04AB_terseLabel_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_8C094F8EFF2E58929A7477A4CB0AE194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_BCE15EC8A96DDB6AF1BBDDD396EF04AB_label_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_8C094F8EFF2E58929A7477A4CB0AE194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes In Significant Accounting Policies Policy [Text Block]</link:label>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_BCE15EC8A96DDB6AF1BBDDD396EF04AB_documentation_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_8C094F8EFF2E58929A7477A4CB0AE194" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Changes in significant accounting policies.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock" xlink:label="loc_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_8C094F8EFF2E58929A7477A4CB0AE194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_8C094F8EFF2E58929A7477A4CB0AE194" xlink:to="lab_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_8C094F8EFF2E58929A7477A4CB0AE194" xlink:type="arc" />
    <link:label id="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_BD1EE597C4DC68C7BAEDDDD396EFA34C_terseLabel_en-US" xlink:label="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_FB761A89577B5CB29DC5F0C854482226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_BD1EE597C4DC68C7BAEDDDD396EFA34C_label_en-US" xlink:label="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_FB761A89577B5CB29DC5F0C854482226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements Policy [Text Block]</link:label>
    <link:label id="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_BD1EE597C4DC68C7BAEDDDD396EFA34C_documentation_en-US" xlink:label="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_FB761A89577B5CB29DC5F0C854482226" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recently adopted accounting pronouncements.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_FB761A89577B5CB29DC5F0C854482226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_FB761A89577B5CB29DC5F0C854482226" xlink:to="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_FB761A89577B5CB29DC5F0C854482226" xlink:type="arc" />
    <link:label id="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D621D412CE2656193AF1DDD396EFCDDB_terseLabel_en-US" xlink:label="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D9DF188B7B1C59F79257A4574035C592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D621D412CE2656193AF1DDD396EFCDDB_label_en-US" xlink:label="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D9DF188B7B1C59F79257A4574035C592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted Policy [Text Block]</link:label>
    <link:label id="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D621D412CE2656193AF1DDD396EFCDDB_documentation_en-US" xlink:label="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D9DF188B7B1C59F79257A4574035C592" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recent accounting pronouncements not yet adopted.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D9DF188B7B1C59F79257A4574035C592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D9DF188B7B1C59F79257A4574035C592" xlink:to="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D9DF188B7B1C59F79257A4574035C592" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_AAD755CC151A6DCC436862F7E934C1BF_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_E051E31EE1ED5905A90057952A3C4972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_E051E31EE1ED5905A90057952A3C4972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_E051E31EE1ED5905A90057952A3C4972" xlink:to="lab_us-gaap_LeasesAbstract_E051E31EE1ED5905A90057952A3C4972" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D92778F9D7A419001BB62FCE5BC0CE1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C9D5FD1BA57157E8A0DFDF1CB69A0D8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Undiscounted Future Lease Payments Under Lease Liability</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5D92778F9D7A419001BB62FCE5BC0CE1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C9D5FD1BA57157E8A0DFDF1CB69A0D8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C9D5FD1BA57157E8A0DFDF1CB69A0D8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C9D5FD1BA57157E8A0DFDF1CB69A0D8C" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C9D5FD1BA57157E8A0DFDF1CB69A0D8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75_label_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D" xlink:to="lab_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_A91E68487AB885EB9EB618985CAF10F6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_A91E68487AB885EB9EB618985CAF10F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_A91E68487AB885EB9EB618985CAF10F6_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_A91E68487AB885EB9EB618985CAF10F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_A91E68487AB885EB9EB618985CAF10F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_A91E68487AB885EB9EB618985CAF10F6" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_A91E68487AB885EB9EB618985CAF10F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_CDD435DD81731A51FB5718985CAF1272_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_CDD435DD81731A51FB5718985CAF1272" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_CDD435DD81731A51FB5718985CAF1272_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_CDD435DD81731A51FB5718985CAF1272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_CDD435DD81731A51FB5718985CAF1272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_CDD435DD81731A51FB5718985CAF1272" xlink:to="lab_us-gaap_OperatingExpenses_CDD435DD81731A51FB5718985CAF1272" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D77320CA8950EB98C4A218985CAFE0C9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D77320CA8950EB98C4A218985CAFE0C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D77320CA8950EB98C4A218985CAFE0C9_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D77320CA8950EB98C4A218985CAFE0C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D77320CA8950EB98C4A218985CAFE0C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_D77320CA8950EB98C4A218985CAFE0C9" xlink:to="lab_us-gaap_OperatingIncomeLoss_D77320CA8950EB98C4A218985CAFE0C9" xlink:type="arc" />
    <link:label id="lab_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A_negatedTerseLabel_en-US" xlink:label="lab_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of convertible note payable</link:label>
    <link:label id="lab_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A_label_en-US" xlink:label="lab_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Convertible Note Payable</link:label>
    <link:label id="lab_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A_documentation_en-US" xlink:label="lab_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Convertible Note Payable</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ChangeInFairValueOfConvertibleNotePayable" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A" xlink:to="lab_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_EBF440A81C0433A993EB18985CAFF2A2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_EBF440A81C0433A993EB18985CAFF2A2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_EBF440A81C0433A993EB18985CAFF2A2_label_en-US" xlink:label="lab_us-gaap_InterestExpense_EBF440A81C0433A993EB18985CAFF2A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_EBF440A81C0433A993EB18985CAFF2A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_EBF440A81C0433A993EB18985CAFF2A2" xlink:to="lab_us-gaap_InterestExpense_EBF440A81C0433A993EB18985CAFF2A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_E4A578963D7A7EDE967118985CAF7E66_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_E4A578963D7A7EDE967118985CAF7E66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_E4A578963D7A7EDE967118985CAF7E66_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_E4A578963D7A7EDE967118985CAF7E66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E4A578963D7A7EDE967118985CAF7E66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_E4A578963D7A7EDE967118985CAF7E66" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_E4A578963D7A7EDE967118985CAF7E66" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213D49C8D02F0D875D4518985CAF720C_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213D49C8D02F0D875D4518985CAF720C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213D49C8D02F0D875D4518985CAF720C_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213D49C8D02F0D875D4518985CAF720C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213D49C8D02F0D875D4518985CAF720C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213D49C8D02F0D875D4518985CAF720C" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213D49C8D02F0D875D4518985CAF720C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_BEEE56ED939E63A9495518985CB089BD_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_BEEE56ED939E63A9495518985CB089BD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefit (expense) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_BEEE56ED939E63A9495518985CB089BD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_BEEE56ED939E63A9495518985CB089BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_BEEE56ED939E63A9495518985CB089BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_BEEE56ED939E63A9495518985CB089BD" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_BEEE56ED939E63A9495518985CB089BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_3D5B1CFC2A8B634C75AD18985CB05AC7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3D5B1CFC2A8B634C75AD18985CB05AC7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3D5B1CFC2A8B634C75AD18985CB05AC7_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_3D5B1CFC2A8B634C75AD18985CB05AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3D5B1CFC2A8B634C75AD18985CB05AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_3D5B1CFC2A8B634C75AD18985CB05AC7" xlink:to="lab_us-gaap_NetIncomeLoss_3D5B1CFC2A8B634C75AD18985CB05AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3C3442D37044CB4B1FEA18985CB042C4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3C3442D37044CB4B1FEA18985CB042C4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3C3442D37044CB4B1FEA18985CB042C4_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3C3442D37044CB4B1FEA18985CB042C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3C3442D37044CB4B1FEA18985CB042C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3C3442D37044CB4B1FEA18985CB042C4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3C3442D37044CB4B1FEA18985CB042C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_BBEFA984728084E003E518985CB0D09E_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_BBEFA984728084E003E518985CB0D09E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_BBEFA984728084E003E518985CB0D09E_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_BBEFA984728084E003E518985CB0D09E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_BBEFA984728084E003E518985CB0D09E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_BBEFA984728084E003E518985CB0D09E" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_BBEFA984728084E003E518985CB0D09E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_AAC1580B3BB1C7402D8D18985CB125BE_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_AAC1580B3BB1C7402D8D18985CB125BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_AAC1580B3BB1C7402D8D18985CB125BE_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_AAC1580B3BB1C7402D8D18985CB125BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_AAC1580B3BB1C7402D8D18985CB125BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_AAC1580B3BB1C7402D8D18985CB125BE" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_AAC1580B3BB1C7402D8D18985CB125BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_27B645E0AAF4865CD32718985CB1C1E8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_27B645E0AAF4865CD32718985CB1C1E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_27B645E0AAF4865CD32718985CB1C1E8_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_27B645E0AAF4865CD32718985CB1C1E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_27B645E0AAF4865CD32718985CB1C1E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_27B645E0AAF4865CD32718985CB1C1E8" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_27B645E0AAF4865CD32718985CB1C1E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_DC9B0162CFD84DBFC0C7E1B240D71D31_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C08C3F29C07B2E418840E1B240D72C24_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6D7872D351825A54A1DE8B809144C3C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C08C3F29C07B2E418840E1B240D72C24_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6D7872D351825A54A1DE8B809144C3C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6D7872D351825A54A1DE8B809144C3C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6D7872D351825A54A1DE8B809144C3C8" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6D7872D351825A54A1DE8B809144C3C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9314CF34FE8DB4AAD6F9E1B240D899DD_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_835FAFBACBC25FE693ACE84C4D535A3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9314CF34FE8DB4AAD6F9E1B240D899DD_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_835FAFBACBC25FE693ACE84C4D535A3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_835FAFBACBC25FE693ACE84C4D535A3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_835FAFBACBC25FE693ACE84C4D535A3E" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_835FAFBACBC25FE693ACE84C4D535A3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_F75346C4EC6071A45BC6E1B240D8D9F3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_99942F970145587DBC4790230F7C152B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_F75346C4EC6071A45BC6E1B240D8D9F3_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_99942F970145587DBC4790230F7C152B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_99942F970145587DBC4790230F7C152B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_99942F970145587DBC4790230F7C152B" xlink:to="lab_us-gaap_PreferredStockSharesIssued_99942F970145587DBC4790230F7C152B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_546408542BFF586B1F5DE1B240D86797_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_D9ABD15ED3A150E3B9281F7D60E15AA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_546408542BFF586B1F5DE1B240D86797_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_D9ABD15ED3A150E3B9281F7D60E15AA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_D9ABD15ED3A150E3B9281F7D60E15AA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_D9ABD15ED3A150E3B9281F7D60E15AA9" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_D9ABD15ED3A150E3B9281F7D60E15AA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4432AEA4654C26F5273AE1B240D8EBCD_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_E7BFE168728F5FDFB33D0CF9AB7AA75D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4432AEA4654C26F5273AE1B240D8EBCD_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_E7BFE168728F5FDFB33D0CF9AB7AA75D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E7BFE168728F5FDFB33D0CF9AB7AA75D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_E7BFE168728F5FDFB33D0CF9AB7AA75D" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_E7BFE168728F5FDFB33D0CF9AB7AA75D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_098ABEA6DBB7BE9C77F1E1B240D867FE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_372DB7BC6F565FAF97D40B931119B72B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_098ABEA6DBB7BE9C77F1E1B240D867FE_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_372DB7BC6F565FAF97D40B931119B72B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_372DB7BC6F565FAF97D40B931119B72B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_372DB7BC6F565FAF97D40B931119B72B" xlink:to="lab_us-gaap_CommonStockSharesIssued_372DB7BC6F565FAF97D40B931119B72B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_F4AC64BFABE59A30D82AE1B240D913D4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_8CDBCBE55E875B5FAAC78F025D0370E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_F4AC64BFABE59A30D82AE1B240D913D4_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_8CDBCBE55E875B5FAAC78F025D0370E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8CDBCBE55E875B5FAAC78F025D0370E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_8CDBCBE55E875B5FAAC78F025D0370E5" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_8CDBCBE55E875B5FAAC78F025D0370E5" xlink:type="arc" />
    <link:label id="lab_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_CA95626292242EAB176EDDD396827A71_terseLabel_en-US" xlink:label="lab_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_ED4644408470550BBD6337F1D618E3D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid and Other Current Assets</link:label>
    <link:label id="lab_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_CA95626292242EAB176EDDD396827A71_label_en-US" xlink:label="lab_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_ED4644408470550BBD6337F1D618E3D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid And Other Current Assets Table [Text Block]</link:label>
    <link:label id="lab_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_CA95626292242EAB176EDDD396827A71_documentation_en-US" xlink:label="lab_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_ED4644408470550BBD6337F1D618E3D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid And Other Current Assets [Table Text Block].</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_ED4644408470550BBD6337F1D618E3D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_ED4644408470550BBD6337F1D618E3D8" xlink:to="lab_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_ED4644408470550BBD6337F1D618E3D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0B65E44F40741564B6F2DDD3968234A4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_19610F22707C5B9880E0DE68D3916CE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0B65E44F40741564B6F2DDD3968234A4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_19610F22707C5B9880E0DE68D3916CE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_19610F22707C5B9880E0DE68D3916CE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_19610F22707C5B9880E0DE68D3916CE2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_19610F22707C5B9880E0DE68D3916CE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5A65FEA3A562C7A3FF7CDDD3968312A7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_09938952C2F35F779ED94B08D19E9D6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5A65FEA3A562C7A3FF7CDDD3968312A7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_09938952C2F35F779ED94B08D19E9D6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_09938952C2F35F779ED94B08D19E9D6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_09938952C2F35F779ED94B08D19E9D6B" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_09938952C2F35F779ED94B08D19E9D6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_5AD5AA192C76AAF2226DDDD39779F85E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_B37115101A005C71AC2EA590F2AE47F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_B37115101A005C71AC2EA590F2AE47F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_B37115101A005C71AC2EA590F2AE47F4" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_B37115101A005C71AC2EA590F2AE47F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_BA27149C4294FC29E4B0DDD39779B435_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C31AE9E089AF51EEB9FCE4787BD6750E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_BA27149C4294FC29E4B0DDD39779B435_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C31AE9E089AF51EEB9FCE4787BD6750E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C31AE9E089AF51EEB9FCE4787BD6750E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C31AE9E089AF51EEB9FCE4787BD6750E" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C31AE9E089AF51EEB9FCE4787BD6750E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_61843CC41FE3E87A4A54DDD3977C910F_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_CBAA2B0491E15A8BBB0CBA2B3ED30F20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheets Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_61843CC41FE3E87A4A54DDD3977C910F_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_CBAA2B0491E15A8BBB0CBA2B3ED30F20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_CBAA2B0491E15A8BBB0CBA2B3ED30F20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_CBAA2B0491E15A8BBB0CBA2B3ED30F20" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_CBAA2B0491E15A8BBB0CBA2B3ED30F20" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_033985CABB430055582B62FD2EA51849_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_8550337A1CC058A78B2883AF49650F2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_033985CABB430055582B62FD2EA51849_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_8550337A1CC058A78B2883AF49650F2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8550337A1CC058A78B2883AF49650F2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_8550337A1CC058A78B2883AF49650F2A" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_8550337A1CC058A78B2883AF49650F2A" xlink:type="arc" />
    <link:label id="lab_allo_LicenseAgreementsTextBlock_BAD311C98ABF8C4FB120DDD3972611FE_terseLabel_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock_92C7399A0E50528B97D02D1F25E5CA0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_BAD311C98ABF8C4FB120DDD3972611FE_label_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock_92C7399A0E50528B97D02D1F25E5CA0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreements [Text Block]</link:label>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_BAD311C98ABF8C4FB120DDD3972611FE_documentation_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock_92C7399A0E50528B97D02D1F25E5CA0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License agreements text block.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAgreementsTextBlock" xlink:label="loc_allo_LicenseAgreementsTextBlock_92C7399A0E50528B97D02D1F25E5CA0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAgreementsTextBlock_92C7399A0E50528B97D02D1F25E5CA0A" xlink:to="lab_allo_LicenseAgreementsTextBlock_92C7399A0E50528B97D02D1F25E5CA0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:to="lab_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:type="arc" />
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_0E2D6CFDE75ACF74F9C837858CAFBEC3_terseLabel_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember_0E2D6CFDE75ACF74F9C837858CAFBEC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAndCollaborationAgreementMember" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_0E2D6CFDE75ACF74F9C837858CAFBEC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAndCollaborationAgreementMember_0E2D6CFDE75ACF74F9C837858CAFBEC3" xlink:to="lab_allo_LicenseAndCollaborationAgreementMember_0E2D6CFDE75ACF74F9C837858CAFBEC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:type="arc" />
    <link:label id="lab_allo_ServierMember_1296FEA6D562E23DCC0737858CAF4528_terseLabel_en-US" xlink:label="lab_allo_ServierMember_1296FEA6D562E23DCC0737858CAF4528" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Servier</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ServierMember" xlink:label="loc_allo_ServierMember_1296FEA6D562E23DCC0737858CAF4528" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ServierMember_1296FEA6D562E23DCC0737858CAF4528" xlink:to="lab_allo_ServierMember_1296FEA6D562E23DCC0737858CAF4528" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:type="arc" />
    <link:label id="lab_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810_terseLabel_en-US" xlink:label="lab_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">127 Months Lease Term</link:label>
    <link:label id="lab_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810_label_en-US" xlink:label="lab_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease One [Member]</link:label>
    <link:label id="lab_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810_documentation_en-US" xlink:label="lab_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease one.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_LeaseOneMember" xlink:label="loc_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810" xlink:to="lab_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810" xlink:type="arc" />
    <link:label id="lab_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC_terseLabel_en-US" xlink:label="lab_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">124 Months Lease Term</link:label>
    <link:label id="lab_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC_label_en-US" xlink:label="lab_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Two [Member]</link:label>
    <link:label id="lab_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC_documentation_en-US" xlink:label="lab_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Two.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_LeaseTwoMember" xlink:label="loc_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC" xlink:to="lab_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:to="lab_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:to="lab_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:type="arc" />
    <link:label id="lab_stpr_NY_F6BFDB6DE897303328B337858CB23A9B_terseLabel_en-US" xlink:label="lab_stpr_NY_F6BFDB6DE897303328B337858CB23A9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York</link:label>
    <link:label id="lab_stpr_NY_F6BFDB6DE897303328B337858CB23A9B_label_en-US" xlink:label="lab_stpr_NY_F6BFDB6DE897303328B337858CB23A9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:label="loc_stpr_NY_F6BFDB6DE897303328B337858CB23A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY_F6BFDB6DE897303328B337858CB23A9B" xlink:to="lab_stpr_NY_F6BFDB6DE897303328B337858CB23A9B" xlink:type="arc" />
    <link:label id="lab_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067_terseLabel_en-US" xlink:label="lab_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Los Angeles</link:label>
    <link:label id="lab_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067_label_en-US" xlink:label="lab_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Los Angeles [Member]</link:label>
    <link:label id="lab_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067_documentation_en-US" xlink:label="lab_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Los Angeles [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_LosAngelesMember" xlink:label="loc_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067" xlink:to="lab_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067" xlink:type="arc" />
    <link:label id="lab_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF_terseLabel_en-US" xlink:label="lab_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Newark</link:label>
    <link:label id="lab_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF_label_en-US" xlink:label="lab_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Newark [Member]</link:label>
    <link:label id="lab_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF_documentation_en-US" xlink:label="lab_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Newark [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_NewarkMember" xlink:label="loc_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF" xlink:to="lab_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:type="arc" />
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610_terseLabel_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of office and laboratory</link:label>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610_label_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area Of New Office Building</link:label>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610_documentation_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Area of new office building.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AreaOfNewOfficeBuilding" xlink:label="loc_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610" xlink:to="lab_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, option to extend term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0" xlink:type="arc" />
    <link:label id="lab_allo_AllowanceForTenantImprovements_CCC662AF95E7D5C18C1537858CB367D3_terseLabel_en-US" xlink:label="lab_allo_AllowanceForTenantImprovements_CCC662AF95E7D5C18C1537858CB367D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for tenant improvements</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AllowanceForTenantImprovements" xlink:label="loc_allo_AllowanceForTenantImprovements_CCC662AF95E7D5C18C1537858CB367D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AllowanceForTenantImprovements_CCC662AF95E7D5C18C1537858CB367D3" xlink:to="lab_allo_AllowanceForTenantImprovements_CCC662AF95E7D5C18C1537858CB367D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate lease liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80" xlink:type="arc" />
    <link:label id="lab_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6_terseLabel_en-US" xlink:label="lab_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6_label_en-US" xlink:label="lab_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Remaining Term</link:label>
    <link:label id="lab_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6_documentation_en-US" xlink:label="lab_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating lease remaining term.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_OperatingLeaseRemainingTerm" xlink:label="loc_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6" xlink:to="lab_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated incremental borrowing rate of lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE" xlink:type="arc" />
    <link:label id="lab_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640_terseLabel_en-US" xlink:label="lab_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of operating lease</link:label>
    <link:label id="lab_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640_label_en-US" xlink:label="lab_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area Of Operating Lease</link:label>
    <link:label id="lab_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640_documentation_en-US" xlink:label="lab_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Area of operating lease.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AreaOfOperatingLease" xlink:label="loc_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640" xlink:to="lab_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640" xlink:type="arc" />
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F_terseLabel_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to extend lease</link:label>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F_label_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Options To Extend Lease</link:label>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F_documentation_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of options to extend lease.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_NumberOfOptionsToExtendLease" xlink:label="loc_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F" xlink:to="lab_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F" xlink:type="arc" />
    <link:label id="lab_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999_terseLabel_en-US" xlink:label="lab_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of lease rental per month</link:label>
    <link:label id="lab_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999_label_en-US" xlink:label="lab_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Lease Rental Per Month</link:label>
    <link:label id="lab_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999_documentation_en-US" xlink:label="lab_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment of lease rental per month.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_PaymentOfLeaseRentalPerMonth" xlink:label="loc_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999" xlink:to="lab_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999" xlink:type="arc" />
    <link:label id="lab_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033_terseLabel_en-US" xlink:label="lab_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in rate for rent per year for lease term</link:label>
    <link:label id="lab_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033_label_en-US" xlink:label="lab_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessor Leasing Arrangements Operating Leases Annual Percentage Increase In Rent</link:label>
    <link:label id="lab_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033_documentation_en-US" xlink:label="lab_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual rental increase percentage per year of lease agreement.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent" xlink:label="loc_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033" xlink:to="lab_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033" xlink:type="arc" />
    <link:label id="lab_allo_OperatingLeasesUndiscountedLeasePayments_A713865D741195EF095D37858CB5BB70_verboseLabel_en-US" xlink:label="lab_allo_OperatingLeasesUndiscountedLeasePayments_A713865D741195EF095D37858CB5BB70" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Undiscounted lease payments</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_OperatingLeasesUndiscountedLeasePayments" xlink:label="loc_allo_OperatingLeasesUndiscountedLeasePayments_A713865D741195EF095D37858CB5BB70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OperatingLeasesUndiscountedLeasePayments_A713865D741195EF095D37858CB5BB70" xlink:to="lab_allo_OperatingLeasesUndiscountedLeasePayments_A713865D741195EF095D37858CB5BB70" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short term lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF" xlink:to="lab_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease payments</link:label>
    <link:label id="lab_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669_label_en-US" xlink:label="lab_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669" xlink:to="lab_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_750D1FA23DBB83F92973DDD396B50E38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9A67D24D897E561888314263974EA5E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Assets And Liabilities Subject To Fair Value Measurements On Recurring Basis And Level Of Inputs Used In Such Measurements By Major Security Type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_750D1FA23DBB83F92973DDD396B50E38_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9A67D24D897E561888314263974EA5E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9A67D24D897E561888314263974EA5E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9A67D24D897E561888314263974EA5E6" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9A67D24D897E561888314263974EA5E6" xlink:type="arc" />
    <link:label id="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359_terseLabel_en-US" xlink:label="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359_label_en-US" xlink:label="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Research And Development Expenses Current</link:label>
    <link:label id="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359_documentation_en-US" xlink:label="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid research and development expenses current.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:label="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359" xlink:to="lab_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedInvestmentIncomeReceivable_5B53B49BF6E9A1EC1C6223C4C8339300_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInvestmentIncomeReceivable_5B53B49BF6E9A1EC1C6223C4C8339300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest on investments</link:label>
    <link:label id="lab_us-gaap_AccruedInvestmentIncomeReceivable_5B53B49BF6E9A1EC1C6223C4C8339300_label_en-US" xlink:label="lab_us-gaap_AccruedInvestmentIncomeReceivable_5B53B49BF6E9A1EC1C6223C4C8339300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Investment Income Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_5B53B49BF6E9A1EC1C6223C4C8339300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInvestmentIncomeReceivable_5B53B49BF6E9A1EC1C6223C4C8339300" xlink:to="lab_us-gaap_AccruedInvestmentIncomeReceivable_5B53B49BF6E9A1EC1C6223C4C8339300" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_0A4D702E3ECB93E6AFE123C4C83455B6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent_0A4D702E3ECB93E6AFE123C4C83455B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other prepaid and current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_0A4D702E3ECB93E6AFE123C4C83455B6_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent_0A4D702E3ECB93E6AFE123C4C83455B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_0A4D702E3ECB93E6AFE123C4C83455B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent_0A4D702E3ECB93E6AFE123C4C83455B6" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent_0A4D702E3ECB93E6AFE123C4C83455B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidInsurance_087CFA1CEF3225C320F323C4C83448D1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance_087CFA1CEF3225C320F323C4C83448D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_087CFA1CEF3225C320F323C4C83448D1_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance_087CFA1CEF3225C320F323C4C83448D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_087CFA1CEF3225C320F323C4C83448D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance_087CFA1CEF3225C320F323C4C83448D1" xlink:to="lab_us-gaap_PrepaidInsurance_087CFA1CEF3225C320F323C4C83448D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D61A82F134F32B0ADEAF23C4C834107E_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D61A82F134F32B0ADEAF23C4C834107E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D61A82F134F32B0ADEAF23C4C834107E_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D61A82F134F32B0ADEAF23C4C834107E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D61A82F134F32B0ADEAF23C4C834107E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D61A82F134F32B0ADEAF23C4C834107E" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D61A82F134F32B0ADEAF23C4C834107E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4BF5205827BB01791F5D27760E1C3876_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_4BF5205827BB01791F5D27760E1C3876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4BF5205827BB01791F5D27760E1C3876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4BF5205827BB01791F5D27760E1C3876" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_4BF5205827BB01791F5D27760E1C3876" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B_label_en-US" xlink:label="lab_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:to="lab_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:to="lab_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:to="lab_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:type="arc" />
    <link:label id="lab_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64_terseLabel_en-US" xlink:label="lab_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Convertible Preferred Stock</link:label>
    <link:label id="lab_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64_label_en-US" xlink:label="lab_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64_documentation_en-US" xlink:label="lab_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_SeriesAConvertiblePreferredStockMember" xlink:label="loc_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64" xlink:to="lab_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64" xlink:type="arc" />
    <link:label id="lab_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B_terseLabel_en-US" xlink:label="lab_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Convertible Preferred Stock Convertible Preferred Shares</link:label>
    <link:label id="lab_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B_label_en-US" xlink:label="lab_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock Convertible Preferred Shares [Member]</link:label>
    <link:label id="lab_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B_documentation_en-US" xlink:label="lab_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock Convertible Preferred Shares [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember" xlink:label="loc_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B" xlink:to="lab_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321" xlink:to="lab_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321" xlink:type="arc" />
    <link:label id="lab_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311_terseLabel_en-US" xlink:label="lab_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscription Receivable from Preferred Stockholders</link:label>
    <link:label id="lab_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311_label_en-US" xlink:label="lab_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subscription Receivable From Preferred Stockholders [Member]</link:label>
    <link:label id="lab_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311_documentation_en-US" xlink:label="lab_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subscription Receivable From Preferred Stockholders [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_SubscriptionReceivableFromPreferredStockholdersMember" xlink:label="loc_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311" xlink:to="lab_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Receivable from Common Stockholders</link:label>
    <link:label id="lab_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F_label_en-US" xlink:label="lab_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables from Stockholder [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F" xlink:to="lab_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25" xlink:to="lab_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:to="lab_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_EAB772ABD85E205DF70127760E206380_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_EAB772ABD85E205DF70127760E206380" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_EAB772ABD85E205DF70127760E206380" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_EAB772ABD85E205DF70127760E206380" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_EAB772ABD85E205DF70127760E206380" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_30774CF4174B21A7C3E827760E2064BC_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_30774CF4174B21A7C3E827760E2064BC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_30774CF4174B21A7C3E827760E2064BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_30774CF4174B21A7C3E827760E2064BC" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_30774CF4174B21A7C3E827760E2064BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_495A95AC40225B718EDE27760E2038EE_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_495A95AC40225B718EDE27760E2038EE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_495A95AC40225B718EDE27760E2038EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_495A95AC40225B718EDE27760E2038EE" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_495A95AC40225B718EDE27760E2038EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA" xlink:to="lab_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA" xlink:type="arc" />
    <link:label id="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50_terseLabel_en-US" xlink:label="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series A convertible preferred stock, net (in shares)</link:label>
    <link:label id="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50_label_en-US" xlink:label="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50_documentation_en-US" xlink:label="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Temporary Equity Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50" xlink:to="lab_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series A convertible preferred stock, net</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series A-1 convertible preferred stock in connection with asset acquisition, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of Series A-1 convertible preferred stock in connection with asset acquisition, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D" xlink:type="arc" />
    <link:label id="lab_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F_terseLabel_en-US" xlink:label="lab_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subscriptions receivable from preferred stockholders</link:label>
    <link:label id="lab_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F_label_en-US" xlink:label="lab_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subscriptions Receivable From Preferred Stockholders</link:label>
    <link:label id="lab_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F_documentation_en-US" xlink:label="lab_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Subscriptions Receivable From Preferred Stockholders</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_SubscriptionsReceivableFromPreferredStockholders" xlink:label="loc_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F" xlink:to="lab_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F" xlink:type="arc" />
    <link:label id="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67_terseLabel_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds received from common stockholders for issuance of founders' stock at inception</link:label>
    <link:label id="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67_label_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Common Stock Issues</link:label>
    <link:label id="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67_documentation_en-US" xlink:label="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issued during period value common stock issues.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_StockIssuedDuringPeriodValueCommonStockIssues" xlink:label="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67" xlink:to="lab_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D5B2AD1483DA9CC0E87927760E20ED13_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D5B2AD1483DA9CC0E87927760E20ED13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D5B2AD1483DA9CC0E87927760E20ED13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D5B2AD1483DA9CC0E87927760E20ED13" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D5B2AD1483DA9CC0E87927760E20ED13" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of early exercised common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_A3E0427AB74BA32E61F427760E20E8DB_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_A3E0427AB74BA32E61F427760E20E8DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_A3E0427AB74BA32E61F427760E20E8DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_A3E0427AB74BA32E61F427760E20E8DB" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_A3E0427AB74BA32E61F427760E20E8DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for fractional shares from forward stock split</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_21C744E52FD40B46B66E27760E242738_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_21C744E52FD40B46B66E27760E242738" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_21C744E52FD40B46B66E27760E242738" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_21C744E52FD40B46B66E27760E242738" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_21C744E52FD40B46B66E27760E242738" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_D003F42948AAC0061C6927760E24BB8F_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_D003F42948AAC0061C6927760E24BB8F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_D003F42948AAC0061C6927760E24BB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_D003F42948AAC0061C6927760E24BB8F" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_D003F42948AAC0061C6927760E24BB8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_49AEE2141524266A9D5527760E24D843_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_49AEE2141524266A9D5527760E24D843" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_49AEE2141524266A9D5527760E24D843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_49AEE2141524266A9D5527760E24D843" xlink:to="lab_us-gaap_StockholdersEquity_49AEE2141524266A9D5527760E24D843" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8EEB90D88E5F1CB0508727760E243E5E_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_8EEB90D88E5F1CB0508727760E243E5E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8EEB90D88E5F1CB0508727760E243E5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_8EEB90D88E5F1CB0508727760E243E5E" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_8EEB90D88E5F1CB0508727760E243E5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_65C3363054678EA983A927760E24154A_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_65C3363054678EA983A927760E24154A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_65C3363054678EA983A927760E24154A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_65C3363054678EA983A927760E24154A" xlink:to="lab_us-gaap_NetIncomeLoss_65C3363054678EA983A927760E24154A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:to="lab_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42_label_en-US" xlink:label="lab_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42" xlink:to="lab_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:type="arc" />
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6_terseLabel_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares as percentage of common shares outstanding</link:label>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6_label_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6_documentation_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares as percentage of common shares outstanding.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6" xlink:to="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6" xlink:type="arc" />
    <link:label id="lab_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B_terseLabel_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option grant period</link:label>
    <link:label id="lab_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B_label_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Granted Period</link:label>
    <link:label id="lab_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B_documentation_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock option granted period.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_StockOptionGrantedPeriod" xlink:label="loc_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B" xlink:to="lab_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B" xlink:type="arc" />
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1_terseLabel_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1_label_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1_documentation_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1" xlink:to="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long term liabilities, related to shares held by employees and directors that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3B88B763B9A3E2D2FE8C18983C1D5DC0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_3B88B763B9A3E2D2FE8C18983C1D5DC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3B88B763B9A3E2D2FE8C18983C1D5DC0_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_3B88B763B9A3E2D2FE8C18983C1D5DC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3B88B763B9A3E2D2FE8C18983C1D5DC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_3B88B763B9A3E2D2FE8C18983C1D5DC0" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_3B88B763B9A3E2D2FE8C18983C1D5DC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_67DF94638A5C86C44E4E241B37ECFC4F_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_67DF94638A5C86C44E4E241B37ECFC4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_67DF94638A5C86C44E4E241B37ECFC4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_67DF94638A5C86C44E4E241B37ECFC4F" xlink:to="lab_us-gaap_DebtDisclosureAbstract_67DF94638A5C86C44E4E241B37ECFC4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_D9D3A760453066FC637B241BBE88E3D2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_D9D3A760453066FC637B241BBE88E3D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable (2018 Notes)</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_D9D3A760453066FC637B241BBE88E3D2_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_D9D3A760453066FC637B241BBE88E3D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_D9D3A760453066FC637B241BBE88E3D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_D9D3A760453066FC637B241BBE88E3D2" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_D9D3A760453066FC637B241BBE88E3D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_E73CAA085C0C48AB92D46310DB821150_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_A5183049A10E54AB8D384ED2957D73DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Unit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_A5183049A10E54AB8D384ED2957D73DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_A5183049A10E54AB8D384ED2957D73DC" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_A5183049A10E54AB8D384ED2957D73DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A15FC84C0B78F21982416310DB833147_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C1E373469AD5E92A4DB471D6C58949B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A15FC84C0B78F21982416310DB833147_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C1E373469AD5E92A4DB471D6C58949B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C1E373469AD5E92A4DB471D6C58949B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C1E373469AD5E92A4DB471D6C58949B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C1E373469AD5E92A4DB471D6C58949B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4C196FBD954045C4E3716310DB84E5EC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99D3CACD435758E0BCDC7EECE0F1D941" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4C196FBD954045C4E3716310DB84E5EC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99D3CACD435758E0BCDC7EECE0F1D941" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99D3CACD435758E0BCDC7EECE0F1D941" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99D3CACD435758E0BCDC7EECE0F1D941" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99D3CACD435758E0BCDC7EECE0F1D941" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_934C7C2E1CC67D0FD48A6310DB84FB98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F6C06F3797E150F8A6E5A1375A236002" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_934C7C2E1CC67D0FD48A6310DB84FB98_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F6C06F3797E150F8A6E5A1375A236002" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F6C06F3797E150F8A6E5A1375A236002" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F6C06F3797E150F8A6E5A1375A236002" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F6C06F3797E150F8A6E5A1375A236002" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_12A9DB68E5DFB690E5366310DB845195_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6A3A93A8D16F5FACBF722D4D9C68746D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_12A9DB68E5DFB690E5366310DB845195_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6A3A93A8D16F5FACBF722D4D9C68746D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6A3A93A8D16F5FACBF722D4D9C68746D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6A3A93A8D16F5FACBF722D4D9C68746D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6A3A93A8D16F5FACBF722D4D9C68746D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_575362C07E69EF641BD86310DB844213_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08347C0B28C452D4B1E495C6FF1AD913" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, unvested, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08347C0B28C452D4B1E495C6FF1AD913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08347C0B28C452D4B1E495C6FF1AD913" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08347C0B28C452D4B1E495C6FF1AD913" xlink:type="arc" />
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_CF7C7888CF0FE2DEF3DE6310DB8441D6_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_71B0DC973E8A5A0FAFBF11FEF1D4CE99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_CF7C7888CF0FE2DEF3DE6310DB8441D6_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_71B0DC973E8A5A0FAFBF11FEF1D4CE99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_CF7C7888CF0FE2DEF3DE6310DB8441D6_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_71B0DC973E8A5A0FAFBF11FEF1D4CE99" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_71B0DC973E8A5A0FAFBF11FEF1D4CE99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_71B0DC973E8A5A0FAFBF11FEF1D4CE99" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_71B0DC973E8A5A0FAFBF11FEF1D4CE99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5A3957D11A4A7733FC086310DB84FFBE_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08E939706FFC559CB3B0C8E5787BB680" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value at date of grant per share, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5A3957D11A4A7733FC086310DB84FFBE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08E939706FFC559CB3B0C8E5787BB680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08E939706FFC559CB3B0C8E5787BB680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08E939706FFC559CB3B0C8E5787BB680" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08E939706FFC559CB3B0C8E5787BB680" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6960F0ED151F8DAB03B76310DB85638D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FE05E67A0C6D5A1E8C3C9492FFC781F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value at date of grant per share, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6960F0ED151F8DAB03B76310DB85638D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FE05E67A0C6D5A1E8C3C9492FFC781F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FE05E67A0C6D5A1E8C3C9492FFC781F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FE05E67A0C6D5A1E8C3C9492FFC781F7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FE05E67A0C6D5A1E8C3C9492FFC781F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E251697C10E8103E85946310DB85F781_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_57424237B3845B3C8A3DE1688F33D228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value at date of grant per share, vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E251697C10E8103E85946310DB85F781_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_57424237B3845B3C8A3DE1688F33D228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_57424237B3845B3C8A3DE1688F33D228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_57424237B3845B3C8A3DE1688F33D228" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_57424237B3845B3C8A3DE1688F33D228" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_8A3525B0F06FE28FC6906310DB85CA41_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_C6FF5A996BCD514FAEB08565B76C8BC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value at date of grant per share, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_8A3525B0F06FE28FC6906310DB85CA41_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_C6FF5A996BCD514FAEB08565B76C8BC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_C6FF5A996BCD514FAEB08565B76C8BC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_C6FF5A996BCD514FAEB08565B76C8BC3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_C6FF5A996BCD514FAEB08565B76C8BC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B52101A10519EC401D6B6310DB85DC55_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71A6DFB365A35B9DAB9B1AB06569E1C1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value at date of grant per share, ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71A6DFB365A35B9DAB9B1AB06569E1C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71A6DFB365A35B9DAB9B1AB06569E1C1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71A6DFB365A35B9DAB9B1AB06569E1C1" xlink:type="arc" />
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_41C8A33DFFF4A0D62FDD6310DB85C041_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_005B79DBF6DD55AA95A98E58F8AB8729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_41C8A33DFFF4A0D62FDD6310DB85C041_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_005B79DBF6DD55AA95A98E58F8AB8729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_41C8A33DFFF4A0D62FDD6310DB85C041_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_005B79DBF6DD55AA95A98E58F8AB8729" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_005B79DBF6DD55AA95A98E58F8AB8729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_005B79DBF6DD55AA95A98E58F8AB8729" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_005B79DBF6DD55AA95A98E58F8AB8729" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:to="lab_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:to="lab_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3B374598310DC2F6BBF5FAB5816AD2C5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3B374598310DC2F6BBF5FAB5816AD2C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3B374598310DC2F6BBF5FAB5816AD2C5_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3B374598310DC2F6BBF5FAB5816AD2C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3B374598310DC2F6BBF5FAB5816AD2C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3B374598310DC2F6BBF5FAB5816AD2C5" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3B374598310DC2F6BBF5FAB5816AD2C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_B31F3FDE886C68C87E39FAB5816AE055_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_B31F3FDE886C68C87E39FAB5816AE055" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_B31F3FDE886C68C87E39FAB5816AE055_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_B31F3FDE886C68C87E39FAB5816AE055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_B31F3FDE886C68C87E39FAB5816AE055" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_B31F3FDE886C68C87E39FAB5816AE055" xlink:to="lab_us-gaap_ShortTermInvestments_B31F3FDE886C68C87E39FAB5816AE055" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1456F83F0EF62AFC8035FAB5816AB04F_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1456F83F0EF62AFC8035FAB5816AB04F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1456F83F0EF62AFC8035FAB5816AB04F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1456F83F0EF62AFC8035FAB5816AB04F" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1456F83F0EF62AFC8035FAB5816AB04F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_2456C6CFF4DAB1F64D24FAB5816B97D8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_2456C6CFF4DAB1F64D24FAB5816B97D8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_2456C6CFF4DAB1F64D24FAB5816B97D8_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_2456C6CFF4DAB1F64D24FAB5816B97D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_2456C6CFF4DAB1F64D24FAB5816B97D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_2456C6CFF4DAB1F64D24FAB5816B97D8" xlink:to="lab_us-gaap_AssetsCurrent_2456C6CFF4DAB1F64D24FAB5816B97D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_309B157C6F97E37E1AA4FAB5816BBA02_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_309B157C6F97E37E1AA4FAB5816BBA02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_309B157C6F97E37E1AA4FAB5816BBA02_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_309B157C6F97E37E1AA4FAB5816BBA02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_309B157C6F97E37E1AA4FAB5816BBA02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_309B157C6F97E37E1AA4FAB5816BBA02" xlink:to="lab_us-gaap_LongTermInvestments_309B157C6F97E37E1AA4FAB5816BBA02" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_A8651471CA68DB38F89AFAB5816B1A37_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_A8651471CA68DB38F89AFAB5816B1A37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_A8651471CA68DB38F89AFAB5816B1A37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_A8651471CA68DB38F89AFAB5816B1A37" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_A8651471CA68DB38F89AFAB5816B1A37" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_596D78F576886BF4145BFAB5816B774B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_596D78F576886BF4145BFAB5816B774B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_596D78F576886BF4145BFAB5816B774B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_596D78F576886BF4145BFAB5816B774B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_596D78F576886BF4145BFAB5816B774B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_596D78F576886BF4145BFAB5816B774B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_596D78F576886BF4145BFAB5816B774B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6CDC2DBDC102C2A21F40FAB5816B15CE_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6CDC2DBDC102C2A21F40FAB5816B15CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6CDC2DBDC102C2A21F40FAB5816B15CE_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6CDC2DBDC102C2A21F40FAB5816B15CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6CDC2DBDC102C2A21F40FAB5816B15CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6CDC2DBDC102C2A21F40FAB5816B15CE" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6CDC2DBDC102C2A21F40FAB5816B15CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_C655568AA560B5DB3768FAB5816B8A3F_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_C655568AA560B5DB3768FAB5816B8A3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_C655568AA560B5DB3768FAB5816B8A3F_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_C655568AA560B5DB3768FAB5816B8A3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_C655568AA560B5DB3768FAB5816B8A3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_C655568AA560B5DB3768FAB5816B8A3F" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_C655568AA560B5DB3768FAB5816B8A3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7F5477FF48C4429FBE62FAB5816C5D06_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_7F5477FF48C4429FBE62FAB5816C5D06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7F5477FF48C4429FBE62FAB5816C5D06_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_7F5477FF48C4429FBE62FAB5816C5D06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7F5477FF48C4429FBE62FAB5816C5D06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_7F5477FF48C4429FBE62FAB5816C5D06" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_7F5477FF48C4429FBE62FAB5816C5D06" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_F79A668B7C4C6D469AA7FAB5816CC15E_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_F79A668B7C4C6D469AA7FAB5816CC15E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_F79A668B7C4C6D469AA7FAB5816CC15E_label_en-US" xlink:label="lab_us-gaap_Assets_F79A668B7C4C6D469AA7FAB5816CC15E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F79A668B7C4C6D469AA7FAB5816CC15E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_F79A668B7C4C6D469AA7FAB5816CC15E" xlink:to="lab_us-gaap_Assets_F79A668B7C4C6D469AA7FAB5816CC15E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_50B2D1A1C2B356182D2EFAB5816CDFE0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_50B2D1A1C2B356182D2EFAB5816CDFE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_50B2D1A1C2B356182D2EFAB5816CDFE0_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_50B2D1A1C2B356182D2EFAB5816CDFE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_50B2D1A1C2B356182D2EFAB5816CDFE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_50B2D1A1C2B356182D2EFAB5816CDFE0" xlink:to="lab_us-gaap_AccountsPayableCurrent_50B2D1A1C2B356182D2EFAB5816CDFE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_96B26977F3C04978AAAFFAB5816DFF90_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_96B26977F3C04978AAAFFAB5816DFF90" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_96B26977F3C04978AAAFFAB5816DFF90_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_96B26977F3C04978AAAFFAB5816DFF90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_96B26977F3C04978AAAFFAB5816DFF90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_96B26977F3C04978AAAFFAB5816DFF90" xlink:to="lab_us-gaap_LiabilitiesCurrent_96B26977F3C04978AAAFFAB5816DFF90" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9D6D3A837B984A4B2E81FAB5816DC729_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9D6D3A837B984A4B2E81FAB5816DC729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability, noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9D6D3A837B984A4B2E81FAB5816DC729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9D6D3A837B984A4B2E81FAB5816DC729" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9D6D3A837B984A4B2E81FAB5816DC729" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_75CEB9CBEA391FB5F7AEFAB5816D07A5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_75CEB9CBEA391FB5F7AEFAB5816D07A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_75CEB9CBEA391FB5F7AEFAB5816D07A5_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_75CEB9CBEA391FB5F7AEFAB5816D07A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_75CEB9CBEA391FB5F7AEFAB5816D07A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_75CEB9CBEA391FB5F7AEFAB5816D07A5" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_75CEB9CBEA391FB5F7AEFAB5816D07A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_96D9AB852087FDBB71F7FAB5816D6052_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_96D9AB852087FDBB71F7FAB5816D6052" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_96D9AB852087FDBB71F7FAB5816D6052_label_en-US" xlink:label="lab_us-gaap_Liabilities_96D9AB852087FDBB71F7FAB5816D6052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_96D9AB852087FDBB71F7FAB5816D6052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_96D9AB852087FDBB71F7FAB5816D6052" xlink:to="lab_us-gaap_Liabilities_96D9AB852087FDBB71F7FAB5816D6052" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_782C553E8120C0D62702FAB5816D669F_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_782C553E8120C0D62702FAB5816D669F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Notes 6 and 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_782C553E8120C0D62702FAB5816D669F_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_782C553E8120C0D62702FAB5816D669F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_782C553E8120C0D62702FAB5816D669F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_782C553E8120C0D62702FAB5816D669F" xlink:to="lab_us-gaap_CommitmentsAndContingencies_782C553E8120C0D62702FAB5816D669F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:to="lab_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_60E2CDF1A426938FB7E7FAB5816E7BD5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_60E2CDF1A426938FB7E7FAB5816E7BD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value: 10,000,000 shares authorized as of September 30, 2019 and December 31, 2018; no shares were issued and outstanding as of September 30, 2019 and December 31, 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_60E2CDF1A426938FB7E7FAB5816E7BD5_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_60E2CDF1A426938FB7E7FAB5816E7BD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_60E2CDF1A426938FB7E7FAB5816E7BD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_60E2CDF1A426938FB7E7FAB5816E7BD5" xlink:to="lab_us-gaap_PreferredStockValue_60E2CDF1A426938FB7E7FAB5816E7BD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_F282B597553914784B32FAB5816EE151_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_F282B597553914784B32FAB5816EE151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: 200,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 121,895,479 and 121,482,671 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_F282B597553914784B32FAB5816EE151_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_F282B597553914784B32FAB5816EE151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F282B597553914784B32FAB5816EE151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_F282B597553914784B32FAB5816EE151" xlink:to="lab_us-gaap_CommonStockValue_F282B597553914784B32FAB5816EE151" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_CC30DEE4343A2318CEF4FAB5816E9F62_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_CC30DEE4343A2318CEF4FAB5816E9F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_CC30DEE4343A2318CEF4FAB5816E9F62_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_CC30DEE4343A2318CEF4FAB5816E9F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_CC30DEE4343A2318CEF4FAB5816E9F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_CC30DEE4343A2318CEF4FAB5816E9F62" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_CC30DEE4343A2318CEF4FAB5816E9F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1C4EBBBC5A32B56BA6CFAB5816FC361_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1C4EBBBC5A32B56BA6CFAB5816FC361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1C4EBBBC5A32B56BA6CFAB5816FC361_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1C4EBBBC5A32B56BA6CFAB5816FC361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1C4EBBBC5A32B56BA6CFAB5816FC361" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1C4EBBBC5A32B56BA6CFAB5816FC361" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1C4EBBBC5A32B56BA6CFAB5816FC361" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_0C281CA316DF75482DCBFAB5816F2AC3_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_0C281CA316DF75482DCBFAB5816F2AC3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0C281CA316DF75482DCBFAB5816F2AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_0C281CA316DF75482DCBFAB5816F2AC3" xlink:to="lab_us-gaap_StockholdersEquity_0C281CA316DF75482DCBFAB5816F2AC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7E7688F25AECE146C973FAB5816F4557_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_7E7688F25AECE146C973FAB5816F4557" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7E7688F25AECE146C973FAB5816F4557_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_7E7688F25AECE146C973FAB5816F4557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7E7688F25AECE146C973FAB5816F4557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7E7688F25AECE146C973FAB5816F4557" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_7E7688F25AECE146C973FAB5816F4557" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:type="arc" />
    <link:label id="lab_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D_terseLabel_en-US" xlink:label="lab_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ByHeart</link:label>
    <link:label id="lab_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D_label_en-US" xlink:label="lab_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">By Heart Inc [Member]</link:label>
    <link:label id="lab_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D_documentation_en-US" xlink:label="lab_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ByHeart, Inc. [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ByHeartIncMember" xlink:label="loc_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D" xlink:to="lab_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D" xlink:type="arc" />
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB_terseLabel_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Two River</link:label>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB_label_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two River Consulting L L C [Member]</link:label>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB_documentation_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two River Consulting LLC [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_TwoRiverConsultingLLCMember" xlink:label="loc_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB" xlink:to="lab_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB" xlink:type="arc" />
    <link:label id="lab_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A_terseLabel_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bellco</link:label>
    <link:label id="lab_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A_label_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bellco Capital L L C [Member]</link:label>
    <link:label id="lab_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A_documentation_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bellco Capital LLC.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_BellcoCapitalLLCMember" xlink:label="loc_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A" xlink:to="lab_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A" xlink:type="arc" />
    <link:label id="lab_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C_terseLabel_en-US" xlink:label="lab_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition Services Agreement</link:label>
    <link:label id="lab_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C_label_en-US" xlink:label="lab_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transition Services Agreement [Member]</link:label>
    <link:label id="lab_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C_documentation_en-US" xlink:label="lab_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transition services agreement.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_TransitionServicesAgreementMember" xlink:label="loc_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C" xlink:to="lab_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C" xlink:type="arc" />
    <link:label id="lab_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28_terseLabel_en-US" xlink:label="lab_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease Agreement</link:label>
    <link:label id="lab_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28_label_en-US" xlink:label="lab_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Agreement [Member]</link:label>
    <link:label id="lab_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28_documentation_en-US" xlink:label="lab_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sublease Agreement [Member]</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_SubleaseAgreementMember" xlink:label="loc_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28" xlink:to="lab_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28" xlink:type="arc" />
    <link:label id="lab_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF_terseLabel_en-US" xlink:label="lab_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting Agreements</link:label>
    <link:label id="lab_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF_label_en-US" xlink:label="lab_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:label id="lab_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF_documentation_en-US" xlink:label="lab_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consulting agreements.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ConsultingAgreementsMember" xlink:label="loc_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF" xlink:to="lab_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:type="arc" />
    <link:label id="lab_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811_terseLabel_en-US" xlink:label="lab_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811_label_en-US" xlink:label="lab_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811_documentation_en-US" xlink:label="lab_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued and other current liabilities.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="loc_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811" xlink:to="lab_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:type="arc" />
    <link:label id="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6_terseLabel_en-US" xlink:label="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of members appointed to board of directors</link:label>
    <link:label id="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6_label_en-US" xlink:label="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Members Appointed To Board Of Directors</link:label>
    <link:label id="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6_documentation_en-US" xlink:label="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of members appointed to board of directors.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:label="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6" xlink:to="lab_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party costs</link:label>
    <link:label id="lab_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D_label_en-US" xlink:label="lab_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D" xlink:to="lab_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction, expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense" xlink:label="loc_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25" xlink:to="lab_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable to related party, current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589_label_en-US" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589" xlink:type="arc" />
    <link:label id="lab_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF_terseLabel_en-US" xlink:label="lab_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of office space</link:label>
    <link:label id="lab_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF_label_en-US" xlink:label="lab_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area Of Office</link:label>
    <link:label id="lab_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF_documentation_en-US" xlink:label="lab_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Area of office.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AreaOfOffice" xlink:label="loc_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF" xlink:to="lab_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12" xlink:to="lab_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12" xlink:type="arc" />
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E_terseLabel_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction monthly payment in arrears</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E_label_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction Monthly Payments In Arrears</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E_documentation_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related party transaction monthly payments in arrears.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E" xlink:to="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E" xlink:type="arc" />
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55_terseLabel_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction compensation percentage</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55_label_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction Compensation Percentage</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55_documentation_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related party transaction compensation percentage.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_RelatedPartyTransactionCompensationPercentage" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55" xlink:to="lab_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619" xlink:type="arc" />
    <link:label id="lab_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2_terseLabel_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2_label_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2_documentation_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory equipment member.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_LaboratoryEquipmentMember" xlink:label="loc_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2" xlink:to="lab_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2" xlink:type="arc" />
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7_terseLabel_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computers equipment and purchased software</link:label>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7_label_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Purchased Software [Member]</link:label>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7_documentation_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer equipment and purchased software.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7" xlink:to="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1" xlink:to="lab_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D8E5CC3073415989C81B14D38F083E73_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D8E5CC3073415989C81B14D38F083E73" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D8E5CC3073415989C81B14D38F083E73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_D8E5CC3073415989C81B14D38F083E73" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_D8E5CC3073415989C81B14D38F083E73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7EBB9FCE21E040BB3503DDD39754FD97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0339A3B21D1C5E2F9932E42C82A5CCD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_7EBB9FCE21E040BB3503DDD39754FD97_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0339A3B21D1C5E2F9932E42C82A5CCD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0339A3B21D1C5E2F9932E42C82A5CCD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0339A3B21D1C5E2F9932E42C82A5CCD7" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0339A3B21D1C5E2F9932E42C82A5CCD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC7E175F8FEFE6FDC28EE2187617DA5E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11086084D82557759BB9D5CC5DCD2447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_DC7E175F8FEFE6FDC28EE2187617DA5E_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11086084D82557759BB9D5CC5DCD2447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11086084D82557759BB9D5CC5DCD2447" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11086084D82557759BB9D5CC5DCD2447" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_11086084D82557759BB9D5CC5DCD2447" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9595E6E1377F1F095C1CE218761897CE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_069A1F1F6F9E5F37944B7278A110CA16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9595E6E1377F1F095C1CE218761897CE_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_069A1F1F6F9E5F37944B7278A110CA16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_069A1F1F6F9E5F37944B7278A110CA16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_069A1F1F6F9E5F37944B7278A110CA16" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_069A1F1F6F9E5F37944B7278A110CA16" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_C17ACCCC4873A8030003E218761865B2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_DD69360A33965DCEBE5E78EB45479DF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_C17ACCCC4873A8030003E218761865B2_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_DD69360A33965DCEBE5E78EB45479DF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_DD69360A33965DCEBE5E78EB45479DF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_DD69360A33965DCEBE5E78EB45479DF1" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_DD69360A33965DCEBE5E78EB45479DF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_EBDF0A8ABEA63EFD7F8AE2187618FAD1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_770EC3300D9E59F1868E3BD31368407A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, measurements, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_EBDF0A8ABEA63EFD7F8AE2187618FAD1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_770EC3300D9E59F1868E3BD31368407A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_770EC3300D9E59F1868E3BD31368407A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_770EC3300D9E59F1868E3BD31368407A" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_770EC3300D9E59F1868E3BD31368407A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_EBC0668D7B7A2512E1E0E21876185D9C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_38DD54E7173B5230ADE91CEE978E7285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_EBC0668D7B7A2512E1E0E21876185D9C_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_38DD54E7173B5230ADE91CEE978E7285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38DD54E7173B5230ADE91CEE978E7285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_38DD54E7173B5230ADE91CEE978E7285" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_38DD54E7173B5230ADE91CEE978E7285" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2107E674BE14E2997C3EE218761985CB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEFA68DA566D5ED783DEABA63802179A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2107E674BE14E2997C3EE218761985CB_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEFA68DA566D5ED783DEABA63802179A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEFA68DA566D5ED783DEABA63802179A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEFA68DA566D5ED783DEABA63802179A" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_EEFA68DA566D5ED783DEABA63802179A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_94F510F47C73FC8C18D9E218761913CD_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_3F853B16092D50039271F3AE1F7F70C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_94F510F47C73FC8C18D9E218761913CD_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_3F853B16092D50039271F3AE1F7F70C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3F853B16092D50039271F3AE1F7F70C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_3F853B16092D50039271F3AE1F7F70C0" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_3F853B16092D50039271F3AE1F7F70C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27E11EFF5EE9F74376C2E2187619EF77_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41257DF7E2F854438D56167DFCABCA25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_27E11EFF5EE9F74376C2E2187619EF77_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41257DF7E2F854438D56167DFCABCA25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41257DF7E2F854438D56167DFCABCA25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41257DF7E2F854438D56167DFCABCA25" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41257DF7E2F854438D56167DFCABCA25" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_977D689B2C2D9E26EE5CE2187619D51A_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_8DC1A8A611835379B382DFD52D0F542A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_977D689B2C2D9E26EE5CE2187619D51A_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_8DC1A8A611835379B382DFD52D0F542A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8DC1A8A611835379B382DFD52D0F542A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_8DC1A8A611835379B382DFD52D0F542A" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_8DC1A8A611835379B382DFD52D0F542A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_C80927649CD56436CAFCE2187619410B_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_C1BD29A9263750548B8C492B53D90481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_C80927649CD56436CAFCE2187619410B_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_C1BD29A9263750548B8C492B53D90481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_C1BD29A9263750548B8C492B53D90481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_C1BD29A9263750548B8C492B53D90481" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_C1BD29A9263750548B8C492B53D90481" xlink:type="arc" />
    <link:label id="lab_allo_FairValueAssetsTransfersBetweenLevelsAmount_A418387F77731C7EAFB1E218761A14FA_terseLabel_en-US" xlink:label="lab_allo_FairValueAssetsTransfersBetweenLevelsAmount_7283977DC8305DEF8855462743275ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfers between fair value measurement levels</link:label>
    <link:label id="lab_allo_FairValueAssetsTransfersBetweenLevelsAmount_A418387F77731C7EAFB1E218761A14FA_label_en-US" xlink:label="lab_allo_FairValueAssetsTransfersBetweenLevelsAmount_7283977DC8305DEF8855462743275ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assets Transfers Between Levels Amount</link:label>
    <link:label id="lab_allo_FairValueAssetsTransfersBetweenLevelsAmount_A418387F77731C7EAFB1E218761A14FA_documentation_en-US" xlink:label="lab_allo_FairValueAssetsTransfersBetweenLevelsAmount_7283977DC8305DEF8855462743275ACF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Assets Transfers Between Levels Amount</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_FairValueAssetsTransfersBetweenLevelsAmount" xlink:label="loc_allo_FairValueAssetsTransfersBetweenLevelsAmount_7283977DC8305DEF8855462743275ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_FairValueAssetsTransfersBetweenLevelsAmount_7283977DC8305DEF8855462743275ACF" xlink:to="lab_allo_FairValueAssetsTransfersBetweenLevelsAmount_7283977DC8305DEF8855462743275ACF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_DA51E0D2BA0F21AE829EDDD3967442A8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9C73ABEDC0853D3BF2046ACBFED6620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity Under Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_DA51E0D2BA0F21AE829EDDD3967442A8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9C73ABEDC0853D3BF2046ACBFED6620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9C73ABEDC0853D3BF2046ACBFED6620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9C73ABEDC0853D3BF2046ACBFED6620" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9C73ABEDC0853D3BF2046ACBFED6620" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_82F4FF13E9B8B8E341A6DDD3967427D3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_709705AEDC965504B64CF19FB3B183D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Units Activity Under Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_82F4FF13E9B8B8E341A6DDD3967427D3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_709705AEDC965504B64CF19FB3B183D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_709705AEDC965504B64CF19FB3B183D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_709705AEDC965504B64CF19FB3B183D7" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_709705AEDC965504B64CF19FB3B183D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C27EDB95DC8846B13BECDDD39674BF3B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F0EE22F8AAB65D9E84EDBF952110A4C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_C27EDB95DC8846B13BECDDD39674BF3B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F0EE22F8AAB65D9E84EDBF952110A4C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F0EE22F8AAB65D9E84EDBF952110A4C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F0EE22F8AAB65D9E84EDBF952110A4C5" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F0EE22F8AAB65D9E84EDBF952110A4C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_286EE9191E76F56A88A827760DCEAAF2_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_286EE9191E76F56A88A827760DCEAAF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_286EE9191E76F56A88A827760DCEAAF2_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_286EE9191E76F56A88A827760DCEAAF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_286EE9191E76F56A88A827760DCEAAF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_286EE9191E76F56A88A827760DCEAAF2" xlink:to="lab_us-gaap_ProfitLoss_286EE9191E76F56A88A827760DCEAAF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_BBD2B94E2A58A4CD6CFF27760DCE2AC3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_BBD2B94E2A58A4CD6CFF27760DCE2AC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in process-research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_BBD2B94E2A58A4CD6CFF27760DCE2AC3_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_BBD2B94E2A58A4CD6CFF27760DCE2AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_BBD2B94E2A58A4CD6CFF27760DCE2AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_BBD2B94E2A58A4CD6CFF27760DCE2AC3" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_BBD2B94E2A58A4CD6CFF27760DCE2AC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_EE7AABD9F87ADC78F22C27760DCE5FA0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_EE7AABD9F87ADC78F22C27760DCE5FA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_EE7AABD9F87ADC78F22C27760DCE5FA0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_EE7AABD9F87ADC78F22C27760DCE5FA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_EE7AABD9F87ADC78F22C27760DCE5FA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_EE7AABD9F87ADC78F22C27760DCE5FA0" xlink:to="lab_us-gaap_ShareBasedCompensation_EE7AABD9F87ADC78F22C27760DCE5FA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_FD6761703399DEFA697D27760DCE43C5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_FD6761703399DEFA697D27760DCE43C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of other intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_FD6761703399DEFA697D27760DCE43C5_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_FD6761703399DEFA697D27760DCE43C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_FD6761703399DEFA697D27760DCE43C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_FD6761703399DEFA697D27760DCE43C5" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_FD6761703399DEFA697D27760DCE43C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationAndAmortization_16E7BBA201050D0BF4CB27760DCE0B89_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_16E7BBA201050D0BF4CB27760DCE0B89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_16E7BBA201050D0BF4CB27760DCE0B89_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_16E7BBA201050D0BF4CB27760DCE0B89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_16E7BBA201050D0BF4CB27760DCE0B89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_16E7BBA201050D0BF4CB27760DCE0B89" xlink:to="lab_us-gaap_DepreciationAndAmortization_16E7BBA201050D0BF4CB27760DCE0B89" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_95917AA973119605848327760DCEA281_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_95917AA973119605848327760DCEA281" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net amortization/accretion on investment securities</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_95917AA973119605848327760DCEA281_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_95917AA973119605848327760DCEA281" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_95917AA973119605848327760DCEA281" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_95917AA973119605848327760DCEA281" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_95917AA973119605848327760DCEA281" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_C77FB271CD3A110A18AF27760DCE8C26_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_C77FB271CD3A110A18AF27760DCE8C26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_C77FB271CD3A110A18AF27760DCE8C26_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_C77FB271CD3A110A18AF27760DCE8C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_C77FB271CD3A110A18AF27760DCE8C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_C77FB271CD3A110A18AF27760DCE8C26" xlink:to="lab_us-gaap_LeaseAndRentalExpense_C77FB271CD3A110A18AF27760DCE8C26" xlink:type="arc" />
    <link:label id="lab_allo_ChangeInFairValueOfConvertibleNotePayable_54AEE73794DE34ED6FD027760DCE1E96_terseLabel_en-US" xlink:label="lab_allo_ChangeInFairValueOfConvertibleNotePayable_54AEE73794DE34ED6FD027760DCE1E96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of convertible notes payable</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ChangeInFairValueOfConvertibleNotePayable" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable_54AEE73794DE34ED6FD027760DCE1E96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ChangeInFairValueOfConvertibleNotePayable_54AEE73794DE34ED6FD027760DCE1E96" xlink:to="lab_allo_ChangeInFairValueOfConvertibleNotePayable_54AEE73794DE34ED6FD027760DCE1E96" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_4397BA8B681F9A5781B727760DCEEC04_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_4397BA8B681F9A5781B727760DCEEC04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs on convertible notes payable</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_4397BA8B681F9A5781B727760DCEEC04_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_4397BA8B681F9A5781B727760DCEEC04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4397BA8B681F9A5781B727760DCEEC04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_4397BA8B681F9A5781B727760DCEEC04" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_4397BA8B681F9A5781B727760DCEEC04" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_737761AA491351F5B07B27760DCEB930_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_737761AA491351F5B07B27760DCEB930" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_737761AA491351F5B07B27760DCEB930_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_737761AA491351F5B07B27760DCEB930" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_737761AA491351F5B07B27760DCEB930" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_737761AA491351F5B07B27760DCEB930" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_737761AA491351F5B07B27760DCEB930" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09258D0A376A34458FBC27760DCEEB63_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09258D0A376A34458FBC27760DCEEB63" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09258D0A376A34458FBC27760DCEEB63_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09258D0A376A34458FBC27760DCEEB63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09258D0A376A34458FBC27760DCEEB63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09258D0A376A34458FBC27760DCEEB63" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09258D0A376A34458FBC27760DCEEB63" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_F1938BE259A5034A182827760DCE0E35_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_F1938BE259A5034A182827760DCE0E35" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_F1938BE259A5034A182827760DCE0E35_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_F1938BE259A5034A182827760DCE0E35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_F1938BE259A5034A182827760DCE0E35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_F1938BE259A5034A182827760DCE0E35" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_F1938BE259A5034A182827760DCE0E35" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6D3DDE085D2B8371C09127760DCE8AC6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6D3DDE085D2B8371C09127760DCE8AC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6D3DDE085D2B8371C09127760DCE8AC6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6D3DDE085D2B8371C09127760DCE8AC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6D3DDE085D2B8371C09127760DCE8AC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6D3DDE085D2B8371C09127760DCE8AC6" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6D3DDE085D2B8371C09127760DCE8AC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3AF3FEE1DC6ABBB431DE27760DD2C53F_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3AF3FEE1DC6ABBB431DE27760DD2C53F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3AF3FEE1DC6ABBB431DE27760DD2C53F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3AF3FEE1DC6ABBB431DE27760DD2C53F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3AF3FEE1DC6ABBB431DE27760DD2C53F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3AF3FEE1DC6ABBB431DE27760DD2C53F" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3AF3FEE1DC6ABBB431DE27760DD2C53F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_977F2F068C972467865827760DD2DA6A_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_977F2F068C972467865827760DD2DA6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_977F2F068C972467865827760DD2DA6A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_977F2F068C972467865827760DD2DA6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_977F2F068C972467865827760DD2DA6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_977F2F068C972467865827760DD2DA6A" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_977F2F068C972467865827760DD2DA6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1CDCA940531970B645DE27760DD21054_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1CDCA940531970B645DE27760DD21054" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1CDCA940531970B645DE27760DD21054_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1CDCA940531970B645DE27760DD21054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1CDCA940531970B645DE27760DD21054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1CDCA940531970B645DE27760DD21054" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1CDCA940531970B645DE27760DD21054" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A8A61E0FCE127CDB7AFF27760DD275A0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A8A61E0FCE127CDB7AFF27760DD275A0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A8A61E0FCE127CDB7AFF27760DD275A0_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A8A61E0FCE127CDB7AFF27760DD275A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A8A61E0FCE127CDB7AFF27760DD275A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A8A61E0FCE127CDB7AFF27760DD275A0" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A8A61E0FCE127CDB7AFF27760DD275A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAssetsInvestingActivities_8A7F5D31188D7351EB9827760DD2ADED_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAssetsInvestingActivities_8A7F5D31188D7351EB9827760DD2ADED" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition of assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAssetsInvestingActivities_8A7F5D31188D7351EB9827760DD2ADED_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAssetsInvestingActivities_8A7F5D31188D7351EB9827760DD2ADED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Assets, Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:label="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities_8A7F5D31188D7351EB9827760DD2ADED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities_8A7F5D31188D7351EB9827760DD2ADED" xlink:to="lab_us-gaap_PaymentsToAcquireAssetsInvestingActivities_8A7F5D31188D7351EB9827760DD2ADED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4544A27400F0AA4404E727760DD29BDB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4544A27400F0AA4404E727760DD29BDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4544A27400F0AA4404E727760DD29BDB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4544A27400F0AA4404E727760DD29BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4544A27400F0AA4404E727760DD29BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4544A27400F0AA4404E727760DD29BDB" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4544A27400F0AA4404E727760DD29BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_A4315702808E3F52489927760E01DBC9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_A4315702808E3F52489927760E01DBC9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_A4315702808E3F52489927760E01DBC9_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_A4315702808E3F52489927760E01DBC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_A4315702808E3F52489927760E01DBC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_A4315702808E3F52489927760E01DBC9" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_A4315702808E3F52489927760E01DBC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F1AFF0C270A5FA7081D827760E018A3E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F1AFF0C270A5FA7081D827760E018A3E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F1AFF0C270A5FA7081D827760E018A3E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F1AFF0C270A5FA7081D827760E018A3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F1AFF0C270A5FA7081D827760E018A3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F1AFF0C270A5FA7081D827760E018A3E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_F1AFF0C270A5FA7081D827760E018A3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_6CB3E38F1FEFE2EC81FB27760E01B5CC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_6CB3E38F1FEFE2EC81FB27760E01B5CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_6CB3E38F1FEFE2EC81FB27760E01B5CC_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_6CB3E38F1FEFE2EC81FB27760E01B5CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_6CB3E38F1FEFE2EC81FB27760E01B5CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_6CB3E38F1FEFE2EC81FB27760E01B5CC" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_6CB3E38F1FEFE2EC81FB27760E01B5CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_33EA8E1AF926613403B627760E01B039_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_33EA8E1AF926613403B627760E01B039" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible notes, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_33EA8E1AF926613403B627760E01B039_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_33EA8E1AF926613403B627760E01B039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_33EA8E1AF926613403B627760E01B039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_33EA8E1AF926613403B627760E01B039" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_33EA8E1AF926613403B627760E01B039" xlink:type="arc" />
    <link:label id="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC_terseLabel_en-US" xlink:label="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from early exercise of stock options</link:label>
    <link:label id="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC_label_en-US" xlink:label="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Shares Under Incentive And Share-Based Compensation Plans, Early Exercise Of Options</link:label>
    <link:label id="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC_documentation_en-US" xlink:label="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Shares Under Incentive And Share-Based Compensation Plans, Early Exercise Of Options</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions" xlink:label="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC" xlink:to="lab_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_A59ED03F8C5F534FD66A27760E050255_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_A59ED03F8C5F534FD66A27760E050255" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of deferred offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_A59ED03F8C5F534FD66A27760E050255_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_A59ED03F8C5F534FD66A27760E050255" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_A59ED03F8C5F534FD66A27760E050255" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_A59ED03F8C5F534FD66A27760E050255" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_A59ED03F8C5F534FD66A27760E050255" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C4AC83F12AE1D262AEC827760E05DF3E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C4AC83F12AE1D262AEC827760E05DF3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C4AC83F12AE1D262AEC827760E05DF3E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C4AC83F12AE1D262AEC827760E05DF3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C4AC83F12AE1D262AEC827760E05DF3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C4AC83F12AE1D262AEC827760E05DF3E" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C4AC83F12AE1D262AEC827760E05DF3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_6DE767C7AB15AED7A3C727760E0540C2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_6DE767C7AB15AED7A3C727760E0540C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_6DE767C7AB15AED7A3C727760E0540C2_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_6DE767C7AB15AED7A3C727760E0540C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_6DE767C7AB15AED7A3C727760E0540C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_6DE767C7AB15AED7A3C727760E0540C2" xlink:to="lab_us-gaap_ProceedsFromStockPlans_6DE767C7AB15AED7A3C727760E0540C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_A7FC0EBC9B4BF932783C27760E053B34_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_A7FC0EBC9B4BF932783C27760E053B34" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_A7FC0EBC9B4BF932783C27760E053B34_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_A7FC0EBC9B4BF932783C27760E053B34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_A7FC0EBC9B4BF932783C27760E053B34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_A7FC0EBC9B4BF932783C27760E053B34" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_A7FC0EBC9B4BF932783C27760E053B34" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5113375C5E56FBE065E527760E0591E8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5113375C5E56FBE065E527760E0591E8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5113375C5E56FBE065E527760E0591E8_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5113375C5E56FBE065E527760E0591E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5113375C5E56FBE065E527760E0591E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5113375C5E56FBE065E527760E0591E8" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5113375C5E56FBE065E527760E0591E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58B2D74681A74547CD6F27760E05631A_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58B2D74681A74547CD6F27760E05631A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58B2D74681A74547CD6F27760E05631A_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58B2D74681A74547CD6F27760E05631A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58B2D74681A74547CD6F27760E05631A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58B2D74681A74547CD6F27760E05631A" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58B2D74681A74547CD6F27760E05631A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08A1501AEAA79DBD32E727760E056DCB_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08A1501AEAA79DBD32E727760E056DCB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8212; end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08A1501AEAA79DBD32E727760E056DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08A1501AEAA79DBD32E727760E056DCB" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08A1501AEAA79DBD32E727760E056DCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E81FA32F7592C78494D127760E054C52_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E81FA32F7592C78494D127760E054C52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment purchase in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E81FA32F7592C78494D127760E054C52_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E81FA32F7592C78494D127760E054C52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E81FA32F7592C78494D127760E054C52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E81FA32F7592C78494D127760E054C52" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E81FA32F7592C78494D127760E054C52" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5DAD85821D19C803332027760E05C8C6_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5DAD85821D19C803332027760E05C8C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5DAD85821D19C803332027760E05C8C6_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5DAD85821D19C803332027760E05C8C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5DAD85821D19C803332027760E05C8C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5DAD85821D19C803332027760E05C8C6" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5DAD85821D19C803332027760E05C8C6" xlink:type="arc" />
    <link:label id="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28_terseLabel_en-US" xlink:label="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 convertible preferred stock issued in asset acquisition</link:label>
    <link:label id="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28_label_en-US" xlink:label="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Issued In Asset Acquisition</link:label>
    <link:label id="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28_documentation_en-US" xlink:label="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Issued In Asset Acquisition</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_ConvertiblePreferredStockIssuedInAssetAcquisition" xlink:label="loc_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28" xlink:to="lab_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2AB7B35176D09E6D891F27760E05A0CC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2AB7B35176D09E6D891F27760E05A0CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs included in accounts payable and accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2AB7B35176D09E6D891F27760E05A0CC_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2AB7B35176D09E6D891F27760E05A0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2AB7B35176D09E6D891F27760E05A0CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2AB7B35176D09E6D891F27760E05A0CC" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2AB7B35176D09E6D891F27760E05A0CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_6782EF2AAD690491FEBF27760E056513_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_6782EF2AAD690491FEBF27760E056513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_6782EF2AAD690491FEBF27760E056513_label_en-US" xlink:label="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_6782EF2AAD690491FEBF27760E056513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Leasing Costs, Commissions, and Tenant Improvements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_6782EF2AAD690491FEBF27760E056513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_6782EF2AAD690491FEBF27760E056513" xlink:to="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_6782EF2AAD690491FEBF27760E056513" xlink:type="arc" />
    <link:label id="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043_terseLabel_en-US" xlink:label="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received for amounts related to tenant improvement allowances</link:label>
    <link:label id="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043_label_en-US" xlink:label="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Received For Amounts Related To Tenant Improvement Allowances</link:label>
    <link:label id="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043_documentation_en-US" xlink:label="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Received For Amounts Related To Tenant Improvement Allowances</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:label="loc_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043" xlink:to="lab_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_93BD39DFCEFD21BF27BA05C2B8B28A9A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_B6C3A3AE57B95AF8A1CF8F136BA9924C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_93BD39DFCEFD21BF27BA05C2B8B28A9A_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_B6C3A3AE57B95AF8A1CF8F136BA9924C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B6C3A3AE57B95AF8A1CF8F136BA9924C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_B6C3A3AE57B95AF8A1CF8F136BA9924C" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_B6C3A3AE57B95AF8A1CF8F136BA9924C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E1047F97DF76F0C1CC7D05C2B8B39FBA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2A27540DD93157EDAE737B3159527F07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_E1047F97DF76F0C1CC7D05C2B8B39FBA_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2A27540DD93157EDAE737B3159527F07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2A27540DD93157EDAE737B3159527F07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_2A27540DD93157EDAE737B3159527F07" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_2A27540DD93157EDAE737B3159527F07" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1A722CAAC4D24A7EEC9605C2B8B3C219_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_1A722CAAC4D24A7EEC9605C2B8B3C219_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_BC4BAD64D56ACC705C9605C2B8B3D6D1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_BC4BAD64D56ACC705C9605C2B8B3D6D1_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_14A7DF98898E1C3AC10BE31FB3A7589C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_A3EEE010FDD250D6B382133DC0273C7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_14A7DF98898E1C3AC10BE31FB3A7589C_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_A3EEE010FDD250D6B382133DC0273C7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_A3EEE010FDD250D6B382133DC0273C7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_A3EEE010FDD250D6B382133DC0273C7A" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_A3EEE010FDD250D6B382133DC0273C7A" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6_label_en-US" xlink:label="lab_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="lab_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_608EB5BB19E908986CCB237BC4E0E89B_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_608EB5BB19E908986CCB237BC4E0E89B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_608EB5BB19E908986CCB237BC4E0E89B_label_en-US" xlink:label="lab_dei_EntityRegistrantName_608EB5BB19E908986CCB237BC4E0E89B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_608EB5BB19E908986CCB237BC4E0E89B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_608EB5BB19E908986CCB237BC4E0E89B" xlink:to="lab_dei_EntityRegistrantName_608EB5BB19E908986CCB237BC4E0E89B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_FA225FE163E0B41075B8237BC4E0988A_terseLabel_en-US" xlink:label="lab_dei_DocumentType_FA225FE163E0B41075B8237BC4E0988A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_FA225FE163E0B41075B8237BC4E0988A_label_en-US" xlink:label="lab_dei_DocumentType_FA225FE163E0B41075B8237BC4E0988A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FA225FE163E0B41075B8237BC4E0988A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_FA225FE163E0B41075B8237BC4E0988A" xlink:to="lab_dei_DocumentType_FA225FE163E0B41075B8237BC4E0988A" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_030206F3569E9E6DB9E0237BC4E06F67_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_030206F3569E9E6DB9E0237BC4E06F67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_030206F3569E9E6DB9E0237BC4E06F67_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_030206F3569E9E6DB9E0237BC4E06F67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_030206F3569E9E6DB9E0237BC4E06F67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_030206F3569E9E6DB9E0237BC4E06F67" xlink:to="lab_dei_CurrentFiscalYearEndDate_030206F3569E9E6DB9E0237BC4E06F67" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5EF714B261701CA679B1237BC4E097D2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_5EF714B261701CA679B1237BC4E097D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_5EF714B261701CA679B1237BC4E097D2_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_5EF714B261701CA679B1237BC4E097D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5EF714B261701CA679B1237BC4E097D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_5EF714B261701CA679B1237BC4E097D2" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_5EF714B261701CA679B1237BC4E097D2" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_BF80A6B989D001C08804237BC4E00D41_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_BF80A6B989D001C08804237BC4E00D41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_BF80A6B989D001C08804237BC4E00D41_label_en-US" xlink:label="lab_dei_AmendmentFlag_BF80A6B989D001C08804237BC4E00D41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_BF80A6B989D001C08804237BC4E00D41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_BF80A6B989D001C08804237BC4E00D41" xlink:to="lab_dei_AmendmentFlag_BF80A6B989D001C08804237BC4E00D41" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_0CAE271CE286E9A09EF7237BC4E143EA_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_0CAE271CE286E9A09EF7237BC4E143EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_0CAE271CE286E9A09EF7237BC4E143EA_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_0CAE271CE286E9A09EF7237BC4E143EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_0CAE271CE286E9A09EF7237BC4E143EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_0CAE271CE286E9A09EF7237BC4E143EA" xlink:to="lab_dei_EntityCentralIndexKey_0CAE271CE286E9A09EF7237BC4E143EA" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_8764FA1B6330042D81B1237BC4E112F5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_8764FA1B6330042D81B1237BC4E112F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_8764FA1B6330042D81B1237BC4E112F5_label_en-US" xlink:label="lab_dei_EntityFilerCategory_8764FA1B6330042D81B1237BC4E112F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8764FA1B6330042D81B1237BC4E112F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_8764FA1B6330042D81B1237BC4E112F5" xlink:to="lab_dei_EntityFilerCategory_8764FA1B6330042D81B1237BC4E112F5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_F53AF02785B4DD824D18237BC4E11E78_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F53AF02785B4DD824D18237BC4E11E78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_F53AF02785B4DD824D18237BC4E11E78_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F53AF02785B4DD824D18237BC4E11E78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F53AF02785B4DD824D18237BC4E11E78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_F53AF02785B4DD824D18237BC4E11E78" xlink:to="lab_dei_DocumentPeriodEndDate_F53AF02785B4DD824D18237BC4E11E78" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_2042CF7539EEF97AAF8D237BC4E1F826_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_2042CF7539EEF97AAF8D237BC4E1F826" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2042CF7539EEF97AAF8D237BC4E1F826_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_2042CF7539EEF97AAF8D237BC4E1F826" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_2042CF7539EEF97AAF8D237BC4E1F826" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_2042CF7539EEF97AAF8D237BC4E1F826" xlink:to="lab_dei_DocumentFiscalYearFocus_2042CF7539EEF97AAF8D237BC4E1F826" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7801B795C7FD099E8F00237BC4E29D30_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_7801B795C7FD099E8F00237BC4E29D30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7801B795C7FD099E8F00237BC4E29D30_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_7801B795C7FD099E8F00237BC4E29D30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7801B795C7FD099E8F00237BC4E29D30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_7801B795C7FD099E8F00237BC4E29D30" xlink:to="lab_dei_DocumentFiscalPeriodFocus_7801B795C7FD099E8F00237BC4E29D30" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_67C9C2EEF577016EAF3F237BC4E218CD_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_67C9C2EEF577016EAF3F237BC4E218CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_67C9C2EEF577016EAF3F237BC4E218CD_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_67C9C2EEF577016EAF3F237BC4E218CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_67C9C2EEF577016EAF3F237BC4E218CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_67C9C2EEF577016EAF3F237BC4E218CD" xlink:to="lab_dei_EntityInteractiveDataCurrent_67C9C2EEF577016EAF3F237BC4E218CD" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3CE10F7DA020D36FE4C7237BC4E23AE4_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_3CE10F7DA020D36FE4C7237BC4E23AE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3CE10F7DA020D36FE4C7237BC4E23AE4_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_3CE10F7DA020D36FE4C7237BC4E23AE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_3CE10F7DA020D36FE4C7237BC4E23AE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_3CE10F7DA020D36FE4C7237BC4E23AE4" xlink:to="lab_dei_EntityEmergingGrowthCompany_3CE10F7DA020D36FE4C7237BC4E23AE4" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_0F70E48AF6742913EEC5237BC4E266ED_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_0F70E48AF6742913EEC5237BC4E266ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_0F70E48AF6742913EEC5237BC4E266ED_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_0F70E48AF6742913EEC5237BC4E266ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_0F70E48AF6742913EEC5237BC4E266ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_0F70E48AF6742913EEC5237BC4E266ED" xlink:to="lab_dei_EntitySmallBusiness_0F70E48AF6742913EEC5237BC4E266ED" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_35C1B723E6C26CE6A8CB237BC4E241CB_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_35C1B723E6C26CE6A8CB237BC4E241CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_35C1B723E6C26CE6A8CB237BC4E241CB_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_35C1B723E6C26CE6A8CB237BC4E241CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_35C1B723E6C26CE6A8CB237BC4E241CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_35C1B723E6C26CE6A8CB237BC4E241CB" xlink:to="lab_dei_EntityExTransitionPeriod_35C1B723E6C26CE6A8CB237BC4E241CB" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_E3818812222BE86AB15C237BC4E309EB_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E3818812222BE86AB15C237BC4E309EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_E3818812222BE86AB15C237BC4E309EB_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_E3818812222BE86AB15C237BC4E309EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E3818812222BE86AB15C237BC4E309EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_E3818812222BE86AB15C237BC4E309EB" xlink:to="lab_dei_EntityCurrentReportingStatus_E3818812222BE86AB15C237BC4E309EB" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_7AE58DAF64B82E819D6A237BC4E39DB3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_7AE58DAF64B82E819D6A237BC4E39DB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_7AE58DAF64B82E819D6A237BC4E39DB3_label_en-US" xlink:label="lab_dei_EntityShellCompany_7AE58DAF64B82E819D6A237BC4E39DB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_7AE58DAF64B82E819D6A237BC4E39DB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_7AE58DAF64B82E819D6A237BC4E39DB3" xlink:to="lab_dei_EntityShellCompany_7AE58DAF64B82E819D6A237BC4E39DB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3E9851A7D6FE10CA3481DDD3967FB2D9_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_A06697091500534B818837EC5A8A9E71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A06697091500534B818837EC5A8A9E71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A06697091500534B818837EC5A8A9E71" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_A06697091500534B818837EC5A8A9E71" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_A3F8F5E002B672CAE48CDDD3967F34C6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_A2C43A8ADE895F359DE59DB4CDF35D46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_A3F8F5E002B672CAE48CDDD3967F34C6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_A2C43A8ADE895F359DE59DB4CDF35D46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_A2C43A8ADE895F359DE59DB4CDF35D46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_A2C43A8ADE895F359DE59DB4CDF35D46" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_A2C43A8ADE895F359DE59DB4CDF35D46" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0AFF7425CCDC46EF981153D93D217064_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0AFF7425CCDC46EF981153D93D217064_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1F6E6DFF479AA52B229F53D93D243455_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_A2E0368DBBE657689CA98DE1A65E7C30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1F6E6DFF479AA52B229F53D93D243455_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_A2E0368DBBE657689CA98DE1A65E7C30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A2E0368DBBE657689CA98DE1A65E7C30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A2E0368DBBE657689CA98DE1A65E7C30" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_A2E0368DBBE657689CA98DE1A65E7C30" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CCFD759BFC8E6B68503053D93D24F1E9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_CCFD759BFC8E6B68503053D93D24F1E9_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C74BDDA494886A7CB45553D93D25CAA0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D190269E15D556BDA7C9994844602801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_C74BDDA494886A7CB45553D93D25CAA0_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D190269E15D556BDA7C9994844602801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D190269E15D556BDA7C9994844602801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D190269E15D556BDA7C9994844602801" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D190269E15D556BDA7C9994844602801" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_C60F134DD8E419142F44DDD3967DB3F3_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_5B71E171533A5331A13E1DC11F55BCF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_C60F134DD8E419142F44DDD3967DB3F3_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_5B71E171533A5331A13E1DC11F55BCF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_5B71E171533A5331A13E1DC11F55BCF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_5B71E171533A5331A13E1DC11F55BCF4" xlink:to="lab_us-gaap_NatureOfOperations_5B71E171533A5331A13E1DC11F55BCF4" xlink:type="arc" />
    <link:label id="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB_terseLabel_en-US" xlink:label="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB_label_en-US" xlink:label="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense Current</link:label>
    <link:label id="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB_documentation_en-US" xlink:label="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued research and development expense, current.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB" xlink:to="lab_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB" xlink:type="arc" />
    <link:label id="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6_terseLabel_en-US" xlink:label="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and related benefits</link:label>
    <link:label id="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6_label_en-US" xlink:label="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Compensation And Related Benefits Current</link:label>
    <link:label id="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6_documentation_en-US" xlink:label="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued liabilities and employee related benefits current.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedCompensationAndRelatedBenefitsCurrent" xlink:label="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6" xlink:to="lab_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6" xlink:type="arc" />
    <link:label id="lab_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8_terseLabel_en-US" xlink:label="lab_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued property and equipment</link:label>
    <link:label id="lab_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8_label_en-US" xlink:label="lab_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Property And Equipment</link:label>
    <link:label id="lab_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8_documentation_en-US" xlink:label="lab_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Property And Equipment</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedPropertyAndEquipment" xlink:label="loc_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8" xlink:to="lab_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8" xlink:type="arc" />
    <link:label id="lab_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F_terseLabel_en-US" xlink:label="lab_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested shares liabilities</link:label>
    <link:label id="lab_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F_label_en-US" xlink:label="lab_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested Shares Liabilities Current</link:label>
    <link:label id="lab_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F_documentation_en-US" xlink:label="lab_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unvested shares liabilities, current.</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_UnvestedSharesLiabilitiesCurrent" xlink:label="loc_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F" xlink:to="lab_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9E9C117FE89AF6F0D23314D38EF86F3E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_9E9C117FE89AF6F0D23314D38EF86F3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9E9C117FE89AF6F0D23314D38EF86F3E_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_9E9C117FE89AF6F0D23314D38EF86F3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9E9C117FE89AF6F0D23314D38EF86F3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_9E9C117FE89AF6F0D23314D38EF86F3E" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_9E9C117FE89AF6F0D23314D38EF86F3E" xlink:type="arc" />
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_E48D0A5531FE442C7CC314D38EF85A55_totalLabel_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent_E48D0A5531FE442C7CC314D38EF85A55" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued and other current liabilities</link:label>
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherLiabilitiesCurrent" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_E48D0A5531FE442C7CC314D38EF85A55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent_E48D0A5531FE442C7CC314D38EF85A55" xlink:to="lab_allo_AccruedAndOtherLiabilitiesCurrent_E48D0A5531FE442C7CC314D38EF85A55" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0F61B2A097D169EA41A9DDD3967A3EFC_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_FBA99D6D65F159A991B690A50D4ABECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0F61B2A097D169EA41A9DDD3967A3EFC_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_FBA99D6D65F159A991B690A50D4ABECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_FBA99D6D65F159A991B690A50D4ABECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_FBA99D6D65F159A991B690A50D4ABECF" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_FBA99D6D65F159A991B690A50D4ABECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:to="lab_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="lab_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_78E3565F0C230BAC2B7427760C695213_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_78E3565F0C230BAC2B7427760C695213" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_78E3565F0C230BAC2B7427760C695213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_78E3565F0C230BAC2B7427760C695213" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_78E3565F0C230BAC2B7427760C695213" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion settlement price as a percentage of IPO price per share</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194" xlink:to="lab_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of convertible notes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>allo-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponents" xlink:href="allo-20190930.xsd#BalanceSheetsComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsAccruedLiabilitiesDetails" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsPropertyAndEquipmentDetails" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:href="allo-20190930.xsd#BalanceSheetsComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheets" xlink:href="allo-20190930.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:href="allo-20190930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementOfCashFlows" xlink:href="allo-20190930.xsd#CondensedStatementOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementOfStockholdersEquityDeficit" xlink:href="allo-20190930.xsd#CondensedStatementOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:href="allo-20190930.xsd#CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CondensedStatementsOfStockholdersEquityDeficitParenthetical" xlink:href="allo-20190930.xsd#CondensedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:href="allo-20190930.xsd#ConvertibleNotesPayable2018NotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2018NotesTables" xlink:href="allo-20190930.xsd#ConvertibleNotesPayable2018NotesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/ConvertibleNotesPayable2019Notes" xlink:href="allo-20190930.xsd#ConvertibleNotesPayable2019Notes" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:href="allo-20190930.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/DescriptionOfBusiness" xlink:href="allo-20190930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/DescriptionOfBusinessDetails" xlink:href="allo-20190930.xsd#DescriptionOfBusinessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:href="allo-20190930.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:href="allo-20190930.xsd#FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail" xlink:href="allo-20190930.xsd#FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:href="allo-20190930.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstruments" xlink:href="allo-20190930.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:href="allo-20190930.xsd#FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails" xlink:href="allo-20190930.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsTables" xlink:href="allo-20190930.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:href="allo-20190930.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/Leases" xlink:href="allo-20190930.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:href="allo-20190930.xsd#LeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LeasesTables" xlink:href="allo-20190930.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetails" xlink:href="allo-20190930.xsd#LeasesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreements" xlink:href="allo-20190930.xsd#LicenseAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreementsDetails" xlink:href="allo-20190930.xsd#LicenseAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShare" xlink:href="allo-20190930.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:href="allo-20190930.xsd#NetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareTables" xlink:href="allo-20190930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:href="allo-20190930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:href="allo-20190930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:href="allo-20190930.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="allo-20190930.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:href="allo-20190930.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:href="allo-20190930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEventsDetails" xlink:href="allo-20190930.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="allo-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://allogene.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="allo-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetsComponents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23A4CB4586615786A376B498D81B38DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_CBAA2B0491E15A8BBB0CBA2B3ED30F20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_23A4CB4586615786A376B498D81B38DF" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_CBAA2B0491E15A8BBB0CBA2B3ED30F20" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F7BD8B813E12FB6972814D38EF7532D" xlink:type="locator" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F7BD8B813E12FB6972814D38EF7532D" xlink:to="loc_allo_AccruedResearchAndDevelopmentExpenseCurrent_40FDCF43762E3772382C14D38EF86DCB" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedCompensationAndRelatedBenefitsCurrent" xlink:label="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F7BD8B813E12FB6972814D38EF7532D" xlink:to="loc_allo_AccruedCompensationAndRelatedBenefitsCurrent_1BA951A3B50DC9640DE714D38EF8C8E6" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedPropertyAndEquipment" xlink:label="loc_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F7BD8B813E12FB6972814D38EF7532D" xlink:to="loc_allo_AccruedPropertyAndEquipment_4D4EAA6B799A4D99D1A81501480BD9D8" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_UnvestedSharesLiabilitiesCurrent" xlink:label="loc_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F7BD8B813E12FB6972814D38EF7532D" xlink:to="loc_allo_UnvestedSharesLiabilitiesCurrent_15D9F92DE87B0C398B0714D38EF8965F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9E9C117FE89AF6F0D23314D38EF86F3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F7BD8B813E12FB6972814D38EF7532D" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9E9C117FE89AF6F0D23314D38EF86F3E" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherLiabilitiesCurrent" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_E48D0A5531FE442C7CC314D38EF85A55" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F7BD8B813E12FB6972814D38EF7532D" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_E48D0A5531FE442C7CC314D38EF85A55" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59A7BA2D966312FDD9A823C4C833B422" xlink:type="locator" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PrepaidResearchAndDevelopmentExpensesCurrent" xlink:label="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59A7BA2D966312FDD9A823C4C833B422" xlink:to="loc_allo_PrepaidResearchAndDevelopmentExpensesCurrent_F778504FCDE0076F058C23C4C8330359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedInvestmentIncomeReceivable" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_5B53B49BF6E9A1EC1C6223C4C8339300" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59A7BA2D966312FDD9A823C4C833B422" xlink:to="loc_us-gaap_AccruedInvestmentIncomeReceivable_5B53B49BF6E9A1EC1C6223C4C8339300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_0A4D702E3ECB93E6AFE123C4C83455B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59A7BA2D966312FDD9A823C4C833B422" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_0A4D702E3ECB93E6AFE123C4C83455B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_087CFA1CEF3225C320F323C4C83448D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59A7BA2D966312FDD9A823C4C833B422" xlink:to="loc_us-gaap_PrepaidInsurance_087CFA1CEF3225C320F323C4C83448D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D61A82F134F32B0ADEAF23C4C834107E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_59A7BA2D966312FDD9A823C4C833B422" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_D61A82F134F32B0ADEAF23C4C834107E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8916168367F50CEB09EB14D38F069763" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8916168367F50CEB09EB14D38F069763" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_B32BFD52A9B7E541DF4D14D38F06FBA7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8FD3FD2642EABA229B2114D38F075619" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LaboratoryEquipmentMember" xlink:label="loc_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="loc_allo_LaboratoryEquipmentMember_85C32DD42EE19C3468E014D38F07D2F2" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_18CA06EF32BE8400212414D38F07CDD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_11C1F7FB99D57DB8364D14D38F0725FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3351068414032F906E9F14D38F0734FE" xlink:to="loc_us-gaap_ConstructionInProgressMember_CAF7129DECF2B5FE414114D38F0805B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7BDD17035E44651E7AB314D38F061BA5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6D6319B9E6CA6DB70AF914D38F084E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1AA0621C6FFC7771774814D38F089672" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D8E5CC3073415989C81B14D38F083E73" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_E791AF67F28E953B205414D38F08BF80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_D8E5CC3073415989C81B14D38F083E73" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetsComponentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4D3F3133FFF15FC986EA61C1443BD508" xlink:type="locator" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_ED4644408470550BBD6337F1D618E3D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4D3F3133FFF15FC986EA61C1443BD508" xlink:to="loc_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock_ED4644408470550BBD6337F1D618E3D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_19610F22707C5B9880E0DE68D3916CE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4D3F3133FFF15FC986EA61C1443BD508" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_19610F22707C5B9880E0DE68D3916CE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_09938952C2F35F779ED94B08D19E9D6B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4D3F3133FFF15FC986EA61C1443BD508" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_09938952C2F35F779ED94B08D19E9D6B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_FDC1960ADDF2233C8563FAB58169192F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FDC1960ADDF2233C8563FAB58169192F" xlink:to="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3B374598310DC2F6BBF5FAB5816AD2C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3B374598310DC2F6BBF5FAB5816AD2C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_B31F3FDE886C68C87E39FAB5816AE055" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:to="loc_us-gaap_ShortTermInvestments_B31F3FDE886C68C87E39FAB5816AE055" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1456F83F0EF62AFC8035FAB5816AB04F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1456F83F0EF62AFC8035FAB5816AB04F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_2456C6CFF4DAB1F64D24FAB5816B97D8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_067E3CE39B815396C749FAB5816AE295" xlink:to="loc_us-gaap_AssetsCurrent_2456C6CFF4DAB1F64D24FAB5816B97D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_309B157C6F97E37E1AA4FAB5816BBA02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:to="loc_us-gaap_LongTermInvestments_309B157C6F97E37E1AA4FAB5816BBA02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_A8651471CA68DB38F89AFAB5816B1A37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_A8651471CA68DB38F89AFAB5816B1A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_596D78F576886BF4145BFAB5816B774B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_596D78F576886BF4145BFAB5816B774B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6CDC2DBDC102C2A21F40FAB5816B15CE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6CDC2DBDC102C2A21F40FAB5816B15CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_C655568AA560B5DB3768FAB5816B8A3F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_C655568AA560B5DB3768FAB5816B8A3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7F5477FF48C4429FBE62FAB5816C5D06" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7F5477FF48C4429FBE62FAB5816C5D06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F79A668B7C4C6D469AA7FAB5816CC15E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_181DA442FF42053B680CFAB58169B5E0" xlink:to="loc_us-gaap_Assets_F79A668B7C4C6D469AA7FAB5816CC15E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_FDC1960ADDF2233C8563FAB58169192F" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_50B2D1A1C2B356182D2EFAB5816CDFE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA" xlink:to="loc_us-gaap_AccountsPayableCurrent_50B2D1A1C2B356182D2EFAB5816CDFE0" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherLiabilitiesCurrent" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_82F975CC66D214AA62AEFAB5816D147A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_82F975CC66D214AA62AEFAB5816D147A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_96B26977F3C04978AAAFFAB5816DFF90" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECD9DC519BD63D1A6594FAB5816C2EEA" xlink:to="loc_us-gaap_LiabilitiesCurrent_96B26977F3C04978AAAFFAB5816DFF90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9D6D3A837B984A4B2E81FAB5816DC729" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9D6D3A837B984A4B2E81FAB5816DC729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_75CEB9CBEA391FB5F7AEFAB5816D07A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_75CEB9CBEA391FB5F7AEFAB5816D07A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_96D9AB852087FDBB71F7FAB5816D6052" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:to="loc_us-gaap_Liabilities_96D9AB852087FDBB71F7FAB5816D6052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_782C553E8120C0D62702FAB5816D669F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:to="loc_us-gaap_CommitmentsAndContingencies_782C553E8120C0D62702FAB5816D669F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_60E2CDF1A426938FB7E7FAB5816E7BD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:to="loc_us-gaap_PreferredStockValue_60E2CDF1A426938FB7E7FAB5816E7BD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F282B597553914784B32FAB5816EE151" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:to="loc_us-gaap_CommonStockValue_F282B597553914784B32FAB5816EE151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_CC30DEE4343A2318CEF4FAB5816E9F62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_CC30DEE4343A2318CEF4FAB5816E9F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BF80411A463425A18254FAB5816F495A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BF80411A463425A18254FAB5816F495A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1C4EBBBC5A32B56BA6CFAB5816FC361" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_D1C4EBBBC5A32B56BA6CFAB5816FC361" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_0C281CA316DF75482DCBFAB5816F2AC3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3D658BBB1A699420449BFAB5816E9359" xlink:to="loc_us-gaap_StockholdersEquity_0C281CA316DF75482DCBFAB5816F2AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7E7688F25AECE146C973FAB5816F4557" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5E782543E12C0BCE080FFAB5816CD68E" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_7E7688F25AECE146C973FAB5816F4557" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6D7872D351825A54A1DE8B809144C3C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6D7872D351825A54A1DE8B809144C3C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_835FAFBACBC25FE693ACE84C4D535A3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_835FAFBACBC25FE693ACE84C4D535A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_99942F970145587DBC4790230F7C152B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:to="loc_us-gaap_PreferredStockSharesIssued_99942F970145587DBC4790230F7C152B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5CFC8EC7774559E0873D2E3C382BB9B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5CFC8EC7774559E0873D2E3C382BB9B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_D9ABD15ED3A150E3B9281F7D60E15AA9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_D9ABD15ED3A150E3B9281F7D60E15AA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_E7BFE168728F5FDFB33D0CF9AB7AA75D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_E7BFE168728F5FDFB33D0CF9AB7AA75D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_372DB7BC6F565FAF97D40B931119B72B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:to="loc_us-gaap_CommonStockSharesIssued_372DB7BC6F565FAF97D40B931119B72B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8CDBCBE55E875B5FAAC78F025D0370E5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C6FAC220FD945F5DAB09B6E7B1718125" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8CDBCBE55E875B5FAAC78F025D0370E5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedStatementOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_286EE9191E76F56A88A827760DCEAAF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:to="loc_us-gaap_ProfitLoss_286EE9191E76F56A88A827760DCEAAF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_BBD2B94E2A58A4CD6CFF27760DCE2AC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_BBD2B94E2A58A4CD6CFF27760DCE2AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_EE7AABD9F87ADC78F22C27760DCE5FA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:to="loc_us-gaap_ShareBasedCompensation_EE7AABD9F87ADC78F22C27760DCE5FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_FD6761703399DEFA697D27760DCE43C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_FD6761703399DEFA697D27760DCE43C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_16E7BBA201050D0BF4CB27760DCE0B89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:to="loc_us-gaap_DepreciationAndAmortization_16E7BBA201050D0BF4CB27760DCE0B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_95917AA973119605848327760DCEA281" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_95917AA973119605848327760DCEA281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_C77FB271CD3A110A18AF27760DCE8C26" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:to="loc_us-gaap_LeaseAndRentalExpense_C77FB271CD3A110A18AF27760DCE8C26" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ChangeInFairValueOfConvertibleNotePayable" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable_54AEE73794DE34ED6FD027760DCE1E96" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:to="loc_allo_ChangeInFairValueOfConvertibleNotePayable_54AEE73794DE34ED6FD027760DCE1E96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4397BA8B681F9A5781B727760DCEEC04" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4397BA8B681F9A5781B727760DCEEC04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_737761AA491351F5B07B27760DCEB930" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7056AF216C702405BA5327760DCE68E6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_737761AA491351F5B07B27760DCEB930" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09258D0A376A34458FBC27760DCEEB63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_09258D0A376A34458FBC27760DCEEB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_F1938BE259A5034A182827760DCE0E35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_F1938BE259A5034A182827760DCE0E35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6D3DDE085D2B8371C09127760DCE8AC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6D3DDE085D2B8371C09127760DCE8AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3AF3FEE1DC6ABBB431DE27760DD2C53F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3AF3FEE1DC6ABBB431DE27760DD2C53F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_977F2F068C972467865827760DD2DA6A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_AF8358DEDCD3D77BCA9B27760DCEBEB3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_977F2F068C972467865827760DD2DA6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1CDCA940531970B645DE27760DD21054" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_E96AF916F201C29E4B9727760DCE7522" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1CDCA940531970B645DE27760DD21054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A8A61E0FCE127CDB7AFF27760DD275A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_A8A61E0FCE127CDB7AFF27760DD275A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:label="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities_8A7F5D31188D7351EB9827760DD2ADED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:to="loc_us-gaap_PaymentsToAcquireAssetsInvestingActivities_8A7F5D31188D7351EB9827760DD2ADED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4544A27400F0AA4404E727760DD29BDB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_4544A27400F0AA4404E727760DD29BDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_A4315702808E3F52489927760E01DBC9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_A4315702808E3F52489927760E01DBC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F1AFF0C270A5FA7081D827760E018A3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_C7E257319AE637CDEF2527760DD21C11" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_F1AFF0C270A5FA7081D827760E018A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_6CB3E38F1FEFE2EC81FB27760E01B5CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_6CB3E38F1FEFE2EC81FB27760E01B5CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_33EA8E1AF926613403B627760E01B039" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_33EA8E1AF926613403B627760E01B039" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions" xlink:label="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:to="loc_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions_F50486DC9F5B6BE06FE727760E0502BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_A59ED03F8C5F534FD66A27760E050255" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_A59ED03F8C5F534FD66A27760E050255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C4AC83F12AE1D262AEC827760E05DF3E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_C4AC83F12AE1D262AEC827760E05DF3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_6DE767C7AB15AED7A3C727760E0540C2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:to="loc_us-gaap_ProceedsFromStockPlans_6DE767C7AB15AED7A3C727760E0540C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_A7FC0EBC9B4BF932783C27760E053B34" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_341DB2F5C226920D6F8227760E010847" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_A7FC0EBC9B4BF932783C27760E053B34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5113375C5E56FBE065E527760E0591E8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5113375C5E56FBE065E527760E0591E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58B2D74681A74547CD6F27760E05631A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58B2D74681A74547CD6F27760E05631A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08A1501AEAA79DBD32E727760E056DCB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_08A1501AEAA79DBD32E727760E056DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E81FA32F7592C78494D127760E054C52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_E81FA32F7592C78494D127760E054C52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5DAD85821D19C803332027760E05C8C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5DAD85821D19C803332027760E05C8C6" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ConvertiblePreferredStockIssuedInAssetAcquisition" xlink:label="loc_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:to="loc_allo_ConvertiblePreferredStockIssuedInAssetAcquisition_AD7D59530250611EABF927760E058A28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2AB7B35176D09E6D891F27760E05A0CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_AF74299F22DDD4DAEAFB27760E0565E1" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2AB7B35176D09E6D891F27760E05A0CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_048AEFA90EE6A0E16E9F27760DCECEDE" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_6782EF2AAD690491FEBF27760E056513" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D" xlink:to="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_6782EF2AAD690491FEBF27760E056513" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances" xlink:label="loc_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_1CDED787D2133D111D0F27760E05004D" xlink:to="loc_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances_3A6491A927A0DCFCDF4127760E050043" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedStatementOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4BF5205827BB01791F5D27760E1C3876" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4BF5205827BB01791F5D27760E1C3876" xlink:to="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_FF801711548031CD178E27760E1C78FA" xlink:to="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SeriesAConvertiblePreferredStockMember" xlink:label="loc_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:to="loc_allo_SeriesAConvertiblePreferredStockMember_8CCCE2C217354896AAD227760E1C8D64" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember" xlink:label="loc_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_F00570ADACCCD3FF802D27760E1CE6CC" xlink:to="loc_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_EC21339BE916DB00AD7027760E1CAE0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1179732F428624C0E49227760E1C32D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1179732F428624C0E49227760E1C32D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1179732F428624C0E49227760E1C32D9" xlink:to="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_PreferredStockMember_A6C6E7C6E27AE0FDDD4527760E1C4321" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SubscriptionReceivableFromPreferredStockholdersMember" xlink:label="loc_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_allo_SubscriptionReceivableFromPreferredStockholdersMember_6D5C940E92E2E4E8044827760E1C8311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_AF27FC392B722B332DC027760E1C273B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_CommonStockMember_AF27FC392B722B332DC027760E1C273B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="loc_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_ReceivablesFromStockholderMember_7E6850E3F2C061F918D127760E1C478F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_93C4FB5BFEB10D42DAA827760E1CCB1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_RetainedEarningsMember_5CA86189AC187DEE8FAC27760E1C4F25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F2B0E202ABBBB518F87F27760E1C34E8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7BB1F5D3D1DEABD726D227760E207A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38BC350DEAFA77BC701127760E1CD90B" xlink:to="loc_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_717DF9FEAD349316695027760E20FE42" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_EAB772ABD85E205DF70127760E206380" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_EAB772ABD85E205DF70127760E206380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_30774CF4174B21A7C3E827760E2064BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_30774CF4174B21A7C3E827760E2064BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_495A95AC40225B718EDE27760E2038EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_495A95AC40225B718EDE27760E2038EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockholdersEquity_6DB1A693ECEA504FFBAB27760E2032BA" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0132772F33735F239EFB27760E207D50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_14329249E59CE2D6949227760E20CA8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_40D09897E7A01F98313727760E20248F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_062799ADC54DFEE141D527760E20C06D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SubscriptionsReceivableFromPreferredStockholders" xlink:label="loc_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_allo_SubscriptionsReceivableFromPreferredStockholders_462776C4A5BD177DF78B27760E20126F" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_StockIssuedDuringPeriodValueCommonStockIssues" xlink:label="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_allo_StockIssuedDuringPeriodValueCommonStockIssues_1DB5B162BB25C139E9D727760E202E67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D5B2AD1483DA9CC0E87927760E20ED13" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_D5B2AD1483DA9CC0E87927760E20ED13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_950C7CE5FBE427FF3D6827760E20A90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9E0B86AA96932FC1F7E627760E202AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_CC80FB3681372A67D23327760E208281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_042923812CB57F5E1C2B27760E209D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_B81C96CAF2E2631B642727760E20DF09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_A3E0427AB74BA32E61F427760E20E8DB" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_A3E0427AB74BA32E61F427760E20E8DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_59610CAD707B1C9C78B527760E20792C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_21C744E52FD40B46B66E27760E242738" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_21C744E52FD40B46B66E27760E242738" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_D003F42948AAC0061C6927760E24BB8F" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_D003F42948AAC0061C6927760E24BB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_49AEE2141524266A9D5527760E24D843" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_StockholdersEquity_49AEE2141524266A9D5527760E24D843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8EEB90D88E5F1CB0508727760E243E5E" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8EEB90D88E5F1CB0508727760E243E5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_65C3363054678EA983A927760E24154A" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_09EBEA877B3670D28AF427760E203E9B" xlink:to="loc_us-gaap_NetIncomeLoss_65C3363054678EA983A927760E24154A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_832E56E5943093D7B56118985CAEE821" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_832E56E5943093D7B56118985CAEE821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_A91E68487AB885EB9EB618985CAF10F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_A91E68487AB885EB9EB618985CAF10F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_CDD435DD81731A51FB5718985CAF1272" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_B7BFB093E2BB955A7DC318985CAED23D" xlink:to="loc_us-gaap_OperatingExpenses_CDD435DD81731A51FB5718985CAF1272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D77320CA8950EB98C4A218985CAFE0C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_us-gaap_OperatingIncomeLoss_D77320CA8950EB98C4A218985CAFE0C9" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ChangeInFairValueOfConvertibleNotePayable" xlink:label="loc_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_allo_ChangeInFairValueOfConvertibleNotePayable_E6432ECDAEF41517232118985CAFCF5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_EBF440A81C0433A993EB18985CAFF2A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_us-gaap_InterestExpense_EBF440A81C0433A993EB18985CAFF2A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_E4A578963D7A7EDE967118985CAF7E66" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_E4A578963D7A7EDE967118985CAF7E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213D49C8D02F0D875D4518985CAF720C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_213D49C8D02F0D875D4518985CAF720C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_BEEE56ED939E63A9495518985CB089BD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_BEEE56ED939E63A9495518985CB089BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3D5B1CFC2A8B634C75AD18985CB05AC7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_us-gaap_NetIncomeLoss_3D5B1CFC2A8B634C75AD18985CB05AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3C3442D37044CB4B1FEA18985CB042C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3C3442D37044CB4B1FEA18985CB042C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_BBEFA984728084E003E518985CB0D09E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9FFE1492B9ABD0091ABD18985CB0E11D" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_BBEFA984728084E003E518985CB0D09E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_AAC1580B3BB1C7402D8D18985CB125BE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_AAC1580B3BB1C7402D8D18985CB125BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_27B645E0AAF4865CD32718985CB1C1E8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_1F11A4484D377966875A18985CAE1F75" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_27B645E0AAF4865CD32718985CB1C1E8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_DF1170BD618FB7DA000323C4C925A3D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B9D544C9C677630F752423C4C925C117" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_DF1170BD618FB7DA000323C4C925A3D6" xlink:to="loc_us-gaap_StatementTable_B9D544C9C677630F752423C4C925C117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_D92CF2E49971CBE4A45423C4C925DB7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B9D544C9C677630F752423C4C925C117" xlink:to="loc_us-gaap_StatementClassOfStockAxis_D92CF2E49971CBE4A45423C4C925DB7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_9BE7E07687E7C5AA847023C4C925BF69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_D92CF2E49971CBE4A45423C4C925DB7F" xlink:to="loc_us-gaap_ClassOfStockDomain_9BE7E07687E7C5AA847023C4C925BF69" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SeriesAConvertiblePreferredStockMember" xlink:label="loc_allo_SeriesAConvertiblePreferredStockMember_C56E7E03BE2E1E69AB9823C4C926D51D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9BE7E07687E7C5AA847023C4C925BF69" xlink:to="loc_allo_SeriesAConvertiblePreferredStockMember_C56E7E03BE2E1E69AB9823C4C926D51D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember" xlink:label="loc_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_D1A3FA3E2FE8CFACA76F23C4C9264E6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9BE7E07687E7C5AA847023C4C925BF69" xlink:to="loc_allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember_D1A3FA3E2FE8CFACA76F23C4C9264E6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_BCBDDC057144B7868D7C23C4C926BA12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B9D544C9C677630F752423C4C925C117" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_BCBDDC057144B7868D7C23C4C926BA12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_166807528C3529B68FF523C4C9265509" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_BCBDDC057144B7868D7C23C4C926BA12" xlink:to="loc_us-gaap_EquityComponentDomain_166807528C3529B68FF523C4C9265509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_2A8EE108E6B69936EAFB23C4C92CF700" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_166807528C3529B68FF523C4C9265509" xlink:to="loc_us-gaap_PreferredStockMember_2A8EE108E6B69936EAFB23C4C92CF700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_7B9B925D679D5BCDC87123C4C92CFA80" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B9D544C9C677630F752423C4C925C117" xlink:to="loc_us-gaap_StatementLineItems_7B9B925D679D5BCDC87123C4C92CFA80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DD542F9F4C7D1B05BE4923C4C92C8A1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7B9B925D679D5BCDC87123C4C92CFA80" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_DD542F9F4C7D1B05BE4923C4C92C8A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_367FD26B7E05147D32A223C4C92D742F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7B9B925D679D5BCDC87123C4C92CFA80" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_367FD26B7E05147D32A223C4C92D742F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4BB5BCE5D87D8971A61227760C68D735" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4BB5BCE5D87D8971A61227760C68D735" xlink:to="loc_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9F4C044112FF292F732F27760C69FEE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:to="loc_srt_RangeAxis_9F4C044112FF292F732F27760C69FEE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_813DFBEC83F1B569DDE127760C692C2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9F4C044112FF292F732F27760C69FEE1" xlink:to="loc_srt_RangeMember_813DFBEC83F1B569DDE127760C692C2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_DE57033657BD64F66DC027760C699BA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_813DFBEC83F1B569DDE127760C692C2E" xlink:to="loc_srt_MinimumMember_DE57033657BD64F66DC027760C699BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_743139B516E854C6C9E027760C69E665" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_813DFBEC83F1B569DDE127760C692C2E" xlink:to="loc_srt_MaximumMember_743139B516E854C6C9E027760C69E665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D333643EC36E8BCA624D27760C68B894" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_679D1E19FB4CDED4C3F127760C695A0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_78E3565F0C230BAC2B7427760C695213" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_78E3565F0C230BAC2B7427760C695213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_69CD86E51EC3FB90041F27760C6990CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_69CD86E51EC3FB90041F27760C6990CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentRate_960A0C6D38B85586EE4327760C69A0C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_LongTermDebtFairValue_31B4D2CCDEF6EDEF3DD927760C690194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_6539BF4802A16160C1A727760C6994FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2EBDE4F57EE8AB51D10A27760C69FF7A" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_B1DE1893A4B45600F04227760C697B84" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2018NotesTables" xlink:type="extended" />
  <link:presentationLink xlink:role="http://allogene.com/role/ConvertibleNotesPayable2019Notes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_67DF94638A5C86C44E4E241B37ECFC4F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_D9D3A760453066FC637B241BBE88E3D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_67DF94638A5C86C44E4E241B37ECFC4F" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_D9D3A760453066FC637B241BBE88E3D2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_608EB5BB19E908986CCB237BC4E0E89B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_EntityRegistrantName_608EB5BB19E908986CCB237BC4E0E89B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_FA225FE163E0B41075B8237BC4E0988A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_DocumentType_FA225FE163E0B41075B8237BC4E0988A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_030206F3569E9E6DB9E0237BC4E06F67" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_CurrentFiscalYearEndDate_030206F3569E9E6DB9E0237BC4E06F67" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5EF714B261701CA679B1237BC4E097D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5EF714B261701CA679B1237BC4E097D2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_BF80A6B989D001C08804237BC4E00D41" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_AmendmentFlag_BF80A6B989D001C08804237BC4E00D41" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_0CAE271CE286E9A09EF7237BC4E143EA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_EntityCentralIndexKey_0CAE271CE286E9A09EF7237BC4E143EA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8764FA1B6330042D81B1237BC4E112F5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_EntityFilerCategory_8764FA1B6330042D81B1237BC4E112F5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F53AF02785B4DD824D18237BC4E11E78" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_DocumentPeriodEndDate_F53AF02785B4DD824D18237BC4E11E78" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_2042CF7539EEF97AAF8D237BC4E1F826" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_DocumentFiscalYearFocus_2042CF7539EEF97AAF8D237BC4E1F826" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7801B795C7FD099E8F00237BC4E29D30" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7801B795C7FD099E8F00237BC4E29D30" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_67C9C2EEF577016EAF3F237BC4E218CD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_EntityInteractiveDataCurrent_67C9C2EEF577016EAF3F237BC4E218CD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_3CE10F7DA020D36FE4C7237BC4E23AE4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_EntityEmergingGrowthCompany_3CE10F7DA020D36FE4C7237BC4E23AE4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_0F70E48AF6742913EEC5237BC4E266ED" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_EntitySmallBusiness_0F70E48AF6742913EEC5237BC4E266ED" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_35C1B723E6C26CE6A8CB237BC4E241CB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_EntityExTransitionPeriod_35C1B723E6C26CE6A8CB237BC4E241CB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_E3818812222BE86AB15C237BC4E309EB" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_EntityCurrentReportingStatus_E3818812222BE86AB15C237BC4E309EB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_7AE58DAF64B82E819D6A237BC4E39DB3" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1604EE6AA9C51781A02237BC4DF71C6" xlink:to="loc_dei_EntityShellCompany_7AE58DAF64B82E819D6A237BC4E39DB3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27478C9CD92751F6ABC38D54D939036C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_5B71E171533A5331A13E1DC11F55BCF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27478C9CD92751F6ABC38D54D939036C" xlink:to="loc_us-gaap_NatureOfOperations_5B71E171533A5331A13E1DC11F55BCF4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B565B1751537EFB71EFB2774EFB5E22E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B565B1751537EFB71EFB2774EFB5E22E" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A7A6623DA6A32FFBF60B2774EFB5B298" xlink:to="loc_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14E359FBF5DB9B0EA1072774EFB680D8" xlink:to="loc_us-gaap_CommonStockMember_05745D8564B5C5D6373E2774EFB63169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0C91EB14FE64B246501E2774EFB6130F" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:to="loc_us-gaap_IPOMember_A60F6B4FB1CF62C8825E2774EFB76A85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5732D45AEC55B7052CB52774EFB718C3" xlink:to="loc_us-gaap_OverAllotmentOptionMember_7869B680561BA05A0EE52774EFB74FFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:to="loc_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_DB4D53C89200ABC758A82774EFB745E5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ConvertiblePromissoryNotesMember" xlink:label="loc_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_C65F1EB0E1AAFBC88FA22774EFB7C0DC" xlink:to="loc_allo_ConvertiblePromissoryNotesMember_1AF11ACFFAEEE0E97A432774EFB76440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_FD8325179F57B06746602774EFB51F5F" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52FE8A0966B8F468DE0E2774EFB71E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_AD0EB71E90F63BF2B8FE2774EFB778F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_9500929A6656AFCCF2762774EFB7330B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_B5FCCD0EF85823E20EEA2774EFB783A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_54D1382EFD81FDEFA4382774EFB7339A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_F13323067906468BEE212774EFB7D6EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_441399A45F938ED99DA32774EFB7574B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1827E97963A86C2DC89F2774EFB7EF80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_3E253F59F20275B178252774EFB774F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_A8CECA89836DAC6BD5B32774EFB78D3F" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6B70868337B30A6FDCDA2774EFB77B84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_F064C2E02963BB834B642774EFB739B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B565B1751537EFB71EFB2774EFB5E22E" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_F064C2E02963BB834B642774EFB739B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0FE95379B2CA319E45822774EFBB675E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B565B1751537EFB71EFB2774EFB5E22E" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0FE95379B2CA319E45822774EFBB675E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7933C3A5B76515C446FC2774EFBBEBD7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_B565B1751537EFB71EFB2774EFB5E22E" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7933C3A5B76515C446FC2774EFBBEBD7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_19B6BBFC2ECE5782AA374D35D2BD147C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_19BCD15A84675C98896328893C936683" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_19B6BBFC2ECE5782AA374D35D2BD147C" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_19BCD15A84675C98896328893C936683" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_57CA1785488954AD9E4FBBCD38DC89E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6A6FD955AC7750CB83ABA73F583AB48F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_57CA1785488954AD9E4FBBCD38DC89E5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6A6FD955AC7750CB83ABA73F583AB48F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4B84BED0B94956AAA2FE9272E5592A0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6A6FD955AC7750CB83ABA73F583AB48F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4B84BED0B94956AAA2FE9272E5592A0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_87A2176A782550F5B7C62D2189CB2A0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4B84BED0B94956AAA2FE9272E5592A0D" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_87A2176A782550F5B7C62D2189CB2A0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_14F0865FF4D059F79D2FCA3CFC328D8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_87A2176A782550F5B7C62D2189CB2A0A" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_14F0865FF4D059F79D2FCA3CFC328D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0B76AE965B9D5EF6A031A8F215667A17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6A6FD955AC7750CB83ABA73F583AB48F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0B76AE965B9D5EF6A031A8F215667A17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9A49C7AAC6B25C7AA63B75DA9DE0F78A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0B76AE965B9D5EF6A031A8F215667A17" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9A49C7AAC6B25C7AA63B75DA9DE0F78A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_77A85D044FFE59D29BD88B4295BADCC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9A49C7AAC6B25C7AA63B75DA9DE0F78A" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_77A85D044FFE59D29BD88B4295BADCC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73ABFC9F342C5905BEFE111F12EB2D28" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_6A6FD955AC7750CB83ABA73F583AB48F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73ABFC9F342C5905BEFE111F12EB2D28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_E5BA140A07CD5775A49B52748BC356B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73ABFC9F342C5905BEFE111F12EB2D28" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_E5BA140A07CD5775A49B52748BC356B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_79E9F0CA883B5B02B6AE0D2CDBAD7E2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73ABFC9F342C5905BEFE111F12EB2D28" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_79E9F0CA883B5B02B6AE0D2CDBAD7E2E" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_FairValueAssetsTransfersBetweenLevelsAmount" xlink:label="loc_allo_FairValueAssetsTransfersBetweenLevelsAmount_98F2EEBF9A6656DF8A7E3D8AA65ADC34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73ABFC9F342C5905BEFE111F12EB2D28" xlink:to="loc_allo_FairValueAssetsTransfersBetweenLevelsAmount_98F2EEBF9A6656DF8A7E3D8AA65ADC34" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9A14F7AE5BF05F07B1EAB4520A839000" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9A14F7AE5BF05F07B1EAB4520A839000" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1A393F72FAA759D98C070A3B17F41507" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1A393F72FAA759D98C070A3B17F41507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9B509AEF3E9E5538A6393F2E827C115E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1A393F72FAA759D98C070A3B17F41507" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9B509AEF3E9E5538A6393F2E827C115E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6E0F9FC35EBE577BBDD3AF4D3959135C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9B509AEF3E9E5538A6393F2E827C115E" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6E0F9FC35EBE577BBDD3AF4D3959135C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21080A62C6FB5104A7491B2D3C828665" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21080A62C6FB5104A7491B2D3C828665" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C53DD61C2E025764A455B586E42743EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_21080A62C6FB5104A7491B2D3C828665" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C53DD61C2E025764A455B586E42743EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_B6C3A3AE57B95AF8A1CF8F136BA9924C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C53DD61C2E025764A455B586E42743EC" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_B6C3A3AE57B95AF8A1CF8F136BA9924C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2A27540DD93157EDAE737B3159527F07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C53DD61C2E025764A455B586E42743EC" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2A27540DD93157EDAE737B3159527F07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_69003A7C97F050ED9D5E758652038591" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_C53DD61C2E025764A455B586E42743EC" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_69003A7C97F050ED9D5E758652038591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_A95D65F5E9AC5E59AA6B6AE21AFE75EF" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8852385AAF3D55499E10ADC8E6FBAAB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8852385AAF3D55499E10ADC8E6FBAAB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_D09DB3B5A50E533CBE77DE63CE9E5432" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="loc_us-gaap_CommercialPaperMember_D09DB3B5A50E533CBE77DE63CE9E5432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_02800BB0E24051A5A291C360FE71147A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_02800BB0E24051A5A291C360FE71147A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_55C93ADFF7C55F76B269A4E94335E44A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_55C93ADFF7C55F76B269A4E94335E44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DABB1D94178E5CD0BD30B43C6D973B8C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_B7B8816B93A25F61A5190A84AFAE70F8" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_DABB1D94178E5CD0BD30B43C6D973B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8B6D96FB06745B0F9ACFCC1E3CB61A0C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1307EE0E843151158DDB89E4175AC31F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8B6D96FB06745B0F9ACFCC1E3CB61A0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2AAB4DD959C85A1A96DDEAC5EDFCDF87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8B6D96FB06745B0F9ACFCC1E3CB61A0C" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2AAB4DD959C85A1A96DDEAC5EDFCDF87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5DEFA2F982C35DDBB53BD4E1245D5D24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9A67D24D897E561888314263974EA5E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5DEFA2F982C35DDBB53BD4E1245D5D24" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9A67D24D897E561888314263974EA5E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9D8DAF4B05225510A6173C8EF98C12D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B79E6A4F2365923ADD6E6B2B27D4AE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_9D8DAF4B05225510A6173C8EF98C12D2" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_6B79E6A4F2365923ADD6E6B2B27D4AE4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D8718C0EFF345AA08CF48139A3377799" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_AA8B6D3BBD425D80918B6C2D48C52A1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D8718C0EFF345AA08CF48139A3377799" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_AA8B6D3BBD425D80918B6C2D48C52A1B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_709FD58D38AF511ABE5C2479CC36E2C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_709FD58D38AF511ABE5C2479CC36E2C6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:to="loc_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_8F30DB0F6FB757338621D1970AB84CA9" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_F9078761C01D56B18B1DC1C115C9EF9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="loc_us-gaap_MoneyMarketFundsMember_F9078761C01D56B18B1DC1C115C9EF9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_3C1348FFC85E5D019C292A63E273D815" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="loc_us-gaap_CommercialPaperMember_3C1348FFC85E5D019C292A63E273D815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_106AB19DAA7655E09AA9652A846C5E5A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_106AB19DAA7655E09AA9652A846C5E5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_43E901317C79523CA8DBC944AB14F96C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_43E901317C79523CA8DBC944AB14F96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2FB8DDC646FD5A4C9627F307D1690F4A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_4F5B5E10F37E50C5920899C6526992AF" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_2FB8DDC646FD5A4C9627F307D1690F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_37B738A0D082514091F29B9DF5A5F2B9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6A70154D907652958BC366CB946D2891" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6A70154D907652958BC366CB946D2891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6CCF37333E165EFFB45233741A6C97CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6CCF37333E165EFFB45233741A6C97CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_B677BC1CCF9A5303B2240C43FB9DFECB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_B677BC1CCF9A5303B2240C43FB9DFECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5C1D9264276C54879E74A781F2D61CA9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5C1D9264276C54879E74A781F2D61CA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_A76683BF50855FF58E88D0DC8BDB0A4F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_A76683BF50855FF58E88D0DC8BDB0A4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D0981054DA8457FAABDB9676BAB63AAD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D0981054DA8457FAABDB9676BAB63AAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5896A6BE1A7A5395AF456E0CC3980AE5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5896A6BE1A7A5395AF456E0CC3980AE5" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_CashEquivalentsAndShortTermInvestments" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_F8D823F872275E3BB0CD017E83EB5914" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5D14CECC9FB9562090E1F6ECF6EC76D1" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_F8D823F872275E3BB0CD017E83EB5914" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_037CC90E966F5E7D9895927B238AB26B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_48C379039F0755C581B364867E409575" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_037CC90E966F5E7D9895927B238AB26B" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_48C379039F0755C581B364867E409575" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A06697091500534B818837EC5A8A9E71" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_A2C43A8ADE895F359DE59DB4CDF35D46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A06697091500534B818837EC5A8A9E71" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_A2C43A8ADE895F359DE59DB4CDF35D46" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_19EF08ADF0BF5E6181580A1615BFB793" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8550337A1CC058A78B2883AF49650F2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19EF08ADF0BF5E6181580A1615BFB793" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8550337A1CC058A78B2883AF49650F2A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_E55C024F30DED82B35CC37858CAD63A8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_E55C024F30DED82B35CC37858CAD63A8" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FEB7FC0D8869A0C2B26937858CAE0298" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1169EC87DA1352B836A637858CAEA6F8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FEB7FC0D8869A0C2B26937858CAE0298" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAndCollaborationAgreementMember" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_0E2D6CFDE75ACF74F9C837858CAFBEC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_FEB7FC0D8869A0C2B26937858CAE0298" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_0E2D6CFDE75ACF74F9C837858CAFBEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9FC1EFC9B23AAC9E05A037858CAF342F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9DF4E43FEE757F7EB01837858CAF4E9D" xlink:to="loc_us-gaap_RelatedPartyDomain_9FC1EFC9B23AAC9E05A037858CAF342F" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ServierMember" xlink:label="loc_allo_ServierMember_1296FEA6D562E23DCC0737858CAF4528" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9FC1EFC9B23AAC9E05A037858CAF342F" xlink:to="loc_allo_ServierMember_1296FEA6D562E23DCC0737858CAF4528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_F97E69BE6801A3A3FA9937858CB031BF" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E2ADFD6733FFBCA3649537858CB0AB75" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_F97E69BE6801A3A3FA9937858CB031BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_CEDBDB474679B3ABC27D37858CB0A140" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LeaseOneMember" xlink:label="loc_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:to="loc_allo_LeaseOneMember_6DC92634278F40634EFD37858CB1C810" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LeaseTwoMember" xlink:label="loc_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_B02E15BB52E8455F1F6637858CB08818" xlink:to="loc_allo_LeaseTwoMember_D27CFFB19EEA09D9916A37858CB185DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_C16FEBF5F2D9B6375D2037858CB1F40B" xlink:to="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY" xlink:label="loc_stpr_NY_F6BFDB6DE897303328B337858CB23A9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:to="loc_stpr_NY_F6BFDB6DE897303328B337858CB23A9B" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LosAngelesMember" xlink:label="loc_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:to="loc_allo_LosAngelesMember_D383B70C113931F4B49137858CB24067" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_NewarkMember" xlink:label="loc_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5B4D8D0DD8E3E355396A37858CB14CE4" xlink:to="loc_allo_NewarkMember_0CB23B80AA8F6117237637858CB24FAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_8524D55E75F58C3AC8D037858CAE5376" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AreaOfNewOfficeBuilding" xlink:label="loc_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_AreaOfNewOfficeBuilding_613F3F9210B11B36D2DF37858CB3F610" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_70ADAD44250373D4F72837858CB342CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_C11FDFDC22328AF4165137858CB38EB0" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AllowanceForTenantImprovements" xlink:label="loc_allo_AllowanceForTenantImprovements_CCC662AF95E7D5C18C1537858CB367D3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_AllowanceForTenantImprovements_CCC662AF95E7D5C18C1537858CB367D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_A490CBEC6C76063635A437858CB4D013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6E163021606ADE31AF1B37858CB4E59A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8631896CB85E7D961ADF37858CB45A80" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_OperatingLeaseRemainingTerm" xlink:label="loc_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_OperatingLeaseRemainingTerm_2DF5A81A925422CEEA8C37858CB454E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_F6BBD5B4063DF6C44EF837858CB404CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_801BCE91C58152126D8537858CB49BAE" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AreaOfOperatingLease" xlink:label="loc_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_AreaOfOperatingLease_B6E61D12EA43C1AF62B937858CB55640" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_NumberOfOptionsToExtendLease" xlink:label="loc_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_NumberOfOptionsToExtendLease_0A8D023E6D50CD0F4EA337858CB56C0F" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PaymentOfLeaseRentalPerMonth" xlink:label="loc_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_PaymentOfLeaseRentalPerMonth_5874C39A3426E526BA6737858CB5C999" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent" xlink:label="loc_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent_72C7CBB0A5A79613968E37858CB56033" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_OperatingLeasesUndiscountedLeasePayments" xlink:label="loc_allo_OperatingLeasesUndiscountedLeasePayments_A713865D741195EF095D37858CB5BB70" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_allo_OperatingLeasesUndiscountedLeasePayments_A713865D741195EF095D37858CB5BB70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_1CD4B85A802D386F04CD37858CB58AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_OperatingLeaseExpense_B19EB894C24A709A851637858CB7DABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableLeasePayment" xlink:label="loc_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_82C8D8D8798322FC2A4737858CB279F9" xlink:to="loc_us-gaap_VariableLeasePayment_FC24548EA11F8FD2ACD737858CB70669" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_E051E31EE1ED5905A90057952A3C4972" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C9D5FD1BA57157E8A0DFDF1CB69A0D8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_E051E31EE1ED5905A90057952A3C4972" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_C9D5FD1BA57157E8A0DFDF1CB69A0D8C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9F2FA288D702B7361D0115283FED9A34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9F2FA288D702B7361D0115283FED9A34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E1A74CE083355116CE7E15283FEE236D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E1A74CE083355116CE7E15283FEE236D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50901D166C478FEB078A15283FEE9EDB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_50901D166C478FEB078A15283FEE9EDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79BAEC4CF60F68629F3915283FEE2700" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79BAEC4CF60F68629F3915283FEE2700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_330F8578B135EF77C0E815283FEE6DC0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_330F8578B135EF77C0E815283FEE6DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FBF78B1CD471C338A02115283FEEBB8F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_FBF78B1CD471C338A02115283FEEBB8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37303F4C73A9D1B1F0D915283FEF6871" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37303F4C73A9D1B1F0D915283FEF6871" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_OperatingLeasesUndiscountedLeasePayments" xlink:label="loc_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_allo_OperatingLeasesUndiscountedLeasePayments_A3EC2890F2B1C0556D8D15283FEFCC16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_030133CE6159301FD00E15283FEF45EA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_030133CE6159301FD00E15283FEF45EA" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AllowanceForTenantImprovements" xlink:label="loc_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_allo_AllowanceForTenantImprovements_176C232F76733AB7C78515283FEF63E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_4255F7419ECA96CF96CC15283FEFFB0E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_202930C3D0D8A304493B15283FE95291" xlink:to="loc_us-gaap_OperatingLeaseLiability_4255F7419ECA96CF96CC15283FEFFB0E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_AC48B182524153918858B1D734D09868" xlink:type="locator" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAgreementsTextBlock" xlink:label="loc_allo_LicenseAgreementsTextBlock_92C7399A0E50528B97D02D1F25E5CA0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_AC48B182524153918858B1D734D09868" xlink:to="loc_allo_LicenseAgreementsTextBlock_92C7399A0E50528B97D02D1F25E5CA0A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_993EFE78C0BCF17E7B1718985B3812CD" xlink:type="locator" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAgreementsTable" xlink:label="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_993EFE78C0BCF17E7B1718985B3812CD" xlink:to="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeAxis" xlink:label="loc_allo_MilestoneTypeAxis_E27C07E969D736928B5018985B3991B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_allo_MilestoneTypeAxis_E27C07E969D736928B5018985B3991B9" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeDomain" xlink:label="loc_allo_MilestoneTypeDomain_A125B4C548405EB034B718985B39B600" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeAxis_E27C07E969D736928B5018985B3991B9" xlink:to="loc_allo_MilestoneTypeDomain_A125B4C548405EB034B718985B39B600" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_DevelopmentAndSalesMember" xlink:label="loc_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeDomain_A125B4C548405EB034B718985B39B600" xlink:to="loc_allo_DevelopmentAndSalesMember_73CC265BB8F97D7CF3F718985B393209" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_Phase1ClinicalTrialFirstPatientDoseMember" xlink:label="loc_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeDomain_A125B4C548405EB034B718985B39B600" xlink:to="loc_allo_Phase1ClinicalTrialFirstPatientDoseMember_518A982208724353BB0418985B3A436D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_26EF86BC24F9A5AE3B8218985B3ABEE0" xlink:to="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PfizerIncMember" xlink:label="loc_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:to="loc_allo_PfizerIncMember_E95D15B968133BDD43E718985B3AFD5E" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_CellectisSAMember" xlink:label="loc_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:to="loc_allo_CellectisSAMember_B82D8E917E89314E8C5E18985B3A5453" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ServierMember" xlink:label="loc_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_B8DD401A8354D4EDAF2318985B3A0030" xlink:to="loc_allo_ServierMember_328E212DF0CE91BD301918985B3BD7C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_E8811B502D1EBB0BC44B18985B3BDB6E" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AssetContributionAgreementMember" xlink:label="loc_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:to="loc_allo_AssetContributionAgreementMember_6F2915F011BE8522BFFD18985B3B9027" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_RegulatoryMilestoneMember" xlink:label="loc_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:to="loc_allo_RegulatoryMilestoneMember_552477ADED79BB1825B318985B3B7EED" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SalesMilestoneMember" xlink:label="loc_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_E106676F394EA447E57218985B3BE3F4" xlink:to="loc_allo_SalesMilestoneMember_C8A8BF7B9C45DDBEC00C18985B3C06C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_999107C8C38270609C0D18985B3C7FFB" xlink:to="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:to="loc_srt_MinimumMember_932DAC2713CEC3692FD018985B3CD237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1F47B6A2B7EB9BCB494F18985B3C113B" xlink:to="loc_srt_MaximumMember_797C707C7CE9EF85565218985B3C9CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59BD6F0AB54645B20CFE18985B3D6D03" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ResearchCollaborationAndLicenseAgreementMember" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:to="loc_allo_ResearchCollaborationAndLicenseAgreementMember_570E0A08651AF570B50718985B3D8A0E" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAndCollaborationAgreementMember" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4032E1EDCE0B52BAE12818985B3D772B" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_2B8614230725D67C11F918985B3DD318" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_LicenseAgreementsLineItems" xlink:label="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsTable_1F3739C327A8B554321418985B3839E8" xlink:to="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestonePayments" xlink:label="loc_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_MilestonePayments_39DF06E3C465489DB24E18985B3E73A6" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_71140B64AC3793D91AFE18985B3E89EE" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AggregatePotentialMilestonePayments" xlink:label="loc_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_AggregatePotentialMilestonePayments_E57290B2EEC5B09DD37918985B3E3F39" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_E390F6FC855E297CAAD918985B3E231B" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_2547B146FEB36E51E4A318985B3E4BD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_85DD55BCF0AFAF8344C918985B3F8A6B" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherLiabilitiesCurrent" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_38C7916B34BACF100E0718985B3F42EB" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_2B0D60E6681BE1F4BB7A18985B3F7F40" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_D3296BA7062705876EA618985B3F1E40" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AggregatePotentialMilestoneReceivable" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_LicenseAgreementsLineItems_905C346962051EBE0F3018985B3E1059" xlink:to="loc_allo_AggregatePotentialMilestoneReceivable_7BC14F899F9792AF536F18985B3F34D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0CAC6D9E46FF597CAFCC0E1A8E2C66F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_FBA99D6D65F159A991B690A50D4ABECF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0CAC6D9E46FF597CAFCC0E1A8E2C66F9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_FBA99D6D65F159A991B690A50D4ABECF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_320EE4A4195B48F734F8F46CDE9F29A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_320EE4A4195B48F734F8F46CDE9F29A5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_BF93251E19097E9950C3F46CDEA0671B" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_B6759C9C652DDEFA4E60F46CDEA1B5CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_8F703DCB9D20F02B6608F46CDEA1F4F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_56BDC58D839D67E8D387F470F7F0D888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_478D8683AFA91E555634F46CDEA1F999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_us-gaap_EmployeeStockMember_F6883FF5DF986F3EF6BCF46CDEA1F09D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_FounderSharesOfCommonStockMember" xlink:label="loc_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_allo_FounderSharesOfCommonStockMember_6F893CA3E445056298C9F46CDEA1F829" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_EarlyExerciseOfStockOptionsMember" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A6BAF8B86FE0F0AAC0FFF46CDEA002E5" xlink:to="loc_allo_EarlyExerciseOfStockOptionsMember_F88BB51CF2669F935F72F46CDEA1378E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F2D8C009B817BF765864F46CDEA0E0B7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_912FE2C9C455CF893B1EF46CDEA28083" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_03D8AF57C016E96545E5F46CDEA249F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_E007DDE2EC7158E7BD84BBFF5EC14166" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0339A3B21D1C5E2F9932E42C82A5CCD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_E007DDE2EC7158E7BD84BBFF5EC14166" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0339A3B21D1C5E2F9932E42C82A5CCD7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_B37115101A005C71AC2EA590F2AE47F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C31AE9E089AF51EEB9FCE4787BD6750E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_B37115101A005C71AC2EA590F2AE47F4" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C31AE9E089AF51EEB9FCE4787BD6750E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4A422D0F6EC0891591CC37858C4A9FB4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4A422D0F6EC0891591CC37858C4A9FB4" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C481F29E4053D0E3FDCC37858C4A3BE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C481F29E4053D0E3FDCC37858C4A3BE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_C481F29E4053D0E3FDCC37858C4A3BE3" xlink:to="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PfizerIncMember" xlink:label="loc_allo_PfizerIncMember_6581E668F3E0C0F8583637858C4BB57D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:to="loc_allo_PfizerIncMember_6581E668F3E0C0F8583637858C4BB57D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ByHeartIncMember" xlink:label="loc_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:to="loc_allo_ByHeartIncMember_CD8370AD5CEEF8CF442037858C4B579D" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_TwoRiverConsultingLLCMember" xlink:label="loc_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:to="loc_allo_TwoRiverConsultingLLCMember_B373359559079C40ACD837858C4C34CB" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_BellcoCapitalLLCMember" xlink:label="loc_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8673E87683BB1E2630CA37858C4A21A1" xlink:to="loc_allo_BellcoCapitalLLCMember_5FCD8D3C8E23A03F243837858C4C930A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_245402D91BF4E6BC7BC237858C4CC06E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_245402D91BF4E6BC7BC237858C4CC06E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_245402D91BF4E6BC7BC237858C4CC06E" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_TransitionServicesAgreementMember" xlink:label="loc_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4" xlink:to="loc_allo_TransitionServicesAgreementMember_B819FE42B1DA448222AE37858C4C587C" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_SubleaseAgreementMember" xlink:label="loc_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4" xlink:to="loc_allo_SubleaseAgreementMember_2BAE380D1FF8F98E18FD37858C4D6D28" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ConsultingAgreementsMember" xlink:label="loc_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_BC7521A050013865F8F137858C4C3DB4" xlink:to="loc_allo_ConsultingAgreementsMember_8F5E71C8B4CCAEB371D837858C4DC7BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F110697479F1588A26F837858C4DD2DD" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_94708FA3472CFB70B54137858C4DD92C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_42DC7F12C79345663D4337858C4E5787" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7A8810D2AF338C8E383C37858C4E8B0D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AccruedAndOtherCurrentLiabilitiesMember" xlink:label="loc_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_9162ED9B8C361FE5D89737858C4E9EA1" xlink:to="loc_allo_AccruedAndOtherCurrentLiabilitiesMember_AB6AA0C55EB4D44C52EA37858C4F9811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6F235CCAFA5F5EBB140437858C4F66CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_srt_RangeAxis_6F235CCAFA5F5EBB140437858C4F66CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CFAB6EB685D7CB06DCBC37858C4FB50B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6F235CCAFA5F5EBB140437858C4F66CC" xlink:to="loc_srt_RangeMember_CFAB6EB685D7CB06DCBC37858C4FB50B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_93A8388E7F8D064E398F37858C50AF35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_CFAB6EB685D7CB06DCBC37858C4FB50B" xlink:to="loc_srt_MaximumMember_93A8388E7F8D064E398F37858C50AF35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_15AA850AA1C50F50A73937858C4A987E" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5F8C49F8432EAB995A2637858C50EE87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5F8C49F8432EAB995A2637858C50EE87" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_NumberOfMembersAppointedToBoardOfDirectors" xlink:label="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_allo_NumberOfMembersAppointedToBoardOfDirectors_E4FBFAF1692DD81721F337858C503FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyCosts" xlink:label="loc_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_RelatedPartyCosts_1DB7CD3FEDE8A0004AA437858C51216D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense" xlink:label="loc_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_SuppliesExpense_890F5D11CEEA4D8DEAD737858C519E25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_4154E037047D2EC8C2DB37858C518589" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_AreaOfOffice" xlink:label="loc_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_allo_AreaOfOffice_9170FF00F23F9490433937858C51EBCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_us-gaap_SubleaseIncome_28CBA03319985827749437858C52FB12" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_545B3BEB1BF55C530B9237858C52A64E" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_RelatedPartyTransactionCompensationPercentage" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4B8AA37266F31E9A719B37858C509802" xlink:to="loc_allo_RelatedPartyTransactionCompensationPercentage_8E08C0F3B7B5EDBC19D337858C52EF55" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFF00D882BB15BA5B56A5709A5A51EDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5C60553C5D87595DBBECD063F04B889C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFF00D882BB15BA5B56A5709A5A51EDF" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5C60553C5D87595DBBECD063F04B889C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E9E1AA98CE37AD27228137858C8E1512" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E9E1AA98CE37AD27228137858C8E1512" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:to="loc_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_72361BDE98C175793C7537858C8EE6CA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_BCFAE9B5EA301EF2446937858C8FBB5B" xlink:to="loc_us-gaap_StockOptionMember_D5061A4A11EDD74FAFAE37858C8F5A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D4E9D382A016533A51FB37858C8F2563" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:to="loc_srt_RangeAxis_D4E9D382A016533A51FB37858C8F2563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FE5FE6CD37D077CEC6A537858C8F0BD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_D4E9D382A016533A51FB37858C8F2563" xlink:to="loc_srt_RangeMember_FE5FE6CD37D077CEC6A537858C8F0BD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_9C802D7F4CBA0261BB1337858C907A6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FE5FE6CD37D077CEC6A537858C8F0BD0" xlink:to="loc_srt_MaximumMember_9C802D7F4CBA0261BB1337858C907A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0F51726ACB2D57F7D5AD37858C8E571A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_9BAB244103C9CDE9F07037858C9004E6" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_StockOptionGrantedPeriod" xlink:label="loc_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_allo_StockOptionGrantedPeriod_9437641422E007CA879037858C90B80B" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_878C8E18CAFB7EBA2C5A37858C9131F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9FC499D7B86D862E405B37858C912C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_CB75DD45F8B38A397B1037858C916DBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_8E48393495660FFA6A1937858C91C22D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_AC03EFC56A56B658C96537858C90D664" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_8D25B02FC4BB5704800D37858C91D468" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5DDEBB3229845752B761DE96F91A02FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5DDEBB3229845752B761DE96F91A02FD" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_C985C36CFFC3582298D1FD9D5CFCE581" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_C985C36CFFC3582298D1FD9D5CFCE581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7C9E9A09DCB959BD9F24ACBA610B5398" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_C985C36CFFC3582298D1FD9D5CFCE581" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7C9E9A09DCB959BD9F24ACBA610B5398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F7672936F885969939173B383330937" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7C9E9A09DCB959BD9F24ACBA610B5398" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4F7672936F885969939173B383330937" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A2E0368DBBE657689CA98DE1A65E7C30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7C9E9A09DCB959BD9F24ACBA610B5398" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_A2E0368DBBE657689CA98DE1A65E7C30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F737DEBD72E05060B4A6D5029562CBAE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D190269E15D556BDA7C9994844602801" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4D1464D6E8E95503A8B6A1D3356DB739" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D190269E15D556BDA7C9994844602801" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_402CC43B00745EE69C40F588D89E1385" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ABD6BB424A0457AC8D3B640E6DFEA5AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_402CC43B00745EE69C40F588D89E1385" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ABD6BB424A0457AC8D3B640E6DFEA5AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E45301313D865574BF6B8927228CCB59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ABD6BB424A0457AC8D3B640E6DFEA5AA" xlink:to="loc_us-gaap_AwardTypeAxis_E45301313D865574BF6B8927228CCB59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7E285A01D35C5F769B8626513949E383" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E45301313D865574BF6B8927228CCB59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7E285A01D35C5F769B8626513949E383" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_A5183049A10E54AB8D384ED2957D73DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7E285A01D35C5F769B8626513949E383" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_A5183049A10E54AB8D384ED2957D73DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ABD6BB424A0457AC8D3B640E6DFEA5AA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C1E373469AD5E92A4DB471D6C58949B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9C1E373469AD5E92A4DB471D6C58949B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99D3CACD435758E0BCDC7EECE0F1D941" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_99D3CACD435758E0BCDC7EECE0F1D941" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F6C06F3797E150F8A6E5A1375A236002" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_F6C06F3797E150F8A6E5A1375A236002" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6A3A93A8D16F5FACBF722D4D9C68746D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6A3A93A8D16F5FACBF722D4D9C68746D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08347C0B28C452D4B1E495C6FF1AD913" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08347C0B28C452D4B1E495C6FF1AD913" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_71B0DC973E8A5A0FAFBF11FEF1D4CE99" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_71B0DC973E8A5A0FAFBF11FEF1D4CE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08E939706FFC559CB3B0C8E5787BB680" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_08E939706FFC559CB3B0C8E5787BB680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FE05E67A0C6D5A1E8C3C9492FFC781F7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_FE05E67A0C6D5A1E8C3C9492FFC781F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_57424237B3845B3C8A3DE1688F33D228" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_57424237B3845B3C8A3DE1688F33D228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_C6FF5A996BCD514FAEB08565B76C8BC3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_C6FF5A996BCD514FAEB08565B76C8BC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71A6DFB365A35B9DAB9B1AB06569E1C1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_71A6DFB365A35B9DAB9B1AB06569E1C1" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_005B79DBF6DD55AA95A98E58F8AB8729" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21557D4A1AE95E3D920C64D01D652F1E" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_005B79DBF6DD55AA95A98E58F8AB8729" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_902ADB3EBDBE587B90D0A8894A26E946" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_902ADB3EBDBE587B90D0A8894A26E946" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7225417AE86B5D70AC74248CFCB0F717" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7225417AE86B5D70AC74248CFCB0F717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1299D34B27CF5AFA9C66D177BAFDCD7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1299D34B27CF5AFA9C66D177BAFDCD7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A76994249C9C542E9EC4D86F84C14F80" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_A76994249C9C542E9EC4D86F84C14F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0E72BF7EF39857B4AA419023984DC415" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0E72BF7EF39857B4AA419023984DC415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6F69D83E76A555F481D7EB409DA116C8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6F69D83E76A555F481D7EB409DA116C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_88DBD0548DF75A9B8E659FA6763F6B1C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_88DBD0548DF75A9B8E659FA6763F6B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31ABFA45D7355F2F91039CDF7C8DB9DE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31ABFA45D7355F2F91039CDF7C8DB9DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0A53C5B4E01255AE9E77110A5374B63E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0A53C5B4E01255AE9E77110A5374B63E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_AB5084C7B3A05BB183726E693B452A5F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_AB5084C7B3A05BB183726E693B452A5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_531C6A61A0CF5FFDB9ADB1FE1F916C9A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_531C6A61A0CF5FFDB9ADB1FE1F916C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FABDD4034C7158E59CA409305A1F4E99" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_FABDD4034C7158E59CA409305A1F4E99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C7C4966D0A1850FA858DFCBBCDA67D51" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_C7C4966D0A1850FA858DFCBBCDA67D51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CC7C79C624935BA983973280D4DD5984" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_CC7C79C624935BA983973280D4DD5984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E6E833F92E3856BBB0498E070380FB9F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_E6E833F92E3856BBB0498E070380FB9F" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_DF79E50A580D51489E8FA6B352B79105" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_DF79E50A580D51489E8FA6B352B79105" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_AC3237E5D77D515BAC32D2F7AC9F77A8" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm_AC3237E5D77D515BAC32D2F7AC9F77A8" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_2C564F740282586DAF7A26118B97DEA5" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1_2C564F740282586DAF7A26118B97DEA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3779A94E6E905B569E6A61D7581A4937" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3779A94E6E905B569E6A61D7581A4937" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_A537C5111233550BB8841BB99EB36BBE" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_F89BD9529E005184A565B62BA929C057" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_A537C5111233550BB8841BB99EB36BBE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6D437C3BEC145FA5BCF342E3147D1985" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9C73ABEDC0853D3BF2046ACBFED6620" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6D437C3BEC145FA5BCF342E3147D1985" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_F9C73ABEDC0853D3BF2046ACBFED6620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_709705AEDC965504B64CF19FB3B183D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6D437C3BEC145FA5BCF342E3147D1985" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_709705AEDC965504B64CF19FB3B183D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F0EE22F8AAB65D9E84EDBF952110A4C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6D437C3BEC145FA5BCF342E3147D1985" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_F0EE22F8AAB65D9E84EDBF952110A4C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1B6F922B6587F5DADF7518981427524F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3B88B763B9A3E2D2FE8C18983C1D5DC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1B6F922B6587F5DADF7518981427524F" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3B88B763B9A3E2D2FE8C18983C1D5DC0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3467E899C911FAED504427760C87BEC8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3467E899C911FAED504427760C87BEC8" xlink:to="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F0627BDBC5E018A90F1C27760C8CE0D5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_NotchTherapeuticsInc.Member" xlink:label="loc_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_AFC80714E5122B9BA95F27760C8C6BFF" xlink:to="loc_allo_NotchTherapeuticsInc.Member_83E01C9D12364AA96B7927760C8CCCEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C10175C8EA932D8FE1C927760C8C2D4A" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_8EA7296D939787D8A85F27760C8CABA1" xlink:to="loc_us-gaap_SubsequentEventMember_E579BC57D2EE51FE70CC27760C8C2F71" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeAxis" xlink:label="loc_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:to="loc_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_MilestoneTypeDomain" xlink:label="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeAxis_C9C1C4C95B71A5E6F82327760C90D0FE" xlink:to="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ResearchMilestoneMember" xlink:label="loc_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:to="loc_allo_ResearchMilestoneMember_1C41CA844224C236ADDF27760C902FB2" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_PreClinicalDevelopmentMilestoneMember" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:to="loc_allo_PreClinicalDevelopmentMilestoneMember_6336C14FFF13EB415B3A27760C900290" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ClinicalRegulatoryandCommercialMilestoneMember" xlink:label="loc_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeDomain_F0B05A34B42FB926D4D527760C9062E4" xlink:to="loc_allo_ClinicalRegulatoryandCommercialMilestoneMember_9321EE16D66C69AA6CCA27760C90B4C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_FB22B1F09E86F974DF0927760C8CD796" xlink:to="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_CollaborativeArrangementInitialFee" xlink:label="loc_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:to="loc_allo_CollaborativeArrangementInitialFee_2609293A2E816D859F0027760C9009B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_66D27D996C577274A6432793EB214BB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_280B710A97F4BDB4CC6627760C903847" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_CollaborativeArrangementContingentConsiderationLiability" xlink:label="loc_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_36A625957CE673C7C20227760C902841" xlink:to="loc_allo_CollaborativeArrangementContingentConsiderationLiability_D03F9F45690C70F6E7F227760C908867" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D4820ABC485555B4A08AE47B50ED5353" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2295527A16A5525986A8C1771596C5A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D4820ABC485555B4A08AE47B50ED5353" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2295527A16A5525986A8C1771596C5A8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://allogene.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8BF1F65351B75DB5BCF047A744589A4A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_173B08AD898E5C46BCDC088190ACF274" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8BF1F65351B75DB5BCF047A744589A4A" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_173B08AD898E5C46BCDC088190ACF274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_DAD7760E0FB55DFDAB7AF49092EA7E35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8BF1F65351B75DB5BCF047A744589A4A" xlink:to="loc_us-gaap_UseOfEstimates_DAD7760E0FB55DFDAB7AF49092EA7E35" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock" xlink:label="loc_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_8C094F8EFF2E58929A7477A4CB0AE194" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8BF1F65351B75DB5BCF047A744589A4A" xlink:to="loc_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock_8C094F8EFF2E58929A7477A4CB0AE194" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_FB761A89577B5CB29DC5F0C854482226" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8BF1F65351B75DB5BCF047A744589A4A" xlink:to="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_FB761A89577B5CB29DC5F0C854482226" xlink:type="arc" />
    <link:loc xlink:href="allo-20190930.xsd#allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D9DF188B7B1C59F79257A4574035C592" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8BF1F65351B75DB5BCF047A744589A4A" xlink:to="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock_D9DF188B7B1C59F79257A4574035C592" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exhibit101image1.jpg
<TEXT>
begin 644 exhibit101image1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ;Q!2L# 2(  A$! Q$!_\0
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MW=2;(XU+2.?X5'4U\6^,/^"]_P#P3]\'^/M2^&U_XU\0KJVA^,-4\+ZQ9_\
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M++'3;74ECT76;B!I$MY/M]E:7"6\CI)#;WEQ;V\5S*HA3$Y\@?2=>(?LC?\
M!.;]BC]@OX?:K\._V0_@)IO@FPUO#:S=:;>74M_?E1((_.OII9+J7R_.E\L-
M*1%YK^7MW'/L?A];M=!L5OX?+G%G&)HP0=K[!D<<<'TXH N4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6=<_\ (V6?_8.N
MO_1D%:-9US_R-EG_ -@ZZ_\ 1D% &C1110 5&_\ Q\1_[K?TJ2HW_P"/B/\
MW6_I0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3:/^&>? /_0P>.?_  Y^O?\ R;7;^9_L-^5'F?[#?E0!Q'_#//@'_H8/'/\
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MP5F>1WFFEFGE /H:BL;_ (1;5O\ HH&L_P#?-K_\8H_X1;5O^B@:S_WS:_\
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MX?\ (D6O_8U:#_Z=[2NOKD/CA_R)%K_V-6@_^G>TKKZ "BBB@ HHHH ****
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M_P"27:I_V4GQG_ZDVIUZ57FO[*/_ "2[5/\ LI/C/_U)M3H ]*HHHH ****
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MV@!U1M_Q[M_NFI*C;_CW;_=- 'EO[!__ "8[\&?^R4^'?_39;UZM7E/[!_\
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M?"^^\)^&[705CECM\[+YM'@N)[>W2]CN-T6HR2N;6>,&>2">WJ?X4?!+XO?
M[X0:7X&T'0?"?BJ^U;XL:UXF\4KK6M3Z?;Z/::OKU_K4S692SN3>W%I)>)'$
ML@MEN#%YIDMCA  1_LF?\E__ &GO^RX:?_Z@GA.O;X/OR_\ 73_V45XA^R9_
MR7_]I[_LN&G_ /J">$Z]O@^_+_UT_P#910 X_P"L'^Z?Z4ZFG_6#_=/]*=0
M4444 %%%% !7FO[5_P#R2O3O^RB^#_\ U)=-KTJO-?VK_P#DE>G?]E%\'_\
MJ2Z;0!V_BJ406%O-Y$4F-3M%"S)N4;IT7/U&[(/8@'M6G63XR_Y!4'_86L?_
M $JBK6H **** "O-?V4?^27:I_V4GQG_ .I-J=>E5YK^RC_R2[5/^RD^,_\
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M>*[KPEH=QJ6E>$-4\07T<#O:Z+HWD+<7CJC,(D>XEB@C9BNU6FEC3<0"XR*
M-BBL'Q=X^T_P+%<:KXGTV\MM'M8(9+G7/+$EO"7F$6'$9:2-4R)))F00Q1[G
M>151RN]0 4444 %%%% !1110 4444 %%%% !4=V,V[=>.>,<<]>:DILH#)AA
MGI_.@!U1M_Q[M_NFI*IKJVG$K8G486FD5_+C5N6P,G ]@03]1ZB@#S7]@_\
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M/4^9']EGN,(#YOE-A#Z9XS .DP C_F+6/_I5%6M0!X__ ,-+_&@?"H?$,_\
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MX2#^SO\ A!_[9\'_ -J"W\CS?[1\S^W_ +#]FW?N=OVK[1YG_+#9^\JI\/\
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MI^GV,$485(H+>SMK>WCC4!4CA10  * /?:*** "BBB@ HHHH **** "BBB@
MHHHH ***;/<06L#W5U,L<<:EI))&PJJ!DDGL * '45D:1XGU#5_$=]I \'ZC
M!8VEO#);ZY.\ MKZ1WE5XHE$AFW1B-69I(TC99X_+>7]YY;-!\>^&]?\1:CX
M,@O1%K>D6]O/JFCS<3V\,X?R9<='C<QRJLB%D+PRH&+1.% -JBBB@ HHHH *
M*** "LZY_P"1LL_^P==?^C(*T:SKG_D;+/\ [!UU_P"C(* -&BBB@ J-_P#C
MXC_W6_I4E1O_ ,?$?^ZW]* )**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;=>\4Z[X&\8_L!?%#2-2T5UN([FWU'0;C3;ZPGN;I+.6&\?48D>X,5L&N+4
MO:R.JDR126]Q/H?$']HKX]>'?"LVM>"/V$OB!K5];S0,^FS^(_#=J9;?SD%P
M8G_M1P9EA,CQ1OL2614C>6!7::/UV+_7R?4?RIM__P ><G^[0!Y;X1_:7\=>
M-O"FF^,M'_8Q^+$-IJVGPWEK#J\>AZ?=QQRH'59K6ZU2.>WD (W12HDB-E75
M6! T?^%X?$S_ *,[^(__ (,O#7_RXKT>B@#A]-^+'CF^T/4M5N?V:/'%G<6"
MPFUTNYOM#,^H[WVL(6CU)H@8Q\S>;)'D?=WM\M'Q$^,7B+P#J8M+7X#^+-=M
M66()J>E:AHL4+RR-M6$"\U""0R%B% V8)8!2:ZSQ%K=GX:\/WWB/48;R2WT^
MSEN9X]/T^:[N&1$+,(H($>69\#Y8XU9W.%522 ?$OA#\:]3^+O[0&EZA]DU[
M2[.30?$\2Z/JWAS5M)WQV]]HZVL[0ZE:VTDLC13.Y=8MD33RP*\AB>60 98_
MMUZC<C0Y=3_8O^,NCP^);&.[T&?Q!IVC6"7".MILBE\_4T^Q7327L<*V5V(+
MN22*<)"PAD9?7-8\;:WIFK76G67PN\0:A#!H;7\.H64ECY-S."<6">9<HXN&
M R&=5@P1F8'BN-\#?&B]^*_C76/AMK_P.UJQT*#P^/[2O/$%G(JK>%(FN-/F
M26(6]TGE7,6RYL9[VVD>*\BD>%H$$_HV@R2W&AV<[3%C):QL68<G*CGF@#A/
M^%X?$S_HSOXC_P#@R\-?_+BN,_:"_;DO/V:_A)JGQH^*7[*/Q"L=!TB2U2^O
M)]<\*P1P^?=16R-)+/K:10H'F3=)*Z1HN6=U52P]<NM+^)$_C5KJ'QEI$/AE
MM':'^S$\/R'45OC)D7"WANC%Y0C^7R3;%M_S>;C]V?$/VZ/@_>ZQ^S=X9T2X
M^,'C"/6M/\;>"],A\60WT"7,LT_B;1X7OYK00_V=<7 ($J++:/ DF=L*HS(0
M#PJ+_@XM_8^G7?%X%;[S+\W[0GPC4Y!(/#>,P<9'!Z$<@D$&OJ7]EK]HCX7?
MMW_LXZ5\>O"?A1O[!UB]N1:V&IZAIFH&.ZT[4IX/,6?3;J[M)"MQ:>;%+#/)
MC$;@AAA?GS_@A7^Q]\,_@/\ L2> ?C1\-]2UZS7XM?!_P%K7B+PNVH1_V+::
MI#X>M8I[VTM$C46]Q>966ZFR[W,D:.[9'/U=\2OC7X!^%UJUQXC;6;ELQ&:S
M\,^%[_6;U%D\T1R-:Z?#-.L9,,B^88]F4VEL\4 ?GO\ LO?\'!'[&'A+]F7X
M<^%]'^'5];VFF^ ]'M;:WU3]H+X51W4,<=E$BI,EUXJM)EE  #"6VMY V0T,
M39C7NO\ B(H_9"S@>!><9Q_PT-\(N_3_ )G2ON72-8T'QK'<1:5=V]Q;V[+#
M?0E?WT,K1QRB*:-ANC8Q2HQC=58*ZG&&%6VBBN7^QP6BQVJQ_-)'\I^@Q@CC
M_/3(!\(-_P '%'[(*]? WU_XR(^$7'_EZ4#_ (.)_P!D1G\L> CNSC'_  T/
M\(O_ )M*^\_*6]4Q6Y,:*Q621?O-U! .<@],DYX/'/(RY;Q/&%Y<:+HLK0V=
MO(4U'4(<H[L.L,+8'.=P>13\A5D7Y]QB /AR+_@XQ_8]FFF@C\"2;H7"2;_V
M@OA(HR5#?*6\9@,,,.5R,Y&<@@,M_P#@XW_8[NI[FWC\!3*UK,(YC)\?OA*B
MEBBOE"WC,"088?,FX!@RYW*P'VW'%%XAE_X1#P@L5EH>GJ+:\OK'"%]FZ-K.
MW*$>64*!7D'W.8TQ(&:&_;Z7826R^%?#5E'I^G6<8B9K2 1*B@8$,.W&W ZL
M!A>@^;)0 ^$]._X.-_V/-0CDF@\"W"[+B2)H[KX]?">W961RAXE\9*64LI*N
M,JRE64E65C8_XB*?V0O^A%_\V(^$/_S:5][2117!^SPQ[0#\T@7!&#_6H8XA
M>'[+:NWDQD;KC/S,<@[5/IC@GMC YZ 'P?\ \1%'[(/;P-]?^,A_A%Q_Y>E
M_P"#BO\ 9 +M&? C*R-AE;]H3X1CMUR?&>#^!K[TBMX,?8;2W6..,?>VCGD^
MF#G(//K22D/,NFVL'W5Q),W\ ]/][D8]CGT! /@T_P#!Q/\ LA ?\B,/I_PT
M1\(N/_+TJG<?\''7['4>KV^D_P#" 7337$,DJE?CQ\*&B5$902TP\8F-"2PP
MK,&8!B 0K8^]9FGU!O[+T6XC7RGV75YM#-%\OW5R"-^<<'( Y/8'-NM1M[K4
MW\!^"XU@EMD#:AJ0AW+9!OX5+ K+<'KM.=BLKR9#1I* ?$2?\'&O['DE])IR
M^ 9O,AB21V;]H#X2K&58L!ASXSVL?E.54DJ"I( 9<J/^#C+]CXW;6/\ P@4@
MD2-9"S?M!?"0(58L!A_^$SVD_*<J#D#!( 89^X+.PLM-A'@7P)!#;K:L3J%\
ML:R"T9R)&!W$E[F3S"^6W8W^9)NW*LM=;NTDO'^''P_18_L8*ZMJBXD_L]FP
MY4E\F2ZD#^9\V[&\2RYWHLP!\3)_P<;?L=/?R::O@27SHH4E?=\?OA*(]KLX
M $A\9;&;*-E58LHVE@ RYI>,O^#@S]DWQ7X4U;PGIVF:AH=UJ.F36]OK6E_M
M ?!J2XL'D1D6XA%UXNFMVEC)WJLL4L991OC=25/WO8:9INB11^%/"5A!;QPR
M-)<R%=WEEW\QR<G+RR%G8L23EB[9) >RMM;6Y72=-MC\RGS)V^;9@;<DD[F8
MXZDD\')H ^-_^"-?Q2^$7QLT7]HCXC?!W3-1BT'Q!^T!/>!+[Q1I6N;;A_"O
MAQIPMYI%_?6+(96<I';W#)$/W6V-HVC3EV_X+V?LM?"?5M8^#WB33-=US5O
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M7=U(9KJZFC&Z5\!?-D(ZG"J !@84*H55 6ZT"VT?D6T&]F).Z3GYB>O/X\<
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MB2W7!D:XMOTB5()8UNS T:*S&.%6VB0\]0.N<G@CK]*F)@@5KZ9U6,+EF_A
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MKBXMYK#7%\/V=S!-!.\$JE)-7&Y?,C;9,A>&9-DL,DD4D<C>N3_ZA_\ =/\
M*G4 ?./B;]OCQMX,_:>\,?LV>)?V'_B=Y_CCPS?:IX3OM-GTB\:1]/DC&HK>
MB*^,&GP1I=:?Y5Q+/MGEN7AVQ.L N?3](^,GQ"U'5K73KW]E/Q_I\-Q<QQ3:
MA>:AX?:&V5F ,KB+57D**#N.Q&; .%)P#Q'Q!_Y2;?"/_LA/Q%_]/7@FO=J
M/#OV:/VN?B?\=OA1K7B_QG^Q'\3_  /XH\,:K_9&M>#]>M[*)KS4(V"7)TNZ
MGN(8=1L4)#QWW[J*XC(,>9!)#'L7OQX^(EU\0?!/@O4?V=?$WARR\1>(I;2]
MU3Q'<:5+$BQ:=>W:K&+*_N'$IDMDP739MWC<'*5ZR.E5-:T>WUVS2RN9[F-8
M[J"X5K6\E@8M%*LJ@M$RL4+( R$E)$+(X9&92 ?)'[2?_!6R/X2:;\0/"WPN
M_84_:2\7^,O"UOJUKX?@L_@'X@DT?6M3MEE6!([^*V:-K6:9%"W";E,;AUR"
M,^W_  5^(D7[4GPV\!?M):9X.\=?#N>:2YDF\*^.O",>EZR+=O-MY=.OX+N%
MYK=#-'#<CR'0R/:VS"62!F67JM:\6^*](U"^LH_@QK&K)::+/?6]YI=YI_EW
MLR2$)8QBXN8G6YD7#@R*ENN<-.#4MQX)M_%/BK1_%WBK3+.2/0E:YT/3;K3+
M>633[^2.2%[M9CO9)A!++ IB* )<W"L91(NP Z2BBB@ HHHH **** "LZY_Y
M&RS_ .P==?\ HR"M&LZY_P"1LL_^P==?^C(* -&BBB@ J-_^/B/_ '6_I4E1
MO_Q\1_[K?TH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#D/CA_R)%K_V-6@_^G>TKKZY#XX?\B1:_P#8U:#_ .G>TKKZ "BBB@ H
MHHH **** .+^/?\ R(]A_P!CIX;_ /3W95VE<7\>_P#D1[#_ +'3PW_Z>[*N
MTH CB_U\GU'\J;?_ /'G)_NTZ+_7R?4?RIM__P ><G^[0!-1110 5BZI\./
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M&L7@!GFVE1(P#%5"C=Y4*G<%'.,DDL[,S7+'2TLKA[R>=IKF9B6D( ^@P .
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MI\S2.6 V@$'K@ #)]LN*"3Q#+_PDOB61K/1K/$NGZ?<+Y7S(3BYGR>F,,D3
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MB9!+>QQUQ@[L_KTF^6=_LML56-?O,GKGIZ8.?YTGEJ&73[.,1PQJ%8*O &.
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MF"2"U@W;V_BP>/?GV/\ 2J]]*T)_LW2W_P!.DC!$DBEMBY^\QQ]<+W.<8 )
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M<YYZ)]M@N+9]:U*=8+&&)I-TDP5-H!W.YX^4#/!XP<GG[N8JPZT?^$H\2/\
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M@ B)=PX8;8 ,*JM@,O!!!!Z8_P XZX\-Y=>.I&,,/EZ&K#]Y)N5M0PV" /\
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M,&Z65LR,O1..3S]* %DF>"9;6&-FDE)9G R%^I_E]/H"B2)IZK;&1IIF7+<
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M:)HWB;PSJ'AOQ'I-M?Z?J%G);7]C>0++#<PNI5XY$8%71E)4J0002#0!Y/\
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MRZJ54L Q/E6\6\$]<;OXY9 '02'PRX>2)M2U[5"0JCY-X3_OKR;>/=UYQO\
MXY),/8M+5O#<33W,S:AJVH,/.FVLOF$#[J@;O*B0$[5YQDY+.[,P!XK^TO\
M#[Q9)\;OV;_$^DZ->:W>:7\:;W4?%.I6=FY2UM?^$(\56D<L@!;[/:K<WEO"
MH)($ER@R\LI+^\V%L]O#]HN7:2XFPTA.< X PH).T>P/J>223X]^T+9?%&#X
MS?L^WG@M-?DLY?B]>?\ ">/I*2^2-)_X0_Q-Y2WWD_(+4:@;#;YO[O[0;?K(
M4)]G,BH<+\TC<%0>G^<T 4]?735LXSJK,W^F0F)03S+YJ^6..WF;?;UXJ6:5
M+!=TC>9<2?+##N&7()Z9Y[\\\"JNO0:6EI%'J-YY<DEY!)$JL 9)%E1U3GLS
M@#./XNQ-/FN%TBW6_P!4'G7DA$4<=K'N9W/1$'ZDG  !9B "0 )=3PZ/!_:V
MI1>;>.NR..WC+/(>2(T&>O7N  "3@ D,$<NE1MK>JI]JU*2,K!!"0VP''[F+
M=C@D LQP6(R=JA55+3&F^7JFONIU&[_=Q6ZMN\G(#&&/ R1E<LV,MC)PJJJP
M7MU'X<VZ_K@-UJ%T!#I^GV^TS23%"S6\!8J&!";OFV@!&=RJJ2@ ^>['AY/[
M:\0;KB\N)A!96MHI=I&;E8HU.,$?-N8D *I=RJJ=E.0S>&X_^$O\46_V[7KJ
M,P6=E8[9/(W*K&TMBPC+*6C#/(VTN5WOLC1%BE*3>'_,\4^(8_[0UJX4PVMG
M9<^7&3N%M &(Z[07D;;O*;G\M$18GZ/87VD*WB7Q;<+<ZM<Q^7'#;_=A7EA!
M$.-QXRSX!<KDA55$0 ETC2;C3KB3Q1XFD6;4IE\H"V#M';0E\K#&#[XWR8!<
MC<0JJB)>C,T;'4;K=YDB*J6^[A/;KC.>_?CT%$4;_:/[2NE)F\LK'#P?+4XS
M@@!N2!G/H.E2QB6W#3W+JTDG\*YQG'0?_JH :F^"/S[\*S^9E,,/ESVR<=,D
M>X_*G1+YF+NYCYZQJRG*_@>_^-$*L7^TW*?-TC7J0,G_ #].M.DN8H#NE/[P
MK\L:MEO\YH )KB"U'FW,@&X_*I_I5.ZDMM,1M<UN8+M&U45=W)*[5 P2S;A@
M 9R3P,FG7CV6EJVMZM/C:05V*Q;)RH4*O+D[L 8))/'.*IW%W!ID+^+/&,ZP
MK&RBUM=N\VY8[%4!03),[,% 7))8(@))+@!=W%MID3>+?&UQ' L$V+*W^]Y&
MX^6@&,EYY"X4!<DEQ&@))+T;.R%Y-#\1/'UMY,D&'T72;A4?^S6973<,#YKN
M1)&C8J2%5C%'D-(\S]-CFEG7QYXYADM9HP_]EZ2?G:SC8!<LL;,LURPXW*#L
M5_*3.9'FNV^D7-U>_P#"2^(CB2-2+&SX_P!&!SR2OWY2#@GD ?*O5V< ^7-4
M^'7PN_X*J?#OP;\=KG18;_P?-JS/+X>\7:+97<=I)9R7UG>Z=>:?>6M[:W<J
M7L1MWFMWBE5&N/LE\(I'^U:OQZ_:E^'W_!,_P1I?@KP-^RC\=OBTMO'8I?:-
M\(O#LGBC4-,CEBFBMKJX2ZNTEV3G3[K?,F\&=7DF*RW2O-\U_P#!-KXN_&OP
MO^R/I^B>%6\61V$'COQD;==,T74+B$,_B?5"P62'PI?1GYV;.VYEP25.T@HO
MNWPB\;_$3Q3\;]?\5>,I->.J6>F^&EMH]5TNYBN(E/\ PDJ@I')H=G(X_>,,
MI:RCAOWF%;RP#SE?^"\44NH+>:G_ ,$8_P!OIMDF8%_X9S)1"0%W<WW7Z#C)
M SDD^G_\$[]3TGX@>*?B'^VUIGQ\^,?B7P_\;(/"?B/P_P""_'EJ#9^%+*[T
MV*6UBL8+./[/"/+NXX[AHS(0+.-[B:1E>9_<+[Q-XJU*ZO[:Y?4%ABUU8;7_
M $:?:8@9@S;O[."E.%R=Y4 #,R[@7\2_X)":??V7_!+SX,ZMHSQ75X_PC\)R
MP6]Y?-##'*OA?3$6-Y A,<;;%)VK(5,I;!.5 !]5V=U:W^F#5QJ$<UK)&)H9
MHY%*;,9#!NA'&X-G'/I4<TL>)-3U>X6WLK;+$SN4P5/#L2=NW!S[8!Z\#"\.
MZ5K6BW>I>-?B-XN@:"3E+5;-;6RMXTGF>&7;(SR"<020PRNTFR1K99$CAW%!
M><IKF/%'BB(6>E:?NN+6VO $SM&?M,X8#81@LB'[@^9_GPL0!'<?9=:0^+/%
MY6ST.Q3[5:P:@?+ V@.+J??CRRN"51L;!\[8?"Q-DMEUV3_A+O%L[V.BZ>S7
M-K8WQ$:DQG(N[C<?E"A0\<9QY?WW'F;5AFW_ -M'_A*_$[-8:38KY]K:7A\K
M[N3]IN-Q&W &Y(VQLQO?Y]JPM3=XCD7Q1XE#6>CVB^=96-TOELS*6_TFX^;[
MNW:T<3 ;/ON/,VK" 07%C#XHG7Q3XPD>ST2P9;FQT^\8(DC(5D2\N Z@QLC)
MNCC)&S_6./,VK#;TZ";Q1(NLZO;7%M8P3!]/L[I2KNP)Q-(I[?=9(V&5(#,-
MV%C+82^)+L:YXALI+73[:97TNTN?D:9A@K/*AY!!Y2-AE2-S#?M$>HUJ=1F$
M]S&RQQL1'&W\73YO4'(X[_3/ !'%#=W-X;MBRVVU0L<DA!.,_,5(X.<8Y[#.
M*\ZE_9^U<?M=O^U7<?M!>-(]$7X:_P#"*M\,)-88>'?.^W_:_P"V/L^=OV[8
M?L_FXSY6%]J]-G+/\[NR1J-Q(X).>GK^%1[!=EI[IT^R>6/+5AU&.6)ST(/3
MV]Z /@7]G7_@GA\6]6_9E\&_&_XN_'#QE#XYNK>P^*/B/P+-\)?A_;VO_"?-
M812W5Q)&GAA+J*\,[36YN%G%YY? N WS5]%?MB7]ZO\ 8,%M^T?\;OA]#(UT
M/^+._"^#Q*;\C[.5^U^=H&K"WV8/EX\GS/,ESYNP>5[A-$VI,T=RJ_93C:-Q
MRY^F!CMW_P 1\8_\%?[_ $OQ8?A7\(I?"%JVI?\ "86_C/P]XPC^%'B;QIJ7
MA>[\/:GI=XMQ;:5H6FRR21SNR6,\CW^FLL%ZYB>X):*@#O/^"<GPP\4^&(_C
M)XQU_P"+?C?Q?9^-OBU#K6E^(/B!X-?0-:N[>/PQX?T__2;;^RM-B&)+"9$:
MWM_+:%8\NTOG8]YGANO&UQ_Q]-%X?CY8@\ZD,$%3N4CR.G(YDSV0 R>(?L!Z
M?:ZW\!4TFP^*WQ.\2>';'4,W6H?%;PGKND75S.UM!)/#;)XBB&J/I6^1Y8GN
M[F^ES*\'VMXK<1U[5,DGQ-* ;D\-)(K_ ,2MJS*RNK AABU!&""/](_ZX_Z\
M 8/)^*T0V".;PE-'\V_;)'KL;)^(^R8;V,Y'_/'_ %^K#_Q4K;H9)%TV-\=Q
M]KQM(93G_5YR.F''^S]YSK_PE0:)UDCTU6&3]W[9URN",^5TY!^?W3[]R:9Y
MWP$_T?D/(&&",9^O7CB@!J2/)=*BADAC[MP&(RN.O3D8X[5Y;^TM\#/&'Q^3
MP&_@WXR>,/!D7@OXH:/XFO?^$4UU[ >(;2TDD6?2KT*I\ZPE20L\!!64QQ@E
M1\X],!;5I=K1;=/C4%68_P"OX_\ 0.?^!8_N_>=K4,NIZ=-:Q;UCDA93(AVR
M GHR$C 8=CV)![4 .$37-P@MS_HZ@K(OF<$$<8'.>W''?Z%Q$=P?(M6V1QMF
M1E;@^HX/U_$5&;A-7LD,+R16\D>7DD1HG7CIA@"K XSG!'(P#TCBE;5KA;?3
M?W=C;,5DD\O'F,I(V)W&""&./8'.2H!'%##K:M9V4V[3]FR>521YQQ]U<  K
M@\L..P[[:-]<7_BS4VT#P]?2V^FV\A75-2M[@K([JPW6T1P<=P\H(*8*(?,W
M/"W4'N/&A'AWPEJ0M='@9H=1U"Q;#,T;;3:PLI&W!4K(ZD%,%$P^7BE6*+5X
MO^$2\*I]@T6Q!M[RZL\Q A05-K;%"#&5(P\B_P"KQL3]YN:$ BM=.M-2@7PC
MX*_XE^BV/^CW5UI[^6#LS&;6W*$;"A7:\@'R?<3]YN:&O+!<^*7_ .$/\&W?
MV#0;&3R-0U"Q?8Q\LA39VQ'"@8VR2#_5@&-,29>!VJP7GC8CP?X4N_[/T&US
M;ZM?6>8VF50R&TM'C96A=&"AYE^X-T<>)<O!JQ117UL-#\.;;?3[?$,DMO\
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MTLX81JBA&$A!;S<)YI\0?^4FWPC_ .R$_$7_ -/7@FO=J  =**!THH ****
M"BBB@ HHHH **** "LZY_P"1LL_^P==?^C(*T:SKG_D;+/\ [!UU_P"C(* -
M&BBB@ J-_P#CXC_W6_I4E1O_ ,?$?^ZW]* )**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH Y#XX?\B1:_\ 8U:#_P"G>TKKZY#XX?\
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MUG^,?$^F>"?"&J^,M:N(X;/2=-GO;N6:ZA@5(HHV=F,D[I%& %.6D=47JS*
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M^O9=.E_X1KPO"DVJ7+>;=7$RY2V!R/M$P!4L"5PJ @N00I559DDN[NZTYO\
MA'_#D"S:I<+YLUQ<*3' I/,TI&,XY"1@@N5P-JJSI MS:>'YQX,\-R_;-8F0
M7=Y-<L&9%8[?M-P5Q]XH51!MW^640(D;-& +-=1^',>$/#/F76K72M<33W6Z
M39N.#<3L,#)P0D8*[MFU B1LT=O0=#M?"]FVF:=(US?7#^?J%]=%6EGE8!3/
M*5"Y)"!0%  "JBA$0!30-"L_#%H^G::QFOKIO/U"^F56DGF*!?/FV[<DA%4
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MP-K#!!&"/NX/X_3KR6H> M!^(OCRP^(DUHWEZ;I=WI]C>I<.K7-O<R6LLJJ
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M+E@'?Q%I\DA8D[FED+,Y8DDLQ=B2?F .@_9F.W]FGX?MZ>!]*_\ 2.*N,_8
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MRK'-& <O\0?^4FWPC_[(3\1?_3UX)KW:O"?B#_RDV^$?_9"?B+_Z>O!->[4
M Z44#I10 4444 %%%% !1110 4444 %9US_R-EG_ -@ZZ_\ 1D%:-9US_P C
M99_]@ZZ_]&04 :-%%% !4;_\?$?^ZW]*DJ-_^/B/_=;^E $E%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 <A\</^1(M?^QJT'_T[VE=
M?7(?'#_D2+7_ +&K0?\ T[VE=?0 4444 %%%>$_M1?M9?LD? _\ 9W\3?M"?
MM9>--#D^%NDZ\VAZE?PVLVN6HG6]%C)%/;6T$C>;'?K);/&%E\MH<L5.\* >
M[45X+XE_:(_8O^)'QO\ !?P*C^*<</C?Q]X07Q/\,/$&CR75O'XBTRVG@O6&
MF:Q$!;:@J[+>XGL(YY/-M6#3026SOGUWX=:CXON_!MBOQ&MX8M>MT:VU:2WM
M5MX+J>)C&UU!$+BX,4$Q7SHHWE>1(Y$60B0.  9'Q[_Y$>P_['3PW_Z>[*NT
MKB?CU+&? ]AB1?\ D=/#??\ ZC=E7:">!ONS*?\ @0H ;%_KY/J/Y4V__P"/
M.3_=K-\)>-_!OC>"\U+P;XKTW5;>TU*XT^[FTZ^CF6"[MI6@N+=RA.V6*5'C
M=#AD=&5@""*/&GC+PIX-T5=4\6^)+#3+2XOK6PBNM0O8X(VNKJ>.VMH SL 9
M)KB6*&-!EGDE1%!9@" >(?$_]D3QEX>_:*M?VK?V88_!\/C3Q!XMT"W\?WGB
M?0["V:;PM KPZC;QWMEIW]HWD[PF&2&&ZNVA2XL;0@QQ1R0S?0],6XMW&4G1
MN2.&':E\Z+_GJO\ WU0 ZN?\0_#+PMXFOK?5[];N*_M9E>VU*RO9(+J)5N([
M@PB9"'\AI8HS)#GRY501R*\>4.]Y\.<><OK]X4&2-3AG4?C0!R]QX&\4:]J$
MUIXN\9B;1%6VDL['2H;BQN?M,5X\Y>>X2X)FB9%M8S %2-PER)!+%<"&'J((
M8[>%+>)=JQJ%5?0 4"6,G D7_OJD^TV^W?YZ;?7</;_$?G0 ^O)?VTT#_!W1
MU/\ T5CP$,^G_%7:17K'G1?\]5_[ZKR?]M!DD^#VCHDG/_"V/ 7W3T_XJ[2.
M: .1_P""4%[]H_X)=?LUV]E\S+\ O!OGN%X3_B1VG'^]T./3ZC/NSF:8G1]*
MBDACVYEO/N[-Q;A,@Y?(Z'@!@3GH?G__ ()6W%U>?\$O/V;=+T]5A63X ^#S
M>73$?)G1++A0/XV!.#_#C)'0'VZ\U<7MU-X#\&2&-[=?+U+4HRK+IY*J^SDG
M=<,CAP""%#!W^\BR@!JFKW&I7$G@CP/<M%- OEZAJD.UAIOR@A1O!5YR&5@I
M#!0P=P04262TL+73+3_A#_ ]LELD;$W=TH'[CS&,CL20?,G<NS_-NR7WR9W
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M4  !550B* N+XQ^,WP?^&_C#PW\,_&/Q>\+Z+XF\97$T?A?1=:URUM;WQ!+
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MQ6\ Z6NJ7VN>(]8C^T6\%PTEEJ.O:A?V;LREA\UK<V[[2=R9VL%8,H[OQ/\
MLQV&I?'C3?C@VL>']/\ ">GZ="^L>%;GPH&:ZGM8M4C@N1.)UCB0)JDS/&T#
MLQAA(>/:P/S/X#_X*N>(_AI\-="\"Z]_P2A_; U*W\,>'[:PN-4L?A39):78
MM[>-#<1_:=1AFCC)0NOFQHX4@LB,-JZ>I_\ !8?Q/>7#ZOXH_P""07[9L.DV
M*K/#!)\*M,5"5^<SSE]5&-F/E7[J%=Y);9Y8!].^/?!/AR7P%K'CQOA%9S+H
M^FSW^BZ#:V-G!=7L\,?FQ.6N6BBBFWJ!$LLL<<;;9)'5@/)\#_X(W6MU>?\
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M,D!RB2_0>EVMII%G;^$/#-JXM[5%22:XF>8^61G>9'+-+(QSEG)9B69B2?F
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MVY8R2N6>32="TS0-1NM:E5;G6-26,7UV%_>.B!O+C R2D*DR;4' +R-RSNS
M',V?PC^&GA&+;/X$T35]?U1MS-)I44:RLJ@?*NUA;V\8(X&<;LGS)9"9"3X7
M_#3PQ(KM\-?#^H^(=65D0+HL,8EV;G4,PC8PV\6\C<<X+_QRR@/V7V=;.Z^T
M^6LEY<+L\SR\9"@D LJ]!GOWZ<D"FP:?'I\LFH"%)-0NHT2:X\O[P3<53U"
MLY"]BS'JQ) ,:^\#^$YGCN/%VA:?KVM7"X6XOK&)F(R,K&'SY<*;@=H)QR3O
M=BS7;;P3H9TK^RM;TBQO(V1%^RR6:F!0O*HJ-D*JY(4= /?).@4BT]FOY(-\
M\Q";DQEO[H)X_P#K9_&B6[FM8_G7?<2!O)AW=3U"_P!,_G0!CS_##X8P?/\
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MV(SQ02:KKK)C<AAA"@>4.P)/5R2>^.@&<$ETVI2:;8/J^M.85ROEP+'O920
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M^)&EV-ZVC3R1WZ6DEE/<JL4#EH9@QB#RJR8;RB _U@$CU.-3D&U93E3CY_\
MZW)_*G2Q_;\V^U?)4C=G!R0W3'X>HH \/^*W[9G_  37^"WCZ\^&?QD_:W^!
MW@OQ)ILD<VI:%XE\>Z/IVH6SRVZM&TD$\R2(7@D1E+*-R,I&5(JK\0_VQO\
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M7$A-O'YGE_ZW+0?84<,-_!_PC.DV7V73K>$V\C0?N_+"C:L<6W[N!@Y!!7
MYSMEMM/T[1K&U\)^'K!=/L;6V6*V6SA18;>-5VI$@Z+@8PN, # H \,^&_[9
M?_!.'XCRZIX:^!7[5'P1U2R\(^%VU3Q%)X3\;Z1</INCVP59)W%M*?LUI")(
M]]PP$48D"@J3E)?AQ^V9_P $U?C5XST_X0_ O]J_X(^)M?OV<Z9H?A'QOHVH
M7]UY<+,XM[>VF>1RD".694(6-&SPIQ[M9Q0BV6RL@/(C41[N,?+QCT[8[#G\
M*\[_ &J/B#\1?A]\(&N/@E>Z):^(;SQ+H.BV-]X@TF74K.R_M'5[*P,\MM!<
MVTDX1+II @GBW>7]\#J <K\,OVU_^":GQH\>:?\ #'X(?M9_ _Q5XGU3STTW
M0_"_CS1[[4+K"--,(H()FED(6-I'VJ?E0LW )H3]LK_@F>/B3_PH:']J[X&M
MXR;6ET ^$!XYT8ZJ=16<P+I_V3S?.-PLS&,0[-X<E=N[(KG/#'B7]O7P5\;?
M#?@+XO\ QS^&?B#0]>\13:+=-X3^#.HZ+<V[?V1=:@ERES=^(+^-F_T1X_*\
MA@"P=F'RH_OVI:G?:K>3>$/"=]Y<L/RZEJB[7_L\L P0!LAIV5@RJP*HI#N"
M"B2@'B'Q#_X*#_\ !,SPMXMNOAKXP_;7^ .CZOH>HR6.J:?K/Q&T2.[TNZAD
M99;=K>6X#Q3K)O0H5RC%MP!&UK_Q9_;?_P""=7P*\:7GP'^+/[6WP6\&ZYID
M$(UC0_%OQ TFRO;)6A62$26]S,LF]HI$=-XY20/R& ;UR9[A57P!X(N986M8
MECO]4DD:9[%"A*E7E#B>Y/RG#EL!_,DW91)9)+BYEF;PAX4F:-K?:NH:DY\S
M[+PIVY<GS)V0@C.0H.]\Y1) #Y(UWXJ?\$Q_V5OVVOBEKWB7]J'X%^ ?&/CC
M1?#'_";_ /"4_$;3K74EGLK>[2*5[:\F 25[*YM%CVC!0>9(#NC$WH'Q"_;D
M_P""<7PBO]#\$ZG^UA\$O"LFM>&[;7=.U;Q%X^TFT\_1[W>\-]:/<R_Z=]H,
M;.L@+(P!E=FRB2^L>%/AWJ/A7XMZSK6CA4TN\\(Z/IL$TDS23F:VN-4EED=F
MW;V8W:$NQ9G?S"W."W86=CI^C6_]DZ-:+;J\DDNV)>-SN6D<_P"T68L2>K,2
M<DF@#P_5?VM?^";_ ,%/ 7A?Q-JO[4GP3\+^'O%5M--X5\1:IXXTBUM-8CA=
M&FDM)Y9PMV0TZLSHSA6E#.27&Z;6_P!M?_@F[X#^'V@_$35/VN_@CHOAGQHU
MY_PC/B:_\?:1!9:X;:00W;6UP\X2[:*38DA1G*,5#8. ?7KKQ;H-GXCL? L6
MO::NK:A:W5W;:=/?J+B:W@>))YHXB=\B1RW-LCL!A&N(P2"Z@W+FY\DMIVDJ
MOVAN6;;E8\\;F_'M_(9( /G7XA_\%+?^"8?@SP5HGQ-N_P!JOX2:QI6M:Y<Z
M!H6O:=XRTFXLY=0ALFO);,WQG%M;.($7F>:*,-+;H6#SP))Y?\1O^"C7_!,G
MXK?L\1^(+']H/X3Z?:Z;\0/"=AK"ZUXTT4QVDPO]+U![47,=Q):W0BMIV+R6
MLT]NABN$\TM#*%]3^-%[\6M _;Y^%GB?X>? [6O&6FV/PQ\:Z3K&MV-]!!!I
M5Q<77AJYA>Z>=HT D%FT<:1EY7<NPC$<,LJ?.7[2O[1/CWXA^-?&VI?LC?".
MZF^(NJ^*O"?P[D\5:Q?V^M>#=$U70-7?581J;:=-]HMD:ZU6XTZ8[S+'<*J^
M0 F9 #UK]FS]N+_@E3J'P1\!^#=%_:1^"OB'Q$?">EP7'A_PSKFFZOJ4<@MX
MDF>2UM&EF2.'+23S.HCMXHYIIFCBBDD7V+]EG]G[2/@U\!KKPOXVT71+K4?%
M'BC7/$_B*"U87EJ+O6=;O-8DM$F>")KJ"WFU!X(II(HV>.)9#'&6*+S'PI^%
M/[0GB7X6?"[QMX*^+WA'3X].^'-G;0:=KO@_4[^']\EI-O:*#6;6WD=!:VP2
M62%Y8V$YCDC2XDBKM+KPO^V[# TK_'_X5LJ_> ^#^I#C\?$- '@'['WP^_9K
MO/V:[CX-_%^Z^'GB3P+\%4\/>#]/\6*(K?1?%NFS^"]$)N[[=*]M?0W)U:XV
M0R-) PDMVVM*D<U?1'@3PA\./&NFR^/OA#XBTF/2M1CU"QU31=/CL=0TFYU"
M.:.W;[2(@6\ZSFM9X###/'&));KS5>3:\?SO^SM^PO\ MK_LW_LO^'/AGX5^
M,GPON-1L[#PI-XGL;/PGK]NUWJ.CV6C6'F17T.N0M(BVVD1*8&@A@O=@BF2&
M*XGKTGP+\)_^"A%YIFC:K)^T5X-\*VJZM/K5YX=U3X<WNJ7EV;R&662PO99O
M$-R((X+JZ=DALK@QQ_8[9(9A:AK9@#M?AEID?C;XB^)](\8Q>"_$5CX:M=/T
MN%M+\,PVQTZ^"S336<T<ES/-&XMYK"95=8T,5S$\>\2$CO/^%6?#'_HG&@_^
M">#_ .)KQCX6_ ']O+X<SZI+J'[8'P_UU;^^NYX/[5^$VJR-;)-J5]>K"A/B
M(XCB2\2VC4#"PVD0' "KU_\ PB7[<'_1P7PI_P##/:G_ /-#0!Z(O@[PBMW;
MWZ^%=-$]K (+686,>^&( @(IQE5P2,#C!/K5,_"SX8GD_#G0?_!/#_\ $UP_
M_")?MP?]'!?"G_PSVI__ #0T?\(E^W!_T<%\*?\ PSVI_P#S0T =]I_P^\ Z
M3=KJ&E>!]'M;B/\ U<UOIL2.O&."%R.*)O '@2[MH=,NO!.DR6UIN^RV\FFQ
M-'#N.6V*5PN3R<=3UK@?^$2_;@_Z."^%/_AGM3_^:&N5T[P-_P %(?#WQ)OI
M]0_:D^$>I^%]85KB,ZG\*KV&XT2Z5+6&&RM8H=647%M-BYG>2>8S0S?*OG13
MHEF >O7?PI^%TMK)')\-M 96C(96T> YX_W*Y/PA\&O@O\*='M_ASX8^"GA7
M1='L=22P\,V#6\'ER6[(LQCMU8?N8X@;A([9/ECBME6-4C547D]5T']M;XL?
M">^N_A-^VG\)+5=>T*9?#_C+P_\ !^YOEM6EA817L'F:_)!.4)610ZO&Q4!@
MRD@^A?L^6_[2%O\ #M!^U3JO@FZ\6->S>9_PK^QO(-/2V#;81_I<KR/(RCS'
M.$53)Y8#B/S9 #Q3XM? OX2Z[_P5!^!UY>^![./^Q_@W\1K^UALMUM#+-_:/
MA"V_TB*(JEU&([F4B*97C$GERA1)%&Z?1%M\-/AS9W,=[:> -$BFAD62&:/2
M85:-U.58$+D$$ @CD$5Y)\0?^4FWPC_[(3\1?_3UX)KW:@#,;P9X/E@NH)?"
MFFM'J$GF7R-8QD7+[MVZ08^<[N<G)SS7*>.?@WX=&I>&O&?@7P)H\6K>&O$D
M-] J3+IT;021RV=VSR16\K2%+2ZN)8X<*LLT<2-)$K-(O?#I10!\#>*_^"!7
M[&OQ/O-9^(GP\_:0^,GA'Q=J'QQ\7?$&'XC?#7X@0:=K&DZEK8BMM8TJWGAM
MBB69>SB4QNCW$;0LGG8>5'^D?V/_ -DKX:_L._L\_#W]C_\ 9FCO+7P7X%@F
M6:XUIWO+F]\QIIIF>;S8]EQ/>7+7+,D;0J%EC2*%6AV=]XN^!OP6^(&JW^N>
M/?A)X;UR\U3P]/H&I76L:'!=276DS',VGR-(C%[60\O <QL>2I-=0B+&FQ!P
M.E #J*** "BBB@ HHHH *SKG_D;+/_L'77_HR"M&LZY_Y&RS_P"P==?^C(*
M-&BBB@ J-_\ CXC_ -UOZ5)4;_\ 'Q'_ +K?TH DHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO(JN S\_ZNVA\W)/S$!L#S)9%61VDZ7<^$K/[7J,[:SXBU(1B\NDC>..:54
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MZX6+.1%QG;QD9R/O?A];"(6!N+E3S_RS;D+_ )X_SFD$6YOM-R@W?PJ.W?\
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MLWA7_P **V_^+H_X7[\#/^BS>%?_  HK;_XNOD4^ /!89@/#%E][_GW%'_"
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M %%%% '%_'O_ )$>P_['3PW_ .GNRKM*XOX]_P#(CV'_ &.GAO\ ]/=E7:4
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MK-CHVG)!<WD0WZK;76FPWD]_;V4*W&HQO$AN>/\ 2Y[%9?+/V#)_#?PZ\/\
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MM_O44-]]O]ZBOQ*7Q,_H6/PH****D85V'[$__)>/'/\ V"[+^0KCZ[#]B?\
MY+QXY_[!=E_(5]-PG_R-?^W7^:/E^,/^1#4]5^9U_P#P4Y\+>*/'7_!-G]H/
MP/X(\-ZAK.M:U\$?%=AH^CZ39O<75_=S:/=1PV\,48+RRN[*BHH+,S  $D"O
M/OVL/V4?BFOA27XS>!?BO\1O''C*&31M A\G4M/TN^T[PE=^)=(N?%,6G2Z=
M#8NES=:;8#][YC7$;6</V-X)7<R^Q?MJ_M,:=^QI^R3\1/VJ=5\'ZAX@B\ ^
M$KW65T/3+6XDDOY(8BT<)-O#,\$;/M$ER8VCMXR\TNV*)V'*_#S]O_X5:IJ/
MAOX??%B"\\/^,M8ATZ/6+;3/#>O76A:'J%]%'+::9>:Q=:7:0V%]*MQ:!+&_
M6SO'>]M4%ONN8!)^G'XF?./[,OP)^+_B3]MW09M2U;]H.W^"-I)XJ\4?#K_A
M*/B/XLMVE\JU^'Z6,.J_:[P7KJ;W_A*#'INKY+I]I(@,. /-OV8OA%^TW\)_
M@%X+^#.O>%OC):_#OP7\#?A?IGQ5T.U\1>*++68+JRO?&4?B)?#\\,\=Q)<0
MW\6BRR0V,C?:-'ACAL4N(Y=.AE^[_AK^UG:?M4_LXR?'K]B'PO\ \)2UY]F;
MPS#\2=/UOP98ZM#*L$PN4GN]*EN&MFMI_,BN8;6:&9@$#CYVC\U^"'_!0;XQ
M:O\ #77/CW^U1\ ?"'@?P-I'BO6O"D$W@7QWK/C#6[[7=.\13:";>'2X?#UM
M)-'-<6UPT;1/),5\K, WOY0!Y;\,?@!\9OC7^T#X%\$_$YOCEH7P6C\._$#4
M?!JQ_%KQEI.LM;M>^$_[);7[Z&_BO&O)#+XAEM;2\E\Z"Q>.*6*.XM[A(^J^
M(LGQP^('[&7[-'Q"_:;T[XR!8=/T75?CE!\*[K6M'\1+?3>'+F)UNK'0%CU"
M:V74KB(S6=H@>.402.@@MYP/5-9_X*=?LC:)X8\.^*I=3^(%W'XHAUR;2]-T
MGX+^*;[4XX]&O(K+4WNK"WTU[JQ6WN)X8V-S%%DRJ5W YK6\-_\ !0K]E'QE
M\5G^$/A#QUK&JWD=YI]H_B+3?!.KS^&UN+ZQM;^RA_MY+4Z5YEQ;WUDT2?:M
MTK7D$:!I)40@'@7_  3:_9Q^-'@C]LWXB?&WX]:5\0H=0UGX0^&8-#;Q9XPU
M/4(;.Q;Q)XO>STF<R7,UG<:E8Z,F@PW+HT\BW$UU/Y\LFI75S>'[*'[$'CCX
MJ?#CQ9I7Q=^*'Q*\(Z39?MA>*?&]MX+71],M;75XK'QW<ZSIKL]UISW;6D\D
M%K<>9#.GF)C8X1B#Z'<?\%AOV+[CX11_&?PS<_$+4M+NVT&71[7_ (5)KUC?
M:Y8ZMJMAID&HZ5:W]I;S:S;1S:G8M*U@MPRK=6X"M)<V\<WM_P 3_P!H?X/?
M!FVU*X^)/C%--?2?!>I>++JS6UFN+E](T\1_;;F&"%'EN?),T =(5=PUQ"NW
M,L88 _.>?]F_]M;0OV//V9[&W^,/QJL[/7/ $^N_''5/$E]XX\2>((/&-[;:
M$MG;R0:1KNFZU:6\9.JQ&"*8V-N1YEU;>9MNHNW^!G[)/[0NN^#/%,O[0_Q0
M_:*NO%6C^.?A]X;TNZF^)6OZ0;S16\,^#[;6[G[%I>J2V):2XFUXSW,,EQY%
MR+F2&Z\V$3CZR^(O[>O[-7PSU_6?!^K:]XDU;7?#_B%M%U7PYX-\ :SK^J17
M*Z;8:E(XLM-M)[B2VCMM5TTR7:1M;Q27UO$\BRR*AXSQY_P5,_9SL+ZY\/\
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MWUOX#UA]#N-6M+.YN[NP36A:?V:]S#%9WGF0K<F2.2UFB91)$Z* >>_\$N/
M,/@B;X^:AH/@WXDZ3X;\1?&NWU7PC-\5IM:FUC4; ^#?#$!N7EUN22^=#<07
M$:K.V^+RC RQ&$Q1_55%% !1110 4444 %%%% !1110 4444 <A\</\ D2+7
M_L:M!_\ 3O:5U]<A\</^1(M?^QJT'_T[VE=?0 4444 %%%% !1110!Q?Q[_Y
M$>P_['3PW_Z>[*NTKB_CW_R(]A_V.GAO_P!/=E7:4 <[\2OB7X-^#G@+Q#\5
M?B%J,]GH7AO1[K5=9N[?3Y[IX+2VMWGFD$5NCR2$1QL0B*SL<*H9B =6#4[;
M6?#\6L6:3K#=VJS1+=6LD$H5E# /'(JO&V#RK*&4\$ @BN7^+/P8\)?&"YT"
M[\4:1IMY)X3\20Z[HZ:GH=I>K'?10RI#(OVB)V@=&E\Q98&BF5D4"38TB/T\
M#W4GAZ*2^ADCF:U4S1RJH96VC((0LN0>NTD>A(YH SM?^&WAKQ'XWT#XA:C=
MZU'?^&5NAIL-CXFO[6QE^T(J2?:K.&9+:^("CRS<QRF%MS1;&9B?._!WQ_\
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M]>A56TC\R9B\ASMW8+'^7;K5:>?[ IN;@B:\FXMK?N"<?*.,XW=6QP.3@#@
M6>62PB\Z\D\Z[D8I;PHP!8^B@\=/F)/H3P!Q!JU]9^&+5M;O+62ZOIF"6]K
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M _*_^NX!# C(*YXVG&>_'#4\_P#"<G.?+\/Q_53J9!'/4?Z-Q_VW_P"N7^N
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MK8A0JOYMQ.VAL84C$;$R#Y51W+*^%V@'M=>2_MJB1O@UI*Q,JN?BMX#",RY
M;_A+=(P2,C(SVR,^HJIX'^&/Q0\:Z++K)_:O^,.E^5JE[9?9M7T3PO%+(+>Z
MEMQ.JC2&S#*(_.B8D%XI(V(4MM'(?MA?"/X@Z=^S==>'C^TYXVOM1UCXB>![
M;2=?U"PT3[1H,[>*=,1;JW2'3HX9'5W23;<1S1DPJ"NTNK $7_!++4_L'_!+
M_P#9KT#PQ LFJ7GP!\'3NTV]HK93HEFOG2GTXPD8(+E=J[55W3UCXG?"OX7?
M$CP'>_ [Q]\.-"\=66O>3-KNE>+M%M]2LKK;(KQW5[!*OER!9(5:-,#YH5$8
M18\Q^1?\$L+N/2?^"7O[-^B^$-/635-2^ OA"YN)&!9(-VB6:^?,<YVC 5$R
M"PC")M2,E/HJQTVUT>V;2K S2SS/ONKJ5OWDC$<RLP&,X&% &!A54*J@* +I
M]A:Z/;OI^DM++//*TES=2-O9I. SNQXSC: O  "JH"J ."^%OPX?PE\9O&GB
M75/AW(FKZQ:Z>!X]^V1NFJ6$<EY]ETU83,TEL;+S92T?EK!(;WST9YIKJ.'T
M:&%+!0BCS)I.7D;&6.!R2 /0#@>G&!Q')(49K.TN8Y+SC(D;.Q23C..1\H.#
MW(H <#>1P+$LJR7+8\PYP%]3CGI_GK3I5^Q(PLH?,FD.3ESZ]<\]S_G%->..
MQ#+8PQM<R?,W W-P!D],\+C\!3DMTMV+C)FEP&;:3V]>P]Z ".-+9V,;[I)G
M^;YL^F>#QP.O3^0JOJVI3:/:K:6%O]JO[@$6]N'*[B!]YCAMB#C<V"!D<%F"
MEVL:I+I<*VMA"MQJ%PK&TM68@.1C)8@'8@R,M@X+  %F53CW&IIX.FCT_#:Q
MXDU;+0VJ2)&\L22*K/EL>7;0^<I8_,P#8 EED59 "1[Z3PLOV7?_ &MXBU)=
MT=O_ *K?C^\1O\BWC+'YCNQNP/,D<"233K"'PI))<W)_M#7-7D!N)EC"--LZ
M 8SY4$8; !)VALDO([,[=*L)_"L'VK49!JGB#5/+%Y<0Q-&LS*.B*S/]GMTR
MQ";FV[B29)9&:30@L9M)@FNC,;G4+K):5E&-V/E55R-L:]E![DDDEF( 6MM)
MH\;7%Q*;J^NF7S9"I4-C^%0,[54$X7ZDDDEBL]W/90 BW>XOI5Q'$NW(^IZ!
M0>2?YG +GGDLUW"/SKJ;=Y,+-@< M@G!VCWY&<#T%.B"V"J]R%DNI%P7^7+#
M=PN<#(&<>OU.: %M(DLE:60>9=2JIGVYZ]AU.U1S@?7J227!9;,+)LWO)(!)
MF0C'')[YY'M3F$%I^_N &D9L*>">O;Z _D*KSM#:W49N'D:::3]TJO\ <7CJ
M,Y*[B < XW#/ R !9)Q9#SYW:2ZD!$-NKC+, 2%7.!D@=_3L!Q#>WMCX=BCO
MM599KZ=C# EO&0\[GG9&A8XX7)YP NYB I(9J6K6?ABQCU#67$E[<L(;:",@
MO/,06$,>=N> QR< *K,Q"J2,[[.F@-_PF?BR-K[6KH&&QT^V*N8RP#BTMMX7
MG]WN:1BN[87<I'&HB $CMCX;F_X3/Q@WVW7+Q?L^GV-KM+(Q4L;.U+;-P.S>
MSOMW;#(Y2-%6*=\>&S_PE7B@K>:S=YMK&UM!NV;OF%K;@XSG8&DD.W=Y9D?9
M'&JQ-GF_X156\4>)F^W:W>JUOI^G6,GW_O2+:6RR,JEB!EY3LW[-[F..-5B9
MHVDWNAW<GC#QI=?;=:OLVUO;V(;RH(MS.EM C'@X_P!9*2ID*[FV(L<<0 :+
MIMUHMTWB[QM<+=:[?(8K:SM<.MHA"DVML2%+*2BL\C %V&YMB*D<6G#;2:?+
M)K^K*LUY(GEJMNK,$3)81H/QY; +$9. %55A@ELG;6M7=9+R1=D4<?W8E)_U
M4><=2%RW!8C)P JK8AM\2?VM?(PFV86/<&\L'L/?UQ0 6\$T3MJ5X[>;)&%6
M'=\L?L,>IQS]*FBW%_/N5VG.$&>WX?7'X4D:2!O/NOO=%4>O&>.W3UIE[J%K
MIL;7-\YX4E51"S$#T R2>>W7I0 MWJ-IIT1N;V3:=O$8^9CS@  =23@#U) [
MBJD,*QS_ -NZXPBD+ 6\);_59^4 X.'<[L=\9P,\EI#%Y3MK&LH-R ^3 G[P
M)C<05^4'>5ZCG'('<F._N;+3F;7M>EV)&0MK&JLQ!/  49WNQ(  !.?E7)Z@
M$=Y<V%CN\4^( 8VMUQ;P!2[)N.T *N2TC$E1M!)W;5SG)JO-:Z9'_P )OX\G
MAL]DBK96LC!A:LY\M ,9\RXDWB/Y<\OY<><LTBRW,&F0-XX\>2+;^2X%C9M^
M\^R;SY:*H4$R7$A<)A=QR_EQ[LEI(]/TB?5-4'C[Q:)%-O&W]DZ:K%ELXW10
MQ=%9EFN&P1O&=BL8X^&D>8 33](N-1U,>./&PVM;L?['TQE#+8 Y7S/ESON7
M#%2PR%4^7'D-(\VU"LS-_:6H91MI\FW!/[M3CK@D,Y]1TS@9Y+'E_O?[3U5E
M7RR?)C+ K%U&[I]\@X/8=!W+.3>JO=WJX7=\L?+=\ XYZ\' [T 5=1U9-+LX
MM5U.WDP]U%$D2_,ZF1PBG ZXW<@9.,]>E7&#&3S[C[J\QKUYY''X8JGKPTQK
M>*XU]?W"WD!CC/.)A*OE-]=^.G'KQFK"6_GLM]JL<:F.0^2N<[<\#\3G_/&
M @22;;J5^K1LJG;$)#QGV'7\L_R#@PG47-Y'Y:1_.I9L8^O3TSR.]*!).PGN
MD"QKRJMC*^GJ/7OZ5%>W=K#:/K.K2K#9VZ>:/-.T;0 V]]P&PJ0>IP.IY^Z
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M96S(VY)(W0++)@>7S&A\W<T !)=7-QXKOV\,>&II;+2;%C%J>I6O[IBZ%?\
M1;<[>A&Y9)D/[O!1")=S0R3V(UV"/PIX7*6.BV:_9KF6SC$8*J-OV>W*D>7M
MVA6=?NC*IAP6B66T77;>/PMX7/\ 9^CV:B"XFL5,.Y NW[/;E,; HX9U'R_=
M0AP6CV+:&&&U73=+C$,-NHCCV1[57;C"@8QCMQQV'L )&L(MELM+58X(0$^3
MA548^5?;'<'@C'7.*LPN]3N?[+L2T-G''MN)EX#Y&-J="&&/O X /&3]T8MK
M#K::3=&.VMY-LEQ"VTAE.#& !AA@LI_ND<<CY;"(+98]%TNP,=O'&4,D>$6+
M 7 'U!/0'!':@!TDIDW:?9%HU$>/M"C*IU&!GC((Z5(L3,BVT)41HHYY.>A'
MX?C4<-OB%+&VF;RX0%D9V)9N.A.<YZ')Y/XYI;B2=_\ 1--*AE/S,RG"G&1T
M_E[_ )@!<7%Q)*MK88;:V))-P(7U!]\'([_USKO4FO)&\+^&)%_=KMU"^4Y6
MT4C.%)!5YCU"G(4'>_!19"\U2>_FD\,>$Y]LL/R7]^%#+9Y[#(P\QZA3D*#O
M?(*I)4:9UE_X0/X=I':BW8G5-2$8D2Q)9':,@L"UU(LC.I8,$SYD@;<B3 "A
M4BB/P\\ G[(+156_U"-0WV$.-WR[PPDN6R&PV0H<22;LHDLDCI%N\#^!L6IA
MRVH:@L>Y;3S"78@N"LMRY)?#9QO\R3.Y5E8DB6Z?\*_\ NT/V,>7J&I>9YQL
M"0KX8R%FENG5P_S[L;O-ESN191Y!$Z^!? L+0^4<ZAJ2J'6TWG>V2V?,N'W%
MOFW8+B23.Y5D 'LT=O(O@GP3#Y/DR?\ $RO57>MINP[9+'Y[A]P;G<07\Q]V
M0LE^RL['3]/CT#0H66W"G=-N,F-Q)+%W),CLVXEB6))+-DGE;:PM;*S3P_H2
M20QQYW3"0[E.<EBS[B[LQRQ;);+%B2>;'E0VBK9VL7WFRS9QU)Y)')/4Y]>I
M]0!8H5L[;[%8CYD4;>I X]S[>N>?>DF:9?W-J^[J9I-_W1]*C$C2M]EL;F.2
M19,7<F>5X&1QT;E>/2FW#QV!73]+LE9I&9IMJA512<LQQW^;@=23V&2 #/\
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M 5&__'Q'_NM_2I*C?_CXC_W6_I0!)1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '(?'#_D2+7_L:M!_].]I77UR'QP_Y$BU_P"QJT'_
M -.]I77T %%%% !1110 4444 <7\>_\ D1[#_L=/#?\ Z>[*NTKB_CW_ ,B/
M8?\ 8Z>&_P#T]V5=I0!'%_KY/J/Y4V__ ./.3_=IT7^OD^H_E3;_ /X\Y/\
M=H >)P<'RWY./NGUQ7/:7X<U:U^+^N>+YH5%C?>&]*L[>3S!EI8+C4'D&.H
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M>W5MXATZ>"U,>FZG=W;F:2-(0+>VGE+2#;&Y^4_95>2_MK"5O@SI*P.JR?\
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M9#!$N6W;2VT9X!*CDD@<5#?WT7ARQ6\U0FYO)IBMO!;QCS)G//E1COPN220
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M[/:/_6[E*W"D#&.N4()!Z$]N.38>.>YE4;A'#$PX*G+_ /UL'WY^E-\LWBJ
M^VV51P /F_P (J1]]Y\D1_==&;'WAR..?Z>] "&62[?9&,1CDR>N#]/Y9KA?
M@\8QX]^*I)"1#Q];_-G'30-'&/;I^7L:[]W4QE_^684ECCK7GOP?5;[X@?%9
M$?$7_">V_P!WJ?\ BGM'X/'3!!_G0!UWBCQ3X<\,^'=0\8>+O$-GH^BZ/9RW
MNJZIJEPEO;VUO"IDEFDDD*K'&B*S,[$!0"3P*HZ5XN\,^-]2U/PGX/\ %EG.
M/#>I+IWB);.^26:UN?(BG^QR ,6AE,,]O*=V&\N>-E^^'&3XW\!:+XLUB/QE
MI/A*QU35O#ZR3>'I-5NGB@MKX0W,.;=PDOV*5UN9X);N&(R>5*\?S\JO,CQE
MXU^)6G2:M#X.N/"NG:7XJM+;[3'?.M[<PCR(9[22,1+&'6::\MV:*2X@V11R
MP3F5_P#10#N]1DE\72R>%M$:2TT:W\R'5M2MY&A9B.#;6[J5*GDAYD/[O:R(
M1)EH9I8QXCA'AWPS-]CTNT/DW%U:J$!V$#[/#QPHP59UQM^ZAWY:/@OAG\1/
M&/Q0\=>(?A;%\)-6\#^%_#-AIZ66I7-Y$)=29S<)-;VOV(RVT<,/DI$66Y-R
MC^8K6\"_9[B?U&TL[6TM%T;2+2.WM[>,1HL,?EJH P%4+C&..@QV'?  ME:V
M-A8II6E6J6]G:H(HTA 6-$ (V+@_*%QCVQ@>U5I)=:F;3;%V6UA;;<72_P 3
MJ?N)D=01RPX'0?-DJZ5[C5[K[%8MMLUW+=7 D*LS8*[$*D$$$\D]",#)SMM
ML"+33Q&JQL!(Q'3I[CMG\?QH :J_9XX[#2;>)+>/Y797PL:X/  [@XXXX/7B
MB*S5(EL++]U$GS;E[G.<<^^<C/3TS3H[6)HOL\'$+9,AV\OD=S[^OM1/+<2Y
MM+!\LF!)(W8\=_7&>Q[9P.H D\C3?Z#8?=&%D=,?(I!]1@GIQGC(.,<&A+J-
MQ>R/X>\-7"^;%D7VH*BE;9N"5 Z&5MV0,%5^\P/RHY+JES=WLGAOPV[B2WD
MO[Z2,LML"-VU<\/*01@<A0=S9^5'KRO<8_X0CP8SP>3'B^U3=YGV/=D_*9 W
MFW#9W8;<%SYDF<JDH C/(I_X03P4'M_LZJ-0U+;N^R*P)RI<,LMRWWL-G:&\
MR3.4259&>W'_  @O@4?9S;JK7VH,GF+:JS;FY8_O;EP6;YBVTMYDF[*I*.I@
M3_A!/ RM:^6K"^U),-]BW@L6!<,);ERV_P"?=][S),Y598I6FCB_X0CX=)'
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M?P_\-K6YO;K[?K&H>._"ANKMHU226-?$5B5C4?P0Q>80JY.-Q)+R.SN =/\
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MHHH **** "BBB@ HHHH *SKG_D;+/_L'77_HR"M&LZY_Y&RS_P"P==?^C(*
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MI/[:?[).MZYXF\.:9^TAX*ENO!8U/_A+L>)+81Z1_9HA.IB>0N$0V7VBW^U
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M0 4444 %>3?MI;O^%.Z/MZ_\+8\!8_\ "NTBO6:\E_;4#GX.:0$(#?\ "V/
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M%\JW7YVC9B !A<EY"<* N3EMJYR2U"6^M-,B/CKQ_<Q6IAP+&RW"3[+O;8H
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M:3OAMX2IENE4#><\Q $>F0V1QG ^8';,B1QK_8FA&.W%LJ;OW1PBY&% XSD
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M<.1O=R #(W&,@8P,        MK2#24:VLR)+N=O,FFE W2MC&]B,=EP,<
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M\<PXJS3$5:\HX; 8>I-72:IT^:3?+"-^:K7J66EY5)V4IRC3@Y0WOBG^UO\
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M2'_3/$#VI-GX=@*L%TO1XG)^RVL2R2(9/]=<&2621OWI1>,_9! '_!4C]L$
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M*[)#;PPJ5CAC10#LJ*** "BBB@ HHHH **** "BBB@ HHHH Y#XX?\B1:_\
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MB K^F'A&PT&RTR>+PSHW]FVS:I>2R6\>F_90]P]Q(\\VPJN3),TDADQB4N9
M6#AVH>'= ^)KQWMM\1/'>DWT,MPILO\ A'=!FTUXX=N&CD>2[N"Y)YWIY1 X
M'/-=(B[$5-Q;:,;FZF@#B?CW&_\ P@]A^_;_ )'3PWZ?]!NR]J[,PSD_\?;
M<_=4?X?YS7'_ ![_ .1'L/\ L=/#?_I[LJ[2@#@?ACX,^,?A'XC^-#XO^*,?
MB+PGJE]!?^$;>ZL8XK_1&=6%S8,\4:I/:JRQR0NX,R^=+&[.J1M6K\8?#'CW
MQ5\.]0TGX8_$IO"OB#;'+I.MR:3%?PPS1RI($GMI-OGV\@0Q31I)#*T4L@AG
MMY?+GCZ6+_7R?4?RIM__ ,><G^[0!CMXFU:+5X](N?#E]%NU-;5;J0H898S;
M><9T*;CL#@PXD$;%U)QM*,^YY;_\]V_3_"O%],\6Q>+OVW=:\#^,[6XU#2?#
MOA71M3\!Q:I\.-02WTK7!_:T&IW=KK$U@MF\\UC?V4 A@O))U2*]!BB7SB_M
M5 $;PSDYCNV''1E!!_E_DT[8Y',S=.< 4ZB@!C12%<"Y<>^!Q^E)+%,[ I=,
MGL%'/7U'O^GUS)10 WRW_P">[?I_A7D_[9RNOP@T<^86_P"+L> N&QC_ )&[
M2.>*]:KR?]M#_DC^CY_Z*QX"_P#4NTB@#C?^"3<20_\ !+K]F\6LS,[_  "\
M'/M9AA<Z):<9QG'YG]*]TO\ 45T66"PMIOM5]<*RPVYVJTN,?,Q4?*B[@6;'
M&1C)(5O!O^"7.MVNE?\ !+K]F>"V@\R[O/@'X/\ L=KN./\ D"6?5L'9&#M!
M8C@E1RS*#[7J$Z^%7!MXEU3Q!JK 0Q,WE^9LP&?^(PV\0DR>N-^!ODE < BU
MJZE\';!I-L=4\2:RSK:V[LZ0RR+&6)=@K_9;9<#+X(#.  \LJK)+9Z<OA6Y:
MYN+Y]4U_5F^>1E5&D522$& ?*MHMYP.2-Q),DLA+NLM,B\+2-?W1_M3Q!J@5
M)[I81&9@A)51U\FWBWMM7)V[V)+RR,TFE8V;Z3&TEW=-=7MRVZ28J55F  "J
M.?+0=ER>Y)+$D@#-.T[^R@TUY?M=7TW^OG6-59EW,54#LB[B .<#)))))>5:
MQN5'F-+=7'\*J!TP"QXZ#Y?Z<D ER\MG*I@+3W4N?+@:3Y1DYR?11TS[XP20
M"L%G_9CM</(UQ<W##S)&P .> !V49  Y/KDY- "16T]F%,EU))=R*/,=5.QF
M"X/!)V+G)P,?CSF29S80M+<32-)*^U/+P2">  ,8[#J.#UXITK1VB_:YHVDE
M;[JJ.>!T'/7&?UJ.:=+:>/SV1KJ93Y,&[DXP3MSUQQGI^% "7<L\$?F",27>
MQC! )5&YMI.W)''<9Q]:J:KJ%IX87^TM2DEN+Z\E$%K:VJ!I)W.XK%&I..@)
M+$A0%+,5525;J.J6_A.R_MO7_P#2=0N-L44-K%EG8X_=1_[(.6+,0% 9F*JI
M*U)1!H++XN\76RW&MWBBUL=/M760E\&06MMOV[B=A=G.S(3>^Q(P(P!L<5UH
M$;>*_%MR]QK%\XM[.UT]6<(&.4MX4;&3@;I)"%!V&1]D<:K%%J%S#X4B7Q=X
MTDDN-:OMMG9V>F0_:&M_-*_Z+;#8&9-R!Y)6"Y$9DD\N*(+%+?7EOX/"^+/%
MV+S6KUC:Z=9V:[F&[YOLEL&QG(3?)(VW=Y9D<QQQJL3DTF#2;C_A.?%EO%=:
M]-;O:V,<(5C;(^US9VQ;;PQB1G=L;VCWML1$6, ^#?V?/-M?",^HZ]'')J$F
MI2"*WMY2ZQ9CC/DP[@,CC)<@;OO-M50%ROV@OA=\??B+XP\"S_#SXDZ?HN@Z
M?K?VWQE;74)E:Y2&6WN+2*&-8EDDQ-!EC]H@7HTB3I^X&U\!0(/"%U=WP$DS
MWSA8U_ZYH=BCGL.O<C)P  O>>0OG+=7 W,&_=KM4LF1R >/Y_D*_'<U=LRJ^
MOZ(_H; K_8X>A1T'PEHOA^[DUE+3S-1N(VAFU"XFDFN)$:>6X\DRRLTGE+)-
M(4C+>7$IVH$0 #05&2;[3/(WHL>_IR#@8QW'N3ZXP XJA_>RHK8^Z=N2,\<?
M6AWBA4W%U,J*N,ECP.<?B><>I[5YQUJ*0-MA9KVZ=O+3^!5!Q[#IDGH!G))
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MRC*RG8F?E'S-\^T11:NTU_;0:M?EH;6.\MWMX&W*3^]'[R0<=CPA'RXW-\V
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MOEMP&[S)-VY$E (V6X7_ (H#P)<26PM@!J.IM^\-F'^?AI WG7+YW?.6QO\
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MI*C?_CXC_P!UOZ4 24444 %%%% !7FW[8W@OQ3\2?V3OB;\.O ^D/J&LZ_\
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M^-7_ $C]^+7_ (,O"W_R[KA_V+_AS\:;?]LC]H3]HKXE_!76O!>C_$8^$_\
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M'<+:$''H#)(<;RF]MB(B1V[2TGM8CK/B%UGOI(]NR ?+ IP3%%G!QD9+'ER
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M+*37[N_NI4CC:"S2:WEM(_M#,HD>SCA8[_(5_5*J-J.C,5)O(<K]TB0#%/\
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MY8#$;5)7[W)!8X^@W$#L:X?X$HZ^%[N6_.WR]2;RX^"(R(D&<@?,Q)/)S@'
MZ$GLIY([.%M4U*4[4.57:6VYX 4 99SD# !)) &>_P".YM_R,JOK^B/Z&P/^
MYP]!TKI;PF^U*;:/EVJ1]TG "X!.6).!CDDX'O7GGALX?^$AUPF-81F"!E#&
M,M\HP!]Z5L[0!GKM7.26)KB*P@.O:\_D+#_J8V.[RLG:I^7.9&R%P,XSM7.2
M6996D]PR^(/$D(5UQ)9V;KN-GE<8;!*O+DGYE^[G:I/+-YIV"VVGR3W$>O\
MB6)4FA8_9+7S0Z6V<J'&!S*RG:>2%W%5SEF>WR"+V]4@C_4P]TR/K@MUY'0<
M#N2A+(/M]^=F.(HF;A,G SV+'(&>@Z#N3)&K*1=WJ;)%;"+N/R?-@''0-[CL
M<>M ;#H%;=]J8%F9/D4J,QC'('UZG/IVIOG%D:=QB-<X*Y^=2!PRXY&1FAB9
M%S,B[?EVJP_B!."IX/.<>^!^+HU>7;/*>OS*O=<C!!]?\]>M,0%6'[Z[VJJK
MDK]X+S][H>0/3WZTTRK<0^9(RBWVARLD>,\9YSV''IR*$DDF_?2B2&-<G:S
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MM5@L;328KJ6/3HXXT^6/%DMON10%5MP4* %'55':VT-G;QVMM$J1QJ%557
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M->\5X3\0./\ @IK\(P/^B$_$7_T]>":]VH !THH'2B@ HHHH **** "BBB@
MHHHH *SKG_D;+/\ [!UU_P"C(*T:SKG_ )&RS_[!UU_Z,@H T:*** "HW_X^
M(_\ =;^E25&__'Q'_NM_2@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .0^.'_(D6O_8U:#_Z=[2NOKD/CA_R)%K_ -C5H/\ Z=[2
MNOH **** "BBB@ HHHH XOX]_P#(CV'_ &.GAO\ ]/=E7:5Q?Q[_ .1'L/\
ML=/#?_I[LJ[2@".+_7R?4?RIM_S9R9'\-</^T8BS?!KQ=:SZIXPTZ"X\-WL%
MUK'P_MY)M<TV)X"KW=A'''*\EU"I,L21Q32L\8$<4KE8WW/A_P")[GQM\*="
M\9WNCR:?-J^@6M[-I\T-U&]LTL*.8F6\@M[A2I;:1/!#*",/%&V4 !H^$?"'
MA/X?^%=-\"> O"^G:'H>BV,-CH^C:18QVUK8VL2!(H(8HP$BC1%"JB@*H
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M?7DU\;_MJVW[:OPU_:Y\,_M8?"W4_ADWAGPGX+U+PSI/AWQ!I5_/J'B"2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!R'QP_Y$BU_[&K0?_3O:5U]<A\</^1(M?\ L:M!
M_P#3O:5U] !1110 4444 %%%% '%_'O_ )$>P_['3PW_ .GNRKM*XOX]_P#(
MCV'_ &.GAO\ ]/=E7:4 1Q@&:4$>G\JS]&\+^&O!'@VS\%^"_#MCH^CZ/IT5
MEI.DZ79I;VME:Q((XH(8HP%CC1%5510%50   *T(O]?)]1_*FW__ !YR?[M
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MW$"QS2J?W%P+B!59E<3Q >8 #JO#WB;1_%&G1:GI-PQ66/=Y,T;1S1^JR1L
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M !4;_P#'Q'_NM_2I*C?_ (^(_P#=;^E $E%%% !1110 4444 %%%% !1110
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MN/!GF(QZ!51<#"A$"1I\ERVLET.W^QZ<6GNII/,N)YL,\C'J[\KV&!C & H
M  !;Z:-'LI+/2W:2ZN79[BZD8%WD*@>:W&,C"@+@ * J@* !:M(#;)RNZ21L
MR?-TR<X_4^E !:1/;1".1MTK<L=Q;'XGG%#W(C?[/$ TW^UQ_P#K[],T2SO$
M?)@7?(W.[G:.<<X_^L.#R*#)#9XBC^>1F^ZN<^I]>@/\A0 (D%F50;3))],^
MY]<9_4U"S+:NT,8\R\E0[=V<#ABNXX.T<8S_ %I3)!:W/E0HTD\^3^[4?(,J
M"<DXP"P.,YZX!JKJ>K#P]:PV-O"UYJ5U\L$$>?G;&2[?>\N)>[<@9  9F56
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M+_1]7TN\2XM;ZUFC62*>&6,E)8W1E974E65@02"#6E0 4444 %%%% !1110
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M"/\ [(3\1?\ T]>":]VKPGX@_P#*3;X1_P#9"?B+_P"GKP37NU  .E% Z44
M%%%% !1110 4444 %%%% !6=<_\ (V6?_8.NO_1D%:-9US_R-EG_ -@ZZ_\
M1D% &C1110 5&_\ Q\1_[K?TJ2HW_P"/B/\ W6_I0!)1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '(?'#_ )$BU_[&K0?_ $[VE=?7
M(?'#_D2+7_L:M!_].]I77T %%%% !115.^US3M/O+?3II6:XNF;R8(8R[E1C
M<Y R0@)4%C\H+*"<L,@%RBLAO%T5JT*ZOH.I6/GS^5&\ML)$!$;R%G>%G6)
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MIYB>3;MAC&Q.%''+.20,+GDX&>I '7-X+.W.KZJC+Y>[R88\EF!Z+M!.YSV
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M!50&\V3/ 4<D _=P"><;7;VU1%U+40UK8QC>MO=+M8D$D2OS\I'!"_P]3\V
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M^X?OL=L8.4]\@D@\8Y, 4>(5P,?V;M[?\O8X(.0?]5_Z'_N??8TNX@":ZF
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M.2S2MD;F9O8< =  %    ;8V$&D6[V5C)YMY-AKJZ8)YDDFW'FR 8SP .
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\5QZ:-3\7?$JW.FV4=I!_97Q@\0V9>-1@&4PWRF>3')ED+2,>68DFOGW]O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$?\ V0GXB_\ IZ\$U[M7A/Q!_P"4FWPC_P"R$_$7_P!/7@FO=J  =**!THH
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M7\>_^1'L/^QT\-_^GNRKM* (XO\ 7R?4?RIM_P#\><G^[3HO]?)]1_*FW_\
MQYR?[M 'CWA3XS^//B!\9Y/ EG\,O'&CZ/H/B))%\1QVJ1:?J]FUOJEK)'<K
MJ4,<Z"*^LF.VS$GF1W&CW4=Q+;7=PD/::'_R<+XH_P"Q,T'_ -*]7K;UGX>^
M ?$?BS1O'OB#P1I%]KGAT7 \/ZU>:;%)=Z8+A%2<6\S*7A\Q%57V$;PH#9 %
M8FAG/[0OBC'_ $)FA?\ I7J] '8JB1@[(P._RCK7G?BGXOZUJGQ0L_@U\)KW
M09M5=;R77-0U"X,\>BQVT-N[QM;PL'EN6:_TXK \D \BY>;S#LCBG[KQ%IEY
MK?A^^T;3O$%YI-Q>6<L,&K:>D+7%D[(56>(3QR1%T)W*)(W3(&Y6&5/D?P]_
M9R\9?!W7[7QAH?Q O_%]U:?VM$UOXFATZQ=UU._L+BZF1M,L+:'>#:S7&QH=
MT\]T_F3Q@^8 #KCH?BCP5HE\WP_U_4/$?B.XTN2\C@\6:E.EIJMY#:V]NGF3
MQPR1:8)&AB++;0",-+<S+;2.SFNTTZZ:^T^WO63:9H5<KZ9&<5XM\.8OBWH_
MC4W6D?$CXH>-$N8=E]I/Q%TO2-)TK1E_M"&*;;-9Z3%<W%TL*W30+&T]O*L6
M9)8DN+>Y/M&GV0L;""R+;O)A5-V,9P,9Q0!Q?[.NF?#G2? .I6WPL\17FJ:6
M_COQ1-<W%]&5>/4I->OY-1@&8X_DBOFNHD.#E(U(>08=L#]M-@GP=TAR#\OQ
M8\!'@9_YF[2*L?LU^!] ^'/@C7!X,\=?\)%::E\1_%.I7UU'YICM[FXUZ\EN
M+5(VE98OLTC2P/LP'DA>38&=E-/]M"_MS\&=+GC8NL?Q4\!2'RU+$C_A+=).
M !DD\=!SF@#B_P#@E?+!I/\ P2P_9PUC7KL-#%\!/!HM8XU)ZZ+9A0J]6D8D
M*!R22%'4Y]RF\O38&\=>,VD5K2$FULU4RFVSQA50'S)WSL^0$\A$!RQD\'_X
M)71Z?I'_  2Y_9M\5^*;Y0EK\ _!RV2;BRQ;M%M$4J,9>:3(4  G+;$SN8O[
M=IEGJ-W+_P + ^(3&T\N/=INCELC3D9<'S-K,LMRQ."RY"AO*CR"\DP [2=.
MU34;K_A-?B#MM_+DQI>CB59([%265)"RC+W,BN%;!94SY4>X%Y)M<"0[=:U=
M/+9?^/6U8_ZG( PVTD,Y/&X9P#M7.6++;I)(W]MZNPCV@FWAW96%2.K8.&<C
MJ>B@[5XW,WDG[-G[26M?M Z]XKU'7/#Z^&)/#MPEC/\ "_7(8O\ A*=$N(IK
MI&N]0$-U+ L5YY2O9B'?')!#]H6YG%T(K4 ]B:*.4K?78XC&44YX]\>N#CIF
MF-<+$C:E?.R*HVK&6^5>0#G!P3D=3T'3'.4>5%3^U-0B:,1@[(V;[O)Y _O$
M'U]AU.7QI(\C7E[)^[X\J)E VGUY'7I_GB@!$1VW7.H!/+1@88Q&?E'J>3GG
MV'X5Y5^SOHWPLT_XO?'K6?!7C>XU+4+[XK6EWXVL;BU>*/1M47PCX=A2U1F5
M1,OV&"PN=ZEU#7;+N#(RKZPJ_:7,URN$3[JLO0_WNGH?PKQK]G/3OAUX<^,'
M[1'BG1_B6NHR7WQ:L]1\5:?<:7+9CP]>IX,\-PBT>20[;D&S@M+SS$PJB\\M
MAOA; !['=7%M;6\FHZK/';VMNI=FFD"J@7.78YQMQ@C/3J>>F';QCQ.5\8^*
M8VL]*LV%UI]I>,T7RJNX7-PCA=A7YF6-QE.'?#A5B1%M_$J'QCXP@6STBSQ=
M6-KJ*^5M6/#BZN%D \LJ0'5&P4VJ[XD 6)]W/;:I!-XL\83)8Z'IT9N88KQ_
M*7;&"QNK@DX"@#<J-C9C>_S[1$ .EC&OM_PD'B=OL>DV,OG6MG=$('*$,MS/
MG[N" R1G[N [_/M6*.&&7Q/_ ,51XBC:STFS)N--L;C]WY@ 5UNKE'4&-U(8
MI$?N##N/,VK#)#:R^)Y_^$@\46S6NEVLHET_3KP!2S(V5NIN>.@:.,X*<.X\
MS:L-A+>X\2R?VCJ4;1V4+;K.T;*L[KG][)S_ -\I_#]YOFP(P#X%^ -L-3\)
M7$VH6R_9SJ!,5I-'U^2(AW4C\E(XZGYL!?0&9'_?S%E5>5]^.I_#/7^>*X;X
M"1J/"ERCA5C74"%7U_=QX_7H*[656=EFFE3R5VL,Q]^3DD],# _/MU_'<V_Y
M&57U_1']#X'_ '.'H2*'E8F:$ *WR_,?FX'..F,]#^(]VF22\D\[=)L!S[N<
MG((QG'\_YC@SG#Q[8QQAOXB<%2.?\GT[IY4U[)B565-WRK_$QR00?8_J/8\^
M<=0V-#J&T+Q;L. OW9E/3!S]W\.1[$[FN9=3FQ&\T=NK?,WW3/\ *.XY"Y[@
M@MCT)!1B=6QY,JFS[LC?ZT@G(_W>Q'?GM42JFMQ[0JKIJ*?EV\7( .>,?ZK'
M_??^Y]]#2ZBX/B$XQ_Q+_P ?]*_^U_\ H?\ N??@#_\ "5R?NW_XE(7#<%6N
MVY!4YZ1=#_TTSV7[["3XPD_B71XSG<) 5U'[K*P*D_N1R"#]\C^Y]_1=!<L(
MRVRWC^\H7;OP>A/]WV'WN_'# $;6Z:B/)4HME]YHX\?Z1D9YXQLYSQRQZ_+D
M/95X[EBZ2;E#'=T(8XZ]3GK[<T(5G;:%;"G'<9;/T'3'8FG'>X#1LT;;F5NQ
MQT_S[4"",*B*+;:J[?N^7C'/;H11_K')7Y1N^;:N,FD8^9QGY1WSU]OI03YF
MZ% NW&&;;T]ASU[YP1T [X!_"/. H6,,K*P.X8QP>@]??TZ=<XJRR3:A*UM;
MR,D<;;9IE;EN/NKW'NW;&!SRJW!ENI#;J&CA7F6;)4M[*1^K9XZ#GE:CR7&K
MS?V?I5RT-K;R;+BZA8;MR':84Z\@C#.,;/NK\X)C8@F>ZU>Y?3K!FAM8V9;N
MZC+1N6^4^7'P.Q8,X/R$%5^?)B=(/[44Z1IQ:&RB_=375K)M;*\&*,]L< N,
MX^Z.02K(4MKNV70]!CCATV&/R7>W&U=J_+Y,17[NW&"1T^ZO.2EY(8[>-=.L
M[98XDCVB-<IL7 V[>.F.F/3VH @G&GP6<=DL:1V\4D20!5^56\S 7 ^[AAV_
M3J%W#43]FLI56W5F6X:-BK;@<;5*D%<$8)]L#VS_ !#(-7M$L[:1E@74+433
M+C]]^]3**?3 P2.G08/(V&0!!:6_[M5&T[5QM '0>GX=* $B2WBB6SLHECC4
M;=L*A511Q@8X]N.F*<I5V\I 1MVAMORD8' _0=NAI0J[1"(<(5RHYVLN1[=,
M9Z'/ZTDDEQ+(85$B[,#S6^@Z=>0,<'C] 0!HG,SRPVR*F-WS;, ,2<_+QZY&
M.#W[ U[B>2XN/[,TN3RVC8?:I@O^K'7:..7(;/MG<>RL7,DMU_Q)[&XD5HU'
MG7(ZQ@Y/!Z%R1T/0-N(/ :NTXEF;P[X9D5&A;;>W<95Q:,0K[""3NF97# ,"
M "'?(*K(AA/+,;D>'M #(T:K]LO&!/V=&#$%696664D [23M#;WR"JR3 F(#
MP_HA,?D@&:X;+^4"<GDGYI6&3DYQG>V<A7A*+"C>&/# %OLW?:KJ/DVS."Y8
M;E823,6W_-G[^]\[E60.T,WA_P ,-'%Y4F;NX4!Q 699"#D_-*X<L-P/7>^=
MRAP!SQS1,NA^'SY>W'VJZ;YO*!!]<[Y3U^8G&[>^<JKSPQPVT7]EZ2C?NF59
MGW$LF[DG<V=S\ELG/J<Y *6R06D+:7H:+^[SYDC,6"L>3ECDF0D[B3GJ2V20
M&M0P1V*I#:P*JCYEC;.'&3DYSZ]3R>??- #8X%M[?[-:C ^8;E/S*QYW'(/<
MYR>I]>:<"QE98]J[FWR,HXSZ8_SQ^K269_LZ2$L% =F)+*N..>_MG_\ 6D\S
M0M]FM"GVAU#@2?W<X+D=QQCZ_0T"%NIWBVP6L+,[$[>ZQ*=QR23Z]!WY]*;;
MQM$OV-I996P#<2LQ#'/&Y>PS@]!@=AT%);VY@7_1UW-(Q\RX;#;F'\)/7C.!
MZ#IVHN+F:.6.PL8>>OS9*1H2>^<C!Y /WN@/4JP$N+N7S_L5H%:XD3YY&7B,
M[0 [@=1@<=R5QZE:<UP^E;-#TD&:^N!YDDTR'8O(!ED(P,G^&,$%R,+M569"
M6[&G2?\ "/Z1)]IOI/WMQ),0?)5B1YTH7!Q\I"H,;BNT;55F1T%LFDI_9NE+
MYUY-B2ZNI57+-MV^=-MVY)V;0!C.T*H55.Q#'BVCT]'T_2PSW4NZ62>7YF4G
MCS7/<\ !>,A=J@*OR^@?\$P-1\/P?!GQ-IGA^#-]'XZF&IF16!,[Z?92!BQ&
M&_=F/ !PJX4!0NT<1%;&T@\FS#LS$EII%+ ''WF/3T 7CL!@#CJ_^"3MK:6O
MPS^(S64"Y;XG.0VT!L-HFD,<X]Z^UX-_C5?1?J?$<=?\BN'^(^I8K."V;<%W
M2,Q/F-R>?Y<?H!1</(@\B!_WS+][C(]_\\4LL@5OLT#YD;ELYR!TSQ_GBF;?
ML,+);?O)MH.UNIX[X'?!Y/>OOS\D',#:+N1 \DC8W<_AUR>/\?I4<LLD+QVO
MWKB56;Y?X!QEL,>@)'3U%*3+:R1H%:66:3YV5/E'N<=./7T JEJFIMX=@CL+
M)&O=3O WV6"21@)'51N=B ?+C'!+ $ G !9E5@ U.^;0$2WL+?[=JEXQ6WB>
M3;OP2=SM@[8DW<GG&0 &9E5J1N+WPM9QQ29UCQ%J2L;>&3]T'91D[BH<06\>
MX MAL;E'[R5U$B23IX1N!%O;5_$6K,QAM_,2-Y(U=0S<_P"JMH?,7<?FV[@!
MYDLBB22WMY?#"-(TBZIX@U%5-Q,(]@FV?PJNYO(@3<VU<L%W$DR2.QD &VUH
MGA2Y,TC?VKKVJ,!=7+*D<LD2LY54&,+!"9<!,G:'9F+R.S267=?#X6>6W2^U
MJ^C"L(_D\S;U/);RX4+9/7&[ #.X#"S/X<C6"63^TM8OF9DC5@A<!@"?]B&,
M,N3R0"/ONX#R:?:)H:,]Q<"ZU2^RTDK97S6&2$ ^8QQ+DX7)"@DDLQ9F $TV
MP;0H#)=W7V[5KM5\^>3Y?-91P%7)$<:Y.%' R2269F:U#%'8#[;>[6NI%'FR
M#.!R.%SG:!GIWZ]<FB&#[#_I5R%EO)1AI%4<<$A1T.WCIUS^)JQ&NS]]*-TC
M=E]/:@#E_C#X^C^&/@*Z\6'^SYM2>:VL="LM4NI[>VNM4N[B*TL+:6:""XDM
MXI;N>")IEAE\H2&0H0A%>4_ _P"(G@'P!^QUX*T#]D2TU3XM6OAGP7I6BZ"E
MOK>G6FI-"-&@N;![\W1M4MI9K5[*9T\I9%6[CD%OL;CV_P 8>'_#/BKPQJ'A
M+QGX<L]:TO5[22SU'2-0LTN;>\@E4H\,L3@K)&RDAE8%2I.>,UA:_P"!O!NE
M_8O%<VD1V_B*RTNXT;PWJ>F64#WUC#<>6TEK:-)&0J.UM;R.C#RB;2)Y%VP*
M4 /.?%'B+Q78Z;X)L] -QX4\8:IXJU*^L_#?CB-==U%K41WB3.(;34ROE>==
MVY#I<F&VCN($<0J%BCWK3PU^TOH.I6WB7QK\7O!M_/<R1P36&D_#V\CF\HL"
M]O:R/JS)$Q ),SQL,@.Z[$6->I\+>!])^'ZW7B6ZM'N=:U6]EFD_TE[EEEG9
M6>&*1P',>47+$ *D2 ".&&***H_Q*^&^F>,=2\/MXUTO5O&NEVMO]L\*Z?JT
M,VH6@N4E>VA$!97C$PMYV620()%@D<L$A/E@&DDND?#K2H[S4))KN\G=;6RL
MX)&FDD<\^3&7.YV.&DDFD()VO)(RHGR?,/[>U_X0NO$WPI\&?$7QUK5K\4-6
MUS4_$?@C3/"6M:E:&W_L_37MYK>WN+'R6GA^T:C8I)#<'_2S/\T1C00P_4FD
M:5?Z3-)XL\9W0O-7NB8K>UL\F*WC)RMM K8R>,O*=ID*[V"(J1Q?.?[3GPD\
M%_&S]O7P#\(/C7IQU3P_XV_9E^*FA>(M+ANIHHYK&[U;P1!+;J\;*Z%HY74R
MJ5?)W IA0H!Z)H'Q]E\$_&;4O@?JFIWOB);+4D-Y?7U_HL$VAPWTSR6)G6*X
MB<6TTDZZ991M;+<2MI<[N]R29G]=\*^)--\9>&=/\6Z/#?1VFJ6,5W:QZEID
M]E<I'(@=5EM[A$F@D .&BE1)$;*LJL"!A_"7X(_##X'> O#/PS^&7A=;#1_!
MWAVVT'PS;S7,MS)I^FP0001VR33L\FSR[:#=EB7:,,Q9LM75T <SXZT+XBS:
MC;^*/A]XP6.6QL9X9/#.I6L3:?JC/+ X>24)]H@F189(HY(W:)%NY7DM[EDA
M$>9)X'^(OC+7K74/&'B>'1M(T[6(;Z'PYH4:2_;G@:[51=7<J!G@<-87(AAB
M@DBN+1D:XN8)&B/<T4 106D<$LDRCYI,!FYR0"<9R3Z_YXJ6BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** &S_P"H?_=/\J\AU/PE\:-._:=;
MQ_=ZM;_\(9?6/]G67A^WF@>)KH-I\J:C-&NE&Z%PPCO82YU!;6..TLA]GDDG
M>2#UZ?\ U#_[I_E3J /"?B#_ ,I-OA'_ -D)^(O_ *>O!->[5X3\0?\ E)M\
M(_\ LA/Q%_\ 3UX)KW:@ '2B@=** "BBB@ HHHH **** "BBB@ K.N?^1LL_
M^P==?^C(*T:SKG_D;+/_ +!UU_Z,@H T:*** "HW_P"/B/\ W6_I4E1O_P ?
M$?\ NM_2@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .0^.'_ ")%K_V-6@_^G>TKKZY#XX?\B1:_]C5H/_IWM*Z^@ HHHH ****
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M8^+O"\NL1Z#=:V9;70Y-/^P68M[2W&]+>-XKJ%3# ZVZO:>8D1EN)Y7^ /\
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MTT<+[61)8Y77<T?E@'K2NGB)QXH\1R?8]'L?W]G:7>8BQ49^T7 ;&T+]Y(V
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MYQMY()3P@*S*0N""0#H!THH'2B@ HHHH **** "BBB@ HHHH *SKG_D;+/\
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M>.C=><_CS0 V"$6\"PQL-W1G7N_!);J1D'.>2?J<T!<+Y4+GYF+,RCCD_-[
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M156-FH:M8^#[6+7/%,JS:I>M]GLK6W92\DA0R?9;?=MW<1LQ9MHQ&SN51/D
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M$'H:YCQ5X2O?%.KR3:WXLO$T&"&SFM]*T>::SG-Y!=BX,LMS#*'DB/EP)]G
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M8F=JD>826V"( ]$67_A)57Q3XCC:ST6U N;*UNLQF0* PN+A7 *%2-R1'[F
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MUF;,S+@-NQP<?AC(_P :X^/XD^+XY5LV^ _BZ2;RU:1C>:1DKD#[PO\ Y>^
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MCB5C][;NR<@;59B0H)  7U[#X?@_M341)<W<S>7;VMO@O([8Q%&#@'[N2QP
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M31NOCY]W T,,,C%59A\^"PRPQTX##GN.G< 1$%ZT=Q*C0PP<QJS%=W PW!'
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MG_V#KK_T9!6C6=<_\C99_P#8.NO_ $9!0!HT444 %1O_ ,?$?^ZW]*DJ-_\
MCXC_ -UOZ4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?%%YK+RV4,C16DTUW>1I/+<26Z0R3>9O99GD4RSX\^3I/M$7]_\ 2@!?,/\
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M&%(((;B'D]OWF/[G^LBR/B ,@&/PW&<\;E;52#^'^B\?]O'_ %Q_UX Q)?\
MA9(\U7V^%DP5DW#_ (G7".LBNK_\>GW@01_I'_7#_CX9;7=O\687VP;O"[+\
MLC!637$*@AE()S:\D=O.QD?N2#,MI>/\3W9HXF7PRK?NY0V#JY&"&4@Y%MVY
M \_'_/'!GM )XS?"_N]!C#!DVE?[1;.#D8'[@8/M-G_GG@R@ F_QM+A),>'U
M4!1M.=2;/.2?^7?IC_GKSUB/[WS#]G.X^&?B#XR?M"6O@G2]3L9K7XN6:>-Y
MKZX5H]1U+_A#_#;+)!Q^[M_L+6,94G<98I6^ZXSZ])&VN.UL5VV(QND5Q_I'
M'0%3PH[^O3IU\H_9G/PMN?C1^T%%\.1X@74#\7+%O'!UA(5M_P"U/^$-\->6
MMCY?S_9O[/\ L&[S0)!<?:<?)Y= 'L) NOW*KMC4X;WP>@_*G1QQK'Y47$?/
M\6<TJ(G*Q#:N[YMHQDU5\R;4+G9:3E;=" S*HPS!N5Y]1D'T^O0 )!=W\[6T
M3^7;JP$C!65F&,_*>A!XY'09[]'&::>7[+8HJPQ<2.N.2!]P?IS^'7H;97E_
ML^RC6&"$*&9,KZ$*HQC& 0>>/Y4YFDUL26>EW+P6<,C)<7$)&92I(:-&!RN"
M-K-U'(7#?,H!\"_ ]GU3PI=6UO<NJ_VHXNYT)5C^[CRBD <D_><'Y>0/FR4Z
MI676D.G:3((=/A8P2O;J 3C(*1L#@#H"PY7&T?-G9Q7P*676O"UYI>G-+:V4
M.I-'-<0+Y?F81 T41&"I&,%UX7.%^;)3OSFYV:?ICF&U@;9))#@=./*7CIV+
M#&,8'.=OXYFW_(RJ^OZ(_HC ?[G#T!8UE4:7ID?V>UA_=R-$NW  _P!6GICH
M6'3H/FR5E,(N$^Q) T=KY>-\;!0PY&T=\8'4$8]:(EBF1(+/RUM8\HRQDJ1C
MHJX(VX/7VXI_[H?Z):1*JKPRQC:J+TP,=#_+%><=7H/$B*1%$WW1]Y<83'8Y
M&#D _P _3,7^M9K:!"L>6$CKD;6_V?Q_+ZTY6,IV0+^[Z._9A@@CUS[]OJ*=
M&RQIY-HL?R_)_N8'7'?M0 $[5^SQ1L.FU^P'^>G;/K1ER?*C;_?DX_PQFFA0
MH^S6Y(V\,V22O?J>I_E^50WLDSL=(TQVAD9<RW"QJPA4X)Z]7(/'!VYW'L"!
ML-N+NX>Z72-#FC62-A]LF9"WD+UVC/!E/! .0 =Q!RH:-56(-H/A]?*V-FZN
M1SY.[).,@AY22#@]-VYLY57'>3S6T/1B59<&ZO&7=Y0)R1D_?E8$GG.W(=\Y
M57DBA2V"Z1HYVB/_ %TC/N,8.>26R6<GGYB2<[FSD;@ 2#[,BZ1I8**B_O)&
M)8H#SG+9WN<YYSUW,3D;DB)$W]EZ0V%C?-Y.S;MF2"0"<YD.<X[9W'J RB')
MDTK36DAVK^^NMOW2P)ZD?,Y//?'4]@UE4BA'V:RB6-=Q+;0."3DD]RQ]3^-
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MN+AL@MGF1\8R><!5QD  ;57*K:62Z3$+.SE::YDYEN;IBS,3QO<CKTX48'
MVJ.)XXXK<_9XI-TS8,CMMW'C&YL8ZXQP,<8X X0!!:I:Q^3#(S2-DM-(I+,<
M\L3C&?;C X PH D55C+/#\S;AN1F)_KP*%BB3S&B7,JJ"3W;T!/X8_SFB9Y5
M7$85I&/R@C SZG IB] E+(N+>%5D;^[C'U/(SC\Z551'W2EMS_=V_09QGH.A
M/U[Y%( 83N_UDC +\S8SSWP#@#GG'MU(IL\WV?\ =Q+NDDX1=V,]>IYP!Z\_
MB>"@] N;IX46!$WS,OR*J_3))[+SG^620#5NKLZ<5BCC^TWUQPD:,$,@5ADG
MKM10XR<' (^\S ,Z[N38%8HHVN;J;/EI\H;'<DXP$7/)[9  9F :-2^BJ'?_
M $W4+QEW+N958J,=,L8HA^/+?Q.Y+, &=% ,B?;-1O ?F6,+D GTR5A0O_M$
M;OXG<EIM/LSI:227-VUS=7# SSM&1N(#;5 &=B#D <]<G)));96::4DEQ-*U
MQ>7!W32,0"W/"J,_*BYX&3C.>222MW<_8R$BB\V\N-WV=&7'0$_,1G"C/7L#
MW)Y!BS2FT&88EGNI,'R]VW/.-QX.U0/8XZ<DG+K.Q2P+3R2M-<3,/-D9L;^P
M '0 #H![GDDDI;6<=B&N)7$UU)_K)GX+<_= YVJ,\ 9P#W.29HXTC?,T@\R0
MC<Q QUXP,C@9Z=?Q)-( C0)\[G=(<DG!].G? XX'ZY)-8'CWQ[#X,%II.D:4
MVK>(-4_=Z7I,,@C:95=5DN92<B&VB\U#++@D;HT199I(89.@=XT*(RDR$,8_
ME!(/<;L?SX_"J;Z?I.FZC)XB?3;;^TKR&.W:XCB"S3QQ[WCA+$Y8*7E8#(52
M[D ;F)8C)\,>$(O!<5UK^MZG)K7B+5%C.IZG]G\MIW4$+#;Q%V^SVR%F\N'>
M0N]WD>262::3N/\ @F+$W@[X5>.?$NNV+S7VI_$9DT.UA*E[O&B:6#%;AF4<
MM!*68D#$9=RJ)\G.3.NDP_VCJFZYN6/EQ1P+N9B?^6:#CTR6.!P68JH^7J?^
M"7^N?9?A3XTUKQ# +G4K7QXVEZ9;6;$M)&=+T^Z6")78+OS*^^3Y-PC#OM2,
M!/M.#?XU7Y?J?$\=?\BJ"_O'TND*^'9#XF\3S?:]6O',%I!:J6\L,=PMH <<
M80,\AQN*%WV(BK&EQ<-X93_A(_$8-[JUXWD6-C9[6(8C=]EM]VW.=A9I&VYV
MEW*1H!&7<P\+H?$_B-I+S5+J06UG:V:%B-[_ "6\*DXST+R':#L+N4CC C;9
M:;=:3)_PE_BO;=:U<((H[6VE+0VBGDP6^X+D<$M*P5I",ML4)'']^?DA)9Z9
M=:9=_P#"4^))6NM6N5-O#':JSPV<;-D11KQD9";Y2 7(#'8@5(]*S@DA7^U=
M5.ZX:,;E5MRQ+@95. <9Y)(W'OT !86<\8_M+5BK73+MZY6(9^XIQT) RV 6
M(&0, !\MU#$%GN"<S,%ACD[\9QWP>OO^E #Y)D1@)V&YVS%'NP3@^GY>O7Z"
MFQ[8@M]J,<:S;,?NSNQZ@< G\NE-4-;I]MU/;)*I(C\N/IR< <GDC&>:BFEL
M4B_MO5KA?*P%A^;<A#G"X'\3-N"@8R2<#KR .EG6Q276-8N-L:_+'&BDXY&
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MEK?AW4OLTL/VNQNX$G@F\N94DCW1R(VUU5AG#*""!T% !1110 4444 %%%%
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MP+I?P]U2R^'?B2XU;3_^%A>+);B\N;-H2M]+X@U"6]@ 9066&[>>!7 PXA#
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M=NQ--N_U _(Y?T!X'4]0&I3&9E;PSX<N&B:-=EW?;PS6F4X*[U97F/RMM8$
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MC(X432]\>B@<XP-J@E9M-TZWT2)K*PE::ZF827=U<$-)+(1CS9<;<D[<< #
M &U5XI:M9PZ791VFG!9+Q[ZWDN+B;+$EID'F.??;@+D9"8&%7*ZL$<%@JVB.
MTDTC%W>1E+NQ'+GIZ <#        '+%';I]G@=C(^29&R23GEB<8S[<#' X
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MB@ HHHH **** "LZY_Y&RS_[!UU_Z,@K1K.N?^1LL_\ L'77_HR"@#1HHHH
M*C?_ (^(_P#=;^E25&__ !\1_P"ZW]* )**** "BBB@ HHHH **** "BBB@
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MW[0WB/3=8\?V?A+38?'&KZ+'ML[[6%M8UO9X!Y<6(GG$C(/+CPK#Y%^Z.MH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIX]^,GC;0_#GAG3H ^K:UXFU.*QL+:-F"#SIYV6.-69E7YB 2P'.<4 >#?\
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M5C$ >SZ9I>F1Z=%X0\'V4.G:/I\2VK'3XQ"BHB^7]G@\LCR]FT*6 &P#8OS
MF/0C$%T%LM,/E6]O\FZ#Y57 QL '!&#C'8CVHC"2L-,L+;R;:W55#1J%0;2,
M*HQT&,<<#IUZ2;7C6.RT^)5B7Y6;<?D&.W'/..X_2@!NTQ;=+T^U*1JA#2)A
M53IQP<Y.3T'4=JCQ(86TVS:3RXHP&NO,&[/U_O?A_P#75(#C^S+*/;;[&WS;
MCU)Z#]>AX_(&7")%]CMHR8XXR&+,2/ID]?S[<T ?GY\!%>#PK-# D;#^T&,F
M7 (_=IV'J?Z_AW"\-Y,&?^FDF[D<8_$]!].?8\5\"_)_X1N]BT^!H8SJ<A52
MV[8I1#C)'S'_ /6?2NKN[HW,BZ;I,D;,DFVXN$(;[*0 >.H,G/0_=ZL#PK?C
MN;?\C*KZ_HC^A\#_ +G#T);F:4.VE:>S1S*HW3;<^2#GU!&_CC/3()SP#3EN
M&EDD\.^'Y]DD9VWU['L8VS,H;H00TS!@V"" &#MG*+(Z036X7P[X>'DF':;F
MY9-RPJ6!*\GF5@21G(7.]LY59'10+8VD>@:'')MC4*\\CM(T:]V+N29)#U)8
MDDDLV<X;S3K'6RVMB5T70K58U$C/-(JG"%FWL2>\CDLQ).26+,22 P"2RZ)I
M3R1^2J_:+EHRWECTR3S(PYYSQ\QSD!FRB0[=%T2)EC+-]JNU92(,_,<;L[Y&
M)'&#C=N;C :Y%%';P+8V.56,;<LQ8KWR2?O-SDYY.<F@/0<JK$HM;9=N/O'T
MX^]SG+''?KU-$?/$ 5EC/SGS.I]/KZ_6C;DF"'Y.I9F4XR>?QSS^/7%->4[C
M%;,K29!D]AGD_P#UJ \D !@1;6S ^7(RWS!.,@D=>33=C(IM[9_F;+%V7<,Y
MP>XP<_\ UNG!&BQ,((B68M^]8$!OJ>/P^O X!Q7N;LV]RNB6 W7LJJTDFSY8
M5QCS)/8@<*.6Q@8 +*Q#KR^9+A=%TLJ]TT9?;(S;88\GYF/89R%7JQX& "RM
MC@331]BTY!)>38>XN)5^^> 99".^!@*,9Q@;5!*D2?V</[.L<37DQ\RXGD7N
M>#(^/IA5&.FU=JJ2K9[K^S&_LO2X&NKV3$DY;&0""/-D/ R=N%7C.,#"J2J'
ML-GNUL'.AZ/)YNH2H9))9%\P19X$LN"."1@*,9VX&U5)5UC:P:.&L+,>9=SY
MGNIV12S,>/,DQMSG 4 8X7  53M+2,:5_P 2JTE:YNY29;B:9B3SQYC^F<;5
M48!(PH55)6S%&+.)XK5/,E)#2,V"S,1C<WW<].V,    8% "J%M5\JVC+.SY
M9F8\GN2<'MTSQ@ # Q4@5X8\1QLW=VQ[\G\:<L;!"T04DM\YW8R?UY^M-,L0
M=A&<R;5W1[AD>^,\=:8>1#JL#3P^7!(=WVJ*15)P,*ZDC\54_C[5-'"L(Z;V
M;EOFQDX[9)QP*JZJJVT,;12"-WO(2S=R#*H(X'(YQ],U8N)D1V6!8_M$BDHO
M3.!P#[#^9]302*66!NC,\CY;&6V@GKC/"CI@?S.3!<W4EI&MNA$UU-RD/F%5
M9@ ">^Q0",GG _O,0&+F>.SD\N >==7!80JQP3CGD@':BY&3CC<."S -7FE3
M0%6*-&O-0O&/EH<*9,'/4#Y(DR?7&?XG8E@8%H-#EC0I]NU*\.Q6 ",Z@]3U
MV1)N]\9_B=LM/9VG]FKY]U*;B[FPLUQMQNQG Q_ HSPHX!/=F)*V]H=-WN\@
MNKJ9LR3;=I8#L.I1!GA?4]V;)+NXEL<&"VDN+F;Y8DZ94'^-@-H502<X]0,D
MX((;=:@UF\=J0T]W,V8[=<'9Q@N?[B#@$YQD@<EAF33K+[ K2W,HFN[A0UQ,
ML>W>RKT YPHYP/?U8Y+&T%D2TUS)-<7#9DDD;MDX '\*J&Z#]2>9BTBY;R@7
M92RIP"0.V>Y^I'/I2*!25W$)\[8W8).!GC/MGO@#OZT.\B0L$*^8WW<]&;G&
M<8^G;@?C3CYL4>3^\;=C/3)]!GV!('UZ<U#)/%:K%]ID\RX"[%"CER3V Z X
MZ]L9X'  "YE@MF6XF&Z1L+'&J\DXZ+_4GTR<#I7EN(M.B_M"_C\RZF^2*WB;
M+.V,B)-Q SP3DX'!9B%7Y5DN8=.'VV_7=<S,(XH8@&8G&1&G0G@$DG'"ECA5
M^5(XY+#_ (FNJXDNYL1QPP_,$R ?*C) SR,EB!G&3M50% &BWCTZ;^V=859K
MYMT4 ACW>6K8)BC.,X.P,S'&=NX[550G$^"M/M/!FLZCK$?A'36_M#4+Z&.^
M2&.WU"Z<7<EPMI'!]EM_,C6YEO6$K.P<(ERQ8W$CQ]OY\=AC4M49I+J4K%'#
M"I8KGD1HN>O4EN,A=S;54;,O2_"6@:#K=_X]_P"$?L7U[5$1+N6SM8_,D "A
M4WX#,=L40,C<L(4SM1$6.DR)1YK'$_"R/Q#9^-DU#QGX<UJZU1='N($NM068
M?V*D[6<L>E+,P6+4V^23-XI9D6S596WN6??\ V_P_M/$MBB_$.UU'Q)8^'6L
M;R-=6B$\\*&UE>6>V@VJ[I]IMCO,?[M;M-@C6Y(?/^ ]UI%K;V/@^VUO6KFZ
MTC2ULY[&31;B#3["2-$!@@EN+=)'4 80/*[LBAFW$ CSK]E;X[0?$WXX^(-#
M\6_"6\T;Q%9KJJQS366E7!L7@DTX7U@+^PO)6F*QW&CJR/%&0]NRL[F+9"Q+
M<^C&W*A:X;Y6*_NL@J6 X(SW/;I[]Z[/_@E[X9MO#GPE\7:_/+&W]J>/)+BW
M&T!E7^R]-C*'ID[X6(]0<\$FN-D,%JAGNYQ][:9,\'L !ZGTZDGZ"NF_X)4S
MWM]\-?'TNI7+3)9?$AH[&-II'\J/^Q-(;Y0Q^7+-(2H&,N??/V7!O\:KZ+]3
MXOCK_D5P_P 7Z'U"J3>;_:%ZN"%Q"N>5SU4CIG(&"#DD_G+++%8PM=WTO"M\
MI^IP !Z\[0!R?QQ3998]/A>^O)>V<;23NX&T 9)).,  DGIG.*S[[4;;1PWB
M/Q7>+;QQR^7:V^T.2Q)5/+"C>\CABH0 DD[0"<EOOS\E&W.JPZ/:OXK\7SK;
MPQ\6]NJ.S*S?*%"#)DE;@*J DEMJ[B<M26T5KQ?'_P 1(H[=K5P-'T^3;*+!
MFW1AP5!WW4JR;#L+ ;O*CW9=YGQQRB4?$#QS ;=K:,_V;IH7S6L@^%P0F[S;
ME^%^3<!N\N/=EWEN6MM/-<CQ7XF5H6A4_8K L&%HIXW';G=,P."1D*"40D%V
MD $L;.\NIU\7>)H71XHBUAINW)L@4^;<%9EDG/*EER%4E$X+O)?M5ENI6OKS
M<JJQ$49R% ]2,\GW[<X]2VU6>[E^V:E;>7MVF&%]K;&P1D' .<''\O4VFDC5
MM\S!?[BYY^M  S*H\Z7(7LI'^>:B,/FM]JNW4(O*KVQ@CG/L1T__ %J(/-?[
M5.N..%'48P>WOVJ.Z>-";R^F,<,7S* 3SP<YQR1T..V* $GDC++>7]PL4(8*
ML<C#YFR-OXYR  >?RPR..*=!JNKQPJD+&2VW9'EKM*[CNQM)5B".U$LD5M%<
M:OKUQ#%;PG>OG*%$*+SN9LX/(W#ICCN*S]1$5XDGB;Q5>PV6CZ>K7&R\8)&(
MU4/]HE+[?**,NX9X4#<?F(V  [MJHD\1^*'2RTBS5IHX;J0(H5#N^T39X P"
M0I.$ #-\V!'YQ^UO82>,/V5OB5KGB:T,&DVO@'6)=,TNZC ,LBV;O'=3HRY1
MU=0T41^X<.X\W8L'H<$=UXGN5\2^*()+'2K.3S=-TRZ78[NC-BZGPQ&"-KQ0
ML 8\!Y!YNU(//_VLH;[7_P!EKXG:WXC4VFGP> =::QL;C +M]AE"S2=,?-RD
M9Y!(9OFVK& =^TD6H6?_  EGB^5;#1]/C^TPPWA,6WRRQ^T39; 4+AE5@-N-
MS8;"Q\]\3/B7H7@O3[7QU\3/#_B631%OUCTW2]!\':CK-R\Z[Y%NKB#3X9Y%
M0"/='O0+&=I<B5HTBZ.TMKKQ/+;^(-<B:VTNTVSZ?8SJT;NP'%Q.IQC@Y2)A
M\F [_O-JPZ,3?VK<I<7]H8X58FWCF&&;!1A(01E2&' ^A(ST /.?$?[47PWT
MLZ9J>M^&/B4]K?6*WMG;Z;\&_$MV61Q\IN%AT]S"X'_+&79(A/SJ"!CYM_X*
M,_M@_"#Q#'X+^&<'C/XJ>%M4^W7GB,B#X.:Q#;W&CV^EO#=/>W%[I,D-M8))
MJ=E'<W):#[*+E=\T!!=?N']Y=2?O4*P]0=W7G\^<_I7S-^T_\,? ?QQ_;\^'
M_P %OBIX?&I^&?%W[,GQ6T7Q!IK7,L/VRQNM5\#P3P[XF62/='(R[D97&<JP
M(!H ^GHD5HU=96PPR/FIWE_[;?G6#\)_A=X$^!WPL\,_!3X7:%_9?AGP?X?L
M]$\.Z;]JEG^R6%I D%O#YDS/))MBC1=SLS-C+$DDUT% #?+_ -MOSH\O_;;\
MZ=10 WR_]MOSH\O_ &V_.G44 -\O_;;\Z/+_ -MOSIU% #?+_P!MOSH\O_;;
M\Z=10 WR_P#;;\Z/+_VV_.G44 -\O_;;\Z/+_P!MOSIU% #?+_VV_.CR_P#;
M;\Z=10 WR_\ ;;\Z/+_VV_.G44 -\O\ VV_.CR_]MOSIU% #?+_VV_.CR_\
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M5"#&=R(1*KM!<M;73DTZ/PQX6AAT[1=.C\B22SQ%''&F5-O!M(\L)MVLPP$
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M@!+:%;*-H;9=TK-NE=FY=N!N8XZX [8    & )8QL01M,HDXW;E^]ZGC'Z4
M,J>49#O925;KWZ\GH*)+B(3[1_K&7[H/(4=S^=,02NBR;O*!E93MX_3../\
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MW^!/BR;5UF D.Z328],.H00_NF_?R6ZPDE ')D0-4_X;D^#'_"L/^%NCP/\
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M1^\U*867B2S\0?9QJ$5G&ERT"A[1YXY&$SHRIYNU([B8G;)E*[2@!L_^H?\
MW3_*G4V?_4/_ +I_E7(V_C/6(O&6L>&M0UW269-4A.DV\<;*T-F8+02).V]M
MTWG2NR@!/EFMP1SO8 \Y^(/_ "DV^$?_ &0GXB_^GKP37NU>$_$'_E)M\(_^
MR$_$7_T]>":]VH !THH'2B@ HHHH **** "BBB@ HHHH *SKG_D;+/\ [!UU
M_P"C(*T:SKG_ )&RS_[!UU_Z,@H T:*** "HW_X^(_\ =;^E25&__'Q'_NM_
M2@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .0^.'
M_(D6O_8U:#_Z=[2NOKD/CA_R)%K_ -C5H/\ Z=[2NOH **** "BBB@ HHHH
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M(QVPH21YKGKC(. .6(P, $J1QKIF[3M,+33S/YLTT_\ %T7S'VC&<# 48SC
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M!//0DM@<*68JJ_*6]N]G)_;.K[9+R91%''&VY8^/]5&2!U(RS$#<0"<*JJ@
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M_$'_ )2;?"/_ +(3\1?_ $]>":]VKPGX@_\ *3;X1_\ 9"?B+_Z>O!->[4
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M[4VJ/XTN[GP=X5B>VT>QS:ZEJ4.^$E@!_H]K@#*@95YD.(V!C3]XLA@^8?\
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MBK$-L5UI[SM&Q!R04G122#MY#8YQU-<A_P $:O!W[<>FZQ\=?$7CGXS>$9O
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M*C?_ (^(_P#=;^E $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ !CODY..1R1^.!Q_G.:0%75;.2ZCAACEC\W[1$Y:3@;5D#'IS[>O3/K5HF
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MG33UDUG6KGRXXVQ##][;DX' SND8G: N3SM7).2 $ERMG"VJZ_-'%'N5887
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M"1G@6VC-X<,&2->FUL;O_P!7^>.IA+Y=TJ#RASSW/^<U(J((]F-L:X"\]A0
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MRH\N/_GFOY4ZB@!OEQ_\\U_*CRX_^>:_E3J* &^7'_SS7\J/+C_YYK^5.HH
M;Y<?_/-?RH\N/_GFOY4ZB@!OEQ_\\U_*CRX_^>:_E3J* &^7'_SS7\J/+C_Y
MYK^5.HH ;Y<?_/-?RIMQ%&86RH&.?N9_0=:DJ.Z!,6%*CYE^\V!]X4 >=?L<
M^'_"7AC]D7X5^&O WC-/$VB:?\.=#MM'\2+IKV@U6UCL(5BNQ!(2T/FH%D\M
MB67=@DD9KT?RX_\ GFOY5YS^QQX03X>_LB?"OP#'XHTC7%T/X<:'IZZUX?OO
MM5AJ'DV$,?VBVFPOFP/MWH^!N1E.!G%>D4 -\N/_ )YK^5'EQ_\ /-?RIU%
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M ."6W[-=M82[%C^ O@T7#!?^H)9Y ]^?\]_H0G;MM;- B[OO*O YR>GX_C0
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M+X2\/-H]U8::T/\ 8.DMI6D9N)7\BU<P9CY8[\FV@^9LL-G!^9L[""=KAC*
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MW!'K]U?;)YP  'EMJI:[U&#;9PG?!#SF0C)WL >1Z*1[GG %J-OMA.>(T;&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Y#XX?\ (D6O_8U:#_Z=[2NOKD/CA_R)%K_V-6@_^G>TKKZ "BBB@ HH
MHH **** .+^/?_(CV'_8Z>&__3W95VE<7\>_^1'L/^QT\-_^GNRKM* (XO\
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MY<:F63&W<3C 48SMP-JJ2OH4$*Z= T%M'YDDSYEFD8;F;*Y<G'7  P!C;A0
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M\I-OA'_V0GXB_P#IZ\$U[M0 #I10.E% !1110 4444 %%%% !1110 5G7/\
MR-EG_P!@ZZ_]&05HUG7/_(V6?_8.NO\ T9!0!HT444 %1O\ \?$?^ZW]*DJ-
M_P#CXC_W6_I0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEO:V%K"@CB@ABC 2*-$555% 554    4 :H8$X!KC-#_ .3A?%'_ &)F@_\
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M&'[7/P?\+Z?KOPE\&:?X3\7:A\)K]--\%&71X91!KDIUXQW5S/%Y4,4[-IT
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MI+;3H=DD4@X !]BW]]XWAN6CTCPSIMQ;@#9+<:P\3GZJ(& _[Z-0?VG\2?\
MH3='_P#"@E_^1:J_ _0?BAX5^"O@_P +_&[QQ;^)_&FF^%]/M?%WB2TLDMHM
M6U2.VC2ZNTA156)99A)($5550V  !BNHH P?[3^)/_0FZ/\ ^%!+_P#(M']I
M_$G_ *$W1_\ PH)?_D6MZB@#!_M/XD_]";H__A02_P#R+1_:?Q)_Z$W1_P#P
MH)?_ )%K>HH P?[3^)/_ $)NC_\ A02__(M']I_$G_H3='_\*"7_ .1:WJ*
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MU8V,<4FHW2V\-LL\[* 9I!!;P0AW)81P1IG:B@ &B.E% Z44 %%%% !1110
M4444 %%%% !6=<_\C99_]@ZZ_P#1D%:-9US_ ,C99_\ 8.NO_1D% &C1110
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M"/\ [(3\1?\ T]>":]VKPGX@_P#*3;X1_P#9"?B+_P"GKP37NU  .E% Z44
M%%%% !1110 4444 %%%% !6=<_\ (V6?_8.NO_1D%:-9US_R-EG_ -@ZZ_\
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MPMX \*:7X$\#>&]/T;1-%T^&PT?1])LX[:UL;6&,1Q00Q1A4BC1%5510%55
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MCQ/H]GXE\/75OJ%A?6Z7&GW]G<)+%/"ZADDC=20RLI!# X(-6O-E_P"?9O\
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M/$WPR^ I?R[7PGY+6/B#Q_!NS)+>R ^9I^FR >4D$9$T\;2R,\:O!MW/A/\
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MP,:')/R)]T=\99L<6Q_[Z%>P?G1)14?FS;-WV5L[@-NX?G1YLO\ S[-_WT*
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M^&%08&%6- B*-EJSM+72G_LVVN6FNYV,EQ<3,K2%MNWS' QU"@#  XP  .
MLK'^R8_[.LKMI[Z3,MQ<7#<N2>7;''; 48P %& .+$=K%IN8[0%IIVW222-E
MGY')_/TP![ "B.TBL5\NV"FXEYDF(&YVQ]X_E]!P.E.E$EC'F&,232-M&YCC
MV/<XH \7U+QQ9:'^T1)IGQ#\>:YIFI?VHUOX)L=!\.ZQ'IUWI<T6FI-'J#R0
MRZ?/<'49?ENHQ&\4<D4*NN^Z\[V;:\+[D=9+A@!*V#Q^ Z<X_#\ZX'5M0\2Z
MAXHU*R\%>&_[4AM=<MAK\/B*SO%Q>!],=9-/^U%('@CM/-DWV[&/[2G&Z9;A
M:[Z:Y6S>.SC_ 'EU,&V94\@=6)[ <>G8#M0 EU>"S_T.UVM>31L\<;$G) ZM
MCHN<#..X%4[^_.A/';VULM]J]\#Y46X)YFT#+,0#Y<2;ERV#C<  SNJLMU>O
MH:PVJ(;[5;SB./<JLX##<Q/\,2;^3SC( #.RJV;JE])X+15MK?\ MCQ-K7RP
M1X>..61$[MB3[+:IU).0"^!YDTH$@ :AJ$7@J=8H(I-:\2ZQ@1PJ51I(T?EC
M_P \K:'S22>2 V/WLTBB2]8:0?#\$U[=S+>ZSJ"_Z5=%&57<+PH'S>3 O0+S
MC<22\CLSNT[3AX?1KV\D-]K%]\T\S#;NV]%4<^5"@8@ 9QDDEY'9G;JE^V@V
MZ6L:-?:M?#;&K+MWX!^8E0PCB0GD]!N_B=@' /@;X'7;67A&X2*,7%U)J#%8
M=^,_)&"V<$J@^AQV!8G=W-GIILA)<N\EQ<RE3-*S8W=  !T51T'U/5B2>%_9
MULS8^#+B>\D6:^DOB9IGXW-LCX7KM0$G"C. >Y))]!C3R6_>7'[R3 =N.1G@
M8R.!GIR?J<FOQW-O^1E5]?T1_0V!_P!SA;L$,7EC?*V^0\LVT]<=.^!QP#^>
M232@Q)*(Q(&E*C=ZD9/S;<\>Y'ISTH)B5E1E_>%6*94$].1G'\_Y4V:X^SQ;
MK@*SLV(D50"QQD*/?@G\,]J\TZQ)W$"-,L($TG"JAR6[ =L]LYP/4@ 8JW=S
M'I,*WVHD27DW[NWMXL;I9-I;RHP2,G"L>2!A2S%5!*NF<:9"M]J):>X9MD,<
M*!F+'_EF@./3))P, LQ51\L2(VEEM:U=O/OK@>5#! W &2PBB#,!GNS_ "[M
MNYMJHJH#\AT<*V$O]LZN!->S9BMUB3=Y2M@^3'P#@[ S,<;BNYMJJJHRZNI-
M)M_[4U!//OI5*6]I;LI+,5W>1%N*;L["=S8SM+-M5<(LS_V4G]JZKNGNI7$4
M,-O&6(RWRQQC\<LYP"%+L51 $+2"XL5_MK7) ]]-&(U@BD+1Q=_+3.._+2$#
M=C)VJJJC DMX9+*3^TM7D6:\ERL,,/\ RS4X/EQYP3PH+,<;MNXA55562SMF
MCE;5+M_,GDC QC ACR/E&<< X)/5CCC[JA8+?9,VI70_TB0,%C>3Y8P 3M7T
M!QDGJW&0,!1-)*$/F,C;O^6<9 W9P,C/IWYZ?AP"!Y O[QE+?-A54'YN3M)4
MG@@''YGCLKGR(FNKD_<7+*O(R,]/KP/KZ4B1X;SKEEW=%]AZ>Y_6F;I&(O+I
M2NW_ %<:L<#C&2>.OOT[4# .SR>9<X/S?Z/;D#(]R3_%UY'&.U+-<06@$\WS
M.1_"OS;25R,9^;:<>I].3BEGGCM8C)<=Y.."R[N0"."5!'ZGN<57N+F*QB;5
MM:F6.(%1#$R[C&S':!QG<[%@HV^N!G))!!<W$.G"35=;F2-%8+"BL6Z\* !]
MZ1B< #)YVC))S7\L +K_ (FVPM&1]FMF8$6[,2@QCK*VX+P3RVQ,Y)=J;DC;
MQ/XB+KY:EK:T52Y@5E'RE8RPEF)RN5!/S;$SEFDL6\<P;^V]8_=M'N%O;*VY
M85/&>!S(PP#C.W.U<Y9G0R&:S2]6+4O$#>6RS1O9V[;=T+AL@=2&E/W3C/!*
MKU+-H)$SLE[>H4D3)CC\W(CRN.<'#-@D9YQD@=R8[JQENXU>YD5&6:.55VAO
M+V/G'^\1P2,X[9[S,ZHOGSG:H_A].?;J:8>HN5+*9F"[F 13Z_U-,AW3M]KE
M@92@8*K+R /O'\=N<^GXDNCC>6?S)HF5EDVQ N,?7Z\D?3\R%BR;Y?E7 .UC
MCD<YR0"/QX/%(-P#22 LR?)NRJJ,[EP.".01GG\O2E=TA3S[R=845<R,S?*O
MN<>G3C/MGBD=U6(W5W(%5078EN%&.I^GY53<M=L=3U*1K6SM]SI%,0F[:<B6
M0YX  R%/ ZG) PQ#3.E] VKZM+'#IL<0E6.X0+P!DR2;ON@#!'3').> K>=1
M/]KZR/LUE;MOM[>X^4DJ3B:3GIT*H?N\,WSX$:[7U-_[7U4-#9VY\VWMY,J3
MC/[V4?JJ$?+@,WS8$:1_\3?_ (G&IEHK&-1);02@IN7 ;S90>A!'"G[O4\D!
M45L#+_:&[5-9+6UI:LTD<4DFT?+G]\YP,8'(&<+U/S<*]$.L.NH7@DCM8SOM
MX),INQR)'! (/4JI^[PQ ? C; PU4+JEZC06<+![>&;,;<#_ %DJG&T@X*HP
M^7 9L/@1VDC$X\VX410K@K')@ 8.0YS]WUYZ=3@]&(4PK=%9Y\^7'B2-6RO\
M*ME@0""I!Z]",]0,6&4H59U9&5MWWNGU_P .V/RC 6ZCW2HC1M@JK#/'!!/O
MW'IWYZ.4><<_PGMZ^] 6N #7!R?F4].^ZG9S)B"3<N,-\A!+9'3VX_'/I3=Z
M3IB,?+W;<") 001C'3G@YYQD<8S1#-K[;E;_ $'/L?M?((/7_5]>OW_]S_6
MOB%4MK?W!_H.W^[S<Y![8^YTP?X_]W[\EQ'_ &@/W\NVU7)D!R/-P>ASCY.,
MGLW'\.0R^6NH1A2RFWX.U<$2C'3/]WU]<>F0:*B3Q:0^^:+2U8%0/E-\, A@
MP.1%G@@C]YC^YG>ACDW>*T\TR+_9;<^7MYNL$<'J#%P3D??R/X?O]Q_P3%T2
MQU?X/^*KB'4=VFWGCR2XU&)I5S/.-.TZ,1X4#9!Y<<;;3DR[^?W1Q+QDKC78
MV=S_ ,2\+\Q_Y^NN1C'^K_\ 0_\ =^_Z!_P3%\+30_!WQ5>37BS66M>-9+MH
M]G4?V7IT 3(;D?N23D#.[';)^TX-_C5?1?J?$\>?\BN'^(^D&">((!YR,EKP
MS*QP7()RIX/''4'GITZSR,+AC:B/; JC,N1C.>@^F/U^M-D<WKBVB1?LOEGS
M)%;KQPN/0@YR#V]ZD@7>OEQ*T<:_+\WWC@]>>?0Y/7]:_0#\C"%8WA6..-5A
M4#9\O\./\_Y-*_\ I?[I#^[_ (CZ^W2@2-<2^7'\J+RQZ$]#^'>G(BDE(1M4
M-\Q48R>/;T[T *J*5,48VQ]_?/I63<37GB6\DT_3;N2"Q@DV75U"=K2LI^:*
M-N>A&UF&-OS*#NR8R9V\3R2:;I5X\.GPGR[BZMF \Q@Q5X4(.5(P59A]WD*=
MX)2O+O\ $+MX5\-EK+2;/]Q?7EIF(MM&TVUNRD%"O1Y%^Y@HA\S<T( CEO$)
M;PIX6;[#I-D/L]Y>V?R;MN5-K;E2-A7&'D'W/N)^\W-#8:%]67_A']!/V+3;
M8F&ZFMLQM\H \F' X'9I%/RXVK\^6C2 #5,^'O#S?9=-LML,UQ;X7.W'[B+'
M0 ?*S#[OW5^;<8[=I:0PQ+I&CVZ6UG;KY:B' 7;@C "D%2"#Z=.^> !;6T6V
M@CTG2H?(LX(_+55R" #C //&/H?0]:LISBVM/W<<1PS#VP=HR,$8R">WUZ(%
M$H^S68$<*\-)'CG&04&#P1CD]NW/0C82YMK8;(TP-R]O;MCH1Q0 V0LUOY&F
M[%5%PNW&  .@[>GX>G6OE_X=>&O"G@#_ ((S:'\/_A7\1K;QEX=T+]FF"QT?
MQC!9-;1ZU9P^'@D-ZL#ES$)HU67RV9BH?;DXS7TZTS;/LNE",+"VV0LIX [?
M_7KYL\$> =-^$W_!'/2_A)X<^(FD^+K+PQ^S/#I5MXP\/W"2V.LQV_AU8DOK
M9U+*\4P02(P9@4=3D@C(!]*0Q;(OL5E (%VY9ECQM)SDC(()SV/KD^AY/X@Z
M?XC\=R6_@7X;?$W6/"\MC=K-JVM:';V,[)'L_P"/4_;;>XC:1PX? 4.H"NS!
M65)MB?7;C4=0;PKX6(66/!U+4%52MD3M8I@]9F5MRC!"@AW&"BR5YD$=S_P@
MO@.7[));A7U+4&C:3[.CDL0'<$2W+\G#$E XD<'<BR '$:O\)_'MS/8>!OAC
M^T[XTT;^S41=>OK'3=!F!<@.[R^?ILF;R8OYA"!47>9&0;HTD^3OV]_A]^TO
MX@^-OA_]FW]EW]J#Q;K.K:;\&?'7BVQ\(W=GX=:WU7Q'IJZ#;6%A>7#Z<DBI
M>+KER+C_ $B"1?MT<XFA 3?]S&9#<CX=> 6:'[&,ZMJ6YG^Q!OFV[WSYUTY.
M\AB2 WFRYWHLWBGB[3-,\/\ _!3WX*>&/"RJD=C\!/B.LXF>21MK:WX&9F:1
MLF65C@L68L3)YC%B<, >Z?"/Q'XZ\8?"CPQXN^*'PZ/@_P 3:IX>LKSQ%X2;
M5H[_ /L2^D@1Y['[3$!'<>3(SQ>:@"OLW  $5T-%% !1110 4444 %%%% !2
M/]P_2EI'^X?I0!\,? #]ECXH_M1^(_%FF?M$>*M+F^".B?&;QG=:'\/=)217
M\37B^)+]O,UER<2V\%P)&CM4Q'(PA>3/E['^W](TG2O#VDVN@Z'IUO9V-E;I
M;V=G:PK'%!$BA4C15 "JJ@ *   ,"O(OV(W6/X6^)G8\#XP>/.W_ %-.IUQ7
MQ8_:<^-'Q[\>ZI^SC^P7:6,\^EW9T_QU\8-259=(\)3$#S+:UCX_M/48XSN,
M*GRH9'A69OF=4\/ /#8' 4YV;G-+SE)VT2\EVTC%7;MJS].XFCG7%7%&*PBE
M&&'P\YMMVA1I1YK2J3LM9S=KRM*K4ERP@I/D@=!^TM^V+<>#?%,7[-W[./AJ
MS\<_&#6X3]@\-K=#[)H5L0A?5-7EC)-I:1K(K!3B6X=DBA!+[TL?LN?LAZA\
M,O$=]\??C_XTC\=?%S7H5BU;Q8]B(;?3+,9,>EZ9 <_9+--S%@#OGE9Y922R
MI'TO[-'[)GP<_96\,7.A?#/09FO]3F6X\2>*-6N/M.J^(+O+,]W>W+?//*SR
M2N<X56E?8J@XKT+Q!K^B^%]%N_$7B+5[:PL;&W>XO+Z\F$<-O$@W/([L0%50
M"2Q(  R:[*>'J5*BK8FUUJH_9CY^<O[S6FR2U;^>QF<X7!X6669(FJ<URU*K
M5JM?5/ELF_9TKI-4HM\S2E4E-J"A;9U09=@/K7S=\<_VRO'GBCQU>?LU_L'^
M%]'\<?$2S9QXDUK4KI_^$>\%Q@E VHSP@F2Y:0,B6469CY<KN$6/#\SJOQM_
M: _;^UNX^'7[*%U-X/\ A&MP]CXG^.$-P4OM6*$K<VWAV,@' (\C^TW'EJQF
M:$.\"L_T1\#?@+\(_P!F_P"'MG\+_@MX"T_P]HMG&NVST^ +YLFQ4,LC?>EE
M8(NZ1RSMC)8U/MJN.TH/EAUGU?E#_P"2>G\M]UO'+LOX6C[3-8*IBOLX=OW:
M?GB+-/F[4$U*Z_?."7LZG"_LN_L6>!_V>]7U+XI>(==OO&7Q.\21#_A,/B/K
MR@WNHL2&:&%!\MG: JBI;1814BA4E_+5J?\ M3R-%\5?@-*B;BOQ<G.WGG_B
MEO$''%>M>(O$6@^$]"O?$_BC6[73=-TZSDNM0U"^N%B@M8(T+O+([$*B*H+,
MQ(  )/%?'?B#]K74OVFOVK/@Y+\)?AY-=_"G2?BE>V]K\3KFZ$4&O:O'X>UV
M-X=/A*[I[2,><K7G^K>2,K'N"[VQQGU7!X>G0AI>4+):M^_&[>[]9/J]7=G?
MP['/N),VQ.:5[S4*-?GG)J,8_P"SU%"$;\L5HK4Z4%=1B^2/+%V^A_V,M'\*
M>'OV/_A5X?\  GC'_A(M#L/AQH=MHWB'^SI+/^U+1+"%8;KR)"7A\U LGEL2
MR;MIY!KTJO//V1O"&D_#[]E/X9^ - \96/B*QT+P#H^G67B'3'5K;5(8+**)
M+J(HSJ8Y%42+AF&&&">M>AU[!^>,**** &S_ .H?_=/\J=39_P#4/_NG^5.H
M \)^(/\ RDV^$?\ V0GXB_\ IZ\$U[M7A/Q!_P"4FWPC_P"R$_$7_P!/7@FO
M=J  =*Q_&_AO4?$VBB#0M:73=4M;B.YTO47L8[@03(>C(XYC=2\4@1DD,4L@
M22-B'78'2B@#!N?%1TO3=+A\9:'=+>ZE/%;R6^C6%UJ$$,[=098X1MA# CSI
M5C3&"VT'%<[\$OA5\,/ G@G2?!WPV_9^T_X<^'?"VIZE'X?\(Z?HNG6-K:L;
MN=/MMO!8L\427 :6X7!1REZ?.C24NB>@44 %%%% !1110 4444 %9US_ ,C9
M9_\ 8.NO_1D%:-9US_R-EG_V#KK_ -&04 :-%%% !4;_ /'Q'_NM_2I*C?\
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M&,$9()1<7J "BBB@ HHHH *\D_;7$S?!G2EMY%20_%;P&(V="RJW_"6Z1@D
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M!>=J;F W$DO([,Z:CJO_  CK16,<3:AJ^HR;H[?S-A? P7'41Q)\N?0-_&[
M. /O=530VCLX8_MVK7GS);QN%+8*AF(+$QQ)OR>NT' W.P#/TO1XM!AFNKRX
M6ZU2]7%U=; IF8!BJJN?E11NVKGC)))8LQ=IMA%H@-U?SI<:I=H#<3[2OF$?
MPJ/FV1J6X7D#=DDLQ8V$C,""XNX-]S(I#,JY"C)(7( ^49(!QG\2: /@'X"2
MR)X,F$NYF_M!B%YQN,4>0.N!Q_DFNX9HHWCA9R=TF.3]XX)SC. >/T'I7"_
MB;R?",VY69O[0;&<9&4B+<] .,XSCC\:[BYF6S/FN2VY]L:QJ<GCI^.,\X'T
MQ7X[FW_(RJ^OZ(_H; _[G#T"2<VL>Z5RS,VV*-3][G@#/?U[<9X J&XECTU/
MM5X[2SR-MACC^\[8)"(">N <\@8!)P!PV1TTZ);K4"\T\S+'''"N\LQZ(@P,
M^I)   +,54?*V!9+%1JNJ_-=S*(UBC?<L>['[I"0,C/5B!G&3A0 OFG8$5N+
M"4ZSJ@,]Y(OEQ1QJ&\I3M)BCX!P2H9F/7;DX55"MFG_LR/\ M+4SYEY/B*&V
MA8MEB-PAC#;<YVDECMSM+-M5<(ZX=;"(ZGJ$1FNF^6&&!06R>D4>>_<L< X+
M-M5?E9:P-I[KJ6O3":^N&\J..WW%$Y)$<8)Z\99R%+;<G:JJJ #+2Q-I<KK>
MNM'-JDBNEK#&RMY"L%+00L54D$HK,S8W%03M545+=K;_ +QM7O8U\XQ@;E5O
MW<?'&",CGKW)&3CA06MO(LGV_4"GVAE*+EOE09SM4^AP#ZD_@HE)D'[Z2(Y5
MMT<>T!EX&1UYZ9YZ4 *99 @>5,;OE6-6R&.25)!Z'\<#]:21EMD:[O77Y?3D
M*>G'&>?\*D4&(&65V8A?F\D'E<@XQQN.?I^%0I)*VV[G\R/=M"0LW"L>.2/4
MD#G@$<4P',KS28F"R*C;H8_+ /'\9SGD<\CH#3I)Q;PM=%&;(4$JI#,"5X(X
MZ-T[_CQ39YA! 9I%&[JJ-W?D +U(R#C')/U.*AN&AM2=:U*1E6-1Y,2J6*$\
M8PN2[L2   3D[5R220D;<7(TZ.36]5N'6.)3Y<,:EL \#"@$M(<[<#/)VKG.
M6KLD<$O_  D7B2?RMK!+6V9PRP%F*+CC+2ON5>,\G8F<LTCHPCH/$>NQF-HP
M3;V_WS"",8PF=\IR5^7/WMBYR2\BP^1(=<UQO)\G=]GA+_+ I '..&D/3(SC
M)5<Y8NBAMI937=Q'K6LP;9HSFSLVVG[,Q#+G()!E96*D@D ':O!=GT8V>#%S
M)NCDVD-\Q^4':<'#$$@KU[9_&F>1AO.O%C:2-LIM^81XW#()'7!_#MW)&8 >
M;*#C< JA23DG X[DG%,5KZO8IZ]<-;V<4SS>7NOK=<!L9!E08^I]/PJTB/.Y
MFGM5_=KF'&=X]<CL?H2,?F:>N>>8HVE95C%] %5L?\]4^;/Z'/3UZDWOG=&:
M50%X8*PY!'O_ /K!H&*6.QC(1MR?F4\,OH>2".AICE%B^U7<JK&B[VW':JXR
M<G/H/7I_)S)O(GN&^[EMOI]?7&,_4]^*IO*EQ'_:^HSM;6=NK2>7.?+ VG/F
M/G!  !.#QSD\XPA ZKJ*_;]0D5;&-1)'')@*PQG?)GL.H!Q@C)YQB)6_M0?V
MWK'^CZ?#B6WM[@;,XP1-*& *$'[J'[OWF^? C5P-1!UC6E\BQM?WL-O/@9V_
M,)Y,]",953]W[S?-@1CB/46;5]8:..PM?WL"R,5'RC/FRY.!M()"D?*1N/S
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MPC_[(3\1?_3UX)KW:@ '2B@=** "BBB@ HHHH **** "BBB@ K.N?^1LL_\
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M+X8_X*=?"/5-5UBVAM;#]GSXF3ZK>WM['&EI -9\#L9Y2Q 5 $.6Z#'. "0
M>U_!+X1>#OV?O@QX1^ WPZAN(_#_ ()\,:?H&A1WEP995L[.WCMX0[GEV$<:
MY8\D\UT]&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.\4-;,I3<
M.-R[<Y&>1BI*CO #;L&3<,C<H7.1GGB@#S;]BGP5XH^&W[&_PE^'7C?1Y-/U
MK0?AGH.G:QI\Q!:VNH-/@BEC.TD95U8'!(XKTVO,_P!BY?'2?L>_"E?BBNL+
MXG'PYT0>)%\0B87XU#[!#]I^T^=^\\[S=^_?\V[=GG->F4 %%%% #9_]0_\
MNG^5.IL_^H?_ '3_ "IU 'A/Q!_Y2;?"/_LA/Q%_]/7@FO=J\#^*-]#IG_!2
M?X4ZC<I*T=O\ _B/)(L%N\KE5UCP23M1 6<\<*H))X )KV[0/$6G>);22\TV
M.\18KNXMV6^TZ:U<O#,\+,%F169"T;%) "DJ%9(V='1F +PZ44#I10 4444
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M_A;'@+'_ (5VD5ZU7DO[:1;_ (4[H^P?-_PMCP%C/_8W:10!R7_!*62UM?\
M@EQ^S28XLRR_ 'P=M&1N_P"0'9]3Z=!^5>]PVPM?D$GF7$A^:1R3@?TX]/\
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MH9SDGRHESDGG&>C.P#.TO3&\.P27]\[7NJ7@7[5/'&P$CJIVHH);RXQR I.
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M?L\&<9'RAFD;;N*EVV(H6, ^"/@+&MGX8N=4U0B:Y_M"1+=8H]WEJT<1,<?
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M;"DQH!APIQG(!Y/'3G'YUYQUBXEQF=P-S+MC9AMW]CD]"2?;'YTJHB+]JN9
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M_<^_89H];CRS*NFJH^;=Q<J ,<@_ZK'_ 'W_ +GWW9/B$YS_ ,2_\?\ 2O\
M[5_Z'_N??E42:E+NE6:*V1N%^Z9_E/7/(7/8@;L>A!(/810=7SYT2FS[*Z_Z
MT@C!_P!SN#WX[58ED\_J?D/,DC'AA3I!)(=B#!W'<VWE<'D8/\__ -82'S)7
M1H!\ORM'MY#\],?AT(QR.O2F0#(^-C+A1P5;@CY>&'KU!&#_ "Q22/-/,R@*
MT>T[W\SDL<>G3C)^N/Q""^U()0JI]X;3SQP,^F>H_#UR!0X\J,;5'''?V%(I
M*X8\WY(1\N3NVC[Q]L>]=9_P3.FM=>^$_BK0-#L/L*6/CMDUZ\6,1R7-P=,T
MV50A'WOW+Q*TAY4*%7D;DXN2X;5/W&FS(UN<B:ZB;=NY(,:$<'IRPZ=!SDKK
M_P#!+:+4_$/PV^(GAS2Q)8Z;'\3"NHWL7[MY5_L/2D-O;LK!HF!4;I<#:IQ'
M\Y+Q?:\&_P :KZ+]3XGCQ_\ "7#_ !'U'/=R^)ICH'ABY:TTNUE,6H:E9D*6
M:-L-:P\8'1EDD&"G*(?,W-"VVBL]22/P9X3M/L.BZ;&MO+/8KY485!L^RVY7
M&W;@*S+C9@HI#@F-SM_;$J^&= M6M='M5:.\O;=O) *\>1"001CD-(O"8*J=
M^3'J);6TUI'IFE0K#9Q1JL?DJ%C4+C:B@?P\=L#'%??GY&*L,;K'8:;&8+>W
M"C$(V+MZ! ,=,9Z8QQCOB0H9O]#MRRQK\LLB_*3QT4C]2.G0<]%0*5^SVA\N
M&,X9QVP0=HR,$8R"0>.@YZ(HCE'V.VB"PQ #*C"KCH!QSC';I0 K$7+B&V;"
M)]YD;H?[O!]#^%-=Y&D6SLH_W?/FR*P&TYZ<'KU_SS37D=MMKIY3RT8B:0N?
ME&.@X.>?<=^E"VZQ(NFV*,BK\S2!?E')/?@G(Z#IWQQD ($CA*Z=8'"Q8\P[
M>!T^4G/4@Y_4]LY^MWNK:A<?\(OX4N/*D7Y=0U$\_8E*Y&W(*O,>,*V0H8.V
M1M20UJ]U'49CX7\*3^5(K*NHZ@JAOL:,,X7<"KS$$$*<A00[A@522I]IF"_\
M(-X E6.2U;_B9ZHT?F):$D,Z_,?WER^2P!+!-WF2;LI'* )+>F9I? 'P]G6.
M2U<IJ^J1E)/[.9PLA4@YWW4BR>8-P(4-YDF=R)-7F6>)?^%;_#&W%@D>]M4U
M=5S]A\S,A="ZL)[N1V+X?.-YFEW92.<(NX((/AM\,O\ 1X[-534=8F_TA;),
MJS(?,8M-=R(VY6;> 6\V7=E(Y]"#R]-@3P)X,$BM:0@75XS&4VP/.2SD^9</
MG=\Y)Y+N3E1( .4VNG0MX.\'1BW, )NKI4WK;%SO)8DY>9]Q?)R<MO?.Y0_E
MO_!/;7OB5XI_8%^".J?%"74I/&&I?"/PW>>,;S6%9+PZG-ID$ET\XD7<9VG,
MAD# ,&8[N:]:M[>'3K1=#\/V_P"[C+?:IF8\9Y9BW5I&)+$\DDECU&?+/^">
MOQ,\=_&O_@G_ / _XM_$C5SJ7B;Q=\(O#6M>)=2:UC@^U7UWI=O<7,VR)%C0
MO)([;455!;@  "@#U]V52;2Q3:S$[F7 VG'4_IVIL\=LDRV]N-LS+]Y<9 SU
M)Z^OUP?K3B[6\*V=H=\H49)S@=MQ_'W]:I22K"3H6A-YES)\\TTB;UB0D_,_
M(S]TJJCN,< $@ 'S'.NF:3<^9=CF=F)*QCC)8CG/(PI.3[ $CX,_X*0?$K]G
M'5M>A^)7COXJ6WA?PMH>B>-O@_\ $+1_BMX6U30+'7HM>MK2_FAL]2O);'S-
MXT#8DUFTRR)=EXI%*(6^^B1:AM+T=T:Z8JT\KKTX WN0,%L  #CMC ''RW_P
M4,^*7[._B7X<:]\(M3^('@W5IO"K7C_%#0;[5K>1=&T^Z\-ZK)NU2,EA;1RV
MI>1%G""6)6(.P,P -3X3?\%$/^"//P-^%?AGX*?##_@H=\ -+\,^#_#]GHGA
MW2_^%VZ1-]CL;2!(((?,FO&D?9'&B[G9F.,L22370?\ #V+_ ()9?])+/V?_
M /P\FA__ "563X&_X)K?\$?OB;X0T_Q_\._V /V;]>T/5K5+K2]9T?X4Z!<V
MMY"XRLL4L=L4D0CD,I(-:W_#I[_@EF>#_P $U?@#QT_XL[HG'_DK0 ?\/8O^
M"67_ $DL_9__ /#R:'_\E4?\/8O^"67_ $DL_9__ /#R:'_\E4?\.G/^"6/_
M $C3^ '_ (9O1/\ Y%H_X=.?\$L?^D:?P _\,WHG_P BT '_  ]B_P""67_2
M2S]G_P#\/)H?_P E4?\ #V+_ ()9?])+/V?_ /P\FA__ "51_P .G/\ @EC_
M -(T_@!_X9O1/_D6C_ATY_P2Q_Z1I_ #_P ,WHG_ ,BT '_#V+_@EE_TDL_9
M_P#_  \FA_\ R51_P]B_X)9?])+/V?\ _P /)H?_ ,E4?\.G/^"6/_2-/X ?
M^&;T3_Y%H_X=.?\ !+'_ *1I_ #_ ,,WHG_R+0 ?\/8O^"67_22S]G__ ,/)
MH?\ \E4?\/8O^"67_22S]G__ ,/)H?\ \E4?\.G/^"6/_2-/X ?^&;T3_P"1
M:/\ ATY_P2Q_Z1I_ #_PS>B?_(M !_P]B_X)9?\ 22S]G_\ \/)H?_R51_P]
MB_X)9?\ 22S]G_\ \/)H?_R51_PZ<_X)8_\ 2-/X ?\ AF]$_P#D6C_ATY_P
M2Q_Z1I_ #_PS>B?_ "+0 ?\ #V+_ ()9?])+/V?_ /P\FA__ "51_P /8O\
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M;6\]P%'F/%"\DK1(6R51I)"H(!=R-QYC1(Y_^&A/$X^T_P#,FZ%SM'_/WJ]
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M;75@&.#']ICB\Y?GCWK\U>O1(M@,RS>;-(_4CGDYQP.@YQZ#KW-0W%W'I?\
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M[,>%4 $DG@ <U#I?B'0M<FNK?1M9M;N2QN/(ODMIU<V\VT-Y;X/RN%925."
MP..15/5O"/A[7]<AUG6;22\EL(62WM)+N0V^6E@F$C6^[R9)4DMHFCE=#)$0
M_EL@DD#8VDZ-<^+FM_%7C;P3+X?\1:5-;^=+IVL-);WDBVC_ "I)&8FO;6.2
M]N4C6ZA0>:AF$"D124 =C17@_P"QU!\7=,USQ1HWQ@^)7QLURZ@:R:PA^+^B
M^%(HT@9)CY]C<>&+*&VE#N'CEBFEDGB:VC8Q0QSQ27/O% !1110 4444 -3[
MS_[W]!7GOBFQC^%OQ 7QGHVDZ58>'?%%U))X]NK73K:VD2^CM8EM]7NKM[F$
ME%@LX[%U\JYF<R6 !AAMY2?0D^\_^]_05'?HLMI)"\:LL@V,LB[E(/'([B@#
MQG]F;]L;X7?%7]FCX?\ Q3\;_%GP/8:]XE\#:5JVL:?;Z_!%#;WEQ9Q32Q*D
MDS.BK([*%9F8 8))!-:WC;0O&VD:7<>)O%7A[QGX^U6V:\N]-TOP#K4&BQ>2
M+F"XM[-(I]2MHY9?]%@0RW$K*S/<+N@M[F2"K7[&7BH>/OV._A5XX'AC2-%_
MMSX;Z'?_ -C>'[+[-86'GV$,GV>VBW'RH$W;43)VHJC)Q4?Q(^&K?$;5+/2/
MB/X3\37\.GVL]S9ZEX/\;7FEP3R0I:,J3107ENR3R3M,85/GQHMLS-/$SJA
M.=^(_P <_B%\ -'N/"5QKW@G6KCP]HVE7-UXF^*7CL>&H[JVDBO4FGGN+;3I
MX3<^98&4K';P1%)WVK&(0)/5OACXJU/QS\.-!\:ZUHW]FWFKZ/;7EUI_E74?
MV626)7:+;=V]O<#:3MQ-!#+Q\\4;91>;\+>#?BA#?^)/B=XRM/#\_B35M%L;
M72_#MA?3I86:V]LTGV:6\>(O<$WUQ>_Z6+:+_1V@'V8/'(TO8>$_#.@^"O"^
MG^#O"OAZQTG2M)LX[/2]*TNW6&VLK:)0D4,4: +'&B*JJB@*H    % %Z?\
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MK%ZEUYK-=73'?=+<2#,[_+(OW?N+^MOQP_Y$BU_[&K0?_3O:5XSX0_X*<?\
M!(?P'X=M_"_@K]OW]G71-+M]QM=,TWXK:#!!#N8LVU([G:N6+,<=22>I- 'N
MGPE/Q5/PL\-_\+U3P^OC;^P;/_A,/^$3,_\ 97]J>0GVK[']H_??9O.\SR_-
M_>;-N[YLUT-9WA#Q?X5^('A33/'G@7Q)8:SH>M:?#?Z/K&E7D=Q:W]K,@DBN
M(98R4EB=&5U=2596!!(-:- !1110 4444 <7\>_^1'L/^QT\-_\ I[LJ[2N+
M^/?_ "(]A_V.GAO_ -/=E7:4 1Q?Z^3ZC^5-O_\ CSD_W:=%_KY/J/Y4V_\
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M +=U81O?/&=H3I"A S$A."1\H))P6(!( "JMBZE2*$RW(+';]R.,LW7KZX%
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M1)>MK9;6U_LC0R8PC,)IBY=D8@DMEL[W+=<Y/.3VRVULTM+=M"T51&%.9[D
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MMI0\%H\NW<Z W%Q(J%L*3(5&68UOS_ZA_P#=/\JX#]H3X?\ Q1\3^$;SQ-\
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M:U:&^L;ORY7AD\N>%F1]LD;HV"<,C*>017Y^?#O_ ()U_LL?%KXF?$CXZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%-ED\J)I<?=4F@#DOCA_R)%K_ -C5H/\ Z=[2OQU^*=G_ ,$<OVZ/
MA_<?%']DC_@F_P".--\-^)?@_P",_"&C^(/A]^PO<W]A)JVI2V$=MKT5Q96Z
M1R7.F2Z==QQ[3O#7<X66$JX?]5;CXB>*/B-X"U34?$/A34-)M[7XA>'H-'CU
M'3([=I[?[7I;M(K1W5PMPGG/.HE'E [=H1E19YOS;_X)_P#_  4$^)_[$_[
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M;Z7I_A2VCU_6_$$>_P /Z39WT:_:808A)=NY)\NTB$T;2S -M#HJ+)++#%(
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M#5OJ/B".T36/+TM/L]PUNCK'-]GQY*SE'$;W"H)98X+>.1W2V@6-/BC^R/\
MLR?%+X?ZIX!\9_ SPS-IVI6^R8VFE1VMQ"P8-'/!<0!)K:XCD5)(IXG26&1$
MDC='16'HT7^OD^H_E3;_ /X\Y/\ =H \CTSP[^RGH/C/3_@M9? F6:\W?9+>
M^N/ACJ-U9ADMVF_>ZH]H]O\ <1E\R6?F7;%N,KJAVS^R#^S!_P +%C^*\7P)
M\,PZXNC/I4MS;Z7'''<VIF694GA4"*=HY QBDD1G@$]P(F07,XDPKJWBU;]K
M?_A%/#'C;5K^70[/3?$GBOP[?>*+FTM]'BNH-8L;*[MH8[1EOUNGMYXY;2:Y
M2"%M.@NHXEG+//[)0!SMM\'_ (2V6G7>CV?PM\.PV=^$%]:QZ' L=R$;<@D4
M)A]K<C(.#R*D\0?"SX8^+-0_M;Q3\.-!U*Z\M4^TZAH\,TFT=%W.I.!V%;U%
M ')M\!?@8ZE6^"_A,@\$'PY:\_\ CE;-_P""O!NJWLVI:GX2TRXN+G36T^XN
M+BPC=Y;,DDV[,5RT1)),9^4DGBM.B@#P_P#9A_9F^#'ACX>:MIM[X!\ ZS))
M\1/%MW]NTG3+:YB5+CQ#J$Z6[.8QB6!)%MY8_P#EG+!)&"0@)] O?@/\$Q;,
M;?X+>$V?<NU6\/6HSR./N54_9U^&NO?"?P#J/A7Q'<VLUQ=>._%&LQO92,R"
MWU'7K_48%)95.]8;J-7&,!PP!8 ,>WNLF' ;!W#:3V.10!\I_P#!+'X)?!*Y
M_P""9W[..L:I\+/#E]?7WP'\'O-<WFAVSR.6T:V;<Q,?)+-RQY)(R2:]\/P$
M^!-JH:;X->%)'W$JS>';<X[<?(<<'MUYKRW_ ()2R6UI_P $M_V;9$P6D^ 7
M@TJ. ?\ D!VF!ZXS]>37O%T\6GK]JF97N7RL,:X!D?'W1R,\#N> ">!F@#EY
M?@/\$;&!KN;X,^%9'.T>6OAR!E!+<?\ +,GC/)Q@ 9P *N:SX7\&V_A>WT'Q
M5X2TV^MI/*MK'0%LHI8 RJ"L$,3J%P-F_) "A2QVJGRWKNZ.@VJZSK0^U:E<
M?NK.SME&Z1CEA!$&(YP"68D#"EV*HORH(O[ 9O$&NRM>:E=,8;:"WR0@)R((
M5)'8 NYQNV;FVJJJ@!EV7@?P?X3\/-IVK^&-+F6^CDLH=$L=-C%J(Y27>UAB
MVA2K8+2,P&_:7?:B*L>)J/P7^!_A2T;7]<^"WA?4-4NF>'3M/L_#MGYDK$%E
MM;<.J@L0FYF8J#L9W*1I\G77ERGAE?[>UUI+S4+R1;>SM+5=Q+'D00J<>A9G
M; PI=RB)\E>&QGT64>,/% :[UNXC-O;VUFQDCM5;#?9H =FX$H"TK!2Y7<WE
MHJI& <G8_L\_!OP[--XO\6_"?PK>ZM>*+>.UL_#L7V>WB\QBD,*%2 0&'F3$
M*9"F]A&B)'%T7@_X-?#;PKJ,7BVU^&OA^PUA5_=S:?I,$?V7Y64K$RH",AF!
M;AF#8.!A5WM-L[F ?VUKA62^:,C;&V5@0X)CCR!QD9)(RV!G "JMF2>.%@;E
M_FD;]VF[&<'T_+Z_D* ,2^^&WPQNO$"^,]3\ :)<:NTZS0ZE<:3 UQYB ;&$
MA7<"NT8.<C:/04:_\-/A_P"+[A-=\>_#[1=6O8X?*CEU#2X9V2,$D(#(&P,D
MG&< D^YK:B!0+=Z@L?G?P[><#VR ?_K4U3,&:XN=K2-Q#$O;\P#R1UZ4 <FO
MP*^!I07MU\&/";%N$5/#]L5V$]?N>AY/]*?=? KX%VMK)<WGP;\*$;<JJ^&[
M=L'J!@1G)STP/08S767%S;62?;;J3^'Y5V\]>PZD]..3TQS5+4+JRM+)M>\1
M3K D;J($=<%&)**!CYF=RVT*,[BP502?F /SV_9_TKPKHGP_U",:;I]OILVJ
M/BWALU2.3S(XH\E0/G=QM7&,G(49R<S:_P#LZ_![Q-XDT/XF^,_ T*7WAF[:
M\\.PV,DENMA,R!?,:.V<)<SCD*66383B,9+.Z? E(T\*W.LZZ_E^7J#"WA#9
M$198U&,?>D;(7C/+;%SDE^ZM[6::9=8U<%70_P"BVIVD0$DJ#[R,&VGD@9VK
MU9G_ !W-O^1E5]?T1_0V!_W.'H>5^"_@1X/T_P#:$\3^.=6T7P_/#-X'T.SL
MM!\M9KRS\NZU:22XFB *GS?-1$D ))MYD!(0L_I)^&GP[A=I)/ NBM\N-K:5
M"57#-R/D!R01],<5SGAOP7JUA^TOXJ^)6H?9TM]0\#>'[&TC6ZS+%);W>LO(
M70'&,72!7Y!.]1RI)[IF0%7G<+\V$!]?ZFO/N==KF3;^ ? =E/'J$/@K28)(
M7#PR1Z;&&C8'(8%5SD'!&.0>G-3ZEX<\/>*'CG\1^'K:Z\EBMJM[#',J[MN6
M7((!8@9/!X [9-R(/.YN9[;'EJ1'\OS+_>XY].H/3VY+P[NA=U^3=QMYW+QP
M1R",\TAE._T'P[JFD1:3JV@6<UE#M:.SN+5'B5E!VLJE?EP"1T[UGR?#7X=$
M&XO? >AA4^;:VEPX7CDGY>WY=_IMR,(D^U7DJQI&NYLM\J^Y^@_#],579+V-
MM0U&6-+%(Q(L<RA01C.]]W8<$=,8R>P +T,2X^'/PYE634-7\#Z%;V5L#)^\
MTZ)5(7GS')48 Y^4\=SR!BWHOAG0K+??VOAZSTNR5EDCM8;1(?,9"=LTH4#I
MU1#]W[Q^; 2XN[46&L:MFWLK<B2W@FRAR,_O9>?H50CY?O-\V!&CQ?VI(=2U
MI6M[.U8O#!+)M4E<_OGX&,#E1G ZGY@-J*,K1O"WA.TF?Q;'X>L=)LXH2T*Q
MV,=LS1X#F28C!QD9"-@+C<PW8V+>>!_"?BO4W\4>*?">G-&C!XEO+%/-9EW+
MYLS$\C;M*HP^0 ,WSX$6E&!K976-2#0V,0\RVMYU*;AA6$TJNH*,OS80_<^\
MWSX$5Q(FOW$]S&R1HP:&-LJ3T(9A['H.W4\XVLDQ;?X:_#NY474OP_T:&%22
MD+:3",_[1!0%>_';J>>!8C^&_P /#\[?#_1,= C:3#TXY(V]?Z'G!Z;C*\;*
M\@9&7YL9Z<?_ %^E-YG.7^[GC_:H'\6IGW?A3PSK&G6^CZCX<L9[*U*_9;.>
MS1HX\*4!52,+A25& ."1T.*=_P (]X=N-#;PY_8-C_93(8VLUA4PRH1EE\O;
MMVY/OD@GH03>?]X^%D4QJ,-^[.2V?4]N/3G)[=:Q!U48"XM=N>.LV1G(QT3_
M -"]@/F ^(\X^,7[,'[/'QZ\.6_AOXD?#>WFTB&_$D)TRZFT^265XI+<_O+1
MXI/+,<\B%2VU]V2, %NP7X;?#>_A5AX#T-H3R FEPD/C(Q]SE>AR#S].NE?1
MV>L6ZF^G7['YRM\_ F8,"OWOX<C_ (%QCC[T(5O%B[G?_B5-_"IP;HAAP?6+
M@]#AP?[OWP#'T[P-X-UFZCO])\(Z;9:?'S#/:V$2-?(R=5=.5A()!'!D&1]P
M_/<N_"?A/Q9JG]OWWAG3Y8U=)%O9+)&FN63&U@^,^6-HP<_/@8^0?/H'9KB$
M$!=-4$,"N/M.,@C!'^J_]#_W/OS-$VKDB>)UM5;Y1Y@'GG@@X'(4?7#>XR"A
M[%#4/"7A;QA>IJVL^&K&Z1%"1R75@CO*%9N-S _NP2V!ZDGURP_#?X>,WE1^
M!-%58_E;9I<61CL/E[?_ %JW&D4O@/\ *O+,!\ON/U[?3UPU1'(FS;^["XP<
M\CGY@>H([?GZ4R3'B^'/PX8AX_ FB_*W&-+AX(P>1M(((/3KW]*N6.B^'[?2
M&T'2=(L8M-D#K)9PVZK$P8X;Y%PI#<Y]2.XZW'>29V0%EPWS,5Z_F/\ '//U
M*G,QV*/E[E>_M0%KE+1O#?A[0(Y+?PYH=GI\<C9F6RM5B\Q@,9.T#)]ZS?\
MA7GP\GE:SLO .BHL;#S+A-,@QN#<HHV<]""W;.!R#C6,[W\S6=C(HMT#)<S*
MIR3C&Q#D 8R=S<X( '.=L$C-J;-I.FEK>SA8I=74;LC$C'[N(XZ=0T@(*D;5
M^;+1H;U,!OA]\/M>D;1]&\#:/'80GR[R^ATV >;C?&]O"R$,CHR@.^/EY1/G
MW-%8@\ >"'NTMM \%Z39PVK8:\M-.BC>-U(PD1505([NOW"N!AAE-@"2[D_L
MS26\BTMSY<TT/RX*\>5'QCC&"PQM^ZOS E)HHK=+>/3--MU^R^7M&S(14!P5
M4CI@=.V!@=RH!3U7PIX3U]H;+5?"]G>+;QB-9IK6-C$@YVC(R 3_ '>!R.N<
M6-2T31=?M5TK4M(M;JUCD#>7<6ZR*K+P,*P(Z%AD=,D#OBUDRGR;;"1KPS*,
M#_=7'3'?TZ#GHBA)Q]FCC98D SMQM8<_+],<\>W3- 6MN8R?#CX<S%5A\":'
MY:MB11I<0;V_A]>OK1+\//AY+-Y$'@#0_O9E(TN(;1Z#Y>O\N_;.W),TC^5;
M,!C[SJHPN.WU/_US[HJJ$6&V153JJL"RLN>?7U[GD^V: *>E^&O#VA+-;^']
M!M;#SE43M:6JPNV VUCM4;L'(Y]3[Y\G_P""87_!/+]F]?C9XF_:A^"WA^QT
M/QC;ZY-I^N>(5T5+Z\T6X#6=^1I<]Z98-/6ZM[V]MKJ&&W+O%>1LDMJT6+CU
MR]EN)V;1M,=HI(\"XN.ODKCH/60@C /0?,<\!NJ_X)L1Q+\'_$7A'X>7307%
MQXTDF\0:HO[S[ 6TVS0!"ZLKW++'$=C9"JWFR [XTE^UX-_C5?1?J?#\=?\
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MN&SN^<D_,9'W9"R=#<_#CX>ZGX=M_ATW@_2[K2]-C M;:[L8IXK1@I5=JN"
MX!/;H>>N#JV%M:V&-"T#Y5@;-U(S%B"?F))/WI&R6+'DGYFR3S8BBCLPNFZ>
MN!C]XQ8ENG4GG)XY)[D=<T 9C> O H\.'X?6W@O25T=OFDTLZ?$;7_6"3!BQ
MM^\0W3@\]:R)?@7\$[4QVEK\%?"<DK\-(WAZVPGN?DSCKCGK^)'5S.]N?LNG
MQJTSG+%L?*,_>./3/3O^9$%P\RRR:/I4S+=21%Y+AHMRQ9R Y[9SD[>_L.0
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MF3RMB.&/ 9S@D(H..<9Z^A)P!PS<EE)]LU!UDNY/DC2/G8I_@4=<9'+=R,G
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MNIWGP1;0V\26T*SZ?9^(HYOLE]LD1WM'DAR]N9HU>%;D)-]G:19C;W0C-O(
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M?G^#[Z&5M<\SQ+;12.9$T_\ M"!?+9<?:QYB\\@'R^?^!8X^7[^@2/$8Z_\
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M!P?WDV%:79N?8B1QQ:&CZ?>6['5M>ECDOIEPL8P5MQ@;HXVP,J=H)8@$GDX
M"J:/I5S;7+ZUK<ZR7TP*JL;92%"<^5'GGMR?XB,X "JMN25X4:Y==S8PD:\9
MY]#^'O\ H* ">7R8VNW@\QL8C55RS#KBB.)H)'O+F5F+8VQ\D+VXZ^W^<T@
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MR?8<NE3S"(V4[5;+,LI&XC(QQV[^^!VZUU;^U/NMBU!S\O\ RVX!!!_N<_\
M O\ =X9B^(:?^)P<':;/\&^T>WLGM_%_N\-) \5\A>,;K<KA2R@K*I!!]<KZ
M'C/TP2U)$U,-)M/V7LS$CS><YQ_=XZ_Q _W>6I[3XJD+/N&FJP*,",7IR<@C
MG,7 Y_C_ -WET,CQ_P )F22X.C\J5^8&^X4AE8$?NOO*01^\_P!S[]G!U\X
MVZ>IZ 8^U8[8[1?^A_[GWT8QZ]'\VU=+5>_2Z R,'(_U6/\ OO\ W/OS(/[9
M.]_^/,9_=R0Y\\@C!Y_@ZD$?>X['- ]BKJ5O+XELXS! 'M%NK>9,/CSE656)
MQW0 =#][W&0=*3]^?)4MM7AR/Y?2J^LW,JVT9@7=YD\7F/G(*%U#=/\ 9W9/
M;'Y6/GD8H\>%7@AAC/RY# ]QR",'&?IBF2+&VXAHU&WJI7&,AN01^8QCK^%(
MK/YGE)$\:J%VMP,_3VP,?C[<DC27#D;U9>1)\WS%O3V]>N?PSE43S"(H%^7=
M_"OWCZ"@:$'[SY%)VC@MN.3[>_UJ-KB2:;[-9.%6-L7$FT=B047T.1R>W0<Y
M*LG:6^<V%HSQPKQ/<12%2>G[M"/R8]AE1SDK!+//JUP=/TN9H;6)R+J[A.UF
M96&8H_E(P?F5W!!4Y5?GRT8'Q%>YC;6-WA_27^RZ?&IBO;J%F1I%VLAA@='5
MHW4A=TH^[@JOSY:*P2NH2'2-);[/;VY5)Y(1MQC&(H^..,J6&-N,+\P.QNR.
M]"Z+HO\ H]G;KY<DUKA0NWY?)CQPI& "?X1\J_-DI;2,+!]BTV$01PLJ+L^5
M0HZA,=,#OC&1@<Y(0"1H!!]DTF-88T^3<(_E&., <9'&,@\8P.>5DSYK^3;
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MC/? SCCH,_F.\T(\NW0RS-RS[< #.<?ED#W_ !I7$D7[B [Y9/O2%A\@Z9_
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M"@)+%8@\C2S/+-( <#\0?^4FWPC_ .R$_$7_ -/7@FO=J\)^(/\ RDV^$?\
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MEQS"&./;:V7B34K*UCQ&H'R6]O"FXC<VS<Q9B6/?:M/);:=-<0VLLS1KN6&
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M6 VIU^?_ 'BIP3VY XR6NR2)&!+,2%) 48[_ /ZZ &R311'S)V]3&J@ECQV
MY/%0BT:X8WMRC!]I"+QE1G(&1^HY']52!9O]/OA\N-RQNP94X(].N,9Y/.<=
M\MNY8=BW5[<K#$<(J2.!ER1M'USD8&<^_% 'P#\"%BD\*SL<KLU)R-QP=WE)
MD_S[\@UV\DL%O"]W<2JJ!<M),=JQKU)/^).!@>^>(^ TL"^#KF61518[]SN+
M=!Y<?/I_A7523PWD?]K:E(L5C K/&LV%5EV@F5^>@ .%;[O4@'I^.YM_R,JO
MK^B/Z&P*_P!CAZ'#:#XUUC7_ -I/Q?X+UJ^1=!T/P3X=U73[.:)5\JXN+W6D
MEG<E XRMG;X5F*KY>0%);/;,1J*_VUK/[BPMQYL-O.NW.W#":4,,J01E4_A^
M\WS8$?"Z%XQN=;_:4\7>'O$-I:6>DZ'X(\.ZC:236ZQS.\][K2%YWZLB_94:
M.-N(R[L0';"=L9?[13^W]? L].M0)X(;M?+9=H),LN3@ #D*<;<;CAL;?.9V
M;$H9]1<:KJ0>WM;<L\<4C%0X'(E<<8(QD*>F<D;L;5C,^IW"W^H*8+.,AK6&
M4%&9O^>DF2,=BJ$?+]YOGPL:11WVK72ZC?P20VMN^^WLW7#EU8XE?!.>Q5#C
M9]YOGP(K:H+D^;(VV$8\N/:5W=""P8#!!Z#\3V  "-9;MA=3*8XXVW1H>&X!
M!8^QST[8R>>!.C,-SR+)&58@*V!P.Y_'IZ8S]&CYSYLB+M !C_>'WR2,<'I@
M9.,$GG "HC3L B?+V7;U_P#K4!\0 &9ON_+_  ^]#M%-#L_=M%(N6+#.X<$=
M\8_S]7!Y"=L990#AMO5B">/IQ^/\Z#A=9&,_Z#MPR[?^/C/8@C_5_P#H?^[]
M\%\0[_D,L%#?Z&2-N/\ EX.3Q_N=/]__ '3\[\PW\1+[?LK+M!;I*#@<<\J>
M1S][Z?>D<+.6,B_NUR&W?Q=0<@CI[YY^G7-AD/BV3S8V/]DKPN8P5U#@@]_]
M3^ WD<?)]]#'*(_%I+LJOI6"%W*<W+=-PR!^[QD9R0X/'R_?E)_X27G.=-/_
M ).=#D$'_5?^A_[GWT9EUQ=S-Y>FQC[V=OVG'\HAC_@?^Y]^P%&JJPF@5K1A
M\NX_ZWGKC!RAX(.>?IU!@OF:BX<B:&%),ICY3-Q^8&>Q'./3&9_,DEXAX^;F
M3N,>G^/L?8TC2><&P0(_XG;^(=\?X_\ ZZ5XG90K'"\AD92&''!]QSD8]*"2
M"]O)($BECBW1R31(H5OO;Y N",=O0CG-6,OO9%9D*\<#KQ_D8JEXAD=H40HK
MJUY;@MYG1O.3T]O\^MP S'9&/E)YQ_%]*8+40 2#RX_N#C([^U03L-64V5H\
M<EN^Y+F56)R.5**0?S;MT'.2LKS/,S6UE,T9C?;)(J],;3A<J1T)!/;H.>1G
MQWHUJ9M.T*3R[&VD,=Q>6S+M9D9D>WCVG*LC)M=L?*?D7YPQB0]R1Y/MK'2M
M-+6]G!F*XFBS'T&/*B(QC&<%U/RD%5^8$HKA-1_XE6G PVL+;)I(1MQC_EG&
M1C:1T+#[O0?-DHQ5AO8_[#TB'[/90QB*22W'EJ% V^5&5QM(X!(QMQM'S9V7
M$1D<6-M;^3!$NS<J[>G&U,=,=#QQT'/( &KF5)+"Q_<I%'L291]QAQM ]L<_
MD.>0X*''V6U&R)>&9<C_ ("OI]1TZ#GHJ E5M87;;& K2=^,<#C!XZD=.W/1
M1$MS#Y<2J+?:4#1R8SQCC'8<^G(H#;4'CDF_<Q&2&-<#<J@9P>0,^PZXQSWI
MTC/-N@B'7Y6;NN1D$>O^>O2@,PQ#:;555P&^\%YQMZGD#U]NM-\G<@MXSB,8
MR&S\ZD'E6SSSP: %4&08@==OS;F4_P 0(R&'!YSGWP?QKR74LERVFZ.^QX7S
M<3;1MASSM[YDY!"XP!@GC 9+J[FO;F32=,N=LL2J;BXZ^1TV^S.1_"> .3QA
M6KS3NTK:#X6"0M')_IEX%61;=OE8J06R9G5]P)!"[@[9RJ2,0YLVZCP]X9C\
MH1G]_<,I80JW)P3]^4YSSD#.YLY579/-(R_\(UX9E"M'^[O+Q9-QM,KG<"P8
M23$D$AB<9+/DD*Z"81Y\,>%'$<EOM%U=,OFK;Y.\H2QRTS*Q8$[L%M[Y)"O-
M!!#9P_\ "/:&"BPC%Q.K!C&6^8Y)^]*V=Q)SUW-G< R&$5O%80#0- 3R%A_U
MTBC=Y63N(^;.9&R6R<XSN;.0&GBBBLH4TO38&V+PS$EMN3RQ8G+,22=Q)).2
M<GJL2);Q"QTV+:!NW,#]TG)+9(.6).3GDDY/O8C18 HC3:H;YL+]?ZXZ]J &
MJD:)Y2(OEE3_ !9Z_P#Z\\UVW_!+[7I]2^#/B[2(+3RY-+\>26\;%F82*^F:
M=.&YZ?Z[;C/.W/&<#B6)A1A -TG)7S,D<DGGU STSG'UKHO^"5?'PR^(MMID
M;))-\36=9&1@%3^Q='#$-@C(R2%)Y/MDC[7@W^-5]%^I\1QW_P BN'^(^H))
M#'_Q*=)G$EPQ!FDD&\1J<_,PR,@[2H [^P.'-LM"VGZ'''Y[2!KAF8G9D?>;
MKDX  'I@< <$C^1NTO1WC^U-\TLDBYVY(RS8Q\Q'(^G85%>77V*?^Q]"B62^
MG(>1I"<0IR/-DQSCY2%'5V&,@!F7[\_)!E[,; KHF@0"2\N]TK2,I,<2EL-*
MY_'Y4R&<C P S+4U.\O=&3_A%/!GEW>M7 $UQ/>,66!6.#<S[<9SM(2(%=Y3
M8A1$9XX]6N;W1X)/"'@-X9]?NH_,GOKV(2I:Y0JMY=JC1EP3'M6-2K.5VKL1
M'>.SHND6_A*U;0-$EGNK^YD:ZO+R^D:1F=V^::1L#/((6-=H 4(@2-!L &Z)
MI=OX6LF\.:)>->:G,WG7^H7@5I))"H7[1/L"C<0J@(H4$*%0(B_)>@A71XUL
M;&!I)KB4R32=]S'+.QZ>N!TP  ,  .AC&DJ+.S5KBYFDW32,R[F/ ,CGCMCH
M,      ":WMH]/!2'+33-ND9N2?_ *V <4 $$#6$'DQRM++(Q9G=N2?7\../
M2AY)T79:1;IG.7W$X3N<_P A[_B:;+]H13;6^/M$B_ZQCD*.F[L3CCCU/XT\
M,MF!&$W3.,MCJ3G\\<_@* %(-I;_ &:!F:3'#'U]?2HI;Q-/40I'YEU-EEMU
M?D\C)SV5<C)QZ8!) *AQ8!8MHENI3@;<X)VG!)YVCY3R<\^I.#GW=\N@GR+6
M 7VM7P)BM]Q7> 1\S'GRXD##<W..  SLJL -N;N+PZ?*L+9;[6M49O+B#%59
ME')9L-Y4*$\G!QO  9W :&:XMO!Z_9DE34O$.I1L8XSMC>=4/H,^5;Q&4=FV
M[_XY)/WCI+JT\'/'!-)_:6OZMTVKL:?8>3QGRK>,R =]N\#YY9 )*'G)X#"^
M8DFO>*M<:-I+>&81M*$,<;R(LCG[/:0"4,P4MMWGB6>;]Z :F@:#_P (YYFH
M:A<?VCKFHX^V7GE[/,QTC49;RH(\G:F3C<22\CLSVKR\;38_L<$OVC4KOA%3
MCG !?!)"1J""?P'S,P#5-/74O#FEPVFHWHU77;I1YTL<)CC>3N0N6,-NI)P"
MS%1@9D=LO:T;1QHF^XN[J2[O[K'VBX8?>V]%4?P( >%R>I)W,S,P :-IAT9'
MDN[G[1J%XV^XD"E59L=%7)$:#H![\EF8LUJ3,*,\F6F;B-5ZG!.T''_ZJ;-(
M]OO\MUDN&7,4;$9QVST.,YILEO;VQ^T3*#=2;?N. S8/0'C(YY]N/04 2%5L
M TYWR33,/EW,<G'3T'UP!]*))([0?;)X6:9ODC1.6<^@YQSC/8 <D@ FC<+9
MOM-X-TC,$C$:[B<]L8XP2?8#DGJ::!]G*WMZ5^U2#9&JC>(R0,HO )7*Y)/)
MQDX    TM)9*U[=E9+J082%7X '.Q,]3CJ<#<1S@ !:M]K%KX?B6^U;=+>7!
M\FTM($#33')PBJ#C..6;A5 +,5520W4-:M_#D27VL[IKR[D\K3[&W^:69R-W
ME1[L<\$DDA55=S%54D4G9O#@;Q=XHMEO=<N5:#3[&QPS#(W?8[<OMSGR]SR-
MM#;2[^7&BK& .7[/X=F_X2[Q1"LVM:AMM+:UM&$A7(W"U@+!2P^4NSMMSM9V
MV(@6.>VMIM&#>)O$K+<:I<9BMX81N6!6P1;0G )!* M(0"Y&Y@JJJ([3].GT
MB:;Q1XEG^U:E<8A1+57,=O$7)6&)"3Z@R28!D*[FVHB)'<TRSF\PZOJWS73C
M8J?PPKQE4]B1DGJW&<8   [3;:4N=4U-]TTG$:@';$F3@ 'O@\M@$]P  !99
MQ$/,D_UAX5?Z?I2R2)"/,E/?Y14>QHU^UW85F X5<>V ,]\^^.?R %2,1O\
M:IUPS<;5R<=O\.W;-(Q=&,L\AZXACW8ST/./?BH[B>V@E6>^N%_><00DYW,
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MXV2X2^OM0M'N)E6YN(M.MBR[=I?Z4_X)1?\ *+;]FO\ [(#X-_\ 3):5G?\
M!1JTO+W]G_PSKVIQ21R1_'KX4FWL]V1 #\0?#^YCC^,KD$Y(49 ZL6O_ /!*
M)O\ C5M^S7A"?^+ ^#>?7_B26E 'JWQT\1ZSX/\ @EXQ\6^';S[/J&E^%=0N
M[&X\M6\J:.VD=&PP*G# '!!![@BLSQ!\2_&/@SQ=%I,O@*ZUK1;A;-8;[2F#
MW<4EQ>6UF$^S[F::*'S);FZNF,*PQ>4$2=C*8^E\5Z?H'B[3[OX<>);"2>TU
MS2;J&\AWE5DMR%BE3<I#*2)L CGKR"!7/>'/"5Q\.95\#?"CP8D=MY-N=8\3
M:]JDEU-=.MDUM%-+*\DEUJ5U&MI8QR-<O&7BE5A<.\31D [FBN3.N_$3POXF
ML/#MWX'N=<T6X2&'_A)+/5(#=6\WEWLL\UY;.L*K /(LXD>U:>62:^P;:"&%
MIC>\$?$?0/'[72:+INNVK6?EF9=;\,WNG$[]V-GVJ&/S/NMG9G'&<9&0#>HH
MHH ;/_J'_P!T_P J=39_]0_^Z?Y4Z@#P/XHZA:Z7_P %*?A/?WKLL<?P'^(I
M;;&S,?\ B=>"  JJ"68G "@$DD  D@5[+X-\<^'O'ME=:CX;:]:*RU2ZT^<W
MVE7%HWGV\SPR[5GC0R()$8+*H,;@;D9E(->#_M!^%;KQU^W[\.?!=GXCN-'?
M5OV>?B5:?VI9VMM/-;+)K'@E6=([J*6!V"DX$L4D><;D=<J?3?V='^)L7AG4
M-"^*/A";2;O1;V'2[62/2[.QL=3C@L[=7OM/MK:_O6M[*6;SFBBN91<QC,;J
M51)) #T(=**!THH **** "BBB@ HHHH **** "LZY_Y&RS_[!UU_Z,@K1K.N
M?^1LL_\ L'77_HR"@#1HHHH *C?_ (^(_P#=;^E25&__ !\1_P"ZW]* )***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!D\\=M$9IFPHQ^IQ7
MR]^QBVL_'Z^T'_@I%XMT==0U#XN^#[&U\ V%E;QK'X/\$S-<ZI:O<">9G%_=
MB:S74/LI:)IH-.A5)([%KZ7Z@N9/+A9A[#E<]_2ODW_@E?%HVD?L+_LE:OX@
MLO#$UYJ/[/>FVFCZ]JU[#%K%L]SIVF7HT?3XEMAYMJT%K(\N)5D5=)M2Z7)W
MSP@&-\&_^"L?_!(&\_:?\4_L^:;^T;X=\/\ Q9\-^(-7\-ZU;^/I+FSO7F@U
MJ>.2P@U+40(KB,WDDC6]G#<.$B=5BBC5#&GT;X^^&GB33= MKK]G;5]+\.ZC
MI^K#4;C1GL8UTWQ%&5*3V=YMC:2$2J05NX1YT,T4,C+<Q+-9W/X+_P#!23X)
M?M%?\%0O^"MOQ5^)_P"RU_P10N/B1H/AOPK=> 1KWCR[D\/:'XCUS1=>^S7>
MN_;X;FP%W,@@ETV*&.^,Q@MHWD(2*2T3]&O^" G_  2:_:8_X)4^$?BY:?M
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M,V #))M&,X7'  P     $C@&F12:=IDOG7LN99&FDRQ).-[G'I@#C "@ 8
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MG_V#KK_T9!6C6=<_\C99_P#8.NO_ $9!0!HT444 %1O_ ,?$?^ZW]*DJ-_\
MCXC_ -UOZ4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA=GQ'^S5\1_^#E_XI_#;X2?M$V7QS_9#NM&^)'PUT;_A'/#WC:YUBU;69I[
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MBBB@ J-_^/B/_=;^E25&_P#Q\1_[K?TH DHHHH **** "BBB@ HHHH ****
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M\09IK-M-U+PSJ&G6T,<86X6>V\7^)I)6D;;ED*W<.P%F"D2X4;R6 /TQ7(4
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M\8/2@#YW_P""73:?I/\ P2N_9OUW7Y08;7X ^#?)54);=_8UF$V@<M(Q(4*
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M+%]W;SDYYY/ ]N..Y*1 SK]LOQA=I"Q[@R8/\7OQQS[_ %ITDT3()KDF-/,
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M_P!S.^9BGB!"& 73!QV NQR,8Q_JO_0_]S[X67Q(NXD'3-O7J+P8^O\ JO\
MT/\ W/OS -J[++ND2U1^%,>WSR"0>>Z?@,D=<<$'L(JC6_WF\&S_ (-I.9^G
M/; !X[[O8#FRS,Y90=JJ>6![YY'M3BVXF,2_ZM=AVG[N  ,'VQC';&*;&L;K
MB/B-<;0O'3'4="I''K].*9(Y(U^557Y?X5V]1R,]B"".GI]:C95NHO)&[RV7
M&\2$;A_/_$'N.J@QS#9$JF,YW;EX;U[]#S^/8CDJJJ1Y<0VJO'RCKCM0-:CO
MFG.$;*EOF/4L?2HO.^T%K6R+(L;;)9-N%/RL"J$'.0<9/8@CJ#AC3/>RO96F
M%AC^66ZCEYWAN8UP.P'+9XS@<@D5MQU/_B6:/(T-I =EQ<PX&XJ2IACP<@@K
MAFP-OW5.[+1H/B&RS3:S/)I6EO)#9P,T=Y=)OC8L-I\J$XY&"0TBGY""BG?N
M,2AY[]O[(T8_9;6VPDEQ$NW!4X,4>/3;M9AC;T7YN42*%;B(:#HL2VMA;)Y#
M26JA%"J-OE1;2-A7H6 PN-J_,"4MJD "Z1:Q[8X54-Y1V[5[ 8QP<$''3&!W
MV@%+7$MA86^EV2M#'%>6ZKY,8V!5F0; 1P,=".".@YSC0P)(_LUNVR)%VLZG
ML,C:N#P1C\.W/2EKD;7=ND%G'\HO8/.DCZ\2("!CT Y/;&/I=0K=#R[=RL<;
M;6PA&3@' /\ ,8Z'M3#84(LQ6';^XVX.QL;NVWV'N*)93(QMXW;@8DDW9V<<
M#G_(_*ARID^RVZ*JC[X4GY0>P]^](BJ%^SP?*%X9@VUE/9O_ -8Y/K@Y0#D$
M; )"HV;L\*"K<C(([9SP?7/IS4N9Y;@_V7HRQ[<#[1-@%(D/8#H7(Z*> "&/
M!4,Z]N;NZG-EH\@CD+?Z5=&,'R1@8&#PSD=.P !/&T-#+*LDCZ!X>F6*2-A]
MMNDVN8&(4D')YF96##<" #O;.55V VYDF:;_ (1SPUNA"?\ 'Y>9)-LK*Q&Q
MG1EDF) X;.T,'?.420"?9,>&_#.(6C;-U<;2P@R=QQD$-,V=QW9/S;VR2 R"
M)+-O^$8\-P+#\K-<W2C(M]^YB1G/F2LQ+'))!;>^2P#/VNA.BZ$S*RG%U?,H
M;R>0VWG[\I#9&<XSO?.0KH01H(LZ%H($95MU[<Q]("PW'&X,&E8G.#G&[>V<
MJKVTA-NOV&R01@ DOMX4D@\\Y).2<]SR2320Q1VZ#3M/.U(^&/F%BF<GJ<DM
MGD[B2=V3G/,D4,=I&+>.)F#<LRD \GECT_3G^H,=&BQ(L DDY./,Y<^^23U^
MOK^8K[-MN@^ZOR].!SC(SGMC/_ZJ<69&6-$9ER>K'CIWP1GIUJ.2><#[-;NK
MRX!.YOE7)ZD>G7 '4^G)#$*Q=28X5'F-UD91QP<,1D$CC'Z>I" B-OLT4C.[
M',C[@S*#_$<_3@?D, XC0"T'V2R/F3,<R22=2<#+-@ 9/&!QZ# '!+(T+"PL
MHV:1MS;I <(I;DD\>IP,Y;&!@994/8:9PKFRL!&TY56D;C:.VYA[[<>IQQT)
M6*ZFEM#_ &-H4:/?2*9&:;[L:YP9'/&?]E!@MC:N%4E5NKN:W;^Q]*E62^D7
M>SW&2L:G(,KXZC(P%'7&!M525((4TN#^SK%_,NY/GGN)L;G8Y_>2<C)XVA1C
MA0HVJ,JR1T,4>FI]CM':>ZDPUS<3?,S-C'FR8]<8 &.P&%4E>J_X)2N++X8?
M$*SLED::?XFR&,MEE3_B1:.22<8 S].2<"N918[1A;0[II-V6:1MS*#GYC^7
MMGH, 8'7?\$I(IK;X7?$*=K5O,N/B4661H0GF+_8FDKD< $!E8<>AK[3@W^-
M5]%^I\5QU_R*X?XCZB@1;&+[.DTDTK<-(>3GW]!SZ4!3&6@@<>=LW%NB\D_U
MSZFA66*;[*DK/(V=[%ON_KQU_(4HC2T'E01AI6^\WN>IY^GZ5]^?D@@A2T5H
M[3<TTGWF9^2?4Y^OIZ<8J.><Z?+&BPFXNIV.U595.W(R>2.%SS@9]LG%-O9I
MM,0?8X/M5U,VV.-I"H';<3R0HXR>>OT%5[Z^GT;98P-]LU2]WM;PLS*FX#EC
M][RHEX!;MD ;G8!@ O+N726C@BCCO-8NHL1Q_<WJ"-S$@'9&NX$G!QG W,P!
MI:E?R^#HO*M+8ZQXCUC=]GA^:-)I$3.78!_LULG=B"%W@#S)I0)$O=1C\'21
MV<0.L>)-6_U,.](GF5& +G_GE;0^8"2-VW?@"264"2*-)?",@EF2+6/%.KQ*
MI,<?D^:(_<ES#:Q&0]VV[P ))9/W@ 3/+X.D,R6JZQXHUK,<7RM&DWEJS*KN
MJO\ 9K6/<?F(;:9<#S9I0)9;2,>#I&\^X;6?$&K2%I)-JQLT:OD* ,^5;PB3
M '.-V3OEE)=MO!'X0NY)))1JWB36&3SI/+$3/&A("KU\NVB+L0I8X,C<O)+^
M\U[#3ETM6O+N3[1?7',UPR%0S!>%4<[$'.%R>I)+,68@!INDQ:4TE]/*EQJ%
MPH%Q=>6%+\G:H&>$7)VKDD9/)9F)GEE^S*)2AFDR/E13D<<G'../\]32SRO;
MID*TLW14X&<GKU_K0L26NZY9"TTG.&;]!D\4 -V#3TDN KRS2<[0W4XZ#T''
M6EE,=OMN)B7F9CY,:L%9VVD[!D@$XSU],]LT/)]EMEGOD\R5F&V%!G+]E7/T
MZ\ <DX'1ID^PC[7?R!KB12%16.T8R=JY[XZG@MC/    !O+LI/MMXZR7,F4C
M56 XY(10QZG')_B([  "GJUW#H<*ZMJ$'VB]DD$5C:PXWR3,I'EID@'(!))P
M JEFPJ\.U6Z71+5M5O8FN;F3$=O9PY;S)"Q947.<'U;A0JEFVJI(IN1X?"^(
M_%#_ &K5KQA;V=I:'=M9AN^S6X;&<[-[NV,["[E$C C !\Z 5\3>*'^U:M=-
M]GL[.T!8+N.X6\"G'89>0XW;"[[$C58UL=.N-,E_X2GQ2T=QK5PI2WM[=E86
MRE5+6ELSJA928PS.P4NPW'8JHD<EK;2:,Q\2^*)5N=4N%,,,-N,K"I.X6\.[
M'7:"SG!<J&;:JHD=RRL;Z*?^TM4N]T\C8\F)CY<8[*N?8#)XR<D\8"@"V.GW
M27/]K:K(DEQM98UC3_5(3G8/7MD_Q$9X  6Y)+Y)WN-S-PJKVILCM"GGR+EO
M[N>GK1P@^T7/WCP%]/;]* &YCB'VZZ/S;<CK\J_3\:;(V#YD@W.?]7$3CO\
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M[=@)\Z7)P,?>"G[NW<?F V)<2)<1R>(/$4L=OIMJGG0Q7!V*NWYO.E)X&,9
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M /,?B#_RDV^$?_9"?B+_ .GKP37NU>$_$'_E)M\(_P#LA/Q%_P#3UX)KW:@
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M$%%.\D'(P3@8Y YY%&X^//AG6$;2-.T[48;-"8[NZA55+@ J8HG20,C XW2
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MG\W>[?>SP?<Y/H?QZ^[3'>Q.L<$\?8[3$ H7Z;@><8X[\UQ__"^/#.S TO4
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M\ M@D;@!N9@&^X/RDK:A<:EHLT4%M<0WFL7R_)"L)4.%P&8G<?*B7<,GG&0
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MU=]UTP^6%'S'",?ZM>F1D DGJ0#P H4 @L])U7[0-8U:]A^U,H"QQPDK$O\
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M8;@-F64'BB-?&?C21M.T/3_]+L;&[=H=P4-_I-V"0-H!#)"X_=[1))^\VK
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M+"\/AF8\97'0$>YY("Z7_!*'C_@EK^S6,?\ - ?!O_IDLZ /=O)U'_G^C_\
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M-G<+%!N\J)F:1B\BJ))=L:R.ZPPK& :U%%% !1110 4444 %9US_ ,C99_\
M8.NO_1D%:-9US_R-EG_V#KK_ -&04 :-%%% !4;_ /'Q'_NM_2I*C?\ X^(_
M]UOZ4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/?\ R(]A_P!CIX;_ /3W95VE $<7^OD^H_E3;_\ X\Y/]VG1?Z^3ZC^5-O\
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MFUFM[KQ/JES;R_[LD$T4BGNKBO2+QD2W:25<JA#8"YZ'/3UH \ _X)2ND/\
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M6., ,S%54E<\%?#L7_"2^)B;S5[O=%9V=NRL?F^;[+;[@F0=@+.VW.S>Y5$
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M(TFHZE,L<,:[EW-@+@D$G(XXVG.3SGMUJM/'>0_\)/KLQL]/M8VF2&Z81A5
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M$7_T]>":]VKP?Q\XD_X*9_"&1<X;X#_$4C*D?\QGP37O%  .E% Z44 %%%%
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M*$C\=Q>61CPXHVD/_P Q8?,I5@P_X]NA!!_?_P#7+_77F6ZUJ;<C,+'*C:&
M$N"&#JP.=I!P0>I4#IDD \B\#R?$C7OV^/B6VHOX@'@+_A4/@G^QH[M9O[+E
MU/\ M3Q:M_Y 8&$S>2--\XI\YC6TWDIY6?9?.^W'R;&55CBDVS?+Z9&T>G..
MW3ZUX?X'\6^)M=_X*._%KP&?%FH'0=-^"OP]OK32GN':UAN+C5O&*W$T<3?(
MKS1VUM&\B#<RVT:D_NU ]UVRSR<_+$OW?4D9!^G^?Q "$.[@QQA(U^Z%/7WX
MXZYI-WVAOL\898\?>4<$>GIZ4;WG8+%\L8;EE[XQ],<Y%2-LV[<A8UZMG]*
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M6O?]&M9=L()\Z97SNY8%%(.5((Y/;H.>55=WG+:VD>R*-0/E'R^P'';'8]Z
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MD,B_90I.TKRYQQWQCKQZ^F*FA5G^:2-5CV[5CSQC^7(IJ"29O/G^6->8P/3
MZ^_'3T/Y1DOJ$WER1K]E7[Q\P$.1T&/0YS_P''0\@'@'_!2>4ZA^SSX?$\&V
MW7X_?"C=YB_>_P"+@^'P5.<@CW!P<_G=_P""4:E/^"6_[-:%<8^ /@X8]/\
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M!UU_Z,@H T:*** "HW_X^(_]UOZ5)4;_ /'Q'_NM_2@"2BBB@ HHHH ****
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MGQEXV\,WFGZKHMEY%K<1:)<RWB)-J+VZW ?[641&6Y6*-(HX4B3[8H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\ ?^#YG'F?LOY'\/C7_P!P
M-?K]_P $G/\ E%C^S3_V0#P;_P"F2SK\@?\ @^9_UG[+_'\/C7_W U^OW_!)
MS_E%C^S3_P!D \&_^F2SH ^@**** "BBB@ HHHH XOX]_P#(CV'_ &.GAO\
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M2-)-([99CW=S^0 Z  *H   ;:6K:+;K9V,;7%S-,)+J9B-S,?O2.>F<#  P
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M).>G.."/J#G@]<@#=TFJ2<*OV7@MNS^\! (P0<$9X/7()'ULR3Q+'YTSJL?
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M737%Y,6+232'NS,2QP,*H)PB*J* JJ!>H **** &S_ZA_P#=/\J=39_]0_\
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M1K.N?^1LL_\ L'77_HR"@#1HHHH *C?_ (^(_P#=;^E25&__ !\1_P"ZW]*
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M/[=?[(?_  4)^%MU\1OV*?BC;^)_">B:HVCWUU;:/>:;]FN$A1_LX@NH895
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MJVCV6EZA<?:I#'):VDMU+;H(BVQ"KWMT2ZJ&?S '+".,)Y-\0?\ E)M\(_\
MLA/Q%_\ 3UX)KW:@ '2B@=** "BBB@ HHHH **** "BBB@ K.N?^1LL_^P==
M?^C(*T:SKG_D;+/_ +!UU_Z,@H T:*** "HW_P"/B/\ W6_I4E1O_P ?$?\
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MC-)#=+;PQSI!<WUS8,\/F1M+I\Q60Y*KS/\ P2A_Y1;?LU_]D!\&_P#IDLZ
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M=7RXS:\<8R"&D/4 @@#YFR"JNE[?/J<LOASPY<JCI\M[=IM86@*@@ '(,A#
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M9 _(/FD8'ECU;/.23DGWSWH 2%8XH/L&F8PN0SKCY6SSZ<\D_7MS3C<1P/\
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MAF>_T..SLI;>]DLM0N;F17>6:X5BDKQ@Q;%+%&9OK2@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***:\L4?^LD5?\ >:@!U%"L&&Y3D'D$=Z* /P7_
M .#X[_D2_P!FW_L)^*O_ $7I-?<__!K=_P H*_@A_O\ B;_U)M5KX8_X/CN?
M!?[-O_83\5?^B])K[G_X-;O^4%?P0_W_ !-_ZDVJT ?H#6?XC\3:;X8M$N]0
MCNI/-NK>WCCLM/FN7,DTRPH2L*.RH'<%Y"-D2!I'941F&A7S+\;/VO\ PQX:
M_8X^(7[7MG\=-#^$^G^%_%VLZ+J'C+X@^#WURSTY-'UVXT69/L5C<VTUR)[B
MUE,"+,92]V@"L2(0 >_:O\0O#7A_Q-9>%=>GN+.;4+5YK2ZFL)_L9VSV\'E/
M=;/L\4SRW4*Q0/()9OWAC1Q%(4W*_-#]DK]H'Q#\6O\ @J7X?USXC_\ !5J3
M5M6U7X87^CVOP#UC]FOQ?X TW7+>"<W;ZI81ZYJ30R:G$S1[Y$CFD:SBF3RU
M57FC_1?P78:IHF@KHVJZF+YK6>6*UG192WV99&$"2/-++)+*L6Q9)6<F217?
M";MB@&'\>_\ D1[#_L=/#?\ Z>[*NTKR/]LCXEP_"[X9Z/XIUGPWJ4V@P^.-
M"D\3Z[:QQFW\-Z?#J$%S+J=[OD5H[*,0[99D5Q L@FF$=O%//%ZQ'<QRHLL0
M9E9<JRC@CUH (O\ 7R?4?RIM_P#\><G^[7!_#']H7PO\1?BMXW^#$OAS6M#\
M3>";BU>_TO6[5(S>Z?<B06FJ6K1NZS6<SV]U&CY#K):S)(D;)BM;XS_$B3X5
M?#?4O'__  @FO>((--1)+[3_  W8?:KQ+;S$6:>. ,)+@0QEYFA@$ES*L3)!
M#/,T<+@'65P-OH>E:Q^T7KMQJ-C%-)8^$]#GLI)(E9H)#/K49="0=K&.21,C
M!VNPZ,0>XM+Z*]MH[N&-]DB[D.WJIZ'\17COA#XUV$O[=OC3X'>)/!6O:'J3
M?#W1]0\+ZAJEO"++Q18V]S=B]GL)(Y7+_9)K^U@N(Y5BEC:>%]ABG@ED /2O
MA[X0OO!>@3Z-J.M-J#3:O?WBRR37,FQ+B[EG6(&YGG<*@D"!0XC4+MBCAB$<
M,>2?@!\.)O,>_AU>]F/B.;7;2\U#Q%>W%QIU[(KHS6<TDIDLH_*EEA$,#1Q+
M%+)&$"R.&[+S?^F;?]\T>;_TS;_OF@#BXO@\VM^&/^$(^*'B<^*-'73S8365
MYIT4*ZK;-:102C44C ANFD87+,B1PVY2YV>03&KUVJ*(T"*.%&!2>;_TS;_O
MFCS?^F;?]\T <+^SIIWPZTOP#J5M\+=?N]2TMO'GBB:XN+V,JZ:C)KU_)J$(
MS&GR17S742':04C7#2?ZQI_C_P#&:R^ ?PWF^)-YX+UOQ&\>I:?IUCX?\.?9
M!>ZC>7U[!96T$37D\%NI::XC!:6:-%&26 %97[+6G>%=$^&NJV/@_P 6MKEF
MWQ'\83S7W]F26OEW4WB34IKJUV2<M]GN));?S =LOD>8N%< 97[<%Q=VOP#3
M7+7PWKFJ)HOC[PAJ]]9^'] N]3O#:6?B73+JX>*ULXY;B<I##))LB1W(0X4T
M ?EE_P %P_\ @KS^SW^VY_P2S^+'[-WPMT/3['6]8T_3;ZVN=2^/7PQN(UCL
M-4L]1F40:?XKN;N>4PVLBQQ002R22%$526%?M%$\EZGFW,8CC49*[PP8\Y!^
MF*_+GX _\%#OVU/V0?V,O WP)TK_ ()X:AXZN?A9\,=-T*SCTKPW\5+.Z\0R
M:;IT5NAACN/ATL,$LYA^5)KA(T:0!Y0H+C[:U'Q9_P %#-9/V6\_9<^#JV:G
M$UNWQRU7_2>A )'A@_)U!4@;L8Y7(8 ]>E:/Q#&SSF)=%C4-NW#;=K@$'(.!
M$/0_?QSA?OS2V[:R?]-CC&GIM=4X83]3SU&P?*1T)/7@?-\P?'C]KW]NSX,+
M807_ .QE\-O$5Y=+-?S>&_"_QROIM4ATFTFMUO=82V;P^EQ>V]J;FW$L%I%/
M=.UQ#'%!,\JH>'_:/_;\_;O^%GQ6?X-^-/\ @G;I]YI:Z!::FVM>'-<\<>(-
M+U?SYKJ)K+S]#\#7_EO"+8/-#.L)9;JWV[T,@H ^P(;I?BAYD2P,/#JR+MFW
M%6U-E(;IQ_H_3&<B<9_Y9$&9\AM_'%M([0X\,JKF15AS_:X^8.I3;S;=P1S/
M_P!<O]?\??![]O+]OO\ :C^)[?"O3O\ @G7I.DZ';:+=W^J:QXJ\2^--!T^Y
M:.2S2&T,NM>";)Y3-]IG;RHHWW"QF\TQQLBW'M^I^-/^"BVI2B!/V6_@XD4,
MT9(;X[ZNOFC<I)#+X7R !N&" 6/!PIR0#V61!XD*E)V6Q1@<Q,-MVNT$<@_<
MYY& 21CIG,[2K>&2WMI6ACMVQ(P4KGCD#IV(Y&1GZ$5XM=>.O^"B%P?L$'[*
M_P (84C165T^.FJ@-AN #_PBYP/EY&T\,/>OF'PM_P %@OVTO$?A/3=9UK_@
MF%J.A7-Y8PW%UH.L:/\ %22YL7=-S6TS6WPWG@:6,G8QBEDC+*2DCJ0Q /T,
M1([D8"#8&_[Z_P _RI>+@^7%\L?5F7C/^>:_/RR_X*Z?MF7]HWV[_@G%/:-'
M.\?DW&A_%DEU1V42 Q_#1QM;:KKSNVL-P1LJOM/[/?[3G_!0;X]?"FR^)</[
M#?@/PO#>WM_!%I/C#XJ>(=*OO+M[R:V29K6]\)Q7,4<RP^?&)HHW,4T;%5)*
M@ ^G%1MHB5FVKQN[FLUYKK7IFLK*01V*LR7%Q"_S28X,:D$%#GJPZ8P#DY7Q
M_4/&O_!134)&TY?V7_@_#;JJB:2/X[:P&E!W916'A<%,?+\PSP2!@\CS7]JK
M]K+_ (*(_ /POH5\O["WA76-+U3Q#%INIW?@/XC>)M:GTV VEW/YLD&F^#[F
M\2$O;16S2Q6TA1KR+!C!::$ ^HI9[CQ%.VA>')?LNFVLABO[ZWRI=EX:W@(Q
M@@\/(/N<HO[S<T4) UVW_P"$8\+9L=)M5^SS7MCM3&P[?L\'! VX*NX'R8V+
M\X8Q?"4?_!47]NCQ-JNA?#'P%_P38DMTU+7-*TK?:V_Q*TV&&WNKE;5Y/M.H
M_#ZTM[.&V5Q<32RR(%@CD$6Z7:!].-XN_P""@5K96^D67[+'P=M[6,"%5@^.
MFK#RU7 50?\ A%^ 0,9'(&"".H )_A_H'PR3]N7XB7WA/Q1=?V_)\'_ ]EK&
MA1Z:([6RTJ'4O%9L98I<@%Y99;^-XP/W:VL?0R<>Q-_IQ:VLGVP[B)IHV&6(
MRI12#E6!')[=!SROQQX+U;]MK_AO3XD>(].^$'P;?Q)??!WP-:>(/":_&'7$
M.FV,.I^+'M;M+P^&0DOVB:YO8MBJ'B&G[C_KTV8GQ-_X*:?MT?#CXG>*/A)X
MC_X)S6T9\/WUO;6VKZ3=?$36;'6(9;*VN?M%I=Z/X O;=HU:=[=@TBR+-;2@
MQ@!6< ^Y=GF1QVUE^YB7'W%V[5&, #C'ITKD]1T/4]*\;RII/@S3]0T?7KB&
M;56M;.**Y@OXDVB]N7>11<1^7;VL2E5,T;0Q_?1LV_Q%#_P6!_;2E\27?A<_
M\$Q-0@T^WTZVGAUI]'^*OV2[DEDG62VC"_#<SB2)8HW<O"D96ZB\N21A*L1I
MO_!:;XUZ5\6_ _P6\:_L76.EW?C#Q-I.G+;M)\0;.[AL;O6=.TN?4D76? >F
MVKQ6TFI6[/YES"A+QQA_,FB1P#[F\+>%&TB>;1]#75K*PBUR\O;J>_UC[;+J
M#SYF.'G::18!)<,$CW1^4+6.*-5MU5#K76IM?WLGAWP],J31M_IUT%R+;H=N
M.,RL""!T4,&;(*J_@?[?G[87QY_97O/".B_!G]ER[\>6GB6WU+^UM>$?B.:'
M19+=K,0P&+0/#^M7#27"7%RZ/)#'"GV*0,[,R1M\[O\ \%7?VRK73/\ A%O#
M'_!/BXT]'C?.JQ:+\6)FA;*[B!+\,SF9@S,K.KKN!9P<A7 /O)VN(;O_ (5_
MX$)A:"'.J:Q(A<V:ME@%+*5FN6R6PQ;8&$DH;>BRMVO#.WP]^'LAL_LNUM2U
M)H6E^S>82[8=\B6Y?ESN+D&42R [E67X/G_X*D?MBZ?H#>%?!G_!/:71UF25
M_P"T;7P_\69&CD>3=(Q\WX9'=.YDDD$C*X,@+2;L[7EL_P#@JG^U]HND)X<\
M)?\ !.C^SHV$DINUT'XMRA':0-(S;OAGN>:1G=_,(<%]SON)PX!]Y0VR:9:C
MP'X!_<&U7%Y?22&5K7?EBQ:3<9KERV_YRQ^;S)"=RB2];V26=N=%\-A88_,?
M[1<+M8Q.QW,3DY:1BQ;+9Y8LV>A^"K3_ (*M_M?Z=8+IFG?\$]&B51\TQT7X
MO.SG/S$D_#')=N26.23R<U37_@KS^VAIFNV?A/3_ /@F=JC6MSIUU<2^(%T?
MXK26UI-$\"QP2^9\.!</+,)9'0I$\86UF\R2-C"LH!^A-K -.ACTJP#,J*<R
M2-N;.>^2,GG)/\ZD\Q;=OLUNK/)_$Q7..^2>/?\ &O@/_A[?^V/"/LT/_!.R
M3YE_X^!HOQ<;:WJ<_#+/Z&E?_@K7^V0HS!_P3Q"R2<-+_87Q=;;P>2/^%9#(
M^GKVZT ?>SRRK(UKI?ER3>8#.SR?ZK..2.OW>GK@=!S38H_[,2/3M+@621I,
MW$S #)(R9&P!ECCMCKVX%?!:_P#!6C]L2"W:&U_X)Y,NYF(<Z+\7FPS')//P
MQ]3[^F,=&1?\%9/VPK&%H=/_ ."=(5I79GF_L/XN$!B/O,/^%9 MS@<9/3H.
M0 ?;OC246.F0Z'H@W7DFI63M-*/,$.;I,2R#<I*EA@*""><8"DB6_P!:&AZC
M#X'\,JUWK5[&US)/=1LT=O'O :>=U  ZD1PY4R>6RIM2.1X_@3Q'_P %6/VS
MK3P['I^E_P#!/@FXFU"W>34;C0_BTX682(5EE5OAK$74NJ)LC.X!@%4*/EL:
M-_P5'_:[\)V$T&@_\$ZS)>:A<>=J6J3Z!\6FDN+CRPOVF<+\,8][%8TC^0#:
M!&H"H@"@'WM8Z9;^$T.A>&@MSJ=[-]HU"^O6#2%F7:;F;&-V?+"*@VC"A$V)
M'\E^*VM](/V&R5I;JZ;=-<2*&9FQS(YX[   8  50   /S_E_P""N7[8_A^_
MTW3K#_@FGJ6H1ZEJ3Q:AJEOHOQ6/V%?(ED^U7 E^&T;,A:*. +")&#S1#RUB
M5Y([UE_P5D_;!LH_+/\ P3XDD9F_>3-HGQ=9CSZ?\*P X% 'WW;0BPB6#S6F
MF;EI'ZDG)_+.>*"QBF,%NYDD;[^XY">_Z^O.*^!5_P""L_[8<?S)_P $],.W
MWG&A_%[UR>/^%8_YS26W_!67]KRS.%_X)WR$S2#SIET3XN,Y_P!LY^&(!P/T
M % 'WW'''8_N(%9I)&RSL,\GJ3^1X_\ K5'=SOIV!;PFXNIN(XS(0/J3SA1Q
MD\]NIP*^!Q_P5K_;&@<3+_P3I::1F"M(FB?%L$*3_M?#)>!['\#W;%_P5H_;
M&M-MS+_P3P:XGDV)-)'H/Q=Z9 ) ;X9#"CKC/KC)/(!]X7][+HTOV:T1;[5+
MU2886;;T_B;KLB4MRW)&0 &=@&S[_43X)CCM88VUCQ)K+%848-&L[HI.795?
M[+:Q]"Q!"EP!YDTH$GPK9_\ !5[]LC08I+\?\$Z)]2OKRXB%W-'HOQ:5RI<+
MD!_AFJK%$K,VP-G:&(#R,=^;JG_!6O\ ;7\!>&]6\;V?_!,C4?%^O)8^9+8Z
M'H/Q3@O-3,89DMK<7GPYA@C&681K+.J*7):0EGD8 ^^B$\(79N/LG]J^)M<^
M166+9O$88A68!O(M8M[<G(7?@>9-*!*^ CP?,4GN/[6\1:Q(K2$+Y>]5&!M'
MS>3;1YZ$G!D/+RR_O/@KP[_P5*_;)\-)<:U?_P#!/:35]:OVC74-0'A[XLQ2
M/&)'*1*O_"L@$@A$LFU-S, 6),DCLSW=&_X*K?MD:8CWEW_P3W6ZU&X"_;+Q
M=!^+R!R.@5#\,CMC7^%-Q(Y)+,S,P!]]Z?I,.CM)J%PT=UJ5TJ_:+ID$9DVD
MX4==J+N.U<D@$DEF+,;,TIM KNC33-@;8\ 9.!D G@<=,^ON:^"%_P""M/[8
M>_</^">>YMV=S:+\71CV_P"28@< G_ZYIL7_  5D_:]MIYKB+_@GDSM(V2S:
M+\7@3Z<?\*QP/\\T ??26XM(WD>1I))"6^9N5SZ9Z#_/H*X'PE\*='\)?"]?
MV?&\+7%GX>TOPZ-&T"7P_J4NG"'3?+F@@L;:5+MKN&XM[:*%6N Z$LRRQLAW
M1P_(4G_!6C]L.%I+I/\ @G@\SC+(O]B_%Q2< X'_ "3$#H>Y_&O5_P#@G3_P
M40\;?MO^*OB%I/B?X#0^&X/!D-DEMK&EWFOO;:A=/>ZK:7=CY6NZ%H\\=Q9S
M::T<Q2*6/S)#&9%DA>-0#Z(T2SUB36I/''B"?4()+W3+:.S\-W;6S1Z?(OFM
M(08U8B=_-2.3]])&1;(8]N7W<C\-KY-!\<?%;5;BW>ZNF\?6\=E8Q$%I9#X?
MT=O+0GO\I))("JI8[54D?-/QA_X*;_M:?#+XK^)O".D?\$_IM4M]&UJZM=*U
M":Q^(LK7UO%(\<5R&TGP+J%B?-C"R#RKR4!9%5F5PR)XW\._^"JO[8&@?%'X
MA>)(?^"<]WKEYJ&O/=-):Z1\4!'8-'I>DQ)8HO\ PKPNDDJ()-SHFYHSYFR/
M[,T@!^EKS-X;1?$GBEVNM2O)$MK>SL5>0(6;Y8(5/7^\\I"Y"&1RD<8$:VD$
MNBA?$WBUH[C6+A3##;VK;EAW?-]FMRP7(.T%G;:7*!FVJB)'\$6W_!5C]K_3
MM9N==U'_ ()]#4M3DCF^PJN@_%J-X;7*?N(5;X9< E8R[%OF?:6*J(T2W;_\
M%7/VQXM0?5KK_@GWY\I5EC4:!\74$:9R% _X5B>1W.?F//&%"@'WUIVE72W?
M]L:W+')=-N6-8P=L"G'R*3_NKD\;CDGC:%NR.(5\^7KZ9Z?TZ5\"-_P5N_;#
M#LR_\$\]W79G0_B]P/\ PV']:9+_ ,%:OVP8I6N4_P"">#3,%&T?V'\75/3E
M?^298ZYY)_*@#[[&(Q]HO3AF. O4 ]A]>.O>FRS8C6>2)F;EHX1@;N.G)QT]
M2*^!_P#A[7^V+(2[?\$\2W.55M%^+HQ_YC'U'<_E2+_P5F_:^^T?;3_P3O\
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MU?MB7AV2_P#!.]E59.AT3XN_-P.01\,<XZCG'Y=0#[Y>#^T@4!V6Z_*NQO\
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M"VUA5FELXI' OK54@O0&8_Z1"JQ2_?0!6 KMMLW_ #T7_OG_ .O3J* /D/\
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MXXD"*TUS<O)-<2$*"TLKO([99V9B2="@!J[O-8ECV^7TKXP_;2^%_B'XO_\
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MWP__ .R7>,/_ $X^&J]2KRWQ=_R>M\/_ /LEWC#_ -./AJ@#U*BBB@ HHHH
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M;03W,\22R(999XI9!L$:1Q210A6\DRR '6L,J0?2DC 6-5 _AIQZ4B?<'TH
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.N?\
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M&_8LNO\ @IE'XPD\&MJF[Q''\'?$]B+O[7JEW?#]Q]BEV;1<^7_K&SLW<9P
M#]'_ -B;]L%/VU?A?J7Q/3]F/XO?"C^S?$$FE'P[\:?!?]A:K<;(()OM45OY
MLNZV;S]BR;AEX95P-F3[%7D'[%G[>?[*'_!0_P"%M]\:OV._BK_PF'AC3=>E
MT6^U0:)?6'E7T<,,[P^7>PPR$B.XA;<%*GS, DA@/7Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \/_;F_;/\*?L=?#;^V]0"OK6H6=S-HZWD
M+K8PI!Y?G7%U-E4CBC$J,5+J[ DK\JR.GD/[&?[+/[3OQ5T:^^._[7'Q^^*.
MFW7B" 2^'?"=OXHO-)ELI/LJVHU.ZM;>800R/&BR1Z=Y2PQ,[SW,)NI?*L_+
M?^"IUU^T;\,?V]_!GQXT"?PSJ'A'3? MH/">A>-M+N-2TZ/Q#!?WLES?+;6^
MH6Q6>*&;3RK2*T9;RI!NEMHF@V/B!^W1_P %$?!G[,.A_M)V7Q'^ ETNIVM[
M<WGANX^'^IV]Y;007\=B)XU;Q 3<Q>?/;QR,H!C:Y@&U@Y*@&YX!^.'QO_X)
MV?%F3X2_M6>.M8\3^ ;X3SZ7XNU:ZDNI(U,\L\EW]HG9YV53/MEM9)'^SQQP
MK!B)(TG^[,U^7O\ P4'_ &H/VO\ 3M=\5?LT?%CQ-\%=6TG2X[:;^WO^%9ZI
M:2VDS6L<XN8BVO.(6C\TKN)(9=P8%'9#^EG@.T\46'@G1['QOJEC?:U#IL$>
ML7VF::]E;7%T(P)9(;=YIV@C9]S+$TTI12%,CD;B :U%%% !1110 4444 %%
M%% !7GWQQUO5K62QTJZ\3-X9\*0V-]JWCKQ=<)"EM::;:QKNM?M37<4EA+*9
M?.%TL4R)!97:EK>5[>9?0:X?XS^*M-^&E@OQ/\37WB>30[.SDL=3TSP_H\M^
MA-S-;K'=RPVD$EY^Y(*^9"1'%'/-+,NR,30 $FGOX1T#Q%X9@T(:?9:/%X>N
MK728K.-(K:.+SK"."*(+A0IRJH%P.5"]1GG[KPY_PI3QS#'\,!?#3_'>N^1<
M>'Q9WMQ8Z9J'DF:6_CD198M*A:VMK@O"8X[:YO7@^>&XNYI+CF?V=?@O\"/#
MOPF\&_#_ .%'A;4M)\*W/@V[=([[PF?"]X\H;3T:[?3H[6R&F7+O'Y[)#;6H
M29BZQ1DUN:_X+UOX8>&L? W6O%FJ+X9U*\US5M(E\3OKFH:[,\3,-'#:O*[1
MQRK.TD6V\M$MY8;49^S/-&P!X[^V#XZ\%^._@MK4_@O2+-8]&_:W^%>E:EK=
MCY;)K=Y%XR\(>?/YB#YVA9OL#@LQ1[!HF(,>Q/7O&_C+X0:;\1[CQ'\-/B3X
M??QEH#7$OBKPS;^-/LWGV/EZ.VHW-W:1)/YUQ:V$^F3Q.\ E GM(1<6T%_(T
MGB_[84/PZ^(/P3L?V@?#CS7FHZI^T5\,-&6^NH[+S;.UL?B5H%JVG[[10YC2
M[M[J?R;MWN;:>\NHW%N2UO'ZUJ7P3^!?@GQ))X7^$_PKT76_&&I06UEXJN-0
M\0,VI6>A7WDVUS>WET[2WLGG6^D16Z,=[W,NF64,DB0VGG6H![A4=YM\CYUR
M-RYY_P!H5)39/NT .HHHH **** "BBB@ HHHH !THH'2B@ HHHH *;* 5 (_
MB'\Z=39.@_WA_.@!U%(^_8?+(W8^7=TS3";O/RI'_P!]'_"@#-\9^++#P)X3
MU;QMJUCJ-S:Z1I\EY=6^D:5<7UW)'&A=EAMK9))KB0@';%$CR.V%168@&CX$
M^(#^/]/NM:MO!FM:;9Q740TR?6K,6KZE!)9P7 N$A<B> *TS0/'<QPS++;3
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MLGQUX[\$?#+PCJ'C[XD>,-+\/Z%I5J]SJFM:U?QVMI9PJ,M)+-(52- !DLQ
M%4_'WQ1^%?PK.BCXF_$#0?#I\1ZY!HOAX:YJL%I_:>ISAC#96_FLOG7$FQ]D
M*9=MK8!P:R-)U/X._M&:3''J7@)M4M='U/3=3M[7Q?X.FMGL[](K74;2=(+^
M%)([B'SK>0.$#PS*R$I-#(B '3^#/$NF^-/!^D^,=&@OXK/5M-@O+6/5-*N+
M&Z2.6-7436URD<UO( PW12HDB-E756! TJ:L$*KM$2\?[(H\J+_GDO\ WS0
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MV=U^"OQ&O?A_-\,]'\70:W#:36UI9WLDOVJ"&))'=[]B[#S#)('D:5VD8C[
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M5!)X!H TE,@4!ER<<GUHW-_SS_6B&:*XB6>!PR.H9&7H0>AIU #=S?\ //\
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M*DJ-_P#CXC_W6_I0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ?DO^U,TB?\'@O[.;1)N8?LT7Y5<XR?\ BJ.*^<?V@_\
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M/_AK])_^1Z]FHH \9_X=S?\ !/;_ *,0^#/_ (:_2?\ Y'I'_P""<_\ P3W
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M>C_AW-_P3V_Z,0^#/_AK])_^1Z]FHH \9_X=S?\ !/;_ *,0^#/_ (:_2?\
MY'H_X=S?\$]O^C$/@S_X:_2?_D>O9J* /&?^'<W_  3V_P"C$/@S_P"&OTG_
M .1Z/^'<W_!/;_HQ#X,_^&OTG_Y'KV:B@#P?Q9_P3L_X)^P:7"T'["_P=C+:
MG9*WE_#+2ERINH@0<6_(([5I?\.YO^">W_1B'P9_\-?I/_R/7IFHR7/B:Q$6
MGV$J+#JD3>9=(8]X@N$9B PW8.Q@IQAN&!*E6-;P[\2](UOQ+-X)U33[G1]<
MCCN;B'2-2:+S;FTBNF@^U1-$[QR1L/)EVAS)$EY;>>D+RK'0!YY_P[F_X)[?
M]&(?!G_PU^D__(]'_#N;_@GM_P!&(?!G_P -?I/_ ,CU[-10!XS_ ,.YO^">
MW_1B'P9_\-?I/_R/1_P[F_X)[?\ 1B'P9_\ #7Z3_P#(]>S44 >,_P##N;_@
MGM_T8A\&?_#7Z3_\CT?\.YO^">W_ $8A\&?_  U^D_\ R/7LU% 'C/\ P[F_
MX)[?]&(?!G_PU^D__(]'_#N;_@GM_P!&(?!G_P -?I/_ ,CU[-10!XS_ ,.Y
MO^">W_1B'P9_\-?I/_R/1_P[F_X)[?\ 1B'P9_\ #7Z3_P#(]>S44 >,_P##
MN;_@GM_T8A\&?_#7Z3_\CT?\.YO^">W_ $8A\&?_  U^D_\ R/7LU% 'C/\
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M'\??V8=+T7]B[X36=KK'QPU"TU>WM?ASID<=];KX$\63K#,JP 2()H(90K9
M>*-L952/M2YNK:RMY+N\N(X88U+22R,%5%'4DGH*_+_]K#_@OK_P28NOVF/A
MQH_B7]JY_#>I? GXU:G>>,M*\0?#KQ+'<2;?"^O:-)% L6FR?O([W4XT993$
M0+><C.(Q( ?;W_#N;_@GM_T8A\&?_#7Z3_\ (](__!.7_@GJ<9_80^#7WO\
MHE^D_P#R/6S^R+^UY\$_VWO@;HG[0_P"UF^O/#?B""273I-2TN:SF*I*T+YC
ME53\LL<D>Y=REHV 8X./0(-5N;G5[G31HMRL-O##)'?,T?E3LY<-&HW;PZ;
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M:*** "HW_P"/B/\ W6_I4E1O_P ?$?\ NM_2@"2BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _)C]J-2?^#P?]G$,#M;]FF_
M'_J45]5_M,?\$&/^"1W[7?Q!F^*WQP_8H\.W7B&Y:9[[4M U/4-#-[-+/)/+
M/<+IEQ;I<SO++([32AI&+<L0 !]>;5SNVT4 <G\$?@5\'_V;?AGI?P;^!'P\
MTWPKX7T6#RM,T728/+AA!8LS8ZL[NSR/(Q+R2.[N69F8]9110 4444 %%%%
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M^';;2]4F=[Q#!M>:[&R-0=\DB+;_ +U%$:3%VD=4MP#I**** "BBB@ HHHH
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MHT444 %1O_Q\1_[K?TJ2HW_X^(_]UOZ4 24444 %%%% !1110 4444 %%%%
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MAT[X,ZE>:79ZE%9M>)JMFD]V)#8XO+>%I0K6L0N+OSC+)#<*=/<0V]SYT)8
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MZM-'TW5[OXA:IX7T>RDN/[1UO1=&FO+BTDN8C803@*[PI'"]YY[O>6EW9Q)
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M\W'F *[,49"XBD+PQZEQX!\.7VN:IKFHZ?Y[:M8PV5]#/.\L,\$?FX1H7)C
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M+-@.L6]#A<BNP\0P:!<:!?6_BF*U?2WLY%U%+Y5,!MRA$@DW?+LVYSGC&<T
M>;>&_B'XI\9:$OAKXD_"Z3P?XFCUZW-MX?GU*SNGU.UL[VR^T:G9_9II'EL0
M\Z;9)HX)D5T,T$)=5.CX3O\ Q,GP$M[;P?X=,_B;1_#CV-KH?B"ZN-)AGU"V
M4P>5+,())(86GB*K=1Q2J8V$T0F0H6V/AEXE^"/B?4O%5Y\'?$/AG4KJT\32
M67C:;PY>6\[PZS!!##)!>M"25NXX$MHV27]ZD:0J0%""L>+XQ?LM_$:>ZU32
M_C'X+U2XT/2IKN^O=+\46S36&GI)%).\DD,NZ*VW1PF7<1&P51)D<4 =?8^,
M-%U;5KS1=*-Q<S6-NLLLL-JYMWW231[$GQY3R*\$JO&&+QD+O"AT+>8?M+W_
M ,<_%'@C[#\$? GAO6-*DM=1A\7:9XM\+MJ%SJ\,7[DZ3;6-S>:= 1=@SJ+N
MXNA GEQ#R9X[DS6_K5M?:.E[)H-G>6HN+6WCEFLHY%WPQ.76-R@Y56,4@4XP
M3&P'W3CF=$^,7P#\?V&I>)O#/Q7\(ZQ:^'[-I=7U+3=?MITTVW8%V::2-R(4
M(A+$L0"(B?X> #.^*/C'1_$'@V^NO#*7FK1^']6T[4-0DT:QEO-T5IJBM<I"
M(58W$\7V.X5K:(/.'0)Y>YT#;]G'JNCZKJWBKQ+\18WT?[0UQ9VLD4,,.GVX
MMH$:.23&7Q+'--O++CSRIRJ+B;P+\2_AM\3=/FU7X9^/]#\0VMO-Y5Q<:%JL
M-W'%)@-L9HF8*V"#@\X.:P+OQ]^SEHWQ&D\-WOC_ ,*V/BB:^4W.CR:U!!=7
M-U)%"B/);[P99C%'"J.REP@4(0IP0#BO%KR:C^U[X ^-DL,FF^%]+^'_ (P\
M,WVL:TOV%(M6O==\,P6=J%GV.[3R65PL+("LNU#&S"6,OR/[36F?$/PU^RS\
M7OA[\1_C3)XLU3XJ:#K6A_"?0UTR"/R"OA6<K:&>&*,2RW#6%_J#S3;(T-Q]
MGC^6&,R?3Q4%=IKD]%M?A!X"\)_VCX-@\.Z/HNBZ=_9;7&GK!#:V%IIYE3[-
ME<)'%;$3KY?"Q8D&%PU '6 @C(-8NI:[I]QKLGA3^V+S3;J-;.X6X%KLCN T
MDK>1'++&8I69;>19$0F6.-E;]WOC>O/KGQXW@OXM2>$_$7QY\(Z3-JVI6Y\/
M^&M4FC@NI+1_L$0B$$MR9+F626'45CGB-O&AF1#:W+Q&63M;SXF_!R^\:_\
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MJVFB3[-?W.J>(X+F9)(V20^9%96BE79E7R 4"EY"_2?\$V/VVOCK^UC^T_\
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M(WC3P_J?A?4)]2TRX\(Z1X7NFAN&B^S&XW:]8W7D3"WGN84>W\MBES,CEE?
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M0\,^*/%&K>%=$N%N)-'L8;FZO(ID:W)>YO+9H@P)(DCEL9UD4@;2 .3N I>
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MWG=&69EC%O&?/#+ @8/)Z+'/'/'YD3_+_>*T6^TL_P"_61@V'V_P\=/;K^M
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M0L\49D(](^('PS\/?$6"%-;FU2&2UCN%MYM'\07NFRXFMY;=U,MG+&Y79*6
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M>9<R2]]XDAUZY\.ZA;>%K^UM=3DLI5TVZO[-KB"&<H1&\D2R1M*@;!9!(A8
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M+'07T634I+9KG3?'%]>75NL5CI[6D4MA/!Y%K+(9[^2002(%1+-B+AKF1K<
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MV@\!1/>7,PUN_5M0B75TD;2ODM(K:Y=4TR[AES!J;12^&_\ !SEX5\.^&O\
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M[6GAB3Q9'I?A:ZU&S_X1734U"]U2U\D7!@L54DSM/Y4>R-6Q(PC&3P:\^L?
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MX>M;:UL;:[TFTTOPG?VDTMO.F$DEN9+F>T\]9X+R-[."2=XXOLD\DD?VE80
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MKWC+PM]MNM7D6-%%R_V*>Q@CE8J[R"*(1EI/D2)1MKMHRS6X+9^[_$N#0!^
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M_"^@V-O'(YN4N=-O]?N)WD4H%$;)JMN$(9F)27<J@*7J?L0_!7Q5^S7^Q?\
M"']G/QU?Z?=:WX ^&&@>&]8NM)FDDM9KJQTZ"UE>%I$1VC+Q,5+(K%2,JIX
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MP?LX? _XJ_L_Z+\)M2\(:OH?A/0_$RWND^'=/U[7='^P&UNFFL%A_>6D]M'
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M;_A'XGU1II-=NI$\^<FTM+:X=%A%O;QPNGFSR/-=+]E"I"]SW7_"2>%#K_\
MPCS^)]._M+S#LL/M:>?]T,1LW;CQ\W3I^=>$>![WXA>)_&6K_$73? -YX/\
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M/B])XA^)7C#Q?H=QX?TW0+BUO-.^+5_IFF7<E_J%Q;6=M_9UGJ,8GGDN8UB
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M::ZMJ$,)DO[6V>YMDGGLT^S7*S7*1,YAMWAD2:Y^SQLI5CCE_&&LZ_8_L\^
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M2W=S=6@M4WI;6Z2W(8L!&T"N<A<4 ?IE$"(E#9SM'6G4V&198EE0Y5E!6G4
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MTK5)VD*VQV+;V4MRS[1;M#,8YXOGOP9^W7\9?C3XF^(GA+X+_&+X/^)H]-\
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M599I/'-Y\);/Q-'XCO'2R>.T:-[T>3(5F2U1C*21 K!>0HKSW_@I1^VGJ?\
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M>/-/\+V/P#\6:W8WC0+<>*M+NM)2QL-\A5O-6YOHKEO+4>8WE02#:<)O?*
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MW"K+:R6U_P"2(S$K-?12H%N[67?;^8&D@@NHG /2I-QC8*<';Q7RU^R?\/\
M2O#W[8OQ&\<>'/"'Q$TFW\1'49]87QQJWBES<:O'JLUM-=11W$TNB26DUG!I
M9LFM_*NH+6#RF4J[QVWU,P!4@CM7,:)\7? FJ?$>Z^#2ZE):^)K'18]5?1[V
M%D>6Q>>6!9XGYCG >+YQ&S/#YL/FK&9HPP!<^('AR'Q3H<.FRRZA&T.JV5W
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M;2O%7P[\2Z3:[$DNFTF:^2QNC<0V6MV@CEO;;RI);6Z\I+I/,W6C^=;!2H<
MZ;5_#5QK7A35/"WAGQ'>>&;J]TYH;?7-$M;9KFPD=&5;B%;F&:W:5#AU$D4J
M9"AT9>#Q>E_![XI^ /@SJWAB\_:1\6_$#76U*/4M-U[QKINEQ7,9C>!ULECT
M2'1X9(F:%L"1AN:=UE=XOW8VO'OPPAM?ACXUTCX:W%GHNL>)K.\E;5;J2XC5
MM0DM?)2YFEM98;DE52)=T<T<JQQ(L<D>Q"OE?[/OAO\ :;^'W[)GC*6^U;1?
M$/Q,MY]2ATG7-2^'(\/S>)+[3H5TRVOM2ACU.1+J2\.GQRK<K-;*]K/:CRX
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M^"_!FEW4,]KI'A/3K*WFM]3%[')'%;1HK+<+%$)U(4$2B.,./FV)G:.L4$*
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MC1I88+X),83):W$T4;0&9U,LL<=O-Z!7DW[0/QN\7_#'QUH7AKPKIEGJ8O\
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M,\1+X%\7-KEMIFK+"IO=-FN/LT CN+>?>AA91*(C;RRQP&=8E /BG]DKXH^
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M/AV[L=*URU\.:BEM/+);K;ZE90ZA-;A;IO)%Y,Z6KRBW>'4Y3)!()@U>@ZA
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M>ZAHFH7^E33PR07ELD;7=G)$TNQ;BY9(][&"1XYU$<@AD'61@B-05Q[5Y?\
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MM(/^#7G_ ((7@Y'[#[?^'.\3G_W)T ??:.)$61>C#(R,5GW/_(V6?_8.NO\
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M(NKS5[Q-7M+@NB6UP?L@;869%652OTM)_JVRN[Y?N^M<9\(?V>O@)\!HK_\
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MG1/[2\4>+OA%X'T7PYIWVF.'[5?W7@748+>+S)65(]TCJNYV55SDD $U\X?
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MUG2+[0]<TGP'KGB8V-Y+,NC^'=<AM+AI#"\:R2)<7=M!<0!9'4QR,X$KP2!
M8Q)'N>!M%LO!W@?2?#6F^$['1K73[&*VM](T=%6UL(T4*L,05(P(T "J BX
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MZIIG[+&M>'-659)7UK4-/\3C6KV5KB^OM1(N[V6::XE#7=_J$ZB:1@K7,Y0
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MS3=2AT;QEI-O#X1L+ZTMX],T_P"RZ;+>0ZA*UG=3F[\N6YNXXE,0EBGM(R\
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M:6:1WB'5++XO_"S4M.U#X?\ BK4+/4K^+2;C3=/^U:-?P127,:#48IKS[#-
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MMQY=K;9N(1#>7'D30VC9D+3@[89MCK7L5>2^//$47@GXN7U[=WFKV]OX@MM
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M+/J<EUYDIDFMS&LD*A5D$BI+&LLD26TWRK_P;T> _@#\0O\ @A[XHT?]HO\
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M\5Z;9_8[Z2;_ (2KQ)>:HTUU>WS;S:FZCN$L[/R].AEBM[.]BB5;H+/912)
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M['P%X,^%_@3P[#H7PX\&Z?X=TFR6&WATW3=%73[=(X;:*VAC$0C0;(X(X8D
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M]^ _%'Q&_8@G;Q#J7@W2[K7FN?B!XD@D-Y):1/.6C74%$;>86R@50IX &,4
M>W?\$"?V:?CA^Q]_P25^$_[.G[1_@.3PSXT\._V]_;.AS7D%PUMY^O:C=0YD
MMW>-MT,T3_*QQNP<$$#[$KS_ /9;_9<^!7[%OP)T/]FC]FGP-_PC?@GPU]J_
ML71?[2N;S[/]HNI;J;]]=223/NFGE?YG.-V!A0 /0* .=^)FF^/-3T.*#X=Z
MQ]AO_M<0:?S8E582X61CYEO,'VH6=8P$,CHJ&6)6:1;7@7P]K?A?0/[(\0^-
M]3\177VRYF.J:O#:QS,DDSR)%MM888PD2,L*?)O*1*9&DD+R-F_%CXLZ5\']
M*LO$'B#PUK5]IT]U+%J%UHMB+IM.C2UGG$KP(WVBX\QX4MHX;6.>>2XNH$6(
MAF9+7PS\?_\ "RO#<WB+_A#M<T(V^N:GIK6/B'3_ +-<.;.^GM#<HN3NMY_(
M\^"3CS8)HI,#?@ &;!H/P#\7_$#4M2@\/^%-3\3:'J4,.K7BV=M/>6%ZL%O/
M%'*X!>*8036LJJQ#B.6)P-K*3O>-;/Q-J7A#5-.\%>(8=)UBXT^:+2=5N-.^
MV1V=RR$13/!O3SE1RK&/>FX C<N=PY*\_9;^ >K?%'4?C#KGPGT*^U_4IK.:
M;4+VQ65A-;2V<T4ZJP*).)-.TYFG4"5_[,L [LME;"+NM2U"UTG3YM3OKB.&
M&",O---)M1%'5F;^%0.23P!S0!YA^QS^S9/^RK\)'^%LNH>&KI?[6ENX;CPU
MX?O;!61TC4+-]NU&_FFD4)L61IL+"D,2HJPKF/\ :>@TZ+4O!VOW'C>Q\-WF
MG^)M-_LW6)O"8U:X22?5]-M9+:%#&Q@%W!//8/<!D,"7QFY$99.]^'WCF+X@
MZ)+KL&B7-A&NH7$$$=U<6\IN(8Y66*Z1K>65#%<1!+B+YM_E3Q^8D4F^),;X
MG_'/X?\ PR\16/@W6%FOO$VI:%?ZKX?\/VD<:SZE':W%C:21Q33M';I*USJ=
MA BRS1AFN5YVK(R &3^Q9XQ\4_$/]CSX4^/_ !Q\0;'Q=K6N?#C1-0UCQ5I=
ME);6NM74UA#)+>PPR00/%%,[-(J-#"55P#%&1L67Q!XK\;+\?]%\)6WBG2;/
M3I-#N;M-%?Q)!'?ZM$K;+NZ6R>P>21+.5]*17AND0_VO+YZJT5LMQTGP>^(7
MP\^+GPE\+_%?X1:C#>>$_$_AVRU;PS>6]H\$<^GW,"36\BQNJM&&B="%958
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M/&FN:+H]K+K=MX(U"U8FX:W!(,*7EPEH99DG$<;7,JA5 ,SE789/[+W[0?\
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M36J:SH^A^*K%;RQ6^'AG3+0326LF8;@K#=SA5E1U5G5P Z(Z_IMXN_X)'?\
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MCG2)K?Q)=RZ?H_BC5(M4L9+.6_O&BOM/OE4L8KD9E-C/,TE@OE0+%!;BV\P
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M:#\4AILGAW1=+@U'Q)=>)M)8Z+';>?, 7N9T%K(T3V<C21AV>WQ$\BHLL3.
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M"LOB*^T[3;BZC;66TC6-0TV^G@C#.D=O>Z?=6\]H_GB%F=68/$DL+(1+N3K
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MOXF>--:\/:E\5FMCL>:PM]*OM/5<2PR6Z76HF3<#""\1BFMX0#[P_P"#?#Q
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M>AZ7>23PK>2:EJMS/<.1*L"W5PEU;W-RL%LJB[GN,WFH$B2+HO#NJ_!CX2>
MO$%_HVD:1X&\*^&)]0OM=NKG2AH^G6A)>^O;UFD2*)HF:66>6Y4F-G:5F<L'
M(W?#?BVP\37=S'I\D@6""WD,-U8S6TR^:A<,4F56VD$+TX=)$.'1U4 UZX?X
MV6LT_AUG\-0P77B:020>&=(U#QW>Z#:ZG>>49?)>>T260 1QNY98)F14=@A
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MAB0F3Y\_X.CO^4%7QQ_WO#/_ *D^E4 ?0'_!)W_E%E^S3_V0'P;_ .F2TKZ
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M!TWX<WWA.QTWXH>.4TO0;RU\E8+)O%>JO;/;QB&)4M)(&BEMU5-BV\D*JT@
MD;T;XH^$H?&VCV.B76@KJ$<.M66H)$^J3V:QSVEPEW!(9( 6(6:"/,9^2091
MPREE:[X#\+:9X.\/_P!CZ3X3TG18Y+ZZO)[+18E6%KBXG>XGG.V.,-)+-+)-
M(Y4%Y)'9B2Q8@'A7CF/XMZY^TM=Z5X7_ &Y->T&:V\=:#]G^'.AZ'H^NV$>C
M?9H;JX35$&D"^T@7JV>K017$M]Y0D:!XY6>1+(>O_M!65_J/P(\:6&E:GIME
M=3>%=02WO-8OX+6T@<V[A9)IKBUNX88U/+22VUQ&H!+03*#&WF?BCP<_BW]H
MJX^*OA'P79ZQK7@SQGI6E?9?$OBBXN+>VAEL8OMM_8017<]OI=Y'9ZHV&>TA
MN;B.&X@9A;W\=U'[;XF\0Z=X3\.WWBC5XKR2UT^TDN+B/3]-GO+AT12Q$<$"
M/+,Y PL<:,[' 522!0!QW[.9^'__  ANI?\ "N/CQ<?$.QF\4:I>/K-UXBM]
M4:TDN[N2]-@DT  6"W%RL,$1RT5ND*$L%#',_:-OO%/AS5/#?B;X>:#J%WXB
MN8M6TC3[BU^TSQV@DT^6^#-:A19RL]QIMK"KWMQ8QJ)GC2\CDG2&X[OP1XY\
M&?$30?\ A)O ?B&TU.Q^V7-I)<6<@81W5M.]O<V[CJDT,\4L,D; /')$Z.%9
M6 Y/XM_ KPW\9OB#X?N?B/X-TKQ%X7TWP_KEK>:/KWDW-HUU>Q6]J)#9RVSB
M5FLGU*V,HGCV0WMQ"8ITNF:$ T_V?/!%C\,_@+X)^&^F>&H]%M?#_A+3=-M=
M'A3:EC'!;1Q+ H^T7.T(JA0/M$^,8\Z7_6-5U?X4R:_\8= ^)VH>/]6A@\/6
M6JPV_A^QU>ZMK6]:[^RJ)KN&*=8KIH!#,L7FQL$%T2H5UWMM_"KP&/A9\,/#
MGPR'B_7/$/\ PCNA6FF?V_XGU W>I:GY$*Q?:KN<@>=<2;=\DF!O=F; S5F?
M6_!7]K-IDVI::U^H.^V\Q&FX7)^7[WW>>G2@#6J&2\BB<HR2':P!V(6QGITY
MJ:O#?V@? ^F^(OBUI.L_$7X_:OX7\(V-YX>G_P"$;N-+T271=;U9-83[%'/+
MJ6CS21W+WC:?' +>^CF,IB,,<4JK+( >W26=K+<QWDENC31JRQR;?F5202 ?
M0[1D=\"N%_:4\&^,/''PLO-'\ >&5U?61)$]AI\OQ&U3PG%*WF('WZGI<4US
M HC+L%6*0.RJK!02Z]]7,_%?6O'6@^#[B_\ AEHFBZIX@VXTG2?$/B"32[.\
MFR"8Y+F*VN7C&P2-E8)#\O0#+  =I&@7FG:XTD5D4MX]"LK>*[:Y>>25HVN,
MHS.Q9BH=3N(#-YC99B/EZ2O-_B/\0/CA9Z9HNM?L\_#[P#XHT;4+..635/$W
MQ(N-)CVOM\DP&VTR^6X5E.[<60?=V[LY'I% !7-^+_AMX5\;^(K/4O$G@O2K
MWR-)N[+^T[A?]+B@FFM9)+1"$R;:<VT331EPDGV:%720?<Z2B@!L,0@A6!22
M$4*"W4X%.HHH **** .1\??&SX??#>]NM.\6>(K2QGM-"GU=H]0N$M%FM80Q
ME>.:X:.%O+"CS/G B$D32%%D1CURL'7<IZUY[/+XI7X[Z[;:='+?VLOAC26C
ML-2O);>RAD%QJ&Z2$A)%DF($?F#:A14M\L^\!/0("QA4L><=<=: '4444 -D
M#&-@JACMX#' -9'AGP!X,\(:IJFO>&_"&EZ?J&N7"W.O:A8V$<,VIW"QK&LT
M[(H,KA$50S9(50!P,5LT4 -E0R1-&&QN4C/I7)_#/X/> /A)J.L#X>?##PYH
M,6MW1U/6M0T6QBM;C6=4E=S<W5VD42+)*QV.9F9WD9WR%V@OUU% !1110 44
M44 %<]!X^:3QP_@.[\):Q:7#+<2V-_/I[R6-W;PI:>9*+F$210MYEXL207#0
MSRFWN7BCDBA:2NAKRVS^(GQ<U#X\ZAX*MOA7X1C\*V-QY<OB&Z\57\6M/FU2
M3S(M/?21!+%Y[B'S4OF0#<2WF(UN "Q\*O%FK>+?C!XRTW5-0U&<^$YH])/V
M>\T]=,627_30@MX+N>[2[6TN+#S6O!&&0Q2V\<:W$H;T/48/M%L(_M\EOB:-
MC)'MR0K@[/F!&&QM/?#'!!P11\/^&?"FA:KJ^K^'O"FGZ?>ZY?+>Z]=6=G''
M+J%TMO#;K-.R &:00001!V)(CAC0':B@5?BCX1OO'WP_U3P;IGB&_P!'N-1M
M_)AU;2V@%S8L6&)XA<130NZ??$<T4D,A79(CHS*0#;M_(V;K9E96.<JV17(_
M$+X6>&O$_BK0_B5)\*/"OB+Q)X<O8E\/:CXBC1)M&@GFB2_FM+C[/-)#*;=2
MPC3:L[P11N\2L94F^$?PEL/A#IFH:5I_B?4M574+RWN&FU9;=KA6BL+6S^>>
M.));IW%J)7FN7FG9Y7'F>6L44?64 <O#\-M,MO&DWCF7Q#-)=S:Q]J02Z?8
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M_$7@2W\6:G#>:/IOA-;C2A'%+XDCEL/[2AT&.));4CP_&P-^9%N;34+>4LZ
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M;ZXN8[:"RNDN_)TRUU*\6-_+62:QAMBQ%YYEO[50 4444 >;^'_V9?A9X?\
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M^U8W9?$ME!;W5F)+&TE%LT=N%C4H)!N"HF'+@@D%VYOXQ_!'4?'/Q4A\8_\
M"OO"^K[=,AM-+US6O$#6]_X;D+RB:YTQ/[/G\FY=9(]TRRQF0P6ZE1Y09O2O
M!VB^(-&T^X_X2G7H-1OKJ^FGEGL[62W@5"V(D2*2:4IMB6,-A\/)YD@5/,VC
MSW]HO0M6\1W-AI<'A"WU:PFNEM;ZXEO#IJZ##<07$%YJ<EVS.LP6RDGCBMTM
MY6:YD@61H8G>X@ /6*^?;OXG:-;?L\:E^T)8?&C3M6USQ#\%_P"WM/\ %$<<
MUMX<N+6TL?/%_;6-UJ4$%E"\E\LK>=>PRO'+&DEZ$MTDA^@J\;\"ZGXT\4>)
M=+UVTU+QU8_VAX5NGM;/QAH=JMO#-*FF31O<1VC0[9HC*\1BE^<F&Z",B@/(
M 1? ZU^-W@GX>>(/#7B3XI_#[XB>,-%\1213?V7'J&AV=@9UM[K['=_:;_6)
MXIA'<B:-=P40W%NB11Q[6/(?\$RK']HG2/!/CK1/VC/"GBO0[RQ\3:';Z#I7
MB[Q?<:_-;6:>#?#JRHFHS11"^(O1>^=<1+Y<EX;PY9MS-Z5+#I7[+'@"_P!9
MUKQ=XC\1:3=>);5O.\4>)+1WTH7MU;6\FVYO7AS;)+)+=E))9)$#O!:(R+:6
M2=-\+/BGH/Q9TNZUSP_H&OV$,,ENI'B+PS?:5-*)K."Z1EBO88I<*EPD;@H#
M%-'- X66&1% )(_ -K9_$C6OB9?^,M:GAUCP_IVE-X?O-0W:79?9)[Z4W4$.
M/W=Q/]M\N:3)\Q+2U7 \K)Z*15:-E?[I7#9KP/\ :VTX>*/BQ\+[34TN)+;P
MK\0-)URWMM!MQJ5Y(TT.I:<\EY9;HV@L(WNK5C>1_:"C&1Y(H8X#<#WR<%H'
M4+GY3QZ\4 </\//V=/@O\,?&.H?$+PO\/] A\4:Q<7TNH^)+?P[86NH727-R
M;AXI)K:"-I%#;%R^YW$2-(TDF7;2^,4%E?\ @&XT35/%5YHMKJEW::?=7^GS
M3PW CN+F.%HHI;=EFMY)0_E+/&Z/"9!*K*R CS7X0:?X$L_V@[S5?#'[(^C>
M$M0U+_A((]3\=1Z#]ENM:^SW=CB5)([(;XKB2XG+F[FMI9);%I+:*^M2+U?5
MOB)X4G\;^%9O"T=VD,5Y/ E]YD(D66U\U#<0E3VDA$D6>WF9[4 >+:%\%?@3
MXE^$MU\./AEX/TWXJ:;I_B:*ZNK/XP^/M4U^W2XETZ"9+BVO-674G9?LUQ \
M:1?N@+B0@J[2!O;?AYH2>%_ 6B^&HO#VG:2NG:5;VRZ5H_\ QYV8CC5?)@_=
MQ_NDQM3Y$^4#Y5Z#S/4_V:[O7M A\"?$SQ?XRUVUOO$4%TVL>$O&-]X:NK+R
M])2)YKF;3KRVGGBEN8IF\I7D4/=Q?N]D(>/U3PIX<L?!_AC3_">F7-[-;:99
M16MO-J6I3WEP\<:A5,L]P[RSR$ ;I)'9W.69B230!YC\?/@OJNN:W<?%?0_B
MY?\ A_[#8VTVIZ:GAW2;NUU%+!I[FV$LEQ837*B.XD$H\N0;-K&-4D=I#Z]7
MS?\ M.2_$.W_ &I/A_K-SKEMIOA'1+>XU&"QDL[#4WUK4 -EQ*8;AH[C3UL]
M.-Z%N;.4/)+J48E5TA%M=_2% '":!\9_@[\1/BCXN_9VT'7VN_%'A'2[*X\5
M::UC*PL8-028VVZ61#"YD6&5O+#,0H!90&7.?^S_ /LR?#']G.YU4_#72M/M
M%UA8A?+8^&](T[>82^S<-.LK;S,>:^/,+;=WRXW-G3\,? [X:>!/BCXI^/?A
M7P>X\5>+M-LK7Q%?0WTS&^AL1,+6%(Y9?)AV^?+RBIO9]SD\$6/A7\1?%WCZ
M;4!XI_9^\5>!_L8B\EO$UYI$OVTONW"+^SKZZQLVKN\S9G>NW=AMH!\&_LD_
M"SP)\<O^"P7_  4W^"OQ1T7^TO#/C#P_\+]%\1:;]JDA^UV%UX2NX+B'S(F6
M2/?$[KN1E=<Y5@0"/H3XC_\ !%C_ ()._%/X9:C\(?$O_!/SX7VFB:K<V]Q?
M#PUX7BT6[:6!BT3K>:>(;F,KN=?DD&4DD0Y21U;Y[_9)^%?@/XZ?\%@?^"F_
MP3^*>A_VIX9\8>'_ (7Z)XBTW[5+!]KL;KPE=P3P^9"RR1[XW9=R,K#.00<&
MOA3]N#_@FU_P0C_X)Q?\%;]%\+?MD_L^:GX._9O\1?LYFZT6X?4/%]]9WGC=
M=?*.J75G+-<&5-. +P[_ "D5XV90TD98 _?7X??#OP#\)O!>G?#CX6^"=)\-
M^'M'MQ;Z3H>A:?':6=E$"2(XH8E5(UR3\J@#FMBOA'_@V:\)>*O!7_!#OX$Z
M+XQ\-:AI-Y+8:Y?16NI6;P2/:W6OZC<VTX5P"8YK>:*:-Q\KQRHZDJP)^[J
M./\ C9\0/%OPW\$W/B/P7X-CUV_CMYOL^GS->A7F\IA;AOL-G=S^6UP8(Y'C
M@D,44DDVU_*V/M^#]=UCQ%I4U]K?A*_T6:/4KNWCM-2,!DDBBG>*.X'D2RKY
M<R(LT8+"01RJ)$BD#QIY[^V+I$%_\*H+^'X=+XDU*WUB"UT6VAN[ZQNK.XU
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M3XF\'3:.NGZ#=:-#IYU"Z^T07+>(WOYX;Y=,6*2S>,Z,QN\)J&]7;[(C?2%
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M5GK%SX'M-?OX+=SJDZ1QQQ+->VZQ_P!G7;JSQ1PS2RK#;//<,\*^\4 %%%%
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M56>19=B6?!_AJ3PN^J6D45I#8S:EYVF6MG:I$MO$8(@RD*!DF597R<GYP,X
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M.E^,[>_NK_2]<>UE6"."</";?R)H=0BG#?9I(+@(L<5P]U#+%=6ELXR/V/\
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M*O"WBEK75KK3M<TW3+!5BM(9@MQ;V-W!)/.?.%C<VIDWE1-YHF6*))EC&?\
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MT;2GM])M]/\ ".EPVGD:1HK1B.*TF6&&>W:"VM"L<K);20RJEN3 4E\LUL?
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MTUI/CR?7M8\*P>(+1_"_A^"ZMQ:2W-S;J&>2XC(??:RY7:0!M.><#E/V'_\
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MMK:10WL_DR[;EV :6:(+$L<=V6D,?HE<CXM^$?A'QNVEW/B^QT_4)-,C5?\
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M)"HA9YS#$_LU<7XUU;X(_P#"9:7_ ,+*T[38=3\/W]K<^'M8\0:68HK:^O\
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M'0O"7A^^\5>*-:M=-TS3+.6[U'4;ZX6*"U@C0O)+([$*B*H+%B0  2>*\/\
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MWPI\%V;:V]C&^I-#IM[=*\,=W/=3SK96$4LMW<*;R^N5MX466[F<1>8AD61
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M0TNXLIHV6:PD0AXA-%))"T<JO$1(L7E,Y3S$CDD\IXG;>,_X3:!XP\+>%O\
MA'_&FG^'$N[>16DU#PO;RVUOJD\D,<MW>&TDWM9M)>/=$0^?='9L=IW>1U0
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M9T\?>&OBCXCDT?PSJ/@K5;7Q%K$) :QL)+.5;B<95AE(B[#*L/EZ'I4OP?\
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MC3=2(MK/5[C69EA(M]#C-Y%#:I%)+<6\J0PM=S-7E?\ P=&?\H*_CE_W+/\
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MO$5A-::KHUK-9O<?:;FRN8KR. 1+J6FB1I'@6,+)>0PL7 F+1&1&;^SS\/\
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M?_8.NO\ T9!0!HT444 %1O\ \?$?^ZW]*DJ-_P#CXC_W6_I0!)1110 4444
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M2_$WC#^Q_P"S;[Q3=3PV,?V76+*]D\QX(9I!F.V=5VQMEBH. 2P /J"BBB@
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M7($A &-RBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MIOE1;_,\I=V<[MO/3'\J=10 4444 %%%% !1110 4444 %%%% !1110 4CAF
M1E4X..,BEHH ^;?^"77_  2\^!'_  28^ FL?L[?L\^,O%VN:)K?BZ;Q'=77
MC2^M;BZ2ZEM+6U=%:VMX$$6RTC(!0L&9\L00!])444 %9US_ ,C99_\ 8.NO
M_1D%:-9US_R-EG_V#KK_ -&04 :-%%% !4;_ /'Q'_NM_2I*YKXL?%SX5_ K
MP5=_%/XU_$C0?"/AG2_+&I>(O$VKPV%C:>;-'#'YL\[+''NEDCC7<PRSJ!R0
M* .EHKY\_P"'L_\ P2U_Z21_ /\ \/)H7_R71_P]G_X):_\ 22/X!_\ AY-"
M_P#DN@#Z#HKY\_X>S_\ !+7_ *21_ /_ ,/)H7_R71_P]G_X):_])(_@'_X>
M30O_ )+H ^@Z*^?/^'L__!+7_I)'\ __  \FA?\ R71_P]G_ ."6O_22/X!_
M^'DT+_Y+H ^@Z*^?/^'L_P#P2U_Z21_ /_P\FA?_ "71_P /9_\ @EK_ -)(
M_@'_ .'DT+_Y+H ^@Z*^?/\ A[/_ ,$M?^DD?P#_ /#R:%_\ET?\/9_^"6O_
M $DC^ ?_ (>30O\ Y+H ^@Z*^?/^'L__  2U_P"DD?P#_P##R:%_\ET?\/9_
M^"6O_22/X!_^'DT+_P"2Z /H.BOGS_A[/_P2U_Z21_ /_P /)H7_ ,ET?\/9
M_P#@EK_TDC^ ?_AY-"_^2Z /H.BOGS_A[/\ \$M?^DD?P#_\/)H7_P ET?\
M#V?_ ():_P#22/X!_P#AY-"_^2Z /H.BOGS_ (>S_P#!+7_I)'\ _P#P\FA?
M_)='_#V?_@EK_P!)(_@'_P"'DT+_ .2Z /H.BOGS_A[/_P $M?\ I)'\ _\
MP\FA?_)='_#V?_@EK_TDC^ ?_AY-"_\ DN@#Z#HKY\_X>S_\$M?^DD?P#_\
M#R:%_P#)='_#V?\ X):_])(_@'_X>30O_DN@#Z#HKY\_X>S_ /!+7_I)'\ _
M_#R:%_\ )='_  ]G_P""6O\ TDC^ ?\ X>30O_DN@#Z#HKY\_P"'L_\ P2U_
MZ21_ /\ \/)H7_R71_P]G_X):_\ 22/X!_\ AY-"_P#DN@#Z#HKY\_X>S_\
M!+7_ *21_ /_ ,/)H7_R71_P]G_X):_])(_@'_X>30O_ )+H ^@Z*^?/^'L_
M_!+7_I)'\ __  \FA?\ R71_P]G_ ."6O_22/X!_^'DT+_Y+H ^@Z*^?/^'L
M_P#P2U_Z21_ /_P\FA?_ "71_P /9_\ @EK_ -)(_@'_ .'DT+_Y+H ^@Z*^
M?/\ A[/_ ,$M?^DD?P#_ /#R:%_\ET?\/9_^"6O_ $DC^ ?_ (>30O\ Y+H
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M2U_Z21_ /_P\FA?_ "71_P /9_\ @EK_ -)(_@'_ .'DT+_Y+H ^@Z*^?/\
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M@'_X>30O_DN@#Z#HKY\_X>S_ /!+7_I)'\ __#R:%_\ )='_  ]G_P""6O\
MTDC^ ?\ X>30O_DN@#Z#HKY\_P"'L_\ P2U_Z21_ /\ \/)H7_R71_P]G_X)
M:_\ 22/X!_\ AY-"_P#DN@#Z#HKY\_X>S_\ !+7_ *21_ /_ ,/)H7_R71_P
M]G_X):_])(_@'_X>30O_ )+H ^@Z*^?/^'L__!+7_I)'\ __  \FA?\ R71_
MP]G_ ."6O_22/X!_^'DT+_Y+H ^@Z*^?/^'L_P#P2U_Z21_ /_P\FA?_ "71
M_P /9_\ @EK_ -)(_@'_ .'DT+_Y+H ^@Z*^?/\ A[/_ ,$M?^DD?P#_ /#R
M:%_\ET?\/9_^"6O_ $DC^ ?_ (>30O\ Y+H ^@Z*^?/^'L__  2U_P"DD?P#
M_P##R:%_\ET?\/9_^"6O_22/X!_^'DT+_P"2Z /H.BOGS_A[/_P2U_Z21_ /
M_P /)H7_ ,ET?\/9_P#@EK_TDC^ ?_AY-"_^2Z /H.BOGS_A[/\ \$M?^DD?
MP#_\/)H7_P ET?\ #V?_ ():_P#22/X!_P#AY-"_^2Z /H.BOGS_ (>S_P#!
M+7_I)'\ _P#P\FA?_)='_#V?_@EK_P!)(_@'_P"'DT+_ .2Z /H.BOGS_A[/
M_P $M?\ I)'\ _\ P\FA?_)='_#V?_@EK_TDC^ ?_AY-"_\ DN@#Z#HKY\_X
M>S_\$M?^DD?P#_\ #R:%_P#)='_#V?\ X):_])(_@'_X>30O_DN@#Z#HKY\_
MX>S_ /!+7_I)'\ __#R:%_\ )='_  ]G_P""6O\ TDC^ ?\ X>30O_DN@#Z#
MHKY\_P"'L_\ P2U_Z21_ /\ \/)H7_R71_P]G_X):_\ 22/X!_\ AY-"_P#D
MN@#Z#HKY\_X>S_\ !+7_ *21_ /_ ,/)H7_R71_P]G_X):_])(_@'_X>30O_
M )+H ^@Z*^?/^'L__!+7_I)'\ __  \FA?\ R71_P]G_ ."6O_22/X!_^'DT
M+_Y+H ^@Z*^?/^'L_P#P2U_Z21_ /_P\FA?_ "71_P /9_\ @EK_ -)(_@'_
M .'DT+_Y+H ^@Z*^?/\ A[/_ ,$M?^DD?P#_ /#R:%_\ET?\/9_^"6O_ $DC
M^ ?_ (>30O\ Y+H ^@Z*^?/^'L__  2U_P"DD?P#_P##R:%_\ET?\/9_^"6O
M_22/X!_^'DT+_P"2Z /H.BOGS_A[/_P2U_Z21_ /_P /)H7_ ,ET?\/9_P#@
MEK_TDC^ ?_AY-"_^2Z /H.BOGS_A[/\ \$M?^DD?P#_\/)H7_P ET?\ #V?_
M ():_P#22/X!_P#AY-"_^2Z /H.BOGS_ (>S_P#!+7_I)'\ _P#P\FA?_)='
M_#V?_@EK_P!)(_@'_P"'DT+_ .2Z /H.BOGS_A[/_P $M?\ I)'\ _\ P\FA
M?_)='_#V?_@EK_TDC^ ?_AY-"_\ DN@#Z#K.N?\ D;+/_L'77_HR"O#?^'L_
M_!+7_I)'\ __  \FA?\ R778?!']K7]EG]J/Q=<+^S3^TCX!^(7]A::W]M?\
M(/XRL=6_L_SI$\GSOLDLGE;_ "9=N[&[RWQG:: /4Z*** "OS_\ ^#HK_E!M
M\;/KX9_]2C2*_0"OS_\ ^#HK_E!M\;/KX9_]2C2* /P"_P""&W_!#23_ (+/
MGXH;?VG_ /A6X^&_]BY_XHK^V#J']H?;O^GVV\KR_L7^WN\S^';\WW[_ ,0-
M,O\ TD];_P ,J/\ Y=T__@QFQG]J#'_4E?\ N>K]_: /Y_\ _B!IE_Z2>M_X
M94?_ "[H_P"(&F7_ *2>M_X94?\ R[K^@"B@#^?_ /X@:9?^DGK?^&5'_P N
MZ/\ B!IE_P"DGK?^&5'_ ,NZ_H HH _G_P#^(&F7_I)ZW_AE1_\ +NC_ (@:
M9?\ I)ZW_AE1_P#+NOZ ** /Y_\ _B!IE_Z2>M_X94?_ "[H_P"(&F7_ *2>
MM_X94?\ R[K^@"N7^.'Q>\'_ +/OP5\8?'OXAS7$?A_P/X7U#7]<DM;<RRI9
MV=M)<3%$&"[".-L*.IXH _"?_B!IE_Z2>M_X94?_ "[H_P"(&F7_ *2>M_X9
M4?\ R[K]H/A?^V'HOC[X[7'[.7BOX+>.?!'B9= _M;2E\5V=E]EUF&&WTV34
M?LDUG=7"R?89M6L+2=VV1O<2R+;/<K!.\7L% '\__P#Q TR_])/6_P##*C_Y
M=T?\0-,O_23UO_#*C_Y=U^^&BZV^JW^JV+6XC_LW4%M@P;/F P0R[O;_ %N,
M<],]ZT* /Y__ /B!IE_Z2>M_X94?_+NC_B!IE_Z2>M_X94?_ "[K]_HS(=WF
M;?O?+M]*=0!_/_\ \0-,O_23UO\ PRH_^7='_$#3+_TD];_PRH_^7=?O^I)Z
M^M+0!_/_ /\ $#3+_P!)/6_\,J/_ )=T?\0-,O\ TD];_P ,J/\ Y=U^\WPV
M\7-\0/AYH?CMK'[+_;6D6]]]E$F_R?-C5]F[ W8W8S@9QT%;+DJA8=A0!^ '
M_$#3+_TD];_PRH_^7='_ ! TR_\ 23UO_#*C_P"7=?T 5Y_^UA\<&_9D_9:^
M)7[2*^'O[7/P^\ ZQXD_LDW'D_;?L-E+=>1YF&V;_*V[L'&<X.,4 ?A__P 0
M-,O_ $D];_PRH_\ EW1_Q TR_P#23UO_  RH_P#EW7] %-F<QQEP* /P!_X@
M:9?^DGK?^&5'_P NZ/\ B!IE_P"DGK?^&5'_ ,NZ_;3P]^T?I5MH\VM_%S28
MO"EC_P )5-H5GK5QJ"2:=<7!U6[T^VB,QV-%+*T%N,2QI&9KZ&"*2=S77?$+
MQM_P@_AZWUV&P6\\_7-+T_R_.V ?;+^WM=^<'[HGWXQ\VW&1G( /P=_X@:9?
M^DGK?^&5'_R[H_X@:9?^DGK?^&5'_P NZ_=;_A;_ ((TV_N=)\4^*-)L9[35
MH].N)/[0#0074TEHEK:RRD*L-U/]OLO+MW(DD-POEB088]06.Y0O0]: /P!_
MX@:9?^DGK?\ AE1_\NZ/^(&F7_I)ZW_AE1_\NZ_<CP;\>/!/B+Q%!X%U37=*
MM=>NDU%K&UM]:M[B/4ETY[:'4I;8H^]H[6ZNEM9?-2*1)48-&%*LW3>+]>E\
M,>%]0\116JSM8V,UPL+2;1)L0MMW8.,XQG!Q0!^"/_$#3+_TD];_ ,,J/_EW
M1_Q TR_])/6_\,J/_EW7[O-\3_"UAXFL_!OB:X;1]2U2Z-MH]OJNV%=3GV7<
MHAM7+;+F8V]E<W!AC+2QPQ&21(Q4GC;QCJ?A2VN)M'\&ZAX@NH=$OKZUT;29
M;=+O4)(!&4M83<RPP"24OL4S2Q1AB-[HN6 !^#O_ ! TR_\ 23UO_#*C_P"7
M='_$#3+_ -)/6_\ #*C_ .7=?M!^R'^US/\ M<Z%KGB>V_9M^('@'3]%UZ_T
M6.Y\<S:(PU"^L-0N].OXH%TS4KQA]GNK*6-FE$:ON1H3*A++U/[1/QQT[]G7
MX57'Q1U'P-KOB9H]6TO2['P_X9^R?;M0O-1U&VT^UAB-Y<6]NI:XNH@6EFC1
M5R2W% 'X;?\ $#3+_P!)/6_\,J/_ )=T?\0-,O\ TD];_P ,J/\ Y=U^V'P$
M_:.\2_&7Q7X@\$>-?V8/'_PRU30-/T^^^R^.;S09_M]O=R7<:/"VCZI?J-K6
M<H82F,_,FT,"2NA\=/C?XE^$(TJS\%_L[^-/B5JFJ-,RZ-X)N]%@GMX(@F^X
MD;5]1L8=@:2),)(TA,@(3:&90#\/_P#B!IE_Z2>M_P"&5'_R[H_X@:9?^DGK
M?^&5'_R[K]WOA5XWU_XB^!++Q?XH^%6O^";^Z:9;CPOXHN=.FOK(I*Z#S7TV
M[N[4[U42+Y<[X5U#;7#(O'_&W]H;XF?";Q5#X?\ "'[%?Q.^(EE+8QSR>(/!
M^J^%K>SAE:1U^S,-7UJRG,H"JQ*Q-'B5 '+;U4 _%'_B!IE_Z2>M_P"&5'_R
M[H_X@:9?^DGK?^&5'_R[K]T/V?/C5X6_:2^ ?@?]HKP/I^H6FB^/O!^F^(]'
MM=6B2.ZAM;ZUCN8DF6-W190DJA@KNH8$!F&">PH _G__ .(&F7_I)ZW_ (94
M?_+NC_B!IE_Z2>M_X94?_+NOZ ** /Y__P#B!IE_Z2>M_P"&5'_R[H_X@:9?
M^DGK?^&5'_R[K^@"N<^*_P 4O#/P9\#7?Q#\8:;XBN]/LGC6:#PKX1U'7;YB
M\BHOEV6FP3W,HW,,E(VVKEFPJLP /PB_X@:9?^DGK?\ AE1_\NZ/^(&F7_I)
MZW_AE1_\NZ_<SX(?'CP5^T%X>N_%?@/1_%UC9V=\;.6'QI\/]8\-W9E"*Y*V
MNKVMM.\>UUQ*L9C9MZABR.%[2@#^?_\ X@:9?^DGK?\ AE1_\NZ/^(&F7_I)
MZW_AE1_\NZ_H HH _G__ .(&F7_I)ZW_ (94?_+NC_B!IE_Z2>M_X94?_+NO
MZ ** /Y0?^"TW_!N#)_P2 _9<T']I5OVQ6^(2ZYX]M?#/]C?\*]_LGR#-97M
MUY_F_P!HW.[ LRNS8,^9G<,8/7?\$H/^#6V7_@I[^Q3X?_;#_P"&X_\ A"1K
MVHZA:KX>7X9_VGY'V6ZDM]QG.IV^[=Y>['EC&<9/6OT4_P"#U+_E%CX#S_T7
M[2O_ $R:Y7KG_!I]_P H3OAW_P!C%XB_].MQ0!\/_P#$#3+_ -)/6_\ #*C_
M .7='_$#3+_TD];_ ,,J/_EW7] %>9_'OQEXI\-:UH]CX8\07UB9K6XFOYH;
M[2H;6TLDEMX[F_N?MN92MM%,95,*LF\*LWRNH8 _$O\ X@:9?^DGK?\ AE1_
M\NZ/^(&F7_I)ZW_AE1_\NZ_=[X72^.)? UJ_Q$A9-4WS[UD\OSA#YTGD^=Y1
M,7G^3Y?F&(^49-_EX3;5+PYJ^KWOB6Z$E]KCZ7#8V[6[7VE&!I)F-QYJG="A
MPJK"01CE^2<X !^%W_$#3+_TD];_ ,,J/_EW1_Q TR_])/6_\,J/_EW7[?\
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MB3RM_E;-^Q]N[.UL8/\ 1_7@'_!6'_E%G^TM_P!D \9?^F.\H _E4_X(G?\
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MH_\ EW1_Q TR_P#23UO_  RH_P#EW7] %% '\_\ _P 0-,O_ $D];_PRH_\
MEW1_Q TR_P#23UO_  RH_P#EW7] %% '\_\ _P 0-,O_ $D];_PRH_\ EW1_
MQ TR_P#23UO_  RH_P#EW7] %% '\_\ _P 0-,O_ $D];_PRH_\ EW1_Q TR
M_P#23UO_  RH_P#EW7] %% '\_\ _P 0-,O_ $D];_PRH_\ EW1_Q TR_P#2
M3UO_  RH_P#EW7] %% '\DO_  6W_P"#?9_^".'PF\$_%%OVM&^(G_"8>(I]
M*^P_\('_ &1]D\N S>9O^WW/F9^[MVKCKD]*];_X)=?\&I[_ /!2?]A;P/\
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M\0-,O_23UO\ PRH_^7=?HI_Q$M?\$4?^CT?_ #'/B/\ ^5U'_$2U_P $4?\
MH]'_ ,QSXC_^5U'-'N'++L?G7_Q TR_])/6_\,J/_EW1_P 0-,O_ $D];_PR
MH_\ EW7Z*?\ $2U_P11_Z/1_\QSXC_\ E=7H_P"RO_P6D_X)J_MK_%RU^!/[
M,G[1S>)O%5[:SW%MI8\&ZS9[XH4WR-YMW9Q1#:O."V3V!HYD'++L?E)_Q TR
M_P#23UO_  RH_P#EW1_Q TR_])/6_P##*C_Y=U_0!13)/YO_ -J__@S<F_9A
M_9;^)/[2H_X**-KG_"O? 6L>)FT7_A40M?MXL+*6Z,'G?VQ)Y6\1;=^QMN<[
M3C%=E_P8W?\ (V_M*_\ 8-\)_P#HS5Z_9#_@J]_RBV_:4_[(#XR_],EY7XW_
M /!C=C_A+?VE<?\ 0-\)_P#HS5Z /Z#J*** "OS_ /\ @Z*_Y0;?&SZ^&?\
MU*-(K] *_/\ _P"#HK_E!M\;/KX9_P#4HTB@#X"_X,9NO[4&/^I*_P#<]7[^
MU^ 7_!C-U_:@Q_U)7_N>K]_: #-%> _\%7 S?\$M_P!I0(,M_P *!\8X _[
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M(XT4@8^411  C$:#"CSRV?QC+^U?<7%P]U'HC:NEE;F#7)&AED&E)<>4\/\
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MNX7:2;Y5?8ZFBBBO>/@0HHHH **** "BBB@ HHHH _/_ /X.D/\ E!7\</\
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M+BXC65;:&W A25V6VC\NWC)BA"1F0R2E3)+*[Z-%% &#X/\ ^0]XH_[#R?\
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M/[&OM/:.UPUGJ)_>1_,3@+Y<7EQXP8XO)@\N/8GD0;?)1?CA\&_#OQT\&?\
M"!^*5E6SFFD\RXMYU66W5[>:%F17C>-V*2L@#J0N_P Q2)(T(U?AUX/C\!>$
MX/"T-S<3+;R2E9KJZ\YY TC-N.$18P<Y$4:+%$"(XU6-%  .5L_#WCFQ^*VM
M^)+;Q??7&FW&M1HFDW%G.D46;&R 1'9&#1JT4CB2/$0>[N$;,BY2W^T1XC^(
M'A3X5ZAXC\":18W<EK9W3ZE#>ZDMGY</V2;;(+AYH5A"3>2\DAD4K"LI7+A
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M%[C1;_S)8KS2[F=)&ADCD:,E70X>-MN]&(5F1E+*C$HODOP,\4?MPZ#XVL_
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MILK#Q5?W^@0Z>NGV4TRQ2W7GHRA/*5C)ELK\G((R*^3/VYF_XP%_8U 1MO\
MP@GBT[MO'_(RW->'?LL? B^_:A_:8^'_ .SKI^N-I)\;>,M.T275H[+[2;%+
MFX2$W'E;T\SR]^_9O7=MQN7.0^:7<2Y&<(WWV..K9[TW/M_.G,8]QVKQGC--
MROI4EAGV_G7Z(?\ !KM_RES\)_\ 8JZ[_P"D9K\[\KZ5^B'_  :[8_X>Y^$\
M#_F5==_](S51^)$U/A9_3]11174<IX#_ ,%7O^46W[2G_9 ?&7_IDO*_&_\
MX,;O^1M_:5_[!OA/_P!&:O7[(?\ !5[_ )1;?M*?]D!\9?\ IDO*_&__ (,;
ML?\ "6_M*X'_ ##?"?\ Z,U>@#^@ZBBB@ K\_P#_ (.BO^4&WQL^OAG_ -2C
M2*_0"OS_ /\ @Z*_Y0;?&SZ^&?\ U*-(H ^ O^#&8\_M0?\ <E?^YZOW]K\
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MNC+!-X/N+:;2'0646#8R6L$$$EJ1_JFAAAB:/88XXU*H/!OV1[__ (*_ZO\
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M[K_R:7\$_P#LHM]_Z0&OKC_@UP_Y05_ _P#WO$W_ *DVJT ?H!1110 4444
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MOI-6T&SO'OET&XTL71D@1S+]BNF:>SW%BWV>9FDB!V.2RF@#I**** "BBB@
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M]FKX\>%/VI/V>O _[2?@33-0LM%\>^%;#7])L]7CC2ZAM[N!)XTF6-W02!7
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M"(_]&\O9C,V=^0 ?GX*Q'^K(_P!Y<4XNQ'L_,_=SQ!_P7Z_X-Z_%FDZ+X?\
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M_2,T1^)$R?-3NC^GZBBBNHYSP'_@J]_RBV_:4_[(#XR_],EY7XW_ /!C>?\
MBK?VE/\ L&^$_P#T9J]?LA_P5>_Y1;?M*?\ 9 ?&7_IDO*_&_P#X,;O^1M_:
M5_[!WA/_ -&:O0!_0=1110 5^?\ _P '17_*#;XV?7PS_P"I1I%?H!7Y_P#_
M  =%?\H-OC9]?#/_ *E&D4 ? 7_!C-G/[4&?^I*_]SU?O[7X!?\ !C-G/[4&
M?^I*_P#<]7[^T >0?\%"/BCX[^!W[ WQP^-7PMUS^R_$W@_X0>)=;\.ZE]EB
MF^R7]II5S/;S>7*K1R;98T;:ZLK8PP()%?DIXM_X//M,^(VF>'?A_P#L:_\
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MVJ_V>_!OBRS\7^%3=_V3<:EXNGNH5^TV<UG*&B<8;,-Q(!Z$@]J /NJO /\
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MM[87VJ1ZC<Q:E=6UTL$"WD$U_'=2QW2PQ+<)(LRQH) H\Z_X*+?\$@?V+O\
M@J9>>$K[]K?P[K^H/X)2^701HWB"6Q$8N_L_G;MGW\_9HL9Z8/J: /XILFO[
M1/\ @@[_ ,H>/V>?^R;V?\WKY]_XA&?^",__ $3GQU_X7US_ (5^@'[-7[//
MPW_9.^ WA;]G#X/VEW!X8\':2FG:)#?71GF2!"=H:0\N>>IH _'_ /X/=,_\
M,F?!/'_11+[_ -(#7UQ_P:X?\H*_@?\ [WB;_P!2;5:^1_\ @]TS_P ,F?!/
M'_11+[_T@-?7'_!KA_R@K^!_^]XF_P#4FU6@#] **** "BBB@ HHHH ****
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MA_\ ".RZ/_9UD+=/(M_L$T<<EEY<>U/LSQH\6W8R*5*CYV_X*(_\$9_V'_\
M@J+XI\->,/VL_#/B#4+WPG87%GH[:-XBEL52*9U=PP3[QRB\GI0!_%CDU_;9
M_P $>O\ E%%^S=_V0_PQ_P"FRWKY5_XA&?\ @C/_ -$Y\=?^%]<_X5^A?P%^
M"O@?]F_X)^$_V?\ X90747AWP5X>M-$T**\N#-+'9VT2Q1*[GEV"*H+'DXR>
M: /BS_@Z0_Y05_'#_>\,_P#J3:57P#_P8S$[_P!J'/IX)_\ <]7W]_P=(?\
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M?A7Q9HOQ5TNQM;J^OYX;Z1KJQ6U<M%'%]@,<]O-O>W,]J/.E\T[>8Z3]&O\
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M_J4:10!\!?\ !C-G/[4&?^I*_P#<]7[^U^ 7_!C-G/[4&?\ J2O_ '/5^_M
M'@/_  5?_P"46G[2O_9 ?&7_ *9+ROQY_P"#67]CKXD>/?\ @F]\0OVI/V//
MC'<?#_XX:9\8[C3]/O\ 5+JXNO#?B:QL],TRXAT;6].W%)+5WO+Q1=VZI>VQ
MNF>*4@-#)^XO[5_P-_X:?_9:^)7[-)\4?V'_ ,+$\ :SX9_MK[#]I_L_[?8S
M6OVCR=Z>;L\W?LWINVXW+G(^/O\ @B)_P2^_:D_X(^:7XT_96USQ[X'^(7PA
MU_Q$?$GA[QEI\=UIGB*UU22SMK>XAN]/<36YM&6UC$<D5T94="61UG_T4 ],
M^$'_  57\#:+\1V_9G_X* ^"V^ ?Q1COYK32X_%VH[?#'C-4E@1+GP]K<\<$
M&IAUN[-C:E8KR)YVC>W!AD8?67F1XW;UXZ\]*\__ &F?V4?V<?VROA?=?!C]
MJ'X-:#XV\-W6]O[-UW3UE^SRM#)#]HMY/]9:W"QRR!+B%DFCW$HZGFOSY^*/
M_!M#JGAKP]_PB/\ P3T_X*V_M'? 3P^VL7%U'X)L_&5YJ7A_3K>61I1;6=K!
M=64D061B?,FGG=NKEG)<@'R[_P '<7[57PD_9^_:;_9_^*G[,_Q4O=!_::^'
M]U=77]K>$S:B6PT&904@U&3:99/,D9Q!:OO@:"YU$2QE;E1)^]5?EU_P3#_X
M-5_V,/\ @GY\6="_:.^)?Q+USXO?$#PS-)/H-QK6EV]CHNG70=3!?0Z>#,_V
MJ$*?+DEN)$1V$J1I+'%)'^HM !1110 4444 8/@__D/>*/\ L/)_Z06E;U8/
M@_\ Y#WBC_L/)_Z06E;U "+W^M+2+W^M+0 B]/Q/\Z6D7I^)_G2T <7^SA_R
M;WX%_P"Q0TW_ -)HZ[*3_5M_NUQO[.'_ ";WX%_[%#3?_2:.NRD_U;?[M #J
M\!_X*N_\HN/VDO\ L@GC#_TRW=>_5X#_ ,%7?^47'[27_9!/&'_IENZ /?JC
MN?\ 4G\/YU)4=S_J3^'\Z )"<=:X?]H3_D0K'_L=_#/_ *?;&O!_VG/VS/%>
MG:U\0O@CX._9R\4>+O&?A;Q!I,GP]T?POJ.O0V7B6XCMM/U18-0UO2M/EL_#
MSF9VA-KJ,RQS0K%)<[+.^5C[M\?B6^'FFDG/_%:^&.1W_P")Y84 =T65?O''
M:FM]Y:^9? 7[>_@GXX_%35O@KX,\'ZU=>)/#/Q2GT!7T^WUN[T>%+.54O)+[
M6]-T^XTJTNQ!]HFCTV:Z+$M9PW!L[B62&V^FN<KD?YQ0 >?#\H\Y?F^[\PY^
ME#?ZQ?QK\I?V=_AY\/\ Q%_P52LOBA\,_@=XFU;38_'6MOJ'C2U^'.G:?%#J
MO]HZS!=6\&LP>!K2XO(H%@ADNKF77T6Y:YN+59]782PWGZM-_K%_&@!JW5L[
M;$N(V;.-H85DZA_R4#2O^P3??^C+6ORV_P""7W[,'[-WACXA_LX_'OX$_!GX
MH?VGJ=E.^KQZU\,](T>R\+0-X;E>:XE\06GA73[CQ1#Y]U:6<<LM]+%?R7/V
M]#</9L\?ZDZA_P E TK_ +!-]_Z,M: -JBBB@ HHHH **** "BBB@ HHHH *
M\W_:SL+?5_@=JFC3_#GX@>+?M5Q:I'X?^%WC8^'=<NF$Z-_H^H?VEIOD;0I=
M_P#2XM\:.GS[_+?TBO,/VPM8LO#?P*O?$VIV6I75KINK:9<75GH^O:OIUY<Q
MK?0;H[=]&AFO9YB#^[LX8V^VOMM'Q'<.P /%/^"87P5^-?PHUSQ5>?$[1/CU
MI5C/X)\+:8MK\</B+;^(CJ.LVCZL=1U:S:+Q'K/V/[2MQ9"6VS!&GV>+89LM
MY?UU7S=^QK\1;_XI?M&_%[Q=IVO:YI/AV;3O#:Z7\,_%UKJMCJVDW"I?BXU=
MK#4K>'[':WH\F"(6GFVLLFD7,GF"Z:\CC^D: "BBB@ HHHH _(/_ (/4O^46
M/@/_ ++]I7_IDURO7/\ @T^_Y0G?#O\ [&+Q%_Z=;BO(_P#@]2_Y18^ _P#L
MOVE?^F37*]<_X-/O^4)WP[_[&+Q%_P"G6XH _2"BBOD#]MKQ;\)+;]I5?#O[
M0OQU\<67@^R^'4&IR:5\/_%'C#P^?"%S]NN8_P"UM7O_  V%BCTZ]B\Q3/JD
M\$-D- N)8EF22]DM #Z_HKDO@5HOQ,\._"30]%^,-WILGB*"U87T>DWUU>06
MJEV,5L+J[/GWS0Q&.%KR58WNGC:<PP&7R8^MH **\[_:7_:)M/V:O $7C=_@
M]X^\>75YJMMINF^&?AOX7DU34;NXG?:N1E(+6%0&9[FZF@@C"X:0,R*U?]ES
M]H[2/VGO!FI>/_#UQX8^PV^K+90VGA_QO9ZY<V$@M;>2>TU)K+?;6M_#/)+#
M);P3W486..19V\W:@!Z91110 4444 %%%% !1110 5Y#_P %!=4ET/\ 8)^-
MVM076DV[V?PA\2SI/KVDIJ%C&4TNY8-<6LD4R7,(QEX6BD61=RE'!*GUZO.?
MVPO&>J?#G]DCXI?$+0_&M]X;O=!^'.N:C9^(M+\/QZM<Z5+!832)=Q6,K(EY
M)$RB1;=V5964(6 8D 'SO\&=;_:/TS]J7X<R:?\ MC_L]^.O#>I3:II7C#PG
M\+_@S=Z=>BU;3IKJ#46O(M9U/[.8;JRMX!YXM[5UOY49WN6LDK[.K\_?"&@?
MM8?$S]KGX;^!?!_[9?[2]Y8> _$EKJWQEC\4V_P^MM,T9Y_#][<1^&[LZ5ID
M,E]?$W6G/+';F[MHX+@3++%-]CN$_0*@ HHHH *\ _X*P_\ *+/]I;_L@'C+
M_P!,=Y7O]> ?\%8?^46?[2W_ &0#QE_Z8[R@#\)/^#)HG_AO3XL9_P"B1G_T
MZ6=?LE_P5NMM N]&\-CQKXV_X1S1K?PSXLN?M[?&;4?"XU&_CTII+72Q;6NO
MZ)'?^<R-,\LUR5@ALIHL0)?27MK^-O\ P9-9_P"&]/BQG_HD9_\ 3I9U^U7_
M  4[_9_\<?&O_A$9= _9HO/B/H7]GZYHGC*R\+ZY]AUU]-U"VCCDL8R^NZ)"
MVGSF)6NA+=3@R6MD%LI6Q=60!ZM^P[H>@^%_V6?#'A;PS\3K'QE:Z7]NLO\
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MK+3;:UM8C!"]MYZWQF:XNHUE>:V /H:^\!6>I?%#1?B@NI,LFB^']2TJ.T5
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M[&UM['Q!+XL\(:OH\TU\EM"\KQKJNF:;+=19D&+J.S@AE;>5BA(>&./]J_\
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MV0#QE_Z8[RO?Z\ _X*P_\HL_VEO^R >,O_3'>4 ?A'_P9,_\GZ?%C_LD9_\
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MD$E]\(=8U*XTJ^A+DHXBU&VCEMG52J,GF3ABAD#KO\M/6*** "BBB@ HHHH
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M (2^M?\ RXK]_O\ ATW_ ,$LO^D:OP!_\,[HG_R+1_PZ;_X)9?\ 2-7X _\
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MU#_@J;_T0GX!_P#A+ZU_\N*/^(U#_@J;_P!$)^ ?_A+ZU_\ +BOW^_X=-_\
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MU#_@J;_T0GX!_P#A+ZU_\N*_?[_ATW_P2R_Z1J_ '_PSNB?_ "+1_P .F_\
M@EE_TC5^ /\ X9W1/_D6@#\ ?^(U#_@J;_T0GX!_^$OK7_RXH_XC4/\ @J;_
M -$)^ ?_ (2^M?\ RXK]_O\ ATW_ ,$LO^D:OP!_\,[HG_R+1_PZ;_X)9?\
M2-7X _\ AG=$_P#D6@#\ ?\ B-0_X*F_]$)^ ?\ X2^M?_+BC_B-0_X*F_\
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M5^ /_AG=$_\ D6C_ (=-_P#!++_I&K\ ?_#.Z)_\BT ?@#_Q&H?\%3?^B$_
M/_PE]:_^7%'_ !&H?\%3?^B$_ /_ ,)?6O\ Y<5^_P!_PZ;_ ."67_2-7X _
M^&=T3_Y%H_X=-_\ !++_ *1J_ '_ ,,[HG_R+0!^ /\ Q&H?\%3?^B$_ /\
M\)?6O_EQ1_Q&H?\ !4W_ *(3\ __  E]:_\ EQ7[_?\ #IO_ ()9?](U?@#_
M .&=T3_Y%H_X=-_\$LO^D:OP!_\ #.Z)_P#(M 'X _\ $:A_P5-_Z(3\ _\
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MOP!_\,[HG_R+0!^ /_$:A_P5-_Z(3\ __"7UK_Y<4?\ $:A_P5-_Z(3\ _\
MPE]:_P#EQ7[_ '_#IO\ X)9?](U?@#_X9W1/_D6C_ATW_P $LO\ I&K\ ?\
MPSNB?_(M 'X _P#$:A_P5-_Z(3\ _P#PE]:_^7%<?^T)_P '<W_!2/\ :3^
M?CC]G3QU\&/@E:Z'X^\'ZGX<UBZTGPWJ\=U#:WUK);2O"TFJNBR!)6*ED90P
M&589!_HN_P"'3?\ P2R_Z1J_ '_PSNB?_(M'_#IO_@EE_P!(U?@#_P"&=T3_
M .1: /Y(/^"7?_!5K]H?_@DK\6O$'QE_9P\'>#-9U3Q)X=_L:^@\:Z?=7,"6
M_GQS[HUM;JW8/NB49+,,$\9P1]P_\1J'_!4W_HA/P#_\)?6O_EQ7[_?\.F_^
M"67_ $C5^ /_ (9W1/\ Y%H_X=-_\$LO^D:OP!_\,[HG_P BT ?@#_Q&H?\
M!4W_ *(3\ __  E]:_\ EQ1_Q&H?\%3?^B$_ /\ \)?6O_EQ7[_?\.F_^"67
M_2-7X _^&=T3_P"1:/\ ATW_ ,$LO^D:OP!_\,[HG_R+0!^ /_$:A_P5-_Z(
M3\ __"7UK_Y<4?\ $:A_P5-_Z(3\ _\ PE]:_P#EQ7[_ '_#IO\ X)9?](U?
M@#_X9W1/_D6C_ATW_P $LO\ I&K\ ?\ PSNB?_(M 'X _P#$:A_P5-_Z(3\
M_P#PE]:_^7%'_$:A_P %3?\ HA/P#_\ "7UK_P"7%?O]_P .F_\ @EE_TC5^
M /\ X9W1/_D6C_ATW_P2R_Z1J_ '_P ,[HG_ ,BT ?@#_P 1J'_!4W_HA/P#
M_P#"7UK_ .7%'_$:A_P5-_Z(3\ __"7UK_Y<5^_W_#IO_@EE_P!(U?@#_P"&
M=T3_ .1:/^'3?_!++_I&K\ ?_#.Z)_\ (M 'X _\1J'_  5-_P"B$_ /_P )
M?6O_ )<4?\1J'_!4W_HA/P#_ /"7UK_Y<5^_W_#IO_@EE_TC5^ /_AG=$_\
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M)_\ (M'_  Z;_P""67_2-7X _P#AG=$_^1: /Y_Q_P 'IO\ P5*5BP^ _P
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M:A_P5-_Z(3\ _P#PE]:_^7%?O]_PZ;_X)9?](U?@#_X9W1/_ )%H_P"'3?\
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M^7%?O]_PZ;_X)9?](U?@#_X9W1/_ )%H_P"'3?\ P2R_Z1J_ '_PSNB?_(M
M'X _\1J'_!4W_HA/P#_\)?6O_EQ1_P 1J'_!4W_HA/P#_P#"7UK_ .7%?O\
M?\.F_P#@EE_TC5^ /_AG=$_^1:/^'3?_  2R_P"D:OP!_P##.Z)_\BT ?@#_
M ,1J'_!4W_HA/P#_ /"7UK_Y<4?\1J'_  5-_P"B$_ /_P )?6O_ )<5^_W_
M  Z;_P""67_2-7X _P#AG=$_^1:/^'3?_!++_I&K\ ?_  SNB?\ R+0!^ /_
M !&H?\%3?^B$_ /_ ,)?6O\ Y<4?\1J'_!4W_HA/P#_\)?6O_EQ7[_?\.F_^
M"67_ $C5^ /_ (9W1/\ Y%H_X=-_\$LO^D:OP!_\,[HG_P BT ?@#_Q&H?\
M!4W_ *(3\ __  E]:_\ EQ1_Q&H?\%3?^B$_ /\ \)?6O_EQ7[_?\.F_^"67
M_2-7X _^&=T3_P"1:/\ ATW_ ,$LO^D:OP!_\,[HG_R+0!^ /_$:A_P5-_Z(
M3\ __"7UK_Y<4?\ $:A_P5-_Z(3\ _\ PE]:_P#EQ7[_ '_#IO\ X)9?](U?
M@#_X9W1/_D6C_ATW_P $LO\ I&K\ ?\ PSNB?_(M 'X _P#$:A_P5-_Z(3\
M_P#PE]:_^7%'_$:A_P %3?\ HA/P#_\ "7UK_P"7%?O]_P .F_\ @EE_TC5^
M /\ X9W1/_D6C_ATW_P2R_Z1J_ '_P ,[HG_ ,BT ?@#_P 1J'_!4W_HA/P#
M_P#"7UK_ .7%'_$:A_P5-_Z(3\ __"7UK_Y<5^_W_#IO_@EE_P!(U?@#_P"&
M=T3_ .1:/^'3?_!++_I&K\ ?_#.Z)_\ (M 'X _\1J'_  5-_P"B$_ /_P )
M?6O_ )<4?\1J'_!4W_HA/P#_ /"7UK_Y<5^_W_#IO_@EE_TC5^ /_AG=$_\
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M_P#XW1_PS1^SC_T;_P""?_"4L_\ XW7;44 <3_PS1^SC_P!&_P#@G_PE+/\
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M_P""?_"4L_\ XW7;44 <3_PS1^SC_P!&_P#@G_PE+/\ ^-T?\,T?LX_]&_\
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M44 <3_PS1^SC_P!&_P#@G_PE+/\ ^-T?\,T?LX_]&_\ @G_PE+/_ .-UVU%
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M_P#@G_PE+/\ ^-T?\,T?LX_]&_\ @G_PE+/_ .-UVU% '$_\,T?LX_\ 1O\
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M_P#C==M10!Q/_#-'[./_ $;_ ."?_"4L_P#XW1_PS1^SC_T;_P""?_"4L_\
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M_P!&_P#@G_PE+/\ ^-T?\,T?LX_]&_\ @G_PE+/_ .-UVU% '$_\,T?LX_\
M1O\ X)_\)2S_ /C='_#-'[./_1O_ ()_\)2S_P#C==M10!Q/_#-'[./_ $;_
M ."?_"4L_P#XW1_PS1^SC_T;_P""?_"4L_\ XW7;44 <3_PS1^SC_P!&_P#@
MG_PE+/\ ^-T?\,T?LX_]&_\ @G_PE+/_ .-UVU% '$_\,T?LX_\ 1O\ X)_\
M)2S_ /C='_#-'[./_1O_ ()_\)2S_P#C==M10!Q/_#-'[./_ $;_ ."?_"4L
M_P#XW1_PS1^SC_T;_P""?_"4L_\ XW7;44 <3_PS1^SC_P!&_P#@G_PE+/\
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M_P""?_"4L_\ XW7;44 <3_PS1^SC_P!&_P#@G_PE+/\ ^-T?\,T?LX_]&_\
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M44 <3_PS1^SC_P!&_P#@G_PE+/\ ^-T?\,T?LX_]&_\ @G_PE+/_ .-UVU%
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M_P#@G_PE+/\ ^-T?\,T?LX_]&_\ @G_PE+/_ .-UVU% '$_\,T?LX_\ 1O\
MX)_\)2S_ /C='_#-'[./_1O_ ()_\)2S_P#C==M10!Q/_#-'[./_ $;_ ."?
M_"4L_P#XW1_PS1^SC_T;_P""?_"4L_\ XW7;44 <3_PS1^SC_P!&_P#@G_PE
M+/\ ^-T?\,T?LX_]&_\ @G_PE+/_ .-UVU% '$_\,T?LX_\ 1O\ X)_\)2S_
M /C='_#-'[./_1O_ ()_\)2S_P#C==M10!Q/_#-'[./_ $;_ ."?_"4L_P#X
MW1_PS1^SC_T;_P""?_"4L_\ XW7;44 <3_PS1^SC_P!&_P#@G_PE+/\ ^-T?
M\,T?LX_]&_\ @G_PE+/_ .-UVU% '$_\,T?LX_\ 1O\ X)_\)2S_ /C='_#-
M'[./_1O_ ()_\)2S_P#C==M10!Q/_#-'[./_ $;_ ."?_"4L_P#XW1_PS1^S
MC_T;_P""?_"4L_\ XW7;44 <3_PS1^SC_P!&_P#@G_PE+/\ ^-T?\,T?LX_]
M&_\ @G_PE+/_ .-UVU% '$_\,T?LX_\ 1O\ X)_\)2S_ /C='_#-'[./_1O_
M ()_\)2S_P#C==M10!Q/_#-'[./_ $;_ ."?_"4L_P#XW1_PS1^SC_T;_P""
M?_"4L_\ XW7;44 <3_PS1^SC_P!&_P#@G_PE+/\ ^-T?\,T?LX_]&_\ @G_P
ME+/_ .-UVU% '$_\,T?LX_\ 1O\ X)_\)2S_ /C='_#-'[./_1O_ ()_\)2S
M_P#C==M10!Q/_#-'[./_ $;_ ."?_"4L_P#XW6SX/^%_PT^'LDTW@'X=Z%H;
MW*A;AM'TB&U,H'0-Y:C=CWK=HH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6631984352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Collaboration Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch has granted to Allogene an exclusive, worldwide, royalty-bearing, sublicenseable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Collaboration Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee.  Allogene will reimburse Notch&#8217;s costs incurred in accordance with such plan and budget.  The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Collaboration Agreement, (ii) at Allogene&#8217;s election, following the joint development committee&#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the execution of the Collaboration Agreement, Allogene made an upfront payment to Notch of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">. In addition, Allogene made a </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment in Notch&#8217;s series seed convertible preferred stock, resulting in Allogene having a </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment.  In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#8217;s board of directors.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Collaboration Agreement, Notch will be eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$7.25 million</font><font style="font-family:inherit;font-size:10pt;"> upon achieving certain agreed research milestones, up to </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> per exclusive target upon achieving certain pre-clinical development milestones, and up to </font><font style="font-family:inherit;font-size:10pt;">$283.0 million</font><font style="font-family:inherit;font-size:10pt;"> per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term of the Collaboration Agreement will continue on a product-by-product and country-by-country basis until Allogene&#8217;s payment obligations with respect to such product in such country have expired.  Following such expiration, Allogene&#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free.  Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#8217; prior written notice to Notch.  Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#8217;s insolvency.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801760816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheets Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid and Other Current Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and Other Current Assets consist of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest on investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,337</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other prepaid and current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,376</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,513</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,598</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and Equipment consist of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,233</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,566</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers equipment and purchased software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,496</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,327</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,703</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,711</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,643</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,768</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,048</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,943</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested shares liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,842</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,969</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,307</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid And Other Current Assets [Table Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ScheduleOfPrepaidAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6823658768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number common shares converted from convertible notes payable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,856,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 601,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (335,092)<span></span>
</td>
<td class="num">$ (211,528)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Common stock forward split ratio</a></td>
<td class="nump">0.1905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Underwriting discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Outstanding convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,743,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Convertible Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Outstanding convertible promissory notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of common shares converted from preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,655,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number common shares converted from convertible notes payable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,856,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=allo_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=allo_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001737287-19-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-19-000020-xbrl.zip
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MK=[GO-OJQ6X^''T U '(?C!\JD9H7.]7!7>6"##+&VY*@6.)\4OV_Y=%&I^
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MP7K>7UV!TK;C;J_3[5]7YF4V@>SM8&B L ])@'GHT$*:3R@K*)(&7'OCD7+
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MH+.L<L%#$( @9+&\VMZ)*=&VPN8Z&A3^1^]^YH*^Z8/! >4QK*/".6'9"!M
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M#-;K=+-HY.E>"*6C=@A%9$W4*;E>)11(<I5.*3;T6$N/C5LR+="$<H\54LA
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MTA@//IGSJ:FU)L@&IK2$"!#T'SC5-7VO%HBRZT(W O=+_5O231O=JV[6V:;
M:QYV:SPRBHG@%$1]@NF@"Q\%G"[G3/ET#Q.;PK[=JJL0$;O]!S8'6[R=\E2(
M@?7'V"H6=*",:<$)HRX"D2DHT8K"PVK EE91M=")NP">0E$_-<QLUL^NNMMO
M0=.0+B%(48VWW/.D%[BA!$?-(;3%JV[?6[.4)ZUZC3;# 3-G/<+,4RZ$5-R"
M6QX]%X:DVX#+WM?2(:"MU@Y.6KM;<%FJHYX<'6OM9(6DQ; .X1.#I"9WBB %
M_^:,0FCI3 G;@N.E9=>N9><EKZWS2]V#L!=*@><5L+;("*,1H40 8Y>+GR59
M9NJ-UAQ:>1^LR7"V091.Y;7A>=_MC4?+^?[J&([,VWM#E$K)7X0-=XQ8"3-2
MMUX7P9FA2\=_'G>R7F/TXWQV;<VRG@K!G_40($N%C3*D?M^@)K5"8/2LB*EQ
MCA.T=D_Q-18_4G48",JAW3P$F DG@&^L I_247#OJ:3I IX4["-3#P'ZD:.#
M ;""!!;<=F>)CD$QL%#$^HBI! \9FY!N;*DGP8^$[09 $8W]EHUN4O7(K$KQ
M_;<^Q $WW3MX0QM^;UUGI0A/_\[>#;[BOX;YZ*]/[9NL,TYA6?7[RG_-LG>M
MV^PQ(?AN,&K??+[)\M9=-AYUV\GG^[$B!"PNAAF%KU4G+9;&R\'@/*JC3^T"
M+7/42 B1=&3@KBJCM" T LHK R8R%S!MC+EY=/\*ZCYO]9):ZMQV^UV(6D Q
M?<VFUF#KQ%'$EGCCC9 ^@%NG-0>M[K"D)!W6+5_K@\%C73Q=M69%3UW\*DWO
MF,,L"HE\!+],*0,6E:3X-7H::/G*=B**Y-&!%K\FBZ0EMI)Z'VTL,&T=A':*
M:T\@\C.D?/US:N]\R,6O+%:+,IWK=J2XD1V8WG@0!/ *(&2%P+N4N6.$"+SK
MXB<N3^KN%?/![:3*: SJZ?U=-CTM-NGZ]> :9</P'5XWR#O@EN;W;T;9;7%R
M F;F@UX/IKX!<'.0N*WEQ3L=(W,0RZ4LF@T6(TJI9^".@M<O2\[%:T:97A28
M9P3GF%A;Z45*XL Y0!"Z6PZ!H\%46>&B"-@Z1\KI:0R^PU(WGDM$VSH5(8A)
M!SNB$HY3)A4BSGN+,.AK;\H-;5[STL&B"\7:2MUDJ9=>\P#&F3/)E8G1.6T-
M]9K(<N>GUYA0N607#HJVS6+BE3L2TJ5; !16EO"(I!*24(V5A]C&.+?J<,8&
M\>2^(G=)@ [(.B(<X0&6[,%88,R)LA$'<JA5KA$Z!U88&P62! 8-T93DQQ@Q
M"'Q]*D4NWRY *SAG;RM=R>@. G.,(.1VD0?.K#$<<VE%$(%#*+,VI[#96I<*
MPDV[G9+CPP^M^Y26W)H+=.">I1L(TN6)C"AC-+C0 :<D W'ETY(4J1*&5R_I
MB>M?@W62TJ# KA@IR[6FEN)T-(@%%B'2*C=;?TTQ+3D 3P0@'V>=6:8PY8C[
MG?<C"'VFVJE_/3>V?7[- KM+BH)EFI/(5:3 898ZX#!A:4E]8B*6;@YZZI*?
M%_QUVPY1VJ@CU0("(B>B\DA%Z;1,*5]G2PDO622\#@8]A+G9C$TJ\_@UUF(^
MZPMR1XP@/&T!0ZAG&/R2LKY$4(]L+!<UZ.6T[T;KV@\@R[2:!R3HM'2AD$/<
M2 X:1.+4*Y5'G*YI*A^Y> Y "D(^YN@GE[QNKQ4MR!$%=DL5!!X[)0(2&D0+
M> \;6SZ#QH1: TGEPO8"RQH1DNFDM7&"8*Z+L@YD>%'0@660(%GEK2*Q3L,_
M'9:GJ$1+++C<%B%0Y%RG]JK$4Q>-8$@'14J&=AM0-I;\;>!90R POT@8*J2W
MBAMD-4$1)$DSSP3&L6S"L-9X.PIM#-:'/+MK=3NS[8VI)S)3D#M*$TW;<@JI
M$-*ND&(Z[1AIYB*-QMIR2VXPT:6P:8=U/@>D:W?)P4)1J[0S&J0M;2'@0!DH
M.C!<O-SIY;4JN8!/!G34ZE^G8I;)V+ML%+Y/3PW^.AATOG5[O2T;JK-T56A
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MLV8VNVR]./!1M0B46L\)N*A<.JX,>. .@1"4F^F(11U=N8H=EKD.V=A'#\+
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MQLWW/IA/QJ\!,=N"LC*"> '_(> PJ55>$&!0<)0=./Y96MUDMSEO[,PX/TD
MM^#LM#/:.!P^@:Y3YHFQC*96.YRD;VLFL#\CRJ=+YK8F4P@*@(E33E(NC2(N
MX8F1"66.,R5L]=[V22>\[09]W_TDTTS3X)5BW$MM %!C=)98)F22654M$2)J
MX_I\R^WX3HAV!1E9;-M@$%,("DJ;.R=0?1,P3,+0RDS/_]#2,',D1#B.'(<4
M?!X-(**:%-TKQQ%.)!:"/.%#IA(I@_6:@ZVAP:3"X?31"IB:&RFWP5D+T-.
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M3,%YB-5!K1.M,\-HY7)=6+TQ<>ZL<+^,>G=4*D<2#^%\&IM.L/#)9I[A8H[
M*^J=BZJK<$DT.5Z]"X*[G\';4 8UMS5&)1)X0WD'G"UK$F1272H)GJ3?+=9B
M$0O.67#24"R[YNBDN12X@X6*6ZNTWDQM7QH=3M#O/L%:$&F9Y[@K2'HO-+ &
M^+C $K:F&%_Q2Z?"*1J>4\.!_1U36DIIC,/*:<\%)L<\J:X=8I+QQJU]923*
MWCLNP6R2NF L59(J[9,TE1D$*"X#DVTJ^3#T8PX#>F,<RG$@[QSTE;$,UQP&
M;X04CF%/=99F./L]!?FJ\)N0]M"@8P/FU<F@VPNH_VO_E-%5"S2<S :QM'4^
M&'2S7.O82:4^'PQZHZ3[T)]V!S__G.Q;W::H=LKBI3[QEAB;>DJ-C5TDH*:K
ME8P;2>L*45X?Q3Y^'?W>_X*-S?-'[R<;2VG069HH2=#X9=YR"',L321/K*A&
MNINY_N<F6WRQCZ_%2;:]?+(QB?9DZOUVU_]7S%CN8[149& "#'68/;7!""I-
M4. P$>>2ZI!OOGF+U@#)#I@ ?$FRF1AN<#>M%1 (&IT))@0PF2 F4W4!XQED
M\Z4I=HILICC,2S/%,I_(S&N;$2H=5I,$DP19N:'7+TRVEY?-D#A"T@#D(4I:
M'+042 #G%3PY)L&?JU!L<]KT4TEF7]X*'&TW00JUICSA2GK0_R(EF4NT@.C=
M\G3OU,TW0+%39%,F+...!)]8+R%D-BHD1B0X5RV(S%6;5%^8;"\OFQ [:><]
M4R"0X%R /O/$J0S<-16<-94$0]/:[+#!^9<DFHQJ8R$0$))PF0EK4YXE!-L2
MK%>A9FO?VZ/8*:))(8!*,P^B*9T4%GPUF?J,*$&]3N&E^FZRER/;RXLF4$81
M39D$SQ9B?"RKRX J%&P!3BVLE"N)S5&V>T@VR7%S+42D 5?3CF),>NJ@&;#D
M66)2"/$L1/0D<7$ A/,\$##Q-8,M2%R]L@;L#GB>#/C)AY6 <LCA(Y,/[O#M
M'',0UW=S#&_G6SL.W-+A0"-[&;*@<8\;!Y_<@<Y1A&=:9+KJH%<US462]+F7
MG?B4$ZNIX(H9G&SK6&+ 9]<>&#7P&H5=#0W/1L>=<T<49TQ;ESD E1!I$P:2
M#T*6,2%U6I%_BLNPU3-"_BJ%RAL7,L>#PXW!G*5.&B<#39W".39)=3S3LS+#
MJQ$JEQE"798EEFDN$JJ<=502A]=4B:CNAM95>WX>.NZ9SD6"\G@C;H-.) 3O
MCE,J,A4"=2K)JO.BN+4;.>CS OXJ90J'U&0^=<8K(2%N<%8%G26) 2]%V&KY
M4&52P(72]+F%RD"0#ZQ)@U6X-M<8E>K,4)+23*G45PH$Z3,*U4Y+!5+$G''*
M@/<7%+>!2:K0?4T@JM05N*W<7+Q\7L!?I5#!N4O*4V<9!7-O4QLX!SESB01E
M)?V6@.GR:?K<0L6I(PXX3GAE@3DQ4QO P^,*]#Z'\+-Z@]<L'>,%/X2/)XS7
M2UD2B/&XZQ4<.P;R9$"E*IUPI4-UVP$E5O!#', %2$^"?E_S0ZJ(XAD%%8 W
MI]P09JFUB7,0\#NQJVOP.*BGXWX/V R7G)\\C%8EA&;"))C!44GB<<B?5K@#
M#G18S8!HMC$F9AL8IX&ZZT*:Q_G#::# P9(8YS+"&%5IRC(&RK=R-2A. W5]
M0_'*<.B0W_5[_2/I"^XA)R$%EO"XP,,[Y<&MRICA(H68IF8W*Z62F0VX]\'T
M5 QV3N[$ HJ4 I> B:,!N%E)#_@$F28BD=7%XQPWD&X:N>?&8"W3*S'< 8X.
MC,O,,X.D3X.&&)-9QJL+1@"#ZK7"41BL+T_Z]:;X\D_#])^]SZCGL]'XH#VA
M!^A*<#P3S$%1;[0$U#QE*<^L 8WI!-7506= C(W3.1W:LR&]1\6B=V4M=RF5
MF4P9N.%:!IX%\,.YH6E%%S2/[4IK_F^@5.JGG)ROO5^F*DLAXA0^!1DT6 ,>
M&+,AP;5+6;)!@.5T%&JN5X]^&Q9KF-8V2AV?U DNT5Y1,(U,!IIY#_$R=\)(
M#TB(ZHQEIC;BSWI 3@%U#W?Y!(#T 1B).FF NP++'"@+"$L"Q'K5D@I&-W;!
MG@KJBAOH'Y<?*8=GN:_=\6W\C[\5<_O@N/JC6[K74XW?J0[%6W:W57:/B=2E
M.% :)PDD*%G24^Q+@_B%)"%)O_N/W\3?]^%[&C:-4*D8$O53K#:-%S^Q1>PC
M"'C9S@=2?I?WIRCXQ>^>2,2E4Q')^0<PQN3W#W_LDU_+4Q: E Q7GVMKC'7$
MI*EC0EK/[:K\SL=S,";WL]A92/,\)_(7> 3.I'R)XP#Z6V(=50J<!:$8..N<
M9%IG"D=.977#8:B.S77/<2#KE'F)T]C8)1C?#.#\9-W^N&:N2O/'Q59U$P2&
MX.1H8M!79LY9#^='.1@_AS5<VVP?T]="/?]Y[:7=\QSH+Z-BNNKM+S,D[NX^
MG4:%"PR]3L 7=489F1J<])%RY;TE7DJYEC&O&47T;!2YD&-8+:9O]!@R'(#E
M)1-.$PGQ$'J.(0.#[G2B4UZOXS2G\EETW,L>QI'ZK6%Q655NVG!'$TD5CBGC
MBGB\[Y9>0>AMN55VFW(CU\_C'!Q.LLL_P@9%;?4($\:Y#"0E,A'2^6 93E+,
MN%'<"IZ$%[=/EW:&?XO O(SGQXU,I)>)(=9$K<ATAN,,O0A80EDWY!+\\.<X
MI76JO,1)7)37!Z?#G00G/<V8-#S8U&(O: I>(%/6RJU2):^M>/[S>A[1*G\Z
M_6<^[O4GN"5PAUNQ<V(JR[R%_P+7P =A2$:"Q5RID(&&NFA48$\J9PT0=AL.
M9R+0QL&4[^0Q_;67;&RM$(09@T7I.M,RT]12)Q+%,V=5:N6.%!R8:GX6NNU"
MK4EJE@D";%K=I[1W9$" KX#KG&<F!;%.#/Q%O'(AH;ACI"XJ8/!829LC70T>
M39)I/0RLZ9T]A$S"A@SDS!"P19(Y8T$PD[A$65BN,EE')FTHITUX$ML1:9).
M*X-E=\2F.TCD ]$X:)LX+C-JG</9OB;3 ?XIUV8RSDFD&9=2-!'8;,/AF0FT
M>Y W8XI"')$D%!=XIH[)+,&U2+@I.5V;"S4G$' 7H[P)N_G,!#I.O6_PU7H@
MEJ9>D4P(@;ON0#7%0I0@O> J(62;>M?7ND&K>"!F%T',7;92"D_2+,TR"?ZV
MU98F% PE!$<2J+FY1WC%5O)K=1XI?2YJ%EXA=K__\R%'E_?C"%]ZJD@KJ8U*
M,QHDA7 D!4IB$PZ#<--C]52=66A<I ]%[7G)V1C/$C K!LRL2S(OE<!UCX0H
M EZ+<EX&_TP\^S2,CZ+]Y#!7,]^6VMY!ZWI79Y7<69+23"K&*"X;RJS)4DK3
M0#(O%#5ZJSO-KODQ+F&C.#9*W1IOM$GZQHDC!$([D7JI,;PC&:AB%P@CQFYG
M9WM<M-(PEHU2>.>]S).(:["?.UBFA+ R!561.$]4D%:GH)'5=N;5UT<EDYK#
ML$+8F_TJZN;H$/3W_+[;'\:]O\/I&"@UZPX^YN/[K24+JP4CEGO#J7"&)> ^
M4,M 101AB<-UJ9)^]Q^_V<T2A.=%HDD:+G*RFY?P%Y6$8^"V$>8)SK !ST-;
M(U.68%VK)21E8A>?;]K$%R%6DT>VW01OXQA65S4EUMD>M#.V.\J T\[@_VR"
MX^%!FU"%BY%%9'O]5\I#<_0\ 9.+(V15?X 6)CPA)E56:@SF,AP[#>$;?%R)
M+!*2J;=#QJ,]Q:=HY]3Z0'7@#%P(+.?#)>,L$PE7U&9$Z>:IVQQZS1-];G$7
M>J:>A+OZ\SS8.16LLTDBI;#!I4$E0F80.J=*)I5*?$U)M>3P#(B\)+&.7/[H
M;F_CW(+NX+>XP*:<;+%GHB $SQ X*Q5$"I3W!-@YTU9E#%</BNH K3=/^)V[
M"9AG/A'>X5C6E!M'@TM"HIU1/J1)I3.?&_/VJ?4L;)J(C&MB$V&YC$N%96:,
M9"QX4,&,5@?BO@SE1^,IZMBMVR+V-<PH"CXF#39SP4NIJ6-<>JPY)D$[\']J
M-@U;R380K0)Q/)"[>F(H3:0/"MPS(V3BA<F"$B$-CF0L5*[^<#@Q85(<!R0Z
MY<4JQS ;+ZJCXPE-BFTX$SB5M<TX'_(>+L387"Y?OV5I8]&PQIX8HIFR&3;Y
M9%GBF& ,>$X'1>JN"+21"CS3%92>!/+9D3]22N'E^]&P=A-Q$PT<S -3",I(
M9@(H4F8S15)+":A6Q0V_)(*G]P^#T6.>%VTBY1SO[1M*CK?;%5)O)YMC+/%.
M"VNY5ED 3S/S5 2AN+/:J;I;8\7A?PXDVG94ST6MX\W'$=1*$V=3D5&3,B*-
MDI:F6-B!N]M5EJV-'9Y3BQ((ZMGSD>N7_&M\:[_4-B%U5M-$)5I 4)A(;1+#
M;0J1M# !/>ZL;G<M(YN3WP[#YR4H\"M(N1L,1M&<K'?V;*.(YD[CV'A',R&=
MEI;@[ 5P+$#I)TE6=WG.SDR0.2/]>E<L[]P[,N:)B^9KWXB0/,,*>H]U'8;Q
M8#P!;T[ZC%O@4H.U6(R[NJIL3HW6^E 9W:3FP<>PNOQLGCJNJ?,Q9];XH+HR
MED%\!KI>*L.]=BRUP4@3AZG6,2C'R?#\4 :MQ?,,5#JKID\X441 =.:%L-J&
MS#L"=M&0E.HLA+IUSY*@4;@H*IW;>P USSPXZJ#:N%2>6R.,55PR<'99EM86
M4Q%0B.;"B+2S8DRJU%KA*$E-)C-*#,104LO K("HQ>HZ@2%"'NQ8/B.29Y07
M1H// G=!6YD$:K-$@!ETQ"7 %DF=^PU$,NS<1(HA]5:WZNBD8N;!+S:>DLS9
MA#,'K,ZCN^P,4:$Z'("2C9D9)X%Y-CR?)=&"VU2XU"QS-"3*"NK+$$/!/YFN
M[I"Z8)KMW+9JA?&2TRP35+),61,";HK,$G"1?<VNK,UMD9>%Y[/PA@J"^!BA
M)P1(EX*NX%XF"42EB=-^_X;-L]+LC3O.Z]<EE-I$0WR;&",ILC)/!$]8 L(J
MLYIQ$I1J?5#84DO*0X_@**=YQU92#] :#3$Z^+)&>VIYHJD,@0O@O&H2]&"\
MGF277BPB6+^"4,%Y0CQAEH&B=C9PAA.VDI!(%FAE+]K%$6>74@;38ZG0P3 '
M]B=Q3FD-QD<GU$KPYJLSVRX0N;.=O"22&,(H55Q0IC0EVL4@)\N44569ORSB
M[''5M,X23Q/+G*$2O';P*;(TU6EJP/-P677FM=(7B-ZS6&$CB&-&,^JR($V:
M62:H33-'@@K2\<J.D#=!JB/$1%BCN6$9M4$*+ZSVX/"G.,T(#(NNC/V^+,KL
MTHXT24UB=1ITYJ0.N*=#!<^,-$$2;BH*0).+4P'/Y:EJ0^'PJ>0IXY)KX3C7
M4@4%7A/!;=%54EV6G6P^ ; ^892EWFA+.,\$KID I9MFPO*44"U24EVNVC!Q
M<.ME/IX4V%0OG_6.&_),")6"M\,37!8L4Y\D6<IIH#0!9'3E9-^S*NQK/W\"
M< >>2Q%%S&XFO7$_4N3WO)?WOV"-;38>W:\[_.6O[EL&ZVV:QK#5 _ZIQ0%E
MC/D$5%LF4U?9#?!"F"^$=SDG,O:+X\?&^>=\..E_R7\:]D;W^Q8A&XE)NP!>
MH+<2O%WK&14D,9:F(,V^$@N\-,(G:2LAI2"I 16548QW#!RNL2S+A/*IJ6Y1
M>6$D#]<S.E.!):!J4HGC7*05DGK< )>F@>AJO113+R:L\T\M972"0KKR(_M6
M=FOPPG3&O2.9E-K:3"M.I;5$$9;2ZJQ;>0&XKH]UW;N4W,I$IFD"X@<^!W5P
MC,HYES+GC&?52;*LQJ@^"47S7VR[82 ^%2I)N.# :S9S@E.1990PX#DF*X6,
M[RFS0M3D1)X*X<M9!^0WQVD*AD!)3Z@#'S$!A4DM#8GSE?#Y?;E(X*5(T)R9
MP$WQTC((A@4(GP\^8'&VR+B1\(ZM.#0OC?")3JV-0[!P$(P,"7 U2!X3C"HC
M/"$5_]^0S:J[%T#U<&/A D2R$-JDP8&'XZU/F<'QVS(%!T_JRJCMC3GA+X'<
MR<9"!!R:"R8_R8Q4VEGE$P+6$522(;IZE"^.YU&&PB@&FD=K9B'8\J"3",ZG
M#@&4,TVEKZP >$_!]6%-.^IF5PFK8S+E6F=>&YF $0-GRX A2RW7$%)7Z/\>
M94PT;\[X"QH+JC"MFH7$X&8![I-@C<X2'211RE=\LQ?"O#D; =HE&$TP-\0E
MIM$=)8%ISA-G')C-ZIF+YC7,T6B?9"EL"";CH$NX"Y*ZU*>29F R7(J+FF@E
M!X8SQ%Z.N8\W%5Y+KU+'$J>L!-8UF?0>K%VB%5A#4:U KTE@/#-R)YL*K5)L
M,C,D"TYJ:GP*T7!0+,DR!][>>4/^4_ \RE1PW!9&/$U"D-((ZFU@RH$K3\$P
M:EK=KT$-);2FXN"):.[88:(MR(X%U9$**:QSEC-'!:B.D/HLK<1UFG!@P>8!
M?,&D4YI"_*Z-2&F0SCH;"+C:Q"O!G5-5Q?E"F#=G*00/&A,5*?@$,F'&01P)
M9I++8"01M.(=8/7A2YWWTPP%$SZ8-$L4Q(S@AQ)O: ),+AE)(&IRE;C)4L%4
MTXF+XY$](J@0RJ0)7ILH$&*"E2M@[76J*&%,)=75>JQY4_%\*:A4"R\3<',"
ME4I)7"=(F"#.^XQ[5DF!O#B>1YD*G_C4*@/&7CN9,G#(';$FZ,QDGE%=N?>L
M6R;U=#3MCA04,)BESB0)V&KI&'$2W"X0*@DN"1CN2K):27!>FI8F^Y(9J$P2
MJC/F5;!6@KT$.P%J)3-)ZKW+U'GS,(=CWIRID,$QIQ(.QM%(*9@QDJ/PI3P!
M3J75##=532N8$] ^R58 IR;@"5!FC9#!9CXCN)#<BR \.&N5J!Y":4V:]M2.
M1_9P6Y$EN'B=TA3;6&DLI<->> &FPSNN*KXH;3QE<3QV)]N*A'"568U#WJ24
MQ'M<AN"SC!$>DJ3*N"^.YU&V@DEC# 1,&=%*>EP0AL7?FG$:-'COE7;Q]\P(
M+FOJ9)Z(YO8,E(!8!Z(*FWH"TL2U=Q#C8?P*;B?)JE?PBEI-FW8S[4LFH!C*
MF@M!.$5DD@IO0&,&E>&R>^#-\WHKAV/>G*W@X%%KFX8,0BB9<NZ4%81ERECC
M2:C>$%*C7N[ GV8KL!95.0MG&FR\B6(N88GE5#O!.:U4:4#$85C3%U''(WNX
MK5#" 8*9=("93, +R!SE1.A K5&65Q3,.6S%LZ6@P,!SS60:#+,2_K*"DDPH
MD@9IP<?96U+W['@>92M2,'M&L40EF$9TQ BBA!4L!*,2FE3SPC4K7H]%\Y?1
MM"B5^O PZ$^7PPI^QZDDZY-6EJW06/^\Q$&L#>/'9?'>21P;@OU-&9>9 CL.
M9HV9M0,:QJ&TN#&'KN]O.Q+&-?QFP%/=2:D%]Y;$;]D<OF9GXO,V5GWO>\#6
MU>/^\7_G\ J MZ\Q3E&60=A(X( %TY0J\ &I,0&D6P!_[+R76R/"D>0Y8+'Z
MRY!G;96PQ+TC&=9\2*>SH%.B0X;)!F82ZJI*KQ'JV MFGC7J.% 6'"*'@/NJ
ML$<[TSX0"N>;>)96LX:;2Y:?1*+7P4""@YH*@6:4"<DXUK@IB!$]!U^8JU )
M(=D1)'H +95/<#K><+)?!Q5/6-B3GT>][H)&2S+4K:,O?^$PDBUI%%^,GM2'
M?/REW\LG35'_M[O^O_+Q?N);!5:.9VDB) 2VU-F4)UXF#"LM GB:M?45Z]1?
MH_&QY/_[MTU^ZE*3.>ZX,FD<M =1@ O&@N.?@B-9X7U5U0^GD]]^\]R?I2(%
M@^65D$0:IQU0GT(HHAAX2J2:$6B.\-\XWT-X*\"1YIHG2F*Y*",V11\[,[AT
MN!HI'<'W'W,( ,;=\6,9#W3'XT?P^-W]:#:<NNETW+^933'@^3@"Z 'G ZMF
M3VL(?H:V7VTL#P;G]V:2&V&3U(6@">$XQU[NJ@4XFE0-T[FVZ.Q2Z6P5812O
M?%F@TJ:I2S27L9>=!6QVK[388<BP'A&^/+UKPN9+I3=0+W-&X*0.*65B'$^$
M V5!L]0:F[T.>K\B/9*&-/'< 8=3H'<LT$R844XS[-.PE9N."Z)S[=7!I=*9
M)"SQB4M33IFD"<X>Q$A99TPHW#EYT71^1?J#A$1EDB495Q!Z<^59EO+@#<2:
M<4#&9=*Y5!NCWI33!=XAOYDNUZPNB;Q&W=%]?S(9C6.*KC)MY+1)D>NAHK$R
M26PPB?&20*QB($CD5F"+H<ZJ?5N4D<U0O4FZ%E-55D;=OSXW;F.J7Y82J1.-
MPPVDM<%KX1*O">,X2WFMA7\^?VL[:2O4>1HE+]U1VQC@J2&(SG@(PF@I-$1V
MRAEE52J($5+7SGBE6G!K]/,1]+(UZ<:00"(5<]@Y!:QI(&#V4H'SF_$$]( 2
M[B((^IID'9Q:S6Q(($(#VZ2TR12H4(A_.<,[A1>5]4MWIM8I&82V&5:7^<1*
M2IDA(4L8I88'B!YTW;#89Z3D:Q)R3R5SS'D*/I)T"84_L&:1020@!?$OQ9.U
M#E$CDZ\5EI0(""HUV AJ4L=\DC"P#\$KG&MY=JV&0&\9F5$_ ?NM#:RSEFD3
M#+CF$.NGS"F9:+R@#AG-,EFI?>'"4KW+H3R(HI=^(N>GNTN<4-:83..^2Y&Z
MC'+K<9-@PKRRE<B(*<$W"OR?2OB_=<=]=/1_QIN[<K/*0?/!UF\.O93* T^D
MB4R(-1(".]R4FCH5@JORST8X4@?$*I ;R[.*U;UPGB@>*R+NNY-^#Q/S_<%L
M>MAH0[*V*#,STGK"A09%JS*G&<4[.)$*(4CMN'.!DZVI76)R&J1GPO7OVW%E
MF<NL4CA#UDGM/-H;QZ6D),U\(NJF35-*!![J)2);Y<]59'7*99+""=(,O.;$
M>>8S+4## ;L*I=,Z9 G# C\A+A3;'4=KO</UQ)D/,I$6@BZ6"N]2%KCGRF5U
M,8*UAE!"&CE:5*T_))]Q<=/DI^&'_J=A_Z[?ZPZGKM?#[ +JI-&@WP/5&__[
M\2/@Y@>@M@[9FQ@LDX1SP[22U!LK<+)> &P5.$K,??<?_W,P_?&V_Z4SF3X.
M\G__[@X>^?ZN>]\?//[PL7\/1@.T8.?WT7UW^&-\;]+_5_X#)0_3'[_[GY^F
M/VY\?= ?YN\_1UK\0!GYTX\/W5O$^_UT]/ #$P__W/H0?+T.B/[P,VCDZ>;W
MBG_BQW_  LY^KWCE:_'3-Z/!;?'H%7IVE@3MS"F*O_QG_.8<C#\#,L?B99I#
M*W[O([R5=SYWO^2=FSP?=H:CSF0%C5[!*YWIJ#/]G'>Z2ZP>2JPZM]&4Q;<K
M&)X"T?3S.(=?&MYVAD"(1A[9N8<7/T\Z^? 61+:11W[('Z;1?_B?W?N''_\'
M5>1'3JXZ*!>-//^JTT4?ZOX!9/IV3O[5DZD]BAR+S&_@"_UA!S.<'=H9W15'
M$\$TC)$?8^H3'YGUA]UAK]\==!;NTV3Q.?HC/@2_BLY4=_@X?X?J'R>=[NP6
MU^9V[A:/F"P> =_K#6:W!11]^+<;#F?PB=]S<(:FUSO%8/[W__KSZ:IJH>A^
M[O?PVGMQ;3\Y1IMQR@)8F<2#7P=V*7BG4@U!D+>&*BG,V;59D\JKHJI*TG26
MM+DT[72HTHUCMH%'AT5>O#\:+I'J?.U//W>*<HM+PR]^[R< ]F'<'Z#>,%>K
MT@:Z:IJ/HPR!I';A<[OP?(??+/!<OOK]*OJ=A]EX,D/% 8_[^KG?^[SV:]T>
M1"CX<SV(MKH@M]TXO?RJE.68;BC?0='!I;B3J*,!O'PPR...W,[#>/0 GWKL
MW(W&\?&WRRJ<^.GN[7U_V)_ ]R,"H)MZGT%4QOT>O#WM?P(#-,Y[H%KA^^\2
M]_OWG8]+_=J#'YHL'CT=Y]VXKBH^!910/K[N?%Q!J3^!9Y58 <[WW7_D'3B0
M?#*%R+#S4 0RD\X, L7.9-;KY9/)W6P0=>X@GX,WSC]AX\IH_!CAGW3A^\NG
M3#KPJ6YGVAU_RJ?O;Q[?%W]U;L#S6H$TOCA9(27N#8G/\^\1*8!M.BM),B?#
M.Y_\U7U_!>!\B6QP\]BI.^,"Y>XG^/<GT+]@"J;P*NKCHU'] G'>:#9917D%
MT=(6X+9W@";:BX(!\-5TA@</3 IO(P[CAER!?^/DFB 4 WAL,YX G$DSH*FF
M0;L":7G(B]3>:+C".5>%'-<=\@9[KHK;*I/>P=&C##2#N1'-HPZ:XTL?78;I
MY^YT33.!( U'(.0W@SXB'V49.!K$;LGA*&FKI'C QP%Y2J;=8$_\=+>0M/>%
M)(*S #*7@Q8"G=/YV(E""<^XG?6 ^J7S!>X"TC46 X((?B[\LWL<U(LG@08C
M>E4@8*!;\S$@"\ <+Z"@UT IKBC<;N$^#4&Q%/H'/>0)-IQ,"C]O#-SAHA;M
M7I7(7H&]Z,._W R5[:#?C?SQ:P^H ']'<_%Q#N+W!446OU?TN43'L=1<>Y10
MDP+/9-,2#Q:I1*0XBXH.+[D$B)!_&B'A)VA[P:!$O.!P,/M5:/KH>8X?4=67
M?Y:Z'AW207S,H#N)-C;_YP.8'J0B<G%)LM]'C]T!V$?<WQL]_*7'?@.2^_6J
M9,['.?<A<)&AYC]7 OMQR5_@0_S:FX[PR-"/O5I_O_,5?@5@Z<;0!UV)P:!\
M6'^)^]?1>'![#:RTPI4H4R6X"P;]BL'B??<VGW]Q/5A[A7%6A!V]+Y"[R0/X
M,7U0H8^[@Y1#O46J&G872RX"?NL.)L!BH!(Q,X['.HX=BB#WD4]+[D$^G3,2
MXKF-?:_*DRXY8@((#/+WM_#T*8H/A K3[J?2V]E41LBPY6_L5Q31(P(%/\."
M[U+=S)&J=201:OR%PF,%K=V/6Z_1%,3.6@#D:^=V//N$2A^"A,*)>O?3+^%[
M)--=?PS2> <\?8O PX-N<I3SPNM>LI1"CF)\S8%<BW?GDE":(?R1:)1+IHF"
MU?D$!S!<E=SY2PMBYY_ZPU+-1Y43P4,ZHIZ(<KY-[I$0(%:3N6N =>511[_K
M?[_$(RJ=A6^]4$>]0;=_/U=%):&0;QZZT_)4WO7[WS<CL)1U'O/NN!I/GB2=
M=^/1_9&D:D9V7R)_.&]?  X<#+HWHT5(<-NIQ.L%^R6%R/0O+GHO0W/@L/%T
MSHJ;VN!J_@K$FOU/PV6::Q&4=HZB2/1J?@5'K(^*84&:2D"\?.?#M;N&.'/^
M[^^O.[\..W^-/VBN5JQI?4R^#80#?OEZ*;++OWZ*L?4P[RW52^%WYKW9JDC7
M/#^J_1V (\&67RN,QSHN$ >B0NFNH_)S\>H2CZM]>83U'\+O%<<*#@\<RS3O
M[#ND6M)\W/.E9<JQBRJYX)G>&L\ $$#=J#!N^Y-HJ IP'\;Y^Q[(!>C$P7K"
M IV!N/$>OXP!PA@16(8(X+Z!B]?#H 2#EM)9GN2#XC4P@NC*1QEXO"J)];5,
MZP*]BP3I?\[ ;T('Y%)]CI7SWLI]RQ<_C>&S-:(\!#Z&(YI$'R6ZFU\AWIL[
M'N"2P)FA[STH9.IJ5V:E#(@GLYOBT_B],OZ:@><Y7DU5%2,XX"OK[X H+77G
MJJ&O=4-6TV"8T/[H?DY_*4PR?A0^M>"RO/=Y.()P\O%JGG2Z0F_G"MEB ,_!
M@@ @&'YWA+-0OO8G*.(/@U%_[J/-8THXAY+9%O[5*K_-42GY;A5&S!U==;*?
M/_*K3OCY9UZ(9="DD&I7QKN=C\57OR_"CL^S>SBFT;"'\$,LC.!U'W+0/;TK
M^.7NI^%H$O]&LGQ^'*!\]$H1&I5OHGIX&$WR28Q+NN4$E*L%L$M&J??WRF.<
M<Q&(T/(;%9:*7#:/QQ\V^#2=L]M"34<BK.F$I?ZX*9YWDT^_XBW8_*'X6F&D
M@ (Q^S /M<H@1,WE>H\IZZ\G>K]"@ O\"S_RI="(<_VXHN9W*\G7JRM6R3(_
MYQ63T1F.AN]WZXH[>-85!B8/>>2>F(<>C_,OH\*M7>B0)M3$:+8E-MDEX!OR
M?:I,;_H3<WF]T./_6'_D\^1>$2MN7@ELI&.6N88RAIRS2L-)3&K.DFB:QR0Q
MRNTO#W?IRG0_P0%/$/?E:QL*>4?"]V#J34<8:0#'-TDT=FTZ-PV2K')A4\GR
M+MFI&0P:/_3%3=<HZI=2=Q?1*H37_<(YC5[#;[@7N*$@NQG@%V[O=(S,!<"[
MGW_^];VF\GK54D]6N'=+WJD#F&(TL<PC+7-%"PV^DC4J<Q$+)1CE!=.M:ZKR
M=E,)Q(_A!614SJB8>Z-Q=+Y  7?GN<E9<13CXH&8^\#TSW@E.W6UUQ$I;4C%
MD!?V88MQVW"O?BNQ _\*P!['*[,R;_H95/+6/-MUYP/F,Y:TO.]B[@AH#8_+
M;TO?> 'A2K)O\[4]63]DWAC7@..6+]),,:,WUR.WL[S$N7SVI.#Q_OBV"&R6
MO%%DDP#Z@]R J+UF-_]=9L_FE@\L?_Y0VN*-:Z#5V]P^@'0_[-\]KD6;I68=
M#%8!+#@ OS[HKD0F*YKT"@@\G-V!/QM+F:[6F+#TR<8Q9UFR[>8)%[S6+]AN
MMDAXU"42[S%OA\)V$^]YYA\=YP\8M\+YE[A_[8[1-XJ25'#NL#N,T>44#PC,
MP[PZ9QMQ5P5X0;NKO31?I>V:N_TLU-WA&U7<H!JJU\=TST'S"W;)EGIDY3ZK
M.26R>O55EY,N<EBU>>FU:[+XZN*G"UU2J.QX)[>2\?TQIJO7?V$PFDPV"C;F
M003.1NS>P0%B?FA7YKB0&WCVYL,1%KQ]&/9QD%]W_#B'%V/"=9N_<B5\2++Z
MQ\[GT5>0E3&&[UA\"7_C*7_NQ@!QS0K<K!Q>]?(!I;'? ]S'E4.%6"E2&S'Y
MBHYD7H]-/09H#E91N%!.#YO%$YOZ8MV>X/5]MP@'$?T"]7%^-YN@(S3>?&>8
M?QJ! S[/)#[,QKWHS8T6U"ZN*I8_NBP(*'5A379GH>?FRC72N:+H+I3B?^QR
MA:K4GEN;V_X *YQZ^<IE6J039I& I2>5RK%-NX#E7K?]VV4)TFB#KA@)K7\#
M8[.-* L%#C]XW_UO.,7[[O@?^71QW?8UED5OHE ZN[=UQ2;7G9_6K/["Z@P>
M2[L3H8W"UH^FK8X,T?_J]@>1(+T9P("2#I!: LKFL7"*JG>/E5Q@4812X!F3
M33WLWL&/WN2QFG"#%D4IWV2:=V^+S]_D<6!BM\*-%\N, V2=O#L>8.)N<=\0
M<^Q8*SV^Q1K!@G)(?_S$W,>L\>0C$>;&Z:0K]7C+NV[X4*EOU%2LG?[FL<93
MK)CCS?O.M2 :V30Z-U%_56Y>ZE#MEMA&@%7!9RO^$_QN'V_@@?+3V"  9@8L
M4-[']-8\MD6K,L[Q@GR\*W-_W4F+KQ6^(\8U>^&[.O(W2LK;PQ"9NW2%W2T-
MX6@)XYHC.1NB2-YN.I3E"=20%A&,(?--OLJ2&U%MA'<#+ R',>"%V'4=Q!@"
M+W^KD%/X[^[P'^/9P[2(BB>CP9?R9K_NX:5.*<\Z<B9&U9/9_?V25\O>CUA>
M"P(W'@W6/.SSZ 'VY#OG6-XTF4XVTN]P<,5M9\T=Z_RFLA!\5/R@Z$>?AC$#
M$=5^>:.X66.9%W/U@*V?DH]9XKR\^6PBO9/-ZX]?>XW65>??&GF.;"9IN<@@
M%J(QF=?%+9AL(Q;&<DY@FKDKT^W4WC8O<[CS%-,J6UYW#CG-Q4',KZ?,54-Y
M4W(M&J[#KB===S(9@1>'U)L;PT+T)N4,3O3D("*YW[P<K">:B\KME3!Y8QGN
MAGKF2B9?X>:]K#LOEOU:.,M%R%V:+W#"QC,\XOG56">>.7Q_T._>@#<\72E(
M18\MJNYRT,5MX0+== ?1BYM\SIOR1%^BT.N0&^G(_N4]]-NL[AH>>4<?D^OS
MF_G5DJ1(JI^!>7XNOC8"-W&R^.0']R$^%D?#]:>S*;!NY_<<PK%Q#,E^PCJH
M85E.NO&U=UA"-*\)OIJ_]?U*4+^:W,QK(OQ%#?^RQ6#9=U!M-EB);%?K.?Z
M3W[$FJ[:+IQ%I=CH89Z?&-T4X> \$  U^ 6/8K&19@6*+4%U+$3?U1BQ^H5E
MGK9,9* R6/FU>?U]?;'Z,L4\+Q?[VD6F0*=_F4:)&-8^]E(CTGEZI,*S-:FH
ME?JH14;I<#8K&631RM#/![?%906<\G1VCV=YB^R!5+V_GPU'17'/8RU'S>^?
M5V&JY:U)]W[!8)%?ED=3PR3;6LB K>\6-+H=Y47#3ZRL*G-MD]E&0FA<=XF
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M%]?F0F."?VL\3; X[,-.ZU75U,P=(6QC6\]0-*4=&HX=%^6'\]*99RZ;V1C
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MJ0Y..K^B,.KB=/WA=:IO9_36-:=M;J>5K3:W<VF9U#:WLVSBO\O[#69WSE&
M>#$L]HXQ<D5E<TK]0&)]VUY5J^#?<.K(7A/>9HY:@6@S1]O7E%W;@RU.6Q:U
MKRSJF-$)9QN\UB3-7\=L.WLE++NBO+EU>R<3^9L8>_>*HL*W;UPN/GG3UF2M
M?H_R:]56?[::IDW</5<(J)\K<??:W=BRUQOG"%V&*_M$C[7FB1?#E^)*2GXE
M7F8@<W.$>74&H[4+%U- >;F.YJOR)TF;Y&RUP 5H@<MV @^N(&V3G%N(^+=\
M,HW3R&\[^3\?\CA_=SJ*PW$OPUL\5^+SDMW(R\Q\?L/^Y04I@[=O<BX^_=6F
M/MO49ZMI+DS37!#A+C'UN7V1U;-)P0J%+FX.?NWVB5<Z$']E@5.Q7V2&N)QG
M/OXVA%:^LR9_W](\?-W(/'S]U*'J_%6/A'_>B?)/_/EV0&,[D/[)UFJ';3I4
M33\S@"O[FEYOJO)RA:*=__YZAS9WLF[_4G=)_"TNJ>M..Z$[O=3ITJ.[SE_B
M6KR'BUW)$=?QGA"1M?<0J]_[8_BEN(EH9U ^Q<881MGY4RJ7PC1M,NX"W)-O
MISF_%;'C1>R;;YO^2SL*;WE5=*6MO+*DL>NB2SGD<QNBUMY<C%1<[FWR:]($
M3%^+=B#F<P6'K]Z(%E5J%^G67XQ(O6/-#=1LA[:U<6$;%QYLS.2U;:Y4LXT(
MWWA$F+4#M(XR:^Q*'E[HW\[/:N/-UU^3<'9SMJ<::AZC'3Y_^JER=RDB=+$Q
MW&NW>HL+OK?<5'3!TY3HE=;\BIY+HMMI2FT,^3RYWO/,E[CTJ*NYGJ,GZ\;7
M$#4TFE\^G627PCTO';._=N?EXKNDWW S] LX+FW/<YL#>!F9O!3F>CYWH_4J
MME'F4GBA0>?A%76A4C5O53P363^.IMU!)W9HOK_I3G),.=X_Y,-)%_=L=,;Y
MH%NZ&447YZC8OW%5W]\)K^?W#X/18YZ7KS[,QKW/\-S.PZ [C*X+NBO8*SJZ
MB^V?=Z/8"CI9E#7J'Q&$>_CQX@E?NY-.=U(VF4XZ[_I#^-YH-H%G3;X_O6?T
M4**V/:0@[*J1)E+Q3;5A7MC76^1?+?2O"OFV^_B)-WWZLF_Z3FQFVV.TXC\K
M36T?/X_!D?@KO/=YTDG!SJ[<VW3XL]_&M]SY5KGSJ%;+7\#+>SI3MGJR;4@_
MG^;\_]M[TR;'C6-M]//QKT#,*\<=1:!;V$F.9$5P]=$Y6L8S([_7GVZ@P6(3
M$@C06+JG_>MO9A5 @LVEN11(@,P(>]0DL51EY5Y9^<A,^Q+3$=/MRW32CD<3
MTQ'3D:8CIJLMT^VMZ:@6;PM_?F()<V-ORK/"8_;$@F@^@T6\I#37OH:"NOZ6
M[[-5VY0&4%'[M<?[J!BPAIOPI&FN7M-8QM[]CDG/D)XA/4-ZYK@Z0U/5='G
M?75??%(U-0CU;^>,O&61:%67M[BN],3?6<AB-^#9"7<\\T,_26,W]9_V;K-Z
MB(PU3I1:JJGILH2I+FM>M3DBJW/%$F&IACS/C22")*+Q$J%W5+TE+6]"(D$B
MT7R1,%3#)DSMDV.-6^DYN?M\CK1@]JS=#!K1>:,9K0X:TO7%4-LU@Y&N+^-1
M2K2FNR^D)$E)5IH^<,P:]!YK!-^1CB0=V11>)1TICY:FH>IM4I*D)$E)DI(D
M);DUVG8ZU&#U[)G+!K45,BS@9DED%!_Q\@]^"JODB6_6SLP,W3AX489?6>SY
MF,?\3702DC*?MKSIB*SKE"G]: 8L^:*XHN^0!]+A^B&V+?+39-'F*.'U(?C-
MV(^9ET9Q@LV26#[-HE^2\B@ ^!3>[(@W/L(S1,I'[(HTC_TH+CHYPI3N%7Q_
M@HB^2;D#$^,49 L*KG1D4N!J)<D>_H!!X,7I<@JEUDJ)@@V X!WPW$5K)JZ"
ME&P>A4K*XID?BMY/,%,Q2SR4H\ ($Q8_^1[,*=SZ](?(C<=XYY(:;LJO#E@"
M]Q==GR)X)[PG*/6'BOFC8V7B^K$R<^,_6:H\%>#0>$_JSQC>OQSYO?(3##/F
M%"WZ8.*54V Z%@N2Q.S?&8R%$W >1T_^F(&Z"8'.&9(PG](JP<0"P-6@R,;B
M,7[HISZPP@L\T,-7PJ*'BNMY<9:WY(S@ ;$2^.Z#'\"U#%M6B97VLCA&$LZC
M& FKEB^/D(.!Z!MO!*E_=>^&D<%X C=)_(F?3]+UQW<P-L^=HSQB[RQ\UMIZ
M\TY0R;W239"H:V)XC-@<TH/TF.?SU84I8TLP*0_\QKAO*W!5L&DOY9@''L =
M^*V<25CW3G63V,6GY>YP0EM-63!6'EY>J<>2:IR",#^S5555%FAD;ZXC@Q?4
M4OECN6Z;1L\A<G.4I4D*C\7??:&*0*#![4>=. &M$GH^WS.#L:'J2A10>"CC
M<.%"+X_AQ_O=1C[_^X?OLN3NT77G'P9^X@51DL7LMTF_M OW29"A'R5IPG'8
M>[A1]]'EBC/Y MY++P!-_>-?_NN'XE%@#$,8?_*1Q?R.Q45<-\&'3VSRMW>C
M 8K./\Q_?1F\4_PQ?.%ZZ9W>M[IMPW1,K6W;K8'5ZXWTKM[J]ENZ,QSVV^]^
M?&4ZR^N^#^3&6Y97IN.PWET%U/[/49(H0!KE;53[0SR$2O=I>2M#=!60+<LL
M.H]28 -A.\9^D&$%Z4)<7/C[@;$0&-,+,A2Y21S-!$^[@9<%"U/,;X7?0Z!/
M@/29 WWX8Q;F K[QHS%8!Y8P[FR,L\*R@4D%_\._6PP ''20/FJ?>([VB7*Z
M)[;L$_NX-;N+W7E?3]V93BS<LAO6)ZQ]'+G:6^U8N2>8>D0V@=CN&+:[!$R:
MW*XETAFQ?@URI"4&B0^;Q8?4,^=4KOR\DO+#;$^1U"GW3)>6^[]*B/*.:G4,
M59=8D'CM1T%I)[BJG>"K%#!'U5JVVI8(/'7M G;K9ZW[4<CGB"F=><PF+(Z+
M_:U+NJZUD:C%'ILA3?749>FKMDUD@JY8+AQ==6Q;[1AT[IHBJ,--31BE+%'F
M[@LOW"&?[KP6Z.J].@J;*&PZ@$XMM6T[JMZ2A^UX[0)VZV'3IXT8C.72FKRB
MD)S%QPH@G.O"!A1"40A5)\?N6N2"8J@MA!U^G3-A=4096[$)592W#PL,8+%=
M];'8H\)J=_(!=]HHQU!;&B7.:\DEMV33KE.\*(M!0=:A]!L)@/K"UD6357CZ
M4K UR=(L9A1SE>V9K>J6I1J&M&*+NK %!5T4=!U-#D-7#4U7.YHTO,QK$0N*
MN;;%7#L/_U9NA:[3'S154W-4K2T/2O[:O4$*N"C@.H!.MJH9FFJ3@)TMW+J.
MCL?2V*625DN-: -D=-1VJPT&3A[DT9NM@&ZAXP\%;B22QV9#(.9KZYIJ:6=L
MSW4+,KE7%Z[=S3VV=N0HM^T8N7[\3^Q)U$T2EB:_,!>[@8Q_"S\Q;-0#]_?<
MQ%^V_-BCFT?/&AK#3MON.9V>K;=;/:?5LCJ:V1VVARVCIU?>S:,L7;HSE]M(
M:[1HQ^)RBO%V,.46,N7 %1L_B8Y/,T%8T;TE"A476](( BL/2&'^'-%6ZHD%
MO"E7.,_@XBP1;6N2S)NN/N;A19FY?_ V5O H/WU1TI<YXPUE&M+^2$#1\?$.
MF)<?+M=5T4D,&X$L.W_D?7&6'4FX5"0?2NI\/\5./4#D] #1Y30!L3J7[<*A
M-;J'"$V>)M^ R5,7D!.[+^C4?>8 5X1ZT53#A68M>H#L'_]=FF=_YJZ\-$SA
M"[18(5:]*5:M*+%*K$JL*IM5I2&.$JL2JU;%JIA=57AZE7S4ND1*C8^$WO-4
M:)0E;CA.OJV&L6ZC#&V+T"XR_&)/9'=+Z6,UY1F)VP3YK0VQ&JOXB..(XXCC
MZDRXVA"+..X6..[FZRY_B4+V4@!O38 I$N6]OK?#7*/C.O4%IVQ2Y;:N&ZK9
MH6-[9^#S*[,_I >N20]0?QC2!:0+2!>0+B!=0+J = '%!Y+3"'MF81J?7^A'
MLQDV+T#0;W?.XF,R6F_":E5VB/H*3.W5'YVFI+&$I#&)&(D8B1B)&(D8B1B)
M&(G8-8K8S>_U]J-X'L5NRI2'*!PG54@8"=+U)#4HN7G#<J%W$&2O13)!,D$R
M0;:"Y(+D@FP%;0K)H>SO]Y_OE33F?;I>BLY</JLD(KF>F-_03-4QY9WIO?9X
MGU)JE%*CE!J)&(D8B1B)&(G838@8.8FT*71X+.8^LM"K.A)KG"Q1OH_R?93O
M6[_/LE7'<4@D2"1(),A4D%R07)"IJ,7.D.DT/1KA,'#*Y!5^C+1HMA(0JFU+
MTP@,)FFG&-^&I'J+A1L/]&7JCJH9TO;!CZ=H(SB/$J,U/91-6I*T9)49:K.E
MFD9%K<E)2Y*6)"U)6K+Q6K**K7+2E*0I25/6@5=)4\JCI6V;JFEKEZ=H(SA/
M8NIR/\SMTKQV00FO08*L#KGTE!5M45LPX9D;/_JA&*2;I5'QA5#X_!N!$MKI
MW#M:QVS9A#K\ZG;"GFWLZ&GR39D\86D1ZO!>]-J.M35@WFO089V##K>/<"J(
M"8]A0L(<)-!A8M4K9E4"'296;0BK$N@PL6KM695 A^L7*#4^$"+085GLMD5H
M"72X;EM[]>'$VA&..(XXCCBN$82K#;&(XVZ!XVZ^YP"!#A.H6.D^1U<U>07A
M=5E*O(_.S5[.;I,::)@:H#/TI M(%Y N(%U NH!T >D""@_D)A%NI;L\00Y?
MV-)>?=-02AE+2!G?CHA9:D>7UQ6&A(N$BX2+[!>)&(D8V:_Z"=?-[^X2S##E
M,RF?2?V!]VH&9UFJUJ(&P203)!-D*T@N2"[(5M!&D"3*$LSP,50S+4/5-'F]
M$:X]WJ=D&B73*%]-(D8B1B)&(D8B=A,B1DXB;0H='HN=!6;XPOT6FV'.WJ!1
M7;B&\H4U,E[7)E>.H>JZ32)%(D4B1::*Y(KDJK9R1::J3CMC!+-\"'\1X-,C
M 3[)I*6EF:IF6)>G:",XCQ+#-3V'3EJ2M&2E8/2ZJFM[0["0EB0M25JR$;Q*
M6K)!"2O2E*0I25.2IFR\IFSIEJJ;%>%0D9;<GKK<#K-\MH$=!))<YO@VL'=Y
M9*]!DY5M0]R!2MS>1XNO<F)5<*@PQ4,8;@W_^M7L5Q3T"DKU,2LMHZ,VYL1E
MSO"D"?T4>D$V9F/EV4^G?JAX;C)5W' L_F#_SOPG-V!AFB@1XO PI1_-8*@O
M"Q^O]7VB/+B!&WI,2:;L@(SWF^+XPW=9<O?HNO,/B"S%@:4$1LTO_/0)&_\6
M?L*JIQC6M^<F?O(%E$\OB+P_?_S+?_VP=N_ 3[P@PAN7%P+I0U19G]CD;^]&
M T/3._\P__5E\$[QQ_"%ZZ5WNJ7IW:%EMWN#H=VSM5[;Z;8&NM75AOWN2!N\
M^_'5>NV2S:VB>:PR,*P*M,%>/MUM:P/^<0U,R;R_&NVP>8)+B#<E%\(9*H>3
M17[7A#;:/EE[=DN-ILS$A!*N_F(VCV+0>C[\_[4J5.'7)(U]+V5"3ZK\%C]\
M@J\Y/10W529(JB<DU6ZFV'?JNB-Y[AL (]R8%608K\X!U;\+\\[5+:A\T+=*
MEN#?_\XBI,0<*))3#Y_C!6Z2^!,?GY0H',9R&9_I]\I/97)M?R^\"+Z#M_OA
M/$,S!$8H!DODAJ_>"U^E_$'@R/I/\/TDCF9*])"P^(EKUWRF8S=U=PU2,?)7
MU739@&5AX,_XS]H CWE>&$EY3$X\,]_V5J)8"7SWP0]X33)2-YK(&?!G-D]?
M8Z-K'!N](V<FG#GX> L4=J4 7Z\I3XQ>%1WP*93)GV0/?S O5=*H+%NSD@K?
M+.#X'/3Z KZX0)%<"C,42G 7D\R;KC[F 57*'[#Z>4'ZBY*^S-FUK#]7&G-0
M_XA[R2F U)E$01 ](]6X44L^E!)1^Z6D=G'.OB%UZ1EK;@Y_AA^.8=C\<_DE
M813/W&"505=<HX.<TP.\7^%MZAK,,<\_@*L3N/.$?2C^6)O\9O=UZ2(Y&TO*
M]G<_<P^X\]=#'>"5^_43;]<N^WJ:/$W^^B=/X--5@T]?N&2X>G#J0UP1@D"_
M$$IF!4RX3LO]-U NS;,B3I-WRO@LY"56O5U6K6A[E%B56%4VJTH#5")6)5:M
MBE67>SCDH]8E4FI\)/2>IT*C+''#<;)WC41E;38;?)9PB] N,ORB!.)#)9KR
MC,1M@OS6AEB-57S$<<1QQ'%U)EQMB$4<=PL<=_,]^S947<DH*I851US#P9+J
MYBS_!(BN&ZK9D=9WH2YKB?=1XZ;+&6[2 PW3 X1/1+J = 'I M(%I M(%Y N
MH/A <AKA5O#9^M%LQF*^4S1WYRP^)J-U.Y ;A&I#S6;.:9Q)Q$C$2,1(Q$C$
M2,1(Q$C$KEK$;GZOMQ_%\RAV4Z8\1.&X$F V$J3K26I0<O.&Y4+OZ*ICMT@F
M2"9()LA6D%R07)"MH$TA.93E0-%IS/MT50X5?34QOZ&9JF/*.]-[[?$^I=0H
MI48I-1(Q$C$2,1(Q$K&;$#%R$FE3Z/!8S'UDH5=U)-8X6:)\'^7[*-^W?I]E
MJX[CD$B02)!(D*D@N2"Y(%-1BYTATVEZ-/(E2MU F;S"CY$6S1)\;F6G& D^
M]WM3=U3-D+8/3O"YE!@ED/%:\"II28D9:K.EFD9%K<E)2Y*6)"U)6K+Q6K**
MK7+2E*0I25/6@5=)4\JCI6V;JFEKEZ=H(SA/8NKR.P[$N_'ZTM^E>>V"$EZ#
M!%D=<NDI*]JBMF#",S=^]$,Q2#=+H^(+H?#Y-P(EM-.Y=[2.V;()=?C5[80]
MV]C1T^2;,GG"TB+4X;WHM1UK:\"\UZ##.@<=;A_A5! 3'L.$A#E(H,/$JE?,
MJ@0Z3*S:$%8ET&%BU=JS*H$.UR]0:GP@1*##LMAMB] 2Z'#=MO;JPXFU(QQQ
M''$<<5PC"%<;8A''W0+'W7S/ 0(=)E"QTGV.KFKR"L+KLI1X'YV;O9S=)C70
M,#5 9^A)%Y N(%U NH!T >D"T@44'LA-(MQ*=WF"'+ZPI;WZIJ&4,I:0,KX=
M$;/4CBZO*PP)%PD7"1?9+Q(Q$C&R7_43KIO?W2688<IG4CZ3^@/OU0S.LE2M
M10V"229()LA6D%R07)"MH(T@290EF.%CJ&9:AJII\GHC7'N\3\DT2J91OII$
MC$2,1(Q$C$3L)D2,G$3:%#H\%CL+S/"%^RTVPYR]0:.Z< WE"VMDO*Y-KAQ#
MU76;1(I$BD2*3!7)%<E5;>6*3%6==L8(9OD0_B+ IT<"?)))2TLS5<VP+D_1
M1G >)89K>@Z=M"1IR4K!Z'55U_:&8"$M25J2M&0C>)6T9(,25J0I25.2IB1-
MV7A-V=(M53<KPJ$B+;D]=;D=9OEL SL()+G,\6U@[_+(7H,F*]N&N .5N+V/
M%E_EQ*K@4&&*AS#<&O[UJ]FO*.@5E.IC5EI&1VW,B<N<X4D3^BGT@FS,QLJS
MGT[]4/'<9*JXX5C\P?Z=^4]NP,(T42+$X6%*/YK!4%\6/E[K^T1Y< ,W])B2
M3-D!&>^MXKAK[F5!T)U"$F1E\.$GICSC/VN3..9Y823E,4H:NV$R83%0FJ7/
MC(4*1X5+%(2$5:)8,4'F8[X\<WA*-%;F,4L0FFE\OWLU\K]_^"Y+[AY==_X!
M,;PXA-? 3[P@2C)XT!?0Z;T@\O[\\2__]</BPF*?XZ<P2>-LACRRO&=Q"_!V
MB#;A$YO\[=UH8&AZYQ_FO[X,WBG^&+YPO?1N9#I6O]?NM3J.9IN:UNW;MN/T
M!O!7K]<9]=[]^(HI=BF_;>QP!GGB'W?@*Y4(M7-1]F7_MGSN5R8(X?:$Z\^5
M@#N+0'7]A^$V<9(JT61=+?#+GEP_0 F^ S:\2^"74CFB\H"H!'\ ?^;?O2CI
MRQR>G^#SI C(9S9/7Z,E:QPMN2-' /DD^7@+7&:E@&-67- 6"W%3?*$E)U$
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MXM0 HBW]2TZ8536 *U$TAV&\M0U+\?E *0^6T$\7[:,>6,@F\%DTJP+JA^,
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MJS#ENFSG5'/)0+I@[%M %:.:2E\0["*+N5Y3@:H/J3+Q0TS\A8\)FEH!Z96
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MHB_J>H1Q2I8S/'3S?7U+O;SA_C%&<YB^? 0[GG;#\1#L*K?3B^WY?3;@!_9
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MY4V"?*TMOQ+D:Y7]O#S&)I,KZ^=51!Q;#RL4N:5+FI>M:U$7*E8)S;C*=4V
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M4OYQK;?-9][=_D6))DJ)8LJ29$I!LYV<L&O\92&0V*I??,3+/_@IB("W98;
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ML+2<^4)UQ=4J^K_P=1"X#U&\K$#Z&=0$ZJ+N8\R$,G\O[B]?N/CQ6R&^X#V
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M47::-,W5:YJ6VI8'%UO[M3]5T]SZZ=O"U_&B&?HTO*B.^SLQ$]5V#RQD$Y_
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M^;-!R>>73&/4Y/^':VZPF!W=[C@]N].U1QVMUS6[W;YCC?2^W>YT].*Q@?O
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MBGY_AS;:T=4>(9;R=HZ5K7@^&2O9&IRPBK#0B2OI\+BQ:_XK4/CTT)B&0E^
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MJ$9BL17I42RUFZ"J];_'+B:/2F\+8W/$7]%<#S\<$M=[O%!.D_%-OJ\F=AF
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M/@GB19=DQLLPF\3DYORMS7:K;!JK94'DWV"\R_H<9=N&>W6G9ZMU(#%/%F/
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MASKUECLCQ!F%1S=<180D[K]8CCRV5M?VE)\YVDO",9<F"VW@;R(MJTPQVM^
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M$2^$5-]89T%W](,EX9V$PEU"N/+^F_\#4$L#!!0    ( %: 94_^+W2X7AD
M ,$& 0 5    86QL;RTR,#$Y,#DS,%]C86PN>&ULY5U9<QLYDGZ?7Z'U/*.-
M^YB8G@D>4H<CW&V'CYW9IPJ<<NU0I*>*M*W]]9M5I&1)IL@2ZR#EZ8B61:H
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MTQ_KB#^X&E58HFR^\^UKEREC<# A(@GC(>X"0XSBM %%,TRI.GS>^;.>]Q[
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MI7/$RUWC>*9ISHS*\CZHMCF3KY;+<OIEM8P;#9^+S14W]>>]XWUEP?NCV-,
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MO29AU,><0,6,Y*;YU9'I;CL? @F3H#MT9KX+_TK)S"?]9YIQKD-X:D)D2C'
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MC]QH#E3S:2#\U_?1?!Q/TWW.YZ/Y\NWM75E\RP\>,SS<*C/&,(:4ER'FM]1
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M;L_9EW.;KB.3V?Q;/BONUF4YYY-80__(F8J]#3*.C4&,:BV\Y)8;C_U.8HQ
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MJVLW*F/M])WX[PZ4P^KZ%9F$R#MD8L8E-8$S6$/G"3/6*22 J+7CGP;%AZO
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M89VRO-)'.M1\5N\E/[?;HY2MH.FM%,%X',^<5W61'J%Q\$J/4YIG!%+B .:
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MB(6$$<N<<))2@)70862R&-,P17)<ZW!'ZG2U;G2NG[K6X?LRSS&W3EN.'*"
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MN;AN_L!7UQ^J8FTC5O/'RQNS6%DA7LR75NHV11W*UOSS>E/-KS8S@3 2@""
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MTQBOH9UZ>K]Z#,Z<,Y^KK\7U?7T:F7^;+Y;U<HXIJ_I\\F'[=OL\L+;YE90
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MY"AV0M$\UW'';$?'!=\?I G]8M.I>#3&%>01&3ZW8CR!=IU&X)D$$T_7H*>
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M.=H*V;]Z2ZD0"$B38<P,@\B0K#4*"77:+0UD*G8&6@-,BAW"=K[<;J&&T/X
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M5%8/\]5U?;]O?<WC?/D4 8,9T!I@A;'$C',LY1Z!R*73H;H8=B,'CA;M17+
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M.HTT-(0C3]^>"L6-\[[XXLMJ<;.XFJ\VSVT?'BDPV%"1:JX5D5*R#.9Z/Z!
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MAY78>)3'UMFF1::NMH_H#2"YW9KKQ]+=CCYV%-\^C(96X!DD,(4FEP1RIH
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M]><H9@P<++R9/Q<+XC7C1*0^HH-/E3PVET/-*TQ9W12+^NKP?5R9:2L8E.8
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M$@?C-)%W+!R]J?K$P]-1,%G9)GNP3;:+EV&B8A>RSD?&J/1/)CK&]?)YA!R
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M$J6MIQ]=XKCM$6,B\NX::5Y MK<HA#:<T9QD-*6YMNSK_1*'2IGV67[H8V>
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M*N7KB(-"=>+&H^3BMER=S^Y0CO.4HCP3QB"*!;#3WG8T8<*(CTRYV%-U^2)
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M@ETWG ?EUG?C>0ON(FG@/6;T!>$;>BOZ->K.;DD'XWT:N7Q(AYYM40?FROG
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MZQ'.PY0F4-Y]GH?7<O! +$XH'P_ET4NY>5"V^A8-B(?C_](,;Z9,KG-HM$5
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MD"]N;#6IM?5V6]WO3 'V18P15Q1PJ6"29!PFL?ZB-9-B 5R4R/G#1YJSKSM
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MQ7'*8X:P2@#!6A3:/@HA2%%;O_WS?KG;6\[I1\-..) 0P30G5&22)#05+$5
MY#S#)"5.UVB>NMFG[S>GAN]- [G2_]-@O8J^%M_6VZUKU?BYMPO+=8I?LC$X
MKGL,/W[8%A Z<3=JMBCVVN'VLEM5+T%WC:KQ^A<YHN@:S!#G%X,UJ'F,?3/D
MQ=?)Q\"1FWY,KB_Y56^W[2V_E .2*R9(ENITG:?:ETYZ4YE)/LH9?%?01,\O
M..4BA1G*L(P9%QQ)R66L@"!IZ(MWYT;A[FKK#$=<UZA//> &#/A<Q]O&9?-@
M["]U(\ QE).,MCU;TY]]L.U+RVAC[:"X33_4_K/.$X[P8<H13R3@/$<B5B+%
MM!-=Q0CN\6[Y:-A5SN-<0420!%FL-'"940!11A.8Q['=JO'@%\_/#;Q-0C;'
M<=>U"4P][H8(^\S'W<;E/]^X^SB4DXR[/5O3GWW<[4O+:./NH+A-/^ZJ<G=3
MK$\]  DE@N589D*QG,0R@WFGNQD@V:R&WN?P<PHI@10+D*M,4<X42A*1"L)S
MC-+<[B)$L-'WIL,[QP&X1UN8>@P.%/^9#\,'K_]\(_&S@$XR&/=O5G_V\7@
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M*]"I@.>47-RE'\#@/#1GF O/=K$'\V&K*!]WQ=UR7:\=;:M"ZUJ]O/0HC5N
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M#J6*I4P2A2EE>2:(Q*D&K4B6 !#3E(<^;7(J074+>,.>I:*1_&F^[EVI;/3
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MHOEQ5]PMU]>=AK?23;?7'\P!I?9014P2C26F$.44IFF&%3N<#9,LAZX;@T%
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MXO9X7Y8JE":$J"010J1"XSA<V,IT=NM6(]^;U<"[>AKHF[KCGQ13T5W?1W4
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MY,B?1#SR_Z) ]&-J+O+0$_TS<1C"@LL>R,?NG:]Z'45ED*HX03ACJ1 X207
M!SL26143[O_I8^V*M(_VNB^3]B3-?J<D'%\]MTQLJ?*Y>_*(A%>V4?H1-KU8
M#,3_PL;*$"9<!..X^*KT=ZI%HO6(*Y1!(J4BB%*%16=)X<3J08DAGS^6:)SN
M%=3(W&7#F3I[X0C)6D_IL"?,IW@\(>(5^>A+VWP$I+<'+TC(,#;<1:21K,86
MPC%@B&0<*1$3(K&*NQV<A @8]Y,1%PLC"TD[L@Z2$B<"7<4D%'?#Y,2*-O^"
M<D*&E:3T(6]NHM++A[.RTI\1^Y6.MUO=,>MG1 N=!2W;[>)%CCCAB=:P#*$8
MY)(JJ#IS '.KXL"#C8RS]G$"SB3LRZB%Y[H*TI=)V^60$4CLM2[BS)^_%9*7
M*;FX5#*0Q>D%QX\;SQ9/O/!B+SORMMA]6V^__6U7_K'_SLO;N^7V80&Y!+%"
M@L9)+&"N9,J[Y=P$4IFZJ4X_&^.(3H<M:L!%+3I7S>E)HZWDA&>PE^*XDN=/
M<%XDY*+>#*-P+G(ST(MG:N.#%7NQ^7R[W&S8?;7>%E6UT!9BF6*J<O-.,X!2
M\JRSDN?2,;5Q^^QQQ*7&%'6@7#7%D2U;+0E'5"\-L>3(GW0\\O^B9/1C:BY2
MT1/],XD8PH)#'O*S?I"E?L6KF6XM8,;U3"N!,N=)SF5.\>'R3)("[GCUK8>!
MD3*0G]$16;M&X)Q^]&#/.O<(2UR_Q,.%,X]9QS,J+J<<_9F;BX@,<>%YLC&4
M#X>#9LVTZ5-Q5^[,Z[>?]\O]?;60$ .,0:+_PR3.*0,9;\W!F$A'2>EI9*1C
M9^T]D0.ZJ('G?/JL)Y.V\C("B;TDQID_CT?27J3D\LFT82S.16Z&NO'\G)H/
M7APF.-^+S::;12$J,RQTII0RG$@,B,AI9X0(9O4 1L^/'FEZ8R#U73%QH\IZ
M<A.*I7YS&RN"/$YM3KR_/+/I0]-<1*(?^.?SFOX<V%8$>[M=E;?%E^5/<7CB
M\% _!$J",T"1R)4$,:<PQ4 ( 4F.%$N$;:W62R9HG.<$Q01D<9Q![9G6/(CT
MA(UB2B0*>*VC015I6-$1UV1O#U[@Z(5>XI/9>=1^\N))Z;_=#>Y,I\6D%%:9
MC..$Y2CA5*:8=[T)IMSJ))>=H82G4/LA)":9@AD14O_#4B[TOX@T])&N8\=R
MK7 WC+[>8A2&.2]J-%FUNDLTN0F2.[NS5:0>KKPN27WYL7[B>?6]N+[?%!]N
MY.W=IGPHBL_%[L=Z5=3W9=FR*JY-AE%LJ^:UU4U-O/[JPXTI4OIMN_[OXKI9
M"JF?^*M+Y"UBJA1*DXQSP=-<*H(!R* @4"0 Q;G5[FM8A I!)"03*#%O(N4Q
M2VDNLC@A69YP1F5@%>R<,E5$.[>BUJ_F'OJ;K\:SZ-2UJ^CHG/G#HWO=P:SF
MX?JFEN5Y29A30["3Y?FW 3<]GS3\85['#A&A"T/)M"UB'F/0Q!P\?:=[!A&Q
M'?7^5FR+W7)#M]?T^G:]K0O>F?-*\J?!5[2/Q@"5RUPHE2)":9:P)"&J%:\4
MIIG594TWBU1["7,L&)-YAG),."582$#S3"(>_)1T"[*N6KU\!--M+/%$K]W8
M,#ZS;EI_2NICA%$+<:(WJ*R(NR#!?HF?AZ1Z]JD,V53=),^/*+];;XNW^^*V
M6G"N!,H(4QS+G.4XBV'<]5X%I-,+5[ZQI0*D>2IRB27)-#"*64Z!@##+!4.0
MA$[NSR1P$=WM].\U[_E^?7B4Z+4OID?TC^7N^NKQGQGOHM^->U'MGV-F/WKD
M[71[SD%WS.8GBW>0<<%S8"Z,(%,U@7F,-9-Y7\ZC([J-7RV XOIE?.T0NN H
M94+0E*08YQ1QIA/)5IPR3JG5349'DP*0.,F)!)G(LIP);940;3]-\SC!<>B*
M;'5UNU955B?PW 8)7_3::?\$S+I)^@'@V=68+GD?5YOMB+L@N9Z9GX>2^G:J
M#-I:W73O_7)_ORL^W'RX*W:U.9V Y;$"T%26D"D@($U4FK9[78)!974LY\+'
M9PP!"1#((*3Z'T !E$!P %26,:Y"7VL21;7:K>^Z54ZWNP=#6+.3KL"$N<E4
M \;0=(0SX;;@<VXN*-$ (N>A.D,<*+TU*CLU66H)6]#5:G=?7'\JJD+__G>Z
MO1;FC>SRSLQ$6A7K;FNFL1+:"D1Y(B%""<0)!ZF 6"J<"[NK"]Z-!E:>%FJT
M:['62W;71[11T<"UU"+_G%]6J$GI=DRO6J8[F!$U):Y.F.Y61ITNT/LG_+HM
MHE#WR7D2_PBB]Z9^%:T:S-;/MADRZO.=,8%Q/3JXTO/"F!&,X6E'DG!NE8%;
MIONH\V@Q8:O1;$Q&S8IM<;/>5YU]P"C) (4LBP4G>1H+B3K[9KG1==CQ8W6D
M<>=T]EYWR%T#-_K:XG6704^LVP\\XQ/>;^1YO$Z[-4-1PW4'M?_0XXES][%G
M?.Z'#3Z;]?+K>E._M%HW]Z(["?.TW7L>A*QX>F44\LOU?(8ASWZ], Z%8,YE
M(/JX*_4L:_^@;9NGN^M1<)&*5%*:,T0(304A E ,LABD.&:""*O2NX.-C#3,
MW+78FC[7H7/7N7Y$V@\EP3GL-W)TL.I10XY-G_NH$)S&88. (YU.0O^2ZZ_H
M^B"VYB/CP]QX0;4]\&(ETO_8_BBJ;JF]>G?,$ X#0R:((HF0&+&80X)9?!@8
M2)XI:Z4>;"FP7'?XHJIYENPD6W(0F^%\6@CVJ%2ZJ?:!Q?9QMQ-P/3+\X6PZ
MZ/>HK/83\0MMU-O*T6LTG!-T;_3-0-7]^5*&:&!N.YH?]M^+W0O6B"0< *0D
M)E3E*A8)A(>U)P6ER[9F7QN!-;V&Y;:3V9LMN^W,,8AR4^P:T:E.7_4I SM\
M,_,,,Q=V-(=R.8]MS<%>E'Y;F/L,7^>HYXS*%(N89AD$2J9IPA'G!Z,9-5<Z
MROUR8S_/'V#*26H.J*R[T1?S)]&RG669J7Y9=ZQV5+9*)YTF6^>I>&7*Y8'#
M&0S1'IUY8?KEC2/KZP++W7:]_59]+'9U>G"\AQRK'+"$FB=R04XD30$E[3D:
M"J7B3@?_SUI1C.KY9"YTE@$RHK\&+"?:S5BDE$D>>O+UOMA'[\JJ,C<KFZF#
MXYG[_O39C=OC,.<V<G>8CJ1->!;I+$$7!O#AI,YC"/?@Q],SXIZ8L94?47S=
MO]U6^UT]*6VN@@H(89Y"R6$N,>,T3U*1()3'/,<,$Z>B GT^/[#DG-X)?U=N
MO[W1GW$;&:#1$6G/R_V]Z+03HM!,NDF0)Q*#*-(+3%W0HB&\SD.%!GE0^FME
M0Y3GW>%62R*9D*G*D)28L@P($-/6&E$*63WT/=1&8 5ZTDT&7#GL36(?S0G#
MGYON]*)N!)5Y9W$+;RB;<U2;'EY<5)R^K/13';5<%?2VO*]?S2$"2$"4*?0D
M1<JA IVYC,8#9,?!2.B#"=^^[8IORWT1W>W6V]7ZSBQ<U,B&J(X+B7UD)Q!_
M@W3G*C*H(GJ9O!%TYTB.M?#TX'..RM/'C8O2TYL76^WYN"M717%=*>T9+[<_
MBMU^K?,K@V*!L(29GMK%/($QHSQA*#U83 !<Z-_^6MH*T!!++GWH%)1U5^K
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M9&]70'H7A36[3F7-USR(,W4_QM.[R[@>_EF6EW].IM,]@*K3/3 3;4ZKK8$
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MRWB\3HO(H8=(@R]E<SM>&Q\7.(CL] @RPP$B@&I%<<59)EQ.LIVA>]<[A/(
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M11%TLK>4RV<,L58EU(^1L[EAG%V;<G&$B?.T6R!8<JV$9@)ZJ2@74&]];,X
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MTIGH \WRORN\_7LQN;Z)TU/Q]!I=%Q_N4EV=BZL5!8^"->O#\+0! ^*:$>J
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M:,:>U@&E7+.>4RR=\Y(KY86M2/$"Y=1D&6JJ[&:1D<?03K"Q!F]]=#QJ'[@
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M,>=<UJI+V@X';/%U^6#\J^]1'$E_\^4\54Q)Y2+V4'^X<U J:<%8QQ,042N
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M6CF(1,4/SM$Y*B - :3LDO$9?HUU=*PIIQ$MY7PMI-GE\\5VR-EQS"B!<N"
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MM-"[M50OKE[ :L=YW<X'!8^L, !(+2#7GC,J&%ES5$4[2_<6Y=OG#E$;9>6
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MK3T<^"XCXY!BVHB00EQKJ2!B3[.4+L?_GGI=_3![6 Z[>X?(T4GI]X>$NYC
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M,"YX;6Q02P$"% ,4    " !6@&5/7Z7I;=80  #EL0  $0
M@ $_#0$ 86QL;RTR,#$Y,#DS,"YX<V102P$"% ,4    " !6@&5/_B]TN%X9
M  #!!@$ %0              @ %$'@$ 86QL;RTR,#$Y,#DS,%]C86PN>&UL
M4$L! A0#%     @ 5H!E3W=N&O 100  'A(# !4              ( !U3<!
M &%L;&\M,C Q.3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( %: 94^,5.,;+[T
M -1:"0 5              "  1EY 0!A;&QO+3(P,3DP.3,P7VQA8BYX;6Q0
M2P$"% ,4    " !6@&5/:%U;)E9J  !V104 %0              @ %[-@(
K86QL;RTR,#$Y,#DS,%]P<F4N>&UL4$L%!@     &  8 B@$   2A @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812445008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">29,878,302<span></span>
</td>
<td class="nump">101,810,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">9,492,134<span></span>
</td>
<td class="nump">6,075,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61,655,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,856,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units subject to vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,773,155<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Expected shares purchased under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">162,709<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember', window );">Founder shares of common stock subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">15,144,224<span></span>
</td>
<td class="nump">21,201,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember', window );">Early exercised stock options subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">3,306,080<span></span>
</td>
<td class="nump">5,020,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812698656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Unit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, unvested, beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted (in shares) | shares</a></td>
<td class="nump">1,795,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units, vested (in shares) | shares</a></td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units, forfeited (in shares) | shares</a></td>
<td class="num">(22,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, unvested, ending balance (in shares) | shares</a></td>
<td class="nump">1,773,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Restricted stock units, vested and expected to vest (in shares) | shares</a></td>
<td class="nump">1,773,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, granted (in dollars per share) | $ / shares</a></td>
<td class="nump">27.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, vested (in dollars per share) | $ / shares</a></td>
<td class="nump">25.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">27.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">27.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 27.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6652830928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on</font><font style="font-family:inherit;font-size:10pt;"> November&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Initial Public Offering </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company completed an initial public offering (IPO) of its common stock. In connection with its IPO, the Company issued and sold </font><font style="font-family:inherit;font-size:10pt;">20,700,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock, which included </font><font style="font-family:inherit;font-size:10pt;">2,700,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock issued pursuant to the over-allotment option granted to the underwriters, at a price to the public of </font><font style="font-family:inherit;font-size:10pt;">$18.00</font><font style="font-family:inherit;font-size:10pt;"> per share. As a result of the IPO, the Company received approximately </font><font style="font-family:inherit;font-size:10pt;">$343.3 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds, after deducting underwriting discounts and commissions of </font><font style="font-family:inherit;font-size:10pt;">$26.1 million</font><font style="font-family:inherit;font-size:10pt;"> and offering expenses of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> payable by the Company. At the closing of the IPO, all </font><font style="font-family:inherit;font-size:10pt;">11,743,987</font><font style="font-family:inherit;font-size:10pt;"> shares of outstanding convertible preferred stock were automatically converted into </font><font style="font-family:inherit;font-size:10pt;">61,655,922</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and our outstanding convertible promissory notes in </font><font style="font-family:inherit;font-size:10pt;">$120.2 million</font><font style="font-family:inherit;font-size:10pt;"> principal amount were automatically converted into </font><font style="font-family:inherit;font-size:10pt;">7,856,176</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. Following the IPO, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares of convertible preferred stock or preferred stock outstanding.</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Need for Additional Capital</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities. The Company had cash and cash equivalents and investments of </font><font style="font-family:inherit;font-size:10pt;">$601.9 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. Since inception through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company has incurred cumulative net losses of </font><font style="font-family:inherit;font-size:10pt;">$335.1 million</font><font style="font-family:inherit;font-size:10pt;">. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed financial statements are filed with the Securities and Exchange Commission (SEC).</font></div><div style="line-height:120%;padding-top:24px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Forward Stock Split</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2018, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward split of shares of the Company&#8217;s common stock on a </font><font style="font-family:inherit;font-size:10pt;">1-for-5.25</font><font style="font-family:inherit;font-size:10pt;"> basis (the Forward Stock Split). In connection with the Forward Stock Split, the conversion ratio for the Company&#8217;s then-outstanding convertible preferred stock was proportionately adjusted such that the common stock issuable upon conversion of such preferred stock was increased in proportion to the Forward Stock Split. The par value of the common stock was not adjusted as a result of the Forward Stock Split. All references to common stock, options to purchase common stock, early exercised options, share data, per share data, convertible preferred stock (to the extent presented on an as-converted to common stock basis) and related information contained in these condensed financial statements have been retrospectively adjusted to reflect the effect of the Forward Stock Split for all periods presented.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801604736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 39,995<span></span>
</td>
<td class="nump">$ 10,870<span></span>
</td>
<td class="nump">$ 95,172<span></span>
</td>
<td class="nump">$ 133,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,016<span></span>
</td>
<td class="nump">11,317<span></span>
</td>
<td class="nump">42,261<span></span>
</td>
<td class="nump">26,440<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">55,011<span></span>
</td>
<td class="nump">22,187<span></span>
</td>
<td class="nump">137,433<span></span>
</td>
<td class="nump">159,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(55,011)<span></span>
</td>
<td class="num">(22,187)<span></span>
</td>
<td class="num">(137,433)<span></span>
</td>
<td class="num">(159,796)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ChangeInFairValueOfConvertibleNotePayable', window );">Change in fair value of convertible note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,415)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,358)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">4,309<span></span>
</td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">13,693<span></span>
</td>
<td class="nump">1,573<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(50,702)<span></span>
</td>
<td class="num">(43,497)<span></span>
</td>
<td class="num">(123,740)<span></span>
</td>
<td class="num">(180,996)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (expense) from income taxes</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(50,735)<span></span>
</td>
<td class="num">(43,497)<span></span>
</td>
<td class="num">(123,564)<span></span>
</td>
<td class="num">(180,996)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments, net of tax</a></td>
<td class="num">(295)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (51,030)<span></span>
</td>
<td class="num">$ (43,645)<span></span>
</td>
<td class="num">$ (122,004)<span></span>
</td>
<td class="num">$ (181,144)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (10.71)<span></span>
</td>
<td class="num">$ (1.24)<span></span>
</td>
<td class="num">$ (16.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">102,186,644<span></span>
</td>
<td class="nump">4,060,419<span></span>
</td>
<td class="nump">99,801,001<span></span>
</td>
<td class="nump">11,048,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ChangeInFairValueOfConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Convertible Note Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ChangeInFairValueOfConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6810916848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding', window );">Number of shares as percentage of common shares outstanding</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares) | shares</a></td>
<td class="nump">9,915,688<span></span>
</td>
<td class="nump">9,915,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Other long term liabilities, related to shares held by employees and directors that were subject to repurchase</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockOptionGrantedPeriod', window );">Stock option grant period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate', window );">Option exercise price as percentage of fair value of common stock on grate date</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares as percentage of common shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise price as percentage of fair value of common stock on grate date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockOptionGrantedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option granted period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockOptionGrantedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6812686144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets Components - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 9,380<span></span>
</td>
<td class="nump">$ 7,808<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedCompensationAndRelatedBenefitsCurrent', window );">Accrued compensation and related benefits</a></td>
<td class="nump">6,672<span></span>
</td>
<td class="nump">4,111<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedPropertyAndEquipment', window );">Accrued property and equipment</a></td>
<td class="nump">4,444<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_UnvestedSharesLiabilitiesCurrent', window );">Unvested shares liabilities</a></td>
<td class="nump">2,842<span></span>
</td>
<td class="nump">4,590<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,969<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Total accrued and other current liabilities</a></td>
<td class="nump">$ 25,307<span></span>
</td>
<td class="nump">$ 17,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedCompensationAndRelatedBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities and employee related benefits current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedCompensationAndRelatedBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Property And Equipment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_UnvestedSharesLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested shares liabilities, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_UnvestedSharesLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6810651056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 551,187<span></span>
</td>
<td class="nump">$ 713,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2,174<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">112,394<span></span>
</td>
<td class="nump">85,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">340,254<span></span>
</td>
<td class="nump">366,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">100,702<span></span>
</td>
<td class="nump">261,966<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CashEquivalentsAndShortTermInvestments', window );">Total cash equivalents and investments</a></td>
<td class="nump">553,350<span></span>
</td>
<td class="nump">714,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">112,394<span></span>
</td>
<td class="nump">61,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">112,394<span></span>
</td>
<td class="nump">61,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">190,467<span></span>
</td>
<td class="nump">244,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">191,657<span></span>
</td>
<td class="nump">244,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">202,893<span></span>
</td>
<td class="nump">341,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">203,633<span></span>
</td>
<td class="nump">342,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">45,433<span></span>
</td>
<td class="nump">61,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 45,666<span></span>
</td>
<td class="nump">$ 62,115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813112848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheets Components<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheets Components</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheets Components</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Prepaid expenses and Other Current Assets</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and Other Current Assets consist of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest on investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,337</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,108</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other prepaid and current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,938</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">758</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid insurance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,376</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,513</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,598</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and Equipment consist of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,233</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,566</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computers equipment and purchased software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,496</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,327</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,703</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,711</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,643</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,768</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,048</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cff0fc;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,943</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accrued Liabilities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued research and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,808</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,672</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested shares liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,842</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,969</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">612</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued and other current liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,307</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,121</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813114736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (2019 Notes)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable (2018 Notes)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Notes Payable (2018 Notes)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, the Company entered into a note purchase agreement pursuant to which it sold and issued an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$120.2 million</font><font style="font-family:inherit;font-size:10pt;"> in convertible promissory notes (convertible notes payable or 2018 Notes) and received net cash proceeds of </font><font style="font-family:inherit;font-size:10pt;">$116.8 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2018 Notes did not accrue interest. The 2018 Notes were settled in </font><font style="font-family:inherit;font-size:10pt;">7,856,176</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock in connection with the closing of the Company&#8217;s IPO (see Note 1) at a settlement price equal to </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the IPO price per share. &#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On issuance, the Company elected to account for the 2018 Notes at fair value with any changes in fair value being recognized through the statements of operations until the 2018 Notes settled. The fair value of the 2018 Notes was determined to be </font><font style="font-family:inherit;font-size:10pt;">$120.2 million</font><font style="font-family:inherit;font-size:10pt;"> on issuance and </font><font style="font-family:inherit;font-size:10pt;">$139.6 million</font><font style="font-family:inherit;font-size:10pt;"> as of September 30, 2018. For the three-months and nine-months ended September 30, 2018, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;"> in the accompanying condensed statements of operations as the change in fair value of the 2018 Notes. On issuance, total debt issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> were expensed and recognized as interest expense in the accompanying condensed statements of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6826211760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statement of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Subscription Receivable from Preferred Stockholders</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Notes Receivable from Common Stockholders</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th">
<div>Series A-1 Convertible Preferred Stock </div>
<div>Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Series A-1 Convertible Preferred Stock Convertible Preferred Shares </div>
<div>Convertible Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,249,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A convertible preferred stock, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,557,990<span></span>
</td>
<td class="nump">998,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A convertible preferred stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264,365<span></span>
</td>
<td class="nump">$ 34,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of Series A-1 convertible preferred stock in connection with asset acquisition, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,187,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of Series A-1 convertible preferred stock in connection with asset acquisition, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockIssuedDuringPeriodValueCommonStockIssues', window );">Proceeds received from common stockholders for issuance of founders' stock at inception</a></td>
<td class="nump">5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,020,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">4<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,695<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(148)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Adjustment for fractional shares from forward stock split</a></td>
<td class="num">(1)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,743,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="num">(168,443)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,693<span></span>
</td>
<td class="num">(181,019)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,270,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(180,996)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,743,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,714,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2018</a></td>
<td class="num">(129,440)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(150,000)<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,054<span></span>
</td>
<td class="num">(137,522)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_SubscriptionsReceivableFromPreferredStockholders', window );">Subscriptions receivable from preferred stockholders</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,555,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(148)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,743,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="num">(168,443)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,693<span></span>
</td>
<td class="num">(181,019)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,270,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,497)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">121,482,671<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 703,164<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">914,265<span></span>
</td>
<td class="num">(211,528)<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">304,576<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">3,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">32,189<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">1,783<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 619,716<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">952,820<span></span>
</td>
<td class="num">(335,092)<span></span>
</td>
<td class="nump">1,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">121,895,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,895,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (123,564)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(123,564)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, beginning balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, beginning balance at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,631,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2019</a></td>
<td class="nump">655,635<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">937,709<span></span>
</td>
<td class="num">(284,357)<span></span>
</td>
<td class="nump">2,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">710<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,835<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(295)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, ending balance at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 619,716<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 952,820<span></span>
</td>
<td class="num">(335,092)<span></span>
</td>
<td class="nump">$ 1,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">121,895,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,895,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (50,735)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (50,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockIssuedDuringPeriodValueCommonStockIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockIssuedDuringPeriodValueCommonStockIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_SubscriptionsReceivableFromPreferredStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscriptions Receivable From Preferred Stockholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_SubscriptionsReceivableFromPreferredStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6821907616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Nov. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,902,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6632377728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the condensed statements of operations and comprehensive loss for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the condensed statements of stockholders&#8217; equity (deficit) as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the condensed statements of cash flows for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 8, 2019.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no significant changes to the accounting policies during the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued&#160;Accounting Standards Update No.&#160;2018-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement &#8211; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</font><font style="font-family:inherit;font-size:10pt;">, which provided amended guidance to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Additionally, under the new guidance, an entity will be required to provide certain disclosures regarding stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company adopted this guidance on January 1, 2019. Adoption of the new guidance had no significant impact on the Company&#8217;s condensed financial statements.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles &#8211; Goodwill and other &#8211; Internal-Use Software (Subtopic 350-40)</font><font style="font-family:inherit;font-size:10pt;">, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is evaluating the impact of adopting this amendment to its financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6822018464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets Components - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 49,711<span></span>
</td>
<td class="nump">$ 9,643<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(3,768)<span></span>
</td>
<td class="num">(1,048)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">45,943<span></span>
</td>
<td class="nump">8,595<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">25,233<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">11,566<span></span>
</td>
<td class="nump">5,534<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember', window );">Computers equipment and purchased software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">3,496<span></span>
</td>
<td class="nump">1,327<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">2,638<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 6,778<span></span>
</td>
<td class="nump">$ 2,703<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6824819248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities (Detail) - Fair value, measurements, recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 553,350,000<span></span>
</td>
<td class="nump">$ 714,132,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">112,394,000<span></span>
</td>
<td class="nump">61,023,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,917,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">191,657,000<span></span>
</td>
<td class="nump">244,076,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">203,633,000<span></span>
</td>
<td class="nump">342,001,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">45,666,000<span></span>
</td>
<td class="nump">62,115,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">316,027,000<span></span>
</td>
<td class="nump">403,024,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">112,394,000<span></span>
</td>
<td class="nump">61,023,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">203,633,000<span></span>
</td>
<td class="nump">342,001,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">237,323,000<span></span>
</td>
<td class="nump">311,108,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,917,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">191,657,000<span></span>
</td>
<td class="nump">244,076,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">45,666,000<span></span>
</td>
<td class="nump">62,115,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6823700112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Undiscounted Future Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2019 (remaining 3 months)</a></td>
<td class="nump">$ 1,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">5,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">7,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">7,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">8,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2024 and thereafter</a></td>
<td class="nump">63,516<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">94,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OperatingLeasesUndiscountedLeasePayments', window );">Less: Undiscounted lease payments related to Newark lease</a></td>
<td class="num">(36,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(17,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Less: Tenant improvement allowance</a></td>
<td class="num">(2,849)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 38,017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OperatingLeasesUndiscountedLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases undiscounted lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OperatingLeasesUndiscountedLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6638448272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsTextBlock', window );">License Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License Agreements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Asset Contribution Agreement with Pfizer</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;">, depending on the target, with aggregate potential regulatory and development milestones of up to </font><font style="font-family:inherit;font-size:10pt;">$840.0 million</font><font style="font-family:inherit;font-size:10pt;">, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are </font><font style="font-family:inherit;font-size:10pt;">$325.0 million</font><font style="font-family:inherit;font-size:10pt;"> per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and 2018 respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) </font><font style="font-family:inherit;font-size:10pt;">12 years</font><font style="font-family:inherit;font-size:10pt;"> from the first sale of such product in such country.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research Collaboration and License Agreement with Cellectis</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of our intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Cellectis Agreement provides for development and sales milestone payments by the Company of up to </font><font style="font-family:inherit;font-size:10pt;">$185.0 million</font><font style="font-family:inherit;font-size:10pt;"> per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to </font><font style="font-family:inherit;font-size:10pt;">$2.8 billion</font><font style="font-family:inherit;font-size:10pt;">. The Company is obligated to pay Cellectis </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the dosing of the first patient in its Phase </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;"> clinical trial of ALLO-715. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#8217; prior written notice in the event of the other party&#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.</font></div><div style="line-height:120%;padding-top:16px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">All costs the Company incurred in connection with this agreement were recognized as research and development expenses. </font><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">For the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, $</font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;">.0 million of costs were incurred related to the achievement of a clinical development milestone under this agreement. For the three and nine months ended September 30, 2018, </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of costs were incurred associated with research services performed by Cellectis under this agreement. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.0</font><font style="font-family:inherit;font-size:10pt;"> million related to a clinical development milestone payable was recorded in the accrued and other current liabilities in the accompanying condensed balance sheet.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License and Collaboration Agreement with Servier</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19 in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For product candidates that the Company is co-developing with Servier, including UCART19 and ALLO-501, the Company is responsible for </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;"> of the specified development costs and Servier is responsible for the remaining </font><font style="font-family:inherit;font-size:10pt;">40%</font><font style="font-family:inherit;font-size:10pt;"> of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#8217;s sole expense.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to </font><font style="font-family:inherit;font-size:10pt;">$137.5 million</font><font style="font-family:inherit;font-size:10pt;"> upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to </font><font style="font-family:inherit;font-size:10pt;">$78.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are </font><font style="font-family:inherit;font-size:10pt;">$42 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">&#8364;70.5 million</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">$77.1 million</font><font style="font-family:inherit;font-size:10pt;">), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#8217;s election not to pursue such rights.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and </font><font style="font-family:inherit;font-size:10pt;">$4.5 million</font><font style="font-family:inherit;font-size:10pt;"> of costs incurred under the cost-sharing terms of the Servier Agreement as research and development expenses. For the three and nine months ended September 30, 2018, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;"> of costs as research and development expenses. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, amounts due to Servier of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> were recorded in accrued and other current liabilities in the accompanying condensed balance sheet.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813112848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, Pfizer held </font><font style="font-family:inherit;font-size:10pt;">22,032,040</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock and had appointed one member to the Company&#8217;s board of directors.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, the Company and Pfizer entered into a transition services agreement (the Pfizer TSA) for Pfizer to provide professional services to the Company related to research and development, project management, and other administrative functions. For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the costs incurred under the Pfizer TSA were&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> and $</font><font style="font-family:inherit;font-size:10pt;">4.9</font><font style="font-family:inherit;font-size:10pt;"> million, respectively. For the three and nine months ended September 30, 2018, the costs incurred under the Pfizer TSA were $</font><font style="font-family:inherit;font-size:10pt;">3.8</font><font style="font-family:inherit;font-size:10pt;"> million and $</font><font style="font-family:inherit;font-size:10pt;">7.4</font><font style="font-family:inherit;font-size:10pt;"> million, respectively.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also purchased certain lab supplies from Pfizer in connection with its research and development activities. For the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the total lab supplies and services purchased from Pfizer were </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and $</font><font style="font-family:inherit;font-size:10pt;">1.1</font><font style="font-family:inherit;font-size:10pt;"> million, respectively. For the three and nine months ended September 30, 2018, the total lab supplies and services purchased from Pfizer were $</font><font style="font-family:inherit;font-size:10pt;">2.8</font><font style="font-family:inherit;font-size:10pt;"> million and $</font><font style="font-family:inherit;font-size:10pt;">6.1</font><font style="font-family:inherit;font-size:10pt;"> million, respectively. </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2018, the Company had an amount payable to Pfizer of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> and $</font><font style="font-family:inherit;font-size:10pt;">5.7</font><font style="font-family:inherit;font-size:10pt;"> million, respectively, which was recorded in the accrued and other current liabilities on the accompanying condensed balance sheets.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2019, the Company and Pfizer terminated the Pfizer TSA.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sublease Agreement</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2019, the Company subleased </font><font style="font-family:inherit;font-size:10pt;">2,180</font><font style="font-family:inherit;font-size:10pt;"> square feet of its office space in New York, New York, to ByHeart, Inc., formerly known as Second Science, Inc. (ByHeart).&#160;ByHeart is a development-stage infant formula company.&#160;Two of the Company&#8217;s board members have beneficial ownership in ByHeart and </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> serves on the board of directors of ByHeart. In September 2019, the Company entered into an amendment to the sublease agreement and increased the subleased space to </font><font style="font-family:inherit;font-size:10pt;">2,907</font><font style="font-family:inherit;font-size:10pt;"> square feet. Sublease income for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and $</font><font style="font-family:inherit;font-size:10pt;">0.2</font><font style="font-family:inherit;font-size:10pt;"> million, respectively, and was recognized as other income. Sublease income for the three and nine months ended September 30, 2018 was </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consulting Agreements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and $</font><font style="font-family:inherit;font-size:10pt;">0.5</font><font style="font-family:inherit;font-size:10pt;"> million for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$0.3</font><font style="font-family:inherit;font-size:10pt;"> million and $</font><font style="font-family:inherit;font-size:10pt;">0.7</font><font style="font-family:inherit;font-size:10pt;"> million for the three and nine months ended September 30, 2018.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the Company entered into a consulting agreement with Bellco Capital LLC (Bellco). The Company&#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is the Chairman and an owner of Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company pays Bellco </font><font style="font-family:inherit;font-size:10pt;">$33,333.33</font><font style="font-family:inherit;font-size:10pt;"> per month in arrears commencing January 2019 and, in the Company&#8217;s discretion, may pay Bellco an annual performance award in an amount up to </font><font style="font-family:inherit;font-size:10pt;">60%</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The cost incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and $</font><font style="font-family:inherit;font-size:10pt;">0.4</font><font style="font-family:inherit;font-size:10pt;"> million for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;"> million and </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;"> million for the three and nine months ended September 30, 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6822823840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_FairValueAssetsTransfersBetweenLevelsAmount', window );">Transfers between fair value measurement levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">553,350,000<span></span>
</td>
<td class="nump">$ 714,132,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value, measurements, recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_FairValueAssetsTransfersBetweenLevelsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assets Transfers Between Levels Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_FairValueAssetsTransfersBetweenLevelsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6607884832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the condensed statements of operations and comprehensive loss for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the condensed statements of stockholders&#8217; equity (deficit) as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the condensed statements of cash flows for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and the financial data and other financial information disclosed in the notes to the condensed financial statements are unaudited. The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for the year ending </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, or for any other future annual or interim period. These condensed financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 8, 2019.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of common stock, the fair value of stock options, the fair value of convertible notes payable, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no significant changes to the accounting policies during the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, the FASB issued&#160;Accounting Standards Update No.&#160;2018-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Statement &#8211; Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income</font><font style="font-family:inherit;font-size:10pt;">, which provided amended guidance to allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Additionally, under the new guidance, an entity will be required to provide certain disclosures regarding stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company adopted this guidance on January 1, 2019</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements Not Yet Adopted</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued Accounting Standards Update No. 2018-15,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles &#8211; Goodwill and other &#8211; Internal-Use Software (Subtopic 350-40)</font><font style="font-family:inherit;font-size:10pt;">, which amended its guidance for costs of implementing a cloud computing service arrangement and aligns the requirements for capitalizing implementation costs incurred in a&#160;hosting arrangement&#160;that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. This new standard also requires customers to expense the capitalized implementation costs of a&#160;hosting arrangement&#160;that is a service contract over the term of the&#160;hosting arrangement.&#160;The guidance is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is evaluating the impact of adopting this amendment to its financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ChangesInSignificantAccountingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RecentAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently adopted accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6592157184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Undiscounted Future Lease Payments Under Lease Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The undiscounted future lease payments under the lease agreements as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ending December&#160;31:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 (remaining 3 months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,981</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,961</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024 and thereafter </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,516</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total undiscounted lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Undiscounted lease payments related to Newark lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,231</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Present value adjustment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Tenant improvement allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6824572576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Director </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>Director </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>Director </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="nump">121,895,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,895,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,895,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="nump">22,032,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,032,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,032,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumberOfMembersAppointedToBoardOfDirectors', window );">Number of members appointed to board of directors | Director</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Accrued and Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable to related party, current</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Transition Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Transition Services Agreement | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Related party transaction, expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartIncMember', window );">ByHeart | Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfOffice', window );">Area of office space | ft&#178;</a></td>
<td class="nump">2,907<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember', window );">Two River | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears', window );">Related party transaction monthly payment in arrears</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,333.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RelatedPartyTransactionCompensationPercentage', window );">Related party transaction compensation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfOffice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of office.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfOffice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfMembersAppointedToBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of members appointed to board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfMembersAppointedToBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RelatedPartyTransactionCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction compensation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RelatedPartyTransactionCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction monthly payments in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RelatedPartyTransactionMonthlyPaymentsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=allo_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=allo_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_TransitionServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_TransitionServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ByHeartIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6822053552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance (in shares) | shares</a></td>
<td class="nump">7,235,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, options granted (in shares) | shares</a></td>
<td class="nump">2,781,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, options exercised (in shares) | shares</a></td>
<td class="num">(304,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, options forfeited (in shares) | shares</a></td>
<td class="num">(220,151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance (in shares) | shares</a></td>
<td class="nump">9,492,134<span></span>
</td>
<td class="nump">7,235,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable (in shares) | shares</a></td>
<td class="nump">4,553,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, vested and expected to vest (in shares) | shares</a></td>
<td class="nump">9,492,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">27.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">9.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">13.65<span></span>
</td>
<td class="nump">$ 7.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">10.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested and expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 13.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contract term, outstanding</a></td>
<td class="text">9 years 26 days<span></span>
</td>
<td class="text">9 years 7 months 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, options granted</a></td>
<td class="text">9 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm', window );">Weighted-average remaining contract term, options exercised</a></td>
<td class="text">7 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, options forfeited</a></td>
<td class="text">8 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, exercisable</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, vested and expected to vest</a></td>
<td class="text">9 years 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently forfeited or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently granted or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6821775200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (123,564)<span></span>
</td>
<td class="num">$ (180,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in process-research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">32,189<span></span>
</td>
<td class="nump">12,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of other intangible assets acquired</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,720<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization/accretion on investment securities</a></td>
<td class="num">(3,136)<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Non-cash rent expense</a></td>
<td class="nump">4,827<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ChangeInFairValueOfConvertibleNotePayable', window );">Change in fair value of convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Debt issuance costs on convertible notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(176)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">86<span></span>
</td>
<td class="num">(3,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(2,863)<span></span>
</td>
<td class="num">(1,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,137)<span></span>
</td>
<td class="nump">3,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">7,510<span></span>
</td>
<td class="nump">12,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(1,991)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) operating activities</a></td>
<td class="num">(87,083)<span></span>
</td>
<td class="num">(23,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(36,679)<span></span>
</td>
<td class="num">(1,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAssetsInvestingActivities', window );">Cash paid for acquisition of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,098)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from maturities of investments</a></td>
<td class="nump">355,765<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(162,931)<span></span>
</td>
<td class="num">(315,399)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">156,155<span></span>
</td>
<td class="num">(319,410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">299,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">116,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions', window );">Proceeds from early exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock and upon exercise of stock options</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">1,783<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,486<span></span>
</td>
<td class="nump">426,660<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">71,558<span></span>
</td>
<td class="nump">84,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8212; beginning of period</a></td>
<td class="nump">93,731<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8212; end of period</a></td>
<td class="nump">165,289<span></span>
</td>
<td class="nump">84,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchase in accounts payable and accrued liabilities</a></td>
<td class="nump">6,571<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ConvertiblePreferredStockIssuedInAssetAcquisition', window );">Series A-1 convertible preferred stock issued in asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">111,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred offering costs included in accounts payable and accrued and other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">2,182<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances', window );">Cash received for amounts related to tenant improvement allowances</a></td>
<td class="nump">$ 2,934<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Received For Amounts Related To Tenant Improvement Allowances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CashReceivedForAmountsRelatedToTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ChangeInFairValueOfConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Convertible Note Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ChangeInFairValueOfConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ConvertiblePreferredStockIssuedInAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock Issued In Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ConvertiblePreferredStockIssuedInAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Shares Under Incentive And Share-Based Compensation Plans, Early Exercise Of Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansEarlyExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy; for costs that are essential to originating the lease and would not otherwise have been incurred without the lease agreement, including but not limited to, evaluating the lessee's credit condition, guarantees, and collateral and costs incurred in negotiating, processing, and executing the lease agreement; and for any commission(s) incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6822179072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">121,895,479<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">121,895,479<span></span>
</td>
<td class="nump">121,482,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6630842288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and as of December 31, 2018 are presented in the following tables:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">September&#160;30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Gains</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Losses</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,633</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,433</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551,187</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,174</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Classified as:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,254</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,702</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Gains</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Losses</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341,696</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">713,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Classified as:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,952</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">,&#160;the remaining contractual maturities of available-for-sale securities were less than </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;">. There have been no significant realized losses on available-for-sale securities for the period presented. Based on the Company&#8217;s review of its available-for-sale securities, the Company believes it had&#160;no&#160;other-than-temporary impairments on these securities as of&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, because the Company does not intend to sell these securities&#160;nor does the Company believe that it will be required to sell these securities before the recovery of their amortized cost basis. Gross realized gains and gross realized losses were immaterial for the three and nine months ended&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6635300720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the Company adopted the 2018 Equity Incentive Plan (2018 Plan). The 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#8217;s board of directors and consultants of the Company under terms and provisions established by the Company&#8217;s board of directors. In October 2018, the Board of Directors approved an amendment and restatement of the 2018 Plan, increasing the shares of common stock issuable under the 2018 Plan as well as allowing for an automatic annual increase to the shares issuance under the 2018 Plan to the amount equal to </font><font style="font-family:inherit;font-size:10pt;">5%</font><font style="font-family:inherit;font-size:10pt;"> of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;">. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the fair market value of the Company&#8217;s common stock on the grant date. Options granted typically vest over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a four-year period but may be granted with different vesting terms.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">9,915,688</font><font style="font-family:inherit;font-size:10pt;"> shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Activity</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes option activity under the 2018 Plan:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,235,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.62</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,781,316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.55</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(304,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.72</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(220,151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.91</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,492,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,553,432</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.00</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,492,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit Activity</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes restricted stock unit activity under the 2018 Plan:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value at Date</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of Grant per</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,795,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27.55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended September 30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,212</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,253</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,639</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,695</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Early Exercised Options</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company allows certain of its employees and its directors to exercise options granted under the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Company&#8217;s board of directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the noncurrent portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> recorded in accrued and other liabilities and </font><font style="font-family:inherit;font-size:10pt;">$4.6 million</font><font style="font-family:inherit;font-size:10pt;"> recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed financial statements since the exercise date.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6709049776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,492,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,075,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,655,922</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,856,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units subject to vesting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected shares purchased under Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Founder shares of common stock subject to future vesting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,144,224</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,201,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Early exercised stock options subject to future vesting</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,306,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,020,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,878,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,810,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6825593952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 39,995,000<span></span>
</td>
<td class="nump">$ 10,870,000<span></span>
</td>
<td class="nump">$ 95,172,000<span></span>
</td>
<td class="nump">$ 133,356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">25,307,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,307,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">$ 17,121,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RoyaltyObligationPeriodFromDateOfFirstSale', window );">Royalty obligation period from date of first sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones', window );">Aggregate potential regulatory and development milestones</a></td>
<td class="nump">840,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget', window );">Maximum payments required per product against selected target</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PercentageOfDevelopmentCostPayableByTheCompany', window );">Percentage of development costs payable by the Company</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner', window );">Percentage of development cost payable by collaboration partner</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Regulatory Milestone | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestoneReceivable', window );">Aggregate potential milestone receivable</a></td>
<td class="nump">$ 42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Regulatory Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">137,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Sales Milestone | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestoneReceivable', window );">Aggregate potential milestone receivable</a></td>
<td class="nump">77,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70.5<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Sales Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">78,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember', window );">Development and Sales | Cellectis | Maximum | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestoneTypeAxis=allo_Phase1ClinicalTrialFirstPatientDoseMember', window );">Phase 1 Clinical Trial First Patient Dose | Cellectis | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsLineItems', window );"><strong>License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential regulatory and development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialRegulatoryAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum payments required per product against selected target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Development Cost Payable By Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PercentageOfDevelopmentCostPayableByCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PercentageOfDevelopmentCostPayableByTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Development Cost Payable By The Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PercentageOfDevelopmentCostPayableByTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RoyaltyObligationPeriodFromDateOfFirstSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation Period From Date Of First Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RoyaltyObligationPeriodFromDateOfFirstSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestoneTypeAxis=allo_Phase1ClinicalTrialFirstPatientDoseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestoneTypeAxis=allo_Phase1ClinicalTrialFirstPatientDoseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6644441776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Maximum remaining contractual maturities of available-for-sale securities</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>47
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %: 94\?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ 5H!E3R?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M]8??5=@'ZW;N'QM?!'4-O^Y"?P%02P,$%     @ 5H!E3YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M0 ;H<T\ (A:XP P5F 'ZTA. "!+C"G-480[YQ"MB!\D<I.D@E"QC2N*)T[)
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MGP*#]K[:W0YJ_SR,7]/PO;N\-[P<#.WI^DXTN;V87?\+4$L#!!0    ( %:
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MI0++L' E Y;R&AT[!)^%:B:RS?J[I.\(V@[W)!@OZ^(?4$L#!!0    ( %:
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M&3$4Q(9,Z@>^KI7QM1YHL;>XV ^,N<H_"(5?M!RGE=&X=G <2'_*(_GGP!1
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ML)$,&LF $6\FY9FHA SY0R1%26BFJ @3( )>8A\!D:AGP8J]@2R 3%%@A%0
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MH8["5*44+(S0R&,2$D@C$Q^%)"$GIB%(-;.,TL R90Q"!HFD\:K*^1;B+FZ
MQ+TRI#KD!J.0 0J-CT*6B!-NI$2Y?2VP1S"&((,TTOB;!'^>1@+)(N7 6N#
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M[X-MQS4;'8_=](+8_(R+WU!+ P04    " !6@&5/\>15T[,!  #2 P  &
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;'U386_<( S]*X@?4'*YK.M.2:1>
MIVF3-NG4:>UG+G$25, ID$OW[P<D3;,MVQ? QN_YV9A\1/-D.P!'7I34MJ"=
M<_V!,5MUH+B]PAZTOVG0*.Z\:5IF>P.\CB E69HDUTQQH6F91]_)E#D.3@H-
M)T/LH!0W/X\@<2SHCKXZ[D7;N>!@9=[S%KZ#^]&?C+?8PE(+!=H*U,1 4]#;
MW>&8A?@8\"!@M*LS"96<$9^"\:4N:!($@83*!0;NMPO<@92!R,MXGCGIDC(
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MEV [S?+WC)TT1+L1+_',Y)PS%X^SP;IGWP($\J*5\3EM0^B.C/FR!2W\G>W
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M^+*Q_[4Q'E!*<H4CU.('6PP%M0_'CWBVTYA-AC?]_(/8\HV+7U!+ P04
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MK1UX*=F-'Z'>?[#%$-"Z</S@SV8>L]EP>D@_B"S?N/H-4$L#!!0    ( %:
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M<+;3F$V&QW[^06SYQN5/4$L#!!0    ( %: 94_+<(TSM0$  -(#   9
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M\];;9ERST7'832^(S<\X_P!02P,$%     @ 5H!E3_QAUKFS 0  T@,  !D
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M]RQ<<;JG?C95",91Q']>O/71<TFS)"?G0#3G'*8<NLI)EPSBV9<2=*O$@7Z
MTVWX;E/A+L)WZ^I?[K8)LDV"+!)D[UI,KUK<RKE6258SE6#:N$T657I0<9-7
MT65A[VF\D__IT[;_8*;ERJ*3=OYFX_P;K1UX*<F-7Z'./[#%$="X8-YYVTQK
M-CE.]_,+(LLS+O\!4$L#!!0    ( %: 94]I-U:MSP$  )P$   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;&U4;6_;(!#^*X@?4!+BN%ED6VHZ39VT
M25&GM9^)?7Y1P;B X^[?#[#C>AY? G=^7NX(1S)(]:9K (,^!&]UBFMCNB,A
M.J]!,'TG.VCMEU(JP8P-545TIX 5GB0XH9M-3 1K6IPE/G=662)[PYL6S@KI
M7@BF_IR RR'%6WQ+/#=5;5R"9$G'*O@%YG=W5C8BLTK1"&AU(UNDH$SQP_9X
MBAW> UX:&/1BCUPG%RG?7/"]2/'&%00<<N,4F%VN\ B<.R%;QONDB6=+1USN
M;^K??.^VEPO3\"CY:U.8.L4'C HH6<_-LQR>8.IGC]'4_ ^X K=P5XGUR"77
M_A?EO3923"JV%,$^QK5I_3I,^C=:F$ G ET1R&CD*__*#,L2)0>DQK/OF/N+
MMT=JSR9W27\4_ILM7MOL-:/1+B%7)S1A3B.&+C#;&4&L^FQ!0Q8G^A^=ANF[
M8(4[3]\MW0^'L$ 4%(B\0/1/B]&JQ1!F'S;9!TWV 8%X91+"W(=-XJ!)'! X
MK$Q"F"\K$[*X'0)4Y>="HUSVK9_)178>O0?J;]<G?)S;GTQ53:O111I[1_U-
M*J4T8$O9W-F&:_M4S &'TKCMO=VK<6#&P,AN>@O(_"!E?P%02P,$%     @
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MVA@/*"6YPQ%J\8,MAH+:A^,'/-MIS";#FW[^06SYQL5?4$L#!!0    ( %:
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M!5*O0&H%TBN!V4T5!LS,8EJ+B?PA,F^(S!,B]PO,O *SQTWF7H'<D\'\QN2
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M@" 'I!P0Y("4 X(<D') D -2#@ARP,H!0PY8.6"\QY4#AAQPM?TA!ZP<,.2
ME0.&'+!RP) #5@X8<L#* 4,.6#E@R($H!P(YD.K+$N1 E .!'(AR(+@&5$4
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M!!.>_A100JR B)CORGEV;@*V;E;DU@9R##.$YSZ!XL!&VHK<ASX;C84)0(
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ML^TU>*)!<\5NJ8CC9-2$.H,Q#0REL<5  &9!($T*0PA8*S$!R"0 CAP!8C!
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MS>GP*(3B.I<HT-O^K%\8QD;)CZJ[9?I>]J?FOJ%$,[P1A.-KR>8/4$L#!!0
M   ( %: 94\$XB/P; (  %@(   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q
M+GAM;)66VXZ;,!"&7P5QWQB;<T20DJVJ5FJE:*NVUT[B!+2 J>V$[=O7-H12
M,FC;F_C S/_-F'B&K./B11:,*>>UKAJY<0NEVC5"\EBPFLH5;UFCGYRYJ*G2
M2W%!LA6,GJQ372'B>1&J:=FX>6;W]B+/^%559</VPI'7NJ;BUXY5O-NXV+UO
M/)>70ID-E&<MO;"O3'UK]T*OT*AR*FO6R)(WCF#GC;O%ZQT.C8.U^%ZR3D[F
MCDGEP/F+67PZ;5S/1,0J=E1&@NKAQIY851DE'<?/0=0=F<9Q.K^K?[#)ZV0.
M5+(G7OTH3ZK8N(GKG-B97BOUS+N/;$@H=)TA^\_LQBIM;B+1C".OI/UUCE>I
M>#VHZ%!J^MJ/96/';M"_N\$.9' @HX-O'5 /LI&_IXKFF>"=(_K#;ZEYQWA-
M]-D<S:8]"OM,!R_U[BT/XC!#-R,TV.QZ&S*QP:,%TNHC@D"('7EP#X(8%O#!
M&'TKX$\%? (+!*! 8 6"OY*,9DGV-J&U::R-!R-"$!$"B'B&"!\0.$[#U MA
M4 2"(@"4S$#1 ^@="1?2B4%*#%#2&24&*!JSP$E 3O+(2;P9)P&.+?9QN'!L
M*0A* 1">@=+_ V$/OE$>@"+S*]4;16__W?#"O<4 Q9]3AMM-)A@2KX)H 07>
MWRTF "J8HPB "E=IL("";SKV =1#.?+!K!9?$UP3,% 4DGE1&(S^^0#AVH"!
MXI#,B\-@E+Q!0I/"7C-QL2U-.D=^;6P_G>R.;7-+;&/X8][WW"]47,I&.@>N
M='NQ3>#,N6(Z&F^EHRETFQ\7%3LK,XWU7/2]KE\HW@Y]'(T?$_EO4$L#!!0
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MA/:>4FM/Z:RGU+?S%U;^XG%3Y:BW#@?_ 5L'T/3\)-(.PU<+*H2F9UL+"BR
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MM=]4Z,#$,N5KTDUOW8;A5DVF7C\>S_\!4$L#!!0    ( %: 94^.RV"%ZP,
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M#!L81086#%!@ Z-W&!C%!D;'&!C5_09IL@(XAAXL@'.AQI\:9[]$[%X4N=?
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M+W-H965T-#4N>&ULE5;M;ILP%'T5Q ,4^QKS4261FDS3)FU2U6G=;S=Q$E3
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ML1H.Y&%B9#=>-F2Z\<I_4$L#!!0    ( %: 94\)V@'NS$\  #]9 0 4
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M2 MM!P^+K<7NMN"X+)2?&C)NW@&[+5 LV=!YE'E&$5N:>H*L5I1B1.*\B&Y
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MAUDB)=;$+;1[HRWT*<R8)PN8\,5DF!I28C=,VJD5/UIO_LO5N^R185;(B*V
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M=\G%\)LU';AC.NW#_3/.4V_N[RB=VBW!G9]W5^<\]3?"7?Q_^/H#4$L#!!0
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M%%D3%%D3%%D3%%D3%%F3*\K:'>-:E<U?23ZU7A[FL^[/Q=DW4$L! A0#%
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %: 94^B!3=XE@(   T*   8
M          "  ?@(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " !6@&5/QI]M3*T$  "D%0  &               @ '$"P  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 5H!E3[GS[W9  @  N <
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M965T-RYX;6Q02P$"% ,4    " !6@&5/.7OS!; !  #2 P  &
M    @ 'R)@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M5H!E3_'D5=.S 0  T@,  !@              ( !V"@  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( %: 94\ $BP*M $  -(#   9
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M970Q-"YX;6Q02P$"% ,4    " !6@&5/U0G%&[4!  #2 P  &0
M    @ %6-   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M %: 94_!5AAFM@$  -(#   9              "  4(V  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ 5H!E3\^3'V*U 0  T@,  !D
M             ( !+S@  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " !6@&5/$.0B$K4!  #2 P  &0              @ $;.@  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( %: 94_XUEY!L0$
M -(#   9              "  0<\  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ 5H!E3\MPC3.U 0  T@,  !D              ( !
M[ST  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !6@&5/
MQ+K<>NX!  !F!0  &0              @ ';/P  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( %: 94^ 37Y9M $  -(#   9
M      "  0!"  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ 5H!E3_QAUKFS 0  T@,  !D              ( !ZT,  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !6@&5/:3=6K<\!  "<!
M&0              @ '510  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( %: 94^-0_"JM@$  -(#   9              "  =M'  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 5H!E3P=]B6C2
M 0  G 0  !D              ( !R$D  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " !6@&5/76_:4[(!  #2 P  &0
M@ '12P  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %:
M94^L2D;+7@,  # .   9              "  ;I-  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ 5H!E3\K/1W@P @  K08  !D
M         ( !3U$  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    " !6@&5/ROI99:@$  #,'   &0              @ &V4P  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( %: 94]"1_#8* 0  -P4
M   9              "  958  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ 5H!E3^;I1TB7 0  6 ,  !D              ( !]%P
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !6@&5//6P0
M7E4"   Z!P  &0              @ '"7@  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( %: 94]AF8&FX@(  ) +   9
M  "  4YA  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M5H!E3U?Y^>)N @  RP<  !D              ( !9V0  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " !6@&5/]\ "8EP%  !,'   &0
M            @ $,9P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( %: 94^X3:( G 4  /8@   9              "  9]L  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 5H!E3X<2@>]& @
M:P<  !D              ( !<G(  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " !6@&5/B$J#2& "   T"   &0              @ 'O
M=   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %: 94_9
MDZ0W' ,  *(,   9              "  89W  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ 5H!E3P3B(_!L @  6 @  !D
M     ( !V7H  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %: 94\J8"&9'0(  /T&   9              "
M 8B*  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 5H!E
M3PG: >[,3P  /UD! !0              ( !W(P  'AL+W-H87)E9%-T<FEN
M9W,N>&UL4$L! A0#%     @ 5H!E3Z>23BQR @  9 T   T
M ( !VMP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !6@&5/4GA-?AD$  #,
M'@  #P              @ %WWP  >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ 5H!E3R4:.3S$ 0  3QP  !H              ( !O>,  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 5H!E3[1F&&*[ 0  9!P
M !,              ( !N>4  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ #< -P#S#@  I><

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6629774704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and as of December 31, 2018 are presented in the following tables:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">September&#160;30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Gains</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Losses</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">190,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,195</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202,893</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,633</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,433</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,666</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">551,187</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,174</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Classified as:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">340,254</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,702</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Gains</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Unrealized&#160;Losses</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">341,696</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">181</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">713,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">743</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Classified as:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366,952</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term investments</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">261,966</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total cash equivalents and investments</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6618566624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,492,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,075,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,655,922</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,856,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units subject to vesting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected shares purchased under Employee Stock Purchase Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">162,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Founder shares of common stock subject to future vesting</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,144,224</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,201,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Early exercised stock options subject to future vesting</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,306,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,020,580</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,878,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,810,405</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801545072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Notch Therapeutics Inc. - Subsequent Event<br></strong></div></th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborativeArrangementInitialFee', window );">Collaborative arrangement, initial fee</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire interest in affiliate</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsInc.Member', window );">Research Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborativeArrangementContingentConsiderationLiability', window );">Collaborative arrangement, contingent consideration payable</a></td>
<td class="nump">$ 7,250,000.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsInc.Member', window );">Pre-Clinical Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborativeArrangementContingentConsiderationLiability', window );">Collaborative arrangement, contingent consideration payable</a></td>
<td class="nump">4,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsInc.Member', window );">Clinical, Regulatory, and Commercial Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborativeArrangementContingentConsiderationLiability', window );">Collaborative arrangement, contingent consideration payable</a></td>
<td class="nump">$ 283,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborativeArrangementContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Contingent Consideration, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborativeArrangementContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborativeArrangementInitialFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Initial Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborativeArrangementInitialFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestoneTypeAxis=allo_ResearchMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestoneTypeAxis=allo_ResearchMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestoneTypeAxis=allo_PreClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestoneTypeAxis=allo_PreClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestoneTypeAxis=allo_ClinicalRegulatoryandCommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestoneTypeAxis=allo_ClinicalRegulatoryandCommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801719088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 12,834<span></span>
</td>
<td class="nump">$ 4,639<span></span>
</td>
<td class="nump">$ 32,189<span></span>
</td>
<td class="nump">$ 12,695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">5,533<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="nump">13,012<span></span>
</td>
<td class="nump">442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 7,301<span></span>
</td>
<td class="nump">$ 4,212<span></span>
</td>
<td class="nump">$ 19,177<span></span>
</td>
<td class="nump">$ 12,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6654228256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets And Liabilities Subject To Fair Value Measurements On Recurring Basis And Level Of Inputs Used In Such Measurements By Major Security Type</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and as of December 31, 2018 are presented in the following tables:&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">316,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included within cash and cash equivalents on the Company&#8217;s balance sheets</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6605637824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes option activity under the 2018 Plan:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contract</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Term</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In years)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,235,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.62</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,781,316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.55</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(304,576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.72</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(220,151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.91</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,492,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,553,432</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.03</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.00</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,492,134</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.07</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity Under Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes restricted stock unit activity under the 2018 Plan:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Average Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value at Date</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">of Grant per</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Share</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,795,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27.55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unvested September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,773,155</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27.46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended September 30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,533</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">442</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,212</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,177</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,253</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,639</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,695</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6822279920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (2018 Notes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,200<span></span>
</td>
<td class="nump">$ 120,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">116,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number common shares converted from convertible notes payable (in shares)</a></td>
<td class="nump">7,856,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentRate', window );">Debt conversion settlement price as a percentage of IPO price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesPayableCurrent', window );">Change in fair value of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,200<span></span>
</td>
<td class="nump">120,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,600<span></span>
</td>
<td class="nump">$ 139,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6821940960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=allo_SeriesAConvertiblePreferredStockMember', window );">Series A-1 Convertible Preferred Stock | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs | $</a></td>
<td class="nump">$ 635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember', window );">Series A-1 Convertible Preferred Stock Convertible Preferred Shares | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs | $</a></td>
<td class="nump">$ 84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=allo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=allo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=allo_SeriesAConvertiblePreferredStockConvertiblePreferredSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6821895616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 160,990<span></span>
</td>
<td colspan="2" class="nump">$ 92,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">340,254<span></span>
</td>
<td colspan="2" class="nump">366,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,513<span></span>
</td>
<td colspan="2" class="nump">8,598<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">509,757<span></span>
</td>
<td colspan="2" class="nump">467,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">100,702<span></span>
</td>
<td colspan="2" class="nump">261,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">31,437<span></span>
</td>
<td colspan="2" class="nump">33,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">45,943<span></span>
</td>
<td colspan="2" class="nump">8,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">301<span></span>
</td>
<td colspan="2" class="nump">754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">4,299<span></span>
</td>
<td colspan="2" class="nump">1,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">3,105<span></span>
</td>
<td colspan="2" class="nump">244<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">695,544<span></span>
</td>
<td colspan="2" class="nump">773,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,047<span></span>
</td>
<td colspan="2" class="nump">12,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">25,307<span></span>
</td>
<td colspan="2" class="nump">17,121<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,354<span></span>
</td>
<td colspan="2" class="nump">29,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, noncurrent</a></td>
<td class="nump">37,689<span></span>
</td>
<td colspan="2" class="nump">34,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">4,785<span></span>
</td>
<td colspan="2" class="nump">6,776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">75,828<span></span>
</td>
<td colspan="2" class="nump">70,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Notes 6 and 7)</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: 10,000,000 shares authorized as of September 30, 2019 and December 31, 2018; no shares were issued and outstanding as of September 30, 2019 and December 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 200,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 121,895,479 and 121,482,671 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">122<span></span>
</td>
<td colspan="2" class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">952,820<span></span>
</td>
<td colspan="2" class="nump">914,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(335,092)<span></span>
</td>
<td colspan="2" class="num">(211,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,866<span></span>
</td>
<td colspan="2" class="nump">306<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">619,716<span></span>
</td>
<td colspan="2" class="nump">703,164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 695,544<span></span>
</td>
<td colspan="2" class="nump">$ 773,855<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 305<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84242212&amp;loc=d3e2352-115587<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6641077824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a history of losses, and expects to record a loss in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6813114192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><table cellpadding="0" cellspacing="0" style="padding-top:24px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3.</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> Level 3 assets or liabilities as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and as of December 31, 2018.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and as of December 31, 2018 are presented in the following tables:&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">112,394</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,657</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">316,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,323</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">553,350</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,023</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">244,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. agency securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total financial assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">714,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included within cash and cash equivalents on the Company&#8217;s balance sheets</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> transfers between Levels 1, 2 or 3 for the period presented.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6591955072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately </font><font style="font-family:inherit;font-size:10pt;">68,000</font><font style="font-family:inherit;font-size:10pt;"> square feet located in South San Francisco, California. The lease term is </font><font style="font-family:inherit;font-size:10pt;">127 months</font><font style="font-family:inherit;font-size:10pt;"> beginning August 2018 through February 2029 with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the addition of laboratory space, with a lease incentive allowance of </font><font style="font-family:inherit;font-size:10pt;">$5.0</font><font style="font-family:inherit;font-size:10pt;"> million. The rent payments began on March 1, 2019 after an abatement period. In connection with the&#160;lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.0</font><font style="font-family:inherit;font-size:10pt;"> million. In connection with this lease, the Company recognized an operating lease right-of-use asset of </font><font style="font-family:inherit;font-size:10pt;">$23.6 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and an aggregate lease liability of </font><font style="font-family:inherit;font-size:10pt;">$29.8 million</font><font style="font-family:inherit;font-size:10pt;"> in the accompanying condensed balance sheet. The remaining lease term is 9 years and 5 months, and the estimated incremental borrowing rate is </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">.&#160;</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of </font><font style="font-family:inherit;font-size:10pt;">14,943</font><font style="font-family:inherit;font-size:10pt;"> square feet located in South San Francisco, California. The lease term is </font><font style="font-family:inherit;font-size:10pt;">124 months</font><font style="font-family:inherit;font-size:10pt;"> beginning November 2018 through February 2029, with an option to extend the term for another </font><font style="font-family:inherit;font-size:10pt;">seven years</font><font style="font-family:inherit;font-size:10pt;"> which is not reasonably assured of exercise. The Company has the right to make tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;"> million. Rent payments began in November 2018. In connection with the lease, the Company has maintained a letter of credit for the benefit of the landlord in the amount of </font><font style="font-family:inherit;font-size:10pt;">$0.2</font><font style="font-family:inherit;font-size:10pt;"> million. In connection with this lease, the Company recognized an operating lease right-of-use asset of </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and an aggregate lease liability of </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;"> in the accompanying balance sheet. The remaining lease term is 9 years and 5 months, and the estimated incremental borrowing rate is </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">December 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into two operating leases for office space in New York and Los Angeles for </font><font style="font-family:inherit;font-size:10pt;">4,358</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">1,293</font><font style="font-family:inherit;font-size:10pt;"> square feet respectively. The Company recognized operating lease right-of-use assets of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;"> million as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and aggregate lease liabilities of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> respectively for these leases. The lease term for the New York operating lease is 6 years and 7 months, with no option for renewal. The lease term for the Los Angeles operating lease is </font><font style="font-family:inherit;font-size:10pt;">3 years</font><font style="font-family:inherit;font-size:10pt;"> with an option to extend the lease term for another </font><font style="font-family:inherit;font-size:10pt;">two years</font><font style="font-family:inherit;font-size:10pt;"> which is not reasonably certain of exercise. There were no lease incentive allowances for either location. In connection with the New York lease, the Company maintains a letter of credit for the benefit of the landlord in the amount of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">. The remaining lease terms were </font><font style="font-family:inherit;font-size:10pt;">5 years and 9 months</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2 years and 2 months</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and the estimated incremental borrowing rates applied were </font><font style="font-family:inherit;font-size:10pt;">8.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2019, the Company entered into a lease agreement for approximately </font><font style="font-family:inherit;font-size:10pt;">118,000</font><font style="font-family:inherit;font-size:10pt;"> square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease has a term of </font><font style="font-family:inherit;font-size:10pt;">188 months</font><font style="font-family:inherit;font-size:10pt;"> and is expected to commence in April 2020. Upon certain conditions, the Company has two ten-year options to extend the lease. Subject to rent abatement for the second through nine months of the lease, the Company will be required to pay </font><font style="font-family:inherit;font-size:10pt;">$159,150</font><font style="font-family:inherit;font-size:10pt;"> per month for rent for the first twelve months of the lease term which will increase at a rate of </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> per year. The Company will be entitled to a tenant improvement allowance of&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.9</font><font style="font-family:inherit;font-size:10pt;"> million for costs related to the design and construction of certain Company improvements. In connection with the lease, the Company maintains a letter of credit for the benefit of the landlord in the amount of </font><font style="font-family:inherit;font-size:10pt;">$3.0</font><font style="font-family:inherit;font-size:10pt;"> million. The total commitment of undiscounted lease payments for this lease was </font><font style="font-family:inherit;font-size:10pt;">$36.2 million</font><font style="font-family:inherit;font-size:10pt;"> as at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. The Company had not recognized a right-of-use asset or aggregate lease liability as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> as the underlying asset was unavailable for use by the Company at any time in the period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The undiscounted future lease payments under the lease agreements as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;"> were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year ending December&#160;31:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in&#160;thousands)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 (remaining 3 months)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,381</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,981</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,961</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,213</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024 and thereafter </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,516</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total undiscounted lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Undiscounted lease payments related to Newark lease</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(36,231</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Present value adjustment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: Tenant improvement allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,849</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense for all operating leases was </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. Short-term lease expense was </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">. Variable lease payments for operating expenses was </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6826018640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Renewal</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,849,000<span></span>
</td>
<td class="nump">$ 2,849,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,437,000<span></span>
</td>
<td class="nump">31,437,000<span></span>
</td>
<td class="nump">$ 33,015,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Aggregate lease liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,689,000<span></span>
</td>
<td class="nump">37,689,000<span></span>
</td>
<td class="nump">$ 34,456,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OperatingLeasesUndiscountedLeasePayments', window );">Undiscounted lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,231,000<span></span>
</td>
<td class="nump">36,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeasePayment', window );">Variable lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of office and laboratory | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,358<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">79 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Aggregate lease liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated incremental borrowing rate of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=allo_LosAngelesMember', window );">Los Angeles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of office and laboratory | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,293<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Aggregate lease liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OperatingLeaseRemainingTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated incremental borrowing rate of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=allo_NewarkMember', window );">Newark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">188 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfOperatingLease', window );">Area of operating lease | ft&#178;</a></td>
<td class="nump">118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumberOfOptionsToExtendLease', window );">Number of options to extend lease | Renewal</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PaymentOfLeaseRentalPerMonth', window );">Payment of lease rental per month</a></td>
<td class="nump">$ 159,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent', window );">Increase in rate for rent per year for lease term</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OperatingLeasesUndiscountedLeasePayments', window );">Undiscounted lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,200,000<span></span>
</td>
<td class="nump">$ 36,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseOneMember', window );">127 Months Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of office and laboratory | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">127 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,600,000<span></span>
</td>
<td class="nump">23,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Aggregate lease liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,800,000<span></span>
</td>
<td class="nump">$ 29,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated incremental borrowing rate of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 5 months<span></span>
</td>
<td class="text">9 years 5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseTwoMember', window );">124 Months Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of office and laboratory | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">124 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AllowanceForTenantImprovements', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Aggregate lease liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OperatingLeaseRemainingTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Estimated incremental borrowing rate of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember', window );">License and Collaboration Agreement | Servier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Short term lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfNewOfficeBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of new office building.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfNewOfficeBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual rental increase percentage per year of lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LessorLeasingArrangementsOperatingLeasesAnnualPercentageIncreaseInRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfOptionsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfOptionsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OperatingLeaseRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease remaining term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OperatingLeaseRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OperatingLeasesUndiscountedLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases undiscounted lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OperatingLeasesUndiscountedLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PaymentOfLeaseRentalPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of lease rental per month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PaymentOfLeaseRentalPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for variable lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=allo_LosAngelesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=allo_LosAngelesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=allo_NewarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=allo_NewarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=allo_LeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=allo_LeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=allo_LeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>246</ContextCount>
  <ElementCount>341</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0002000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Statement of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedStatementOfStockholdersEquityDeficit</Role>
      <ShortName>Condensed Statement of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Condensed Statements of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedStatementsOfStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Statements of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedStatementOfCashFlows</Role>
      <ShortName>Condensed Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Balance Sheets Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetsComponents</Role>
      <ShortName>Balance Sheets Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Convertible Notes Payable (2019 Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://allogene.com/role/ConvertibleNotesPayable2019Notes</Role>
      <ShortName>Convertible Notes Payable (2019 Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://allogene.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/FinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Balance Sheets Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetsComponentsTables</Role>
      <ShortName>Balance Sheets Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/BalanceSheetsComponents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionOfBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/DescriptionOfBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashAndInvestmentsClassifiedAsAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Balance Sheets Components - Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetsComponentsPrepaidAndOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheets Components - Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Balance Sheets Components - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetsComponentsPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheets Components - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Balance Sheets Components - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetsComponentsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheets Components - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/LicenseAgreements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Leases - Undiscounted Future Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LeasesUndiscountedFutureLeasePaymentsDetails</Role>
      <ShortName>Leases - Undiscounted Future Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Convertible Notes Payable (2018 Notes) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://allogene.com/role/ConvertibleNotesPayable2018NotesDetails</Role>
      <ShortName>Convertible Notes Payable (2018 Notes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/ConvertibleNotesPayable2019Notes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/RelatedPartyTransactions</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/NetLossPerShareTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="allo-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/SubsequentEvents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>allo-20190930.xml</File>
    <File>allo-20190930.xsd</File>
    <File>allo-20190930_cal.xml</File>
    <File>allo-20190930_def.xml</File>
    <File>allo-20190930_lab.xml</File>
    <File>allo-20190930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6631617904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets Components - Prepaid and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PrepaidResearchAndDevelopmentExpensesCurrent', window );">Prepaid research and development expenses</a></td>
<td class="nump">$ 4,124<span></span>
</td>
<td class="nump">$ 2,356<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInvestmentIncomeReceivable', window );">Accrued interest on investments</a></td>
<td class="nump">2,337<span></span>
</td>
<td class="nump">3,108<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid and current assets</a></td>
<td class="nump">1,938<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 8,513<span></span>
</td>
<td class="nump">$ 8,598<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December 31, 2018 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PrepaidResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PrepaidResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
